http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3918
MTHFR
amino acid and derivative metabolism
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/3918
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/APOA1
_:header6306108131335206335033
Mon, 23 Apr 2012 18:32:10 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/APOA1
http://symbol.bio2rdf.org/symbol:APOA1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AAPOA1%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/564
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1475
_:header21120686861335206335545
Jetty(6.1.10)
application/rdf+xml
Keep-Alive
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2560
Galactoside O-acetyltransferase
Carbohydrate transport and metabolism
Thiogalactoside acetyltransferase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/6444453
http://bio2rdf.org/pfam:PF00132
http://bio2rdf.org/uniprot:P07464
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP07464%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3922433
GAT
http://www4.wiwiss.fu-berlin.de/drugbank/reso<http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2560
cytoplasm
http://www.pdb.org/pdb/explore/explore.do?structureId=1KRV
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1KRV%3E
EC 2.3.1.18
THGA_ECOLI
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17016423
acetyl-CoA + a beta-D-galactoside = CoA + a 6-acetyl-beta-D-galactoside
Essential
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17139284
http://bio2rdf.org/pdb:1KRV
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1KRV%3E
>612 bp	TTGAACATGCCAATGACCGAAAGAATAAGAGCAGGCAAGCTATTTACCGATATGTGCGAA	GGCTTACCGGAAAAAAGACTTCGTGGGAAAACGTTAATGTATGAGTTTAATCACTCGCAT	CCATCAGAAGTTGAAAAAAGAGAAAGCCTGATTAAAGAAATGTTTGCCACGGTAGGGGAA	AACGCCTGGGTAGAACCGCCTGTCTATTTCTCTTACGGTTCCAACATCCATATAGGCCGC	AATTTTTATGCAAATTTCAATTTAACCATTGTCGATGACTACACGGTAACAATCGGTGAT	AACGTACTGATTGCACCCAACGTTACTCTTTCCGTTACGGGACACCCTGTACACCATGAA	TTGAGAAAAAACGGCGAGATGTACTCTTTTCCGATAACGATTGGCAATAACGTCTGGATC	GGAAGTCATGTGGTTATTAATCCAGGCGTCACCATCGGGGATAATTCTGTTATTGGCGCG	GGTAGTATCGTCACAAAAGACATTCCACCAAACGTCGTGGCGGCTGGCGTTCCTTGTCGG	GTTATTCGCGAAATAAACGACCGGGATAAGCACTATTATTTCAAAGATTATAAAGTTGAA	TCGTCAGTTTAA
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=551814
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D551814%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11937062
http://pfam.sanger.ac.uk/family?acc=PF00132
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00132%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9278503
lacA
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3901000
http://www.uniprot.org/uniprot/P07464
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP07464%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02632
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/2560
RDF Description of Galactoside O-acetyltransferase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01992
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00095
_:header15568212281335206335868
RDF Description of Efalizumab
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00095
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/drugs
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3815
DB00095
Liquid
Sequence listed in Werther WA, Gonzalez TN, O'Connor SJ, McCabe S, Chan B, Hotaling T, Champe M, Fox JA, Jardieu PM, Berman PW, Presta LG. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol. 1996 Dec 1;157(11):4986-95
http://129.128.185.122/drugbank2/drugs/DB00095/inserts/1243/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00095%2Finserts%2F1243%2Ffull%3E
2008-03-19 16:49:08 UTC
http://dbpedia.org/page/Efalizumab
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FEfalizumab%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1693
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1693%3E
Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin.
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1694
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1694%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/immunomodulatoryAgents
Efalizumab
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2789
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2789%3E
Average efalizumab bioavailability following subcutaneous administration was estimated at 30 to 50%.
anti alphaL integrin
For the treatment of adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy.
antiCD11 alpha
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1173
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1173%3E
http://www4.wiwiss.fu-berlin.de/drugbank/vocab/resource/class/Offer
biod00074
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugtype/investigational
PA10304
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3814
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/181
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F181%3E
Lymphocyte activation and trafficking to skin play a role in the pathophysiology of chronic plaque psoriasis. In psoriatic skin, ICAM-1 cell surface expression is upregulated on endothelium and keratinocytes. Raptiva inhibits the binding of LFA-1 to the intercellular adhesion molecule-1 (ICAM-1), thereby inhibiting the adhesion of leukocytes to other cell types.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/784
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3817
hu1124
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/immunosuppressiveAgents
Raptiva (Genentech Inc)
http://bio2rdf.org/cas:214745-43-4
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A214745-43-4%3E
efalizumab
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3365
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3365%3E
http://data.linkedct.org/resource/intervention/12083
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F12083%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3819
61 oC (FAB fragment), 71 oC (whole mAb)-Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000).
http://data.linkedct.org/resource/intervention/22305
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F22305%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugtype/approved
2005-06-01	/drugs/95/fda_labels/635
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4136
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F4136%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/572
Raptiva
http://www.rxlist.com/cgi/generic3/raptiva.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric3%2Fraptiva.htm%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3820
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/833
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F833%3E
2005-06-13 13:24:05 UTC
http://data.linkedct.org/resource/intervention/36996
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F36996%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/698
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F698%3E
http://data.linkedct.org/resource/intervention/43605
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F43605%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/602
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F602%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3818
84:92.00
http://dbpedia.org/resource/Efalizumab
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FEfalizumab%3E
Humanized anti-CD11a antibody
L04AA21
http://en.wikipedia.org/wiki/Efalizumab
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FEfalizumab%3E
http://www.dbpedia.org/resource/Efalizumab
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FEfalizumab%3E
btd00074
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3004
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3004%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/powderForSolutionSubcutaneous
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3020
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3020%3E
5 days
http://data.linkedct.org/resource/intervention/49403
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F49403%3E
http://www.drugbank.ca/drugs/DB00095
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00095%3E
http://205.193.93.51/dpdonline/searchRequest.do?din=02272504
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02272504%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/1102
http://129.128.185.122/drugbank2/drugs/DB00095/inserts/370/full
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/701
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F701%3E
http://129.128.185.122/drugbank2/drugs/DB00095/inserts/2246/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00095%2Finserts%2F2246%2Ffull%3E
Humans and other mammals
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3821
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3816
Efalizumab binds to CD11a, a subunit of leukocyte function antigen-1 (LFA-1), which is expressed on all leukocytes. As a result efalizumab decreases cell surface expression of CD11a.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugtype/biotech
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00095_DB01253
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/PDE6A
_:header9560383451335206336337
Mon, 23 Apr 2012 18:32:11 GMT
RDF Description of PDE6A
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PDE6A
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/genes
http://symbol.bio2rdf.org/symbol:PDE6A
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3APDE6A%3E
PDE6A
http://www.dbpedia.org/resource/PDE6A
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FPDE6A%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3763
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/992
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB03868
_:header9528061771335206336879
RDF Description of 3-Dehydroquinic Acid
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03868
7.02e+02 mg/mL
WVMWZWGZRAXUBK-WXRBYKJCCB
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3183
(1R,3R,4S)-1,3,4-trihydroxy-5-oxocyclohexane-1-carboxylic acid
O[C@H]1C[C@@](O)(CC(=O)[C@@H]1O)C(O)=O
DQA
InChI=1/C7H10O6/c8-3-1-7(13,6(11)12)2-4(9)5(3)10/h3,5,8,10,13H,1-2H2,(H,11,12)/f/h11H
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugtype/smallMolecule
OC1CC(O)(CC(=O)C1O)C(O)=O
expt01264
2008-08-26 14:57:10 UTC
3-Dehydroquinic Acid
http://www.drugbank.ca/drugs/DB03868
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB03868%3E
Solid
1J2Y
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugtype/experimental
DB03868
C7H10O6
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/560
_:header338696971335206337305
Mon, 23 Apr 2012 18:32:12 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/560
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/diseases
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2695
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04136
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB04136%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02723
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB02723%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3090
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3090%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3512
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3512%3E
Hyperprothrombinemia
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04697
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB04697%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00641
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00641%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04898
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB04898%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04591
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB04591%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3714
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3714%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00025
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00025%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3097
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3097%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04786
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB04786%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04771
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB04771%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/4266
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F4266%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00278
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00278%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04772
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB04772%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1077
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F1077%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00006
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00006%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04722
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB04722%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1681
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F1681%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/798
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F798%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00682
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00682%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00170
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00170%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03847
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB03847%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00055
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00055%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00100
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00100%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00001
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00001%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/F2
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01109
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01109%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01123
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01123%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02351
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB02351%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseaseClass/Hematological
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/978
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F978%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01225
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01225%3E
RDF Description of Hyperprothrombinemia
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00132
_:header11553346801335206337803
RDF Description of Alpha-Linolenic Acid
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00132
Alpha Linolenic Acid (ALA) is an 18-carbon polyunsaturated fatty acid with three double bonds. It is also called an omega-3 fatty acid, and is essential for all mammals. Alpha-linolenic acid (or omega 3 fatty acid) intake can decrease the risk of cardiovascular diseases by 1) preventing arrhythmias that can lead to sudden cardiac death, 2) decreasing the risk of thrombosis (blood clot formation) that can lead to heart attack or stroke, 3) decreasing serum triglyceride levels, 4) slowing the growth of atherosclerotic plaque, 5) improving vascular endothelial function, 6) lowering blood pressure slightly, and 7) decreasing inflammation. ALA deficiencies can lead to visual problems and sensory neuropathy. Scaly and hemorrhagic skin or scalp inflammations may also develop.
1FK6
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3993
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/micronutrient
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3994
http://bio2rdf.org/cas:463-40-1
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A463-40-1%3E
0.000124 mg/mL at 25 oC [MEYLAN,WM et al. (1996)]
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1237
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1237%3E
http://en.wikipedia.org/wiki/Alpha-linolenic_acid
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FAlpha-linolenic_acid%3E
Alpha Linolenic Acid or ALA is considered an essential fatty acid because it is required for human health, but cannot be synthesized by humans. It is in fact  a plant-derived fatty acid. Humans can synthesize other omega-3 fatty acids from ALA, including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). EPA is a precursor of the series-3 prostaglandins, the series-5 leukotrienes and the series-3 thromboxanes. These eicosanoids have anti-inflammatory and anti-atherogenic properties. ALA metabolites may also inhibit the production of the pro-inflammatory eicosanoids, prostaglandin E2 (PGE2) and leukotriene B4 (LTB4), as well as the pro-inflammatory cytokines, tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1 beta). Omega-3 fatty acids like ALA and its byproducts can modulate the expression of a number of genes, including those involved with fatty acid metabolism and inflammation. They regulate gene expression through their effects on the activity of transcription factors including NF-kappa B and members of the peroxisome proliferator-activated receptor (PPAR) family. Incorporation of ALA and its metabolites in cell membranes can affect membrane fluidity and may play a role in anti-inflammatory activity, inhibition of platelet aggregation and possibly in anti-proliferative actions of ALA.
http://bio2rdf.org/chebi:27432
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fchebi%3A27432%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3312
Alpha-Linolenic Acid
http://www.drugbank.ca/drugs/DB00132
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00132%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugtype/nutraceutical
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3037
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3037%3E
Alpha-linolenic acid (ALA) is a polyunsaturated omega-3 fatty acid. It is a component of many common vegetable oils and is important to human nutrition. [Wikipedia]
InChI=1/C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h3-4,6-7,9-10H,2,5,8,11-17H2,1H3,(H,19,20)/b4-3-,7-6-,10-9-/f/h19H
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/1053
http://dbpedia.org/page/Alpha-linolenic_acid
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FAlpha-linolenic_acid%3E
9,12,15-Octadecatrienoic acid
http://www.dbpedia.org/resource/D-Aminolevulinic_acid
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FD-Aminolevulinic_acid%3E
For nutritional supplementation and for treating dietary shortage or imbalance.
2008-08-26 16:50:53 UTC
linolenate
ALA
DTOSIQBPPRVQHS-PDMBBZMKDZ
(9Z,12Z,15Z)-octadeca-9,12,15-trienoic acid
(9Z,12Z,15Z)-Octadecatrienoic acid
/drugs/132/safety_sheets/812
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/dietarySupplement
DB00132
CCC=C/CC=C/CC=C/CCCCCCCC(O)=O
-16.5 oC
LNL
2.66e-04 mg/mL
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3973
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3973%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/1395
C18H30O2
http://bio2rdf.org/cpd:C06427
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC06427%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/1558
CCC=CCC=CCC=CCCCCCCCC(O)=O
alpha-Linolenate
http://dbpedia.org/resource/Alpha-linolenic_acid
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FAlpha-linolenic_acid%3E
nutr00034
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1089
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1089%3E
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/228
_:header18143707601335206338254
Mon, 23 Apr 2012 18:32:13 GMT
RDF Description of Chondrocalcinosis
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/228
http://www.dbpedia.org/resource/Chondrocalcinosis
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FChondrocalcinosis%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseaseClass/Connective%5Ftissue%5Fdisorder
Chondrocalcinosis
http://data.linkedct.org/resource/condition/2657
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fcondition%2F2657%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/ANKH
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1864
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/VPS13A
_:header16605551371335206338627
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/VPS13A
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/232
http://symbol.bio2rdf.org/symbol:VPS13A
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AVPS13A%3E
VPS13A
http://bio2rdf.org/hgnc:1908
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A1908%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=1908
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D1908%3E
http://bio2rdf.org/geneid:23230
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fgeneid%3A23230%3E
http://www.dbpedia.org/resource/VPS13A
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FVPS13A%3E
RDF Description of VPS13A
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1873
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/4645
_:header21062441561335206339155
Mon, 23 Apr 2012 18:32:14 GMT
RDF Description of Oxytetracycline
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4645
http://www4.wiwiss.fu-berlin.de/sider/resource/sider/drugs
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0002994
Oxytetracycline
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0002792
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0349506
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0014868
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000004645
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000004645%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0032302
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0015967
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0011991
http://sideeffects.embl.de/drugs/4645
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F4645%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0702166
CID0000004645
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0042109
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0024141
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0040034
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0011168
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0018190
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0027497
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0021311
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0011606
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0014356
http://dbpedia.org/resource/Oxytetracycline
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FOxytetracycline%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0040592
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0007947
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0031046
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000004645&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000004645%26input_query_species%3D9606%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0038999
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0002438
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0002878
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0041912
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0033845
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0009763
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0029291
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0039128
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0034152
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0027947
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0014457
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00595
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00595%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0003123
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020517
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0017675
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0042963
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0035436
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0024286
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00576
_:header11119999001335206339491
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00576
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00563_DB00576
J01EB02
Sulamethizole
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2198
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2198%3E
A sulfathiazole antibacterial agent. [PubChem]
98-99%
Methazol
208 oC
Solfametizolo [Dcit]
52:10.00
Urodiaton
4-amino-N-(5-methyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide
http://dbpedia.org/page/Sulfamethizole
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FSulfamethizole%3E
Salimol
InChI=1/C9H10N4O2S2/c1-6-11-12-9(16-6)13-17(14,15)8-4-2-7(10)3-5-8/h2-5H,10H2,1H3,(H,12,13)/f/h13H
6.11e-01 mg/mL
Famet
Sulphamethyltiadiazole
Sulfamethizole is a sulfonamide antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of <i>p</i>-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus.
Sulfamethizolum [INN-Latin]
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/338
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F338%3E
S01AB01
Urosulfin
Tetracid
CC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)S1
Lucosil
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1436
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1436%3E
Sulfamethylthiadiazole
Urocydal
2008-08-26 15:43:03 UTC
Ayerlucil
Renasul
Sulfametizol [INN-Spanish]
http://en.wikipedia.org/wiki/Sulfamethizole
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FSulfamethizole%3E
Sulfamethizole is a competitive inhibitor of bacterial para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid.
Rapidly absorbed.
http://www.drugbank.ca/drugs/DB00576
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00576%3E
Thiosulfil Forte
/drugs/576/safety_sheets/1042
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/891
3-8 hours
Sulfamethizole [Usan:Inn:Jan]
Sulfamethizole
http://129.128.185.122/drugbank2/drugs/DB00576/inserts/1308/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00576%2Finserts%2F1308%2Ffull%3E
http://bio2rdf.org/kegg:D00870
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD00870%3E
Sulfa Gram
Uroz
VACCAVUAMIDAGB-NDKGDYFDCM
Sulfamethazole
Sulfstat
Microsul
D06BA04
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/anti-infectives
http://bio2rdf.org/cas:144-82-1
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A144-82-1%3E
Proklar
C9H10N4O2S2
B05CA04
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/anti-infectiveAgents
Urolucosil
-2.41 [ADME Research, USCD]
1050 mg/L
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/tabletOral
Sulfamethizol
For the treatment of urinary tract infection
http://bio2rdf.org/cpd:C08050
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC08050%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/587
Sulfurine
Enteric bacteria and other eubacteria
Hepatic.
Sulfapyelon
Ultrasul
http://129.128.185.122/drugbank2/drugs/DB00576/inserts/2307/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00576%2Finserts%2F2307%2Ffull%3E
Thidicur
http://dbpedia.org/resource/Sulfamethizole
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FSulfamethizole%3E
DB00576
aprd00684
Sulfamethiazole
Sulphamethizole
Rufol
Thiosulfil
http://129.128.185.122/drugbank2/drugs/DB00576/inserts/415/full
PA451543
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/81
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F81%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00672_DB00576
RDF Description of Sulfamethizole
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00576
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01320_DB00576
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00414_DB00576
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/2836
_:header10305298501335206340069
RDF Description of Potassium voltage-gated channel subfamily A member 4
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2836
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/targets
480-499
cellular physiological process
binding
voltage-gated potassium channel complex
transport
http://www.pdb.org/pdb/explore/explore.do?structureId=1QDV
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1QDV%3E
protein complex
physiological process
transporter activity
RHK1
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/gene/KCNA4
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fgene%2FKCNA4%3E
541-563
protein binding
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=X16002
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DX16002%3E
ion transport
KCNA4_RAT
RCK4
406-426
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2384173
>Potassium voltage-gated channel subfamily A member 4	MEVAMVSAESSGCNSHMPYGYAAQARARERERLAHSRAAAAAAVAAATAAVEGTGGSGGG	PHHHHQTRGAYSSHDPQGSRGSREEEATRTEKKKKLHHRQSSFPHCSDLMPSGSEEKILR	ELSEEEEDEEEEEEEEEEGRFYYSEEDHGDGCSYTDLLPQDDGGGGGYSSVRYSDCCERV	VINVSGLRFETQMKTLAQFPETLLGDPEKRTQYFDPLRNEYFFDRNRPSFDAILYYYQSG	GRLKRPVNVPFDIFTEEVKFYQLGEEALLKFREDEGFVREEEDRALPENEFKKQIWLLFE	YPESSSPARGIAIVSVLVILISIVIFCLETLPEFRDDRDLIMALSAGGHSRLLNDTSAPH	LENSGHTIFNDPFFIVETVCIVWFSFEFVVRCFACPSQALFFKNIMNIIDIVSILPYFIT	LGTDLAQQQGGGNGQQQQAMSFAILRIIRLVRVFRIFKLSRHSKGLQILGHTLRASMREL	GLLIFFLFIGVILFSSAVYFAEADEPTTHFQSIPDAFWWAVVTMTTVGYGDMKPITVGGK	IVGSLCAIAGVLTIALPVPVIVSNFNYFYHRETENEEQTQLTQNAVSCPYLPSNLLKKFR	SSTSSSLGDKSEYLEMEEGVKESLCGKEEKCQGKGDDSETDKNNCSNAKAVETDV
cell
310-328
Inorganic ion transport and metabolism
373-394
Kcna4
X16002
http://bio2rdf.org/pfam:PF07941
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF07941%3E
membrane
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=57037
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D57037%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12590144
cation transport
ion channel activity
RK3
http://bio2rdf.org/pfam:PF00520
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00520%3E
multi-passMembraneProtein
http://pfam.sanger.ac.uk/family?acc=PF07941
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF07941%3E
http://pfam.sanger.ac.uk/family?acc=PF00520
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00520%3E
445-463
>1968 bp	ATGGAGGTGGCAATGGTGAGTGCCGAGAGCTCAGGGTGCAACAGCCACATGCCTTATGGT	TATGCTGCCCAGGCCAGGGCTCGAGAGAGGGAGAGACTTGCTCACTCCAGGGCAGCTGCA	GCTGCTGCTGTTGCAGCTGCCACGGCTGCGGTGGAAGGCACTGGAGGTTCTGGTGGAGGC	CCCCACCATCATCATCAGACACGTGGGGCCTACTCCTCCCATGATCCTCAAGGAAGCCGA	GGTAGTCGGGAGGAGGAGGCCACACGAACTGAGAAGAAGAAGAAACTCCACCACAGGCAG	AGCAGTTTTCCTCATTGCTCAGACCTGATGCCCAGTGGCTCTGAAGAGAAGATCCTTAGG	GAGCTGAGCGAGGAGGAGGAAGACGAGGAGGAGGAAGAGGAGGAGGAAGAGGAGGGAAGG	TTTTACTATAGTGAAGAGGACCATGGGGATGGGTGTTCCTACACTGACCTACTGCCACAG	GACGATGGGGGTGGCGGCGGCTACAGTTCAGTCCGCTACAGTGACTGTTGTGAACGCGTG	GTAATAAATGTGTCTGGTCTACGCTTCGAAACCCAAATGAAAACTTTGGCTCAGTTTCCA	GAAACTCTGTTGGGAGACCCTGAGAAGAGGACTCAGTACTTCGACCCTTTGCGCAATGAG	TATTTTTTTGATAGGAACCGTCCCAGCTTTGATGCCATTTTGTATTATTACCAGTCAGGA	GGCCGCCTGAAGAGGCCAGTCAATGTCCCCTTTGATATCTTCACTGAGGAGGTGAAGTTC	TATCAGTTGGGAGAGGAAGCCCTGCTCAAGTTCCGTGAGGATGAGGGCTTTGTGAGAGAA	GAGGAGGACAGGGCTCTGCCAGAAAATGAATTTAAAAAACAGATTTGGCTTCTCTTTGAA	TATCCCGAGAGTTCCAGCCCTGCCAGGGGCATAGCCATCGTATCTGTCCTGGTCATCTTA	ATCTCTATTGTCATATTTTGCCTGGAAACCTTGCCTGAGTTCAGGGATGATAGGGACCTC	ATCATGGCCCTCAGCGCAGGTGGACACAGCAGATTATTGAATGACACCTCGGCACCCCAC	CTGGAGAACTCAGGGCACACAATATTCAATGACCCTTTCTTCATTGTGGAGACAGTATGT	ATCGTGTGGTTTTCCTTTGAGTTTGTGGTTCGATGCTTTGCTTGTCCCAGTCAAGCACTC	TTCTTCAAAAACATCATGAACATCATTGATATCGTCTCCATTTTGCCTTACTTCATCACT	CTGGGCACCGATCTGGCCCAGCAGCAGGGGGGTGGCAACGGCCAGCAGCAGCAGGCTATG	TCCTTTGCCATCCTCAGGATCATCCGTCTGGTCCGAGTGTTCCGGATCTTCAAGCTCTCC	AGACACTCCAAGGGCCTGCAGATCCTGGGCCACACCCTAAGAGCCAGCATGCGTGAACTG	GGCCTTCTTATCTTTTTCCTCTTCATCGGGGTCATCCTCTTTTCCAGCGCTGTGTATTTT	GCAGAGGCAGATGAACCTACCACCCATTTCCAAAGCATTCCAGATGCGTTTTGGTGGGCT	GTGGTAACCATGACAACTGTGGGCTACGGGGACATGAAGCCCATCACAGTGGGAGGAAAG	ATTGTGGGGTCCCTGTGTGCCATTGCGGGTGTCTTAACCATTGCTTTGCCCGTGCCGGTG	ATTGTGTCTAACTTTAACTATTTCTACCACAGAGAGACTGAAAACGAAGAACAGACCCAG	CTGACCCAAAACGCAGTCAGTTGCCCATACCTACCTTCTAATTTGCTCAAGAAATTTCGG	AGCTCTACTTCTTCTTCCCTGGGGGACAAGTCAGAGTATCTAGAGATGGAAGAAGGGGTC	AAGGAGTCTTTATGTGGAAAGGAAGAGAAGTGTCAGGGAAAGGGGGATGACAGCGAGACA	GATAAAAACAACTGTTCTAATGCAAAGGCTGTGGAGACTGATGTGTGA
Potassium voltage-gated channel subfamily A member 4
http://bio2rdf.org/uniprot:P15385
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP15385%3E
ion transporter activity
monovalent inorganic cation transport
voltage-gated potassium channel activity
http://bio2rdf.org/pdb:1QDV
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1QDV%3E
http://www.uniprot.org/uniprot/P15385
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP15385%3E
http://bio2rdf.org/pfam:PF02214
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF02214%3E
http://pfam.sanger.ac.uk/family?acc=PF02214
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF02214%3E
Voltage-gated potassium channel subunit Kv1.4
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9000078
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2555158
potassium ion transport
voltage-gated ion channel activity
Mediates the voltage-dependent potassium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a potassium-selective channel through which potassium ions may pass in accordance with their electrochemical gradient
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02299
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/3852
_:header5567356991335206340452
Mon, 23 Apr 2012 18:32:15 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3852
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00039
http://www.pdb.org/pdb/explore/explore.do?structureId=1KEX
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1KEX%3E
http://symbol.bio2rdf.org/symbol:NRP1
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ANRP1%3E
10p12
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9094999
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10520995
cellular process
http://bio2rdf.org/uniprot:O14786
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AO14786%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10821861
cell adhesion
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9288753
>2772 bp	ATGGAGAGGGGGCTGCCGCTCCTCTGCGCCGTGCTCGCCCTCGTCCTCGCCCCGGCCGGC	GCTTTTCGCAACGATGAATGTGGCGATACTATAAAAATTGAAAGCCCCGGGTACCTTACA	TCTCCTGGTTATCCTCATTCTTATCACCCAAGTGAAAAATGCGAATGGCTGATTCAGGCT	CCGGACCCATACCAGAGAATTATGATCAACTTCAACCCTCACTTCGATTTGGAGGACAGA	GACTGCAAGTATGACTACGTGGAAGTCTTCGATGGAGAAAATGAAAATGGACATTTTAGG	GGAAAGTTCTGTGGAAAGATAGCCCCTCCTCCTGTTGTGTCTTCAGGGCCATTTCTTTTT	ATCAAATTTGTCTCTGACTACGAAACACATGGTGCAGGATTTTCCATACGTTATGAAATT	TTCAAGAGAGGTCCTGAATGTTCCCAGAACTACACAACACCTAGTGGAGTGATAAAGTCC	CCCGGATTCCCTGAAAAATATCCCAACAGCCTTGAATGCACTTATATTGTCTTTGCGCCA	AAGATGTCAGAGATTATCCTGGAATTTGAAAGCTTTGACCTGGAGCCTGACTCAAATCCT	CCAGGGGGGATGTTCTGTCGCTACGACCGGCTAGAAATCTGGGATGGATTCCCTGATGTT	GGCCCTCACATTGGGCGTTACTGTGGACAGAAAACACCAGGTCGAATCCGATCCTCATCG	GGCATTCTCTCCATGGTTTTTTACACCGACAGCGCGATAGCAAAAGAAGGTTTCTCAGCA	AACTACAGTGTCTTGCAGAGCAGTGTCTCAGAAGATTTCAAATGTATGGAAGCTCTGGGC	ATGGAATCAGGAGAAATTCATTCTGACCAGATCACAGCTTCTTCCCAGTATAGCACCAAC	TGGTCTGCAGAGCGCTCCCGCCTGAACTACCCTGAGAATGGGTGGACTCCCGGAGAGGAT	TCCTACCGAGAGTGGATACAGGTAGACTTGGGCCTTCTGCGCTTTGTCACGGCTGTCGGG	ACACAGGGCGCCATTTCAAAAGAAACCAAGAAGAAATATTATGTCAAGACTTACAAGATC	GACGTTAGCTCCAACGGGGAAGACTGGATCACCATAAAAGAAGGAAACAAACCTGTTCTC	TTTCAGGGAAACACCAACCCCACAGATGTTGTGGTTGCAGTATTCCCCAAACCACTGATA	ACTCGATTTGTCCGAATCAAGCCTGCAACTTGGGAAACTGGCATATCTATGAGATTTGAA	GTATACGGTTGCAAGATAACAGATTATCCTTGCTCTGGAATGTTGGGTATGGTGTCTGGA	CTTATTTCTGACTCCCAGATCACATCATCCAACCAAGGAGACAGAAACTGGATGCCTGAA	AACATCCGCCTGGTAACCAGTCGCTCTGGCTGGGCACTTCCACCCGCACCTCATTCCTAC	ATCAATGAGTGGCTCCAAATAGACCTGGGGGAGGAGAAGATCGTGAGGGGCATCATCATT	CAGGGTGGGAAGCACCGAGAGAACAAGGTGTTCATGAGGAAGTTCAAGATCGGGTACAGC	AACAACGGCTCGGACTGGAAGATGATCATGGATGACAGCAAACGCAAGGCGAAGTCTTTT	GAGGGCAACAACAACTATGATACACCTGAGCTGCGGACTTTTCCAGCTCTCTCCACGCGA	TTCATCAGGATCTACCCCGAGAGAGCCACTCATGGCGGACTGGGGCTCAGAATGGAGCTG	CTGGGCTGTGAAGTGGAAGCCCCTACAGCTGGACCGACCACTCCCAACGGGAACTTGGTG	GATGAATGTGATGACGACCAGGCCAACTGCCACAGTGGAACAGGTGATGACTTCCAGCTC	ACAGGTGGCACCACTGTGCTGGCCACAGAAAAGCCCACGGTCATAGACAGCACCATACAA	TCAGAGTTTCCAACATATGGTTTTAACTGTGAATTTGGCTGGGGCTCTCACAAGACCTTC	TGCCACTGGGAACATGACAATCACGTGCAGCTCAAGTGGAGTGTGTTGACCAGCAAGACG	GGACCCATTCAGGATCACACAGGAGATGGCAACTTCATCTATTCCCAAGCTGACGAAAAT	CAGAAGGGCAAAGTGGCTCGCCTGGTGAGCCCTGTGGTTTATTCCCAGAACTCTGCCCAC	TGCATGACCTTCTGGTATCACATGTCTGGGTCCCACGTCGGCACACTCAGGGTCAAACTG	CGCTACCAGAAGCCAGAGGAGTACGATCAGCTGGTCTGGATGGCCATTGGACACCAAGGT	GACCACTGGAAGGAAGGGCGTGTCTTGCTCCACAAGTCTCTGAAACTTTATCAGGTGATT	TTCGAGGGCGAAATCGGAAAAGGAAACCTTGGTGGGATTGCTGTGGATGACATTAGTATT	AATAACCACATTTCACAAGAAGATTGTGCAAAACCAGCAGACCTGGATAAAAAGAACCCA	GAAATTAAAATTGATGAAACAGGGAGCACGCCAGGATACGAAGGTGAAGGAGAAGGTGAC	AAGAACATCTCCAGGAAGCCAGGCAATGTGTTGAAGACCTTAGAACCCATCCTCATCACC	ATCATAGCCATGAGCGCCCTGGGGGTCCTCCTGGGGGCTGTCTGTGGGGTCGTGCTGTAC	TGTGCCTGTTGGCATAATGGGATGTCAGAAAGAAACTTGTCTGCCCTGGAGAACTATAAC	TTTGAACTTGTGGATGGTGTGAAGTTGAAAAAAGACAAACTGAATACACAGAGTACTTAT	TCGGAGGCATGA
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10688880
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=2407641
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D2407641%3E
Non-Essential
http://pfam.sanger.ac.uk/family?acc=PF00629
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00629%3E
http://bio2rdf.org/pfam:PF00431
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00431%3E
NRP1
http://bio2rdf.org/hgnc:8004
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A8004%3E
>Neuropilin-1	MERGLPLLCAVLALVLAPAGAFRNDKCGDTIKIESPGYLTSPGYPHSYHPSEKCEWLIQA	PDPYQRIMINFNPHFDLEDRDCKYDYVEVFDGENENGHFRGKFCGKIAPPPVVSSGPFLF	IKFVSDYETHGAGFSIRYEIFKRGPECSQNYTTPSGVIKSPGFPEKYPNSLECTYIVFAP	KMSEIILEFESFDLEPDSNPPGGMFCRYDRLEIWDGFPDVGPHIGRYCGQKTPGRIRSSS	GILSMVFYTDSAIAKEGFSANYSVLQSSVSEDFKCMEALGMESGEIHSDQITASSQYSTN	WSAERSRLNYPENGWTPGEDSYREWIQVDLGLLRFVTAVGTQGAISKETKKKYYVKTYKI	DVSSNGEDWITIKEGNKPVLFQGNTNPTDVVVAVFPKPLITRFVRIKPATWETGISMRFE	VYGCKITDYPCSGMLGMVSGLISDSQITSSNQGDRNWMPENIRLVTSRSGWALPPAPHSY	INEWLQIDLGEEKIVRGIIIQGGKHRENKVFMRKFKIGYSNNGSDWKMIMDDSKRKAKSF	EGNNNYDTPELRTFPALSTRFIRIYPERATHGGLGLRMELLGCEVEAPTAGPTTPNGNLV	DECDDDQANCHSGTGDDFQLTGGTTVLATEKPTVIDSTIQSEFPTYGFNCEFGWGSHKTF	CHWEHDNHVQLKWSVLTSKTGPIQDHTGDGNFIYSQADENQKGKVARLVSPVVYSQNSAH	CMTFWYHMSGSHVGTLRVKLRYQKPEEYDQLVWMAIGHQGDHWKEGRVLLHKSLKLYQVI	FEGEIGKGNLGGIAVDDISINNHISQEDCAKPADLDKKNPEIKIDETGSTPGYEGEGEGD	KNISRKPGNVLKTLEPILITIIAMSALGVLLGAVCGVVLYCACWHNGMSERNLSALENYN	FELVDGVKLKKDKLNTQSTYSEA
AF018956
CD304 antigen
1-21
http://bio2rdf.org/pfam:PF00629
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00629%3E
http://pfam.sanger.ac.uk/family?acc=PF00431
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00431%3E
The soluble isoform 2 binds VEGF-165 and appears to inhibit its binding to cells. It may also induce apoptosis by sequestering VEGF-165. May bind as well various members of the semaphorin family. Its expression has an averse effect on blood vessel number and integrity
NRP1_HUMAN
cellMembrane
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9890894
857-879
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9529250
Neuropilin-1
http://pfam.sanger.ac.uk/family?acc=PF00754
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00754%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=8004
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D8004%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AF018956
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAF018956%3E
http://www.uniprot.org/uniprot/O14786
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FO14786%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17717967
Neuropilin-1 precursor
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10748121
Vascular endothelial cell growth factor 165 receptor
http://bio2rdf.org/pfam:PF00754
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00754%3E
http://bio2rdf.org/pdb:1KEX
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1KEX%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04895
RDF Description of Neuropilin-1
http://www4.wiwiss.fu-berlin.de/dblp/data/person/101830
_:header16948589511335206341233
Jetty(6.1.1)
application/rdf+xml; charset=utf-8
http://www4.wiwiss.fu-berlin.de/dblp/resource/person/101830
http://xmlns.com/foaf/0.1/Person
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/focs/DagumLMV88
Michael Luby
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/focs/AlbaneseBELS94
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/stoc/KarpLM84
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/istcs/LubySZ93
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/stoc/BlumLR90
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/jcss/BlumLR93
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/ipl/HambruschL91
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/algorithmica/LubyR89
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/dagstuhl/AlbaneseL95
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/algorithmica/Luby96
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tcs/DagumL92
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/focs/KarpL83
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/coco/Ben-DavidCGL89
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigcomm/LubyGSH02
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/jal/KarpLM89
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/icalp/LubyR85
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/focs/GoldreichKL88
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/random/1998
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/stoc/LubyMSS98
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/focs/AwerbuchGLP89
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/istcs/AdlerBBLR97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigcomm/ByersLMR98
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tit/LubyMSS01a
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/infocom/ByersLM01
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/siamcomp/DagumKLR00
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/computer/HornKLLR01
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/homepages/l/MichaelLuby
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/siamcomp/HastadILL99
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tit/AlonL96
http://www.informatik.uni-trier.de/~ley/db/copyright.html
RDF Description of Michael Luby
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/jcss/Ben-DavidCGL92
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/stoc/LinialLSZ93
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/jcss/Luby93
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/focs/DagumKLR95
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/soda/LubyNO94
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/siamcomp/GoldreichKL93
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/crypto/GoldreichKL88
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/approx/OrCLR04
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/focs/LubyMR83
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/siamcomp/LubyR88
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/soda/LubyMS98
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/ai/DagumL93
http://www4.wiwiss.fu-berlin.de/dblp/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fxmlns.com%2Ffoaf%2F0.1%2FPerson%3E
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/ngc/ByersFHLMRS00
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/ipl/CookL88
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/focs/AlonEL95
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/stacs/LubyE94
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/eccc/ECCC-TR04-052
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/combinatorica/LinialLSZ97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/focs/Luby02
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/siamcomp/Luby86
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/stoc/EvenGLNV92
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/siamcomp/LubyRS01
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/stoc/LubyN93
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/random/Luby98
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/siamcomp/KarmarkarKLLL93
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/rsa/Luby97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/algorithmica/LubyV96
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/rsa/EvenGLNV98
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/stoc/ImpagliazzoLL89
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/stoc/Luby85
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/joc/LubyR89
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/istcs/LubyVW93
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/mm/LamparterAKL95
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/jal/KarpinskiL93
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/jal/FiatKLMSY91
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tit/AlbaneseBELS96
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/stoc/LubyV97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/soda/KarpinskiL91
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/focs/Luby88
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/stoc/LubyR86
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/jc/KarpL85
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/eurocrypt/LubyS98
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/ai/DagumL97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/algorithmica/KarpLH96
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/crypto/HerzbergL92
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/focs/ImpagliazzoL89
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/ipl/LubySZ93
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/crypto/LubyR85
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/stoc/LubyMSSS97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/crypto/JuelsLO97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/crypto/LubyR87
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/stoc/Ben-DavidCGL89
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/usits/Luby03
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/focs/LubyRS95
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tit/LubyMSS01
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/infocom/ByersLM99
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/corr/cs-DS-0205038
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/ton/ByersKLM06
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/siamdm/LubyNO96
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/stoc/LubyV91
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/rsa/LubyV99
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/stoc/KarpLH92
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tit/LubyM05
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/soda/BeameL90
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/crypto/Luby91
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Phillips_David_Graham_1867-1911
_:header21257145261335206341398
Mon, 23 Apr 2012 18:32:16 GMT
RDF Description of Phillips, David Graham, 1867-1911
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Phillips_David_Graham_1867-1911
Phillips, David Graham, 1867-1911
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext11614
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext430
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext431
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext478
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext20449
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext433
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext457
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext450
http://www4.wiwiss.fu-berlin.de/gutendata/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fxmlns.com%2Ffoaf%2F0.1%2FPerson%3E
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7832
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7989
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext4929
http://www4.wiwiss.fu-berlin.de/factbook/data/Monaco
_:header18230563821335206341816
RDF Description of Monaco
http://www4.wiwiss.fu-berlin.de/factbook/resource/Monaco
http://www4.wiwiss.fu-berlin.de/factbook/ns#Country
Monaco
hilly, rugged, rocky
18 years of age; universal
$920600000; including capital expenditures of $920600000
last held 9 February 2003 (next to be held February 2008)
none
none; there are no first-order administrative divisions as defined by the US Government, but there are four quarters (quartiers, singular - quartier); Fontvieille, La Condamine, Monaco-Ville, Monte-Carlo
Monegasque or Monacan
Principaute de Monaco
Principality of Monaco
constitutional monarchy
AM 1, FM NA, shortwave 8
modern automatic telephone system
https://www.cia.gov/library/publications/the-world-factbook/flags/mn-lgflag.gif
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Flibrary%2Fpublications%2Fthe-world-factbook%2Fflags%2Fmn-lgflag.gif%3E
Mont Agel
17 December 1962
percent of vote by party - NA%; seats by party - UNAM 21, UND 3
age 15 and over can read and write
mn
http://www4.wiwiss.fu-berlin.de/factbook/resource/France
two equal horizontal bands of red (top) and white; similar to the flag of Indonesia which is longer and the flag of Poland which is white (top) and red
https://www.cia.gov/library/publications/the-world-factbook/flags/mn-flag.gif
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Flibrary%2Fpublications%2Fthe-world-factbook%2Fflags%2Fmn-flag.gif%3E
Mediterranean with mild, wet winters and hot, dry summers
https://www.cia.gov/cia/publications/factbook/geos/mn.html
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Fcia%2Fpublications%2Ffactbook%2Fgeos%2Fmn.html%3E
based on French law; has not accepted compulsory ICJ jurisdiction
Monaco, bordering France on the Mediterranean coast, is a popular resort, attracting tourists to its casino and pleasant climate. In 2001, a major construction project extended the pier used by cruise ships in the main harbor. The principality has successfully sought to diversify into services and small, high-value-added, nonpolluting industries. The state has no income tax and low business taxes and thrives as a tax haven both for individuals who have established residence and for foreign companies that have set up businesses and offices. The state retains monopolies in a number of sectors, including tobacco, the telephone network, and the postal service. Living standards are high, roughly comparable to those in prosperous French metropolitan areas.
country code - 377; no satellite earth stations; connected by cable into the French communications system
none; the monarchy is hereditary; minister of state appointed by the monarch from a list of three French national candidates presented by the French Government
1.75 children born/woman
https://www.cia.gov/library/publications/the-world-factbook/maps/mn-map.gif
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Flibrary%2Fpublications%2Fthe-world-factbook%2Fmaps%2Fmn-map.gif%3E
National Day (Saint Rainiers Day), 19 November
Mediterranean Sea
77 (Bahamas 17, Barbados 1, Bermuda 2, France 1, Georgia 13, Isle of Man 3, Liberia 10, Malta 1, Marshall Islands 8, Norway 4, Panama 9, Saint Kitts and Nevis 1, Saint Vincent and the Grenadines 4, Switzerland 2, unknown 1)
Monegasque(s) or Monacan(s)
Council of Government is under the authority of the monarch
euro (EUR)
Minister of State Jean-Paul PROUST (since 1 June 2005)
EUR
The Genoese built a fortress on the site of present-day Monaco in 1215. The current ruling Grimaldi family secured control in the late 13th century, and a principality was established in 1338. Economic development was spurred in the late 19th century with a railroad linkup to France and the opening of a casino. Since then, the principalitys mild climate, splendid scenery, and gambling facilities have made Monaco world famous as a tourist and recreation center.
Prince ALBERT II (since 6 April 2005)
Western Europe, bordering the Mediterranean Sea on the southern coast of France, near the border with Italy
UTC+1 (6 hours ahead of Washington, DC during Standard Time)
Supreme Court or Tribunal Supreme (judges appointed by the monarch on the basis of nominations by the National Council)
+1hr, begins last Sunday in March; ends last Sunday in October
43 44 N, 7 25 E
1419 (beginning of rule by the House of Grimaldi)
.mc
unicameral National Council or Conseil National (24 seats; 16 members elected by list majority system, 8 by proportional representation; to serve five-year terms)
calendar year
about three times the size of The Mall in Washington, DC
http://www4.wiwiss.fu-berlin.de/factbook/resource/European_Union
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Seton_Ernest_Thompson_1860-1946
_:header19888163301335206342276
Mon, 23 Apr 2012 18:32:17 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Seton_Ernest_Thompson_1860-1946
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1088
Seton, Ernest Thompson, 1860-1946
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9333
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9330
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3031
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2284
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6818
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext14226
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13499
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext11135
RDF Description of Seton, Ernest Thompson, 1860-1946
http://www4.wiwiss.fu-berlin.de/dblp/data/person/143645
_:header11747216931335206342954
http://www4.wiwiss.fu-berlin.de/dblp/resource/person/143645
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/ifip/CousotC04
Patrick Cousot
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sas/CousotC91
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/popl/CousotC04
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/popl/CousotC77
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sas/1993
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/plilp/CousotC92
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/popl/CousotC79
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/vmcai/Cousot05
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/cav/CousotC02
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sas/2001
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tcs/CousotC93
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sas/CousotC91a
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/popl/CousotC02
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/cav/CousotC95
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sara/Cousot00
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/fpca/CousotC95
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/ldrs/CousotC77
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/logcom/CousotC92
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/csur/Cousot99
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/vmcai/Cousot03
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/entcs/Cousot97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/popl/Cousot97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/iccl/CousotC94
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/ershov/CousotC93
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/agp/Cousot95
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/spin/Cousot02
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/dagstuhl/Cousot01
RDF Description of Patrick Cousot
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/jlp/CousotC92
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/ase/CousotC99
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/icalp/CousotC80
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/emsoft/CousotC01
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/sigplan/Cousot97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/homepages/c/PCousot
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/csur/Cousot96a
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sas/Cousot97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tcs/Cousot02
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/acta/CousotC87
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/popl/CousotH78
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/csur/Cousot96
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/lomaps/NielsonCDDJMT96
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/aplas/Cousot05
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/popl/CousotC92
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/popl/CousotC00
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/esop/CousotCFMMMR05
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/iandc/CousotC89
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/iclp/Cousot01
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/cc/CousotC02
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/pldi/BlanchetCCFMMMR03
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/iclp/Cousot91
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/amast/CousotC97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/books/el/leeuwen90/Cousot90
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tcs/CousotC03
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/birthday/Cousot03
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/entcs/CousotC01
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/birthday/BlanchetCCFMMMR02
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0027051
_:header11490032381335206343321
Mon, 23 Apr 2012 18:32:18 GMT
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0027051
http://www4.wiwiss.fu-berlin.de/sider/resource/sider/side_effects
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/60831
MYOCARDIAL INFARCTION
C0027051
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/disease/Myocardial_Infarction
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fdisease%2FMyocardial_Infarction%3E
http://sideeffects.embl.de/se/C0027051
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0027051%3E
myocardial infarctions
myocardial infarcts
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/797
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F797%3E
http://dbpedia.org/resource/Myocardial_infarction
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FMyocardial_infarction%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4212
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3825
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2550
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4829
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4183806
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/60795
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4485
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2369
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5584
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3911
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/10631
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/159
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4205
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5487
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/772
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5538
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4543
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/42113
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2771
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3461
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2232
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/110635
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/65999
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3339
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3948
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3157
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/6691
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2140
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4171
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5090
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3114
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3734
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/681
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2244
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3285
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/60184
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/1302
RDF Description of MYOCARDIAL INFARCTION
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2160
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4894
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/122316
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/72467
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/6398970
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/951
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2250
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2520
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5645
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5372
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4659569
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3333
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5311039
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3672
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3661
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5005
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/48041
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3696
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4547
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3962
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3784
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5311048
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2554
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3367
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4140
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/34633
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3937
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/365716
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2375
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4054
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4614
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/119607
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/47725
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2909
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4428
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3075
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3902
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2477
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/91270
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5195
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2311
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/163742
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3724
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4932
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5731
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5038
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2585
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4259
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3878
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4473
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5523
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3676
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/31477
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4159
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/60612
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5376
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/60169
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/191
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/60198
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2801
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5095
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4011
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3355
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/216326
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3003
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5311082
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4946
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/170361
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2162
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2995
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/104865
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/60754
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3640
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4440
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2907
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3475
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4745
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5732
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2443
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3394
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5203
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3222
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3148
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5029
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3519
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/151165
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/93860
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3961
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5358
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3081884
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4583
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/807
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/18140
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3386
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2895
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/158
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5656
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3143
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/27661
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2187
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3741
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5212
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5525
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5426
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3883
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3015
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4052
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4679
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/861
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5070
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3007
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/71329
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/71273
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5210
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2751
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/110634
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2182
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4539
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/123606
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3404
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2818
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4889
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5281104
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3032
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3086258
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2405
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5466
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4976
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3108
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3749
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5533
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/150310
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/62816
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5478
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4510
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/1125
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3062316
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5234
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/57469
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3826
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/444
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/853
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2806
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/450
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4913
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/27991
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/147912
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5077
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/77993
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/60707
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/77992
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5076
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3706
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/71301
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2141
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3152
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/13342
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3154
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5073
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3308
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3685
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/158440
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3340
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3403
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/125017
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2662
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3345
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3648
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2764
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/213039
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5544
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4856
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/937
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2170
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/176870
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2958
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5516
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4409
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3446
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/71158
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5078
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5878
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/125889
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/60953
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3410
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3066
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/477468
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5486
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3750
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/77999
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3310
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4943
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3385
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/1972
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2249
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/59768
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4595
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4819
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/60835
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/71616
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5978
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/41317
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2541
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4044
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5650
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/39042
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4666
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/54454
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3419
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5672
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4885
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/1935
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4691
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3019
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/SLC3A1
_:header8419908661335206343712
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/SLC3A1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2634
http://symbol.bio2rdf.org/symbol:SLC3A1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ASLC3A1%3E
SLC3A1
http://www.dbpedia.org/resource/SLC3A1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FSLC3A1%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/524
RDF Description of SLC3A1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2058
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/299
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0151714
_:header14493391841335206344189
Mon, 23 Apr 2012 18:32:19 GMT
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0151714
http://dbpedia.org/resource/Hypermagnesemia
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FHypermagnesemia%3E
http://sideeffects.embl.de/se/C0151714
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0151714%3E
hypermagnesemia
C0151714
RDF Description of hypermagnesemia
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/1690
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2524
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/68740
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/1581
_:header3516355021335206344708
RDF Description of G protein-activated inward rectifier potassium channel 2
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/1581
U24660
>G protein-activated inward rectifier potassium channel 2	MAKLTESMTNVLEGDSMDQDVESPVAIHQPKLPKQARDDLPRHISRDRTKRKIQRYVRKD	GKCNVHHGNVRETYRYLTDIFTTLVDLKWRFNLLIFVMVYTVTWLFFGMIWWLIAYIRGD	MDHIEDPSWTPCVTNLNGFVSAFLFSIETETTIGYGYRVITDKCPEGIILLLIQSVLGSI	VNAFMVGCMFVKISQPKKRAETLVFSTHAVISMRDGKLCLMFRVGDLRNSHIVEASIRAK	LIKSKQTSEGEFIPLNQTDINVGYYTGDDRLFLVSPLIISHEINQQSPFWEISKAQLPKE	ELEIVVILEGMVEATGMTCQARSSYITSEILWGYRFTPVLTLEDGFYEVDYNSFHETYET	STPSLSAKELAELASRAELPLSWSVSSKLNQHAELETEEEEKNLEEQTERNGDVANLENE	SKV
>1272 bp	ATGGCCAAGCTGACAGAATCCATGACTAACGTCCTGGAGGGCGACTCCATGGATCAGGAC	GTCGAAAGCCCAGTGGCCATTCACCAGCCAAAGTTGCCTAAGCAGGCCAGGGATGACCTG	CCAAGACACATCAGCCGAGATCGGACCAAAAGGAAAATCCAGAGGTACGTGAGGAAAGAC	GGAAAGTGCAATGTTCATCACGGCAACGTGAGGGAGACCTATCGCTACCTGACCGATATC	TTCACCACATTAGTGGACCTGAAGTGGAGATTCAACCTATTGATTTTTGTCATGGTTTAC	ACAGTGACCTGGCTCTTTTTTGGAATGATCTGGTGGTTGATCGCATACATACGGGGAGAC	ATGGACCACATAGAGGACCCCTCCTGGACTCCTTGTGTTACCAACCTCAACGGGTTCGTC	TCTGCTTTTTTATTCTCAATAGAGACAGAAACCACCATTGGTTATGGCTACCGGGTCATC	ACAGATAAATGCCCGGAGGGAATTATTCTTCTCTTAATCCAATCTGTGTTGGGGTCCATT	GTCAATGCATTCATGGTGGGATGCATGTTTGTAAAAATCTCTCAACCCAAGAAGAGGGCA	GAGACCCTGGTCTTTTCCACCCATGCAGTGATCTCCATGCGGGATGGGAAACTGTGCCTG	ATGTTCCGGGTAGGGGACCTTAGGAATTCCCACATTGTGGAGGCTTCCATCAGAGCCAAG	TTGATCAAATCCAAACAGACCTCGGAGGGGGAGTTCATCCCGTTGAACCAGACGGATATC	AACGTAGGGTATTACACGGGGGATGACCGTCTGTTTCTGGTGTCACCGCTGATCATTAGC	CATGAAATTAACCAACAGAGTCCTTTCTGGGAGATCTCCAAAGCCCAGCTGCCCAAAGAG	GAACTGGAAATTGTGGTCATCCTAGAAGGAATGGTGGAAGCCACAGGGATGACATGCCAA	GCTCGAAGCTCCTACATCACCAGTGAGATCCTGTGGGGTTACCGGTTCACACCTGTCCTG	ACCCTGGAGGATGGGTTCTACGAAGTTGACTACAACAGCTTCCATGAGACCTATGAGACC	AGCACCCCATCCCTTAGTGCCAAAGAGCTGGCCGAGTTAGCCAGCAGGGCAGAGCTGCCC	CTGAGTTGGTCTGTATCCAGCAAACTCAACCAACATGCAGAACTGGAGACTGAAGAGGAA	GAAAAGAACCTCGAAGAGCAAACAGAAAGAAATGGTGATGTGGCAAACCTGGAGAATGAA	TCCAAAGTTTAG
Potassium channel, inwardly rectifying subfamily J member 6
http://bio2rdf.org/uniprot:P48051
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP48051%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/16243998
http://www.genenames.org/data/hgnc_data.php?hgnc_id=6267
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D6267%3E
KATP-2
GIRK2
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7592809
G protein-activated inward rectifier potassium channel 2
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7796919
inward rectifier potassium channel activity
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/15175324
BIR1
KCNJ6
167-188
G-protein activated inward rectifier potassium channel activity
IRK6_HUMAN
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7729621
Inward rectifier K(+) channel Kir3.2
http://bio2rdf.org/hgnc:6267
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A6267%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10659995
90-114
http://symbol.bio2rdf.org/symbol:KCNJ6
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AKCNJ6%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=U24660
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DU24660%3E
http://bio2rdf.org/pfam:PF01007
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF01007%3E
http://www.uniprot.org/uniprot/P48051
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP48051%3E
This potassium channel may be involved in the regulation of insulin secretion by glucose and/or neurotransmitters acting through G-protein-coupled receptors. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium
http://pfam.sanger.ac.uk/family?acc=PF01007
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF01007%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=1052875
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D1052875%3E
Involved in inward rectifier potassium channel activity
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01159
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/34
_:header13546214261335206345163
Mon, 23 Apr 2012 18:32:20 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/34
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00157
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9465114
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=4191398
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D4191398%3E
306-326
>1428 bp	ATGGCTGCAAAATCGCAACCCAACATTCCCAAAGCCAAGAGTCTAGATGGCGTCACCAAT	GACAGAACCGCATCTCAAGGGCAGTGGGGCCGTGCCTGGGAGGTGGACTGGTTTTCACTG	GCGAGCGTCATCTTCCTACTGCTGTTCGCCCCCTTCATCGTCTACTACTTCATCATGGCT	TGTGACCAATACAGCTGCGCCCTGACCGGCCCTGTGGTGGACATCGTCACCGGACATGCT	CGGCTCTCGGACATCTGGGCCAAGACTCCACCTATAACGAGGAAAGCCGCCCAGCTCTAT	ACCTTGTGGGTCACCTTCCAGGTGCTTCTGTACACGTCTCTCCCTGACTTCTGCCATAAG	TTTCTACCCGGCTACGTAGGAGGCATCCAGGAGGGGGCCGTGACTCCTGCAGGGGTTGTG	AACAAGTATCAGATCAACGGCCTGCAAGCCTGGCTCCTCACGCACCTGCTCTGGTTTGCA	AACGCTCATCTCCTGTCCTGGTTCTCGCCCACCATCATCTTCGACAACTGGATCCCACTG	CTGTGGTGCGCCAACATCCTTGGCTATGCCGTCTCCACCTTCGCCATGGTCAAGGGCTAC	TTCTTCCCCACCAGCGCCAGAGACTGCAAATTCACAGGCAATTTCTTTTACAACTACATG	ATGGGCATCGAGTTTAACCCTCGGATCGGGAAGTGGTTTGACTTCAAGCTGTTCTTCAAT	GGGCGCCCCGGGATCGTCGCCTGGACCCTCATCAACCTGTCCTTCGCAGCGAAGCAGCGG	GAGCTCCACAGCCATGTGACCAATGCCATGGTCCTGGTCAACGTCCTGCAGGCCATCTAC	GTGATTGACTTCTTCTGGAACGAAACCTGGTACCTGAAGACCATTGACATCTGCCATGAC	CACTTCGGGTGGTACCTGGGCTGGGGCGACTGTGTCTGGCTGCCTTATCTTTACACGCTG	CAGGGTCTGTACTTGGTGTACCACCCCGTGCAGCTGTCCACCCCGCACGCCGTGGGCGTC	CTGCTGCTGGGCCTGGTGGGCTACTACATCTTCCGGGTGGCCAACCACCAGAAGGACCTG	TTCCGCCGCACGGATGGGCGCTGCCTCATCTGGGGCAGGAAGCCCAAGGTCATCGAGTGC	TCCTACACATCCGCCGACGGGCAGAGGCACCACAGCAAGCTGCTGGTGTCGGGCTTCTGG	GGCGTGGCCCGCCACTTCAACTACGTCGGCGACCTGATGGGCAGCCTGGCCTACTGCCTG	GCCTGTGGCGGTGGCCACCTGCTGCCCTACTTCTACATCATCTACATGGCCATCCTGCTG	ACCCACCGCTGCCTCCGGGACGAGCACCGCTGCGCCAGCAAGTACGGCCGGGACTGGGAG	CGCTACACCGCCGCAGTGCCTTACCGCCTGCTGCCTGGAATCTTCTAA
http://bio2rdf.org/pfam:PF01222
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF01222%3E
7-DHC reductase
7-dehydrocholesterol reductase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9634533
11q13.2-q13.5
DHCR7
DHCR7_HUMAN
map00100	Biosynthesis of steroids
http://www.dbpedia.org/resource/7-Dehydrocholesterol_reductase
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2F7-Dehydrocholesterol_reductase%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AF096305
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAF096305%3E
http://bio2rdf.org/uniprot:Q9UBM7
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ9UBM7%3E
>7-dehydrocholesterol reductase	MAAKSQPNIPKAKSLDGVTNDRTASQGQWGRAWEVDWFSLASVIFLLLFAPFIVYYFIMA	CDQYSCALTGPVVDIVTGHARLSDIWAKTPPITRKAAQLYTLWVTFQVLLYTSLPDFCHK	FLPGYVGGIQEGAVTPAGVVNKYQINGLQAWLLTHLLWFANAHLLSWFSPTIIFDNWIPL	LWCANILGYAVSTFAMVKGYFFPTSARDCKFTGNFFYNYMMGIEFNPRIGKWFDFKLFFN	GRPGIVAWTLINLSFAAKQRELHSHVTNAMVLVNVLQAIYVIDFFWNETWYLKTIDICHD	HFGWYLGWGDCVWLPYLYTLQGLYLVYHPVQLSTPHAVGVLLLGLVGYYIFRVANHQKDL	FRRTDGRCLIWGRKPKVIECSYTSADGQRHHSKLLVSGFWGVARHFNYVGDLMGSLAYCL	ACGGGHLLPYFYIIYMAILLTHRCLRDEHRCASKYGRDWERYTAAVPYRLLPGIF
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9653161
420-440
Putative sterol reductase SR-2
http://www.uniprot.org/uniprot/Q9UBM7
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ9UBM7%3E
266-286
EC 1.3.1.21
331-351
177-197
40-60
cholesterol + NADP+ = cholesta-5,7-dien-3beta-ol + NADPH + H+
endoplasmicReticulumMembrane
Sterol Delta(7)-reductase
http://symbol.bio2rdf.org/symbol:DHCR7
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ADHCR7%3E
http://bio2rdf.org/hgnc:2860
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A2860%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10677299
154-174
Production of cholesterol by reduction of C7-C8 double bond of 7-dehydrocholesterol (7-DHC)
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10995508
AF096305
endoplasmicReticulum
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12949967
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9878250
http://pfam.sanger.ac.uk/family?acc=PF01222
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF01222%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=2860
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D2860%3E
Involved in 7-dehydrocholesterol reductase activity
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9683613
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11175299
RDF Description of 7-dehydrocholesterol reductase
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/39507
_:header12629376271335206345645
RDF Description of Vexol
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/39507
http://www.fda.gov/medwatch/SAFETY/2003/03APR_PI/Vexol_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2003%2F03APR_PI%2FVexol_PI.pdf%3E
rimexolone
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0019348
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000039507&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000039507%26input_query_species%3D9606%3E
http://www.fda.gov/cder/foi/label/2007/020474s019lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2007%2F020474s019lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0042164
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0015403
Vexol
http://www.fda.gov/cder/foi/label/2003/20474slr016_vexol_lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2003%2F20474slr016_vexol_lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0013604
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0344232
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000039507
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000039507%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0314719
VEXOL
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0018681
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3070
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3070%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0151827
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00896
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00896%3E
http://dbpedia.org/resource/Rimexolone
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FRimexolone%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0031350
http://sideeffects.embl.de/drugs/39507
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F39507%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0086543
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0022568
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0010043
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0033774
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0035455
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0085636
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020649
CID0000039507
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01248
_:header19800895071335206346049
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01248
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01248_DB01321
http://data.linkedct.org/resource/intervention/23271
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F23271%3E
http://data.linkedct.org/resource/intervention/29606
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F29606%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/radiation-sensitizingAgents
Practically insoluble (0.025 mg/L)
http://data.linkedct.org/resource/intervention/29523
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F29523%3E
http://data.linkedct.org/resource/intervention/57855
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F57855%3E
http://data.linkedct.org/resource/intervention/52908
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F52908%3E
http://data.linkedct.org/resource/intervention/35727
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35727%3E
http://data.linkedct.org/resource/intervention/38709
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F38709%3E
http://data.linkedct.org/resource/intervention/34042
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F34042%3E
http://data.linkedct.org/resource/intervention/60129
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F60129%3E
http://data.linkedct.org/resource/intervention/29532
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F29532%3E
http://data.linkedct.org/resource/intervention/29489
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F29489%3E
Docetaxel
http://data.linkedct.org/resource/intervention/36094
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F36094%3E
http://bio2rdf.org/cpd:C11231
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC11231%3E
http://data.linkedct.org/resource/intervention/38736
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F38736%3E
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)C2=CC=CC=C2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C3=CC=CC=C3)C(C)=C([C@@H](O)C1=O)C2(C)C
http://data.linkedct.org/resource/intervention/29510
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F29510%3E
http://dbpedia.org/page/Docetaxel
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FDocetaxel%3E
http://data.linkedct.org/resource/intervention/50997
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F50997%3E
http://data.linkedct.org/resource/intervention/27091
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F27091%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2019
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2019%3E
http://data.linkedct.org/resource/intervention/58978
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F58978%3E
http://data.linkedct.org/resource/intervention/41565
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F41565%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/673
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F673%3E
http://data.linkedct.org/resource/intervention/25782
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F25782%3E
http://129.128.185.122/drugbank2/drugs/DB01248/inserts/1683/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB01248%2Finserts%2F1683%2Ffull%3E
http://205.193.93.51/dpdonline/searchRequest.do?din=02177080
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02177080%3E
http://data.linkedct.org/resource/intervention/29516
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F29516%3E
Hepatic. In vitro drug interaction studies revealed that docetaxel is metabolized by the CYP3A4 isoenzyme (1 major, 3 minor metabolites).
http://data.linkedct.org/resource/intervention/35812
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35812%3E
http://data.linkedct.org/resource/intervention/35769
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35769%3E
http://data.linkedct.org/resource/intervention/35759
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35759%3E
PA449383
About 94% protein bound, mainly to a1-acid glycoprotein, albumin, and lipoproteins.
232 oC
http://data.linkedct.org/resource/intervention/38378
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F38378%3E
Taxotere
http://data.linkedct.org/resource/intervention/35795
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35795%3E
http://data.linkedct.org/resource/intervention/56341
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F56341%3E
http://data.linkedct.org/resource/intervention/35782
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35782%3E
http://data.linkedct.org/resource/intervention/39284
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F39284%3E
http://data.linkedct.org/resource/intervention/35788
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35788%3E
http://data.linkedct.org/resource/intervention/23566
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F23566%3E
http://data.linkedct.org/resource/intervention/29495
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F29495%3E
Docetaxel interferes with the normal function of microtubule growth. Whereas drugs like colchicine cause the depolymerization of microtubules in vivo, docetaxel arrests their function by having the opposite effect; it hyper-stabilizes their structure. This destroys the cell's ability to use its cytoskeleton in a flexible manner. Specifically, docetaxel binds to the &beta;-subunit of tubulin. Tubulin is the "building block" of mictotubules, and the binding of docetaxel locks these building blocks in place. The resulting microtubule/docetaxel complex does not have the ability to disassemble. This adversely affects cell function because the shortening and lengthening of microtubules (termed dynamic instability) is necessary for their function as a transportation highway for the cell. Chromosomes, for example, rely upon this property of microtubules during mitosis. Further research has indicated that docetaxel induces programmed cell death (apoptosis) in cancer cells by binding to an apoptosis stopping protein called Bcl-2 (B-cell leukemia 2) and thus arresting its function.
Docetaxel anhydrous
http://data.linkedct.org/resource/intervention/35756
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35756%3E
Docetaxel is a taxoid antineoplastic agent. It promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. In addition, docetaxel induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.
http://data.linkedct.org/resource/intervention/29139
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F29139%3E
http://data.linkedct.org/resource/intervention/39286
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F39286%3E
DB01248
http://data.linkedct.org/resource/intervention/38477
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F38477%3E
Oral LD<sub>50</sub> in rat is >2000 mg/kg. Anticipated complications of overdosage include: bone marrow suppression, peripheral neurotoxicity, and mucositis. In two reports of overdose, one patient received 150 mg/m<sup>2</sup> and the other received 200 mg/m<sup>2</sup> as 1-hour infusions. Both patients experienced severe neutropenia, mild asthenia, cutaneous reactions, and mild paresthesia, and recovered without incident.
http://data.linkedct.org/resource/intervention/35740
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35740%3E
C43H53NO14
http://data.linkedct.org/resource/intervention/24167
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F24167%3E
http://data.linkedct.org/resource/intervention/35802
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35802%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/29
http://data.linkedct.org/resource/intervention/58443
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F58443%3E
http://data.linkedct.org/resource/intervention/26745
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F26745%3E
http://dbpedia.org/resource/Docetaxel
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FDocetaxel%3E
http://data.linkedct.org/resource/intervention/35793
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35793%3E
http://data.linkedct.org/resource/intervention/35775
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35775%3E
http://data.linkedct.org/resource/intervention/38772
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F38772%3E
http://data.linkedct.org/resource/intervention/35764
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35764%3E
aprd00932
http://data.linkedct.org/resource/intervention/35799
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35799%3E
http://data.linkedct.org/resource/intervention/29521
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F29521%3E
1999-12-01	/drugs/1248/fda_labels/476
http://data.linkedct.org/resource/intervention/41523
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F41523%3E
http://data.linkedct.org/resource/intervention/29081
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F29081%3E
http://www.dbpedia.org/resource/Docetaxel
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FDocetaxel%3E
http://129.128.185.122/drugbank2/drugs/DB01248/inserts/2663/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB01248%2Finserts%2F2663%2Ffull%3E
http://data.linkedct.org/resource/intervention/58852
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F58852%3E
http://data.linkedct.org/resource/intervention/35817
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35817%3E
http://data.linkedct.org/resource/intervention/35809
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35809%3E
TXL
http://data.linkedct.org/resource/intervention/23565
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F23565%3E
http://data.linkedct.org/resource/intervention/29420
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F29420%3E
http://data.linkedct.org/resource/intervention/35751
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35751%3E
http://129.128.185.122/drugbank2/drugs/DB01248/inserts/676/full
http://data.linkedct.org/resource/intervention/35736
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35736%3E
http://data.linkedct.org/resource/intervention/38697
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F38697%3E
L01CD02
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2943
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2943%3E
docetaxel
http://data.linkedct.org/resource/intervention/35743
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35743%3E
http://data.linkedct.org/resource/intervention/38726
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F38726%3E
http://data.linkedct.org/resource/intervention/29514
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F29514%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/solutionIntravenous
http://data.linkedct.org/resource/intervention/25972
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F25972%3E
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1/f/h44H
For the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Also used as a single agent in the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Lastly, for use, in combination with prednisone, in the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer.
http://data.linkedct.org/resource/intervention/49949
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F49949%3E
http://data.linkedct.org/resource/intervention/35780
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35780%3E
http://data.linkedct.org/resource/intervention/23562
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F23562%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/273
Docetaxel, Trihydrate
http://data.linkedct.org/resource/intervention/38624
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F38624%3E
http://data.linkedct.org/resource/intervention/33130
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F33130%3E
http://www.drugbank.ca/drugs/DB01248
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01248%3E
http://data.linkedct.org/resource/intervention/26735
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F26735%3E
http://data.linkedct.org/resource/intervention/29599
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F29599%3E
http://data.linkedct.org/resource/intervention/40008
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F40008%3E
http://data.linkedct.org/resource/intervention/29603
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F29603%3E
http://data.linkedct.org/resource/intervention/35734
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35734%3E
Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of 1 mole docetaxel per mole tubulin in microtubules.
http://www.rxlist.com/cgi/generic3/docetaxel.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric3%2Fdocetaxel.htm%3E
/drugs/1248/safety_sheets/927
http://data.linkedct.org/resource/intervention/35797
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35797%3E
http://data.linkedct.org/resource/intervention/26910
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F26910%3E
http://data.linkedct.org/resource/intervention/29148
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F29148%3E
http://data.linkedct.org/resource/intervention/39834
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F39834%3E
http://data.linkedct.org/resource/intervention/59035
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F59035%3E
http://data.linkedct.org/resource/intervention/29526
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F29526%3E
http://data.linkedct.org/resource/intervention/29173
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F29173%3E
http://data.linkedct.org/resource/intervention/29498
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F29498%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/antineoplasticAgents
10:00.00
Dose-dependent. Doses of 70 mg per square meter of body surface area (mg/m 2 ) or higher produce a triphasic elimination profile. With lower doses, assay limitations precluded detection of the terminal elimination phase. Alpha (distribution) 4 minutes. Beta 36 minutes. Gamma (terminal) 11.1 hours.
http://data.linkedct.org/resource/intervention/35758
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35758%3E
http://data.linkedct.org/resource/intervention/35785
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35785%3E
http://data.linkedct.org/resource/intervention/35754
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35754%3E
http://data.linkedct.org/resource/intervention/52902
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F52902%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/antineoplasticAgents,Phytogenic
1.27e-02 mg/mL
http://data.linkedct.org/resource/intervention/28839
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F28839%3E
ZDZOTLJHXYCWBA-ZNTUMJQLDY
http://en.wikipedia.org/wiki/Docetaxel
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FDocetaxel%3E
http://bio2rdf.org/cas:114977-28-5
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A114977-28-5%3E
http://data.linkedct.org/resource/intervention/29482
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F29482%3E
http://data.linkedct.org/resource/intervention/35791
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35791%3E
http://data.linkedct.org/resource/intervention/49947
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F49947%3E
http://data.linkedct.org/resource/intervention/35766
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35766%3E
CC(=O)OC12COC1CC(O)C1(C)C2C(OC(=O)C2=CC=CC=C2)C2(O)CC(OC(=O)C(O)C(NC(=O)OC(C)(C)C)C3=CC=CC=C3)C(C)=C(C(O)C1=O)C2(C)C
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/antimalarials
http://www4.wiwiss.fu-berlin.de/drugbank/resource/enzymes/1
2008-08-26 14:03:42 UTC
http://data.linkedct.org/resource/intervention/29484
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F29484%3E
http://data.linkedct.org/resource/intervention/30575
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F30575%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00199_DB01248
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01173_DB01248
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01248_DB00199
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01248_DB01026
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01248_DB00624
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00624_DB01248
RDF Description of Docetaxel
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00673_DB01248
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01369_DB01248
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01248_DB01420
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01248_DB00683
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01026_DB01248
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01248_DB01369
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01248_DB00673
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01248_DB01173
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00683_DB01248
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Danton_Georges_Jacques_1759-1794
_:header10248294741335206346469
Mon, 23 Apr 2012 18:32:21 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Danton_Georges_Jacques_1759-1794
Danton, Georges Jacques, 1759-1794
RDF Description of Danton, Georges Jacques, 1759-1794
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6691
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/1859
_:header5893547241335206347007
RDF Description of Prostatic acid phosphatase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/1859
http://bio2rdf.org/pdb:1ND6
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1ND6%3E
PPAP_HUMAN
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2395659
http://www.genenames.org/data/hgnc_data.php?hgnc_id=125
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D125%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7951074
map00361	gamma-Hexachlorocyclohexane degradation
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=M97589
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DM97589%3E
>1161 bp	ATGAGAGCTGCACCCCTCCTCCTGGCCAGGGCAGCAAGCCTTAGCCTTGGCTTCTTGTTT	CTGCTTTTTTTCTGGCTAGACCGAAGTGTACTAGCCAAGGAGTTGAAGTTTGTGACTTTG	GTGTTTCGGCATGGAGACCGAAGTCCCATTGACACCTTTCCCACTGACCCCATAAAGGAA	TCCTCATGGCCACAAGGATTTGGCCAACTCACCCAGCTGGGCATGGAGCAGCATTATGAA	CTTGGAGAGTATATAAGAAAGAGATATAGAAAATTCTTGAATGAGTCCTATAAACATGAA	CAGGTTTATATTCGAAGCACAGACGTTGACCGGACTTTGATGAGTGCTATGACAAACCTG	GCAGCCCTGTTTCCCCCAGAAGGTGTCAGCATCTGGAATCCTATCCTACTCTGGCAGCCC	ATCCCGGTGCACACAGTTCCTCTTTCTGAAGATCAGTTGCTATACCTGCCTTTCAGGAAC	TGCCCTCGTTTTCAAGAACTTGAGAGTGAGACTTTGAAATCAGAGGAATTCCAGAAGAGG	CTGCACCCTTATAAGGATTTTATAGCTACCTTGGGAAAACTTTCAGGATTACATGGCCAG	GACCTTTTTGGAATTTGGAGTAAAGTCTACGACCCTTTATATTGTGAGAGTGTTCACAAT	TTCACTTTACCCTCCTGGGCCACTGAGGACACCATGACTAAGTTGAGAGAATTGTCAGAA	TTGTCCCTCCTGTCCCTCTATGGAATTCACAAGCAGAAAGAGAAATCTAGGCTCCAAGGG	GGTGTCCTGGTCAATGAAATCCTCAATCACATGAAGAGAGCAACTCAGATACCAAGCTAC	AAAAAACTTATCATGTATTCTGCGCATGACACTACTGTGAGTGGCCTACAGATGGCGCTA	GATGTTTACAACGGACTCCTTCCTCCCTATGCTTCTTGCCACTTGACGGAATTGTACTTT	GAGAAGGGGGAGTACTTTGTGGAGATGTACTACCGGAATGAGACGCAGCACGAGCCGTAT	CCCCTCATGCTACCTGGCTGCAGCCCCAGCTGTCCTCTGGAGAGGTTTGCTGAGCTGGTT	GGCCCTGTGATCCCTCAAGACTGGTCCACGGAGTGTATGACCACAAACAGCCATCAAGGT	ACTGAGGACAGTACAGATTAG
3q21-q23
http://pfam.sanger.ac.uk/family?acc=PF00328
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00328%3E
a phosphate monoester + H2O = an alcohol + phosphate
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2842184
EC 3.1.3.2
hydrolase activity
http://symbol.bio2rdf.org/symbol:ACPP
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AACPP%3E
ACPP
http://bio2rdf.org/pfam:PF00328
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00328%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2712834
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1375464
phosphoric monoester hydrolase activity
M97589
http://www.pdb.org/pdb/explore/explore.do?structureId=1ND6
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1ND6%3E
phosphoric ester hydrolase activity
>Prostatic acid phosphatase precursor	MRAAPLLLARAASLSLGFLFLLFFWLDRSVLAKELKFVTLVFRHGDRSPIDTFPTDPIKE	SSWPQGFGQLTQLGMEQHYELGEYIRKRYRKFLNESYKHEQVYIRSTDVDRTLMSAMTNL	AALFPPEGVSIWNPILLWQPIPVHTVPLSEDQLLYLPFRNCPRFQELESETLKSEEFQKR	LHPYKDFIATLGKLSGLHGQDLFGIWSKVYDPLYCESVHNFTLPSWATEDTMTKLRELSE	LSLLSLYGIHKQKEKSRLQGGVLVNEILNHMKRATQIPSYKKLIMYSAHDTTVSGLQMAL	DVYNGLLPPYASCHLTELYFEKGEYFVEMYYRNETQHEPYPLMLPGCSPSCPLERFAELV	GPVIPQDWSTECMTTNSHQGTEDSTD
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1989985
Prostatic acid phosphatase precursor
acid phosphatase activity
hydrolase activity, acting on ester bonds
cytoplasmic
Prostatic acid phosphatase
http://bio2rdf.org/hgnc:125
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A125%3E
1-32
A phosphate monoester + H(2)O = an alcohol + phosphate
catalytic activity
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=189613
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D189613%3E
Involved in acid phosphatase activity
http://bio2rdf.org/uniprot:P15309
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP15309%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9804805
http://www.uniprot.org/uniprot/P15309
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP15309%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03965
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03577
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03390
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02944
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/711
_:header8631681401335206347446
Mon, 23 Apr 2012 18:32:22 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/711
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AF061016
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAF061016%3E
http://bio2rdf.org/uniprot:O60701
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AO60701%3E
UDPGDH
UDP-glucose + 2 NAD+ + H2O = UDP-glucuronate + 2 NADH + 2 H+
UDP-GlcDH
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9850599
http://symbol.bio2rdf.org/symbol:UGDH
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AUGDH%3E
generation of precursor metabolites and energy
http://pfam.sanger.ac.uk/family?acc=PF00984
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00984%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3804697
UGDH_HUMAN
http://www.genenames.org/data/hgnc_data.php?hgnc_id=12525
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D12525%3E
cellular metabolism
http://bio2rdf.org/pfam:PF03720
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF03720%3E
UDP-glucose 6-dehydrogenase
http://pfam.sanger.ac.uk/family?acc=PF03721
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF03721%3E
EC 1.1.1.22
Cell wall/membrane/envelope biogenesis
UGDH
http://bio2rdf.org/hgnc:12525
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A12525%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=3127127
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D3127127%3E
electron transport
http://pfam.sanger.ac.uk/family?acc=PF03720
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF03720%3E
metabolism
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1472079
>1485 bp	ATGTTTGAAATTAAGAAGATCTGTTGCATCGGTGCAGGCTATGTTGGAGGACCCACATGT	AGTGTCATTGCTCATATGTGTCCTGAAATCAGGGTAACGGTTGTTGATGTCAATGAATCA	AGAATCAATGCGTGGAATTCTCCTACACTTCCTATTTATGAGCCAGGACTAAAAGAAGTG	GTAGAATCCTGTCGAGGAAAAAATCTTTTTTTTTCTACCAATATTGATGATGCCATCAAA	GAAGCTGATCTTGTATTTATTTCTGTGAATACTCCAACAAAAACCTATGGAATGGGGAAA	GGCCGGGCAGCAGATCTGAAGTATATTGAAGCTTGTGCTAGACGCATTGTGCAAAACTCA	AATGGGTACAAAATTGTGACTGAGAAAAGCACAGTTCCAGTGCGGGCAGCAGAAAGTATC	CGTCGCATATTTGATGCAAACACAAAACCCAACTTGAATTTACAGGTGCTGTCCAACCCT	GAGTTTCTGGCAGAGGGAACAGCCATCAAGGACCTAAAGAACCCAGACAGAGTACTGATT	GGAGGGGATGAAACTCCAGAGGGCCAGAGAGCTGTGCAGGCCCTGTGTGCTGTATATGAG	CACTGGGTTCCCAGAGAAAAGATCCTCACCACTAATACTTGGTCTTCAGAGCTTTCCAAA	CTGGCAGCAAATGCTTTTCTTGCCCAGAGAATAAGCAGCATTAACTCCATAAGTGCTCTG	TGTGAAGCAACAGGAGCTGATGTAGAAGAGGTAGCAACAGCGATTGGAATGGACCAGAGA	ATTGGAAACAAGTTTCTAAAAGCCAGTGTTGGGTTTGGTGGGAGCTGTTTCCAAAAGGAT	GTTCTGAATTTGGTTTATCTCTGTGAGGCTCTGAATTTGCCAGAAGTAGCTCGTTATTGG	CAGCAGGTCATAGACATGAATGACTACCAGAGGAGGAGGTTTGCTTCCCGGATCATAGAT	AGTCTGTTTAATACAGTAACTGATAAGAAGATAGCTATTTTGGGATTTGCATTCAAAAAG	GACACTGGTGATACAAGAGAATCTTCTAGTATATATATTAGCAAATATTTGATGGATGAA	GGTGCACATCTACATATATATGATCCAAAAGTACCTAGGGAACAAATAGTTGTGGATCTT	TCTCATCCAGGTGTTTCAGAGGATGACCAAGTGTCCCGGCTCGTGACCATTTCCAAGGAT	CCATATGAAGCATGTGATGGTGCCCATGCTGTTGTTATTTGCACTGAGTGGGACATGTTT	AAGGAATTGGATTATGAACGCATTCATAAAAAAATGCTAAAGCCAGCCTTTATCTTCGAT	GGACGGCGTGTCCTGGATGGGCTCCACAATGAACTACAAACCATTGGCTTCCAGATTGAA	ACAATTGGCAAAAAGGTGTCTTCAAAGAGAATTCCATATGCTCCTTCTGGTGAAATTCCG	AAGTTTAGTCTTCAAGATCCACCTAACAAGAAACCTAAAGTGTAG
http://www.uniprot.org/uniprot/O60701
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FO60701%3E
http://bio2rdf.org/pfam:PF03721
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF03721%3E
http://bio2rdf.org/pfam:PF00984
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00984%3E
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/gene/UGDH
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fgene%2FUGDH%3E
UDP-Glc dehydrogenase
>UDP-glucose 6-dehydrogenase	MFEIKKICCIGAGYVGGPTCSVIAHMCPEIRVTVVDVNESRINAWNSPTLPIYEPGLKEV	VESCRGKNLFFSTNIDDAIKEADLVFISVNTPTKTYGMGKGRAADLKYIEACARRIVQNS	NGYKIVTEKSTVPVRAAESIRRIFDANTKPNLNLQVLSNPEFLAEGTAIKDLKNPDRVLI	GGDETPEGQRAVQALCAVYEHWVPREKILTTNTWSSELSKLAANAFLAQRISSINSISAL	CEATGADVEEVATAIGMDQRIGNKFLKASVGFGGSCFQKDVLNLVYLCEALNLPEVARYW	QQVIDMNDYQRRRFASRIIDSLFNTVTDKKIAILGFAFKKDTGDTRESSSIYISKYLMDE	GAHLHIYDPKVPREQIVVDLSHPGVSEDDQVSRLVTISKDPYEACDGAHAVVICTEWDMF	KELDYERIHKKMLKPAFIFDGRRVLDGLHNELQTIGFQIETIGKKVSSKRIPYAPSGEIP	KFSLQDPPNKKPKV
AF061016
4p15.1
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9737970
map00040	Pentose and glucuronate interconversions	map00500	Starch and sucrose metabolism	map00520	Nucleotide sugars metabolism
RDF Description of UDP-glucose 6-dehydrogenase
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/3081884
_:header17144074591335206347961
RDF Description of COPAXONE
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0002418
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0003467
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0038362
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0438215
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0014724
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0025222
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0080274
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0006852
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0041976
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0009421
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0027651
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0042345
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0004998
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0038990
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0027769
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0018099
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0011124
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0017574
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0398353
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0018524
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0014591
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020569
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0456909
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0151970
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0038363
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0007642
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0019360
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0085096
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0699893
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0010709
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0016867
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0428977
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0006849
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0032285
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020550
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0231528
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0021116
GLATIRAMER ACETATE
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0023067
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0038454
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0085631
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0023798
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0029134
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0026846
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0011334
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0018621
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0027796
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0028738
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0004238
COPAXONE
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0851578
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0018021
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0013295
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0016204
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0019270
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0012569
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0677481
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0243026
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0024902
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0085669
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0030193
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0017152
http://www.fda.gov/cder/foi/label/2001/20622s15lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2001%2F20622s15lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C1527304
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0002170
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0008031
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0085606
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0036454
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0013144
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0026769
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020443
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0016382
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0004134
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0018800
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0034065
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0009319
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020255
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0302314
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0151825
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0002871
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0013428
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0027720
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0007859
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0004623
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0004604
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0017601
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0085633
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0029925
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0022116
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0033860
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0037763
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0018944
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0564408
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0036830
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0019209
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0010200
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0016059
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0017160
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0025874
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0038002
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0031039
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0003811
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0025209
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0034186
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0151514
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0392699
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0027339
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0019080
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020565
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0030486
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0009806
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0009676
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0003081884&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0003081884%26input_query_species%3D9606%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0085649
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0035078
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0013404
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0878544
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0042571
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0002962
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0031085
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0018965
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0043094
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0036572
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0011603
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0497156
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0085593
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0002622
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0002103
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=ZNpLeFZ5%2F0I=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DZNpLeFZ5%252F0I%3D%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0039231
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0233632
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0025323
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0013395
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0039520
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020676
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0085628
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0003864
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0232726
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0026975
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0040822
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0033377
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0030312
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0042267
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0023890
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0018802
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0026848
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0025289
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0007097
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0037287
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0029443
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0041582
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0267596
http://dbpedia.org/resource/Glatiramer_acetate
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FGlatiramer_acetate%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0151950
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0011551
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0039070
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0004096
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0008350
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0043096
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0003537
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0016199
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0042940
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0149745
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0010692
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0015170
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0018926
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0003862
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0006444
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0017565
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0085624
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0002453
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0024236
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0030252
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0149931
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0000737
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0043037
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020538
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0151315
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0012833
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0006277
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020651
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0575081
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0014743
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0152459
CID0003081884
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0030305
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0029878
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0029927
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0038358
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0015732
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=LUtYbjVxUSM=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DLUtYbjVxUSM%3D%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0008325
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0042798
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0558489
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0678222
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0013595
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1057
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F1057%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0699885
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0015469
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0040264
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0233794
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0851140
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0030554
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0019158
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0028734
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0000833
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0024299
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0013456
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB05259
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB05259%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0038663
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0037199
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0042029
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0011053
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0042024
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0013491
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0011616
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0022650
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0041834
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0032227
http://sideeffects.embl.de/drugs/3081884
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F3081884%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0015230
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0231218
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0003081884
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0003081884%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0013390
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0021400
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0151706
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0917801
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0232257
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0023530
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0684249
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0016034
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0033117
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0004093
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0011630
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0003873
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0151908
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0043352
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Meslier_Jean_1664-1729
_:header17273515811335206348261
Mon, 23 Apr 2012 18:32:23 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Meslier_Jean_1664-1729
Meslier, Jean, 1664-1729
RDF Description of Meslier, Jean, 1664-1729
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17607
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/5769
_:header17560721821335206348793
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/5769
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04810
oxidoreductase activity
heme oxidation
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10409691
http://bio2rdf.org/uniprot:Q54AI1
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ54AI1%3E
Heme oxygenase
AB019621
>Heme oxygenase	MTTATAGLAVELKQSTAQAHEKAEHSTFMSDLLKGRLGVAEFTRLQEQAWLFYTALEQAV	DAVRASGFAESLLDPALNRAEVLARDLDKLNGSSEWRSRITASPAVIDYVNRLEEIRDNV	DGPALVAHHYVRYLGDLSGGQVIARMMQRHYGVDPEALGFYHFEGIAKLKVYKDEYREKL	NNLELSDEQREHLLKEATDAFVFNHQVFADLGKGL
Q54AI1_CORDI
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AB019621
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAB019621%3E
http://www.uniprot.org/uniprot/Q54AI1
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ54AI1%3E
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen
porphyrin metabolism
heme oxygenase (decyclizing) activity
http://www.pdb.org/pdb/explore/explore.do?structureId=1V8X
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1V8X%3E
http://bio2rdf.org/pdb:1V8X
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1V8X%3E
heterocycle metabolism
>648 bp	ATGACCACTGCAACCGCAGGCCTCGCTGTCGAACTCAAGCAGTCCACTGCGCAAGCCCAC	GAAAAAGCTGAGCACTCCACCTTCATGAGCGACCTTTTAAAAGGTCGCTTGGGGGTAGCG	GAATTCACTCGTCTGCAGGAGCAAGCATGGTTGTTCTACACAGCGCTCGAGCAGGCAGTA	GATGCCGTACGTGCCTCCGGATTTGCGGAGTCCCTTCTAGATCCCGCTCTCAACCGTGCT	GAAGTACTGGCTCGCGACCTAGACAAGCTAAACGGATCCAGTGAGTGGCGATCGCGTATC	ACAGCATCGCCAGCTGTTATCGATTACGTTAACCGTCTTGAAGAAATCCGCGACAATGTT	GACGGGCCCGCACTAGTTGCTCACCACTACGTACGCTACCTCGGTGACCTCTCGGGTGGC	CAGGTTATCGCACGTATGATGCAGCGCCACTACGGCGTTGATCCTGAAGCCCTAGGTTTC	TACCACTTCGAAGGGATCGCCAAGCTCAAGGTATACAAGGATGAGTACCGTGAAAAGCTC	AACAACCTAGAGCTCAGCGATGAACAGCGTGAGCACCTTCTTAAGGAAGCAACCGATGCT	TTCGTTTTCAACCACCAAGTGTTCGCAGATTTGGGTAAAGGGCTGTAA
heme metabolism
Involved in heme oxygenase (decyclizing) activity
http://bio2rdf.org/pfam:PF01126
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF01126%3E
http://pfam.sanger.ac.uk/family?acc=PF01126
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF01126%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04809
RDF Description of Heme oxygenase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04811
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01570
_:header4356175251335206349224
Mon, 23 Apr 2012 18:32:24 GMT
RDF Description of Beta-hydroxy-3-methylfentanyl
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01570
FRPRNNRJTCONEC-UHFFFAOYAR
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugtype/illicit
2007-07-31 13:10:35 UTC
http://bio2rdf.org/cas:78995-14-9
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A78995-14-9%3E
Beta-hydroxy-3-methylfentanyl
N-[1-(2-hydroxy-2-phenylethyl)-3-methylpiperidin-4-yl]-N-phenylpropanamide
CCC(=O)N(C1CCN(CC1C)CC(O)C1=CC=CC=C1)C1=CC=CC=C1
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/analgesics
C23H30N2O2
InChI=1/C23H30N2O2/c1-3-23(27)25(20-12-8-5-9-13-20)21-14-15-24(16-18(21)2)17-22(26)19-10-6-4-7-11-19/h4-13,18,21-22,26H,3,14-17H2,1-2H3
8.71e-02 mg/mL
http://www.drugbank.ca/drugs/DB01570
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01570%3E
CCC(=O)N([C@@H]1CCN(C[C@H]1C)C[C@@H](O)C1=CC=CC=C1)C1=CC=CC=C1
2008-08-26 14:59:41 UTC
DB01570
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Bury_J_B_(John_Bagnell)_1861-1927
_:header3833699931335206349585
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Bury_J_B_(John_Bagnell)_1861-1927
Bury, J. B. (John Bagnell), 1861-1927
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext4557
RDF Description of Bury, J. B. (John Bagnell), 1861-1927
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext10684
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/3624
_:header13190031461335206350112
RDF Description of Protein kinase C delta type
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3624
transferase activity, transferring phosphorus-containing groups
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9748166
cytoplasm.Membrane
http://bio2rdf.org/pfam:PF00130
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00130%3E
nucleotide binding
purine nucleotide binding
intracellular signaling cascade
http://bio2rdf.org/pfam:PF00433
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00433%3E
nPKC-delta
http://bio2rdf.org/uniprot:P28867
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP28867%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1765103
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7781068
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11558579
>2025 bp	ATGGCACCCTTCCTGCGCATCTCCTTCAATTCCTATGAGCTGGGCTCCCTGCAAGTTGAG	GACGAAGCAAGCCAGCCTTTCTGTGCTGTGAAGATGAAGGAGGCACTCAGCACAGAGCGA	GGGAAGACACTGGTACAGAAGAAGCCCACCATGTATCCTGAGTGGAAGACAACGTTCGAC	GCCCACATCTATGAAGGCCGTGTTATCCAGATTGTGCTGATGCGGGCAGCTGAAGACCCC	GTGTCTGAGGTCACGGTGGGCGTGTCAGTACTGGCTGAGCGCTGCAAGAAGAACAACGGC	AAGGCTGAGTTCTGGCTGGATCTGCAGCCTCAGGCCAAGGTGCTGATGTGTGTGCAGTAT	TTCCTGGAGGATGGGGATTGCAAACAGTCTATGCGTAGTGAGGAGGAGGCAAAGTTTCCA	ACCATGAACCGTCGTGGAGCCATTAAACAGGCCAAGATCCACTACATCAAGAACCACGAG	TTTATCGCCACCTTCTTCGGGCAGCCCACCTTCTGTTCTGTGTGCAAAGAGTTTGTCTGG	GGCCTCAACAAGCAAGGCTACAAATGCAGGCAATGCAACGCTGCCATCCACAAGAAATGC	ATTGACAAGATTATCGGCCGCTGCACTGGCACTGCCACCAATAGCCGGGACACCATCTTC	CAGAAAGAACGCTTCAACATCGACATGCCTCACCGATTCAAGGTTTATAACTACATGAGC	CCCACCTTCTGTGACCACTGTGGCAGTTTGCTCTGGGGACTGGTGAAGCAGGGATTAAAG	TGTGAAGATTGTGGCATGAATGTGCACCACAAATGCCGGGAGAAGGTGGCCAACCTGTGT	GGTATCAACCAAAAGCTCTTGGCTGAGGCCTTGAACCAAGTGACCCAGAGATCTTCCCGG	AAGCTGGACACAACAGAGTCTGTCGGAATATACCAGGGATTTGAGAAGAAGCCAGATGTC	TCTGGGAGTGACATCCTAGACAACAACTGGACCTATGGCAAGATCTGGGTGGGGAGCACC	CGGTGCACCCTTGAGAACTTCACCTTCCAAAAAGTACTTGGCAAAGGCAGCTTTGGCAAG	GTGCTGCTGGCAGAGCTGAAGGGCAAAGACAAGTACTTTGCAATCAAGTGTCTGAAGAAG	GACGTGGTGTTGATTGACGATGATGTAGAGTGTACCATGGTGGAGAAGCGGGTGCTGGCG	CTCGCCTGGGAGAGTCCCTTCCTCACCCACCTCATCTGTACCTTCCAGACCAAGGACCAC	CTGTTCTTCGTGATGGAGTTTCTCAATGGGGGTGACCTGATGTTCCACATTCAGGACAAA	GGCCGCTTCGAACTCTACCGGGCTACGTTTTATGCAGCTGAGATCATCTGCGGACTGCAG	TTTCTACACAGCAAAGGCATTATTTACAGGGACCTCAAGCTGGACAATGTGATGCTAGAC	AGGGACGGCCACATCAAGATCGCTGACTTTGGGATGTGCAAAGAGAATATATTTGGGGAG	GACCGCCCCAGCACATTCTGCGGCACTCCTGACTACTCCGCCCCTGAGATCCTGCAGGGC	CTGAAGTACTCCTTCTCGGTGGACTGGTGGTCTTTCGGGGTCCTCCTGTACGAAATGCTC	ATCGGCCAGTCCCCCTTCCACGGCGACGATGAGGACGAGCTCTTCGAGTCCATCCGGGTG	GACACACCACACTATCCCCGTTGGATCACCAAGGAATCCAAGGACATCATGGAGAAGCTA	TTCGAGAGGGACCCTGACAAGAGGCTGGGAGTAACAGGAAACATCAGGATTCACCCCTTT	TTCAAGACTATCAACTGGTCCCTCCTGGAGAAGCGGAAGGTGGAGCCGCCCTTTAAGCCC	AAAGTGAAATCCCCTTCAGACTACAGCAACTTTGACCCAGAGTTCCTGAATGAGAAACCT	CAGCTTTCCTTCAGTGACAAGAACCTCATCGACTCTATGGACCAGGAAGCCTTCCATGGC	TTCTCCTTTGTGAATCCCAAGTTTGAGCAATTCCTGGACATTTAA
protein modification
KPCD_MOUSE
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=200381
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D200381%3E
ATP + a protein = ADP + a phosphoprotein
http://pfam.sanger.ac.uk/family?acc=PF00130
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00130%3E
Protein kinase C delta type
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1868068
biopolymer metabolism
protein kinase activity
cell communication
kinase activity
EC 2.7.11.13
peripheralMembraneProtein(bySimilarity)
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11976686
M69042
biopolymer modification
This is calcium-independent, phospholipid-dependent, serine- and threonine-specific enzyme. PKC is activated by diacylglycerol which in turn phosphorylates a range of cellular proteins. PKC also serves as the receptor for phorbol esters, a class of tumor promoters. May play a role in antigen-dependent control of B-cell function
protein serine/threonine kinase activity
http://www.uniprot.org/uniprot/P28867
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP28867%3E
Prkcd
http://bio2rdf.org/pfam:PF00069
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00069%3E
Involved in protein serine/threonine kinase activity
macromolecule metabolism
>Protein kinase C delta type	MAPFLRISFNSYELGSLQVEDEASQPFCAVKMKEALSTERGKTLVQKKPTMYPEWKTTFD	AHIYEGRVIQIVLMRAAEDPVSEVTVGVSVLAERCKKNNGKAEFWLDLQPQAKVLMCVQY	FLEDGDCKQSMRSEEEAKFPTMNRRGAIKQAKIHYIKNHEFIATFFGQPTFCSVCKEFVW	GLNKQGYKCRQCNAAIHKKCIDKIIGRCTGTATNSRDTIFQKERFNIDMPHRFKVYNYMS	PTFCDHCGSLLWGLVKQGLKCEDCGMNVHHKCREKVANLCGINQKLLAEALNQVTQRSSR	KLDTTESVGIYQGFEKKPEVSGSDILDNNGTYGKIWEGSTRCTLENFTFQKVLGKGSFGK	VLLAELKGKDKYFAIKCLKKDVVLIDDDVECTMVEKRVLALAWESPFLTHLICTFQTKDH	LFFVMEFLNGGDLMFHIQDKGRFELYRATFYAAEIICGLQFLHSKGIIYRDLKLDNVMLD	RDGHIKIADFGMCKENIFGEGRASTFCGTPDYIAPEILQGLKYSFSVDWWSFGVLLYEML	IGQSPFHGDDEDELFESIRVDTPHYPRWITKESKDIMEKLFERDPDKRLGVTGNIRIHPF	FKTINWSLLEKRKVEPPFKPKVKSPSDYSNFDPEFLNEKPQLSFSDKNLIDSMDQEAFHG	FSFVNPKFEQFLDI
adenyl nucleotide binding
http://pfam.sanger.ac.uk/family?acc=PF00433
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00433%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=M69042
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DM69042%3E
protein amino acid phosphorylation
transferase activity
signal transduction
ATP binding
http://pfam.sanger.ac.uk/family?acc=PF00069
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00069%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04376
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/2574
_:header6057395301335206350442
Mon, 23 Apr 2012 18:32:25 GMT
RDF Description of Hemophilia A
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2574
http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=306700
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fdispomim.cgi%3Fid%3D306700%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/HEMA
Hemophilia A
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/F8C
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/502
http://data.linkedct.org/resource/condition/5816
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fcondition%2F5816%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/F8
http://www4.wiwiss.fu-berlin.de/diseasome/resource/chromosomalLocation/Xq28
http://bio2rdf.org/omim:306700
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fomim%3A306700%3E
http://www.dbpedia.org/resource/Haemophilia_A
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FHaemophilia_A%3E
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0037199
_:header11919861441335206350964
http://sideeffects.embl.de/se/C0037199
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0037199%3E
Sinusitis
C0037199
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4075
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5496
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/150311
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/444033
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4513
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/60147
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3121
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5481350
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/60879
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2267
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2978
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/60877
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5311027
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3241
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/130881
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2802
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5035
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/60865
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2462
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2269
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/160051
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2675
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4674
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4920
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4659568
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5155
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2769
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4236
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4201
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5721
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2092
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5625
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5245
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4451
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2609
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3325
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5282226
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/50294
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5064
RDF Description of Sinusitis
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/34312
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5040
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2435
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/62959
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5311297
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5718
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5291
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2583
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2308
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4603
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/214
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/54374
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3016
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3261
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2713
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/60871
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3414
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/64147
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/62819
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4475485
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/9571074
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/123620
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3002190
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4594
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2487
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3899
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/14888
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5726
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4449
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/54786
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4200
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2083
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5665
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2676
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3702
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4542
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/74989
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/6447131
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4173
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/56339
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5394
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5152
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5512
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2955
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/62924
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2658
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/942
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5514
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2678
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3348
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/60787
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4739
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3161
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2478
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/40976
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/96312
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3379
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5636
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3381
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2786
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4196
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3793
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/54841
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/60937
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/60613
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/54547
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4634
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/197712
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3510
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5487301
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4158
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/1775
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/148211
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3219
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/57537
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/508230
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/59708
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3746
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/444013
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5401
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/85
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/72054
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4635
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/CBFB
_:header2413991561335206351703
Mon, 23 Apr 2012 18:32:26 GMT
RDF Description of CBFB
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/CBFB
http://symbol.bio2rdf.org/symbol:CBFB
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ACBFB%3E
CBFB
http://www.dbpedia.org/resource/CBFB
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FCBFB%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/791
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3274
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/3219
_:header15973434481335206352227
Mon, 23 Apr 2012 18:32:27 GMT
RDF Description of Peptidyl-glycine alpha-amidating monooxygenase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3219
http://bio2rdf.org/pfam:PF01082
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF01082%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=2934942
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D2934942%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2911604
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/gene/PAM
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fgene%2FPAM%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1448112
http://pfam.sanger.ac.uk/family?acc=PF01082
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF01082%3E
867-890
1-25
Peptidyl-glycine alpha-amidating monooxygenase precursor
copper ion binding
monooxygenase activity
U52650
PHM
>Peptidyl-glycine alpha-amidating monooxygenase precursor	MAGRARSGLLLLLLGLLALQSSCLAFRSPLSVFKRFKETTRSFSNECLGTIGPVTPLDAS	DFALDIRMPGVTPKESDTYFCMSMRLPVDEEAFVIDFKPRASMDTVHHMLLFGCNMPSST	GSYWFCDEGTCTDKANILYAWARNAPPTRLPKGVGFRVGGETGSKYFVLQVHYGDISAFR	DNHKDCSGVSVHLTRVPQPLIAGMYLMMSVDTVIPPGEKVVNADISCQYKMYPMHVFAYR	VHTHHLGKVVSGYRVRNGQWTLIGRQNPQLPQAFYPVEHPVDVTFGDILAARCVFTGEGR	TEATHIGGTSSDEMCNLYIMYYMEAKYALSFMTCTKNVAPDMFRTIPAEANIPIPVKPDM	VMMHGHHKEAENKEKSALMQQPKQGEEEVLEQGDFYSLLSKLLGEREDVHVHKYNPTEKT	ESGSDLVAEIANVVQKKDLGRSDAREGAEHEEWGNAILVRDRIHRFHQLESTLRPAESRA	FSFQQPGEGPWEPEPSGDFHVEEELDWPGVYLLPGQVSGVALDSKNNLVIFHRGDHVWDG	NSFDSKFVYQQRGLGPIEEDTILVIDPNNAEILQSSGKNLFYLPHGLSIDTDGNYWVTDV	ALHQVFKLDPHSKEGPLLILGRSMQPGSDQNHFCQPTDVAVEPSTGAVFVSDGYCNSRIV	QFSPSGKFVTQWGEESSGSSPRPGQFSVPHSLALVPHLDQLCVADRENGRIQCFKTDTKE	FVREIKHASFGRNVFAISYIPGFLFAVNGKPYFGDQEPVQGFVMNFSSGEIIDVFKPVRK	HFDMPHDIVASEDGTVYIGDAHTNTVWKFTLTEKMEHRSVKKAGIEVQEIKEAEAVVEPK	VENKPTSSELQKMQEKQKLSTEPGSGVSVVLITTLLVIPVLVLLAIVMFIRWKKSRAFGD	HDRKLESSSGRVLGRFRGKGSGGLNLGNFFASRKGYSRKGFDRVSTEGSDQEKDEDDGTE	SEEEYSAPLPKPAPSS
http://bio2rdf.org/pfam:PF03712
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF03712%3E
Peptidyl-glycine alpha-amidating monooxygenase
http://pfam.sanger.ac.uk/family?acc=PF03712
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF03712%3E
Pam
http://www.uniprot.org/uniprot/P14925
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP14925%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9360928
http://www.pdb.org/pdb/explore/explore.do?structureId=1SDW
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1SDW%3E
AMD_RAT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1740449
transition metal ion binding
http://pfam.sanger.ac.uk/family?acc=PF01436
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF01436%3E
http://bio2rdf.org/pfam:PF01436
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF01436%3E
http://bio2rdf.org/uniprot:P14925
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP14925%3E
PAM
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2211657
Bifunctional enzyme that catalyzes 2 sequencial steps in C-terminal alpha-amidation of peptides. The monooxygenase part produces an unstable peptidyl(2-hydroxyglycine) intermediate that is dismutated to glyoxylate and the corresponding desglycine peptide amide by the lyase part. C-terminal amidation of peptides such as neuropeptides is essential for full biological activity
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1988445
note=secretoryGranules
>2931 bp	ATGGCCGGACGCGCCCGCAGCGGTCTGCTACTGCTGCTGCTGGGGCTGCTCGCCCTGCAG	AGCAGCTGCCTGGCCTTCAGAAGCCCACTTTCTGTCTTTAAGAGGTTTAAAGAAACTACC	AGATCATTTTCCAATGAATGCCTTGGTACCATTGGACCAGTCACCCCTCTTGATGCATCA	GATTTTGCGCTGGATATTCGCATGCCTGGGGTTACACCTAAAGAGTCTGACACATACTTC	TGCATGTCCATGCGTCTGCCTGTGGATGAGGAAGCCTTCGTGATTGACTTCAAGCCTCGT	GCCAGCATGGATACTGTCCACCATATGCTGCTGTTTGGATGCAATATGCCCTCGTCCACT	GGAAGTTACTGGTTTTGTGATGAAGGAACCTGTACAGATAAAGCCAATATTCTATATGCC	TGGGCAAGGAATGCTCCCCCCACCCGGCTCCCGAAAGGTGTTGGATTCAGAGTTGGAGGA	GAAACTGGAAGCAAATACTTCGTCCTTCAAGTTCACTATGGCGATATCAGTGCTTTTCGA	GATAATCACAAAGACTGCTCTGGCGTGTCCGTACATCTCACACGTGTGCCCCAGCCTTTA	ATTGCGGGCATGTACCTTATGATGTCTGTTGACACTGTCATACCACCAGGAGAGAAAGTA	GTGAATGCTGACATTTCGTGCCAATACAAAATGTATCCAATGCATGTGTTTGCCTACAGA	GTCCACACTCACCATTTAGGTAAGGTGGTGAGCGGATACAGAGTAAGAAACGGACAGTGG	ACACTGATTGGACGCCAGAACCCCCAGCTGCCACAGGCTTTCTACCCTGTGGAACACCCC	GTTGATGTTACTTTTGGTGATATACTGGCAGCCAGATGTGTGTTCACTGGTGAAGGGAGG	ACAGAGGCCACCCACATCGGCGGCACTTCTAGTGACGAAATGTGTAACCTGTACATCATG	TATTACATGGAAGCCAAATATGCACTTTCCTTCATGACCTGTACAAAGAACGTGGCTCCA	GATATGTTCAGAACTATCCCAGCAGAGGCCAATATCCCAATTCCTGTCAAACCGGACATG	GTTATGATGCACGGGCATCACAAAGAAGCAGAAAACAAAGAAAAGAGTGCTTTAATGCAG	CAGCCAAAACAGGGAGAGGAAGAAGTATTAGAGCAGGGTGATTTCTATTCACTGCTTTCC	AAGCTGCTAGGAGAAAGGGAAGATGTTCATGTGCACAAGTATAATCCTACAGAAAAGACA	GAATCTGGGTCAGACCTGGTAGCTGAGATTGCAAACGTGGTCCAGAAAAAGGACCTTGGT	CGGTCTGACGCCAGAGAAGGTGCAGAGCATGAGGAATGGGGTAATGCTATCCTAGTCAGA	GACAGGATCCACAGATTCCACCAGCTAGAGTCAACTCTGAGGCCAGCTGAGAGCAGAGCT	TTCTCGTTCCAGCAGCCTGGCGAAGGCCCTTGGGAACCAGAACCCTCAGGAGATTTCCAT	GTGGAAGAAGAACTGGACTGGCCTGGAGTGTACTTGTTACCAGGCCAGGTTTCTGGGGTG	GCCCTGGATTCTAAGAATAACCTAGTGATTTTCCACAGAGGTGACCATGTTTGGGATGGA	AACTCTTTTGACAGCAAGTTTGTTTACCAGCAAAGAGGTCTTGGGCCAATTGAAGAAGAC	ACCATCCTGGTCATTGACCCAAATAATGCTGAAATCCTCCAGTCCAGTGGCAAGAACCTG	TTTTATTTACCACACGGCTTGAGCATAGATACAGATGGAAATTATTGGGTCACAGATGTG	GCTCTCCACCAGGTGTTCAAATTGGACCCGCATAGCAAAGAAGGCCCTCTCTTAATTCTG	GGAAGGAGCATGCAACCTGGGAGTGACCAAAATCATTTCTGCCAGCCCACCGATGTGGCT	GTGGAGCCCAGTACTGGAGCTGTCTTCGTGTCAGACGGTTACTGTAACAGTCGGATTGTG	CAGTTTTCACCAAGCGGAAAGTTCGTCACCCAGTGGGGAGAAGAGTCCTCTGGAAGCAGT	CCTAGGCCAGGCCAGTTCAGTGTTCCTCACAGTTTGGCCCTTGTGCCTCATTTGGACCAG	TTGTGTGTGGCAGACAGGGAAAATGGCCGAATCCAATGCTTCAAAACTGACACCAAAGAA	TTTGTGAGAGAGATTAAGCACGCATCATTTGGAAGGAATGTCTTTGCCATTTCATATATA	CCAGGTTTCCTCTTTGCCGTAAACGGGAAGCCTTACTTTGGAGACCAAGAGCCCGTGCAA	GGATTTGTGATGAACTTTTCCAGTGGGGAAATTATAGACGTCTTCAAGCCAGTACGCAAG	CACTTCGACATGCCTCATGATATTGTGGCTTCTGAAGATGGGACTGTGTACATTGGAGAC	GCACACACAAACACCGTGTGGAAGTTCACCCTGACTGAAAAAATGGAGCATCGGTCAGTT	AAAAAGGCTGGCATTGAAGTCCAGGAAATCAAAGAAGCCGAGGCAGTTGTTGAACCCAAA	GTGGAGAACAAACCCACCTCCTCAGAATTGCAGAAGATGCAAGAGAAACAGAAACTGAGC	ACAGAGCCCGGCTCGGGAGTGTCCGTGGTTCTCATTACAACCCTTCTGGTTATTCCTGTG	CTGGTCCTGCTGGCCATTGTCATGTTTATTCGGTGGAAAAAATCAAGGGCCTTTGGAGAT	CATGACCGCAAGCTCGAGTCAAGTTCTGGAAGAGTCCTGGGAAGATTCCGAGGAAAGGGA	AGCGGCGGCTTAAATCTGGGAAATTTCTTTGCAAGTCGAAAAGGCTACAGCAGAAAAGGG	TTTGACCGAGTGAGCACAGAGGGGAGTGACCAAGAGAAAGATGAGGACGACGGAACTGAG	TCTGAAGAGGAGTACTCGGCCCCGCTGCCCAAGCCTGCACCTTCCTCCTGA
ion binding
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2401356
Peptidyl-alpha-hydroxyglycine alpha-amidating lyase
peptide metabolism
peptidylglycine monooxygenase activity
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2337358
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12369828
peptidylglycine + ascorbate + O2 = peptidyl(2-hydroxyglycine) + dehydroascorbate + H2O
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced ascorbate as one donor, and incorporation of one atom of oxygen
http://bio2rdf.org/pdb:1SDW
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1SDW%3E
EC 4.3.2.5
cation binding
EC 1.14.17.3
Involved in monooxygenase activity
Peptidylamidoglycolate lyase
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=U52650
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DU52650%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04150
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02598
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/4015
_:header8617183511335206352718
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4015
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00141
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9722550
http://bio2rdf.org/hgnc:17378
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A17378%3E
golgiApparatus
http://symbol.bio2rdf.org/symbol:NAGPA
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ANAGPA%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=6425040
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D6425040%3E
http://www.uniprot.org/uniprot/Q9UK23
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ9UK23%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17927214
N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase
16p13.3
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8294420
>N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase	MATSTGRWLLLRLALFGFLWEASGGLDSGASRDDDLLLPYPRARARLPRDCTRVRAGNRE	HESWPPPPATPGAGGLAVRTFVSHFRDRAVAGHLTRAVEPLRTFSVLEPGGPGGCAARRR	ATVEETARAADCRVAQNGGFFRMNSGECLGNVVSDERRVSSSGGLQNAQFGIRRDGTLVT	GYLSEEEVLDTENPFVQLLSGVVWLIRNGSIYINESQATECDETQETGSFSKFVNVISAR	TAIGHDRKGQLVLFHADGHTEQRGINLWEMAEFLLKQDVVNAINLDGGGSATFVLNGTLA	SYPSDHCQDNMWRCPRQVSTVVCVHEPRCQPPDCHGHGTCVDGHCQCTGHFWRGPGCDEL	DCGPSNCSQHGLCTETGCRCDAGWTGSNCSEECPLGWHGPGCQRRCKCEHHCPCDPKTGN	CSVSRVKQCLQPPEATLRAGELSFFTRTAWLALTLALAFLLLISIAANLSLLLSRAERNR	RLHGDYAYHPLQEMNGEPLAAEKEQPGGAHNPFKD
NAGPA
http://www.genenames.org/data/hgnc_data.php?hgnc_id=17378
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D17378%3E
NAGPA_HUMAN
449-469
>1548 bp	ATGGCGACCTCCACGGGTCGCTGGCTTCTCCTCCGGCTTGCACTATTCGGCTTCCTCTGG	GAAGCGTCCGGCGGCCTCGACTCGGGGGCCTCCCGCGACGACGACTTGCTACTGCCCTAT	CCACGCGCGCGCGCGCGCCTCCCCCGGGACTGCACACGGGTGCGCGCCGGCAACCGCGAG	CACGAGAGTTGGCCTCCGCCTCCCGCGACTCCCGGCGCCGGCGGTCTGGCCGTGCGCACC	TTCGTGTCGCACTTCAGGGACCGCGCGGTGGCCGGCCACCTGACGCGGGCCGTTGAGCCC	CTGCGCACCTTCTCGGTGCTGGAGCCCGGTGGACCCGGCGGCTGCGCGGCGAGACGACGC	GCCACCGTGGAGGAGACGGCGCGGGCGGCCGACTGCCGTGTCGCCCAGAACGGCGGCTTC	TTCCGCATGAACTCGGGCGAGTGCCTGGGGAACGTGGTGAGCGACGAGCGGCGGGTGAGC	AGCTCCGGGGGGCTGCAGAACGCGCAGTTCGGGATCCGCCGCGACGGGACCCTGGTCACC	GGGTACCTGTCTGAGGAGGAGGTGCTGGACACTGAGAACCCATTTGTGCAGCTGCTGAGT	GGGGTCGTGTGGCTGATTCGTAATGGAAGCATCTACATCAACGAGAGCCAAGCCACAGAG	TGTGACGAGACACAGGAGACAGGTTCCTTTAGCAAATTTGTGAATGTGATATCAGCCAGG	ACGGCCATTGGCCACGACCGGAAAGGGCAGCTGGTGCTCTTTCATGCAGACGGCCATACG	GAGCAGCGTGGCATCAACCTGTGGGAAATGGCGGAGTTCCTGCTGAAACAGGACGTGGTC	AACGCCATCAACCTGGATGGGGGTGGCTCTGCCACCTTTGTGCTCAACGGGACCTTGGCC	AGTTACCCGTCAGATCACTGCCAGGACAACATGTGGCGCTGTCCCCGCCAAGTGTCCACC	GTGGTGTGTGTGCACGAACCCCGCTGCCAGCCGCCTGACTGCCACGGCCACGGGACCTGC	GTGGACGGGCACTGCCAATGCACCGGGCACTTCTGGCGGGGTCCCGGCTGTGATGAGCTG	GACTGTGGCCCCTCTAACTGCAGCCAGCACGGACTGTGCACGGAGACCGGCTGCCGCTGT	GATGCCGGATGGACCGGGTCCAACTGCAGTGAAGAGTGTCCCCTTGGCTGGCATGGGCCG	GGCTGCCAGAGGCGTTGTAAGTGTGAGCACCATTGTCCCTGTGACCCCAAGACTGGCAAC	TGCAGCGTCTCCAGAGTAAAGCAGTGTCTCCAGCCACCTGAAGCCACCCTGAGGGCGGGA	GAACTCTCCTTTTTCACCAGGACCGCCTGGCTAGCCCTCACCCTGGCGCTGGCCTTCCTC	CTGCTGATCAGCATTGCAGCAAACCTGTCCTTGCTCCTGTCCAGAGCAGAGAGGAACCGG	CGCCTGCATGGGGACTATGCATACCACCCGCTGCAGGAGATGAACGGGGAGCCTCTGGCC	GCAGAGAAGGAGCAGCCAGGGGGCGCCCACAACCCCTTCAAGGACTGA
http://pfam.sanger.ac.uk/family?acc=PF00008
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00008%3E
Catalyzes the second step in the formation of the mannose 6-phosphate targeting signal on lysosomal enzyme oligosaccharides by removing GlcNAc residues from GlcNAc-alpha-P- mannose moieties, which are formed in the first step
glycoprotein N-acetyl-D-glucosaminyl-phospho-D-mannose + H2O = N-acetyl-D-glucosamine + glycoprotein phospho-D-mannose
http://bio2rdf.org/pfam:PF00008
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00008%3E
http://pfam.sanger.ac.uk/family?acc=PF07974
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF07974%3E
http://bio2rdf.org/uniprot:Q9UK23
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ9UK23%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10551838
1-24
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AF187072
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAF187072%3E
http://bio2rdf.org/pfam:PF07974
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF07974%3E
AF187072
N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase precursor
EC 3.1.4.45
Mannose 6- phosphate-uncovering enzyme
Phosphodiester alpha-GlcNAcase
RDF Description of N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/3134
_:header5360440751335206353047
Mon, 23 Apr 2012 18:32:28 GMT
RDF Description of Mesothelioma
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3134
Mesothelioma
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/BCL10
http://data.linkedct.org/resource/condition/7985
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fcondition%2F7985%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/chromosomalLocation/1p22
http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=603517
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fdispomim.cgi%3Fid%3D603517%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseaseClass/Cancer
http://bio2rdf.org/omim:603517
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fomim%3A603517%3E
http://www.dbpedia.org/resource/Mesothelioma
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FMesothelioma%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/750
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/DCC
_:header11262209111335206353471
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/DCC
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/254
http://symbol.bio2rdf.org/symbol:DCC
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ADCC%3E
DCC
http://www.dbpedia.org/resource/Deleted_in_Colorectal_Cancer
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FDeleted_in_Colorectal_Cancer%3E
RDF Description of DCC
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1935
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/3938
_:header18779559321335206353996
RDF Description of Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3938
endoplasmic reticulum
http://www.uniprot.org/uniprot/O60568
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FO60568%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10686427
Forms hydroxylysine residues in -Xaa-Lys-Gly- sequences in collagens. These hydroxylysines serve as sites of attachment for carbohydrate units and are essential for the stability of the intermolecular collagen cross-links
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AF046889
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAF046889%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12853948
PLOD3
AF046889
http://bio2rdf.org/hgnc:9083
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A9083%3E
>Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3	MTSSGPGPRFLLLLPLLLPPAASASDRPRGRDPVNPEKLLVITVATAETEGYLRFLRSAE	FFNYTVRTLGLGEEWRGGDVARTVGGGQKVRWLKKEMEKYADREDMIIMFVDSYDVILAG	SPTELLKKFVQSGSRLLFSAESFCWPEWGLAEQYPEVGTGKRFLNSGGFIGFATTIHQIV	RQWKYKDDDDDQLFYTRLYLDPGLREKLSLNLDHKSRIFQNLNGALDEVVLKFDRNRVRI	RNVAYDTLPIVVHGNGPTKLQLNYLGNYVPNGWTPEGGCGFCNQDRRTLPGGQPPPRVFL	AVFVEQPTPFLPRFLQRLLLLDYPPDRVTLFLHNNEVFHEPHIADSWPQLQDHFSAVKLV	GPEEALSPGEARDMAMDLCRQDPECEFYFSLDADAVLTNLQTLRILIEENRKVIAPMLSR	HGKLWSNFWGALSPDEYYARSEDYVELVQRKRVGVWNVPYISQAYVIRGDTLRMELPQRD	VFSGSDTDPDMAFCKSFRDKGIFLHLSNQHEFGRLLATSRYDTEHLHPDLWQIFDNPVDW	KEQYIHENYSRALEGEGIVEQPCPDVYWFPLLSEQMCDELVAEMEHYGQWSGGRHEDSRL	AGGYENVPTVDIHMKQVGYEDQWLQLLRTYVGPMTESLFPGYHTKARAVMNFVVRYRPDE	QPSLRPHHDSSTFTLNVALNHKGLDYEGGGCRFLRYDCVISSPRKGWALLHPGRLTHYHE	GLPTTWGTRYIMVSFVDP
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3
intracellular membrane-bound organelle
procollagen-lysine 5-dioxygenase activity
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 precursor
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=3153235
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D3153235%3E
map00310	Lysine degradation
>2217 bp	ATGACCTCCTCGGGGCCTGGACCCCGGTTCCTGCTGCTGCTGCCGCTGCTGCTGCCCCCT	GCGGCCTCAGCCTCCGACCGGCCCCGGGGCCGAGACCCGGTCAACCCAGAGAAGCTGCTG	GTGATCACTGTGGCCACAGCTGAAACCGAGGGGTACCTGCGTTTCCTGCGCTCTGCGGAG	TTCTTCAACTACACTGTGCGGACCCTGGGCCTGGGAGAGGAGTGGCGAGGGGGTGATGTG	GCTCGAACAGTTGGTGGAGGACAGAAGGTCCGGTGGTTAAAGAAGGAAATGGAGAAATAC	GCTGACCGGGAGGATATGATCATCATGTTTGTGGATAGCTACGACGTGATTCTGGCCGGC	AGCCCCACAGAGCTGCTGAAGAAGTTCGTCCAGAGTGGCAGCCGCCTGCTCTTCTCTGCA	GAGAGCTTCTGCTGGCCCGAGTGGGGGCTGGCGGAGCAGTACCCTGAGGTGGGCACGGGG	AAGCGCTTCCTCAATTCTGGTGGATTCATCGGTTTTGCCACCACCATCCACCAAATCGTG	CGCCAGTGGAAGTACAAGGATGATGACGACGACCAGCTGTTCTACACACGGCTCTACCTG	GACCCAGGACTGAGGGAGAAACTCAGCCTTAATCTGGATCATAAGTCTCGGATCTTTCAG	AACCTCAACGGGGCTTTAGATGAAGTGGTTTTAAAGTTTGATCGGAACCGTGTGCGTATC	CGGAACGTGGCCTACGACACGCTCCCCATTGTGGTCCATGGAAACGGTCCCACTAAGCTG	CAGCTCAACTACCTGGGAAACTACGTCCCCAATGGCTGGACTCCTGAGGGAGGCTGTGGC	TTCTGCAACCAGGACCGGAGGACACTCCCGGGGGGGCAGCCTCCCCCCCGGGTGTTTCTG	GCCGTGTTTGTGGAACAGCCTACTCCGTTTCTGCCCCGCTTCCTGCAGCGGCTGCTACTC	CTGGACTATCCCCCCGACAGGGTCACCCTTTTCCTGCACAACAACGAGGTCTTCCATGAA	CCCCACATCGCTGACTCCTGGCCGCAGCTCCAGGACCACTTCTCAGCTGTGAAGCTCGTG	GGGCCGGAGGAGGCTCTGAGCCCAGGCGAGGCCAGGGACATGGCCATGGACCTGTGTCGG	CAGGACCCCGAGTGTGAGTTCTACTTCAGCCTGGACGCCGACGCTGTCCTCACCAACCTG	CAGACCCTGCGTATCCTCATTGAGGAGAACAGGAAGGTGATCGCCCCCATGCTGTCCCGC	CACGGCAAGCTGTGGTCCAACTTCTGGGGCGCCCTGAGCCCCGATGAGTACTACGCCCGC	TCCGAGGACTACGTGGAGCTGGTGCAGCGGAAGCGAGTGGGTGTGTGGAATGTACCATAC	ATCTCCCAGGCCTATGTGATCCGGGGTGATACCCTGCGGATGGAGCTGCCCCAGAGGGAT	GTGTTCTCGGGCAGTGACACAGACCCGGACATGGCCTTCTGTAAGAGCTTTCGAGACAAG	GGCATCTTCCTCCATCTGAGCAATCAGCATGAATTTGGCCGGCTCCTGGCCACTTCCAGA	TACGACACGGAGCACCTGCACCCCGACCTCTGGCAGATCTTCGACAACCCCGTCGACTGG	AAGGAGCAGTACATCCACGAGAACTACAGCCGGGCCCTGGAAGGGGAAGGAATCGTGGAG	CAGCCATGCCCGGACGTGTACTGGTTCCCACTGCTGTCAGAACAAATGTGTGATGAGCTG	GTGGCAGAGATGGAGCACTACGGCCAGTGGTCAGGCGGCCGGCATGAGGATTCAAGGCTG	GCTGGAGGCTACGAGAATGTGCCCACCGTGGACATCCACATGAAGCAGGTGGGGTACGAG	GACCAGTGGCTGCAGCTGCTGCGGACGTATGTGGGCCCCATGACCGAGAGCCTGTTTCCC	GGTTACCACACCAAGGCGCGGGCGGTGATGAACTTTGTGGTTCGCTACCGGCCAGACGAG	CAGCCGTCTCTGCGGCCACACCACGACTCATCCACCTTCACCCTCAACGTTGCCCTCAAC	CACAAGGGCCTGGACTATGAGGGAGGTGGCTGCCGCTTCCTGCGCTACGACTGTGTGATC	TCCTCCCCGAGGAAGGGCTGGGCACTCCTGCACCCCGGCCGCCTCACCCACTACCACGAG	GGGCTGCCAACGACCTGGGGCACACGCTACATCATGGTGTCCTTTGTCGACCCCTGA
PLOD3_HUMAN
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9582318
EC 1.14.11.4
LH3
procollagen L-lysine + 2-oxoglutarate + O2 = procollagen 5-hydroxy-L-lysine + succinate + CO2 ALL_REAC (other) R03376
organelle
protein metabolism
http://www.genenames.org/data/hgnc_data.php?hgnc_id=9083
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D9083%3E
7q22
http://pfam.sanger.ac.uk/family?acc=PF03171
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF03171%3E
http://bio2rdf.org/pfam:PF03171
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF03171%3E
http://symbol.bio2rdf.org/symbol:PLOD3
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3APLOD3%3E
membrane-bound organelle
Lysyl hydroxylase 3
http://bio2rdf.org/uniprot:O60568
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AO60568%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9724729
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00126
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00139
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/23
_:header8941563341335206354485
Mon, 23 Apr 2012 18:32:29 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/23
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00679
Involved in dopamine receptor activity
193-218
5q35.1
transmembrane receptor activity
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/16492766
http://pfam.sanger.ac.uk/family?acc=PF00001
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00001%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1822319
>1341 bp	ATGAGGACTCTGAACACCTCTGCCATGGACGGGACTGGGCTGGTGGTGGAGAGGGACTTC	TCTGTTCGTATCCTCACTGCCTGTTTCCTGTCGCTGCTCATCCTGTCCACGCTCCTGGGG	AACACGCTGGTCTGTGCTGCCGTTATCAGGTTCCGACACCTGCGGTCCAAGGTGACCAAC	TTCTTTGTCATCTCCTTGGCTGTGTCAGATCTCTTGGTGGCCGTCCTGGTCATGCCCTGG	AAGGCAGTGGCTGAGATTGCTGGCTTCTGGCCCTTTGGGTCCTTCTGTAACATCTGGGTG	GCCTTTGACATCATGTGCTCCACTGCATCCATCCTCAACCTCTGTGTGATCAGCGTGGAC	AGGTATTGGGCTATCTCCAGCCCTTTCCGGTATGAGAGAAAGATGACCCCCAAGGCAGCC	TTCATCCTGATCAGTGTGGCATGGACCTTGTCTGTACTCATCTCCTTCATCCCAGTGCAG	CTCAGCTGGCACAAGGCAAAACCCACAAGCCCCTCTGATGGAAATGCCACTTCCCTGGCT	GAGACCATAGACAACTGTGACTCCAGCCTCAGCAGGACATATGCCATCTCATCCTCTGTA	ATAAGCTTTTACATCCCTGTGGCCATCATGATTGTCACCTACACCAGGATCTACAGGATT	GCTCAGAAACAAATACGGCGCATTGCGGCCTTGGAGAGGGCAGCAGTCCACGCCAAGAAT	TGCCAGACCACCACAGGTAATGGAAAGCCTGTCGAATGTTCTCAACCGGAAAGTTCTTTT	AAGATGTCCTTCAAAAGAGAAACTAAAGTCCTGAAGACTCTGTCGGTGATCATGGGTGTG	TTTGTGTGCTGTTGGCTACCTTTCTTCATCTTGAACTGCATTTTGCCCTTCTGTGGGTCT	GGGGAGACGCAGCCCTTCTGCATTGATTCCAACACCTTTGACGTGTTTGTGTGGTTTGGG	TGGGCTAATTCATCCTTGAACCCCATCATTTATGCCTTTAATGCTGATTTTCGGAAGGCA	TTTTCAACCCTCTTAGGATGCTACAGACTTTGCCCTGCGACGAATAATGCCATAGAGACG	GTGAGTATCAATAACAATGGGGCCGCGATGTTTTCCAGCCATCATGAGCCACGAGGCTCC	ATCTCCAAGGAGTGCAATCTGGTTTACCTGATCCCACATGCTGTGGGCTCCTCTGAGGAC	CTGAAAAAGGAGGAGGCAGCTGGCATCGCCAGACCCTTGGAGAAGCTGTCCCCAGCCCTA	TCGGTCATATTGGACTATGACACTGACGTCTCTCTGGAGAAGATCCAACCCATCACACAA	AACGGTCAGCACCCAACCTGA
http://symbol.bio2rdf.org/symbol:DRD1
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ADRD1%3E
http://bio2rdf.org/hgnc:3020
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A3020%3E
61-87
G-protein coupled receptor activity
This is one of the five types (D1 to D5) of receptors for dopamine. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12453049
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2168520
rhodopsin-like receptor activity
cell surface receptor linked signal transduction
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10618483
97-119
dopamine receptor activity
http://bio2rdf.org/uniprot:P21728
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP21728%3E
http://www.uniprot.org/uniprot/P21728
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP21728%3E
http://bio2rdf.org/pfam:PF00001
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00001%3E
139-163
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17468175
DRD1
>D(1A) dopamine receptor	MRTLNTSAMDGTGLVVERDFSVRILTACFLSLLILSTLLGNTLVCAAVIRFRHLRSKVTN	FFVISLAVSDLLVAVLVMPWKAVAEIAGFWPFGSFCNIWVAFDIMCSTASILNLCVISVD	RYWAISSPFRYERKMTPKAAFILISVAWTLSVLISFIPVQLSWHKAKPTSPSDGNATSLA	ETIDNCDSSLSRTYAISSSVISFYIPVAIMIVTYTRIYRIAQKQIRRIAALERAAVHAKN	CQTTTGNGKPVECSQPESSFKMSFKRETKVLKTLSVIMGVFVCCWLPFFILNCILPFCGS	GETQPFCIDSNTFDVFVWFGWANSSLNPIIYAFNADFRKAFSTLLGCYRLCPATNNAIET	VSINNNGAAMFSSHHEPRGSISKECNLVYLIPHAVGSSEDLKKEEAAGIARPLEKLSPAL	SVILDYDTDVSLEKIQPITQNGQHPT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8471124
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17301410
multi-passMembraneProtein.EndoplasmicReticulum
receptor activity
m
273-299
D(1A) dopamine receptor
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17449449
DRD1_HUMAN
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=X55760
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DX55760%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17455212
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=30397
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D30397%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2144334
signal transducer activity
amine receptor activity
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8720030
integral to membrane
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17394052
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10531405
24-49
http://www.genenames.org/data/hgnc_data.php?hgnc_id=3020
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D3020%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1975640
G-protein coupled receptor protein signaling pathway
X55760
313-337
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11752352
intrinsic to membrane
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00061
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01235
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00589
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00623
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00353
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00334
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00907
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224
RDF Description of D(1A) dopamine receptor
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00714
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00372
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01038
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00988
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00777
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00408
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01186
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00875
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00915
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00502
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00433
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00420
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01063
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00800
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01624
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00508
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01239
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00805
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/3475
_:header6132910721335206354957
RDF Description of GLICLAZIDE
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0018799
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=QaI1ZsjhESs=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DQaI1ZsjhESs%3D%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0011849
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0442874
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0003860
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=RXf4vaCVEBc=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DRXf4vaCVEBc%3D%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0022408
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0010054
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0001339
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0029882
GLICLAZIDE
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0037299
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0032617
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0039503
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0001925
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0023222
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C1458155
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0007286
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0026946
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C1565489
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0018801
http://sideeffects.embl.de/drugs/3475
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F3475%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020557
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0017168
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=kD5aeln+xY0=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DkD5aeln%2BxY0%3D%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0019112
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0022658
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0025345
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01120
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01120%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020635
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0040460
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0030552
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0035309
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0007820
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=cXfmQoB3YfM=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DcXfmQoB3YfM%3D%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0032708
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0022660
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=7vnORv%2FNs0w=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3D7vnORv%252FNs0w%3D%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0162429
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0017979
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020473
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0040584
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020615
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C1384666
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0040046
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0151436
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0042769
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0085605
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0040261
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0016167
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=dhG319HMbwQ=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DdhG319HMbwQ%3D%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0015672
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0040435
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0870082
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0154251
http://dbpedia.org/resource/Gliclazide
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FGliclazide%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0022346
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0001824
CID0000003475
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000003475
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000003475%3E
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000003475&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000003475%26input_query_species%3D9606%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0033046
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0000768
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0037036
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020456
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0024894
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0022679
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/2274
_:header4606563381335206355432
Mon, 23 Apr 2012 18:32:30 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2274
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01716
http://www.pdb.org/pdb/explore/explore.do?structureId=4SLI
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D4SLI%3E
carbohydrate metabolism
Anhydrosialidase
Anhydrosialidase precursor
http://bio2rdf.org/pfam:PF02973
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF02973%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=U46666
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DU46666%3E
extracellularSpace
http://bio2rdf.org/pfam:PF02012
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF02012%3E
http://bio2rdf.org/pdb:4SLI
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A4SLI%3E
http://bio2rdf.org/uniprot:Q27701
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ27701%3E
hydrolase activity, hydrolyzing O-glycosyl compounds
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=1353880
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D1353880%3E
>2289 bp	ATGGGAAGAATTGGAAAAAAAGCAATGGCAATCGCACTGGTATCAGCAGTCATGGTTACA	CCTTTAAATGTATGTGCGACGGTAGAAAATCAGGAACAGCAACAGGTAACGCAAGGAGCA	GAGGACATAGCCGTTATAGATGACGCTCAGGAAACGGTTGCCGCAGACGAAGCACAGGCA	GATGAAGCAGCGGCTATCACTGTTGAAGGACGGGAGACAGCTGAAGAGAGCAGCGCATCA	ATTCCGGAAGGCATTCTGATGGAAAAGAACAATGTTGATATAGCCGAAGGGCAGGGATAC	AGCCTGGACCAGGAGGCTGGCGCCAAATATGTAAAGGCTATGACCCAGGGTACAATTATC	CTATCCTATAAATCAACAAGTGAAAATGGAATCCAGTCTCTGTTCAGCGTAGGAAACAGT	ACCGCGGGCAATCAGGACAGGCATTTCCACATCTATATAACAAACTCTGGCGGCATAGGC	ATAGAACTTAGAAACACGGACGGTGTCTTCAATTATACATTGGACAGACCGGCATCAGTG	CGTGCTCTGTATAAAGGAGAACGGGTATTCAATACAGTTGCATTAAAAGCCGATGCAGCA	AATAAACAGTGCAGATTATTTGCAAATGGCGAGCTTCTCGCAACACTGGATAAAGATGCG	TTTAAGTTTATCAGTGACATTACAGGCGTAGATAACGTTACATTAGGCGGCACGAAGAGG	CAGGGGAAGATTGCATATCCGTTCGGGGGAACGATTGGTGACATTAAGGTATATAGTAAT	GCACTGTCCGACGAAGAATTGATACAGGCAACAGGAGTGACAACATATGGTGAGAATATA	TTCTATGCCGGGGATGTCACCGAATCAAATTACTTCCGAATCCCGTCATTGCTGACTTTA	AGCACAGGTACCGTTATCTCTGCTGCTGATGCAAGGTATGGCGGCACCCACGATTCAAAA	AGTAAGATAAATATTGCTTTTGCCAAAAGCACTGATGGCGGAAATACATGGTCTGAGCCG	ACGCTGCCGCTTAAGTTTGACGATTACATAGCTAAAAATATAGACTGGCCAAGAGACTCT	GTAGGGAAAAATGTGCAGATCCAGGGAAGTGCGTCTTATATAGATCCGGTATTGCTGGAG	GACAAGCTTACTAAAAGAATTTTCCTGTTTGCAGATCTGATGCCCGCGGGTATCGGAAGC	TCCAACGCTTCTGTAGGCTCTGGCTTTAAAGAAGTGAATGGCAAAAAGTATCTAAAACTC	AGATGGCATAAGGATGCAGGCAGGGCATATGACTACACGATCCGCGAAAAAGGAGTAATA	TACAATGATGCTACCAACCAGCCAACAGAGTTTCGTGTAGATGGAGAATATAATCTTTAC	CAGCATGATACGAACCTGACCTGTAAGCAGTATGATTACAATTTTAGCGGGAATAATCTA	ATTGAAAGCAAGACAGATGTTGATGTAAACATGAACATATTTTATAAAAATTCTGTATTC	AAAGCATTCCCCACCAACTATCTGGCAATGAGATATTCTGACGATGAAGGGGCAAGCTGG	TCAGATTTAGATATTGTCAGCAGCTTTAAGCCGGAAGTCTCCAAATTCCTGGTAGTGGGC	CCAGGTATTGGAAAGCAGATATCTACAGGTGAGAATGCAGGAAGGCTGCTTGTGCCTTTA	TATTCTAAGTCTTCAGCAGAGCTTGGGTTTATGTACAGTGACGACCACGGGGACAACTGG	ACCTATGTGGAGGCGGATAACCTTACAGGCGGCGCGACAGCCGAAGCGCAGATTGTCGAG	ATGCCGGATGGTTCACTTAAGACGTATCTGCGAACAGGTTCCAATTGTATTGCCGAAGTT	ACCAGCATTGACGGAGGAGAGACATGGAGCGACAGAGTACCGCTGCAGGGAATCAGCACC	ACCTCTTATGGAACACAGCTATCAGTCATTAATTATTCACAGCCTATAGACGGGAAGCCG	GCAATCATCTTATCTTCGCCAAATGCCACAAATGGACGTAAGAACGGGAAAATATGGATT	GGGCTTGTCAATGATACAGGAAATACCGGAATAGATAAGTATTCGGTAGAGTGGAAGTAC	TCCTATGCCGTAGATACGCCTCAAATGGGATATTCCTATTCCTGCCTGGCAGAGTTGCCT	GACGGTCAAGTAGGATTATTGTATGAAAAGTATGATTCCTGGTCACGGAACGAATTACAT	CTGAAAGATATACTGAAGTTTGAGAAATATTCAATCAGTGAGCTGACGGGGCAAGCTTCA	GGAAATTAA
Sialidase L
Elimination of alpha-sialyl groups in N- acetylneuraminic acid glycosides, releasing 2,7-anhydro-alpha-N- acetylneuraminate
secretedProtein
Elimination of alpha-sialyl groups in N-acetylneuraminic acid glycosides, releasing 2,7-anhydro-alpha-N-acetylneuraminate
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8034634
hydrolase activity, acting on glycosyl bonds
exo-alpha-sialidase activity
>Anhydrosialidase precursor	MGRIGKKAMAIALVSAVMVTPLNVCATVENQEQQQVTQGAEDIAVIDDAQETVAADEAQA	DEAAAITVEGRETAEESSASIPEGILMEKNNVDIAEGQGYSLDQEAGAKYVKAMTQGTII	LSYKSTSENGIQSLFSVGNSTAGNQDRHFHIYITNSGGIGIELRNTDGVFNYTLDRPASV	RALYKGERVFNTVALKADAANKQCRLFANGELLATLDKDAFKFISDITGVDNVTLGGTKR	QGKIAYPFGGTIGDIKVYSNALSDEELIQATGVTTYGENIFYAGDVTESNYFRIPSLLTL	STGTVISAADARYGGTHDSKSKINIAFAKSTDGGNTWSEPTLPLKFDDYIAKNIDWPRDS	VGKNVQIQGSASYIDPVLLEDKLTKRIFLFADLMPAGIGSSNASVGSGFKEVNGKKYLKL	RWHKDAGRAYDYTIREKGVIYNDATNQPTEFRVDGEYNLYQHDTNLTCKQYDYNFSGNNL	IESKTDVDVNMNIFYKNSVFKAFPTNYLAMRYSDDEGASWSDLDIVSSFKPEVSKFLVVG	PGIGKQISTGENAGRLLVPLYSKSSAELGFMYSDDHGDNWTYVEADNLTGGATAEAQIVE	MPDGSLKTYLRTGSNCIAEVTSIDGGETWSDRVPLQGISTTSYGTQLSVINYSQPIDGKP	AIILSSPNATNGRKNGKIWIGLVNDTGNTGIDKYSVEWKYSYAVDTPQMGYSYSCLAELP	DGQVGLLYEKYDSWSRNELHLKDILKFEKYSISELTGQASGN
Anhydroneuraminidase
U46666
alpha-sialidase activity
NANL_MACDE
1-27
http://pfam.sanger.ac.uk/family?acc=PF02973
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF02973%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8702601
http://pfam.sanger.ac.uk/family?acc=PF02012
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF02012%3E
http://www.uniprot.org/uniprot/Q27701
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ27701%3E
EC 4.2.2.15
RDF Description of Anhydrosialidase
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/3156
_:header1158326401335206355907
RDF Description of DOPRAM
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3156
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0042514
http://www.fda.gov/cder/foi/label/2004/14879slr040_dopram_lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2004%2F14879slr040_dopram_lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000003156
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000003156%3E
http://www.fda.gov/cder/foi/label/2005/14879s044lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2005%2F14879s044lbl.pdf%3E
http://sideeffects.embl.de/drugs/3156
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F3156%3E
CID0000003156
DOPRAM
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0024115
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0242184
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0006266
doxapram
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0042510
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000003156&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000003156%26input_query_species%3D9606%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00561
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00561%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0003578
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0024117
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020440
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0031542
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0009951
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0497247
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0233485
http://dbpedia.org/resource/Doxapram
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FDoxapram%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0019521
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/1189
_:header16675840731335206356271
Mon, 23 Apr 2012 18:32:31 GMT
RDF Description of Weill-Marchesani syndrome
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1189
http://www.dbpedia.org/resource/Weill-Marchesani_syndrome
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FWeill-Marchesani_syndrome%3E
Weill-Marchesani syndrome
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/FBN1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/ADAMTS10
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4168
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4167
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/468
_:header4332892741335206356678
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/468
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2514
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/KIAA1279
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseaseClass/multiple
Goldberg-Shprintzen megacolon syndrome
RDF Description of Goldberg-Shprintzen megacolon syndrome
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/2304
_:header2838190301335206357204
Mon, 23 Apr 2012 18:32:32 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2304
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03461
http://bio2rdf.org/pfam:PF00248
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00248%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=L14950
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DL14950%3E
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/gene/AKR1B1
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fgene%2FAKR1B1%3E
Aldehyde reductase
alditol + NAD(P)+ = aldose + NAD(P)H + H+
http://bio2rdf.org/uniprot:P80276
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP80276%3E
EC 1.1.1.21
map00040	Pentose and glucuronate interconversions
ALDR_PIG
>Aldose reductase	MASHLVLYTGAKMPILGLGTWKSPPGKVTEAVKVAIDLGYRHIDCAHVYQNENEVGLGLQ	EKLQGQVVKREDLFIVSKLWCTDHEKNLVKGACQTTLRDLKLDYLDLYLIHWPTGFKPGK	DPFPLDGDGNVVPDESDFVETWEAMEELVDEGLVKAIGVSNFNHLQVEKILNKPGLKYKP	AVNQIEVHPYLTQEKLIEYCKSKGIVVTAYSPLGSPDRPWAKPEDPSLLEDPRIKAIAAK	YNKTTAQVLIRFPMQRNLIVIPKSVTPERIAENFQVFDFELSPEDMNTLLSYNRNWRVCA	LMSCASHKDYPFHEEY
AKR1B1
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8281941
Catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their corresponding alcohols with a broad range of catalytic efficiencies
AR
Involved in oxidoreductase activity
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9195881
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=294212
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D294212%3E
L14950
>951 bp	ATGGCCAGCCACCTCGTGCTCTACACCGGTGCCAAGATGCCCATCTTGGGGCTGGGCACC	TGGAAGTCCCCTCCAGGCAAAGTGACAGAGGCTGTGAAGGTGGCCATTGACCTTGGGTAC	CGCCACATTGACTGTGCCCATGTGTACCAGAACGAGAACGAGGTGGGGCTGGGCCTCCAG	GAGAAGCTCCAAGGGCAGGTGGTGAAGCGTGAGGACCTCTTCATCGTCAGTAAGCTGTGG	TGCACAGACCATGAGAAGAACCTGGTGAAAGGGGCCTGCCAGACGACCCTCCGCAACCTG	AAGCTGGACTACCTGGACCTCTACCTTATCCACTGGCCCACTGGCTTCAAGCCTGGCAAG	GACCCTTTCCCGCTGGATGGCGACGGCAACGTGGTTCCTGATGAGAGCGATTTTGTGGAG	ACGTGGGAGGCCATGGAGGAGCTGGTGGACGAAGGGCTGGTGAAAGCCATTGGCGTCTCC	AACTTCAACCATCTGCAAGTGGAGAAGATCTTAAACAAACCTGGCCTGAAATACAAGCCA	GCCGTTAACCAGATCGAGGTCCACCCATACCTCACTCAGGAGAAGTTAATCGAATACTGC	AAGTCCAAAGGCATCGTGGTGACTGCCTACAGCCCCCTCGGCTCTCCCGACAGGCCCTGG	GCCAAGCCTGAGGACCCTTCCCTCCTGGAGGACCCCAGGATCAAAGCGATTGCAGCCAAG	TACAATAAAACCACAGCCCAGGTTCTGATCCGGTTCCCCATGCAGAGGAACTTGATCGTC	ATCCCCAAGTCCGTGACGCCTGAACGCATTGCCGAGAACTTCCAGGTCTTTGACTTTGAA	CTGAGCCCTGAGGATATGAACACCTTACTGAGCTACAACAGGAACTGGAGGGTCTGTGCC	TTGATGAGCTGTGCCTCCCACAAGGATTATCCCTTTCACGAGGAATATTGA
http://www.uniprot.org/uniprot/P80276
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP80276%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1734286
http://pfam.sanger.ac.uk/family?acc=PF00248
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00248%3E
Aldose reductase
http://bio2rdf.org/pdb:1AH0
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1AH0%3E
http://www.pdb.org/pdb/explore/explore.do?structureId=1AH0
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1AH0%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8493902
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01689
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02383
RDF Description of Aldose reductase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02518
http://www4.wiwiss.fu-berlin.de/drugbank/data/enzymes/4
_:header14352493061335206357593
http://www4.wiwiss.fu-berlin.de/drugbank/resource/enzymes/4
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/enzymes
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00586
http://bio2rdf.org/uniprot:P48775
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP48775%3E
http://www.uniprot.org/uniprot/P48775
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP48775%3E
Tryptophan 2,3-dioxygenase
>P48775|T23O_HUMAN Tryptophan 2,3-dioxygenase	MSGCPFLGNNFGYTFKKLPVEGSEEDKSQTGVNRASKGGLIYGNYLHLEKVLNAQELQSE	TKGNKIHDEHLFIITHQAYELWFKQILWELDSVREIFQNGHVRDERNMLKVVSRMHRVSV	ILKLLVQQFSILETMTALDFNDFREYLSPASGFQSLQFRLLENKIGVLQNMRVPYNRRHY	RDNFKGEENELLLKSEQEKTLLELVEAWLERTPGLEPHGFNFWGKLEKNITRGLEEEFIR	IQAKEESEEKEEQVAEFQKQKEVLLSLFDEKRHEHLLSKGERRLSYRALQGALMIYFYRE	EPRFQVPFQLLTSLMDIDSLMTKWRYNHVCMVHRMLGSKAGTGGSSGYHYLRSTVSDRYK	VFVDLFNLSTYLIPRHWIPKMNPTIHKFLYTAEYCDSSYFSSDESD
TDO2
RDF Description of Tryptophan 2,3-dioxygenase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01361
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00532
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00213
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00468
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01104
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00190
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00624
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00286
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00908
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00176
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00683
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01045
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00967
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00220
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01242
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00752
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00983
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00762
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01026
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00184
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00477
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01037
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00736
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00356
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01124
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01171
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01424
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00377
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00458
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01259
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00622
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01340
_:header15806699301335206358097
Mon, 23 Apr 2012 18:32:33 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01340
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00594_DB01340
2007-06-30 18:09:29 UTC
2008-08-26 20:59:45 UTC
O.CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]1CCCN2CCC[C@H](N2C1=O)C(O)=O
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/561
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F561%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/angiotensin-convertingEnzymeInhibitors
Cilazapril
Cilazapril is a pyridazine ACE inhibitor. It competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. As angiotensin II is a vasoconstrictor and a negative feedback mediator for renin activity, lower angiotensin II levels results in a decrease in blood pressure, an increase in renin activity, and stimulation of baroreceptor reflex mechanisms. Kininase II, an enzyme which degrades the vasodilator bradykinin, is identical to ACE and may also be inhibited.
DB01340
O.CCOC(=O)C(CCC1=CC=CC=C1)NC1CCCN2CCCC(N2C1=O)C(O)=O
http://205.193.93.51/dpdonline/searchRequest.do?din=01911465
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D01911465%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/1694
24:32.04
http://en.wikipedia.org/wiki/Cilazapril
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FCilazapril%3E
Take without regard to meals.
C09AA08
Food decreases cilazapril absorption with no significant clinical impact.
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3639
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3639%3E
PA10315
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3730
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3730%3E
http://dbpedia.org/page/Cilazapril
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FCilazapril%3E
C22H33N3O6
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2701
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2701%3E
InChI=1/C22H31N3O5.H2O/c1-2-30-22(29)18(13-12-16-8-4-3-5-9-16)23-17-10-6-14-24-15-7-11-19(21(27)28)25(24)20(17)26;/h3-5,8-9,17-19,23H,2,6-7,10-15H2,1H3,(H,27,28);1H2/t17-,18-,19-;/m0./s1/f/h27H;
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/antihypertensiveAgents
JQRZBPFGBRIWSN-OHVQNRRIDW
One of the angiotensin-converting enzyme inhibitors (ACE inhibitors) used for hypertension.  It is a prodrug that is hydrolyzed after absorption to its main metabolite cilazaprilat. [PubChem]
http://www.drugbank.ca/drugs/DB01340
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01340%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/949
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F949%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1283
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1283%3E
http://bio2rdf.org/cas:92077-78-6
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A92077-78-6%3E
http://dbpedia.org/resource/Cilazapril
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FCilazapril%3E
(1S,9S)-9-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-10-oxo-1,2,3,4,6,7,8,9-octahydropyridazino[1,2-a]diazepine-1-carboxylic acid hydrate
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01356_DB01340
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01345_DB01340
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01340_DB01395
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01340_DB01356
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01340_DB00697
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01340_DB01345
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01340_DB00594
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00697_DB01340
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01340_DB00421
RDF Description of Cilazapril
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01340_DB00384
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00384_DB01340
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Sardou_Victorien_1831-1908
_:header9154954061335206358413
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Sardou_Victorien_1831-1908
Sardou, Victorien, 1831-1908
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19540
RDF Description of Sardou, Victorien, 1831-1908
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/FXN
_:header739567771335206358800
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/FXN
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/418
http://symbol.bio2rdf.org/symbol:FXN
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AFXN%3E
FXN
http://www.dbpedia.org/resource/Frataxin
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FFrataxin%3E
RDF Description of FXN
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/29
_:header4725105041335206359332
Mon, 23 Apr 2012 18:32:34 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00309
guanyl nucleotide binding
nucleoside-triphosphatase activity
cellular protein metabolism
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=11230445
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D11230445%3E
TUBB1
Tubulin beta-1 chain
http://pfam.sanger.ac.uk/family?acc=PF00091
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00091%3E
http://www.uniprot.org/uniprot/Q9H4B7
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ9H4B7%3E
TBB1_HUMAN
http://www.genenames.org/data/hgnc_data.php?hgnc_id=16257
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D16257%3E
hydrolase activity, acting on acid anhydrides
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11780052
20q13.32
GTP binding
http://bio2rdf.org/pfam:PF03953
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF03953%3E
http://pfam.sanger.ac.uk/family?acc=PF03953
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF03953%3E
http://bio2rdf.org/pfam:PF00091
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00091%3E
structural molecule activity
>1356 bp	ATGCGTGAAATTGTCCATATTCAGATTGGCCAGTGTGGCAACCAGATCGGAGCCAAGTTC	TGGGAGATGATTGGTGAGGAACACGGGATCGACTTGGCTGGGAGCGACCGCGGGGCCTCG	GCCTTGCAGCTGGAGAGAATCAGCGTGTACTACAACGAAGCCTACGGTAGGAAATATGTG	CCCCGAGCAGTCTTGGTGGACCTAGAACCTGGGACGATGGACAGCATTCGATCTAGCAAA	TTAGGAGCTCTCTTTCAACCCGACAGTTTTGTCCATGGTAACTCTGGGGCTGGCAACAAC	TGGGCCAAAGGCCACTACACGGAGGGAGCCGAGCTGATCGAGAATGTCCTAGAGGTGGTG	AGGCACGAGAGTGAGAGCTGTGACTGCCTGCAGGGCTTCCAGATCGTCCACTCCCTGGGC	GGGGGCACAGGCTCCGGGATGGGCACTCTGCTCATGAACAAGATTAGAGAGGAGTACCCG	GACCGGATCATGAATTCCTTCAGCGTCATGCCTTCTCCCAAGGTGTCGGACACGGTGGTG	GAGCCCTACAACGCGGTTCTGTCTATCCACCAGCTGATTGAGAATGCAGATGCCTGTTTC	TGCATTGACAATGAGGCCCTCTATGACATCTGCTTCCGTACCCTGAAGCTGACGACACCC	ACCTATGGGGATCTCAACCACCTAGTGTCCTTGACCATGAGCGGCATAACCACCTCCCTC	CGGTTCCCGGGTCAGCTCAACGCAGACCTGCGCAAGCTGGCGGTGAACATGGTCCCCTTC	CCCCGCCTGCACTTCTTTATGCCCGGCTTTGCCCCACTCACGGCCCAGGGCAGCCAGCAG	TACCGAGCCCTCTCCGTGGCCGAGCTCACCCAGCAGATGTTCGATGCCCGCAATACCATG	GCTGCCTGTGACCTCCGCCGTGGCCGCTACCTCACAGTGGCCTGCATTTTCCGGGGCAAG	ATGTCCACCAAGGAAGTGGACCAGCAACTGCTCTCCGTGCAGACCAGGAACAGCAGCTGC	TTTGTGGAGTGGATTCCCAACAACGTCAAGGTGGCTGTCTGCGACATCCCGCCCCGGGGG	CTGAGCATGGCCGCCACCTTCATTGGCAACAACACGGCCATCCAAGAGATCTTTAATAGG	GTCTCTGAGCATTTCTCAGCCATGTTCAAAAGGAAAGCTTTTGTGCACTGGTACACCAGC	GAAGGGATGGACATAAACGAATTTGGGGAAGCTGAAAATAACATCCATGATTTGGTATCC	GAGTACCAACAATTTCAAGATGCCAAAGCAGTTCTAGAGGAAGATGAAGAGGTCACGGAG	GAGGCAGAAATGGAGCCAGAAGATAAGGGACATTAA
GTPase activity
protein polymerization
Cell cycle control, cell division, chromosome partitioning
http://bio2rdf.org/uniprot:Q9H4B7
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ9H4B7%3E
hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides
microtubule cytoskeleton
non-membrane-bound organelle
>Tubulin beta-1 chain	MREIVHIQIGQCGNQIGAKFWEMIGEEHGIDLAGSDRGASALQLERISVYYNEAYGRKYV	PRAVLVDLEPGTMDSIRSSKLGALFQPDSFVHGNSGAGNNWAKGHYTEGAELIENVLEVV	RHESESCDCLQGFQIVHSLGGGTGSGMGTLLMNKIREEYPDRIMNSFSVMPSPKVSDTVV	EPYNAVLSIHQLIENADACFCIDNEALYDICFRTLKLTTPTYGDLNHLVSLTMSGITTSL	RFPGQLNADLRKLAVNMVPFPRLHFFMPGFAPLTAQGSQQYRALSVAELTQQMFDARNTM	AACDLRRGRYLTVACIFRGKMSTKEVDQQLLSVQTRNSSCFVEWIPNNVKVAVCDIPPRG	LSMAATFIGNNTAIQEIFNRVSEHFSAMFKRKAFVHWYTSEGMDINEFGEAENNIHDLVS	EYQQFQDAKAVLEEDEEVTEEAEMEPEDKGH
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AJ292757
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAJ292757%3E
microtubule
cytoskeleton
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha-chain
http://symbol.bio2rdf.org/symbol:TUBB1
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ATUBB1%3E
cytoskeleton organization and biogenesis
microtubule-based process
cell organization and biogenesis
organelle organization and biogenesis
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12665801
AJ292757
microtubule-based movement
http://bio2rdf.org/hgnc:16257
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A16257%3E
intracellular non-membrane-bound organelle
pyrophosphatase activity
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01394
RDF Description of Tubulin beta-1 chain
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03010
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01229
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01873
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/SOX10
_:header21217600081335206359656
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/SOX10
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4149
http://symbol.bio2rdf.org/symbol:SOX10
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ASOX10%3E
SOX10
http://www.dbpedia.org/resource/SOX10
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FSOX10%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1180
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4200
RDF Description of SOX10
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/905
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1210
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3554
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/BBS3
_:header19927622651335206360067
Mon, 23 Apr 2012 18:32:35 GMT
RDF Description of BBS3
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/BBS3
http://symbol.bio2rdf.org/symbol:BBS3
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ABBS3%3E
BBS3
http://www.dbpedia.org/resource/ARL6
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FARL6%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1555
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1558
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/316
_:header16905509361335206360460
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/316
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2140
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/ERCC6
De Sanctis-Cacchione syndrome
http://www.dbpedia.org/resource/Xeroderma_pigmentosum
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FXeroderma_pigmentosum%3E
RDF Description of De Sanctis-Cacchione syndrome
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Drinkwater_John_1882-1937
_:header15417572231335206360884
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Drinkwater_John_1882-1937
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17091
Drinkwater, John, 1882-1937
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5628
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9850
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext11172
RDF Description of Drinkwater, John, 1882-1937
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00496
_:header2124254971335206361395
Mon, 23 Apr 2012 18:32:36 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00496
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01211_DB00496
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/muscarinicAntagonists
darifenacin
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/urinaryAntispasmodics
http://dbpedia.org/page/Darifenacin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FDarifenacin%3E
NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1
Enablex
Darifenacin is a competitive muscarinic receptor antagonist. <i>In vitro</i> studies using human recombinant muscarinic receptor subtypes show that darifenacin has greater affinity for the M3 receptor than for the other known muscarinic receptors (9 and 12-fold greater affinity for M3 compared to M1 and M5, respectively, and 59-fold greater affinity for M3 compared to both M2 and M4). Muscarinic receptors play an important role in several major cholinergically mediated functions, including contractions of the urinary bladder smooth muscle and stimulation of salivary secretion. Adverse drug effects such as dry mouth, constipation and abnormal vision may be mediated through effects on M3 receptors in these organs.
http://bio2rdf.org/cas:133099-04-4
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A133099-04-4%3E
86:12.00
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3518
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3518%3E
Emselex
http://dbpedia.org/resource/Darifenacin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FDarifenacin%3E
http://data.linkedct.org/resource/intervention/21247
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F21247%3E
http://www.rxlist.com/cgi/generic3/enablex.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric3%2Fenablex.htm%3E
http://data.linkedct.org/resource/intervention/35247
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35247%3E
Darifenacin (Enablex��, Novartis) is a medication used to treat urinary incontinence.	Darifenacin works by blocking the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions. It thereby decreases the urgency to urinate. It should not be used in people with urinary retention.	It is not known whether this selectivity for the M3 receptor translates into any clinical advantage when treating symptoms of overactive bladder syndrome.
http://www.drugbank.ca/drugs/DB00496
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00496%3E
http://129.128.185.122/drugbank2/drugs/DB00496/inserts/1099/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00496%2Finserts%2F1099%2Ffull%3E
C28H30N2O2
http://129.128.185.122/drugbank2/drugs/DB00496/inserts/2108/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00496%2Finserts%2F2108%2Ffull%3E
http://bio2rdf.org/kegg:D01699
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD01699%3E
Darifenacin
http://www.dbpedia.org/resource/Darifenacin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FDarifenacin%3E
For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.
The mean oral bioavailability at steady state is estimated to be 15% and 19% for 7.5 mg and 15 mg tablets, respectively.
Overdosage can potentially result in severe central anticholinergic effects.
NC(=O)C(C1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1
http://en.wikipedia.org/wiki/Darifenacin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FDarifenacin%3E
G04BD10
2004-12-01	/drugs/496/fda_labels/261
http://data.linkedct.org/resource/intervention/21249
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F21249%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/51
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/tabletExtendedReleaseOral
HXGBXQDTNZMWGS-WOPQRDCQDH
2008-08-26 15:32:56 UTC
aprd00903
Darifenacin is approximately 98% bound to plasma proteins (primarily to alpha-1-acid-glycoprotein).
The elimination half-life of darifenacin following chronic dosing is approximately 13-19 hours.
http://data.linkedct.org/resource/intervention/35249
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35249%3E
DB00496
Hepatic. Primarily mediated by the cytochrome P450 enzymes CYP2D6 and CYP3A4.
2.98e-04 mg/mL
Darifenacin selectively antagonizes the muscarinic M3 receptor. M3 receptors are involved in contraction of human bladder and gastrointestinal smooth muscle, saliva production, and iris sphincter function.
InChI=1/C28H30N2O2/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26/h1-12,19,25H,13-18,20H2,(H2,29,31)/t25-/m1/s1/f/h29H2
http://www4.wiwiss.fu-berlin.de/drugbank/resource/enzymes/2
2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-di(phenyl)acetamide
http://data.linkedct.org/resource/intervention/35245
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35245%3E
http://129.128.185.122/drugbank2/drugs/DB00496/inserts/274/full
RDF Description of Darifenacin
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01167_DB00496
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00496_DB00989
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00496_DB01211
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00496_DB01167
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00674_DB00496
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00496_DB00843
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01149_DB00496
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00496_DB01149
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00427_DB00496
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01026_DB00496
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00843_DB00496
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00496_DB01026
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00209_DB00496
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00496_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00496_DB00674
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00496_DB00220
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00220_DB00496
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00382_DB00496
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0033581
_:header11692068491335206361729
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0033581
http://sideeffects.embl.de/se/C0033581
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0033581%3E
Prostatitis
C0033581
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2575
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2617
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3354
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2673
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2666
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2559
RDF Description of Prostatitis
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/85
_:header15762272451335206362150
Mon, 23 Apr 2012 18:32:37 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/85
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1447
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/ABCB7
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2881
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2881%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/ALAS2
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PKLR
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3628
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3628%3E
http://data.linkedct.org/resource/condition/928
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fcondition%2F928%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1349
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F1349%3E
http://www.dbpedia.org/resource/Anemia
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FAnemia%3E
Anemia
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00114
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00114%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02726
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB02726%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/SLC11A2
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/RHAG
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/disease/Anemia
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fdisease%2FAnemia%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00145
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00145%3E
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fsider%2Fresource%2Fside_effects%2FC0002871%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/SPTB
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/RPS19
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/CDAN1
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04551
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB04551%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00119
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00119%3E
http://www.dbpedia.org/resource/Nominal_aphasia
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FNominal_aphasia%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/NT5C3
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1446
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1441
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1440
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1442
RDF Description of Anemia
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1445
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1448
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1444
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1443
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/3920
_:header12847416851335206362695
RDF Description of Methylenetetrahydrofolate reductase intermediate form
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3920
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=7271189
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D7271189%3E
methylenetetrahydrofolate reductase (NADPH) activity
sulfur amino acid metabolism
1p36.3
oxidoreductase activity, acting on the CH-NH group of donors
>Methylenetetrahydrofolate reductase intermediate form	MCRGCGCLPPDAPCPTLCSRNPAMVNEARGNSSLNPCLEGSASSGSESSKDSSRCSTPGL	DPERHERLREKMRRRLESGDKWFSLEFFPPRTAEGAVNLIS
http://symbol.bio2rdf.org/symbol:MTHFR
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AMTHFR%3E
AJ249275
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11730351
methionine metabolism
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10893069
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10196703
>305 bp	ATGTGTCGGGGGTGTGGCTGCCTGCCCCCTGATGCTCCCTGCCCCACCCTGTGCAGTAGG	AACCCAGCCATGGTGAACGAAGCCAGAGGAAACAGCAGCCTCAACCCCTGCTTGGAGGGC	AGTGCCAGCAGTGGCAGTGAGAGCTCCAAAGATAGTTCGAGATGTTCCACCCCGGGCCTG	GACCCTGAGCGGCATGAGAGACTCCGGGAGAAGATGAGGCGGCGATTGGAATCTGGTGAC	AAGTGGTTCTCCCTGGAATTCTTCCCTCCTCGAACTGCTGAGGGAGCTGTCAATCTCATC	TCAAG
Q9NY62_HUMAN
Methylenetetrahydrofolate reductase intermediate form
http://www.genenames.org/data/hgnc_data.php?hgnc_id=7436
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D7436%3E
http://www.uniprot.org/uniprot/Q9NY62
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ9NY62%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12370778
http://bio2rdf.org/hgnc:7436
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A7436%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12605391
oxidoreductase activity, acting on the CH-NH group of donors, NAD or NADP as acceptor
http://pfam.sanger.ac.uk/family?acc=PF02219
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF02219%3E
amino acid metabolism
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AJ249275
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAJ249275%3E
http://bio2rdf.org/uniprot:Q9NY62
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ9NY62%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11457468
http://bio2rdf.org/pfam:PF02219
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF02219%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00116
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/C4A
_:header16012866531335206362985
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/C4A
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1700
http://symbol.bio2rdf.org/symbol:C4A
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AC4A%3E
C4A
http://bio2rdf.org/hgnc:1323
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A1323%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=1323
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D1323%3E
http://bio2rdf.org/geneid:720
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fgeneid%3A720%3E
http://www.dbpedia.org/resource/C4A
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FC4A%3E
RDF Description of C4A
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/16
_:header14331304221335206363546
Mon, 23 Apr 2012 18:32:38 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/16
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10661490
nucleotide receptor activity, G-protein coupled
47-69
Adenosine A1 receptor
>981 bp	ATGCCGCCCTCCATCTCAGCTTTCCAGGCCGCCTACATCGGCATCGAGGTGCTCATCGCC	CTGGTCTCTGTGCCCGGGAACGTGCTGGTGATCTGGGCGGTGAAGGTGAACCAGGCGCTG	CGGGATGCCACCTTCTGCTTCATCGTGTCGCTGGCGGTGGCTGATGTGGCCGTGGGTGCC	CTGGTCATCCCCCTCGCCATCCTCATCAACATTGGGCCACAGACCTACTTCCACACCTGC	CTCATGGTTGCCTGTCCGGTCCTCATCCTCACCCAGAGCTCCATCCTGGCCCTGCTGGCA	ATTGCGGTGGACCGCTACCTCCGGGTCAAGATCCCTCTCCGGTACAAGATGGTGGTGACC	CCCCGGAGGGCGGCGGTGGCCATAGCCGGCTGCTGGATCCTCTCCTTCGTGGTGGGACTG	ACCCCTATGTTTGGCTGGAACAATCTGAGTGCGGTGGAGCGGGCCTGGGCAGCCAACGGC	AGCATGGGGGAGCCCGTGATCAAGTGCGAGTTCGAGAAGGTCATCAGCATGGAGTACATG	GTCTACTTCAACTTCTTTGTGTGGGTGCTCCCCCCGCTTCTCCTCATGGTCCTCATCTAC	CTGGAGGTCTTCTACCTAATCCGCAAGCAGCTCAACAAGAAGGTGTCGGCCTCCTCCGGC	GACCCGCAGAAGTACTATGGGAAGGAGCTGAAGATCGCCAAGTCGCTGGCCCTCATCCTC	TTCCTCTTTGCCCTCAGCTGGCTGCCTTTGCACATCCTCAACTGCATCACCCTCTTCTGC	CCGTCCTGCCACAAGCCCAGCATCCTTACCTACATTGCCATCTTCCTCACGCACGGCAAC	TCGGCCATGAACCCCATTGTCTATGCCTTCCGCATCCAGAAGTTCCGCGTCACCTTCCTT	AAGATTTGGAATGACCATTTCCGCTGCCAGCCTGCACCTCCCATTGACGAGGATCTCCCA	GAAGAGAGGCCTGATGACTAG
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17085856
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8425287
http://www.genenames.org/data/hgnc_data.php?hgnc_id=262
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D262%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9858381
http://www.dbpedia.org/resource/Adenosine_A1_receptor
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FAdenosine_A1_receptor%3E
ADORA1
177-201
http://bio2rdf.org/hgnc:262
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A262%3E
Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17126319
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/15140630
purinergic nucleotide receptor activity, G-protein coupled
http://bio2rdf.org/uniprot:P30542
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP30542%3E
http://www.uniprot.org/uniprot/P30542
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP30542%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=S45235
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DS45235%3E
S45235
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8300646
268-292
81-102
adenosine receptor activity, G-protein coupled
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1530647
AA1R_HUMAN
236-259
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17372967
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12735630
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1339301
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/15572277
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/15765150
1q32.1
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12126876
http://symbol.bio2rdf.org/symbol:ADORA1
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AADORA1%3E
11-33
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8405101
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9353368
A1 adenosine receptor activity, G-protein coupled
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17162470
124-146
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/14992338
Involved in A1 adenosine receptor activity, G-protein coupled
>Adenosine A1 receptor	MPPSISAFQAAYIGIEVLIALVSVPGNVLVIWAVKVNQALRDATFCFIVSLAVADVAVGA	LVIPLAILINIGPQTYFHTCLMVACPVLILTQSSILALLAIAVDRYLRVKIPLRYKMVVT	PRRAAVAIAGCWILSFVVGLTPMFGWNNLSAVERAWAANGSMGEPVIKCEFEKVISMEYM	VYFNFFVWVLPPLLLMVLIYLEVFYLIRKQLNKKVSASSGDPQKYYGKELKIAKSLALIL	FLFALSWLPLHILNCITLFCPSCHKPSILTYIAIFLTHGNSAMNPIVYAFRIQKFRVTFL	KIWNDHFRCQPAPPIDEDLPEERPDD
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=256155
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D256155%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/16702031
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04932
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01223
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00277
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00201
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00996
RDF Description of Adenosine A1 receptor
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0014550
_:header15124168321335206363951
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0014550
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/798
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F798%3E
http://dbpedia.org/resource/Myoclonic_epilepsy
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FMyoclonic_epilepsy%3E
http://sideeffects.embl.de/se/C0014550
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0014550%3E
Myoclonic Seizures
C0014550
myoclonic epilepsy
RDF Description of Myoclonic Seizures
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01189
_:header5998663431335206364489
Mon, 23 Apr 2012 18:32:39 GMT
RDF Description of Desflurane
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01189
Rapidly absorbed into the circulation via the lungs following inhalation.
3.54e+00 mg/mL
Suprane
http://bio2rdf.org/chebi:4445
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fchebi%3A4445%3E
FC(F)OC(F)C(F)(F)F
PA449232
/drugs/1189/safety_sheets/1113
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/374
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F374%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1090
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1090%3E
http://data.linkedct.org/resource/intervention/35571
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35571%3E
http://bio2rdf.org/kegg:D00546
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD00546%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/540
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F540%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3975
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3975%3E
DPYMFVXJLLWWEU-UHFFFAOYAB
C3H2F6O
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/872
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/705
Desflurane is a general inhalation anesthetic. It induces muscle relaxation and reduces pains sensitivity by altering tissue excitability. It does so by decreasing the extent of gap junction mediated cell-cell coupling and altering the activity of the channels that underlie the action potential.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/482
http://129.128.185.122/drugbank2/drugs/DB01189/inserts/2463/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB01189%2Finserts%2F2463%2Ffull%3E
N01AB07
Desfluranum [INN-Latin]
Desflurane
2008-08-26 14:31:42 UTC
Desflurano [INN-Spanish]
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2666
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2666%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2312
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2312%3E
http://bio2rdf.org/cas:57041-67-5
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A57041-67-5%3E
DB01189
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3974
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3974%3E
Negligible
http://en.wikipedia.org/wiki/Desflurane
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FDesflurane%3E
http://dbpedia.org/resource/Desflurane
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FDesflurane%3E
http://www.dbpedia.org/resource/Desflurane
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FDesflurane%3E
Desflurane is a highly fluorinated methyl ethyl ether used for maintenance of general anaesthesia. Volatile agents such as desflurane may activate GABA channels and hyperpolarize cell membranes. In addition, they may inhibit certain calcium channels and therefore prevent release of neurotransmitters and inhibit glutamate channels. Volatile anesthetics easily partition into cellular membranes and could expand the volume of the cell membrane and subsequently distort channels necessary for sodium ion flux and the development of action potentials necessary for synaptic transmission. Desflurane preconditions human myocardium against ischemia through activation of mitochondrial K(ATP) channels, adenosine A1 receptor, and alpha and beta adrenoceptors.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/neuroprotectiveAgents
2-(difluoromethoxy)-1,1,1,2-tetrafluoroethane
InChI=1/C3H2F6O/c4-1(3(7,8)9)10-2(5)6/h1-2H
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/559
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/anesthetics,Inhalation
23.5 oC (boiling point)
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/liquidRespiratory(inhalation)
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/241
http://129.128.185.122/drugbank2/drugs/DB01189/inserts/1465/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB01189%2Finserts%2F1465%2Ffull%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/372
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F372%3E
For use as an inhalation agent for induction and/or maintenance of anesthesia for inpatient and outpatient surgery in adults.
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2531
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2531%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/858
http://dbpedia.org/page/Desflurane
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FDesflurane%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/479
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F479%3E
http://www.drugbank.ca/drugs/DB01189
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01189%3E
http://bio2rdf.org/cpd:C07519
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC07519%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2331
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2331%3E
FC(F)O[C@H](F)C(F)(F)F
Minimally biotransformed in the liver in humans (approximately 0.02% of the quantity absorbed).
http://www.rxlist.com/cgi/generic2/desflurane.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric2%2Fdesflurane.htm%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/976
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F976%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/537
http://data.linkedct.org/resource/intervention/16971
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F16971%3E
2006-05-01	/drugs/1189/fda_labels/633
aprd00907
28:04.00
http://205.193.93.51/dpdonline/searchRequest.do?din=02227428
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02227428%3E
Desflurane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times. Desflurane also activates calcium dependent ATPase in the sarcoplasmic reticulum by increasing the fluidity of the lipid membrane. It also appears to bind the D subunit of ATP synthase and NADH dehydogenase. Desflurane also binds to the GABA receptor, the large conductance Ca<sup>2+</sup> activated potassium channel, the glutamate receptor and the glycine receptor.
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Lewis_Meriwether_1774-1809
_:header20138073471335206364776
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Lewis_Meriwether_1774-1809
Lewis, Meriwether, 1774-1809
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8419
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext16565
RDF Description of Lewis, Meriwether, 1774-1809
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/1206
_:header12001554321335206365290
Mon, 23 Apr 2012 18:32:40 GMT
RDF Description of DESOXYN
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/1206
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0233477
http://www.fda.gov/cder/foi/label/2007/005378s026lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2007%2F005378s026lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0262630
http://sideeffects.embl.de/drugs/1206
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F1206%3E
http://www.fda.gov/cder/foi/label/2006/005378s024lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2006%2F005378s024lbl.pdf%3E
methamphetamine
CID0000001206
Desoxyn
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0033975
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0013146
DESOXYN
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0151611
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2701
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2701%3E
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000001206
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000001206%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01577
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01577%3E
http://dbpedia.org/resource/Methamphetamine
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FMethamphetamine%3E
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000001206&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000001206%26input_query_species%3D9606%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0011570
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0022107
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0036341
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0028754
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0041671
http://www.fda.gov/cder/foi/label/2001/05378s20ltr.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2001%2F05378s20ltr.pdf%3E
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Prudentius_Aurelius_Clemens
_:header11556828951335206365706
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Prudentius_Aurelius_Clemens
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext14959
Prudentius, Aurelius Clemens
RDF Description of Prudentius, Aurelius Clemens
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/3296
_:header5128046591335206366236
Mon, 23 Apr 2012 18:32:41 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3296
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04099
NMNAT1
coenzyme biosynthesis
http://pfam.sanger.ac.uk/family?acc=PF01467
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF01467%3E
1p32-p35
http://bio2rdf.org/pdb:1KQO
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1KQO%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11891043
nucleus
http://bio2rdf.org/pfam:PF01467
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF01467%3E
http://bio2rdf.org/hgnc:17877
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A17877%3E
NMNA1_HUMAN
http://www.pdb.org/pdb/explore/explore.do?structureId=1KQO
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1KQO%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AF314163
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAF314163%3E
ATP + nicotinamide ribonucleotide = diphosphate + NAD+
Nicotinamide mononucleotide adenylyltransferase 1
>Nicotinamide mononucleotide adenylyltransferase 1	MENSEKTEVVLLACGSFNPITNMHLRLFELAKDYMNGTGRYTVVKGIISPVGDAYKKKGL	IPAYHRVIMAELATKNSKWVEVDTWESLQKEWKETLKVLRHHQEKLEASDCDHQQNSPTL	ERPGRKRKWTETQDSSQKKSLEPKTKAVPKVKLLCGADLLESFAVPNLWKSEDITQIVAN	YGLICVTRAGNDAQKFIYESDVLWKHRSNIHVVNEWIANDISSTKIRRALRRGQSIRYLV	PDLVQEYIEKHNLYSSESEDRNAGVILAPLQRNTAEAKT
http://symbol.bio2rdf.org/symbol:NMNAT1
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ANMNAT1%3E
NAD biosynthesis
pyridine nucleotide biosynthesis
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11751893
ATP + nicotinamide ribonucleotide = diphosphate + NAD(+)
nucleotidyltransferase activity
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=11245478
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D11245478%3E
http://bio2rdf.org/uniprot:Q9HAN9
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ9HAN9%3E
EC 2.7.7.1
map00760	Nicotinate and nicotinamide metabolism
Coenzyme transport and metabolism
cofactor metabolism
>840 bp	ATGGAAAATTCCGAGAAGACTGAAGTGGTTCTCCTTGCTTGTGGTTCATTCAATCCCATC	ACCAACATGCACCTCAGGTTGTTTGAGCTGGCCAAGGACTACATGAATGGAACAGGAAGG	TACACAGTTGTCAAAGGCATCATCTCTCCTGTTGGTGATGCCTACAAGAAGAAAGGACTC	ATTCCTGCCTATCACCGGGTCATCATGGCAGAACTTGCTACCAAGAATTCTAAATGGGTG	GAAGTTGATACATGGGAAAGTCTTCAGAAGGAGTGGAAAGAGACTCTGAAGGTGCTAAGA	CACCATCAAGAGAAATTGGAGGCTAGTGACTGTGATCACCAGCAGAACTCACCTACTCTA	GAAAGGCCTGGAAGGAAGAGGAAGTGGACTGAAACACAAGATTCTAGTCAAAAGAAATCC	CTAGAGCCAAAAACAAAAGCTGTGCCAAAGGTCAAGCTGCTGTGTGGGGCAGATTTATTG	GAGTCCTTTGCTGTTCCCAATTTGTGGAAGAGTGAAGACATCACCCAAATCGTGGCCAAC	TATGGGCTCATATGTGTTACTCGGGCTGGAAATGATGCTCAGAAGTTTATCTATGAATCG	GATGTGCTGTGGAAACACCGGAGCAACATTCACGTGGTGAATGAATGGATCGCTAATGAC	ATCTCATCCACAAAAATCCGGAGAGCCCTCAGAAGGGGCCAGAGCATTCGCTACTTGGTA	CCAGATCTTGTCCAAGAATACATTGAAAAGCATAATTTGTACAGCTCTGAGAGTGAAGAC	AGGAATGCTGGGGTCATCCTGGCCCCTTTGCAGAGAAACACTGCAGAAGCTAAGACATAG
biosynthesis
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11248244
coenzyme metabolism
http://www.uniprot.org/uniprot/Q9HAN9
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ9HAN9%3E
NMN adenylyltransferase 1
http://www.genenames.org/data/hgnc_data.php?hgnc_id=17877
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D17877%3E
AF314163
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01907
RDF Description of Nicotinamide mononucleotide adenylyltransferase 1
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03227
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0022951
_:header1892710481335206366663
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0022951
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5719
http://dbpedia.org/resource/Lactose_intolerance
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FLactose_intolerance%3E
http://sideeffects.embl.de/se/C0022951
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0022951%3E
lactose intolerance
C0022951
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/153941
RDF Description of lactose intolerance
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00853
_:header15764957741335206367129
Mon, 23 Apr 2012 18:32:42 GMT
RDF Description of Temozolomide
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00853
http://data.linkedct.org/resource/intervention/29499
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F29499%3E
http://data.linkedct.org/resource/intervention/14036
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F14036%3E
http://data.linkedct.org/resource/intervention/52970
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F52970%3E
http://bio2rdf.org/cas:85622-93-1
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A85622-93-1%3E
http://data.linkedct.org/resource/intervention/52844
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F52844%3E
http://data.linkedct.org/resource/intervention/24298
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F24298%3E
http://data.linkedct.org/resource/intervention/26079
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F26079%3E
Temodal
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/capsuleOral
http://data.linkedct.org/resource/intervention/29517
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F29517%3E
http://dbpedia.org/resource/Temozolomide
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FTemozolomide%3E
3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
http://data.linkedct.org/resource/intervention/38424
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F38424%3E
Rapid and complete absorption in the gastrointestinal tract
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/874
E. Lunt et al., Ger. pat. 3,231,255 (1983 to May & Baker), C.A. 98, 198285m (1983)
http://data.linkedct.org/resource/intervention/31591
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F31591%3E
Temozolomidum [Latin]
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/antineoplasticAgents,Alkylating
/drugs/853/safety_sheets/672
Temozolomide is not active until it is converted at physiologic pH to the active form, 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC). The cytotoxicity of MTIC is due to alkylation of DNA at the O6 and N7 positions of guanine.
Temozolomide
1999-08-01	/drugs/853/fda_labels/1119
http://www.drugbank.ca/drugs/DB00853
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00853%3E
Temozolodida [Spanish]
http://data.linkedct.org/resource/intervention/52972
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F52972%3E
C6H6N6O2
temozolomide
http://data.linkedct.org/resource/intervention/21289
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F21289%3E
CN1N=NC2=C(N=CN2C1=O)C(N)=O
http://dbpedia.org/page/Temozolomide
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FTemozolomide%3E
http://data.linkedct.org/resource/intervention/52968
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F52968%3E
http://data.linkedct.org/resource/intervention/45382
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F45382%3E
aprd00557
5.09e+00 mg/mL
http://data.linkedct.org/resource/intervention/24386
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F24386%3E
http://data.linkedct.org/resource/intervention/37789
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F37789%3E
http://data.linkedct.org/resource/intervention/52354
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F52354%3E
http://data.linkedct.org/resource/intervention/52976
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F52976%3E
http://data.linkedct.org/resource/intervention/60267
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F60267%3E
DB00853
PA451609
For the treatment of adult patients diagnosed with anaplastic astrocytoma who have relapsed following chemotherapy
2008-08-26 16:21:48 UTC
http://data.linkedct.org/resource/intervention/60153
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F60153%3E
212 oC
Temozolomide (Temodar and Temodal) is an oral alkylating agent used for the treatment of refractory anaplastic astrocytoma -- a type of cancerous brain tumor. Temozolomide is not active until it is converted at physiologic pH to the active form, 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC). The cytotoxicity of MTIC is due to alkylation of DNA at the O6 and N7 positions of guanine.
http://129.128.185.122/drugbank2/drugs/DB00853/inserts/2387/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00853%2Finserts%2F2387%2Ffull%3E
InChI=1/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13)/f/h7H2
http://en.wikipedia.org/wiki/Temozolomide
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FTemozolomide%3E
http://www.dbpedia.org/resource/Temozolomide
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FTemozolomide%3E
Temozolamide
http://data.linkedct.org/resource/intervention/32493
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F32493%3E
Temodar
http://data.linkedct.org/resource/intervention/38784
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F38784%3E
http://data.linkedct.org/resource/intervention/36497
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F36497%3E
http://129.128.185.122/drugbank2/drugs/DB00853/inserts/470/full
http://data.linkedct.org/resource/intervention/34954
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F34954%3E
http://data.linkedct.org/resource/intervention/38912
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F38912%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/68
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F68%3E
L01AX03
Approximately 1.8 hours.
http://www.rxlist.com/cgi/generic2/temoz.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric2%2Ftemoz.htm%3E
http://data.linkedct.org/resource/intervention/52965
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F52965%3E
http://data.linkedct.org/resource/intervention/31215
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F31215%3E
http://data.linkedct.org/resource/intervention/49247
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F49247%3E
http://data.linkedct.org/resource/intervention/14039
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F14039%3E
http://data.linkedct.org/resource/intervention/23283
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F23283%3E
15%
BPEGJWRSRHCHSN-IAUQMDSZCR
http://205.193.93.51/dpdonline/searchRequest.do?din=02241094
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02241094%3E
http://data.linkedct.org/resource/intervention/29528
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F29528%3E
http://129.128.185.122/drugbank2/drugs/DB00853/inserts/1389/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00853%2Finserts%2F1389%2Ffull%3E
http://data.linkedct.org/resource/intervention/44326
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F44326%3E
Temozolomide is an antineoplastic agent. It causes death of of rapidly replicating cells, especially malignant cells, leading to regression or slowed tumor growth.
Methazolastone
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Housman_A_E_1859-1936
_:header3710627381335206367500
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Housman_A_E_1859-1936
Housman, A. E., 1859-1936
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7848
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5720
RDF Description of Housman, A. E., 1859-1936
http://www4.wiwiss.fu-berlin.de/factbook/data/Cape_Verde
_:header1994272851335206367968
https://www.cia.gov/cia/publications/factbook/geos/cv.html
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Fcia%2Fpublications%2Ffactbook%2Fgeos%2Fcv.html%3E
https://www.cia.gov/library/publications/the-world-factbook/flags/cv-lgflag.gif
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Flibrary%2Fpublications%2Fthe-world-factbook%2Fflags%2Fcv-lgflag.gif%3E
https://www.cia.gov/library/publications/the-world-factbook/flags/cv-flag.gif
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Flibrary%2Fpublications%2Fthe-world-factbook%2Fflags%2Fcv-flag.gif%3E
http://www4.wiwiss.fu-berlin.de/factbook/resource/Cape_Verde
Cape Verde
Republica de Cabo Verde
Pedro PIRES reelected president; percent of vote - Pedro PIRES (PAICV) 51.2%, Carlos VIEGA (MPD) 48.8%
new constitution came into force 25 September 1992; a major revision on 23 November 1995 substantially increased the powers of the president; a 1999 revision created the position of national ombudsman (Provedor de Justica)
.cv
The uninhabited islands were discovered and colonized by the Portuguese in the 15th century; Cape Verde subsequently became a trading center for African slaves and later an important coaling and resupply stop for whaling and transatlantic shipping. Following independence in 1975, and a tentative interest in unification with Guinea-Bissau, a one-party system was established and maintained until multi-party elections were held in 1990. Cape Verde continues to exhibit one of Africas most stable democratic governments. Repeated droughts during the second half of the 20th century caused significant hardship and prompted heavy emigration. As a result, Cape Verdes expatriate population is greater than its domestic one. Most Cape Verdeans have both African and Portuguese antecedents.
Supreme Tribunal of Justice or Supremo Tribunal de Justia
1 (plus 7 repeaters)
25.5% of GDP
Mindelo, Praia, Tarrafal
Western Africa, group of islands in the North Atlantic Ocean, west of Senegal
President Pedro Verona PIRES (since 22 March 2001)
17 municipalities (concelhos, singular - concelho); Boa Vista, Brava, Maio, Mosteiros, Paul, Praia, Porto Novo, Ribeira Grande, Sal, Santa Catarina, Santa Cruz, Sao Domingos, Sao Filipe, Sao Miguel, Sao Nicolau, Sao Vicente, Tarrafal
temperate; warm, dry summer; precipitation meager and very erratic
$370400000; including capital expenditures of $NA
5 July 1975 (from Portugal)
major service provider is Cabo Verde Telecom (CVT); fiber optic ring, completed in 2001, links all islands providing Internet access and ISDN services; cellular service introduced in 1998
Praia
Cape Verdean(s)
country code - 238; 2 coaxial submarine cables; HF radiotelephone to Senegal and Guinea-Bissau; satellite earth station - 1 Intelsat (Atlantic Ocean)
Independence Day, 5 July
effective system, extensive modernization from 1996-2000 following partial privatization in 1995
Council of Ministers appointed by the president on the recommendation of the prime minister
This island economy suffers from a poor natural resource base, including serious water shortages exacerbated by cycles of long-term drought. The economy is service-oriented, with commerce, transport, tourism, and public services accounting for 66% of GDP. Although nearly 70% of the population lives in rural areas, the share of food production in GDP in 2004 was only 12%, of which fishing accounted for 1.5%. About 82% of food must be imported. The fishing potential, mostly lobster and tuna, is not fully exploited. Cape Verde annually runs a high trade deficit, financed by foreign aid and remittances from emigrants; remittances supplement GDP by more than 20%. Economic reforms are aimed at developing the private sector and attracting foreign investment to diversify the economy. Future prospects depend heavily on the maintenance of aid flows, the encouragement of tourism, remittances, and the momentum of the governments development program. Cape Verde has been exploring European Union membership in recent years.
Cabo Verde
3.28 children born/woman
steep, rugged, rocky, volcanic
https://www.cia.gov/library/publications/the-world-factbook/maps/cv-map.gif
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Flibrary%2Fpublications%2Fthe-world-factbook%2Fmaps%2Fcv-map.gif%3E
AM 0, FM 22 (plus 12 repeaters), shortwave 0
cv
Cape Verdean escudo (CVE)
derived from the legal system of Portugal
CVE
Atlantic Ocean
Prime Minister Jose Maria Pereira NEVES (since 1 February 2001)
last held 22 January 2006 (next to be held in January 2011)
five unequal horizontal bands; the top-most band of blue - equal to one half the width of the flag - is followed by three bands of white, red, and white, each equal to 1/12 of the width, and a bottom stripe of blue equal to one quarter of the flag width; a circle of 10, yellow, five-pointed stars, each representing one of the islands, is centered on the red stripe and positioned 3/8 of the length of the flag from the hoist side
UTC-1 (4 hours ahead of Washington, DC during Standard Time)
Cape Verdean
unicameral National Assembly or Assembleia Nacional (72 seats; members are elected by popular vote to serve five-year terms)
2 (Spain 1, UK 1)
Mt. Fogo
slightly larger than Rhode Island
percent of vote by party - PAICV 52.3%, MPD 44%, UCID 2.7%; seats by party - PAICV 41, MPD 29, UCID 2
14 55 N, 23 31 W
soil erosion; deforestation due to demand for wood used as fuel; water shortages; desertification; environmental damage has threatened several species of birds and reptiles; illegal beach sand extraction; overfishing
Republic of Cape Verde
225 (as of 2001)
republic
president elected by popular vote for a five-year term (eligible for a second term); election last held 12 February 2006 (next to be held in February 2011); prime minister nominated by the National Assembly and appointed by the president
RDF Description of Cape Verde
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00432
_:header2547905651335206368398
Mon, 23 Apr 2012 18:32:43 GMT
RDF Description of Trifluridine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00432
2008-08-26 14:09:00 UTC
Trifluridine interferes with DNA synthesis in cultured mammalian cells. Trifluridine presumably stops replication of herpes viral DNA in 3 ways: 1) competitive inhibition of viral DNA polymerase, 2) incorporation into and termination of the growing viral DNA chain, and 3) inactivation of the viral DNA polymerase. Trifluridine targets HSV and VSV thymidine kinase.
OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(C(=O)NC1=O)C(F)(F)F
1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione
Trifluridine [USAN:INN]
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/antimetabolites
http://www.rxlist.com/cgi/generic2/trifluridine.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric2%2Ftrifluridine.htm%3E
DB00432
InChI=1/C10H11F3N2O5/c11-10(12,13)4-2-15(9(19)14-8(4)18)7-1-5(17)6(3-16)20-7/h2,5-7,16-17H,1,3H2,(H,14,18,19)/t5-,6+,7+/m0/s1/f/h14H
Systemic absorption of trifluridine following therapeutic dosing with trifluridine ophthalmic appears to be negligible.
C10H11F3N2O5
OCC1OC(CC1O)N1C=C(C(=O)NC1=O)C(F)(F)F
Approximately 12 to 18 minutes following ophthalmic administration.
Human Herpes Virus
PA451775
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2871
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2871%3E
/drugs/432/safety_sheets/1215
http://129.128.185.122/drugbank2/drugs/DB00432/inserts/1710/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00432%2Finserts%2F1710%2Ffull%3E
Viroptic
http://bio2rdf.org/kegg:D00391
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD00391%3E
52:04.20
Virophta
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/359
6.69e+00 mg/mL
186-189 oC
One major metabolite, 5-carboxy-2'-deoxyuridine found on the endothelial side of the cornea, indicating localized metabolism.
Trifluridine
1560 mg/L
S01AD02
aprd01275
F3T
F3TDR
Ophthalmic solution for the treatment of primay keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus, types 1 and 2.
VSQQQLOSPVPRAZ-FKWPSYMCDZ
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/antiviralAgents
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/338
Trifluorothymidine
Trifluridine is a fluorinated pyrimidine nucleoside with in vitro and in vivo activity against herpes simplex virus, types 1 and 2 and vacciniavirus. Some strains of adenovirus are also inhibited in vitro. Trifluridine is also effective in the treatment of epithelial keratitis that has not responded clinically to the topical administration of idoxuridine or when ocular toxicity or hypersensitivity to idoxuridine has occurred. In a smaller number of patients found to be resistant to topical vidarabine, trifluridine was also effective. Trifluridine interferes with DNA synthesis in cultured mammalian cells. However, its antiviral mechanism of action is not completely known.
http://bio2rdf.org/cas:70-00-8
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A70-00-8%3E
F3DThd
Trifluridinum [INN-Latin]
TFDU
Trifluridina [INN-Spanish]
http://dbpedia.org/resource/Trifluridine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FTrifluridine%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/509
http://dbpedia.org/page/Trifluridine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FTrifluridine%3E
Trifluoromethyldeoxyuridine
http://www.drugbank.ca/drugs/DB00432
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00432%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/4122
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F4122%3E
http://129.128.185.122/drugbank2/drugs/DB00432/inserts/2688/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00432%2Finserts%2F2688%2Ffull%3E
http://en.wikipedia.org/wiki/Trifluridine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FTrifluridine%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/solutionOphthalmic
Fluridine
Overdosage by ocular instillation is unlikely because any excess solution should be quickly expelled from the conjunctival sac. Acute overdosage by accidental oral ingestion has not occurred. However, should such ingestion occur, the 75 mg dosage of trifluridine in a 7.5 mL bottle of trifluridine is not likely to produce adverse effects. Single intravenous doses of 1.5 to 30 mg/kg/day in children and adults with neoplastic disease produce reversible bone marrow depression as the only potentially serious toxic effect and only after three to five courses of therapy. The acute oral LD<sub>50</sub> in the mouse and rat was 4379 mg/kg or higher.
http://205.193.93.51/dpdonline/searchRequest.do?din=02248529
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02248529%3E
An antiviral derivative of thymidine used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p557)
TFT
trifluorothymine deoxyriboside
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/181
_:header3944100171335206368931
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/181
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01718
CFA1_MYCTU
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7604045
http://pfam.sanger.ac.uk/family?acc=PF02353
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF02353%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12218036
http://www.uniprot.org/uniprot/Q11195
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ11195%3E
http://bio2rdf.org/pdb:1KPH
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1KPH%3E
transferase activity, transferring one-carbon groups
lipid biosynthesis
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=U27357
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DU27357%3E
Cyclopropane mycolic acid synthase 1
cmaA1
EC 2.1.1.79
>864 bp	ATGCCCGACGAGCTGAAGCCGCACTTCGCCAACGTGCAGGCGCACTACGACCTGTCCGAC	GACTTCTTCCGGCTGTTCCTCGATCCCACTCAGACCTACAGCTGCGCCTACTTCGAGCGC	GACGACATGACGCTGCAAGAGGCGCAGATCGCCAAGATCGATCTCGCGCTGGGCAAACTC	GGATTGCAGCCGGGCATGACACTGTTGGACGTCGGCTGCGGCTGGGGCGCCACCATGATG	CGCGCGGTGGAAAAATACGACGTCAACGTCGTCGGTCTGACCCTGAGCAAAAACCAGGCC	AACCACGTTCAGCAGCTGGTCGCCAACTCCGAAAATCTACGCTCCAAACGCGTTCTGCTG	GCCGGCTGGGAACAGTTTGACGAGCCCGTCGACCGCATCGTCAGCATCGGTGCTTTCGAA	CATTTCGGTCACGAGCGCTACGACGCGTTCTTCAGCCTGGCGCATCGCCTGCTGCCCGCT	GACGGGGTCATGCTGCTGCACACCATCACCGGGTTGCATCCGAAAGAGATCCACGAACGC	GGCCTGCCCATGTCGTTCACCTTCGCTCGTTTCCTGAAATTCATTGTGACCGAGATCTTT	CCGGGTGGGCGGCTGCCCTCGATACCGATGGTGCAGGAGTGTGCCAGCGCAAACGGCTTC	ACCGTCACCAGAGTTCAATCGTTGCAGCCGCACTATGCGAAAACCCTCGACCTCTGGTCC	GCGGCGTTGCAGGCCAACAAGGGCCAGGCCATCGCGCTGCAATCCGAGGAAGTCTACGAG	CGGTATATGAAGTACCTCACCGGCTGCGCCGAGATGTTTCGCATCGGATACATCGACGTC	AACCAGTTCACCTGCCAGAAGTGA
methyltransferase activity
http://bio2rdf.org/uniprot:Q11195
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ11195%3E
http://bio2rdf.org/pfam:PF02353
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF02353%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9634230
CFA synthase
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=886102
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D886102%3E
cyclopropane-fatty-acyl-phospholipid synthase activity
Transfers a methylene group from S-adenosyl-L-methionine to the cis double bond of an unsaturated fatty acid chain resulting in the replacement of the double bond with a methylene bridge. Mycolic acids, which represent the major constituent of mycobacterial cell wall complex, act as substrates
Cyclopropane-fatty-acyl-phospholipid synthase 1
S-adenosylmethionine-dependent methyltransferase activity
Cyclopropane fatty acid synthase
S-adenosyl-L-methionine + phospholipid olefinic fatty acid = S-adenosyl-L-homocysteine + phospholipid cyclopropane fatty acid
U27357
http://www.pdb.org/pdb/explore/explore.do?structureId=1KPH
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1KPH%3E
>Cyclopropane-fatty-acyl-phospholipid synthase 1	MPDELKPHFANVQAHYDLSDDFFRLFLDPTQTYSCAYFERDDMTLQEAQIAKIDLALGKL	GLQPGMTLLDVGCGWGATMMRAVEKYDVNVVGLTLSKNQANHVQQLVANSENLRSKRVLL	AGWEQFDEPVDRIVSIGAFEHFGHERYDAFFSLAHRLLPADGVMLLHTITGLHPKEIHER	GLPMSFTFARFLKFIVTEIFPGGRLPSIPMVQECASANGFTVTRVQSLQPHYAKTLDLWS	AALQANKGQAIALQSEEVYERYMKYLTGCAEMFRIGYIDVNQFTCQK
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00339
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03166
RDF Description of Cyclopropane-fatty-acyl-phospholipid synthase 1
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01752
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04221
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/COL2A1
_:header5140049971335206369244
Mon, 23 Apr 2012 18:32:44 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/COL2A1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3905
http://symbol.bio2rdf.org/symbol:COL2A1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ACOL2A1%3E
COL2A1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/648
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/19
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/876
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1096
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1182
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3981
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1306
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3459
RDF Description of COL2A1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1066
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4156
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2859
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/1161
_:header20031491691335206369645
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1161
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4111
Unipolar depression
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseaseClass/Psychiatric
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/TPH2
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00150
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00150%3E
http://www.dbpedia.org/resource/Major_depressive_disorder
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FMajor_depressive_disorder%3E
RDF Description of Unipolar depression
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Sapir_Edward_1884-1939
_:header5298184111335206370073
Mon, 23 Apr 2012 18:32:45 GMT
RDF Description of Sapir, Edward, 1884-1939
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Sapir_Edward_1884-1939
Sapir, Edward, 1884-1939
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext12629
http://www4.wiwiss.fu-berlin.de/factbook/data/Puerto_Rico
_:header13998030381335206370590
https://www.cia.gov/cia/publications/factbook/geos/rq.html
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Fcia%2Fpublications%2Ffactbook%2Fgeos%2Frq.html%3E
RDF Description of Puerto Rico
http://www4.wiwiss.fu-berlin.de/factbook/resource/Puerto_Rico
https://www.cia.gov/library/publications/the-world-factbook/flags/rq-flag.gif
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Flibrary%2Fpublications%2Fthe-world-factbook%2Fflags%2Frq-flag.gif%3E
increasing numbers of illegal migrants from the Dominican Republic cross the Mona Passage to Puerto Rico each year looking for work
18 years of age; universal; island residents are US citizens but do not vote in US presidential elections
$NA
Senate - percent of vote by party - PNP 43.4%, PPD 40.3%, PIP 9.4%; seats by party - PNP 17, PPD 9, PIP 1; House of Representatives - percent of vote by party - PNP 46.3%, PPD 43.1%, PIP 9.7%; seats by party - PNP 32, PPD 18, PIP 1
Commonwealth of Puerto Rico
rq
digital telephone system; cellular telephone service
Puerto Rico
erosion; occasional drought causing water shortages
ratified 3 March 1952; approved by US Congress 3 July 1952; effective 25 July 1952
Populated for centuries by aboriginal peoples, the island was claimed by the Spanish Crown in 1493 following COLUMBUS second voyage to the Americas. In 1898, after 400 years of colonial rule that saw the indigenous population nearly exterminated and African slave labor introduced, Puerto Rico was ceded to the US as a result of the Spanish-American War. Puerto Ricans were granted US citizenship in 1917. Popularly-elected governors have served since 1948. In 1952, a constitution was enacted providing for internal self government. In plebiscites held in 1967, 1993, and 1998, voters chose not to alter the existing political status.
Anibal ACEVEDO-VILA elected governor; percent of vote - 48.4%
.pr
five equal horizontal bands of red (top and bottom) alternating with white; a blue isosceles triangle based on the hoist side bears a large, white, five-pointed star in the center; design initially influenced by the US flag, but similar to the Cuban flag, with the colors of the bands and triangle reversed
$9600000000; including capital expenditures of $NA (FY99/00)
President George W. BUSH of the US (since 20 January 2001); Vice President Richard B. CHENEY (since 20 January 2001)
1.77 children born/woman
Caribbean, island between the Caribbean Sea and the North Atlantic Ocean, east of the Dominican Republic
Governor Anibal ACEVEDO-VILA (since 2 January 2005)
Supreme Court; Appellate Court; Court of First Instance composed of two sections: a Superior Court and a Municipal Court (justices for all these courts appointed by the governor with the consent of the Senate)
Cerro de Punta
Puerto Rico has one of the most dynamic economies in the Caribbean region. A diverse industrial sector has far surpassed agriculture as the primary locus of economic activity and income. Encouraged by duty-free access to the US and by tax incentives, US firms have invested heavily in Puerto Rico since the 1950s. US minimum wage laws apply. Sugar production has lost out to dairy production and other livestock products as the main source of income in the agricultural sector. Tourism has traditionally been an important source of income, with estimated arrivals of nearly 5000000 tourists in 2004. Growth fell off in 2001-03, largely due to the slowdown in the US economy, recovered in 2004-05, but declined again in 2006.
1 (Saint Vincent and the Grenadines 1)
under the US Constitution, residents of unincorporated territories, such as Puerto Rico, do not vote in elections for US president and vice president; governor elected by popular vote for a four-year term (no term limits); election last held 2 November 2004 (next to be held in November 2008)
https://www.cia.gov/library/publications/the-world-factbook/maps/rq-map.gif
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Flibrary%2Fpublications%2Fthe-world-factbook%2Fmaps%2Frq-map.gif%3E
bicameral Legislative Assembly consists of the Senate (at least 27 seats - currently 29; members are directly elected by popular vote to serve four-year terms) and the House of Representatives (51 seats; members are elected by popular vote to serve four-year terms)
Caribbean Sea
country code - 1-787, 939; satellite earth station - 1 Intelsat; submarine cable to US
24353 km (includes 427 km of expressways)
modern system integrated with that of the US by high-capacity submarine cable and Intelsat with high-speed data capability
commonwealth
mostly mountains with coastal plain belt in north; mountains precipitous to sea on west coast; sandy beaches along most coastal areas
AM 74, FM 53, shortwave 0
3 (US 3)
Senate - last held 2 November 2004 (next to be held November 2008); House of Representatives - last held 2 November 2004 (next to be held in November 2008)
Puerto Rican(s) (US citizens)
slightly less than three times the size of Rhode Island
18 28 N, 66 07 W
US dollar (USD)
Cabinet appointed by the governor with the consent of the legislature
none (territory of the US with commonwealth status)
USD
Puerto Rican
tropical marine, mild; little seasonal temperature variation
UTC-4 (1 hour ahead of Washington, DC during Standard Time)
based on Spanish civil code and within the US Federal system of justice
none (territory of the US with commonwealth status); there are no first-order administrative divisions as defined by the US Government, but there are 78 municipalities (municipios, singular - municipio) at the second order; Adjuntas, Aguada, Aguadilla, Aguas Buenas, Aibonito, Anasco, Arecibo, Arroyo, Barceloneta, Barranquitas, Bayamon, Cabo Rojo, Caguas, Camuy, Canovanas, Carolina, Catano, Cayey, Ceiba, Ciales, Cidra, Coamo, Comerio, Corozal, Culebra, Dorado, Fajardo, Florida, Guanica, Guayama, Guayanilla, Guaynabo, Gurabo, Hatillo, Hormigueros, Humacao, Isabela, Jayuya, Juana Diaz, Juncos, Lajas, Lares, Las Marias, Las Piedras, Loiza, Luquillo, Manati, Maricao, Maunabo, Mayaguez, Moca, Morovis, Naguabo, Naranjito, Orocovis, Patillas, Penuelas, Ponce, Quebradillas, Rincon, Rio Grande, Sabana Grande, Salinas, San German, San Juan, San Lorenzo, San Sebastian, Santa Isabel, Toa Alta, Toa Baja, Trujillo Alto, Utuado, Vega Alta, Vega Baja, Vieques, Villalba, Yabucoa, Yauco
Las Mareas, Mayaguez, San Juan
1 July - 30 June
https://www.cia.gov/library/publications/the-world-factbook/flags/rq-lgflag.gif
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Flibrary%2Fpublications%2Fthe-world-factbook%2Fflags%2Frq-lgflag.gif%3E
San Juan
US Independence Day, 4 July (1776); Puerto Rico Constitution Day, 25 July
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Garnett_Richard_1835-1906
_:header12803542111335206371053
Mon, 23 Apr 2012 18:32:46 GMT
RDF Description of Garnett, Richard, 1835-1906
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Garnett_Richard_1835-1906
Garnett, Richard, 1835-1906
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext16757
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext10095
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0018794
_:header14730921621335206371531
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0018794
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4062
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/488
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F488%3E
http://dbpedia.org/resource/Heart_block
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FHeart_block%3E
http://sideeffects.embl.de/se/C0018794
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0018794%3E
heart block
C0018794
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/16231
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4873
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4828
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3779
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4585
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3736
RDF Description of heart block
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3914
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3494
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/148192
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3869
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/206
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/60815
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3062
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5071
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3958
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2756
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4411
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2474
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/3066
_:header17658751821335206371943
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3066
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00819
lyase activity
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10336468
carbonate dehydratase activity
one-carbon compound metabolism
291-311
http://www.pdb.org/pdb/explore/explore.do?structureId=1RJ6
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1RJ6%3E
>1014 bp	ATGTTGTTCTTCGCTCTCCTGTTAAAGGTGACTTGGATCCTGGCTGCAGATGGGGGTCAC	CACTGGACATATGAAGGCCCACACGGTCAGGACCATTGGCCAACCTCTTATCCTGAGTGT	GGAGGCGATGCCCAGTCCCCCATCAATATCCAGACAGACAGTGTGATATTTGACCCCGAT	CTGCCTGCTGTACAGCCCCATGGATATGACCAGCTTGGGACTGAGCCTTTGGATCTACAC	AATAATGGCCATACAGTGCAGCTTTCCCTGCCCCCAACCCTGCACCTGGGTGGACTGCCC	CGAAAATACACAGCAGCCCAGCTCCACCTGCACTGGGGTCAGAGAGGATCCCTCGAGGGA	TCAGAGCACCAGATCAACAGTGAAGCCACGGCTGCGGAGCTCCACGTGGTTCACTATGAC	TCCCAGTCCTACAGCAGCTTGAGTGAGGCAGCTCAGAAGCCACAGGGCCTGGCTGTCCTA	GGCATCCTCATTGAGGTGGGCGAGACTGAGAATCCAGCTTATGATCACATTCTGAGTCGT	CTACATGAAATAAGATACAAAGATCAGAAGACCTCTGTGCCTCCCTTCAGCGTGAGAGAG	CTGTTCCCCCAACAGCTGGAGCAATTCTTCCGCTACAACGGCTCACTCACAACTCCCCCC	TGCTACCAGAGTGTGCTCTGGACAGTCTTCAACAGAAGGGCCCAGATTTCAATGGGACAG	TTAGAGAAGCTCCAGGAGACATTGTCCTCTACAGAAGAGGACCCCTCTGAGCCCCTTGTA	CAGAACTACAGAGTCCCCCAGCCTCTCAACCAGAGGACCATCTTTGCTTCTTTCATCCAA	GCAGGACCACTGTATACCACAGGAGAGATGCTGGGTCTAGGTGTGGGAATCTTGGCTGGA	TGTCTTTGCCTTCTGCTGGCTGTTTATTTCATCGCTCAAAAAATTAGGAAGAAGCGGCTG	GGAAACAGGAAAAGTGTGGTTTTCACCTCTGCTCGGGCTACCACAGAGGCGTGA
1-15
Carbonate dehydratase XIV
single-passTypeIMembraneProtein(potential)
http://bio2rdf.org/pfam:PF00194
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00194%3E
map00910	Nitrogen metabolism
http://bio2rdf.org/uniprot:Q9WVT6
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ9WVT6%3E
H2CO3 = CO2 + H2O
Carbonic anhydrase 14
Carbonic anhydrase 14 precursor
hydro-lyase activity
carbon-oxygen lyase activity
CAH14_MOUSE
Reversible hydration of carbon dioxide
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=5030908
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D5030908%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AB005450
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAB005450%3E
AB005450
http://bio2rdf.org/pdb:1RJ6
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1RJ6%3E
Ca14
http://www.uniprot.org/uniprot/Q9WVT6
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ9WVT6%3E
CA-XIV
Carbonic anhydrase XIV
EC 4.2.1.1
http://pfam.sanger.ac.uk/family?acc=PF00194
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00194%3E
>Carbonic anhydrase 14 precursor	MLFFALLLKVTWILAADGGHHWTYEGPHGQDHWPTSYPECGGDAQSPINIQTDSVIFDPD	LPAVQPHGYDQLGTEPLDLHNNGHTVQLSLPPTLHLGGLPRKYTAAQLHLHWGQRGSLEG	SEHQINSEATAAELHVVHYDSQSYSSLSEAAQKPQGLAVLGILIEVGETENPAYDHILSR	LHEIRYKDQKTSVPPFSVRELFPQQLEQFFRYNGSLTTPPCYQSVLWTVFNRRAQISMGQ	LEKLQETLSSTEEDPSEPLVQNYRVPQPLNQRTIFASFIQAGPLYTTGEMLGLGVGILAG	CLCLLLAVYFIAQKIRKKRLGNRKSVVFTSARATTEA
zinc ion binding
RDF Description of Carbonic anhydrase 14
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02687
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01395
_:header10732842781335206372442
Mon, 23 Apr 2012 18:32:47 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01395
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00876_DB01395
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2347
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2347%3E
InChI=1/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1
Oral bioavailability is approximately 76%.
30 hours
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/614
http://129.128.185.122/drugbank2/drugs/DB01395/inserts/4191/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB01395%2Finserts%2F4191%2Ffull%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/aldosteroneAntagonists
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3165
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3165%3E
http://dbpedia.org/resource/Drospirenone
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FDrospirenone%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/486
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F486%3E
DB01395
Drospirenona [inn-spanish]
PA10729
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/382
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F382%3E
Drospirenone
C24H30O3
http://www.drugbank.ca/drugs/DB01395
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01395%3E
http://data.linkedct.org/resource/intervention/17181
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F17181%3E
http://www.dbpedia.org/resource/Drospirenone
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FDrospirenone%3E
http://data.linkedct.org/resource/intervention/4536
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F4536%3E
2.25e-03 mg/mL
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/764
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F764%3E
http://205.193.93.51/dpdonline/searchRequest.do?din=02261731
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02261731%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2539
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2539%3E
DRSP
Drospirenone is a synthetic progestin that is an analog to spironolactone. It is found in a number of birth control formulations. Drospirenone differs from other synthetic progestins in that its pharmacological profile in preclinical studies shows it to be closer to the natural progesterone. As such it has anti-mineralocorticoid properties, counteracts the estrogen-stimulated activity of the renin-angiotensin-aldosterone system, and is not androgenic.
Yasmin (drospirenone + ethinylestradiol)
CC12CCC(=O)C=C1C1CC1C1C2CCC2(C)C1C1CC1C21CCC(=O)O1
http://en.wikipedia.org/wiki/Drospirenone
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FDrospirenone%3E
Hepatic, minor (CYP3A4-mediated).
Drospirenone differs from other synthetic progestins in that its pharmacological profile in preclinical studies shows it to be closer to the natural progesterone. As such it has anti-mineralocorticoid properties, counteracts the estrogen-stimulated activity of the renin-angiotensin-aldosterone system, and is not androgenic.
Yaz (drospirenone + ethinylestradiol)
http://bio2rdf.org/cas:67392-87-4
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A67392-87-4%3E
For the prevention of pregnancy in women who elect an oral contraceptive.
http://data.linkedct.org/resource/intervention/59995
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F59995%3E
97%
Progestins such as drospirenone diffuse freely into target cells in the female reproductive tract, mammary gland, hypothalamus, and the pituitary and bind to the progesterone receptor. Once bound to the receptor, progestins slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH surge.
2008-08-26 16:32:59 UTC
Drospirenonum [inn-latin]
http://dbpedia.org/page/Drospirenone
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FDrospirenone%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/136
C[C@]12CCC(=O)C=C1[C@@H]1C[C@@H]1[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1
2007-07-08 17:03:23 UTC
METQSPRSQINEEU-HXCATZOEBK
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00678_DB01395
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00796_DB01395
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01029_DB01395
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01345_DB01395
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01109_DB01395
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00722_DB01395
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00384_DB01395
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00584_DB01395
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00881_DB01395
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00178_DB01395
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00275_DB01395
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00790_DB01395
RDF Description of Drospirenone
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00542_DB01395
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00966_DB01395
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01197_DB01395
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00492_DB01395
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Beaverbrook_Max_Aitken_Baron_1879-1964
_:header14412937151335206372790
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Beaverbrook_Max_Aitken_Baron_1879-1964
Beaverbrook, Max Aitken, Baron, 1879-1964
RDF Description of Beaverbrook, Max Aitken, Baron, 1879-1964
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext15248
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00913
_:header18809367331335206373231
Mon, 23 Apr 2012 18:32:48 GMT
RDF Description of Anileridine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00913
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/988
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F988%3E
DB00913
ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/narcotics
http://en.wikipedia.org/wiki/Anileridine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FAnileridine%3E
Anileridine is a synthetic opioid and strong analgesic medication. It is a narcotic pain reliever used to treat moderate to severe pain. Narcotic analgesics act in the central nervous system (CNS) to relieve pain. Some of their side effects are also caused by actions in the CNS.
CCOC(=O)C1(CCN(CCC2=CC=C(N)C=C2)CC1)C1=CC=CC=C1
N01AH05
Alidine
http://www.drugbank.ca/drugs/DB00913
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00913%3E
83 oC
Sulfathalidine
PA10249
Symptoms of overexposure include dizziness, perspiration, a feeling of warmth, dry mouth, visual difficulty, itching, euphoria, restlessness, nervousness and excitement have been reported.
http://dbpedia.org/page/Anileridine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FAnileridine%3E
Weijlard et al., J. Am. Chem. Soc. 78, 2342 (1956)
Adopol
http://129.128.185.122/drugbank2/drugs/DB00913/inserts/2608/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00913%2Finserts%2F2608%2Ffull%3E
http://www.dbpedia.org/resource/Anileridine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FAnileridine%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/847
LKYQLAWMNBFNJT-UHFFFAOYAF
Hepatic
Nipecotan
Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Opioids such as anileridine close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3733
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3733%3E
http://205.193.93.51/dpdonline/searchRequest.do?din=00010014
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D00010014%3E
Leritine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/opiateAgonists
aprd00741
Anileridine
> 95%
http://bio2rdf.org/cas:144-14-9
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A144-14-9%3E
Apodol
Anileridine, a potent analgesic, is an analog of pethidine. Anileridine is useful for the relief of moderate to severe pain. It may also be used as an analgesic adjunct in general anesthesia in the same manner as meperidine to reduce the amount of anesthetic needed, to facilitate relaxation, and to reduce laryngospasm. In addition, anileridine exerts mild antihistaminic, spasmolytic and antitussive effects. Anileridine's main pharmacologic action is exerted on the CNS. Respiratory depression, when it occurs, is of shorter duration than that seen with morphine or meperidine when equipotent analgesic doses are used.
Anileridina [INN-Spanish]
Phthalylsulfathiazole
2008-08-26 13:59:30 UTC
Anileridine is absorbed by all routes of administration.
For treatment and management of pain (systemic) and for use as an anesthesia adjunct.
1.24e-02 mg/mL
http://dbpedia.org/resource/Anileridine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FAnileridine%3E
http://129.128.185.122/drugbank2/drugs/DB00913/inserts/1620/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00913%2Finserts%2F1620%2Ffull%3E
Leritin
Anileridinum [INN-Latin]
C22H28N2O2
InChI=1/C22H28N2O2/c1-2-26-21(25)22(19-6-4-3-5-7-19)13-16-24(17-14-22)15-12-18-8-10-20(23)11-9-18/h3-11H,2,12-17,23H2,1H3
Apidol
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/683
_:header9468767991335206373653
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/683
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2968
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PPARGC1A
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PPARG
Lipodystrophy
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/BSCL2
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04270
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB04270%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/AGPAT2
http://www.dbpedia.org/resource/Lipodystrophy
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FLipodystrophy%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00159
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00159%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseaseClass/Metabolic
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01076%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01132
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01132%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0023787
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fsider%2Fresource%2Fside_effects%2FC0023787%3E
http://data.linkedct.org/resource/condition/7312
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fcondition%2F7312%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00197
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00197%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04689
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB04689%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00412
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00412%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/LMNA
RDF Description of Lipodystrophy
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2969
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2970
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2966
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2967
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Farina_Salvatore_1846-1918
_:header10486684921335206374104
Mon, 23 Apr 2012 18:32:49 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Farina_Salvatore_1846-1918
Farina, Salvatore, 1846-1918
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19884
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17896
RDF Description of Farina, Salvatore, 1846-1918
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19437
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/1435
_:header4839803301335206374569
RDF Description of Synaptic vesicle glycoprotein 2A
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/1435
multi-passMemb
Synaptic vesicle glycoprotein 2A
627-647
synapticVesicleMembrane
170-190
SV2A
713-731
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/16556440
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9872452
synapticVesicle
Plays a role in the control of regulated secretion in neural and endocrine cells, enhancing selectively low-frequency neurotransmission. Positively regulates vesicle fusion by maintaining the readily releasable pool of secretory vesicles
234-254
http://www.uniprot.org/uniprot/Q7L0J3
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ7L0J3%3E
448-468
SV2A_HUMAN
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/16434140
http://bio2rdf.org/pfam:PF07690
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF07690%3E
http://bio2rdf.org/hgnc:20566
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A20566%3E
599-619
335-355
cytoplasmicVesicle
secretoryVesicle
>Synaptic vesicle glycoprotein 2A	MEEGFRDRAAFIRGAKDIAKEVKKHAAKKVVKGLDRVQDEYSRRSYSRFEEEDDDDDFPA	PSDGYYRGEGTQDEEEGGASSDATEGHDEDDEIYEGEYQGIPRAESGGKGERMADGAPLA	GVRGGLSDGEGPPGGRGEAQRRKEREELAQQYEAILRECGHGRFQWTLYFVLGLALMADG	VEVFVVGFVLPSAEKDMCLSDSNKGMLGLIVYLGMMVGAFLWGGLADRLGRRQCLLISLS	VNSVFAFFSSFVQGYGTFLFCRLLSGVGIGGSIPIVFSYFSEFLAQEKRGEHLSWLCMFW	MIGGVYAAAMAWAIIPHYGWSFQMGSAYQFHSWRVFVLVCAFPSVFAIGALTTQPESPRF	FLENGKHDEAWMVLKQVHDTNMRAKGHPERVFSVTHIKTIHQEDELIEIQSDTGTWYQRW	GVRALSLGGQVWGNFLSCFGPEYRRITLMMMGVWFTMSFSYYGLTVWFPDMIRHLQAVDY	ASRTKVFPGERVEHVTFNFTLENQIHRGGQYFNDKFIGLRLKSVSFEDSLFEECYFEDVT	SSNTFFRNCTFINTVFYNTDLFEYKFVNSRLINSTFLHNKEGCPLDVTGTGEGAYMVYFV	SFLGTLAVLPGNIVSALLMDKIGRLRMLAGSSVMSCVSCFFLSFGNSESAMIALLCLFGG	VSIASWNALDVLTVELYPSDKRTTAFGFLNALCKLAAVLGISIFTSFVGITKAAPILFAS	AALALGSSLALKLPETRGQVLQ
>2247 bp	AGTGCCCCAAGCCCCATCATGGAAGAGGGCTTCCGAGACCGGGCAGCTTTCATCCGTGGG	GCCAAAGACATTGCTAAGGAAGTCAAAAAGCATGCGGCCAAGAAGGTGGTGAAGGGCCTG	GACAGAGTCCAGGACGAATATTCCCGAAGATCGTACTCCCGCTTTGAGGAGGAGGATGAT	GATGATGACTTCCCTGCTCCCAGTGATGGTTATTACCGAGGAGAAGGGACCCAGGATGAG	GAGGAAGGTGGTGCATCCAGTGATGCTACTGAGGGCCATGACGAGGATGATGAGATCTAT	GAAGGGGAATATCAGGGCATTCCCCGGGCAGAGTCTGGGGGCAAAGGCGAGCGGATGGCA	GATGGGGCGCCCCTGGCTGGAGTAAGGGGGGGCTTGAGTGATGGGGAGGGTCCCCCTGGG	GGCCGGGGGGAGGCACAACGACGGAAAGAACGAGAAGAACTGGCCCAACAGTATGAAGCC	ATCCTACGGGAGTGTGGCCACGGCCGCTTCCAGTGGACACTGTATTTTGTGCTTGGTCTG	GCGCTGATGGCTGACGGTGTGGAGGTCTTTGTGGTGGGCTTCGTGCTGCCCAGCGCTGAG	AAAGACATGTGCCTGTCCGACTCCAACAAAGGCATGCTAGGCCTCATCGTCTACCTGGGC	ATGATGGTGGGAGCCTTCCTCTGGGGAGGTCTGGCTGACCGGCTGGGTCGGAGGCAGTGT	CTGCTCATCTCGCTCTCAGTCAACAGCGTCTTCGCCTTCTTCTCATCTTTTGTCCAGGGT	TACGGCACTTTCCTCTTCTGCCGCCTACTTTCTGGGGTTGGGATTGGAGGGTCCATCCCC	ATTGTCTTCTCCTATTTCTCCGAGTTTCTGGCCCAGGAGAAACGAGGGGAGCATTTGAGC	TGGCTCTGCATGTTTTGGATGATTGGTGGCGTGTACGCAGCTGCTATGGCCTGGGCCATC	ATCCCCCACTATGGGTGGAGTTTTCAGATGGGTTCTGCCTACCAGTTCCACAGCTGGAGG	GTCTTCGTCCTCGTCTGCGCCTTTCCTTCTGTGTTTGCCATTGGGGCTCTGACCACGCAG	CCTGAGAGCCCCCGTTTCTTCCTAGAGAATGGAAAGCATGATGAGGCCTGGATGGTGCTG	AAGCAGGTCCATGATACCAACATGCGAGCCAAAGGACATCCTGAGCGAGTGTTCTCAGTA	ACCCACATTAAGACGATTCATCAGGAGGATGAATTGATTGAGATCCAGTCGGACACAGGG	ACCTGGTACCAGCGCTGGGGGGTCCGGGCCTTGAGCCTAGGGGGGCAGGTTTGGGGGAAT	TTTCTCTCCTGTTTTGGTCCCGAATATCGGCGCATCACTCTGATGATGATGGGTGTGTGG	TTCACCATGTCATTCAGCTACTATGGCCTGACCGTCTGGTTTCCTGACATGATCCGCCAT	CTCCAGGCAGTGGACTACGCATCCCGCACCAAAGTGTTCCCCGGGGAGCGCGTAGAGCAT	GTAACTTTTAACTTCACGTTGGAGAATCAGATCCACCGAGGCGGGCAGTACTTCAATGAC	AAGTTCATTGGGCTGCGGCTCAAGTCAGTGTCCTTTGAGGATTCCCTGTTTGAAGAGTGT	TATTTTGAGGATGTCACATCCAGCAACACGTTTTTCCGCAACTGCACATTCATCAACACT	GTGTTCTATAACACTGACCTGTTCGAGTACAAGTTTGTGAACAGCCGTCTGATAAACAGT	ACATTCCTGCACAACAAGGAGGGCTGCCCGCTAGACGTGACAGGGACGGGCGAAGGTGCC	TACATGGTATACTTTGTGAGCTTCCTGGGGACACTGGCAGTGCTTCCTGGGAATATCGTG	TCTGCCCTGCTCATGGACAAGATCGGCAGGCTCAGAATGCTTGCTGGCTCCAGCGTGATG	TCCTGTGTCTCCTGCTTCTTCCTGTCTTTTGGGAACAGTGAGTCGGCCATGATCGCTCTG	CTCTGCCTTTTTGGCGGGGTCAGCATTGCATCCTGGAATGCGCTGGACGTGTTGACTGTT	GAACTCTACCCCTCAGACAAGAGGACCACAGCTTTTGGCTTCCTGAATGCCCTGTGTAAG	CTGGCAGCTGTGCTGGGGATCAGCATCTTCACATCCTTCGTGGGAATCACCAAGGCTGCA	CCCATCCTCTTTGCCTCAGCTGCCCTTGCCCTTGGCAGCTCTCTGGCCCTGAAGCTGCCT	GAGACCCGGGGGCAGGTGCTGCAGTGA
AB018279
263-283
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/15367040
295-315
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/15210974
http://pfam.sanger.ac.uk/family?acc=PF07690
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF07690%3E
http://symbol.bio2rdf.org/symbol:SV2A
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ASV2A%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=40788343
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D40788343%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17431542
652-672
http://www.genenames.org/data/hgnc_data.php?hgnc_id=20566
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D20566%3E
206-226
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AB018279
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAB018279%3E
686-708
1q21.2
http://bio2rdf.org/uniprot:Q7L0J3
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ7L0J3%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01202
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Flinders_Matthew_1774-1814
_:header8090896441335206374869
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Flinders_Matthew_1774-1814
Flinders, Matthew, 1774-1814
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext12929
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13121
RDF Description of Flinders, Matthew, 1774-1814
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/60184
_:header3217325521335206375413
Mon, 23 Apr 2012 18:32:50 GMT
RDF Description of PERINDOPRIL ERBUMINE
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0042373
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0030196
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0025061
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0034069
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0267406
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0032781
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0085580
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020545
Aceon
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0151480
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0023518
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C1456822
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0014742
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0026821
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C1260880
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=SuXRfJhnr3w=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DSuXRfJhnr3w%3D%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0522055
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0019345
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0232492
http://www.fda.gov/medwatch/SAFETY/2003/03Oct_PI/Aceon_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2003%2F03Oct_PI%2FAceon_PI.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0018808
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0009782
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0262428
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0033687
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00790
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00790%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0005758
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0038325
PERINDOPRIL ERBUMINE
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=fgxlYdpl5Ps=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DfgxlYdpl5Ps%3D%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0006145
http://sideeffects.embl.de/drugs/60184
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F60184%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0030807
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0338656
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020903
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C1527407
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0042384
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020458
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0033953
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0018790
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0040247
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0015927
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0019825
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0037383
CID0000060184
http://dbpedia.org/resource/Perindopril
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FPerindopril%3E
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000060184
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000060184%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020461
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0151636
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3448
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3448%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0392525
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0262398
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=7OUBk%2FnfxXw=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3D7OUBk%252FnfxXw%3D%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0277925
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000060184&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000060184%26input_query_species%3D9606%3E
perindopril
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0034150
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020625
http://www.fda.gov/cder/foi/label/2005/020184s011lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2005%2F020184s011lbl.pdf%3E
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=Xjje%2FLCWJ5o=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DXjje%252FLCWJ5o%3D%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0699744
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Sunzi_6th_cent_BC
_:header6504100821335206375827
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Sunzi_6th_cent_BC
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17405
Sunzi, 6th cent. B.C.
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext12407
RDF Description of Sunzi, 6th cent. B.C.
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext132
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/HF1
_:header15483570881335206376221
Mon, 23 Apr 2012 18:32:51 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/HF1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3030
http://symbol.bio2rdf.org/symbol:HF1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AHF1%3E
HF1
http://www.dbpedia.org/resource/Factor_H
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FFactor_H%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3341
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2571
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2361
RDF Description of HF1
http://www4.wiwiss.fu-berlin.de/dailymed/data/organization/sanofi-aventis
_:header20836030601335206376697
RDF Description of sanofi-aventis
http://www4.wiwiss.fu-berlin.de/dailymed/resource/organization/sanofi-aventis
http://www4.wiwiss.fu-berlin.de/dailymed/resource/dailymed/organization
http://data.linkedct.org/resource/agency/420
http://www4.wiwiss.fu-berlin.de/dailymed/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fagency%2F420%3E
http://www.dbpedia.org/resource/Sanofi-Aventis
http://www4.wiwiss.fu-berlin.de/dailymed/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FSanofi-Aventis%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1923
sanofi-aventis
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Atkinson_Eleanor_Stackhouse_1863-1942
_:header17082074821335206377145
Mon, 23 Apr 2012 18:32:52 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Atkinson_Eleanor_Stackhouse_1863-1942
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2693
Atkinson, Eleanor Stackhouse, 1863-1942
RDF Description of Atkinson, Eleanor Stackhouse, 1863-1942
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Morley_Henry_1822-1894
_:header19500421231335206377490
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Morley_Henry_1822-1894
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2173
Morley, Henry, 1822-1894 
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2458
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1739
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext18638
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17667
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2831
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext20934
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext623
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext4010
RDF Description of Morley, Henry, 1822-1894 
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17882
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2706
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17923
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext20933
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6332
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17490
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17574
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17678
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1149
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2176
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/ARL6
_:header17003454841335206377906
RDF Description of ARL6
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/ARL6
http://symbol.bio2rdf.org/symbol:ARL6
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AARL6%3E
ARL6
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/135
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Clough_Arthur_Hugh_1819-1861
_:header378878401335206378367
Mon, 23 Apr 2012 18:32:53 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Clough_Arthur_Hugh_1819-1861
Clough, Arthur Hugh, 1819-1861
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext674
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1393
RDF Description of Clough, Arthur Hugh, 1819-1861
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/320
_:header20811769591335206379135
Mon, 23 Apr 2012 18:32:54 GMT
RDF Description of Diastrophic dysplasia
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/320
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/SLC26A2
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseaseClass/Skeletal
Diastrophic dysplasia
http://www.dbpedia.org/resource/Diastrophic_dysplasia
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FDiastrophic_dysplasia%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2176
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2177
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/915
_:header12274739021335206380078
RDF Description of Delta 1-pyrroline-5-carboxylate synthetase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/915
oxidoreductase activity, acting on the aldehyde or oxo group of donors, NAD or NADP as acceptor
EC 2.7.2.11
glutamine family amino acid metabolism
glutamate 5-kinase activity
ALDH18A1
GK
http://bio2rdf.org/hgnc:9722
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A9722%3E
Aldehyde dehydrogenase 18 family member A1
>2388 bp	ATGTTGAGTCAAGTTTACCGCTGTGGGTTCCAGCCCTTCAACCAACATCTTCTGCCCTGG	GTCAAGTGTACAACCGTCTTCAGATCTCATTGTATCCAGCCTTCAGTCATCAGACATGTT	CGTTCTTGGAGCAACATCCCGTTTATCACTGTACCCCTCAGTCGTACACATGGCAAGTCC	TTCGCCCACCGCAGTGAGCTGAAGCATGCCAAGAGAATCGTGGTGAAGCTCGGCAGTGCC	GTGGTGACCCGAGGGGATGAATGTGGCCTGGCCCTGGGGCGCTTGGCATCTATTGTTGAG	CAGGTATCAGTGCTGCAGAATCAGGGCAGAGAGATGATGCTGGTGACCAGTGGAGCCGTA	GCCTTTGGCAAACAAACGTTGCGCCATGAGATCCTTCTGTCTCAGAGCGTGCGGCAGGCC	CTCCACTCGGGGCAGAACCAGCTGAAAGAAATGGCAATTCCAGTCTTAGAGGCACGAGCC	TGTGCAGCTGCCGGACAGAGTGGGCTGATGGCCTTGTATGAGGCTATGTTTACCCAGTAC	AGCATCTGTGCTGCCCAGATTTTGGTGACCAATTTGGATTTCCATGATGAGCAGAAGCGC	CGGAACCTCAATGGAACACTTCATGAACTCCTTAGAATGAACATTGTCCCCATTGTCAAC	ACAAATGATGCTGTTGTCCCCCCAGCTGAGCCCAACAGTGACCTGCAGGGGGTAAATGTT	ATTAGTGTTAAAGATAATGATAGCCTGGCTGCCCGACTGGCTGTGGAAATGAAAACTGAT	CTCTTGATTGTCCTTCCAGATGTAGAAGGCCTTTTTGACAGCCCCCCAGGTTCAGATGAT	GCAAAGCTTATTGATATATTTTATCCCGGAGATCAGCAGTCTGTGACATTTGGACCCAAG	TCTAGAGTGGGAAATGGGTGCATGGAAGCCAAGGTGAAAAGCACCCTCTGGGCTTTGCAA	GGTGGCACTTCTGTTGTTATTGCCAATGGAACCCACCCAAAGGTGTCTGGGCACGTCATC	ACAGACATTGTGGAGGGGAAGAAAGTTGGTACCTTCTTTTCAGAAGTAAAGCCTGCAGGC	CCTACTGTTGAGCAGCAGGGAGAAATGGCGCGATCTGGAGGAAGGATGTTGGCCACCTTG	GAACCTGAGCAGAGAGCAGAAATTATCCATCATCTGGCTGATCTGTTGACGGACCAGCGT	GATGAGATCCTGTTAGCCAACAAAAAAGACTTGGAGGAGGCAGAGGGGAGACTTGCAGCT	CCTCTGCTGAAACGTTTAAGCCTCTCCACATCCAAATTGAACAGCCTGGCCATCGGTCTG	CGACAGATCGCAGCCTCCTCCCAGGACAGCGTGGGACGTGTTTTGCGCCGCACCCGAATC	GCCAAAAACTTGGAACTGGAACAAGTGACTGTCCCAATTGGAGTTCTGCTGGTGATCTTT	GAATCTCGTCCTGACTGTCCTACCCCAGGTGGCAGCTTTGCTATCGCAAGTGGCAATGGC	TTGTTACTCAAAGGAGGGAAGGAGGCTGCACACAGCAACCGGATTCTCCACCTCCTGACC	CAGGAGGCTCTCTCAATCCATGGAGTCAAGGAGGCCGTGCAACTGGTGAATACCAGAGAA	GAAGTTGAAGATCTTTGCCGCCTAGACAAAATGATAGATCTGATCATTCCACGTGGCTCT	TCCCAGCTGGTCAGAGACATCCAGAAAGCTGCTAAGGGGATTCCAGTGATGGGGCACAGC	GAAGGGATCTGTCACATGTATGTGGATTCCGAGGCCAGTGTTGATAAGGTCACCAGGCTA	GTCAGAGACTCTAAATGTGAATATCCAGCTGCCTGTAATGCTTTGGAGACTTTGTTAATC	CACCGGGATCTGCTCAGGACACCATTATTTGACCAGATCATTGATATGCTGAGAGTGGAA	CAGGTAAAAATTCATGCAGGCCCCAAATTTGCCTCCTATCTGACCTTCAGCCCCTCCGAA	GTGAAGTCACTCCGAACTGAGTATGGGGACCTGGAATTATGCATTGAAGTAGTGGACAAC	GTTCAGGATGCCATTGACCACATCCACAAGTATGGCAGCTCCCACACGGATGTCATCGTC	ACAGAGGACGAAAACACAGCGGAGTTCTTCCTGCAGCACGTAGACAGTGCCTGTGTGTTC	TGGAATGCCAGCACTCGCTTTTCTGATGGTTACCGCTTTGGACTGGGAGCTGAAGTGGGA	ATCAGTACATCGAGAATCCACGCCCGGGGACCAGTAGGACTTGAGGGACTGCTTACTACT	AAGTGGCTGCTGCGAGGGAAGGACCACGTGGTCTCAGATTTCTCAGAGCATGGAAGTTTA	AAATATCTTCATGAGAACCTCCCTATTCCTCAGAGAAACACCAACTGA
10q24.3
oxidoreductase activity, acting on the aldehyde or oxo group of donors
X94453
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=X94453
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DX94453%3E
http://bio2rdf.org/uniprot:P54886
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP54886%3E
proline biosynthesis
Amino acid transport and metabolism
Delta 1-pyrroline-5-carboxylate synthetase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12513997
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9622938
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8761662
P5CS_HUMAN
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/114173
proline metabolism
http://www.uniprot.org/uniprot/P54886
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP54886%3E
Gamma-glutamyl kinase
glutamate-5-semialdehyde dehydrogenase activity
Gamma-glutamyl phosphate reductase
amino acid biosynthesis
phosphotransferase activity, carboxyl group as acceptor
intracellular
http://bio2rdf.org/pfam:PF00696
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00696%3E
GPR
EC 1.2.1.41
mitochondrion
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=1304314
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D1304314%3E
P5CS
>Delta 1-pyrroline-5-carboxylate synthetase	MLSQVYRCGFQPFNQHLLPWVKCTTVFRSHCIQPSVIRHVRSWSNIPFITVPLSRTHGKS	FAHRSELKHAKRIVVKLGSAVVTRGDECGLALGRLASIVEQVSVLQNQGREMMLVTSGAV	AFGKQRLRHEILLSQSVRQALHSGQNQLKEMAIPVLEARACAAAGQSGLMALYEAMFTQY	SICAAQILVTNLDFHDEQKRRNLNGTLHELLRMNIVPIVNTNDAVVPPAEPNSDLQGVNV	ISVKDNDSLAARLAVEMKTDLLIVLSDVEGLFDSPPGSDDAKLIDIFYPGDQQSVTFGTK	SRVGMGGMEAKVKAALWALQGGTSVVIANGTHPKVSGHVITDIVEGKKVGTFFSEVKPAG	PTVEQQGEMARSGGRMLATLEPEQRAEIIHHLADLLTDQRDEILLANKKDLEEAEGRLAA	PLLKRLSLSTSKLNSLAIGLRQIAASSQDSVGRVLRRTRIAKNLELEQVTVPIGVLLVIF	ESRPDCLPQVAALAIASGNGLLLKGGKEAAHSNRILHLLTQEALSIHGVKEAVQLVNTRE	EVEDLCRLDKMIDLIIPRGSSQLVRDIQKAAKGIPVMGHSEGICHMYVDSEASVDKVTRL	VRDSKCEYPAACNALETLLIHRDLLRTPLFDQIIDMLRVEQVKIHAGPKFASYLTFSPSE	VKSLRTEYGDLELCIEVVDNVQDAIDHIHKYGSSHTDVIVTEDENTAEFFLQHVDSACVF	WNASTRFSDGYRFGLGAEVGISTSRIHARGPVGLEGLLTTKWLLRGKDHVVSDFSEHGSL	KYLHENLPIPQRNTN
mitochondrialInnerMembrane
L-glutamate 5-semialdehyde + phosphate + NADP+ = L-glutamyl 5-phosphate + NADPH + H+
Glutamate-5-semialdehyde dehydrogenase
http://pfam.sanger.ac.uk/family?acc=PF00696
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00696%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10037775
http://www.genenames.org/data/hgnc_data.php?hgnc_id=9722
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D9722%3E
map00220	Urea cycle and metabolism of amino groups
http://symbol.bio2rdf.org/symbol:ALDH18A1
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AALDH18A1%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00142
http://www4.wiwiss.fu-berlin.de/factbook/data/Angola
_:header16446179771335206380998
Mon, 23 Apr 2012 18:32:55 GMT
https://www.cia.gov/library/publications/the-world-factbook/flags/ao-flag.gif
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Flibrary%2Fpublications%2Fthe-world-factbook%2Fflags%2Fao-flag.gif%3E
https://www.cia.gov/cia/publications/factbook/geos/ao.html
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Fcia%2Fpublications%2Ffactbook%2Fgeos%2Fao.html%3E
http://www4.wiwiss.fu-berlin.de/factbook/resource/Angola
http://www4.wiwiss.fu-berlin.de/factbook/resource/Congo_Republic_of_the
slightly less than twice the size of Texas
two equal horizontal bands of red (top) and black with a centered yellow emblem consisting of a five-pointed star within half a cogwheel crossed by a machete (in the style of a hammer and sickle)
6.27 children born/woman
President Jose Eduardo DOS SANTOS (since 21 September 1979); note - the president is both chief of state and head of government
Council of Ministers appointed by the president
AM 21, FM 6, shortwave 7
overuse of pastures and subsequent soil erosion attributable to population pressures; desertification; deforestation of tropical rain forest, in response to both international demand for tropical timber and to domestic use as fuel, resulting in loss of biodiversity; soil erosion contributing to water pollution and siltation of rivers and dams; inadequate supplies of potable water
Republic of Angola
Angolas high growth rate is driven by its oil sector, with record oil prices and rising petroleum production. Oil production and its supporting activities contribute about half of GDP and 90% of exports. Increased oil production supported 12% growth in 2004, 19% growth in 2005, and nearly 14% growth in 2006. A postwar reconstruction boom and resettlement of displaced persons has led to high rates of growth in construction and agriculture as well. Much of the countrys infrastructure is still damaged or undeveloped from the 27-year-long civil war. Remnants of the conflict such as widespread land mines still mar the countryside even though an apparently durable peace was established after the death of rebel leader Jonas SAVIMBI in February 2002. Subsistence agriculture provides the main livelihood for most of the people, but half of the countrys food must still be imported. In 2005, the government started using a $2000000000 line of credit from China to rebuild Angolas public infrastructure, and several large-scale projects were completed in 2006. The central bank in 2003 implemented an exchange rate stabilization program using foreign exchange reserves to buy kwanzas out of circulation. This policy became more sustainable in 2005 because of strong oil export earnings; it has significantly reduced inflation. Although consumer inflation declined from 325% in 2000 to about 13% in 2006, the stabilization policy has put pressure on international net liquidity. To fully take advantage of its rich national resources - gold, diamonds, extensive forests, Atlantic fisheries, and large oil deposits - Angola will need to implement government reforms and to reduce corruption. The government has made little progress on reforms recommended by the IMF, such as promoting greater transparency in government spending, and continues to be without a formal monitoring agreement with the institution. Corruption, especially in the extractive sectors, is a major challenge facing Angola.
president elected by universal ballot for a five-year term (eligible for a second consecutive or discontinuous term) under the 1992 constitution; President DOS SANTOS originally elected (in 1979) without opposition under a one-party system and stood for reelection in Angolas first multiparty elections 29-30 September 1992 (next to be held in 2009)
semiarid in south and along coast to Luanda; north has cool, dry season (May to October) and hot, rainy season (November to April)
many Cabindan separatists have returned to the province from exile since the 2006 ceasefire and peace agreement; concerns from international experts and local populations over the Okavango Delta ecology in Botswana and human displacement scuttled Namibian plans to construct a hydroelectric dam at Popavalle (Popa Falls) along the Angola-Namibia border
last held 29-30 September 1992 (next to be held in September 2008)
AOA
Jose Eduardo DOS SANTOS 49.6%, Jonas SAVIMBI 40.1%, making a run-off election necessary; the run-off was not held and SAVIMBIs National Union for the Total Independence of Angola (UNITA) repudiated the results of the first election; the civil war resumed leaving DOS SANTOS in his current position as the president
5 (Bahamas 5)
17 years of age for compulsory military service; conscript service obligation - 2 years plus time for training
8 48 S, 13 14 E
45870000000 cu m (1 January 2005 est.)
Angola
Angola is rebuilding its country after the end of a 27-year civil war in 2002. Fighting between the Popular Movement for the Liberation of Angola (MPLA), led by Jose Eduardo DOS SANTOS, and the National Union for the Total Independence of Angola (UNITA), led by Jonas SAVIMBI, followed independence from Portugal in 1975. Peace seemed imminent in 1992 when Angola held national elections, but UNITA renewed fighting after being beaten by the MPLA at the polls. Up to 1500000 lives may have been lost - and 1500000 people displaced - in the quarter century of fighting. SAVIMBIs death in 2002 ended UNITAs insurgency and strengthened the MPLAs hold on power. While President DOS SANTOS had pledged to hold legislative elections in 2007, he has since announced that legislative elections will be held in 2008, with Presidential elections planned for 2009. A specific election timetable has yet to be established.
Morro de Moco
14.6% of GDP
Independence Day, 11 November
adopted by Peoples Assembly 25 August 1992
32.7% of GDP
limited system of wire, microwave radio relay, and tropospheric scatter
telephone service limited mostly to government and business use; HF radiotelephone used extensively for military links
11 November 1975 (from Portugal)
Luanda
country code - 244; satellite earth stations - 29; fiber optic submarine cable (SAT-3/WASC) provides connectivity to Europe and Asia
President Jose Eduardo DOS SANTOS (since 21 September 1979); Fernando de Piedade Dias DOS SANTOS was appointed prime minister on 6 December 2002
https://www.cia.gov/library/publications/the-world-factbook/flags/ao-lgflag.gif
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Flibrary%2Fpublications%2Fthe-world-factbook%2Fflags%2Fao-lgflag.gif%3E
18 provinces (provincias, singular - provincia); Bengo, Benguela, Bie, Cabinda, Cuando Cubango, Cuanza Norte, Cuanza Sul, Cunene, Huambo, Huila, Luanda, Lunda Norte, Lunda Sul, Malanje, Moxico, Namibe, Uige, Zaire
Angolan
Republica de Angola
narrow coastal plain rises abruptly to vast interior plateau
http://www4.wiwiss.fu-berlin.de/factbook/resource/Zambia
republic; multiparty presidential regime
https://www.cia.gov/library/publications/the-world-factbook/maps/ao-map.gif
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Flibrary%2Fpublications%2Fthe-world-factbook%2Fmaps%2Fao-map.gif%3E
Cabinda, Luanda, Soyo
based on Portuguese civil law system and customary law; recently modified to accommodate political pluralism and increased use of free markets
Angolan(s)
Southern Africa, bordering the South Atlantic Ocean, between Namibia and Democratic Republic of the Congo
$9700000000; including capital expenditures of $9700000000
Supreme Court and separate provincial courts (judges are appointed by the president)
unicameral National Assembly or Assembleia Nacional (220 seats; members elected by proportional vote to serve four-year terms)
ao
percent of vote by party - MPLA 54%, UNITA 34%, other 12%; seats by party - MPLA 129, UNITA 70, PRS 6, FNLA 5, PLD 3, other 7
kwanza (AOA)
.ao
http://www4.wiwiss.fu-berlin.de/factbook/resource/Namibia
RDF Description of Angola
http://www4.wiwiss.fu-berlin.de/factbook/resource/Congo_Democratic_Republic_of_the
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/4114
_:header6351970231335206381570
Mon, 23 Apr 2012 18:32:56 GMT
RDF Description of METHOXSALEN
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4114
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000004114&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000004114%26input_query_species%3D9606%3E
UVADEX
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00553
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00553%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0162835
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0026113
METHOXSALEN
http://dbpedia.org/resource/Methoxsalen
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FMethoxsalen%3E
Oxsoralen-Ultra
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0023218
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=Df3KlIOnfEY=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DDf3KlIOnfEY%3D%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2732
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2732%3E
http://www.fda.gov/cder/foi/label/2003/09048slr037_methoxsalen_lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2003%2F09048slr037_methoxsalen_lbl.pdf%3E
Methoxsalen
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=l4wqC713Hsw=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3Dl4wqC713Hsw%3D%3E
http://www.fda.gov/cder/foi/label/2003/19600slr006,009_oxsoralen-ultra_lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2003%2F19600slr006%2C009_oxsoralen-ultra_lbl.pdf%3E
OXSORALEN
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2991
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2991%3E
http://sideeffects.embl.de/drugs/4114
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F4114%3E
CID0000004114
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000004114
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000004114%3E
8-MOP
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0151744
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0042900
http://www.fda.gov/cder/foi/label/1999/20969lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F1999%2F20969lbl.pdf%3E
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=hmip%2FiqP2hM=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3Dhmip%252FiqP2hM%3D%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0016436
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/AKT2
_:header1253522251335206381982
RDF Description of AKT2
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/AKT2
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/gene/AKT2
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fgene%2FAKT2%3E
http://symbol.bio2rdf.org/symbol:AKT2
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AAKT2%3E
AKT2
http://bio2rdf.org/hgnc:392
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A392%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=392
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D392%3E
http://bio2rdf.org/geneid:208
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fgeneid%3A208%3E
http://www.dbpedia.org/resource/AKT2
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FAKT2%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2170
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/319
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Arthur_Wellesley_Duke_of_Wellington_1769-1852
_:header7552814631335206382462
Mon, 23 Apr 2012 18:32:57 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Arthur_Wellesley_Duke_of_Wellington_1769-1852
Arthur Wellesley, Duke of Wellington, 1769-1852
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext15254
RDF Description of Arthur Wellesley, Duke of Wellington, 1769-1852
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/3233
_:header12377372321335206382891
RDF Description of Bile acid receptor
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3233
regulation of metabolism
http://www.genenames.org/data/hgnc_data.php?hgnc_id=7967
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D7967%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10334992
RXR-interacting protein 14
DNA binding
Bile acid receptor
regulation of biological process
http://bio2rdf.org/pdb:1OSH
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1OSH%3E
steroid hormone receptor activity
regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism
regulation of transcription
Farnesol receptor HRR-1
http://bio2rdf.org/pfam:PF00104
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00104%3E
Retinoid X receptor-interacting protein 14
NR1H4_HUMAN
http://bio2rdf.org/uniprot:Q96RI1
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ96RI1%3E
http://symbol.bio2rdf.org/symbol:NR1H4
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ANR1H4%3E
http://bio2rdf.org/hgnc:7967
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A7967%3E
nucleic acid binding
ligand-dependent nuclear receptor activity
12q23.1
NR1H4
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12062799
http://pfam.sanger.ac.uk/family?acc=PF00104
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00104%3E
regulation of physiological process
transcription factor activity
>Bile acid receptor	MVMQFQGLENPIQISPHCSCTPSGFFMEMMSMKPAKGVLTEQVAGPLGQNLEVEPYSQYS	NVQFPQVQPQISSSSYYSNLGFYPQQPEEWYSPGIYELRRMPAETLYQGETEVAEMPVTK	KPRMGASAGRIKGDELCVVCGDRASGYHYNALTCEGCKGFFRRSITKNAVYKCKNGGNCV	MDMYMRRKCQECRLRKCKEMGMLAECMYTGLLTEIQCKSKRLRKNVKQHADQTVNEDSEG	RDLRQVTSTTKSCREKTELTPDQQTLLHFIMDSYNKQRMPQEITNKILKEEFSAEENFLI	LTEMATNHVQVLVEFTKKLPGFQTLDHEDQIALLKGSAVEAMFLRSAEIFNKKLPSGHSD	LLEERIRNSGISDEYITPMFSFYKSIGELKMTQEEYALLTAIVILSPDRQYIKDREAVEK	LQEPLLDVLQKLCKIHQPENPQHFACLLGRLTELRTFNHHHAEMLMSWRVNDHKFTPLLC	EIWDVQ
>1419 bp	ATGGGATCAAAAATGAATCTCATTGAACATTCCCATTTACCTACCACAGATGAATTTTCT	TTTTCTGAAAATTTATTTGGTGTTTTAACAGAACAAGTGGCAGGTCCTCTGGGACAGAAC	CTGGAAGTGGAACCATACTCGCAATACAGCAATGTTCAGTTTCCCCAAGTTCAACCACAG	ATTTCCTCGTCATCCTATTATTCCAACCTGGGTTTCTACCCCCAGCAGCCTGAAGAGTGG	TACTCTCCTGGAATATATGAACTCAGGCGTATGCCAGCTGAGACTCTCTACCAGGGAGAA	ACTGAGGTAGCAGAGATGCCTGTAACAAAGAAGCCCCGCATGGGCGCGTCAGCAGGGAGG	ATCAAAGGGGATGAGCTGTGTGTTGTTTGTGGAGACAGAGCCTCTGGATACCACTATAAT	GCACTGACCTGTGAGGGGTGTAAAGGTTTCTTCAGGAGAAGCATTACCAAAAACGCTGTG	TACAAGTGTAAAAACGGGGGCAACTGTGTGATGGATATGTACATGCGAAGAAAGTGTCAA	GAGTGTCGACTAAGGAAATGCAAAGAGATGGGAATGTTGGCTGAATGCTTGTTAACTGAA	ATTCAGTGTAAATCTAAGCGACTGAGAAAAAATGTGAAGCAGCATGCAGATCAGACCGTG	AATGAAGACAGTGAAGGTCGTGACTTGCGACAAGTGACCTCGACAACAAAGTCATGCAGG	GAGAAAACTGAACTCACCCCAGATCAACAGACTCTTCTACATTTTATTATGGATTCATAT	AACAAACAGAGGATGCCTCAGGAAATAACAAATAAAATTTTAAAAGAAGAATTCAGTGCA	GAAGAAAATTTTCTCATTTTGACGGAAATGGCAACCAATCATGTACAGGTTCTTGTAGAA	TTCACAAAAAAGCTACCAGGATTTCAGACTTTGGACCATGAAGACCAGATTGCTTTGCTG	AAAGGGTCTGCGGTTGAAGCTATGTTCCTTCGTTCAGCTGAGATTTTCAATAAGAAACTT	CCGTCTGGGCATTCTGACCTATTGGAAGAAAGAATTCGAAATAGTGGTATCTCTGATGAA	TATATAACACCTATGTTTAGTTTTTATAAAAGTATTGGGGAACTGAAAATGACTCAAGAG	GAGTATGCTCTGCTTACAGCAATTGTTATCCTGTCTCCAGATAGACAATACATAAAGGAT	AGAGAGGCAGTAGAGAAGCTTCAGGAGCCACTTCTTGATGTGCTACAAAAGTTGTGTAAG	ATTCACCAGCCTGAAAATCCTCAACACTTTGCCTGTCTCCTGGGTCGCCTGACTGAATTA	CGGACATTCAATCATCACCACGCTGAGATGCTGATGTCATGGAGAGTAAACGACCACAAG	TTTACCCCACTTCTCTGTGAAATCTGGGACGTGCAGTGA
regulation of cellular metabolism
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=U68233
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DU68233%3E
U68233
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10334993
http://bio2rdf.org/pfam:PF00105
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00105%3E
http://www.uniprot.org/uniprot/Q96RI1
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ96RI1%3E
Receptor for bile acids such as chenodeoxycholic acid, lithocholic acid and deoxycholic acid. Represses the transcription of the cholesterol 7-alpha-hydroxylase gene (CYP7A1) and activates the intestinal bile acid-binding protein (IBABP). Activates the transcription of bile salt export pump ABCB11 by directly recruiting histone methyltransferase CARM1 within its gene locus
nucleus(probable)
http://pfam.sanger.ac.uk/family?acc=PF00105
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00105%3E
Involved in transcription factor activity
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=1546084
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D1546084%3E
http://www.pdb.org/pdb/explore/explore.do?structureId=1OSH
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1OSH%3E
Farnesoid X-activated receptor
regulation of transcription, DNA-dependent
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02545
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0034065
_:header6204251211335206383326
Mon, 23 Apr 2012 18:32:58 GMT
http://dbpedia.org/resource/Pulmonary_embolism
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FPulmonary_embolism%3E
http://sideeffects.embl.de/se/C0034065
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0034065%3E
Pulmonary Embolism
C0034065
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/disease/Pulmonary_Embolism
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fdisease%2FPulmonary_Embolism%3E
pulmonary embolus
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5734
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/564
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/42615
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2800
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4536
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/115237
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/19090
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2284
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2349
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5515
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/150610
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2578
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4112
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5329102
RDF Description of Pulmonary Embolism
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5526
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/60854
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0032519
_:header17689991851335206383832
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0032519
http://sideeffects.embl.de/se/C0032519
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0032519%3E
polymenorrhea
C0032519
RDF Description of polymenorrhea
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Broughton_Rhoda_1840-1920
_:header4134143291335206384153
Mon, 23 Apr 2012 18:32:59 GMT
RDF Description of Broughton, Rhoda, 1840-1920
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Broughton_Rhoda_1840-1920
Broughton, Rhoda, 1840-1920
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext12304
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0029429
_:header16378525371335206384632
RDF Description of osteochondrosis
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0029429
http://dbpedia.org/resource/Osteochondrosis
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FOsteochondrosis%3E
http://sideeffects.embl.de/se/C0029429
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0029429%3E
osteochondrosis
C0029429
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/1017
_:header430398941335206385184
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/1017
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=M11880
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DM11880%3E
CRP_HUMAN
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8599761
http://bio2rdf.org/hgnc:2367
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A2367%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10780315
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11204580
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/15864233
Displays several functions associated with host defense:it promotes agglutination, bacterial capsular swelling, phagocytosis and complement fixation through its calcium-dependent binding to phosphorylcholine. Can interact with DNA and histones and may scavenge nuclear material released from damaged circulating cells
http://symbol.bio2rdf.org/symbol:CRP
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ACRP%3E
>675 bp	ATGGAGAAGCTGTTGTGTTTCTTGGTCTTGACCAGCCTCTCTCATGCTTTTGGCCAGACA	GACATGTCGAGGAAGGCTTTTGTGTTTCCCAAAGAGTCGGATACTTCCTATGTATCCCTC	AAAGCACCGTTAACGAAGCCTCTCAAAGCCTTCACTGTGTGCCTCCACTTCTACACGGAA	CTGTCCTCGACCCGTGGGTACAGTATTTTCTCGTATGCCACCAAGAGACAAGACAATGAG	ATTCTCATATTTTGGTCTAAGGATATAGGATACAGTTTTACAGTGGGTGGGTCTGAAATA	TTATTCGAGGTTCCTGAAGTCACAGTAGCTCCAGTACACATTTGTACAAGCTGGGAGTCC	GCCTCAGGGATCGTGGAGTTCTGGGTAGATGGGAAGCCCAGGGTGAGGAAGAGTCTGAAG	AAGGGATACACTGTGGGGGCAGAAGCAAGCATCATCTTGGGGCAGGAGCAGGATTCCTTC	GGTGGGAACTTTGAAGGAAGCCAGTCCCTAGTGGGAGACATTGGAAATGTGAACATGTGG	GACTTTGTGCTGTCACCAGATGAGATTAACACCATCTATCTTGGCGGGCCCTTCAGTCCT	AATGTCCTGAACTGGCGGGCACTGAAGTATGAAGTGCAAGGCGAAGTGTTCACCAAACCC	CAGCTGTGGCCCTGA
Involved in host defense response
CRP
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12768071
C-reactive protein precursor
http://www.genenames.org/data/hgnc_data.php?hgnc_id=2367
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D2367%3E
C-reactive protein
http://bio2rdf.org/pfam:PF00354
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00354%3E
http://www.pdb.org/pdb/explore/explore.do?structureId=1LJ7
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1LJ7%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/762075
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=181066
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D181066%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10368284
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3840479
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/6685157
http://bio2rdf.org/pdb:1LJ7
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1LJ7%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11806795
http://pfam.sanger.ac.uk/family?acc=PF00354
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00354%3E
http://bio2rdf.org/uniprot:P02741
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP02741%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12803732
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12945719
http://www.uniprot.org/uniprot/P02741
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP02741%3E
>C-reactive protein precursor [Contains: C-reactive protein(1-205)]	MEKLLCFLVLTSLSHAFGQTDMSRKAFVFPKESDTSYVSLKAPLTKPLKAFTVCLHFYTE	LSSTRGYSIFSYATKRQDNEILIFWSKDIGYSFTVGGSEILFEVPEVTVAPVHICTSWES	ASGIVEFWVDGKPRVRKSLKKGYTVGAEASIILGQEQDSFGGNFEGSQSLVGDIGNVNMW	DFVLSPDEINTIYLGGPFSPNVLNWRALKYEVQGEVFTKPQLWP
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2997165
M11880
1q21-q23
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7881902
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/403526
1-18
http://www.dbpedia.org/resource/C-reactive_protein
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FC-reactive_protein%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/6857266
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/14996776
RDF Description of C-reactive protein
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01393
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03945
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Abercrombie_Lascelles_1881-1938
_:header3151438881335206385454
Mon, 23 Apr 2012 18:33:00 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Abercrombie_Lascelles_1881-1938
Abercrombie, Lascelles, 1881-1938
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext15472
RDF Description of Abercrombie, Lascelles, 1881-1938
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext10716
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Timrod_Henry_1828-1867
_:header6196384121335206385858
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Timrod_Henry_1828-1867
Timrod, Henry, 1828-1867
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext845
RDF Description of Timrod, Henry, 1828-1867
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/ALG2
_:header6837087511335206386251
Mon, 23 Apr 2012 18:33:01 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/ALG2
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/260
http://symbol.bio2rdf.org/symbol:ALG2
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AALG2%3E
ALG2
http://www.dbpedia.org/resource/ALG2
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FALG2%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1976
RDF Description of ALG2
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00252
_:header21159789851335206386720
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00255
Hydantol
Neos-Hidantoina
Fentoin
Aleviatin
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1257
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1257%3E
Phenhydan
Diphenylan Sodium
Lehydan
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1056
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1056%3E
Phentytoin
N03AB04
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2990
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2990%3E
Citrulliamon
Hidantina
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2618
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2618%3E
http://data.linkedct.org/resource/intervention/39990
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F39990%3E
Minetoin
Novophenytoin
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/158
Avoid alcohol.
Dilantin-125
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4131
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F4131%3E
Di-Hydan
Danten
Epised
Dilantin
5,5-di(phenyl)imidazolidine-2,4-dione
Auranile
Solantyl
N03AB05
/drugs/252/safety_sheets/1396
Diphenylhydantoine [French]
Idantoil
PA450947
Epamin
Hidan
Epinat
Causoin
Difenilhidantoina
Zentronal
N03AB02
7.11e-02 mg/mL
Phenytoin acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. By promoting sodium efflux from neurons, phenytoin tends to stabilize the threshold against hyperexcitability caused by excessive stimulation or environmental changes capable of reducing membrane sodium gradient. This includes the reduction of post-tetanic potentiation at synapses. Loss of post-tetanic potentiation prevents cortical seizure foci from detonating adjacent cortical areas.
Diphenylan
Hindatal
Diphenylhydantoin
http://dbpedia.org/resource/Phenytoin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FPhenytoin%3E
Phenytoin
Henze, U.S. Pat. 2,409,754 (1946)
DB00252
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2541
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2541%3E
2008-08-26 16:00:31 UTC
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/156
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F156%3E
Ditoinate
Saceril
Zentropil
Phenitoin
286 oC
Epelin
Epihydan
Convul
Gerot-epilan-D
Dillantin
32 mg/L
http://bio2rdf.org/cpd:C07443
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC07443%3E
Sodanthon
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/liquidIntravenous
Diphentyn
Epasmir 5
-4.57 [ADME Research, USCD]
Di-Lan
Dilantin W Phenobarbital 15mg (Phenobarbital + Phenytoin Sodium)
Hidantal
Dihydantoin
Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication.
Ritmenal
http://129.128.185.122/drugbank2/drugs/DB00252/inserts/1009/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00252%2Finserts%2F1009%2Ffull%3E
Om hidantoina simple
Elepsindon
Phenytoinum [INN-Latin]
Phenhydanin
http://www.dbpedia.org/resource/Phenytoin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FPhenytoin%3E
Hidantina senosian
http://www.dbpedia.org/resource/Diphenhydramine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FDiphenhydramine%3E
Eptal
http://en.wikipedia.org/wiki/Phenytoin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FPhenytoin%3E
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/dil1136.shtml
Hidantilo
Difenilhidantoina [Spanish]
Didan TDC 250
Diphenylhydatanoin
Enkelfel
Prompt Phenytoin Sodium
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F488%3E
TOIN
Mesantoin
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1688
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1688%3E
Phenytex
Diphedan
http://dbpedia.org/page/Phenytoin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FPhenytoin%3E
Fenantoin
http://205.193.93.51/dpdonline/searchRequest.do?din=00780626
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D00780626%3E
Sanepil
Phenytoine
O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1
http://www4.wiwiss.fu-berlin.de/drugbank/resource/enzymes/3
Difetoin
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/liquidIntramuscular
Ekko
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2307
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2307%3E
Dihycon
Lepsin
Labopal
Fenytoine
Phenytoin-Gerot
Dintoina
http://www.rxlist.com/cgi/generic/phenyt.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric%2Fphenyt.htm%3E
http://bio2rdf.org/cas:57-41-0
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A57-41-0%3E
Thilophenyl
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/4053
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F4053%3E
Diphedal
Silantin
Hydantoin
http://bio2rdf.org/kegg:D00512
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD00512%3E
Fenidantoin s
Epilan-D
Dilabid
DPH
Take with food to increase bioavailability and reduce irritation.
Citrullamon
Phenytoin is an antiepileptic drug which can be useful in the treatment of epilepsy. The primary site of action appears to be the motor cortex where spread of seizure activity is inhibited. Phenytoin reduces the maximal activity of brain stem centers responsible for the tonic phase of tonic-clonic (grand mal) seizures. Phenytoin acts to damp the unwanted, runaway brain activity seen in seizure by reducing electrical conductance among brain cells. It lacks the sedation effects associated with phenobarbital. There are some indications that phenytoin has other effects, including anxiety control and mood stabilization, although it has never been approved for those purposes by the FDA.
Novantoina
Dilantin acid
Fenytoin Dak
Eptoin
CXOFVDLJLONNDW-XQMQJMAZCS
Dintoin
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/solutionIntramuscular
Phenytoin AWD
http://www4.wiwiss.fu-berlin.de/drugbank/resource/enzymes/5
Phanantin
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/82
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F82%3E
Dantoinal
Sodantoin
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/anticonvulsants
Hydantoinal
Lepitoin
Dantoine
5,5-Dwufenylohydantoina
Difenin
Ictalis simple
Difhydan
Epifenyl
Diphentoin
Diphenin
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/691
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F691%3E
Di-Phetine
Epdantoine simple
Diphantoin
http://129.128.185.122/drugbank2/drugs/DB00252/inserts/2023/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00252%2Finserts%2F2023%2Ffull%3E
C15H12N2O2
Phenatine
Antisacer
28:12.12
Epilan
Hydantin
Epilan D
Phanatine
Hidantina vitoria
Bioavailability 70-100% oral, 24.4% for rectal and intravenous administration. Rapid rate of absorption with peak blood concentration expected in 1&frac12; to 3 hours.
Kessodanten
Solantin
Epanutin
http://129.128.185.122/drugbank2/drugs/DB00252/inserts/219/full
Toin unicelles
http://www.drugbank.ca/drugs/DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00252%3E
http://data.linkedct.org/resource/intervention/59287
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F59287%3E
An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. [PubChem]
Dantinal
Phenytoin Sodium
Comital
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2542
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2542%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/suspensionOral
Phenytoine [INN-French]
Sylantoic
Om-Hydantoine
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3893
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3893%3E
Oxylan
For the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery.
Highly protein bound
Phenatoine
5,5-diphenylhydantoin
Fenylepsin
Primarily hepatic
Phentoin
Fenitoina [INN-Spanish]
http://data.linkedct.org/resource/intervention/4393
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F4393%3E
Diphenine
Tacosal
Dantoinal klinos
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2321
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2321%3E
Diphenat
Sinergina
Dilantin W Phenobarbital 30mg Cap (Phenobarbital + Phenytoin Sodium)
Epilantin
Comitoina
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/220
Hydantal
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/176
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F176%3E
Neosidantoina
InChI=1/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19)/f/h16-17H
aprd00241
Hidantomin
Denyl
Epdantoin Simple
Solantoin
Idantoin
Oral, mouse: LD<sub>50</sub> = 150 mg/kg; Oral, rat: LD<sub>50</sub> = 1635 mg/kg. Symptoms of overdose include coma, difficulty in pronouncing words correctly, involuntary eye movement, lack of muscle coordination, low blood pressure, nausea, sluggishness, slurred speech, tremors, and vomiting.
Iphenylhydantoin
Dilantine
22 hours (range of 7 to 42 hours)
Sodanton
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00683
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01336
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB04571
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01418
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00472_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00977
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01167
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00367
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00475_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00555_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB04575
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB03585_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00690_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00628
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00951
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00949
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00783
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00363
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00842
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01125
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00628_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00286
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00472
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01199
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00273
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01101
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00619_DB00252
RDF Description of Phenytoin
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00673
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00208
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00762
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01589
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01104
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01268
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01011
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00603
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00976
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00563
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00882_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00897_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00695
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01224_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00860_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00829
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00829_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00842_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00255_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00812_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01303_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00544_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00741_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01223_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00555
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01058
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01045_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00208_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00254_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01303
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00370
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01339
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00446_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01380
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01118_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00290
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00231_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00363_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01080
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00501
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00687
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00908
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01235
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00860
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01023
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00443
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00553_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00254
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00370_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00277_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00776_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00277
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00958
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00690
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00443_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00351
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00379
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01601
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00570
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01234_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00158_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00510
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00317
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00280_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00717_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB04572
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01023_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01167_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00446
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01337
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00959
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01119
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00510_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01223
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00091
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01101_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00877
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01357
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00231
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01114
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01045
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01224
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01263
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00783_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00705_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00582
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00822_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00673_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00440
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00705
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00822
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00643
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00196_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00682
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00338
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01215_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00501_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00544
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00717
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00262
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00563_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00996_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00603_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00404
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00351_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00619
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00515
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00655
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00897
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01254
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00280
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00364
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00176
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00186_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00317_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00683_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00908_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01211_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00651
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00475
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00176_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01226
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00812
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00483
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00401
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00537_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00537
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00732
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01114_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00695_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00196
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01058_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00996
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00266
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00951_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00158
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00404_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00949_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01211
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00186
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00338_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00367_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01234
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00741
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01118
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00988
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00379_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01334
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00687_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00864
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01215
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00269
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00359
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB03585
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00882
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00976_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00635_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00620
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB01384
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00635
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00333_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00643_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00776
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00091_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00286_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00977_DB00252
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB00553
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00252_DB04573
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/396
_:header2362742991335206387376
Mon, 23 Apr 2012 18:33:02 GMT
RDF Description of Alcohol dehydrogenase 4
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/396
Alcohol dehydrogenase 4
Energy production and conversion
http://pfam.sanger.ac.uk/family?acc=PF08240
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF08240%3E
an alcohol + NAD+ = an aldehyde or ketone + NADH + H+
http://bio2rdf.org/uniprot:P08319
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP08319%3E
>1179 bp	ATGGGCACCAAGGGCAAAGTTATTAAATGCAAAGCAGCCATCGCCTGGGAAGCAGGCAAG	CCCCTTTGCATTGAAGAGGTTGAAGTAGCTCCCCCCAAGGCTCATGAAGTTCGCATTCAG	ATCATTGCTACCTCCCTGTGCCATACTGATGCCAGTGTTATCGATTCTAAATTTGAGGGC	CTAGCTTTCCCAGTGATCGTTGGCCATGAGGCTGCAGGTATTGTGGAAAGTATTGGGCCA	GGAGTGACCAACGTCAAACCAGGTGACAAAGTAATTCCACTTTATGCACCTCTATGTAGA	AAATGCAAGTTTTGTCTGAGTCCACTCACAAATTTGTGTGGGAAAATCAGTAATCTCAAA	AGTCCTGCTAGTGATCAACAACTAATGGAAGACAAAACCAGCAGGTTTACCTGCAAAGGA	AAACCAGTTTACCATTTCTTTGGAACCAGTACATTCTCTCAGTACACTGTGGTGTCAGAT	ATCAATCTTGCCAAAATAGATGATGATGCAAATTTAGAGAGAGTTTGTCTGCTTGGATGT	GGGTTTTCAACTGGCTATGGGGCTGCAATCAACAATGCCAAGGTCACCCCTGGTTCGACT	TGTGCTGTCTTTGGCCTAGGAGGTGTGGGTCTTTCTGCTGTAATGGGTTGTAAAGCAGCA	GGAGCTTCCAGAATCATAGGTATTGACATCAACAGTGAGAAGTTTGTGAAGGCTAAAGCC	CTGGGAGCCACTGACTGCCTCAATCCTAGAGACTTACATAAACCGATCCAGGAAGTTATC	ATTGAATTGACCAAGGGAGGTGTGGATTTTGCCCTTGACTGTGCAGGTGGATCTGAAACC	ATGAAAGCAGCCCTGGACTGTACAACCGCAGGCTGGGGATCATGTACTTTCATTGGAGTA	GCTGCTGGTAGCAAAGGATTGACTATTTTTCCAGAGGAGCTAATAATCGGCCGTACTATA	AATGGAACATTCTTTGGTGGTTGGAAAAGTGTAGATTCTATCCCAAAGCTGGTCACTGAC	TATAAGAATAAGAAATTCAATCTGGATGCATTGGTGACCCATACCCTGCCTTTTGACAAA	ATCAGTGAGGCATTTGACCTAATGAACCAAGGAAAAAGCGTCCGAACAATCCTCATCTTT	GGAAGATGCCAGGAGCAATTCAGAATACTATCTGATTGA
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=M15943
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DM15943%3E
http://bio2rdf.org/pfam:PF00107
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00107%3E
http://bio2rdf.org/pfam:PF08240
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF08240%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1938903
map00010	Glycolysis / Gluconeogenesis	map00071	Fatty acid metabolism	map00120	Bile acid biosynthesis	map00350	Tyrosine metabolism	map00561	Glycerolipid metabolism	map00624	1- and 2-Methylnaphthalene degradation
ADH4
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=178121
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D178121%3E
http://pfam.sanger.ac.uk/family?acc=PF00107
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00107%3E
http://www.uniprot.org/uniprot/P08319
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP08319%3E
ADH4_HUMAN
Alcohol dehydrogenase class II pi chain
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11306066
M15943
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1889753
http://symbol.bio2rdf.org/symbol:ADH4
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AADH4%3E
>Alcohol dehydrogenase 4	GTKGKVIKCKAAIAWEAGKPLCIEEVEVAPPKAHEVRIQIIATSLCHTDATVIDSKFEGL	AFPVIVGHEAAGIVESIGPGVTNVKPGDKVIPLYAPLCRKCKFCLSPLTNLCGKISNLKS	PASDQQLMEDKTSRFTCKGKPVYHFFGTSTFSQYTVVSDINLAKIDDDANLERVCLLGCG	FSTGYGAAINNAKVTPGSTCAVFGLGGVGLSAVMGCKAAGASRIIGIDINSEKFVKAKAL	GATDCLNPRDLHKPIQEVIIELTKGGVDFALDCAGGSETMKAALDCTTAGWGSCTFIGVA	AGSKGLTVFPEELIIGRTINGTFFGGWKSVDSIPKLVTDYKNKKFNLDALVTHTLPFDKI	SEAFDLMNQGKSIRTILIF
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3036213
EC 1.1.1.1
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3593480
http://bio2rdf.org/hgnc:252
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A252%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=252
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D252%3E
4q21-q24|4q22
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/4047
_:header6281103201335206387918
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4047
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00144
diacylglycerol kinase activity
DAG kinase gamma
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/16905533
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=D26135
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DD26135%3E
Lipid transport and metabolism
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10071200
DGKG
Diacylglycerol kinase gamma
EC 2.7.1.107
protein kinase C activation
http://bio2rdf.org/hgnc:2853
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A2853%3E
3q27.2-q27.3
http://bio2rdf.org/pfam:PF00609
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00609%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=516758
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D516758%3E
>2376 bp	ATGGGTGAAGAACGGTGGGTCTCCCTCACTCCAGAAGAATTTGACCAACTCCAGAAATAT	TCAGAATATTCCTCCAAGAAGATAAAAGATGCCTTGACTGAATTTAATGAGGGTGGGAGC	CTCAAACAATATGACCCACATGAGCCGATTAGCTATGATGTCTTCAAGCTGTTCATGAGG	GCGTACCTGGAGGTGGACCTTCCCCAGCCACTGAGCACTCACCTCTTCCTGGCCTTCAGC	CAGAAGCCCAGACACGAGACCTCTGACCACCCGACGGAGGGAGCCAGCAACAGTGAGGCC	AACAGCGCAGATACTAATATACAGAATGCAGATAATGCCACCAAAGCAGACGAGGCCTGT	GCCCCTGATACTGAATCAAATATGGCTGAGAAGCAAGCACCAGCTGAAGACCAAGTGGCT	GCGACCCCCCTGGAACCCCCCGTCCCTCGGTCTTCAAGCTCGGAATCCCCAGTGGTGTAC	CTGAAGGATGTTGTGTGCTACCTGTCCCTGCTGGAGACGGGGAGGCCTCAGGATAAGCTG	GAGTTCATGTTTCGCCTCTATGATTCAGATGAGAACGGTCTCCTGGACCAAGCGGAGATG	GATTGCATTGTCAACCAAATGCTGCATATTGCCCAGTACCTGGAGTGGGATCCCACAGAG	CTGAGGCCTATATTGAAGGAGATGCTGCAAGGGATGGACTACGACCGGGACGGCTTTGTG	TCTCTACAGGAATGGGTCCATGGAGGGATGACCACCATCCCATTGCTGGTGCTCCTGGGG	ATGGATGACTCTGGCTCCAAGGGGGATGGGGGGCACGCCTGGACCATGAAGCACTTCAAG	AAACCAACCTACTGCAACTTCTGCCATATCATGCTCATGGGCGTCCGCAAGCAAGGCCTG	TGCTGCACTTACTGTAAATACACTGTCCACGAACGCTGTGTGTCCAAAAACATTCCTGGT	TGTGTCAAAACGTACTCAAAAGCCAAAAGGAGTGGTGAGGTGATGCAGCACGCATGGGTG	GAAGGGAACTCCTCCGTCAAGTGTGACCGGTGCCACAAAAGTATCAAGTGCTACCAGAGT	GTCACCGCGCGGCACTGCGTGTGGTGCCGGATGACGTTTCACCGCAAATGTGAATTATCA	ACGTTGTGTGACGGTGGGGAACTCAGAGACCACATCTTACTGCCCACCTCCATATGCCCC	ATCACCCGGGACAGGCCAGGTGAGAAGTCTGATGGCTGCGTGTCCGCCAAGGGCGAACTT	GTCATGCAGTATAAGATCATCCCCACCCCGGGTACCCACCCCCTGCTGGTCTTGGTGAAC	CCCAAGAGTGGAGGGAGACAAGGAGAAAGAATTCTTCGGAAATTCCACTATCTGCTCAAC	CCCAAACAAGTTTTCAACCTGGACAATGGGGGGCCTACTCCAGGGTTGAACTTTTTCCGT	GATACTCCAGACTTCCGTGTTTTGGCCTGTGGTGGAGATGGGACAGTTGGCTGGATTTTG	GATTGCATTGATAAGGCCAACTTTGCAAAGCATCCACCAGTGGCTGTCCTGCCTCTTGGA	ACAGGAAATGACCTTGCCCGTTGTCTCCGCTGGGGAGGAGGTTATGAAGGGGGCAGCTTG	ACAAAAATCCTGAAAGACATTGAGCAGAGCCCCTTGGTGATGCTGGACCGCTGGCATCTG	GAAGTCATCCCCAGAGAGGAAGTGGAAAACGGGGACCAGGTCCCATACAGCATCATGAAC	AACTATTTCTCCATTGGTGTGGACGCTTCCATTGCACACAGATTCCATGTGATGAGAGAG	AAACATCCTGAAAAATTCAACAGCAGGATGAAGAACAAGCTGTGGTACTTTGAATTTGGC	ACCTCGGAGACTTTTGCAGCGACCTGCAAGAAACTCCACGACCACATTGAGTTGGAGTGT	GATGGGGTTGGGGTGGACCTGAGCAACATCTTCCTGGAAGGCATTGCCATTCTCAACATT	CCCAGCATGTACGGAGGCACCAATCTCTGGGGAGAAAACAAGAAGAACCGGGCTGTGATC	CGGGAAAGCAGGAAGGGTGTCACTGACCCCAAAGAACTGAAATTCTGCGTTCAAGACCTC	AGTGACCAGCTCCTTGAAGTGGTGGGGCTAGAAGGAGCCATGGAGATGGGGCAGATCTAC	ACCGGCCTGAAGAGTGCAGGCAGGAGGCTGGCCCAGTGCGCCTCTGTCACCATCAGGACA	AACAAGCTGCTGCCAATGCAAGTGGATGGAGAACCCTGGATGCAGCCATGTTGCACGATT	AAAATTACTCACAAGAACCAAGCGCCCATGATGATGGGGCCTCCCCAGAAGAGCAGCTTC	TTCTCGTTGAGAAGGAAGAGCCGTTCAAAAGACTAA
http://pfam.sanger.ac.uk/family?acc=PF00781
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00781%3E
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/gene/DGKG
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fgene%2FDGKG%3E
>Diacylglycerol kinase gamma	MGEERWVSLTPEEFDQLQKYSEYSSKKIKDALTEFNEGGSLKQYDPHEPISYDVFKLFMR	AYLEVDLPQPLSTHLFLAFSQKPRHETSDHPTEGASNSEANSADTNIQNADNATKADEAC	APDTESNMAEKQAPAEDQVAATPLEPPVPRSSSSESPVVYLKDVVCYLSLLETGRPQDKL	EFMFRLYDSDENGLLDQAEMDCIVNQMLHIAQYLEWDPTELRPILKEMLQGMDYDRDGFV	SLQEWVHGGMTTIPLLVLLGMDDSGSKGDGGHAWTMKHFKKPTYCNFCHIMLMGVRKQGL	CCTYCKYTVHERCVSKNIPGCVKTYSKAKRSGEVMQHAWVEGNSSVKCDRCHKSIKCYQS	VTARHCVWCRMTFHRKCELSTLCDGGELRDHILLPTSICPITRDRPGEKSDGCVSAKGEL	VMQYKIIPTPGTHPLLVLVNPKSGGRQGERILRKFHYLLNPKQVFNLDNGGPTPGLNFFR	DTPDFRVLACGGDGTVGWILDCIDKANFAKHPPVAVLPLGTGNDLARCLRWGGGYEGGSL	TKILKDIEQSPLVMLDRWHLEVIPREEVENGDQVPYSIMNNYFSIGVDASIAHRFHVMRE	KHPEKFNSRMKNKLWYFEFGTSETFAATCKKLHDHIELECDGVGVDLSNIFLEGIAILNI	PSMYGGTNLWGENKKNRAVIRESRKGVTDPKELKFCVQDLSDQLLEVVGLEGAMEMGQIY	TGLKSAGRRLAQCASVTIRTNKLLPMQVDGEPWMQPCCTIKITHKNQAPMMMGPPQKSSF	FSLRRKSRSKD
DGKG_HUMAN
D26135
http://bio2rdf.org/uniprot:P49619
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP49619%3E
Diglyceride kinase gamma
http://www.genenames.org/data/hgnc_data.php?hgnc_id=2853
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D2853%3E
http://pfam.sanger.ac.uk/family?acc=PF00609
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00609%3E
http://bio2rdf.org/pfam:PF00781
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00781%3E
ATP + 1,2-diacylglycerol = ADP + 1,2-diacyl-sn-glycerol 3-phosphate
G-protein signaling, coupled to IP3 second messenger (phospholipase C activating)
http://pfam.sanger.ac.uk/family?acc=PF00036
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00036%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8034597
Reverses the normal flow of glycerolipid biosynthesis by phosphorylating diacylglycerol back to phosphatidic acid
map00561	Phosphatidylinositol signaling system
http://symbol.bio2rdf.org/symbol:DGKG
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ADGKG%3E
calcium ion binding
http://www.uniprot.org/uniprot/P49619
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP49619%3E
http://bio2rdf.org/pfam:PF00036
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00036%3E
DGK-gamma
RDF Description of Diacylglycerol kinase gamma
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/PLA2G7
_:header9636662301335206388209
Mon, 23 Apr 2012 18:33:03 GMT
RDF Description of PLA2G7
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PLA2G7
http://symbol.bio2rdf.org/symbol:PLA2G7
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3APLA2G7%3E
PLA2G7
http://www.dbpedia.org/resource/PLA2G7
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FPLA2G7%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/935
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3604
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1505
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1522
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/116
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/122
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Roussel_Raymond_1877-1933
_:header9774064201335206388638
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Roussel_Raymond_1877-1933
Roussel, Raymond, 1877-1933
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19149
RDF Description of Roussel, Raymond, 1877-1933
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Radisson_Pierre_Esprit_1636-1710
_:header1169769951335206389042
Mon, 23 Apr 2012 18:33:04 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Radisson_Pierre_Esprit_1636-1710
Radisson, Pierre Esprit, 1636-1710
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6913
RDF Description of Radisson, Pierre Esprit, 1636-1710
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Lamb_Charles_1775-1834
_:header9695978521335206389432
RDF Description of Lamb, Charles, 1775-1834
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Lamb_Charles_1775-1834
Lamb, Charles, 1775-1834
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1286
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext11576
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9365
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext10130
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext10125
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext14129
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext573
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext10851
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7768
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext20657
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext10343
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0001969
_:header3489815541335206389953
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0001969
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2118
http://sideeffects.embl.de/se/C0001969
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0001969%3E
drunkenness
C0001969
drunk
inebriation
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4616
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3406
RDF Description of drunkenness
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5735
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01484
_:header2138794651335206390397
Mon, 23 Apr 2012 18:33:05 GMT
RDF Description of 4-Bromo-2,5-dimethoxyamphetamine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01484
2007-07-31 13:09:52 UTC
COC1=CC(Br)=C(OC)C=C1C[C@@H](C)N
2008-08-26 15:32:49 UTC
DB01484
4-Bromo-2,5-dimethoxyamphetamine
C11H16BrNO2
http://bio2rdf.org/cas:32156-26-6
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A32156-26-6%3E
1-(4-bromo-2,5-dimethoxyphenyl)propan-2-amine
FXMWUTGUCAKGQL-UHFFFAOYAD
InChI=1/C11H16BrNO2/c1-7(13)4-8-5-11(15-3)9(12)6-10(8)14-2/h5-7H,4,13H2,1-3H3
COC1=CC(Br)=C(OC)C=C1CC(C)N
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/hallucinogens
9.48e-02 mg/mL
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/serotoninAgonists
http://www.drugbank.ca/drugs/DB01484
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01484%3E
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/60953
_:header7653949141335206390870
RDF Description of Xeloda
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0242429
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0221150
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0007787
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0022573
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0043117
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0005779
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0035854
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0032326
Xeloda
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0151786
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0019572
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0041657
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020598
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0152025
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0021807
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C1291710
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000060953&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000060953%26input_query_species%3D9606%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0022602
Capecitabine
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2504
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2504%3E
Xeloda capecitabine Tablets
http://www.bccancer.bc.ca/NR/rdonlyres/08AB775B-8C52-407C-B6F3-83CB7AAF57F4/28810/Capecitabinemonograph_14Apr08RW.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.bccancer.bc.ca%2FNR%2Frdonlyres%2F08AB775B-8C52-407C-B6F3-83CB7AAF57F4%2F28810%2FCapecitabinemonograph_14Apr08RW.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0030578
http://www.fda.gov/medwatch/SAFETY/2005/Jun_PI/Xeloda_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2005%2FJun_PI%2FXeloda_PI.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0013182
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0031117
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0006826
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0006625
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0024312
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0152027
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0016470
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0006840
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0009812
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0034886
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0973461
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0003962
http://sideeffects.embl.de/drugs/60953
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F60953%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0037284
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0039240
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0085584
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0149871
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0235974
http://dbpedia.org/resource/Capecitabine
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FCapecitabine%3E
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=cVVSIyiC5eI=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DcVVSIyiC5eI%3D%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0151766
http://www.fda.gov/cder/foi/label/2005/020896s016lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2005%2F020896s016lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0027059
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0019079
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0036974
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0042487
http://www.fda.gov/cder/foi/label/2000/20896lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2000%2F20896lbl.pdf%3E
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=UGFVYYMSNG4=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DUGFVYYMSNG4%3D%3E
http://www.fda.gov/medwatch/SAFETY/2003/03MAR_PI/Xeloda_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2003%2F03MAR_PI%2FXeloda_PI.pdf%3E
XELODA
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020621
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0017181
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020295
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0311394
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000060953
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000060953%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0151723
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0162298
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0030446
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0085619
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0158322
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0019147
http://www.fda.gov/cder/foi/label/2003/20896slr012_xeloda_lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2003%2F20896slr012_xeloda_lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020433
http://www.fda.gov/cder/foi/label/2001/20896S6lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2001%2F20896S6lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0013362
http://www.fda.gov/cder/foi/label/2001/20896S1011lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2001%2F20896S1011lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0149725
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0699790
CID0000060953
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0085661
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0240735
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0700590
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0262576
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0149696
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0000731
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0376356
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C1306341
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0011175
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0347941
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0013298
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01101
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01101%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0015695
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/2746
_:header999356401335206391356
Mon, 23 Apr 2012 18:33:06 GMT
RDF Description of 4-aminobutyrate aminotransferase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2746
http://bio2rdf.org/pdb:1SFF
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1SFF%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=147902
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D147902%3E
transaminase activity
GABA transaminase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9205837
Gamma-amino-N-butyrate transaminase
4-aminobutanoate + 2-oxoglutarate = succinate semialdehyde + L-glutamate
pyridoxal phosphate binding
EC 2.6.1.19
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2178550
M88334
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2254272
(S)-3-amino-2- methylpropionate transaminase
EC 2.6.1.22
vitamin binding
4-aminobutyrate transaminase activity
L-AIBAT
http://bio2rdf.org/pfam:PF00202
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00202%3E
Glutamate:succinic semialdehyde transaminase
transferase activity, transferring nitrogenous groups
http://www.pdb.org/pdb/explore/explore.do?structureId=1SFF
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1SFF%3E
gabT
http://www.uniprot.org/uniprot/P22256
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP22256%3E
http://bio2rdf.org/uniprot:P22256
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP22256%3E
>1281 bp	ATGAACAGCAATAAAGAGTTAATGCAGCGCCGCAGTCAGGCGATTCCCCGTGGCGTTGGG	CAAATTCACCCGATTTTCGCTGACCGCGCGGAAAACTGCCGGGTGTGGGACGTTGAAGGC	CGTGAGTATCTTGATTTCGCGGGCGGGATTGCGGTGCTCAATACCGGGCACCTGCATCCG	AAGGTGGTGGCCGCGGTGGAAGCGCAGTTGAAAAAACTGTCGCACACCTGCTTCCAGGTG	CTGGCTTACGAGCCGTATCTGGAGCTGTGCGAGATTATGAATCAGAAGGTGCCGGGCGAT	TTCGCCAAGAAAACGCTGCTGGTTACGACCGGTTCCGAAGCGGTGGAAAACGCGGTAAAA	ATCGCCCGCGCCGCCACCAAACGTAGCGGCACCATCGCTTTTAGCGGCGCGTATCACGGG	CGCACGCATTACACGCTGGCGCTGACCGGCAAGGTGAATCCGTACTCTGCGGGCATGGGG	CTGATGCCGGGTCATGTTTATCGCGCGCTTTATCCTTGCCCGCTGCACGGCATAAGCGAG	GATGACGCTATCGCCAGCATCCACCGGATCTTCAAAAATGATGCCGCGCCGGAAGATATC	GCCGCCATCGTGATTGAGCCGGTTCAGGGCGAAGGCGGTTTCTACGCCTCGTCGCCAGCC	TTTATGCAGCGTTTACGCGCTCTGTGTGACGAGCACGGGATCATGCTGATTGCCGATGAA	GTGCAGAGCGGCGCGGGGCGTACCGGCACGCTGTTTGCGATGGAGCAGATGGGCGTTGCG	CCGGATCTTACCACCTTTGCGAAATCGATCGCGGGCGGCTTCCCGCTGGCGGGCGTCACC	GGGCGCGCGGAAGTAATGGATGCCGTCGCTCCAGGCGGTCTGGGCGGCACCTATGCGGGT	AACCCGATTGCCTGCGTGGCTGCGCTGGAAGTGTTGAAGGTGTTTGAGCAGGAAAATCTG	CTGCAAAAAGCCAACGATCTGGGGCAGAAGTTGAAAGACGGATTGCTGGCGATAGCCGAA	AAACACCCGGAGATCGGCGACGTACGCGGGCTGGGGGCGATGATCGCCATTGAGCTGTTT	GAAGACGGCGATCACAACAAGCCGGACGCCAAACTCACCGCCGAGATCGTGGCTCGCGCC	CGCGATAAAGGCCTGATTCTTCTCTCCTGCGGCCCGTATTACAACGTGCTGCGCATCCTT	GTACCGCTCACCATTGAAGACGCTCAGATCCGTCAGGGTCTGGAGATCATCAGCCAGTGT	TTTGATGAGGCGAAGCAGTAG
http://pfam.sanger.ac.uk/family?acc=PF00202
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00202%3E
4-aminobutyrate aminotransferase
amino acid derivative metabolism
GABA aminotransferase
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=M88334
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DM88334%3E
>4-aminobutyrate aminotransferase	MNSNKELMQRRSQAIPRGVGQIHPIFADRAENCRVWDVEGREYLDFAGGIAVLNTGHLHP	KVVAAVEAQLKKLSHTCFQVLAYEPYLELCEIMNQKVPGDFAKKTLLVTTGSEAVENAVK	IARAATKRSGTIAFSGAYHGRTHYTLALTGKVNPYSAGMGLMPGHVYRALYPCPLHGISE	DDAIASIHRIFKNDAAPEDIAAIVIEPVQGEGGFYASSPAFMQRLRALCDEHGIMLIADE	VQSGAGRTGTLFAMEQMGVAPDLTTFAKSIAGGFPLAGVTGRAEVMDAVAPGGLGGTYAG	NPIACVAALEVLKVFEQENLLQKANDLGQKLKDGLLAIAEKHPEIGDVRGLGAMIAIELF	EDGDHNKPDAKLTAEIVARARDKGLILLSCGPYYNVLRILVPLTIEDAQIRQGLEIISQC	FDEAKQ
GABA-AT
map00280	Valine, leucine and isoleucine degradation
gamma-aminobutyric acid metabolism
GABT_ECOLI
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02142
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01867
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02783
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/CD59
_:header11426619221335206391724
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/CD59
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1788
http://symbol.bio2rdf.org/symbol:CD59
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ACD59%3E
CD59
http://bio2rdf.org/hgnc:1689
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A1689%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=1689
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D1689%3E
http://bio2rdf.org/geneid:966
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fgeneid%3A966%3E
RDF Description of CD59
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/204
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01463
_:header18012902641335206392231
Mon, 23 Apr 2012 18:33:07 GMT
RDF Description of Fencamfamine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01463
Fencamfamine
InChI=1/C15H21N/c1-2-16-15-13-9-8-12(10-13)14(15)11-6-4-3-5-7-11/h3-7,12-16H,2,8-10H2,1H3
Fencanfamina [inn-spanish]
2-Aethylamino-3-phenyl-nor-camphan
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/centralNervousSystemStimulants
DB01463
N-ethyl-6-phenylbicyclo[2.2.1]heptan-5-amine
http://www.dbpedia.org/resource/Fencamfamine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FFencamfamine%3E
Fencamfamine (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as an appetite suppressant, but was later withdrawn for this application due to problems with dependence and abuse. It is around half the potency of dexamphetamine, and is prescribed at a dose of 10-60mg, although abusers of the drug tend to rapidly develop tolerance and escalate their dose. Reactivan is still rarely used for treating depressive day-time fatigue, lack of concentration and lethargy, particularly in individuals who have chronic medical conditions, as its favourable safety profile makes it the most suitable drug in some cases. [Wikipedia]
Fencamfamin hydrochloride
http://129.128.185.122/drugbank2/drugs/DB01463/inserts/4395/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB01463%2Finserts%2F4395%2Ffull%3E
Overdosage is characterised by nausea, agitation and restlessness, dryness of the mouth, dizziness and tremor. In gross overdosage the above symptoms may also be associated with dyspnoea, tachycardia, disorientation and convulsions.
http://dbpedia.org/page/Fencamfamine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FFencamfamine%3E
Fencamfamin
IKFBPFGUINLYQI-UHFFFAOYAV
http://www.drugbank.ca/drugs/DB01463
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01463%3E
http://en.wikipedia.org/wiki/Fencamfamine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FFencamfamine%3E
CCNC1C2CCC(C2)C1C1=CC=CC=C1
Fencamfaminum [inn-latin]
Fencamfamine hydrochloride
2.95e-03 mg/mL
Fencamfamine increases drive and mental alertness and an elevation of mood and a general feeling of well-being. It is a central nervous system stimulant, which increases locomotor activity.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/713
http://dbpedia.org/resource/Fencamfamine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FFencamfamine%3E
2008-08-26 13:57:13 UTC
For the the treatment of depressive fatigue in convalescence and other debilitated states as well as in the treatment of depressive day-time fatigue, lack of concentration and lethargy.
Fencamfamine acts as an indirect dopamine agonist. It releases dopamine by a similar mechanism to amphetamines, but is 10x less potent than dexamphetamine at producing this effect. The main mechanism of action is instead inhibition of dopamine reuptake, more similar to that of methylphenidate. Also unlike amphetamines, fencamfamine does not inhibit the action of monoamine oxidase enzymes and so is somewhat safer. Some experiments also suggest a role for opioid receptors in the activity of fencamfamine, as low doses can cause paradoxical sedation, and some effects of the drug are blocked by naloxone.
Glucoenergan
3.20 [SANGSTER (1994)]
Euvitol
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/syrupOral
C15H21N
Fencamfamina [dcit]
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/antipsychoticAgents
Reactivan
CCN[C@@H]1[C@H]2CC[C@H](C2)[C@H]1C1=CC=CC=C1
2-Ethylamino-3-phenyl-norcamphane hydrochloride
http://bio2rdf.org/cas:1209-98-9
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A1209-98-9%3E
Fencamfamine [inn-french]
2007-07-31 13:09:44 UTC
2-Ethylamino-3-phenylnorcamphane hydrochloride
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugtype/withdrawn
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/51577
_:header6092047341335206392674
RDF Description of miglitol
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/51577
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1821
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F1821%3E
miglitol
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00491
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00491%3E
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000051577
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000051577%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0011860
CID0000051577
http://dbpedia.org/resource/Miglitol
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FMiglitol%3E
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000051577&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000051577%26input_query_species%3D9606%3E
http://sideeffects.embl.de/drugs/51577
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F51577%3E
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/2655
_:header12465507731335206393216
Mon, 23 Apr 2012 18:33:08 GMT
RDF Description of Hypoxanthine-guanine-xanthine phosphoribosyltransferase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2655
HGPRT
U09219
http://bio2rdf.org/pfam:PF00156
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00156%3E
HGXPRT
purine ribonucleoside salvage
HGXPRTase
HGXR_TOXGO
http://bio2rdf.org/uniprot:Q26997
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ26997%3E
http://bio2rdf.org/pdb:1FSG
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1FSG%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10545171
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=U09219
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DU09219%3E
Hypoxanthine-guanine-xanthine phosphoribosyltransferase
Catalyzes the transfer of a ribosyl phosphate group from PRPP to the N(9) nitrogen of hypothanthine, guanine or xanthine
EC 2.4.2.-
http://www.uniprot.org/uniprot/Q26997
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ26997%3E
nucleobase, nucleoside, nucleotide and nucleic acid metabolism
http://www.pdb.org/pdb/explore/explore.do?structureId=1FSG
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1FSG%3E
Nucleotide transport and metabolism
http://pfam.sanger.ac.uk/family?acc=PF00156
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00156%3E
>693 bp	ATGGCGTCCAAACCCATTGAAGACTACGGCAAGGGCAAGGGCCGTATTGAGCCCATGTAT	ATCCCCGACAACACCTTCTACAACGCTGATGACTTTCTTGTGCCCCCCCACTGCAAGCCC	TACATTGACAAAATCCTCCTCCCTGGTGGATTGGTCAAGGACAGAGTTGAGAAGTTGGCG	TATGACATCCACAGAACTTACTTCGGCGAGGAGTTGCACATCATTTGCATCCTGAAAGGC	TCTCGCGGCTTCTTCAACCTTCTGATCGACTACCTTGCCACCATACAGAAGTACAGTGGT	CGTGAGTCCAGCGTGCCCCCCTTCTTCGAGCACTATGTCCGCCTGAAGTCCTACCAGAAC	GACAACAGCACAGGCCAGCTCACCGTCTTGAGCGACGACTTGTCAATCTTTCGCGACAAG	CACGTTCTGATTGTTGAGGACATCGTCGACACCGGTTTCACCCTCACCGAGTTCGGTGAG	CGCCTGAAAGCCGTCGGTCCCAAGTCGATGAGAATCGCCACCCTCGTCGAGAAGCGCACA	GATCGCTCCAACAGCTTGAAGGGCGACTTCGTCGGCTTCAGCATTGAAGACGTCTGGATC	GTTGGTTGCTGCTACGACTTCAACGAGATGTTCCGCGACTTCGACCACGTCGCCGTCCTG	AGCGACGCCGCTCGCAAAAAGTTCGAGAAGTAA
purine salvage
>Hypoxanthine-guanine-xanthine phosphoribosyltransferase	MASKPIEDYGKGKGRIEPMYIPDNTFYNADDFLVPPHCKPYIDKILLPGGLVKDRVEKLA	YDIHRTYFGEELHIICILKGSRGFFNLLIDYLATIQKYSGRESSVPPFFEHYVRLKSYQN	DNSTGQLTVLSDDLSIFRDKHVLIVEDIVDTGFTLTEFGERLKAVGPKSMRIATLVEKRT	DRSNSLKGDFVGFSIEDVWIVGCCYDFNEMFRDFDHVAVLSDAARKKFEK
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8088544
transferase activity, transferring glycosyl groups
HPRT
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=501060
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D501060%3E
transferase activity, transferring pentosyl groups
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8836106
hypoxanthine phosphoribosyltransferase activity
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10545170
nucleoside metabolism
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01632
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04356
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02309
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/CMKBR2
_:header6944220861335206393470
RDF Description of CMKBR2
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/CMKBR2
http://symbol.bio2rdf.org/symbol:CMKBR2
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ACMKBR2%3E
CMKBR2
http://www.dbpedia.org/resource/CCR2
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FCCR2%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2619
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Mawson_Douglas_1882-1958
_:header9461770761335206393880
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Mawson_Douglas_1882-1958
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6137
Mawson, Douglas, 1882-1958
RDF Description of Mawson, Douglas, 1882-1958
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0162283
_:header7702711711335206394349
Mon, 23 Apr 2012 18:33:09 GMT
RDF Description of nephrogenic diabetes insipidus
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0162283
http://dbpedia.org/resource/Diabetes_insipidus
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FDiabetes_insipidus%3E
http://sideeffects.embl.de/se/C0162283
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0162283%3E
nephrogenic diabetes insipidus
C0162283
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5300
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/28112
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2983
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3690
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/767
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0014549
_:header336178781335206394845
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0014549
http://dbpedia.org/resource/Tonic-clonic_seizure
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FTonic-clonic_seizure%3E
http://sideeffects.embl.de/se/C0014549
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0014549%3E
grand mal
C0014549
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5566
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4917
RDF Description of grand mal
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4060
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3292
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4107
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3559
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2726
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4909
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/16362
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4425
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/356
_:header15664717081335206395239
Mon, 23 Apr 2012 18:33:10 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/356
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2254
Ellis-van Creveld syndrome
http://www.dbpedia.org/resource/Ellis-van_Creveld_syndrome
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FEllis-van_Creveld_syndrome%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/EVC2
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/EVC
RDF Description of Ellis-van Creveld syndrome
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2253
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Agrippa_Camillo_16th_cent
_:header15747809161335206395666
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Agrippa_Camillo_16th_cent
Agrippa, Camillo, 16th cent.
RDF Description of Agrippa, Camillo, 16th cent.
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17986
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/ACTN4
_:header13730818511335206396057
Mon, 23 Apr 2012 18:33:11 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/ACTN4
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2474
http://symbol.bio2rdf.org/symbol:ACTN4
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AACTN4%3E
ACTN4
http://www.dbpedia.org/resource/Actinin_alpha_4
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FActinin_alpha_4%3E
RDF Description of ACTN4
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/452
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB02255
_:header2671455121335206396506
RDF Description of GM6001
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02255
CNC(=O)C(Cc1cnc2ccccc12)NC(=O)C(CC(C)C)CC(=O)NO
4.08e-02 mg/mL
expt01618
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2489
GM6
http://www.drugbank.ca/drugs/DB02255
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB02255%3E
GM6001
CNC(=O)[C@@H](Cc1cnc2ccccc12)NC(=O)[C@@H](CC(C)C)CC(=O)NO
C20H27N4O4
1PWU
DB02255
(2R)-N'-hydroxy-N-[(2S)-3-(5H-indol-3-yl)-1-methylamino-1-oxopropan-2-yl]-2-(2-methylpropyl)butanediamide
2008-08-26 15:28:10 UTC
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/123631
_:header1567251491335206396954
RDF Description of IRESSA
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/123631
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0342579
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000123631&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000123631%26input_query_species%3D9606%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0151904
http://www.fda.gov/cder/foi/label/2003/021399lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2003%2F021399lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0085786
IRESSA
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0014518
http://www.fda.gov/medwatch/SAFETY/2004/nov_PI/Iressa_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2004%2Fnov_PI%2FIressa_PI.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0206062
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2020
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2020%3E
http://www.bccancer.bc.ca/NR/rdonlyres/5A7993BA-954F-4CFC-8FC3-670B0121210A/19545/GefitinibMonograph_2Nov06.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.bccancer.bc.ca%2FNR%2Frdonlyres%2F5A7993BA-954F-4CFC-8FC3-670B0121210A%2F19545%2FGefitinibMonograph_2Nov06.pdf%3E
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000123631
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000123631%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0036508
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0149925
http://dbpedia.org/resource/Gefitinib
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FGefitinib%3E
GEFITINIB
CID0000123631
http://www.fda.gov/cder/foi/label/2004/21399slr003_Iressa_lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2004%2F21399slr003_Iressa_lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0006384
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0032273
Iressa
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0005741
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00317
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00317%3E
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=+xGQg2AVNDw=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3D%2BxGQg2AVNDw%3D%3E
http://www.fda.gov/cder/foi/label/2005/021399s008lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2005%2F021399s008lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0206061
http://www.fda.gov/medwatch/SAFETY/2004/may_PI/Iressa_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2004%2Fmay_PI%2FIressa_PI.pdf%3E
http://sideeffects.embl.de/drugs/123631
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F123631%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C1145670
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/MPZ
_:header11895464921335206397267
Mon, 23 Apr 2012 18:33:12 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/MPZ
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1828
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/gene/MPZ
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fgene%2FMPZ%3E
http://symbol.bio2rdf.org/symbol:MPZ
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AMPZ%3E
MPZ
http://bio2rdf.org/hgnc:7225
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A7225%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=7225
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D7225%3E
http://bio2rdf.org/geneid:4359
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fgeneid%3A4359%3E
http://www.dbpedia.org/resource/Myelin_protein_zero
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FMyelin_protein_zero%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3358
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/305
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/832
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1840
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1839
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3814
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1012
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1823
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2120
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/217
RDF Description of MPZ
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0011860
_:header8975210291335206398187
Mon, 23 Apr 2012 18:33:13 GMT
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/41774
http://sideeffects.embl.de/se/C0011860
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0011860%3E
Type 2 Diabetes
C0011860
mod
NIDDM
noninsulin dependent diabetes mellitus
type 2 diabetes mellitus
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4599
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3488
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2727
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3476
RDF Description of Type 2 Diabetes
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4091
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/82146
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3478
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5503
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/443871
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5591
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/COL4A3
_:header15497716471335206398548
RDF Description of COL4A3
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/COL4A3
http://symbol.bio2rdf.org/symbol:COL4A3
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ACOL4A3%3E
COL4A3
http://www.dbpedia.org/resource/COL4A3
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FCOL4A3%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/70
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1397
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Warton_Joseph_1722-1800
_:header7314148591335206398952
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Warton_Joseph_1722-1800
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext14973
Warton, Joseph, 1722-1800
RDF Description of Warton, Joseph, 1722-1800
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Columbus_Christopher_1451-1506
_:header11580689881335206399353
Mon, 23 Apr 2012 18:33:14 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Columbus_Christopher_1451-1506
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext14125
Columbus, Christopher, 1451-1506
RDF Description of Columbus, Christopher, 1451-1506
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/NBS1
_:header12046248851335206399753
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/NBS1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3386
http://symbol.bio2rdf.org/symbol:NBS1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ANBS1%3E
NBS1
http://www.dbpedia.org/resource/Nibrin
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FNibrin%3E
RDF Description of NBS1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2909
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/MacDonald_George_1824-1905
_:header8069533901335206400150
Mon, 23 Apr 2012 18:33:15 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/MacDonald_George_1824-1905
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5974
MacDonald, George, 1824-1905
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6364
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9103
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8902
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5753
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9096
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8943
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8944
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2370
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext709
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext12387
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9301
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext10578
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5752
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8913
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9155
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8929
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext18614
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8924
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9471
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext18859
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext18810
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext708
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5773
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5969
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8949
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5751
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9154
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5676
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8886
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9057
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9393
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext10093
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5750
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7174
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext325
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext14453
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1953
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8892
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext18811
RDF Description of MacDonald, George, 1824-1905
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9543
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1640
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext697
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8955
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8553
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2561
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5967
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9191
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7127
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext225
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2291
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8551
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5975
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8879
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5968
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5976
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8552
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext10375
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5966
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2433
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9183
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9984
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5973
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext10606
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8201
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8562
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0026986
_:header17622394621335206400592
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0026986
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5353980
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/789
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F789%3E
http://dbpedia.org/resource/Myelodysplastic_syndrome
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FMyelodysplastic_syndrome%3E
http://sideeffects.embl.de/se/C0026986
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0026986%3E
Myelodysplastic syndrome
C0026986
myelodysplasia
myelodysplastic syndromes
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2265
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5453
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/667490
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/1546
RDF Description of Myelodysplastic syndrome
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/596
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/5523
_:header7128809101335206401341
Mon, 23 Apr 2012 18:33:16 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/5523
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04184
http://pfam.sanger.ac.uk/family?acc=PF04732
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF04732%3E
Vimentins are class-III intermediate filaments found in various non-epithelial cells, especially mesenchymal cells
http://pfam.sanger.ac.uk/family?acc=PF00038
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00038%3E
http://www.uniprot.org/uniprot/P02543
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP02543%3E
http://www.dbpedia.org/resource/Vimentin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FVimentin%3E
Vimentin
intermediate filament
http://bio2rdf.org/pfam:PF00038
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00038%3E
VIME_PIG
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7199625
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/6628686
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/6945574
VIM
http://bio2rdf.org/pfam:PF04732
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF04732%3E
http://www.pdb.org/pdb/explore/explore.do?structureId=1GK4
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1GK4%3E
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/gene/VIM
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fgene%2FVIM%3E
http://bio2rdf.org/uniprot:P02543
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP02543%3E
intermediate filament cytoskeleton
http://bio2rdf.org/pdb:1GK4
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1GK4%3E
Involved in structural molecule activity
>Vimentin	STRTVSSSSYRRMFGGPGTASRPSSSRSYVTTSTRTYSLGSALRPSTSRSLSTSSPGGVG	YYATRSSAVRLRSSVPGVRLLQDAVDFSLADAINTEFKWYKSKFADLSEAANRNNDALRQ	AKQESNEYRRQVQSLTCEVDALKGTNESLERQMREMEENFAVEAANYQDTIGRLQDEIQN	MKEEMARHLREYQDLLNVKMALDIEIATYRKLLEGEESRISLPLPNFSSLNLRETNLESL	PLVDTHSKRTLLIKTVETRDGQVINETSQHHNDLE
RDF Description of Vimentin
http://data.linkedmdb.org/data/film/11449
_:header10170307231335206402772
Mon, 23 Apr 2012 18:40:02 GMT
Jetty(6.1.4)
http://data.linkedmdb.org/resource/film/11449
http://data.linkedmdb.org/resource/movie/film
http://data.linkedmdb.org/resource/interlink/143056
http://data.linkedmdb.org/resource/director/8713
1961-10-18
http://mpii.de/yago/resource/The_Devil_at_4_O%27Clock
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fmpii.de%2Fyago%2Fresource%2FThe_Devil_at_4_O%2527Clock%3E
The Devil at 4 O'Clock
http://data.linkedmdb.org/resource/editor/2615
http://www4.wiwiss.fu-berlin.de/flickrwrappr/photos/The_Devil_at_4_O'Clock
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fflickrwrappr%2Fphotos%2FThe_Devil_at_4_O%27Clock%3E
http://data.linkedmdb.org/resource/performance/77582
http://data.linkedmdb.org/resource/music_contributor/5600
http://data.linkedmdb.org/resource/actor/45565
http://data.linkedmdb.org/resource/actor/46694
http://data.linkedmdb.org/resource/film_cut/18215
http://data.linkedmdb.org/resource/performance/83080
http://data.linkedmdb.org/resource/performance/61688
http://data.linkedmdb.org/resource/actor/29794
http://data.linkedmdb.org/resource/cinematographer/39
http://data.linkedmdb.org/resource/performance/44363
http://data.linkedmdb.org/resource/producer/11857
http://www.freebase.com/view/guid/9202a8c04000641f800000000470d5d4
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f800000000470d5d4%3E
http://data.linkedmdb.org/resource/actor/32113
http://data.linkedmdb.org/resource/performance/76977
http://data.linkedmdb.org/resource/writer/525
http://data.linkedmdb.org/resource/actor/29459
http://dbpedia.org/resource/The_Devil_at_4_O%27Clock
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FThe_Devil_at_4_O%2527Clock%3E
http://www.lingvoj.org/lingvo/en
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.lingvoj.org%2Flingvo%2Fen%3E
http://data.linkedmdb.org/resource/interlink/23480
Contents of this file may include content from 			      FreeBase (http://www.freebase.com) or Wikipedia 			      (http://www.wikipedia.org) licensed under CC-BY			      (http://www.freebase.com/view/common/license/cc_attribution_25)			      or GFDL (http://en.wikipedia.org/wiki/Wikipedia:Text_of_the_GNU_Free_Documentation_License). 			      Refer to http://www.linkedmdb.org:8080/Main/Licensing for more details.
RDF Description of The Devil at 4 O'Clock
http://data.linkedmdb.org/resource/interlink/4947
http://data.linkedmdb.org/resource/film_film_distributor_relationship/2964
http://data.linkedmdb.org/resource/interlink/42013
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB03777
_:header1938089561335206403299
Mon, 23 Apr 2012 18:33:18 GMT
RDF Description of Rbt205 Inhibitor
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03777
8.24e-03 mg/mL
expt00703
C25H23N4O2
http://www.drugbank.ca/drugs/DB03777
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB03777%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2347
CN(C)CCCN1C=C(C2=C1C=CC=C2)C1=C(C(=O)NC1=O)c1cnc2ccccc12
Rbt205 Inhibitor
2008-08-26 15:26:56 UTC
BI1
1XWS
3-[2-[[4-(diaminomethylidene)piperazine-1,4-diium-1-yl]methyl]-4-methoxyphenoxy]propylazanium
DB03777
http://data.linkedmdb.org/data/actor/393
_:header17686746921335206404554
Mon, 23 Apr 2012 18:40:05 GMT
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fxmlns.com%2Ffoaf%2F0.1%2FPerson%3E
http://data.linkedmdb.org/resource/actor/393
http://data.linkedmdb.org/resource/film/12353
http://data.linkedmdb.org/resource/performance/67312
http://data.linkedmdb.org/resource/performance/72811
Tom Jackson
Tom Jackson (Actor)
http://data.linkedmdb.org/resource/movie/actor
http://www.imdb.com/name/nm0414103/
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.imdb.com%2Fname%2Fnm0414103%2F%3E
http://www.freebase.com/view/guid/9202a8c04000641f800000000049e4d4
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f800000000049e4d4%3E
RDF Description of Tom Jackson (Actor)
http://data.linkedmdb.org/resource/film/48589
http://data.linkedmdb.org/data/film/15110
_:header10574723421335206404585
Mon, 23 Apr 2012 18:40:03 GMT
RDF Description of The Fighting Sullivans
http://data.linkedmdb.org/resource/film/15110
http://data.linkedmdb.org/resource/actor/33833
http://data.linkedmdb.org/resource/performance/99495
http://data.linkedmdb.org/resource/film_genre/30
http://data.linkedmdb.org/resource/editor/30
http://dbpedia.org/resource/The_Fighting_Sullivans
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FThe_Fighting_Sullivans%3E
http://data.linkedmdb.org/resource/film_cut/20220
http://data.linkedmdb.org/resource/actor/258
http://www.freebase.com/view/guid/9202a8c04000641f80000000055e5701
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000055e5701%3E
The Fighting Sullivans
http://data.linkedmdb.org/resource/writer/15980
http://data.linkedmdb.org/resource/actor/30890
http://mpii.de/yago/resource/The_Fighting_Sullivans
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fmpii.de%2Fyago%2Fresource%2FThe_Fighting_Sullivans%3E
http://data.linkedmdb.org/resource/performance/62827
http://data.linkedmdb.org/resource/producer/78
http://data.linkedmdb.org/resource/film_subject/465
http://data.linkedmdb.org/resource/performance/61469
1944-02-03
http://data.linkedmdb.org/resource/music_contributor/118
http://data.linkedmdb.org/resource/director/9625
http://data.linkedmdb.org/resource/performance/184015
http://www4.wiwiss.fu-berlin.de/flickrwrappr/photos/The_Fighting_Sullivans
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fflickrwrappr%2Fphotos%2FThe_Fighting_Sullivans%3E
http://data.linkedmdb.org/resource/actor/55492
http://data.linkedmdb.org/resource/interlink/75145
http://data.linkedmdb.org/resource/interlink/43627
http://data.linkedmdb.org/resource/interlink/145864
http://data.linkedmdb.org/resource/interlink/6561
http://data.linkedmdb.org/resource/film_film_distributor_relationship/3380
http://data.linkedmdb.org/resource/interlink/25094
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Hutchinson_Woods_1862-1930
_:header4142842511335206404787
Mon, 23 Apr 2012 18:33:19 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Hutchinson_Woods_1862-1930
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext20294
Hutchinson, Woods, 1862-1930
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext18559
RDF Description of Hutchinson, Woods, 1862-1930
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01037
_:header18571280051335206405525
Mon, 23 Apr 2012 18:33:20 GMT
RDF Description of Selegiline
http://129.128.185.122/drugbank2/drugs/DB01037/inserts/1531/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB01037%2Finserts%2F1531%2Ffull%3E
1998-04-01	/drugs/1037/fda_labels/179	2006-03-01	/drugs/1037/fda_labels/736	2006-06-01	/drugs/1037/fda_labels/24
L-Deprenalin
Eldepryl
2BK3
Torok Z et al., Acta Pharm Hung. 1992 Sep;62(5):201-11
LD<sub>50</sub>=63 mg/kg (rats, IV)
C[C@H](CC1=CC=CC=C1)N(C)CC#C
For the adjunct treatment for Parkinson's disease and depression.
N04BD01
http://en.wikipedia.org/wiki/Selegiline
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FSelegiline%3E
http://bio2rdf.org/cas:14611-51-9
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A14611-51-9%3E
2008-08-26 16:41:29 UTC
Emsam
Apo-Selegiline
http://data.linkedct.org/resource/intervention/12936
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F12936%3E
92:00.00
Jumex
2.54e-02 mg/mL
2 hours
http://bio2rdf.org/cpd:C07245
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC07245%3E
http://data.linkedct.org/resource/intervention/60933
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F60933%3E
141-142 oC
> 99.5%
CC(CC1=CC=CC=C1)N(C)CC#C
http://data.linkedct.org/resource/intervention/54836
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F54836%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/dopaminergics
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/antiparkinsonAgents
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3724
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3724%3E
Selegilina [INN-Spanish]
Zelapar
http://dbpedia.org/page/Selegiline
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FSelegiline%3E
http://129.128.185.122/drugbank2/drugs/DB01037/inserts/575/full
DB01037
Dopamine is an essential chemical that occurs in many parts of the body. It is the premature degradation of dopamine that results in the symptoms of Parkinson's disease. Monoamine oxidase (MAO) is an enzyme which accelerates the breakdown of dopamine. Selegiline can prolong the effects of dopamine in the brain by preventing its breakdown through seletively blocking MAO. It also may prevent the removal of dopamine between nerve endings and enhance release of dopamine from nerve cells.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/monoamineOxidaseInhibitors
28:92.00
Rapidly absorbed from the gastrointestinal tract.
Selegeline Hcl
Nu-Selegiline
http://129.128.185.122/drugbank2/drugs/DB01037/inserts/2526/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB01037%2Finserts%2F2526%2Ffull%3E
Selegiline
Sd Deprenyl
N-methyl-N-[(2R)-1-phenylpropan-2-yl]prop-2-yn-1-amine
aprd00525
MEZLKOACVSPNER-GFCCVEGCBI
Carbex
A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson&#39;s disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl. [PubChem]
http://www.rxlist.com/cgi/generic/seleg.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric%2Fseleg.htm%3E
http://205.193.93.51/dpdonline/searchRequest.do?din=02238340
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02238340%3E
Gen-Selegiline
Selegilinum [INN-Latin]
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3939
http://www.dbpedia.org/resource/Selegiline
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FSelegiline%3E
C13H17N
http://bio2rdf.org/kegg:D03731
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD03731%3E
InChI=1/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3/t12-/m1/s1
/drugs/1037/safety_sheets/1295
Novo-Selegiline
http://data.linkedct.org/resource/intervention/52193
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F52193%3E
selegiline
http://dbpedia.org/resource/Selegiline
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FSelegiline%3E
Although the mechanisms for selegiline's beneficial action in the treatment of Parkinson's disease are not fully understood, the inhibition of monoamine oxidase type B (MAO B) is thought to be of primary importance. MAO B is involved in the oxidative deamination of dopamine in the brain. Selegiline is best known as an irreversible inhibitor of MAO. MAO's activity is inhibited when selegiline binds to the isoalloxazine flavin adenine dinucleotide (FAD) at its active center. In addition, there is evidence that selegiline may increase dopaminergic activity through other mechanisms.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/centralNervousSystemAgents
http://www.drugbank.ca/drugs/DB01037
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01037%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/antidyskinetics
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00514_DB01037
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01171_DB01037
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00715_DB01037
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01175_DB01037
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00215_DB01037
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00472_DB01037
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00176_DB01037
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00454_DB01037
http://data.linkedmdb.org/data/film/41263
_:header121294761335206407243
Mon, 23 Apr 2012 18:40:06 GMT
http://sws.geonames.org/1861060/
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsws.geonames.org%2F1861060%2F%3E
http://www.freebase.com/view/guid/9202a8c04000641f80000000004f69e8
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000004f69e8%3E
http://data.linkedmdb.org/resource/film/41263
http://data.linkedmdb.org/resource/director/11606
http://data.linkedmdb.org/resource/actor/31365
Last Life in the Universe
http://data.linkedmdb.org/resource/actor/4894
http://data.linkedmdb.org/resource/producer/13841
http://data.linkedmdb.org/resource/country/TH
http://data.linkedmdb.org/resource/music_contributor/847
http://data.linkedmdb.org/resource/writer/17587
http://data.linkedmdb.org/resource/performance/17428
2003-08-08
http://data.linkedmdb.org/resource/actor/9293
http://data.linkedmdb.org/resource/performance/17427
http://data.linkedmdb.org/resource/performance/85002
http://data.linkedmdb.org/resource/writer/17554
http://data.linkedmdb.org/resource/country/JP
http://data.linkedmdb.org/resource/actor/4893
http://data.linkedmdb.org/resource/performance/17429
http://data.linkedmdb.org/resource/producer/12114
http://sws.geonames.org/1605651/
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsws.geonames.org%2F1605651%2F%3E
RDF Description of Last Life in the Universe
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/52
_:header12761124301335206407830
Mon, 23 Apr 2012 18:33:22 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/52
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9886305
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8476433
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8180378
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9090535
http://bio2rdf.org/pdb:1LIU
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1LIU%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9482576
>1725 bp	ATGTCGATCCAGGAGAACATATCATCCCTGCAGCTTCGGTCATGGGTCTCTAAGTCCCAA	AGAGACTTAGCAAAGTCCATCCTGATTGGGGCTCCAGGAGGGCCAGCGGGGTATCTGCGG	CGGGCCAGTGTGGCCCAACTGACCCAGGAGCTGGGCACTGCCTTCTTCCAGCAGCAGCAG	CTGCCAGCTGCTATGGCAGACACCTTCCTGGAACACCTCTGCCTACTGGACATTGACTCC	GAGCCCGTGGCTGCTCGCAGTACCAGCATCATTGCCACCATCGGGCCAGCATCTCGCTCC	GTGGAGCGCCTCAAGGAGATGATCAAGGCCGGGATGAACATTGCGCGACTCAACTTCTCC	CACGGCTCCCACGAGTACCATGCTGAGTCCATCGCCAACGTCCGGGAGGCGGTGGAGAGC	TTTGCAGGTTCCCCACTCAGCTACCGGCCCGTGGCCATCGCCCTGGACACCAAGGGACCG	GAGATCCGCACTGGGATCCTGCAGGGGGGTCCAGAGTCGGAAGTGGAGCTGGTGAAGGGC	TCCCAGGTGCTGGTGACTGTGGACCCCGCGTTCCGGACGCGGGGGAACGCGAACACCGTG	TGGGTGGACTACCCCAATATTGTCCGGGTCGTGCCGGTGGGGGGCCGCATCTACATTGAC	GACGGGCTCATCTCCCTAGTGGTCCAGAAAATCGGCCCAGAGGGACTGGTGACCCAAGTG	GAGAACGGCGGCGTCCTGGGCAGCCGGAAGGGCGTGAACTTGCCAGGGGCCCAGGTGGAC	TTGCCCGGGCTGTCCGAGCAGGACGTCCGAGACCTGCGCTTCGGGGTGGAGCATGGGGTG	GACATCGTCTTTGCCTCCTTTGTGCGGAAAGCCAGCGACGTGGCTGCCGTCAGGGCTGCT	CTGGGTCCGGAAGGACACGGCATCAAGATCATCAGCAAAATTGAGAACCACGAAGGCGTG	AAGAGGTTTGATGAAATCCTGGAGGTGAGCGACGGCATCATGGTGGCACGGGGGGACCTA	GGCATCGAGATCCCAGCAGAGAAGGTTTTCCTGGCTCAGAAGATGATGATTGGGCGCTGC	AACTTGGCGGGCAAGCCTGTTGTCTGTGCCACACAGATGCTGGAGAGCATGATTACCAAG	CCCCGGCCAACGAGGGCAGAGACAAGCGATGTCGCCAATGCTGTGCTGGATGGGGCTGAC	TGCATCATGCTGTCAGGGGAGACTGCCAAGGGCAACTTCCCTGTGGAAGCGGTGAAGATG	CAGCATGCGATTGCCCGGGAGGCAGAGGCCGCAGTGTACCACCGGCAGCTGTTTGAGGAG	CTACGTCGGGCAGCGCCACTAAGCCGTGATCCCACTGAGGTCACCGCCATTGGTGCTGTG	GAGGCTGCCTTCAAGTGCTGTGCTGCTGCCATCATTGTGCTGACCACAACTGGCCGCTCA	GCCCAGCTTCTGTCTCGGTACCGACCTCGGGCAGCAGTCATTGCTGTCACCCGCTCTGCC	CAGGCTGCCCGCCAGGTCCACTTATGCCGAGGAGTCTTCCCCTTGCTTTACCGTGAACCT	CCAGAAGCCATCTGGGCAGATGATGTAGATCGCCGGGTGCAATTTGGCATTGAAAGTGGA	AAGCTCCGTGGCTTCCTCCGTGTTGGAGACCTGGTGATTGTGGTGACAGGCTGGCGACCT	GGCTCCGGCTACACCAACATCATGAGGGTGCTAAGCATATCCTGA
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8481523
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10772876
glycolysis
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/gene/PKLR
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fgene%2FPKLR%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8483951
KPYR_HUMAN
http://www.genenames.org/data/hgnc_data.php?hgnc_id=9020
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D9020%3E
hexose metabolism
Red cell/liver pyruvate kinase
http://bio2rdf.org/pfam:PF02887
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF02887%3E
R-type/L-type pyruvate kinase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11328279
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17574881
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3126495
glucose metabolism
1q21
AB015983
glucose catabolism
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3566732
Pyruvate kinase 1
PKLR
http://pfam.sanger.ac.uk/family?acc=PF02887
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF02887%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7706479
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10087985
Pyruvate kinase isozymes R/L
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9827908
ATP + pyruvate = ADP + phosphoenolpyruvate
http://www.uniprot.org/uniprot/P30613
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP30613%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8807089
alcohol metabolism
>Pyruvate kinase isozymes R/L	MSIQENISSLQLRSWVSKSQRDLAKSILIGAPGGPAGYLRRASVAQLTQELGTAFFQQQQ	LPAAMADTFLEHLCLLDIDSEPVAARSTSIIATIGPASRSVERLKEMIKAGMNIARLNFS	HGSHEYHAESIANVREAVESFAGSPLSYRPVAIALDTKGPEIRTGILQGGPESEVELVKG	SQVLVTVDPAFRTRGNANTVWVDYPNIVRVVPVGGRIYIDDGLISLVVQKIGPEGLVTQV	ENGGVLGSRKGVNLPGAQVDLPGLSEQDVRDLRFGVEHGVDIVFASFVRKASDVAAVRAA	LGPEGHGIKIISKIENHEGVKRFDEILEVSDGIMVARGDLGIEIPAEKVFLAQKMMIGRC	NLAGKPVVCATQMLESMITKPRPTRAETSDVANAVLDGADCIMLSGETAKGNFPVEAVKM	QHAIAREAEAAVYHRQLFEELRRAAPLSRDPTEVTAIGAVEAAFKCCAAAIIVLTTTGRS	AQLLSRYRPRAAVIAVTRSAQAARQVHLCRGVFPLLYREPPEAIWADDVDRRVQFGIESG	KLRGFLRVGDLVIVVTGWRPGSGYTNIMRVLSIS
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17547515
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9075576
http://bio2rdf.org/hgnc:9020
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A9020%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8161798
EC 2.7.1.40
http://bio2rdf.org/uniprot:P30613
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP30613%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/16365052
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AB015983
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAB015983%3E
http://symbol.bio2rdf.org/symbol:PKLR
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3APKLR%3E
http://pfam.sanger.ac.uk/family?acc=PF00224
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00224%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/16644726
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1896471
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/16720364
monosaccharide metabolism
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2018831
http://www.pdb.org/pdb/explore/explore.do?structureId=1LIU
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1LIU%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=3327365
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D3327365%3E
http://bio2rdf.org/pfam:PF00224
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00224%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1536957
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8664896
pyruvate kinase activity
map00010	Glycolysis / Gluconeogenesis	map00230	Purine metabolism	map00620	Pyruvate metabolism	map00710	Carbon fixation
RDF Description of Pyruvate kinase isozymes R/L
http://data.linkedmdb.org/data/actor/186
_:header210006101335206409250
Mon, 23 Apr 2012 18:40:09 GMT
RDF Description of Richard Deacon (Actor)
http://data.linkedmdb.org/resource/actor/186
http://data.linkedmdb.org/resource/performance/48699
Richard Deacon
http://dbpedia.org/resource/Richard_Deacon
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FRichard_Deacon%3E
http://data.linkedmdb.org/resource/performance/163823
http://data.linkedmdb.org/resource/performance/163822
Richard Deacon (Actor)
http://data.linkedmdb.org/resource/performance/163825
http://www.freebase.com/view/guid/9202a8c04000641f80000000002b7d46
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000002b7d46%3E
http://www4.wiwiss.fu-berlin.de/flickrwrappr/photos/Richard_Deacon
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fflickrwrappr%2Fphotos%2FRichard_Deacon%3E
http://data.linkedmdb.org/resource/performance/163824
http://mpii.de/yago/resource/Richard_Deacon
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fmpii.de%2Fyago%2Fresource%2FRichard_Deacon%3E
http://data.linkedmdb.org/resource/performance/100489
http://data.linkedmdb.org/resource/film/45083
http://data.linkedmdb.org/resource/film/40672
http://data.linkedmdb.org/resource/film/2047
http://data.linkedmdb.org/resource/interlink/94460
http://data.linkedmdb.org/resource/film/13090
http://data.linkedmdb.org/resource/interlink/106281
http://data.linkedmdb.org/resource/film/721
http://data.linkedmdb.org/resource/film/38385
http://data.linkedmdb.org/resource/interlink/118102
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/1668
_:header4043536081335206409853
Mon, 23 Apr 2012 18:33:24 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/1668
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00070
Hyaluronoglucosaminidase-2
Hyaluronidase-2 precursor
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11960552
Hyal-2
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=4378959
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D4378959%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11296287
Hyaluronidase-2
Hydrolyzes high molecular weight hyaluronic acid to produce an intermediate-sized product which is further hydrolyzed by sperm hyaluronidase to give small oligosaccharides. Displays very low levels of activity. Associates with and negatively regulates MST1R
http://bio2rdf.org/pfam:PF01630
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF01630%3E
http://pfam.sanger.ac.uk/family?acc=PF01630
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF01630%3E
hyalurononglucosaminidase activity
HYAL2
HYAL2_HUMAN
http://bio2rdf.org/uniprot:Q12891
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ12891%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10493834
http://bio2rdf.org/hgnc:5321
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A5321%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9712871
http://www.genenames.org/data/hgnc_data.php?hgnc_id=5321
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D5321%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11731268
1-20
Involved in hyalurononglucosaminidase activity
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11804776
lipid-anchor
EC 3.2.1.35
LUCA-2
http://www.uniprot.org/uniprot/Q12891
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ12891%3E
AJ000099
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AJ000099
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAJ000099%3E
>1416 bp	ATGCGGGCAGGCCCAGGCCCCACCGTTACATTGGCCCTGGTGCTGGCGGTGGCATGGGCC	ATGGAGCTCAAGCCCACAGCACCACCCATCTTCACTGGCCGGCCCTTTGTGGTAGCGTGG	GACGTGCCCACACAGGACTGTGGCCCACGCCTCAAGGTGCCACTGGACCTGAATGCCTTT	GATGTGCAGGCCTCACCTAATGAGGGTTTTGTGAACCAGAATATTACCATCTTCTACCGC	GACCGTCTAGGCCTGTATCCACGCTTCGATTCTGCCGGAAGGTCTGTGCATGGTGGTGTG	CCACAGAATGTCAGCCTTTGGGCACACCGGAAGATGCTGCAGAAACGTGTGGAGCACTAC	ATTCGGACACAGGAGTCTGCGGGGCTGGCGGTCATCGACTGGGAGGACTGGCGACCTGTG	TGGGTGCGCAACTGGCAGGACAAAGATGTGTATCGCCGGTTATCACGCCAGCTAGTGGCC	AGTCGTCACCCTGACTGGCCTCCAGACCGCATAGTCAAACAGGCACAATATGAGTTTGAG	TTCGCAGCACAGCAGTTCATGCTGGAGACACTGCGTTATGTCAAGGCAGTGCGGCCCCGG	CACCTCTGGGGCTTCTACCTCTTTCCTGACTGCTACAATCATGATTATGTGCAGAACTGG	GAGAGCTACACAGGCCGCTGCCCTGATGTTGAGGTGGCCCGCAATGACCAGCTGGCCTGG	CTGTGGGCTGAGAGCACGGCCCTCTTCCCGTCTGTCTACCTGGACGAGACACTTGCTTCC	GCCCTCCATGGCCGCAACTTTGTGAGCTTCCGTGTTCAGGAGGCCCTTCGTGTGGCTCGC	ACCCACCATGCCAACCATGCACTCCCAGTCTACGTCTTCACACGACCCACCTACAGCCGC	TGCACGGGGCTTAGTGAGATGGACCTCATCTCTACCATTGGCGAGAGTGCGGCCCTGGGC	GCAGCTGGTGTCATCCTCTGGGGTGACGCGGGGTACACCACAAGCACGGAGACCTGCCAG	TACCTCAAAGATTACCTGACACGGCTGCTGGTCCCCTACGTGGTCAATGTGTCCTGGGCC	ACCCAATATTGCAGCCGGGCCCAGTGCCATGGCCATGGCTGTGTGCCCGGCAACCCCAGT	GCCAGTACCTTCCTGCATCTCAGCACCAACAGTTTCCGCCTAGTGCCTGGCCATGCACCT	GGTGAACCCCAGCTGCGACCTGTGGGGGAGCTCAGTTGGGCCGACATTGACCACCTGCAG	ACACACTTCCGCTGCCAGTGCTACTTGGGCTGGAGTGGTGAGCAATGCCAGTGGGACCAT	AGGCAGGCAGCTGGAGGTGCCAACGAGGCCTGGGCTGGGTCCCACCTCACCAGTCTGCTG	GCTCTGGCAGCCCTGGCCTTTACCTGGACCTTGTAG
http://symbol.bio2rdf.org/symbol:HYAL2
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AHYAL2%3E
3p21.3
Random hydrolysis of 1->4-linkages between N-acetyl-beta-D-glucosamine and D-glucuronate residues in hyaluronate ALL_REAC (other) R07824(G) R07825(G)
gpi-anchor
>Hyaluronidase-2 precursor	MRAGPGPTVTLALVLAVAWAMELKPTAPPIFTGRPFVVAWDVPTQDCGPRLKVPLDLNAF	DVQASPNEGFVNQNITIFYRDRLGLYPRFDSAGRSVHGGVPQNVSLWAHRKMLQKRVEHY	IRTQESAGLAVIDWEDWRPVWVRNWQDKDVYRRLSRQLVASRHPDWPPDRIVKQAQYEFE	FAAQQFMLETLRYVKAVRPRHLWGFYLFPDCYNHDYVQNWESYTGRCPDVEVARNDQLAW	LWAESTALFPSVYLDETLASSRHGRNFVSFRVQEALRVARTHHANHALPVYVFTRPTYSR	RLTGLSEMDLISTIGESAALGAAGVILWGDAGYTTSTETCQYLKDYLTRLLVPYVVNVSW	ATQYCSRAQCHGHGRCVRRNPSASTFLHLSTNSFRLVPGHAPGEPQLRPVGELSWADIDH	LQTHFRCQCYLGWSGEQCQWDHRQAAGGASEAWAGSHLTSLLALAALAFTWTL
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11731267
hexosaminidase activity
RDF Description of Hyaluronidase-2
http://data.linkedmdb.org/data/film/66499
_:header6985821461335206410156
Mon, 23 Apr 2012 18:40:07 GMT
http://data.linkedmdb.org/resource/film/66499
http://data.linkedmdb.org/resource/film_film_distributor_relationship/10340
http://data.linkedmdb.org/resource/performance/146216
Bouncing Babies
1929-10-12
http://data.linkedmdb.org/resource/actor/35732
http://data.linkedmdb.org/resource/actor/30327
http://data.linkedmdb.org/resource/producer/10246
http://data.linkedmdb.org/resource/performance/196442
http://data.linkedmdb.org/resource/actor/35723
http://data.linkedmdb.org/resource/film/66523
http://data.linkedmdb.org/resource/performance/146214
http://data.linkedmdb.org/resource/performance/146212
http://data.linkedmdb.org/resource/producer/106
http://data.linkedmdb.org/resource/actor/35733
http://data.linkedmdb.org/resource/performance/146215
http://data.linkedmdb.org/resource/performance/146213
http://data.linkedmdb.org/resource/actor/35734
http://data.linkedmdb.org/resource/director/126
http://data.linkedmdb.org/resource/film/66657
http://data.linkedmdb.org/resource/film/67016
http://data.linkedmdb.org/resource/film/66623
http://data.linkedmdb.org/resource/actor/365
http://www.freebase.com/view/guid/9202a8c04000641f80000000093ec94d
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000093ec94d%3E
RDF Description of Bouncing Babies
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00544
_:header8783918691335206410669
Mon, 23 Apr 2012 18:33:25 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00544
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00544_DB00501
1H7X
L01BC02
http://129.128.185.122/drugbank2/drugs/DB00544/inserts/93/full
LD<sub>50</sub>=230mg/kg (orally in mice)
http://bio2rdf.org/cpd:C07649
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC07649%3E
Ulup
http://dbpedia.org/resource/Fluorouracil
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FFluorouracil%3E
http://dbpedia.org/page/Fluorouracil
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FFluorouracil%3E
Timazin
http://205.193.93.51/dpdonline/searchRequest.do?din=02182742
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02182742%3E
http://129.128.185.122/drugbank2/drugs/DB00544/inserts/1862/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00544%2Finserts%2F1862%2Ffull%3E
28-100%
http://data.linkedct.org/resource/intervention/58482
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F58482%3E
5 Fluorouracil
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/creamTopical
http://data.linkedct.org/resource/intervention/28711
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F28711%3E
< 0.1 g/100 mL at 19 &deg;C
Ftoruracil
Arumel
http://bio2rdf.org/cas:51-21-8
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A51-21-8%3E
Fluorouracil inhibits thymidylate synthetase, leading to inhibition of DNA and RNA synthesis and cell death.
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, rectum, breast, stomach and pancrease.
280-282oC
Fluracil
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1131
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1131%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4051
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F4051%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/420
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F420%3E
C4H3FN2O2
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2479
Adrucil
http://en.wikipedia.org/wiki/Fluorouracil
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FFluorouracil%3E
5.86e+00 mg/mL
Fluorouracil
Fluracilum
http://data.linkedct.org/resource/intervention/38453
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F38453%3E
http://www.drugbank.ca/drugs/DB00544
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00544%3E
http://data.linkedct.org/resource/intervention/27751
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F27751%3E
expt03204
GHASVSINZRGABV-ZDKSUBDRCT
Effluderm
Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (of the cell cycle), stopping normal development and division. Fluorouracil blocks an enzyme which converts the cytosine nucleotide into the deoxy derivative. In addition, DNA synthesis is further inhibited because Fluorouracil blocks the incorporation of the thymidine nucleotide into the DNA strand.
Carzonal
Heidelberger et al., U.S. Pat 2802005(1956)
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2035
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2035%3E
http://bio2rdf.org/kegg:D00584
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD00584%3E
Queroplex
Vitamin B1 needs increased with long term use.
FC1=CNC(=O)NC1=O
PA449672
Efudix
Fluro Uracil
DB00544
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/409
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F409%3E
Fluoroplex
Carac
Efudex
http://data.linkedct.org/resource/intervention/33141
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F33141%3E
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]
http://data.linkedct.org/resource/intervention/27852
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F27852%3E
Fluril
Phthoruracil
2008-08-26 15:44:34 UTC
FU
Phtoruracil
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3604
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3604%3E
Fluoroblastin
http://data.linkedct.org/resource/intervention/38556
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F38556%3E
aprd00516
/drugs/544/safety_sheets/1045
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2257
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/378
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F378%3E
InChI=1/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)/f/h6-7H
-1.07 [ADME Research, USCD]
http://data.linkedct.org/resource/intervention/39858
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F39858%3E
8-12%
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2412
http://129.128.185.122/drugbank2/drugs/DB00544/inserts/842/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00544%2Finserts%2F842%2Ffull%3E
Fluri
http://data.linkedct.org/resource/intervention/37760
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F37760%3E
5-fluoro-1H-pyrimidine-2,4-dione
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2518
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2518%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2398
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2398%3E
http://www.rxlist.com/cgi/generic3/carac.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric3%2Fcarac.htm%3E
Kecimeton
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/antimetabolites,Antineoplastic
http://data.linkedct.org/resource/intervention/26909
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F26909%3E
Efurix
http://data.linkedmdb.org/data/producer/11947
_:header14587767481335206410759
2000-10-01	/drugs/544/fda_labels/245	2003-12-01	/drugs/544/fda_labels/74	2004-06-01	/drugs/544/fda_labels/1068
URF
Mon, 23 Apr 2012 18:40:11 GMT
10-20 minutes
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00544_DB00682
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00544_DB01418
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00544_DB00916
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01320_DB00544
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00501_DB00544
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00916_DB00544
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00544_DB00532
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00544_DB01125
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00544_DB00754
RDF Description of Fluorouracil
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00544_DB01320
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00544_DB00266
http://data.linkedmdb.org/resource/producer/11947
http://data.linkedmdb.org/resource/movie/producer
http://data.linkedmdb.org/resource/film/1769
Paul Fenech (Producer)
Paul Fenech
http://www.freebase.com/view/guid/9202a8c04000641f80000000008a7e74
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000008a7e74%3E
RDF Description of Paul Fenech (Producer)
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/2655
_:header15657512591335206411597
Mon, 23 Apr 2012 18:33:26 GMT
RDF Description of ceftizoxime
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2655
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0836924
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0242172
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0036690
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0028643
CID0000002655
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C1257843
Ceftizoxime
ceftizoxime
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0002874
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000002655&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000002655%26input_query_species%3D9606%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0018081
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0008148
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01332
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01332%3E
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000002655
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000002655%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F1%3E
http://sideeffects.embl.de/drugs/2655
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F2655%3E
http://data.linkedmdb.org/data/film/46750
_:header19084492221335206411752
Mon, 23 Apr 2012 18:40:12 GMT
http://data.linkedmdb.org/resource/film/46750
http://data.linkedmdb.org/resource/director/1401
http://data.linkedmdb.org/resource/country/DE
http://data.linkedmdb.org/resource/producer/2322
http://data.linkedmdb.org/resource/actor/4108
http://data.linkedmdb.org/resource/performance/12997
http://data.linkedmdb.org/resource/performance/12996
2002-10-03
http://data.linkedmdb.org/resource/actor/4111
http://data.linkedmdb.org/resource/performance/12995
http://data.linkedmdb.org/resource/editor/752
Grill Point
http://data.linkedmdb.org/resource/performance/12994
http://www.freebase.com/view/guid/9202a8c04000641f8000000000b77159
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f8000000000b77159%3E
http://sws.geonames.org/2921044/
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsws.geonames.org%2F2921044%2F%3E
http://data.linkedmdb.org/resource/actor/4110
http://data.linkedmdb.org/resource/music_contributor/5271
http://data.linkedmdb.org/resource/writer/19238
http://data.linkedmdb.org/resource/actor/4109
http://data.linkedmdb.org/resource/film_film_distributor_relationship/2331
RDF Description of Grill Point
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/IBD1
_:header3962392651335206412270
Mon, 23 Apr 2012 18:33:27 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/IBD1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2039
http://symbol.bio2rdf.org/symbol:IBD1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AIBD1%3E
IBD1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3826
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1612
RDF Description of IBD1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3689
http://data.linkedmdb.org/data/film/43518
_:header13374602491335206413199
Mon, 23 Apr 2012 18:40:13 GMT
RDF Description of Terror Train
http://data.linkedmdb.org/resource/film/43518
Terror Train
http://data.linkedmdb.org/resource/performance/73484
http://www.freebase.com/view/guid/9202a8c04000641f800000000079d050
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f800000000079d050%3E
http://data.linkedmdb.org/resource/actor/94
http://data.linkedmdb.org/resource/performance/86297
http://data.linkedmdb.org/resource/actor/41904
http://data.linkedmdb.org/resource/country/CA
http://data.linkedmdb.org/resource/performance/68180
http://data.linkedmdb.org/resource/performance/74069
http://data.linkedmdb.org/resource/actor/138
http://data.linkedmdb.org/resource/performance/74692
1980-10-03
http://sws.geonames.org/6251999/
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsws.geonames.org%2F6251999%2F%3E
http://data.linkedmdb.org/resource/actor/30009
http://data.linkedmdb.org/resource/director/9907
http://data.linkedmdb.org/resource/actor/11792
http://data.linkedmdb.org/resource/film_film_distributor_relationship/1649
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/TPI1
_:header18294194211335206413671
Mon, 23 Apr 2012 18:33:28 GMT
RDF Description of TPI1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/TPI1
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/gene/TPI1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fgene%2FTPI1%3E
http://symbol.bio2rdf.org/symbol:TPI1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ATPI1%3E
TPI1
http://www.dbpedia.org/resource/TPI1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FTPI1%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2570
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/499
http://data.linkedmdb.org/data/film/47525
_:header12248405751335206414751
Mon, 23 Apr 2012 18:40:14 GMT
http://data.linkedmdb.org/resource/film/47525
http://data.linkedmdb.org/resource/director/11255
2004-01-23
http://data.linkedmdb.org/resource/performance/1357
http://data.linkedmdb.org/resource/writer/877
http://data.linkedmdb.org/resource/actor/36276
http://data.linkedmdb.org/resource/producer/635
http://www.freebase.com/view/guid/9202a8c04000641f8000000000c57cf9
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f8000000000c57cf9%3E
http://data.linkedmdb.org/resource/performance/1356
http://data.linkedmdb.org/resource/actor/1700
http://data.linkedmdb.org/resource/producer/636
http://data.linkedmdb.org/resource/music_contributor/4653
http://data.linkedmdb.org/resource/actor/360
http://data.linkedmdb.org/resource/actor/29371
Aetbaar
http://sws.geonames.org/1269750/
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsws.geonames.org%2F1269750%2F%3E
http://data.linkedmdb.org/resource/performance/1359
http://data.linkedmdb.org/resource/producer/633
http://data.linkedmdb.org/resource/performance/107692
http://data.linkedmdb.org/resource/country/IN
http://data.linkedmdb.org/resource/performance/1358
http://data.linkedmdb.org/resource/actor/32635
http://data.linkedmdb.org/resource/writer/876
http://data.linkedmdb.org/resource/writer/17164
http://data.linkedmdb.org/resource/producer/634
RDF Description of Aetbaar
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00342
_:header11853847751335206415314
Mon, 23 Apr 2012 18:33:30 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01369_DB00342
http://bio2rdf.org/cpd:C07463
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC07463%3E
/drugs/342/safety_sheets/1467
1-(4-tert-butylphenyl)-4-[4-[hydroxy-di(phenyl)methyl]piperidin-1-yl]butan-1-ol
http://bio2rdf.org/kegg:D00521
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD00521%3E
Terfenadine
http://en.wikipedia.org/wiki/Terfenadine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FTerfenadine%3E
C32H41NO2
For the treatment of allergic rhinitis, hay fever, and allergic skin disorders.
Seldane
aprd00606
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/antiarrhythmicAgents
http://bio2rdf.org/cas:50679-08-8
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A50679-08-8%3E
http://dbpedia.org/resource/Terfenadine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FTerfenadine%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/101
2008-08-26 15:09:16 UTC
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/anti-allergicAgents
70%
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/492
In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation.
Cyater
http://129.128.185.122/drugbank2/drugs/DB00342/inserts/2074/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00342%2Finserts%2F2074%2Ffull%3E
Terfex
3.5 hours
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/24
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F24%3E
http://129.128.185.122/drugbank2/drugs/DB00342/inserts/250/full
http://www.drugbank.ca/drugs/DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00342%3E
InChI=1/C32H41NO2/c1-31(2,3)26-18-16-25(17-19-26)30(34)15-10-22-33-23-20-29(21-24-33)32(35,27-11-6-4-7-12-27)28-13-8-5-9-14-28/h4-9,11-14,16-19,29-30,34-35H,10,15,20-24H2,1-3H3
DB00342
146.5-148.5oC
Terdin
http://dbpedia.org/page/Terfenadine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FTerfenadine%3E
CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
Allerplus
CC(C)(C)C1=CC=C(C=C1)[C@H](O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1313
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1313%3E
Teldane
A. A. Carr, C. R. Kinsolving, U.S. Pat. 3,878,217 (1975)
http://129.128.185.122/drugbank2/drugs/DB00342/inserts/1062/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00342%2Finserts%2F1062%2Ffull%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/histamineH1Antagonists,Non-sedating
Aldaban
Terfenadine, an H1-receptor antagonist antihistamine, is similar in structure to astemizole and haloperidol, a butyrophenone antipsychotic. The active metabolite of terfenadine is fexofenadine.
Mild (e.g., headache, nausea, confusion), but adverse cardiac events including cardiac arrest, ventricular arrhythmias including torsades de pointes and QT prolongation have been reported. LD<sub>50</sub>=mg/kg (orally in mice)
Ternadin
R06AX12
Triludan
10 mg/L
http://205.193.93.51/dpdonline/searchRequest.do?din=01913395
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D01913395%3E
http://www.rxlist.com/cgi/generic/terfen.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric%2Fterfen.htm%3E
Teldanex
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/antihistamines
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2989
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2989%3E
On the basis of a mass balance study using 14C labeled terfenadine the oral absorption of terfenadine was estimated to be at least 70%
4.58e-04 mg/mL
GUGOEEXESWIERI-UHFFFAOYAL
Terfenadine competes with histamine for binding at H1-receptor sites in the GI tract, uterus, large blood vessels, and bronchial muscle. This reversible binding of terfenadine to H1-receptors suppresses the formation of edema, flare, and pruritus resulting from histaminic activity. As the drug does not readily cross the blood-brain barrier, CNS depression is minimal.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00623_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01182_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01167_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01319_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01211_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00433_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB01244
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01118_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00777
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00705_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00365
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00477
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01403_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00489
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00622
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00850_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00472
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB01608
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00468_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB01035
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00604_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01069_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB01056
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB01321
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00379
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00372
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00850
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB01232
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB01208
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00673
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00540
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB01211
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01035_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00176
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB01167
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00831
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00420
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00679_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00701_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00540_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00701
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB01263
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00196_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00220_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01149_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00976_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB01246
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00908
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00224
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00902
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00508
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB01118
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB01403
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB01195
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00477_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB01026
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01151_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00280
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00343
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00176_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00468
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01242_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00343_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00379_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00196
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB01369
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01195_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01026_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00365_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB01388
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00933
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00604
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00199
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00224_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00458
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB01242
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00705
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00582
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01244_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00622_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00543_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB01142
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB01151
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB01361
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00280_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB01149
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00908_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00472_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01608_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB01182
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00501
RDF Description of Terfenadine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB01069
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00976
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00726
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00321_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00661
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00220
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00344
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00623
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00458_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00679
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00501_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB01063
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00321
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00625
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00543
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00199_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01142_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00831_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB01319
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00933_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00673_DB00342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00342_DB00433
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00625_DB00342
http://data.linkedmdb.org/data/film/40196
_:header19453123881335206415390
Mon, 23 Apr 2012 18:40:15 GMT
http://sws.geonames.org/3017382/
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsws.geonames.org%2F3017382%2F%3E
http://data.linkedmdb.org/resource/film/40196
http://data.linkedmdb.org/resource/director/9349
http://data.linkedmdb.org/resource/editor/1575
http://www.freebase.com/view/guid/9202a8c04000641f8000000000380108
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f8000000000380108%3E
Vampyr
http://data.linkedmdb.org/resource/performance/100053
http://data.linkedmdb.org/resource/actor/7708
http://data.linkedmdb.org/resource/writer/13257
http://data.linkedmdb.org/resource/writer/5840
http://data.linkedmdb.org/resource/performance/172525
http://data.linkedmdb.org/resource/producer/11976
http://data.linkedmdb.org/resource/performance/38154
http://data.linkedmdb.org/resource/producer/10571
http://data.linkedmdb.org/resource/actor/11975
http://data.linkedmdb.org/resource/actor/42143
http://data.linkedmdb.org/resource/actor/40971
http://data.linkedmdb.org/resource/country/DK
http://data.linkedmdb.org/resource/actor/8463
http://data.linkedmdb.org/resource/performance/38152
http://data.linkedmdb.org/resource/writer/14743
http://data.linkedmdb.org/resource/music_contributor/1601
http://sws.geonames.org/2623032/
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsws.geonames.org%2F2623032%2F%3E
http://data.linkedmdb.org/resource/country/FR
http://data.linkedmdb.org/resource/performance/38153
RDF Description of Vampyr
http://data.linkedmdb.org/data/producer/12085
_:header10503771161335206415730
Mon, 23 Apr 2012 18:40:17 GMT
http://data.linkedmdb.org/resource/producer/12085
http://data.linkedmdb.org/resource/film/5235
Bob Rafelson (Producer)
Bob Rafelson
http://www.freebase.com/view/guid/9202a8c04000641f800000000096e777
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f800000000096e777%3E
http://data.linkedmdb.org/resource/film/1282
http://data.linkedmdb.org/resource/film/48863
http://data.linkedmdb.org/resource/film/7474
RDF Description of Bob Rafelson (Producer)
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0020683
_:header19524898821335206415892
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020683
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4253
http://dbpedia.org/resource/Hypovolemia
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FHypovolemia%3E
http://sideeffects.embl.de/se/C0020683
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0020683%3E
hypovolemic shock
C0020683
RDF Description of hypovolemic shock
http://data.linkedmdb.org/data/producer/10103
_:header3933106751335206416328
http://data.linkedmdb.org/resource/producer/10103
Leslie Cheung (Producer)
Leslie Cheung
http://www.freebase.com/view/guid/9202a8c04000641f80000000001607b7
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000001607b7%3E
http://data.linkedmdb.org/resource/film/40859
RDF Description of Leslie Cheung (Producer)
http://www4.wiwiss.fu-berlin.de/dblp/data/person/475884
_:header16869159121335206416474
Mon, 23 Apr 2012 18:33:31 GMT
RDF Description of Donald Davies
http://www4.wiwiss.fu-berlin.de/dblp/resource/person/475884
Donald Davies
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/caise/Davies90
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/3461
_:header11814912191335206417354
Mon, 23 Apr 2012 18:33:32 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3461
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/6301942
>1017 bp	ATGAGAGTTCTGGTTACCGGTGGTAGCGGTTACATTGGAAGTCATACCTGTGTGCAATTA	CTGCAAAACGGTCATGATGTCATCATTCTTGATAACCTCTGTAACAGTAAGCGCAGCGTA	CTGCCTGTTATCGAGCGTTTAGGCGGCAAACATCCAACGTTTGTTGAAGGCGATATTCGT	AACGAAGCGTTGATGACCGAGATCCTGCACGATCACGCTATCGACACCGTGATCCACTTC	GCCGGGCTGAAAGCCGTGGGCGAATCGGTACAAAAACCGCTGGAATATTACGACAACAAT	GTCAACGGCACTCTGCGCCTGATTAGCGCCATGCGCGCCGCTAACGTCAAAAACTTTATT	TTTAGCTCCTCCGCCACCGTTTATGGCGATCAGCCCAAAATTCCATACGTTGAAAGCTTC	CCGACCGGCACACCGCAAAGCCCTTACGGCAAAAGCAAGCTGATGGTGGAACAGATCCTC	ACCGATCTGCAAAAAGCCCAGCCGGACTGGAGCATTGCCCTGCTGCGCTACTTCAACCCG	GTTGGCGCGCATCCGTCGGGCGATATGGGCGAAGATCCGCAAGGCATTCCGAATAACCTG	ATGCCATACATCGCCCAGGTTGCTGTAGGCCGTCGCGACTCGCTGGCGATTTTTGGTAAC	GATTATCCGACCGAAGATGGTACTGGCGTACGCGATTACATCCACGTAATGGATCTGGCG	GACGGTCACGTCGTGGCGATGGAAAAACTGGCGAACAAGCCAGGCGTACACATCTACAAC	CTCGGCGCTGGCGTAGGCAACAGCGTGCTGGACGTGGTTAATGCCTTCAGCAAAGCCTGC	GGCAAACCGGTTAATTATCATTTTGCACCGCGTCGCGAGGGCGACCTTCCGGCCTACTGG	GCGGACGCCAGCAAAGCCGACCGTGAACTGAACTGGCGCGTAACGCGCACACTCGATGAA	ATGGCGCAGGACACCTGGCACTGGCAGTCACGCCATCCACAGGGATATCCCGATTAA
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8611559
http://www.pdb.org/pdb/explore/explore.do?structureId=2UDP
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D2UDP%3E
coenzyme binding
racemase and epimerase activity, acting on carbohydrates and derivatives
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=X06226
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DX06226%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9174344
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8931134
UDP-galactose 4-epimerase
http://bio2rdf.org/pfam:PF01370
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF01370%3E
X06226
cofactor binding
http://bio2rdf.org/uniprot:P09147
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP09147%3E
EC 5.1.3.2
http://www.uniprot.org/uniprot/P09147
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP09147%3E
Galactowaldenase
http://bio2rdf.org/pdb:2UDP
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A2UDP%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8905232
racemase and epimerase activity
UDP-glucose 4-epimerase activity
galE
>UDP-glucose 4-epimerase	MRVLVTGGSGYIGSHTCVQLLQNGHDVIILDNLCNSKRSVLPVIERLGGKHPTFVEGDIR	NEALMTEILHDHAIDTVIHFAGLKAVGESVQKPLEYYDNNVNGTLRLISAMRAANVKNFI	FSSSATVYGDQPKIPYVESFPTGTPQSPYGKSKLMVEQILTDLQKAQPDWSIALLRYFNP	VGAHPSGDMGEDPQGIPNNLMPYIAQVAVGRRDSLAIFGNDYPTEDGTGVRDYIHVMDLA	DGHVVAMEKLANKPGVHIYNLGAGVGNSVLDVVNAFSKACGKPVNYHFAPRREGDLPAYW	ADASKADRELNWRVTRTLDEMAQDTWHWQSRHPQGYPD
nucleotide-sugar metabolism
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9708982
GALE_ECOLI
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1579570
UDP-glucose 4-epimerase
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=41523
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D41523%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9271499
UDP-glucose = UDP-galactose
map00052	Galactose metabolism
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8564363
isomerase activity
galactose metabolism
http://pfam.sanger.ac.uk/family?acc=PF01370
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF01370%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3022232
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2134186
NAD binding
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03435
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03397
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02421
RDF Description of UDP-glucose 4-epimerase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04355
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02790
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04097
http://data.linkedmdb.org/data/film/82975
_:header19844067131335206417474
Mon, 23 Apr 2012 18:40:18 GMT
RDF Description of Us Two
http://data.linkedmdb.org/resource/film/82975
Us Two
http://data.linkedmdb.org/resource/producer/11525
http://data.linkedmdb.org/resource/actor/29791
http://www.freebase.com/view/guid/9202a8c04000641f800000000c3ed435
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f800000000c3ed435%3E
1979-05-23
http://data.linkedmdb.org/resource/producer/10805
http://data.linkedmdb.org/resource/performance/168896
http://data.linkedmdb.org/resource/director/9622
http://data.linkedmdb.org/data/director/1393
_:header559737841335206417825
Mon, 23 Apr 2012 18:40:19 GMT
http://data.linkedmdb.org/resource/director/1393
http://data.linkedmdb.org/resource/film/42164
http://data.linkedmdb.org/resource/film/1550
EugÃ¨ne LouriÃ©
EugÃ¨ne LouriÃ© (Director)
http://data.linkedmdb.org/resource/movie/director
http://www.freebase.com/view/guid/9202a8c04000641f80000000010ef844
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000010ef844%3E
RDF Description of EugÃ¨ne LouriÃ© (Director)
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0000768
_:header597363001335206418094
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2171
C0000768
http://sideeffects.embl.de/se/C0000768
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0000768%3E
malformations
malformation
congenital anomalies
dysgenesis
birth defects
congenital abnormalities
congenital defects
http://dbpedia.org/resource/Congenital_disorder
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FCongenital_disorder%3E
deformity
congenital malformations
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3454
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3255
RDF Description of malformations
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3203
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2512
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Walker_David_1785-1830
_:header13396493411335206418673
Mon, 23 Apr 2012 18:33:33 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Walker_David_1785-1830
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext16516
Walker, David, 1785-1830
RDF Description of Walker, David, 1785-1830
http://data.linkedmdb.org/data/film/83220
_:header7645610871335206419326
RDF Description of Gun Fury
http://data.linkedmdb.org/resource/film/83220
Gun Fury
http://data.linkedmdb.org/resource/producer/16483
http://www.freebase.com/view/guid/9202a8c04000641f800000000c413679
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f800000000c413679%3E
http://data.linkedmdb.org/resource/director/9369
1953-11-11
http://data.linkedmdb.org/resource/performance/168534
http://data.linkedmdb.org/resource/performance/168533
http://data.linkedmdb.org/resource/actor/32061
http://data.linkedmdb.org/resource/actor/30563
http://data.linkedmdb.org/resource/film_film_distributor_relationship/10857
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/155
_:header14124903991335206419680
Mon, 23 Apr 2012 18:33:34 GMT
RDF Description of Bipolar disorder
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/155
Bipolar disorder
http://www.dbpedia.org/resource/Bipolar_disorder
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FBipolar_disorder%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0005586
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fsider%2Fresource%2Fside_effects%2FC0005586%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/XBP1
http://data.linkedct.org/resource/condition/1630
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fcondition%2F1630%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1606
http://data.linkedmdb.org/data/film/44673
_:header13947516201335206420058
Mon, 23 Apr 2012 18:40:20 GMT
http://data.linkedmdb.org/resource/film/44673
http://data.linkedmdb.org/resource/performance/8504
Deewane Huye Pagal
http://data.linkedmdb.org/resource/performance/8507
http://data.linkedmdb.org/resource/writer/2093
http://data.linkedmdb.org/resource/actor/33036
http://data.linkedmdb.org/resource/actor/40951
2005-11-25
http://data.linkedmdb.org/resource/producer/1969
http://data.linkedmdb.org/resource/actor/35203
http://data.linkedmdb.org/resource/producer/13667
http://data.linkedmdb.org/resource/performance/8508
http://data.linkedmdb.org/resource/performance/8505
http://data.linkedmdb.org/resource/actor/41329
http://data.linkedmdb.org/resource/writer/1174
http://data.linkedmdb.org/resource/performance/8506
http://data.linkedmdb.org/resource/actor/34898
http://data.linkedmdb.org/resource/music_contributor/5926
http://data.linkedmdb.org/resource/actor/40697
http://www.freebase.com/view/guid/9202a8c04000641f8000000000907625
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f8000000000907625%3E
http://data.linkedmdb.org/resource/performance/76584
RDF Description of Deewane Huye Pagal
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Le_Bon_Gustave_1841-1931
_:header18236958881335206420544
Mon, 23 Apr 2012 18:33:35 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Le_Bon_Gustave_1841-1931
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext448
Le Bon, Gustave, 1841-1931
RDF Description of Le Bon, Gustave, 1841-1931
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext16102
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext445
http://data.linkedmdb.org/data/film/3128
_:header3430904721335206422004
Mon, 23 Apr 2012 18:40:21 GMT
http://www.imdb.com/title/tt0086346
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.imdb.com%2Ftitle%2Ftt0086346%3E
http://www.rottentomatoes.com/alias?type=imdbid&s=0086346
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rottentomatoes.com%2Falias%3Ftype%3Dimdbid%26s%3D0086346%3E
http://data.linkedmdb.org/resource/film/3128
http://data.linkedmdb.org/resource/interlink/136753
http://data.linkedmdb.org/resource/actor/30098
http://data.linkedmdb.org/resource/actor/31985
http://data.linkedmdb.org/resource/actor/49265
http://data.linkedmdb.org/resource/performance/84748
http://data.linkedmdb.org/resource/performance/27325
http://data.linkedmdb.org/resource/film_genre/31
1983-05-20
http://www.freebase.com/view/guid/9202a8c04000641f800000000064e33e
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f800000000064e33e%3E
http://data.linkedmdb.org/resource/performance/86993
http://data.linkedmdb.org/resource/director/14988
http://data.linkedmdb.org/resource/producer/3572
http://data.linkedmdb.org/resource/actor/34546
http://data.linkedmdb.org/resource/performance/88616
http://data.linkedmdb.org/resource/music_contributor/4434
Spacehunter: Adventures in the Forbidden Zone
http://data.linkedmdb.org/resource/film_cut/5841
http://data.linkedmdb.org/resource/cinematographer/1173
http://data.linkedmdb.org/resource/performance/27322
http://data.linkedmdb.org/resource/performance/27324
http://data.linkedmdb.org/resource/producer/10942
http://data.linkedmdb.org/resource/actor/32367
http://data.linkedmdb.org/resource/performance/27323
http://data.linkedmdb.org/resource/writer/4650
http://data.linkedmdb.org/resource/producer/13194
http://data.linkedmdb.org/resource/actor/34092
http://data.linkedmdb.org/resource/actor/42002
http://data.linkedmdb.org/resource/writer/4651
http://data.linkedmdb.org/resource/film_film_distributor_relationship/1470
RDF Description of Spacehunter: Adventures in the Forbidden Zone
http://data.linkedmdb.org/resource/interlink/71475
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Hugo_Victor_1802-1885
_:header5108236131335206422512
Mon, 23 Apr 2012 18:33:37 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Hugo_Victor_1802-1885
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17493
Hugo, Victor, 1802-1885
Hugo, Victor, 1802-1885 
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9644
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19657
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8490
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9645
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext12137
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9976
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6994
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17489
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13182
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17519
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext20580
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8186
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17494
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6838
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6539
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2523
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext12587
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13628
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8775
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17518
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext135
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5423
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8453
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext10381
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2610
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8454
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext10577
RDF Description of Hugo, Victor, 1802-1885
http://data.linkedmdb.org/data/film/39745
_:header1960158121335206423492
Mon, 23 Apr 2012 18:40:22 GMT
http://data.linkedmdb.org/resource/film/39745
http://data.linkedmdb.org/resource/director/8878
http://www.freebase.com/view/guid/9202a8c04000641f80000000002d5ebe
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000002d5ebe%3E
http://data.linkedmdb.org/resource/performance/20624
http://data.linkedmdb.org/resource/actor/30527
http://data.linkedmdb.org/resource/actor/9697
http://data.linkedmdb.org/resource/film_subject/228
http://data.linkedmdb.org/resource/performance/83321
http://data.linkedmdb.org/resource/actor/54050
http://data.linkedmdb.org/resource/film_production_designer/54
http://data.linkedmdb.org/resource/film_story_contributor/270
http://data.linkedmdb.org/resource/producer/3545
http://data.linkedmdb.org/resource/actor/29536
http://data.linkedmdb.org/resource/performance/179249
http://data.linkedmdb.org/resource/actor/40517
http://data.linkedmdb.org/resource/writer/13975
http://data.linkedmdb.org/resource/performance/20625
My Own Private Idaho
http://data.linkedmdb.org/resource/performance/86268
http://data.linkedmdb.org/resource/film_film_distributor_relationship/14407
RDF Description of My Own Private Idaho
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0010418
_:header20078642071335206424013
Mon, 23 Apr 2012 18:33:38 GMT
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0010418
http://sideeffects.embl.de/se/C0010418
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0010418%3E
Cryptosporidiosis
C0010418
RDF Description of Cryptosporidiosis
http://data.linkedmdb.org/data/film/96801
_:header14314060541335206424704
Mon, 23 Apr 2012 18:40:24 GMT
http://data.linkedmdb.org/resource/film/96801
http://data.linkedmdb.org/resource/director/11085
1932-10-15
Cowboy Counsellor
http://www.freebase.com/view/guid/9202a8c04000641f80000000100982a3
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000100982a3%3E
RDF Description of Cowboy Counsellor
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01844
_:header7864699211335206425123
Mon, 23 Apr 2012 18:33:40 GMT
RDF Description of Dimethylformamide
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01844
2008-08-26 16:06:17 UTC
N,N-dimethylformamide
http://bio2rdf.org/cas:68-12-2
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A68-12-2%3E
Dimethylformamide
http://bio2rdf.org/chebi:17741
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fchebi%3A17741%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2694
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2694%3E
CN(C)C=O
http://bio2rdf.org/cpd:C03134
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC03134%3E
-1.01 [HANSCH,C ET AL. (1995)]
DMF
6EST
InChI=1/C3H7NO/c1-4(2)3-5/h3H,1-2H3
http://www.drugbank.ca/drugs/DB01844
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01844%3E
-60.4 oC
DB01844
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3731
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3731%3E
http://dbpedia.org/resource/Dimethylformamide
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FDimethylformamide%3E
C3H7NO
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2593
1000 mg/mL at 25 oC [ISHOW (NA--) @2ND]
7.25e+02 mg/mL
expt01224
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4274
ZMXDDKWLCZADIW-UHFFFAOYAS
http://en.wikipedia.org/wiki/Dimethylformamide
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FDimethylformamide%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/559
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F559%3E
http://dbpedia.org/page/Dimethylformamide
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FDimethylformamide%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2455
http://data.linkedmdb.org/data/producer/2863
_:header15751763611335206426025
Mon, 23 Apr 2012 18:40:27 GMT
RDF Description of Albert Band (Producer)
http://data.linkedmdb.org/resource/producer/2863
Albert Band (Producer)
Albert Band
http://www.freebase.com/view/guid/9202a8c04000641f80000000010f4106
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000010f4106%3E
http://data.linkedmdb.org/resource/film/8125
http://data.linkedmdb.org/resource/film/1611
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0152128
_:header14282917881335206426468
Mon, 23 Apr 2012 18:33:41 GMT
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0152128
http://sideeffects.embl.de/se/C0152128
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0152128%3E
drug withdrawal
C0152128
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4463
RDF Description of drug withdrawal
http://data.linkedmdb.org/data/film/65787
_:header2236724471335206426715
Mon, 23 Apr 2012 18:40:25 GMT
RDF Description of Emmy of Stork's Nest
http://data.linkedmdb.org/resource/film/65787
http://data.linkedmdb.org/resource/director/3077
http://data.linkedmdb.org/resource/performance/130763
Emmy of Stork's Nest
1915-10-11
http://www.freebase.com/view/guid/9202a8c04000641f80000000092707e2
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000092707e2%3E
http://data.linkedmdb.org/resource/actor/32955
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00490
_:header2092203331335206427276
Mon, 23 Apr 2012 18:33:42 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00490
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00490_DB01367
U.S. Pat. 3,717,634 (1973)
Buspirone HCL
DB00490
28:24.92
http://129.128.185.122/drugbank2/drugs/DB00490/inserts/1175/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00490%2Finserts%2F1175%2Ffull%3E
Buspimen
aprd00222
Buspirona [INN-Spanish]
http://data.linkedct.org/resource/intervention/2394
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F2394%3E
PA448689
Wellbutrin XL
Rapidly absorbed in man. Bioavailability is low and variable (approximately 5%) due to extensive first pass metabolism.
http://data.linkedct.org/resource/intervention/15342
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F15342%3E
Bespar
Anxiron
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2216
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2216%3E
Narol
http://en.wikipedia.org/wiki/Buspirone
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FBuspirone%3E
21.4 mg/L
Censpar
QWCRAEMEVRGPNT-UHFFFAOYAL
Always take at the same time with respect to meals.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/anxiolyticsSedativesAndHypnotics
2-3 hours (although the action of a single dose is much longer than the short halflife indicates).
Lucelan
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/831
An anxiolytic agent and a serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the benzodiazepines, but it has an efficacy comparable to diazepam. [PubChem]
2008-08-26 15:17:46 UTC
http://www.dbpedia.org/resource/Buspirone
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FBuspirone%3E
Ansial
Take with food.
For the management of anxiety disorders or the short-term relief of the symptoms of anxiety, and also as an augmention of SSRI-treatment against depression.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/320
Axoren
http://data.linkedct.org/resource/intervention/52550
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F52550%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/anti-anxietyAgents
/drugs/490/safety_sheets/1133
2001-07-01	/drugs/490/fda_labels/580
http://data.linkedct.org/resource/intervention/56226
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F56226%3E
http://bio2rdf.org/cas:36505-84-7
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A36505-84-7%3E
5.88e-01 mg/mL
N05BE01
Avoid taking grapefruit or grapefruit juice throughout treatment.
201.5-202.5oC
http://bio2rdf.org/cpd:C06861
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC06861%3E
http://129.128.185.122/drugbank2/drugs/DB00490/inserts/324/full
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/347
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F347%3E
Metabolized hepatically, primarily by oxidation by cytochrome P450 3A4 producing several hydroxylated derivatives and a pharmacologically active metabolite, 1-pyrimidinylpiperazine (1-PP)
8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione
Buspirone binds to 5-HT type 1A serotonin receptors on presynaptic neurons in the dorsal raphe and on postsynaptic neurons in the hippocampus, thus inhibiting the firing rate of 5-HT-containing neurons in the dorsal raphe. Buspirone also binds at dopamine type 2 (DA2) receptors, blocking presynaptic dopamine receptors. Buspirone increases firing in the locus ceruleus, an area of brain where norepinephrine cell bodies are found in high concentration. The net result of buspirone actions is that serotonergic activity is suppressed while noradrenergic and dopaminergic cell firing is enhanced.
Oral, rat LD<sub>50</sub> = 136 mg/kg. Symptoms of overdose include dizziness, drowsiness, nausea or vomiting, severe stomach upset, and unusually small pupils.
Buspinol
Buspisal
Buspirone is used in the treatment of generalized anxiety where it has advantages over other antianxiety drugs because it does not cause sedation (drowsiness) and does not cause tolerance or physical dependence. Buspirone differs from typical benzodiazepine anxiolytics in that it does not exert anticonvulsant or muscle relaxant effects. It also lacks the prominent sedative effect that is associated with more typical anxiolytics. <i>in vitro</i> preclinical studies have shown that buspirone has a high affinity for serotonin (5-HT<sub>1A</sub>) receptors. Buspirone has no significant affinity for benzodiazepine receptors and does not affect GABA binding <i>in vitro</i> or <i>in vivo</i> when tested in preclinical models. Buspirone has moderate affinity for brain D2-dopamine receptors. Some studies do suggest that buspirone may have indirect effects on other neurotransmitter systems.
http://bio2rdf.org/chebi:3223
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fchebi%3A3223%3E
http://data.linkedct.org/resource/intervention/16331
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F16331%3E
Buspironum [INN-Latin]
http://data.linkedct.org/resource/intervention/52552
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F52552%3E
95% (approximately 70% bound to albumin, 30% bound to alpha 1 -acid glycoprotein)
O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
http://www.rxlist.com/cgi/generic/buspir.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric%2Fbuspir.htm%3E
http://205.193.93.51/dpdonline/searchRequest.do?din=02242149
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02242149%3E
Buspirone
InChI=1/C21H31N5O2/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20/h5,8-9H,1-4,6-7,10-17H2
Buspar
http://dbpedia.org/page/Buspirone
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FBuspirone%3E
http://dbpedia.org/resource/Buspirone
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FBuspirone%3E
Ansiced
Travin
http://129.128.185.122/drugbank2/drugs/DB00490/inserts/2182/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00490%2Finserts%2F2182%2Ffull%3E
C21H31N5O2
http://www.drugbank.ca/drugs/DB00490
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00490%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00490_DB01045
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00780_DB00490
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00490_DB00752
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00490_DB01321
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01149_DB00490
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00615_DB00490
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00490_DB00615
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00490_DB01167
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00490_DB00780
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00490_DB00199
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00490_DB01211
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00490_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00490_DB01026
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01211_DB00490
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01026_DB00490
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00490_DB00343
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00199_DB00490
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01167_DB00490
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00490_DB00661
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00490_DB01149
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01045_DB00490
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01367_DB00490
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00490_DB01247
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01247_DB00490
RDF Description of Buspirone
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00343_DB00490
http://data.linkedmdb.org/data/film/236
_:header11225217271335206431163
Mon, 23 Apr 2012 18:40:29 GMT
http://data.linkedmdb.org/resource/film/236
http://data.linkedmdb.org/resource/interlink/70347
http://data.linkedmdb.org/resource/performance/39051
http://data.linkedmdb.org/resource/film_genre/4
http://data.linkedmdb.org/resource/performance/39048
http://data.linkedmdb.org/resource/producer/12040
http://data.linkedmdb.org/resource/actor/33924
1916-04-16
http://data.linkedmdb.org/resource/cinematographer/1480
http://data.linkedmdb.org/resource/actor/36348
Where Are My Children?
http://data.linkedmdb.org/resource/cinematographer/1481
http://www.rottentomatoes.com/alias?type=imdbid&s=0007558
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rottentomatoes.com%2Falias%3Ftype%3Dimdbid%26s%3D0007558%3E
http://data.linkedmdb.org/resource/writer/5949
http://data.linkedmdb.org/resource/film_genre/23
http://data.linkedmdb.org/resource/producer/12100
http://data.linkedmdb.org/resource/director/11604
http://www4.wiwiss.fu-berlin.de/flickrwrappr/photos/Where_Are_My_Children?
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fflickrwrappr%2Fphotos%2FWhere_Are_My_Children%3F%3E
http://data.linkedmdb.org/resource/performance/39049
http://data.linkedmdb.org/resource/director/11502
http://www.freebase.com/view/guid/9202a8c04000641f80000000000895fe
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000000895fe%3E
http://data.linkedmdb.org/resource/film_cut/8519
http://www.imdb.com/title/tt0007558
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.imdb.com%2Ftitle%2Ftt0007558%3E
http://data.linkedmdb.org/resource/writer/17551
http://data.linkedmdb.org/resource/performance/39050
http://data.linkedmdb.org/resource/actor/8646
http://data.linkedmdb.org/resource/writer/17435
http://data.linkedmdb.org/resource/writer/5950
http://mpii.de/yago/resource/Where_Are_My_Children%3F
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fmpii.de%2Fyago%2Fresource%2FWhere_Are_My_Children%253F%3E
http://dbpedia.org/resource/Where_Are_My_Children%3F
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FWhere_Are_My_Children%253F%3E
http://data.linkedmdb.org/resource/actor/8645
http://data.linkedmdb.org/resource/writer/19337
http://data.linkedmdb.org/resource/interlink/18662
http://data.linkedmdb.org/resource/interlink/134157
http://data.linkedmdb.org/resource/interlink/37195
http://data.linkedmdb.org/resource/interlink/129
RDF Description of Where Are My Children?
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/768
_:header6372963381335206431412
Mon, 23 Apr 2012 18:33:46 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/768
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00864
EC 5.2.1.8
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10656803
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7529739
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1701173
FKB1A_HUMAN
http://bio2rdf.org/hgnc:3711
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A3711%3E
Posttranslational modification, protein turnover, chaperones
FKBP1A
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1709302
http://www.genenames.org/data/hgnc_data.php?hgnc_id=3711
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D3711%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/16289353
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1716149
20p13
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=182628
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D182628%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12113647
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17524933
Rotamase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1375171
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1709363
>FK506-binding protein 1A	GVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKFDSSRDRNKPFKFMLGKQEVIRGWE	EGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLE
Immunophilin FKBP12
FK506-binding protein 1A
May play a role in modulation of ryanodine receptor isoform-1 (RYR-1), a component of the calcium release channel of skeletal muscle sarcoplasmic reticulum. There are four molecules of FKBP12 per skeletal muscle RYR. PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1695378
peptidylproline (omega=180) = peptidylproline (omega=0)
http://pfam.sanger.ac.uk/family?acc=PF00254
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00254%3E
>327 bp	ATGGGAGTGCAGGTGGAAACCATCTCCCCAGGAGACGGGCGCACCTTCCCCAAGCGCGGC	CAGACCTGCGTGGTGCACTACACCGGGATGCTTGAAGATGGAAAGAAATTTGATTCCTCC	CGGGACAGAAACAAGCCCTTTAAGTTTATGCTAGGCAAGCAGGAGGTGATCCGAGGCTGG	GAAGAAGGGGTTGCCCAGATGAGTGTGGGTCAGAGAGCCAAACTGACTATATCTCCAGAT	TATGCCTATGGTGCCACTGGGCACCCAGGCATCATCCCACCACATGCCACTCTCGTCTTC	GATGTGGAGCTTCTAAAACTGGAATGA
http://bio2rdf.org/uniprot:P62942
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP62942%3E
http://www.pdb.org/pdb/explore/explore.do?structureId=1J4I
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1J4I%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=M34539
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DM34539%3E
M34539
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1696686
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7678431
http://bio2rdf.org/pdb:1J4I
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1J4I%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2477715
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7682113
12 kDa FKBP
PPIase
http://symbol.bio2rdf.org/symbol:FKBP1A
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AFKBP1A%3E
http://www.uniprot.org/uniprot/P62942
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP62942%3E
http://bio2rdf.org/pfam:PF00254
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00254%3E
FKBP-12
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1709301
protein folding
Peptidyl-prolyl cis-trans isomerase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00877
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00337
RDF Description of FK506-binding protein 1A
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/MKL1
_:header11024354281335206431949
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/MKL1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3082
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/gene/MKL1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fgene%2FMKL1%3E
http://symbol.bio2rdf.org/symbol:MKL1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AMKL1%3E
MKL1
http://bio2rdf.org/hgnc:14334
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A14334%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=14334
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D14334%3E
http://bio2rdf.org/geneid:57591
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fgeneid%3A57591%3E
http://www.dbpedia.org/resource/MKL1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FMKL1%3E
RDF Description of MKL1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/734
http://data.linkedmdb.org/data/film/41652
_:header20865702721335206432873
Mon, 23 Apr 2012 18:40:33 GMT
http://data.linkedmdb.org/resource/film/41652
http://data.linkedmdb.org/resource/director/8655
http://data.linkedmdb.org/resource/writer/13555
http://data.linkedmdb.org/resource/performance/14077
http://data.linkedmdb.org/resource/actor/4250
http://data.linkedmdb.org/resource/performance/14078
http://data.linkedmdb.org/resource/producer/2831
http://data.linkedmdb.org/resource/actor/43554
http://data.linkedmdb.org/resource/music_contributor/4771
http://data.linkedmdb.org/resource/actor/4251
http://data.linkedmdb.org/resource/actor/9622
http://data.linkedmdb.org/resource/editor/2710
http://data.linkedmdb.org/resource/performance/14079
http://www.freebase.com/view/guid/9202a8c04000641f8000000000576c8d
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f8000000000576c8d%3E
http://data.linkedmdb.org/resource/producer/11717
Hiroshima Mon Amour
http://data.linkedmdb.org/resource/performance/72002
http://data.linkedmdb.org/resource/music_contributor/6203
RDF Description of Hiroshima Mon Amour
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Skelton_Oscar_Douglas_1878-1941
_:header18216877651335206433376
Mon, 23 Apr 2012 18:33:48 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Skelton_Oscar_Douglas_1878-1941
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2835
Skelton, Oscar Douglas, 1878-1941
RDF Description of Skelton, Oscar Douglas, 1878-1941
http://data.linkedmdb.org/data/film/94522
_:header10836217241335206433611
Mon, 23 Apr 2012 18:40:34 GMT
RDF Description of A Modern Hero
http://data.linkedmdb.org/resource/film/94522
http://data.linkedmdb.org/resource/actor/29789
1934-04-21
http://data.linkedmdb.org/resource/director/9114
A Modern Hero
http://data.linkedmdb.org/resource/performance/181875
http://www.freebase.com/view/guid/9202a8c04000641f800000000f858615
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f800000000f858615%3E
http://data.linkedmdb.org/resource/film_film_distributor_relationship/12633
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/4307
_:header21326525031335206434188
Mon, 23 Apr 2012 18:33:49 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4307
Prmt3
http://bio2rdf.org/uniprot:O70467
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AO70467%3E
http://bio2rdf.org/pfam:PF08241
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF08241%3E
>Protein arginine N-methyltransferase 3	MCSLAAGNGQGAELGPEPLELSDSGDDAGWEDEDADAEPAQGRQHTPCLFCDRLFRSAEE	TFSHCKLEHQFNIDGMVHKHGLEFYGYIKLINFIRLKNPTVEYMNSIYNPVPWDKDEYLK	PVLEDDLLLQFDVEDLYEPVSAPFTYPNGLSENTSAVEKLKLMEARALSAEAALARARED	LQKMKQFAQDFVMNVDVRTCSSTTTIADLQEDEDGVYFSSYGHYGIHEEMLKDKVRTESY	RDFIYQNPHIFKDKVVLDVGCGTGILSMFAAKAGAKKVIAVDQSEILYQAMDIIRLNKLE	DTIVLIKGKIEEVSLPVEKVDVIISEWMGYFLLFESMLDSVLYAKSKYLAKGGSVYPDIC	TISLVAVSDVSKHADRIAFWDDVYGFNMSCMKKAVIPEAVVEVVDHKTLISDPCDIKHID	CHTTSISDLEFSSDFTLRTTKTAMCTAVAGYFDIYFEKNCHNRVVFSTGPQSTKTHWKQT	IFLLEKPFPVKAGEALKGKITVHKNKKDPRSLIVTLTLNSSTQTYSLQ
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AF059530
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAF059530%3E
http://www.uniprot.org/uniprot/O70467
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FO70467%3E
Involved in methyltransferase activity
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9642256
Heterogeneous nuclear ribonucleoprotein methyltransferase-like protein 3
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10899106
ANM3_RAT
>1587 bp	ATGTGTTCGCTGGCGGCGGGGAACGGACAAGGCGCGGAGCTGGGGCCGGAGCCCTTGGAG	CTGTCGGACAGCGGAGACGACGCGGGCTGGGAGGACGAGGACGCGGACGCTGAGCCCGCA	CAGGGCCGGCAGCACACACCCTGCCTGTTCTGTGACAGGCTCTTCAGGTCTGCTGAAGAA	ACGTTTTCACACTGTAAGTTGGAGCATCAATTTAATATTGATGGTATGGTCCACAAACAT	GGACTGGAATTTTATGGATACATTAAACTAATAAATTTTATTAGACTTAAGAATCCTACT	GTTGAGTACATGAATTCCATATACAACCCTGTGCCTTGGGATAAAGATGAGTACCTGAAG	CCAGTGTTGGAAGATGATCTTTTGCTTCAGTTTGATGTAGAAGATCTTTATGAGCCAGTG	TCTGCTCCCTTCACATACCCCAATGGACTCAGCGAAAACACATCTGCTGTTGAGAAATTG	AAGCTCATGGAGGCCCGGGCGCTGTCTGCTGAGGCGGCTCTGGCTCGGGCGCGTGAGGAT	CTGCAGAAGATGAAACAATTTGCTCAGGACTTTGTGATGAACGTAGATGTCAGAACCTGC	TCCTCCACGACTACCATTGCAGACCTGCAGGAGGACGAGGATGGCGTCTACTTCAGCTCC	TATGGGCATTATGGGATACATGAAGAAATGCTAAAGGACAAAGTGCGCACAGAAAGCTAC	AGAGATTTCATATACCAAAATCCACACATCTTCAAAGATAAGGTTGTTCTGGATGTTGGC	TGTGGAACTGGAATTCTCTCCATGTTTGCTGCCAAAGCTGGGGCAAAGAAGGTGATTGCA	GTTGACCAGTCTGAAATCCTCTACCAGGCTATGGATATCATAAGGCTAAATAAACTTGAA	GATACCATTGTACTAATTAAAGGAAAGATCGAAGAAGTGAGTCTTCCTGTGGAAAAGGTG	GATGTTATTATATCAGAGTGGATGGGCTATTTTCTTCTTTTTGAGTCGATGTTGGATTCT	GTCCTTTATGCCAAGAGCAAATACTTGGCAAAAGGGGGATCGGTCTACCCTGACATTTGC	ACCATCAGCCTTGTGGCCGTGAGTGACGTGAGCAAACACGCCGATAGAATTGCCTTCTGG	GATGACGTCTATGGCTTCAACATGTCCTGCATGAAGAAAGCAGTTATACCAGAAGCTGTT	GTGGAAGTTGTAGATCACAAGACTCTCATTTCAGACCCTTGTGATATCAAGCATATAGAT	TGCCACACCACATCTATCTCAGACTTGGAGTTTTCTTCAGACTTTACCCTGAGAACCACA	AAGACAGCCATGTGCACGGCAGTTGCTGGGTACTTTGATATATATTTTGAGAAGAACTGT	CACAACAGGGTTGTATTCTCTACTGGCCCCCAGAGCACCAAAACACACTGGAAACAGACA	ATATTTCTTCTGGAAAAGCCTTTTCCCGTTAAAGCAGGTGAAGCCTTAAAAGGAAAGATC	ACAGTTCACAAGAACAAGAAGGATCCTCGTTCCCTCATTGTGACCCTGACCTTGAACAGT	TCAACCCAGACTTACAGTCTCCAGTGA
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10931850
EC 2.1.1.-
Protein arginine N-methyltransferase 3
http://bio2rdf.org/pdb:1F3L
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1F3L%3E
http://www.pdb.org/pdb/explore/explore.do?structureId=1F3L
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1F3L%3E
Methylates (mono and asymmetric dimethylation) the guanidino nitrogens of arginyl residues in some proteins
http://pfam.sanger.ac.uk/family?acc=PF08241
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF08241%3E
AF059530
RDF Description of Protein arginine N-methyltransferase 3
http://data.linkedmdb.org/data/actor/596
_:header4155788171335206434416
Mon, 23 Apr 2012 18:40:35 GMT
http://www.freebase.com/view/guid/9202a8c04000641f800000000069f103
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f800000000069f103%3E
http://data.linkedmdb.org/resource/actor/596
http://data.linkedmdb.org/resource/film/8805
http://data.linkedmdb.org/resource/performance/30258
David S. Miller
David S. Miller (Actor)
RDF Description of David S. Miller (Actor)
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0003864
_:header239565381335206435001
http://dbpedia.org/resource/Arthritis
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FArthritis%3E
http://sideeffects.embl.de/se/C0003864
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0003864%3E
Arthritis
C0003864
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/disease/Arthritis
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fdisease%2FArthritis%3E
arthritides
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/104741
RDF Description of Arthritis
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5379
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5479
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3767
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/60852
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3449
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4727
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/41781
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4493
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3305
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5352
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2891
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4730
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5002
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5402
http://data.linkedmdb.org/data/film/52394
_:header16299523791335206435906
Mon, 23 Apr 2012 18:40:36 GMT
http://www.freebase.com/view/guid/9202a8c04000641f80000000074c388a
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000074c388a%3E
http://data.linkedmdb.org/resource/film/52394
1924-05-25
The Fortieth Door
http://data.linkedmdb.org/resource/director/130
http://data.linkedmdb.org/resource/actor/10104
http://data.linkedmdb.org/resource/performance/112350
RDF Description of The Fortieth Door
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Galton_Francis_1822-1911
_:header2343097521335206436265
Mon, 23 Apr 2012 18:33:51 GMT
RDF Description of Galton, Francis, 1822-1911
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Galton_Francis_1822-1911
Galton, Francis, 1822-1911
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17128
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext14681
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext11562
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0242216
_:header15365518181335206437228
Mon, 23 Apr 2012 18:33:52 GMT
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0242216
http://sideeffects.embl.de/se/C0242216
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0242216%3E
gallstones
C0242216
gallbladder stones
gallstone
RDF Description of gallstones
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/SLC7A7
_:header8151254681335206438048
Mon, 23 Apr 2012 18:33:53 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/SLC7A7
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3025
http://symbol.bio2rdf.org/symbol:SLC7A7
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ASLC7A7%3E
SLC7A7
http://www.dbpedia.org/resource/SLC7A7
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FSLC7A7%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/703
RDF Description of SLC7A7
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00709
_:header8814285521335206438872
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00709
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00709_DB00943
http://data.linkedct.org/resource/intervention/24341
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F24341%3E
2001-08-01	/drugs/709/fda_labels/797	2002-06-01	/drugs/709/fda_labels/350
Heptovir
http://bio2rdf.org/cas:134678-17-4
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A134678-17-4%3E
http://data.linkedct.org/resource/intervention/61986
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F61986%3E
C8H11N3O3S
5 to 7 hours
DB00709
Trizivir (Abacavir (Abacavir Sulfate) + Lamivudine + Zidovudine)
3TC
70 mg/ml
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/612
http://data.linkedct.org/resource/intervention/18406
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F18406%3E
Lamivudine is a synthetic nucleoside analogue and is phosphorylated intracellularly to its active 5'-triphosphate metabolite, lamivudine triphosphate (L-TP). This nucleoside analogue is incorporated into viral DNA by HIV reverse transcriptase and HBV polymerase, resulting in DNA chain termination.
http://data.linkedct.org/resource/intervention/23253
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F23253%3E
Kivexa (Abacavir (Abacavir Sulfate) + Lamivudine)
http://data.linkedct.org/resource/intervention/24280
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F24280%3E
http://data.linkedct.org/resource/intervention/8007
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F8007%3E
Hepatitis B virus
http://data.linkedct.org/resource/intervention/35871
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35871%3E
/drugs/709/safety_sheets/1283
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/solutionOral
2.76e+00 mg/mL
aprd00681
http://www.drugbank.ca/drugs/DB00709
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00709%3E
http://data.linkedct.org/resource/intervention/8116
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F8116%3E
http://data.linkedct.org/resource/intervention/59200
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F59200%3E
2008-08-26 16:59:48 UTC
Human Immunodeficiency Virus
NC1=NC(=O)N(C=C1)C1CSC(CO)O1
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/nucleosideAndNucleotideReverseTranscriptaseInhibitors
The only detected metabolite of lamivudine is trans-sulfoxide.
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1371
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1371%3E
InChI=1/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1/f/h9H2
Lamivudine was rapidly absorbed after oral administration in HIV-infected patients. Absolute bioavailability in adults is 86% &plusmn; 16% for the tablet and 87% &plusmn; 13% for the oral solution.
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV). Lamivudine is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The lack of a 3'-OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated.
08:18.08.20
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/anti-hivAgents
lamivudine
http://data.linkedct.org/resource/intervention/52840
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F52840%3E
http://129.128.185.122/drugbank2/drugs/DB00709/inserts/472/full
http://data.linkedct.org/resource/intervention/4996
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F4996%3E
Take without regard to meals. Food does not decrease the extent of absorption, but it decreases the Cmax by slowing the rate of absorption.
Epivir-HBV
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/864
http://data.linkedct.org/resource/intervention/24270
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F24270%3E
http://data.linkedct.org/resource/intervention/26880
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F26880%3E
J05AF05
A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3&#39; carbon of the pentose ring. It is used to treat HIV disease. [PubChem]
Zeffix
http://dbpedia.org/resource/Lamivudine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FLamivudine%3E
http://www.dbpedia.org/resource/Lamivudine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FLamivudine%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1375
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1375%3E
160-162 oC
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/reverseTranscriptaseInhibitors
http://205.193.93.51/dpdonline/searchRequest.do?din=02239194
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02239194%3E
Combivir (Lamivudine + Zidovudine)
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1861
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F1861%3E
JTEGQNOMFQHVDC-IRNSGEEPDS
Lamivudine
http://129.128.185.122/drugbank2/drugs/DB00709/inserts/2389/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00709%2Finserts%2F2389%2Ffull%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1372
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1372%3E
4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
Lamivudine [Usan:Ban:Inn]
http://data.linkedct.org/resource/intervention/37627
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F37627%3E
For the treatment of HIV infection and chronic hepatitis B (HBV).
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/com1513.shtml
http://bio2rdf.org/kegg:D00353
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD00353%3E
http://bio2rdf.org/cpd:C07065
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC07065%3E
http://dbpedia.org/page/Lamivudine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FLamivudine%3E
PA450163
Hepitec
http://data.linkedct.org/resource/intervention/45346
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F45346%3E
http://data.linkedct.org/resource/intervention/23557
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F23557%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/682
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F682%3E
http://en.wikipedia.org/wiki/Lamivudine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FLamivudine%3E
36%
http://129.128.185.122/drugbank2/drugs/DB00709/inserts/1391/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00709%2Finserts%2F1391%2Ffull%3E
Epzicom
Epivir
http://www.rxlist.com/cgi/generic3/lamivudine.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric3%2Flamivudine.htm%3E
NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1
http://data.linkedct.org/resource/intervention/55162
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F55162%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1637
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1637%3E
RDF Description of Lamivudine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01610_DB00709
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01338
_:header10494952971335206439627
Mon, 23 Apr 2012 18:33:54 GMT
RDF Description of Pipecuronium
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01338
Pipecuronium bromide
http://dbpedia.org/page/Pipecuronium
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FPipecuronium%3E
DB01338
InChI=1/C35H62N4O4/c1-24(40)42-32-21-26-9-10-27-28(35(26,4)23-31(32)37-15-19-39(7,8)20-16-37)11-12-34(3)29(27)22-30(33(34)43-25(2)41)36-13-17-38(5,6)18-14-36/h26-33H,9-23H2,1-8H3/q+2/t26-,27+,28-,29-,30-,31-,32-,33-,34-,35-/m0/s1
9.50e-05 mg/mL
OWWLUIWOFHMHOQ-XGHATYIMBN
Used as a muscle relaxant during anesthesia and surgical procedures.
[(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-acetyloxy-2,16-bis(4,4-dimethylpiperazin-4-ium-1-yl)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/nicotinicAntagonists
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/813
M03AC06
http://bio2rdf.org/cpd:C07554
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC07554%3E
CC(=O)OC1CC2CCC3C(CCC4(C)C3CC(C4OC(C)=O)N3CC[N+](C)(C)CC3)C2(C)CC1N1CC[N+](C)(C)CC1
Pipecuronium is a nondepolarizing neuromuscular blocking agent. Neuromuscular blocking agents produce skeletal muscle paralysis by blocking neural transmission at the myoneural junction. The paralysis is selective initially and usually appears in the following muscles consecutively: levator muscles of eyelids, muscles of mastication, limb muscles, abdominal muscles, muscles of the glottis, and finally, the intercostal muscles and the diaphragm. Neuromuscular blocking agents have no clinically significant effect on consciousness or the pain threshold.
Nondepolarizing neuromuscular blocking agents inhibit neuromuscular transmission by competing with acetylcholine for the cholinergic receptors of the motor end plate, thereby reducing the response of the end plate to acetylcholine. This type of neuromuscular block is usually antagonized by anticholinesterase agents.
Raplon
http://dbpedia.org/resource/Pipecuronium
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FPipecuronium%3E
http://www.dbpedia.org/resource/Pipecuronium_bromide
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FPipecuronium_bromide%3E
http://en.wikipedia.org/wiki/Pipecuronium
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FPipecuronium%3E
Pipecurium
CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@@H]([C@@H]4OC(C)=O)N3CC[N+](C)(C)CC3)[C@@]2(C)C[C@@H]1N1CC[N+](C)(C)CC1
PA450972
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/neuromuscularNondepolarizingAgents
Pipecuronium
2007-06-30 18:08:08 UTC
2008-08-26 15:34:13 UTC
http://www.drugbank.ca/drugs/DB01338
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01338%3E
C35H62N4O4
http://bio2rdf.org/cas:68399-58-6
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A68399-58-6%3E
Pipecuronium is a piperazinyl androstane derivative which is a non-depolarizing neuromuscular blocking agent.
Distribution Normal renal function: 6.22 (range, 1.34 to 10.66) minutes. Renal function impairment: 4.33 (range, 1.69 to 6.17) minutes. Elimination Normal renal function: 1.7 (range, 0.9 to 2.7) hours. The elimination half-life is not altered by hypothermia and bypass. Renal function impairment: 4 (range, 2 to 8.2) hours. [PharmGKB]
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00319_DB01338
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00479_DB01338
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00798_DB01338
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01190_DB01338
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00684_DB01338
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00955_DB01338
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01627_DB01338
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/PLA2B
_:header14603359381335206440011
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PLA2B
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1949
http://symbol.bio2rdf.org/symbol:PLA2B
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3APLA2B%3E
PLA2B
RDF Description of PLA2B
http://www4.wiwiss.fu-berlin.de/factbook/data/Honduras
_:header15293978971335206440496
Mon, 23 Apr 2012 18:33:55 GMT
http://www4.wiwiss.fu-berlin.de/factbook/resource/Honduras
http://www4.wiwiss.fu-berlin.de/factbook/resource/Guatemala
President Manuel ZELAYA Rosales (since 27 January 2006); Vice President Elvin Ernesto SANTOS Ordonez (since 27 January 2006)
ho
https://www.cia.gov/library/publications/the-world-factbook/flags/ho-flag.gif
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Flibrary%2Fpublications%2Fthe-world-factbook%2Fflags%2Fho-flag.gif%3E
$2028000000; including capital expenditures of $2028000000
Cerro Las Minas
Honduras
https://www.cia.gov/library/publications/the-world-factbook/flags/ho-lgflag.gif
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Flibrary%2Fpublications%2Fthe-world-factbook%2Fflags%2Fho-lgflag.gif%3E
11 (plus 17 repeaters)
percent of vote by party - NA; seats by party - PL 62, PN 55, PUD 5, PDC 4, PINU 2
President Manuel ZELAYA Rosales (since 27 January 2006); Vice President Elvin Ernesto SANTOS Ordonez (since 27 January 2006); note - the president is both the chief of state and head of government
inadequate system
slightly larger than Tennessee
http://www4.wiwiss.fu-berlin.de/factbook/resource/El_Salvador
country code - 504; satellite earth stations - 2 Intelsat (Atlantic Ocean); connected to Central American Microwave System
18 years of age; universal and compulsory
democratic constitutional republic
estimates for this country explicitly take into account the effects of excess mortality due to AIDS; this can result in lower life expectancy, higher infant mortality and death rates, lower population and growth rates, and changes in the distribution of population by age and sex than would otherwise be expected
AM 241, FM 53, shortwave 12
+1hr, begins second Sunday in March; ends first Sunday in November; note - these dates become effective in 2007
International Court of Justice (ICJ) ruled on the delimitation of "bolsones" (disputed areas) along the El Salvador-Honduras border in 1992 with final settlement by the parties in 2006 after an Organization of American States (OAS) survey and a further ICJ ruling in 2003; the 1992 ICJ ruling advised a tripartite resolution to a maritime boundary in the Gulf of Fonseca with consideration of Honduran access to the Pacific; El Salvador continues to claim tiny Conejo Island, not mentioned in the ICJ ruling, off Honduras in the Gulf of Fonseca; Honduras claims the Belizean-administered Sapodilla Cays off the coast of Belize in its constitution, but agreed to a joint ecological park around the cays should Guatemala consent to a maritime corridor in the Caribbean under the OAS-sponsored 2002 Belize-Guatemala Differendum; memorials and countermemorials were filed by the parties in Nicaraguas 1999 and 2001 proceedings against Honduras and Colombia at the ICJ over the maritime boundary and territorial claims in the western Caribbean Sea - final public hearings are scheduled for 2007
3.48 children born/woman
Honduran(s)
Puerto Castilla, Puerto Cortes, San Lorenzo, Tela
HNL
Supreme Court of Justice or Corte Suprema de Justicia (judges are elected for seven-year terms by the National Congress)
Republica de Honduras
15 September 1821 (from Spain)
Republic of Honduras
Cabinet appointed by president
43 (Canada 1, China 3, Egypt 4, Greece 3, Hong Kong 2, Israel 1, Japan 4, South Korea 6, Lebanon 1, Mexico 1, Qatar 1, Singapore 11, Taiwan 2, Tanzania 1, US 1, Vietnam 1)
23.7% of GDP
lempira (HNL)
https://www.cia.gov/cia/publications/factbook/geos/ho.html
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Fcia%2Fpublications%2Ffactbook%2Fgeos%2Fho.html%3E
Tegucigalpa
subtropical in lowlands, temperate in mountains
Honduran
president elected by popular vote for a four-year term; election last held 27 November 2005 (next to be held in November 2009)
https://www.cia.gov/library/publications/the-world-factbook/maps/ho-map.gif
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Flibrary%2Fpublications%2Fthe-world-factbook%2Fmaps%2Fho-map.gif%3E
Once part of Spains vast empire in the New World, Honduras became an independent nation in 1821. After two and a half decades of mostly military rule, a freely elected civilian government came to power in 1982. During the 1980s, Honduras proved a haven for anti-Sandinista contras fighting the Marxist Nicaraguan Government and an ally to Salvadoran Government forces fighting leftist guerrillas. The country was devastated by Hurricane Mitch in 1998, which killed about 5600 people and caused approximately $2000000000 in damage.
Central America, bordering the Caribbean Sea, between Guatemala and Nicaragua and bordering the Gulf of Fonseca (North Pacific Ocean), between El Salvador and Nicaragua
67.1% of GDP
rooted in Roman and Spanish civil law with increasing influence of English common law; recent judicial reforms include abandoning Napoleonic legal codes in favor of the oral adversarial system; accepts ICJ jurisdiction, with reservations
http://www4.wiwiss.fu-berlin.de/factbook/resource/Nicaragua
urban population expanding; deforestation results from logging and the clearing of land for agricultural purposes; further land degradation and soil erosion hastened by uncontrolled development and improper land use practices such as farming of marginal lands; mining activities polluting Lago de Yojoa (the countrys largest source of fresh water), as well as several rivers and streams, with heavy metals
.hn
unicameral National Congress or Congreso Nacional (128 seats; members are elected proportionally to the number of votes their partys presidential candidate receives to serve four-year terms)
UTC-6 (1 hour behind Washington, DC during Standard Time)
Manuel ZELAYA Rosales elected president - 49.8%, Porfirio "Pepe" LOBO Sosa 46.1%, other 4.1%
Honduras, the second poorest country in Central America and one of the poorest countries in the Western Hemisphere, with an extraordinarily unequal distribution of income and massive unemployment, is banking on expanded trade under the US-Central America Free Trade Agreement (CAFTA) and on debt relief under the Heavily Indebted Poor Countries (HIPC) initiative. The country has met most of its macroeconomic targets, and began a three-year IMF Poverty Reduction and Growth Facility (PRGF) program in February 2004. The economy relies heavily on a narrow range of exports, notably bananas and coffee, making it vulnerable to natural disasters and shifts in commodity prices, but in recent years has experienced a rapid rise in exports of light manufacturers. Growth remains dependent on the economy of the US, its largest trading partner, and on reduction of the high crime rate, as a means of attracting and maintaining investment.
18 years of age for voluntary 2 to 3-year military service
mostly mountains in interior, narrow coastal plains
Independence Day, 15 September
last held 27 November 2005 (next to be held in November 2009)
11 January 1982, effective 20 January 1982; amended many times
18 departments (departamentos, singular - departamento); Atlantida, Choluteca, Colon, Comayagua, Copan, Cortes, El Paraiso, Francisco Morazan, Gracias a Dios, Intibuca, Islas de la Bahia, La Paz, Lempira, Ocotepeque, Olancho, Santa Barbara, Valle, Yoro
three equal horizontal bands of blue (top), white, and blue with five blue, five-pointed stars arranged in an X pattern centered in the white band; the stars represent the members of the former Federal Republic of Central America - Costa Rica, El Salvador, Guatemala, Honduras, and Nicaragua; similar to the flag of El Salvador, which features a round emblem encircled by the words REPUBLICA DE EL SALVADOR EN LA AMERICA CENTRAL centered in the white band; also similar to the flag of Nicaragua, which features a triangle encircled by the word REPUBLICA DE NICARAGUA on top and AMERICA CENTRAL on the bottom, centered in the white band
14 06 N, 87 13 W
RDF Description of Honduras
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/PAX9
_:header19584185171335206440842
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PAX9
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2727
http://symbol.bio2rdf.org/symbol:PAX9
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3APAX9%3E
PAX9
http://www.dbpedia.org/resource/PAX9
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FPAX9%3E
RDF Description of PAX9
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3436
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/861
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/575
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/969
_:header19973958281335206441260
Mon, 23 Apr 2012 18:33:56 GMT
RDF Description of Pseudovaginal perineoscrotal hypospadias
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/969
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/SRD5A2
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00548
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00548%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseaseClass/Unclassified
Pseudovaginal perineoscrotal hypospadias
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01126
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01126%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3753
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3753%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1531
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F1531%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3055
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3055%3E
http://www.dbpedia.org/resource/Pseudovaginal_perineoscrotal_hypospadias
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FPseudovaginal_perineoscrotal_hypospadias%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3684
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/4367
_:header19761959511335206441668
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4367
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02379
>1368 bp	ATGCCCACTTGGGAGGAGCTTTATAAAAATGCAATAGAGAAGGCCATAAAATCAGTGCCA	AAGGTTAAAGGGGTTCTGCTTGGATATAACACAAACATCGACGCTATAAAATACTTGGAC	AGCAAGGACCTTGAGGAAAGAATAATAAAAGCTGGAAAAGAGGAAGTGATAAAGTATTCA	GAAGAGCTCCCAGATAAAATCAACACTGTCTCTCAACTCCTTGGTTCAATACTTTGGAGC	ATAAGAAGGGGAAAAGCTGCAGAACTGTTCGTCGAAAGTTGCCCAGTGAGATTTTACATG	AAGAGATGGGGCTGGAATGAGCTCAGAATGGGAGGCCAAGCTGGAATAATGGCAAATCTC	TTGGGAGGAGTTTATGGGGTTCCTGTAATTGTTCACGTTCCCCAGCTTTCAAGACTCCAA	GCTAATCTATTCTTGGACGGCCCGATCTACGTTCCAACTTTGGAGAATGGAGAAGTAAAA	TTGATCCATCCAAAGGAGTTTAGTGGAGACGAAGAGAACTGTATCCACTACATTTATGAA	TTCCCCAGGGGATTCAGAGTTTTTGAGTTTGAAGCACCTAGAGAGAATAGATTCATAGGC	TCCGCCGATGATTACAACACAACTCTCTTCATAAGAGAGGAGTTTAGAGAAAGCTTTAGC	GAAGTAATAAAGAACGTCCAGTTAGCAATACTGAGTGGACTGCAGGCTTTAACAAAAGAG	AACTACAAGGAGCCTTTTGAGATTGTCAAGTCGAACTTGGAGGTTCTGAACGAGAGGGAA	ATCCCAGTTCACTTGGAATTTGCATTTACGCCTGACGAAAAAGTTAGAGAAGAGATATTG	AACGTTCTTGGAATGTTCTACAGTGTAGGGCTTAACGAGGTAGAGCTGGCATCAATAATG	GAAATCTTGGGAGAGAAGAAGCTCGCAAAAGAACTACTGGCCCACGATCCCGTAGATCCA	ATAGCTGTGACTGAAGCAATGTTAAAGCTTGCCAAGAAGACTGGGGTTAAGAGGATACAC	TTCCACACGTATGGTTATTATCTCGCACTAACCGAATACAAGGGAGAGCACGTGAGGGAT	GCTCTCCTATTTGCAGCCCTAGCAGCCGCTGCCAAGGCCATGAAAGGAAACATAACAAGC	CTTGAAGAAATAAGAGAAGCCACAAGTGTTCCAGTCAATGAAAAAGCCACCCAGGTCGAA	GAGAAACTAAGAGCAGAGTATGGAATTAAGGAAGGAATAGGAGAAGTGGAGGGATATCAA	ATAGCTTTCATTCCAACTAAAATAGTGGCAAAACCAAAGAGCACTGTCGGAATTGGGGAC	ACCATCTCAAGCTCGGCATTTATTGGTGAGTTTTCATTCACTCTCTAA
ADP-dependent glucokinase
fructose metabolism
cytoplasm(probable)
http://bio2rdf.org/pdb:1UA4
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1UA4%3E
glkA
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AF127910
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAF127910%3E
ADP-GK
phosphofructokinase activity
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10409652
AF127910
Catalyzes the phosphorylation of D-glucose to D-glucose 6-phosphate using ADP as the phosphate donor. Can also use CDP as the phosphoryl group donor and D-glucosamine and D-1,5- anhydroglucitol as the phosphoryl group acceptor
>ADP-dependent glucokinase	MPTWEELYKNAIEKAIKSVPKVKGVLLGYNTNIDAIKYLDSKDLEERIIKAGKEEVIKYS	EELPDKINTVSQLLGSILWSIRRGKAAELFVESCPVRFYMKRWGWNELRMGGQAGIMANL	LGGVYGVPVIVHVPQLSRLQANLFLDGPIYVPTLENGEVKLIHPKEFSGDEENCIHYIYE	FPRGFRVFEFEAPRENRFIGSADDYNTTLFIREEFRESFSEVIKNVQLAILSGLQALTKE	NYKEPFEIVKSNLEVLNEREIPVHLEFAFTPDEKVREEILNVLGMFYSVGLNEVELASIM	EILGEKKLAKELLAHDPVDPIAVTEAMLKLAKKTGVKRIHFHTYGYYLALTEYKGEHVRD	ALLFAALAAAAKAMKGNITSLEEIREATSVPVNEKATQVEEKLRAEYGIKEGIGEVEGYQ	IAFIPTKIVAKPKSTVGIGDTISSSAFIGEFSFTL
EC 2.7.1.147
ADPGK
Involved in phosphofructokinase activity
http://www.pdb.org/pdb/explore/explore.do?structureId=1UA4
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1UA4%3E
http://bio2rdf.org/uniprot:Q9V2Z6
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ9V2Z6%3E
http://www.uniprot.org/uniprot/Q9V2Z6
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ9V2Z6%3E
phosphotransferase activity, alcohol group as acceptor
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11098152
http://pfam.sanger.ac.uk/family?acc=PF04587
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF04587%3E
http://bio2rdf.org/pfam:PF04587
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF04587%3E
GLKA_PYRFU
RDF Description of ADP-dependent glucokinase
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00492
_:header686717231335206442165
Mon, 23 Apr 2012 18:33:57 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00492
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00697_DB00492
1UZF
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/244
CCC(=O)OC(OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N1CC(CC1C(O)=O)C1CCCCC1)C(C)C
http://www.rxlist.com/cgi/generic/fosinop.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric%2Ffosinop.htm%3E
Fosinopril is an angiotensin-converting enzyme (ACE) inhibitor. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. By blocking ACE, Fosinopril decreases angiotensin II which is a vasoconstrictor. Fosinopril is used to treat hypertension and heart failure, to reduce proteinuria and renal disease in patients with nephropathies, and to prevent stroke, myocardial infarction, and cardiac death in high-risk patients. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex.
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F797%3E
aprd00526
http://205.193.93.51/dpdonline/searchRequest.do?din=02262428
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02262428%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3831
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3831%3E
http://www.drugbank.ca/drugs/DB00492
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00492%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3283
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3283%3E
Avoid salt substitutes containing potassium.
Since fosinoprilat is not biotransformed after intravenous administration, fosinopril, not fosinoprilat, appears to be the precursor for the glucuronide and p-hydroxy metabolites.
Human overdoses of fosinopril have not been reported, but the most common manifestation of human fosinopril overdosage is likely to be hypotension. Oral doses of fosinopril at 2600 mg/kg in rats were associated with significant lethality.
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F319%3E
Staril
http://dbpedia.org/resource/Fosinopril
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FFosinopril%3E
For the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. It is also indicated in the management of heart failure.
87%
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1408
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1408%3E
http://bio2rdf.org/cas:98048-97-6
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A98048-97-6%3E
InChI=1/C30H46NO7P/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35)/t25-,26+,30?,39?/m1/s1/f/h34H
C30H46NO7P
149-153 oC
Insoluble
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3728
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3728%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/143
2003-06-01	/drugs/492/fda_labels/524
CCC(=O)O[C@@H](O[P@@](=O)(CCCCC1=CC=CC=C1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C
2008-08-26 15:24:37 UTC
http://dbpedia.org/page/Fosinopril
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FFosinopril%3E
Fosinoprilat, the active metabolite of fosinopril, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion. Fosinoprilat may also act on kininase II, an enzyme identical to ACE that degrades the vasodilator bradykinin.
http://data.linkedct.org/resource/intervention/17652
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F17652%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/74
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F74%3E
http://en.wikipedia.org/wiki/Fosinopril
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FFosinopril%3E
Avoid natural licorice.
A phosphinic acid-containing angiotensin-converting enzyme inhibitor that is effective in the treatment of hypertension. It is a prodrug that is converted to its active metabolite fosinoprilat. [PubChem]
PA449710
http://bio2rdf.org/kegg:D00622
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD00622%3E
http://129.128.185.122/drugbank2/drugs/DB00492/inserts/1338/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00492%2Finserts%2F1338%2Ffull%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1021
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1021%3E
Acecor
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1455
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1455%3E
(2S,4S)-4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid
http://129.128.185.122/drugbank2/drugs/DB00492/inserts/2338/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00492%2Finserts%2F2338%2Ffull%3E
E. W. Petrillo, Jr., U.S. Pat. 4,337,201 (1982)
Fosinopril
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fsider%2Fresource%2Fdrugs%2F3419%3E
BIDNLKIUORFRQP-AIINYXMPDF
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/89
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F89%3E
Monopril
Fosinopril Sodium
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2174
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2174%3E
Bioavailability is approximately 36% following oral administration.
DB00492
12 hours
http://bio2rdf.org/cpd:C07016
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC07016%3E
1.01e-03 mg/mL
Secorvas
C09AA09
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00594_DB00492
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00492_DB00697
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00492_DB01356
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00492_DB00421
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00492_DB00384
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00492_DB00594
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01356_DB00492
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00384_DB00492
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01345_DB00492
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00492_DB01345
RDF Description of Fosinopril
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/1071
_:header12901781701335206442587
RDF Description of retinol
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/1071
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0038238
retinol
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0024523
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000001071
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000001071%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00162
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00162%3E
http://sideeffects.embl.de/drugs/1071
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F1071%3E
CID0000001071
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000001071&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000001071%26input_query_species%3D9606%3E
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Powell_Baden_1796-1860
_:header1709309331335206442996
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Powell_Baden_1796-1860
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext16775
Powell, Baden, 1796-1860 
RDF Description of Powell, Baden, 1796-1860 
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Jay_John_1745-1829
_:header98972161335206443386
Mon, 23 Apr 2012 18:33:58 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Jay_John_1745-1829
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1404
Jay, John, 1745-1829
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext18
RDF Description of Jay, John, 1745-1829
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0032708
_:header14434494591335206443825
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/945
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F945%3E
http://dbpedia.org/resource/Porphyria
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FPorphyria%3E
http://sideeffects.embl.de/se/C0032708
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0032708%3E
porphyria
C0032708
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/1046
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3652
RDF Description of porphyria
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4168
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3998
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5505
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/6476
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Lucas_E_V_(Edward_Verrall)_1868-1938
_:header5824519021335206444198
Mon, 23 Apr 2012 18:33:59 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Lucas_E_V_(Edward_Verrall)_1868-1938
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext16705
Lucas, E. V. (Edward Verrall), 1868-1938
Lucas, E. V. (Edward Verrall), 1868-1938 
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext14951
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2086
RDF Description of Lucas, E. V. (Edward Verrall), 1868-1938
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext20083
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext10769
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext14678
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7237
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB04510
_:header5147109521335206444646
RDF Description of 3-Phosphoglyceric Acid
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04510
2.10e+01 mg/mL
http://www.drugbank.ca/drugs/DB04510
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB04510%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2956
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2953
O[C@@H](COP(O)(O)=O)C(O)=O
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3294
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3294%3E
OC(COP(O)(O)=O)C(O)=O
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2294
3-Phosphoglyceric Acid
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2288
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2314
expt00187
1M7O
C3H7O7P
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2994
DB04510
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2262
OSJPPGNTCRNQQC-JYGMYEITCG
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F499%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/799
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F799%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2926
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3001
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2569
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2569%3E
3PG
2008-08-26 17:02:35 UTC
(2R)-2-hydroxy-3-phosphonooxypropanoic acid
InChI=1/C3H7O7P/c4-2(3(5)6)1-10-11(7,8)9/h2,4H,1H2,(H,5,6)(H2,7,8,9)/f/h5,7-8H
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/60
_:header1578452641335206444983
RDF Description of Alkaptonuria
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/60
http://data.linkedct.org/resource/condition/749
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fcondition%2F749%3E
Alkaptonuria
http://www.dbpedia.org/resource/Alkaptonuria
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FAlkaptonuria%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/HGD
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1385
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Drayton_Michael_1563-1631
_:header18501206961335206445410
Mon, 23 Apr 2012 18:34:00 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Drayton_Michael_1563-1631
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext15448
Drayton, Michael, 1563-1631
RDF Description of Drayton, Michael, 1563-1631
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17873
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/3824
_:header6042248881335206445942
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3824
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00009
http://pfam.sanger.ac.uk/family?acc=PF06009
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF06009%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11572484
Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components
http://www.genenames.org/data/hgnc_data.php?hgnc_id=6485
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D6485%3E
http://bio2rdf.org/pfam:PF06009
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF06009%3E
Laminin subunit alpha-5
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9271224
http://pfam.sanger.ac.uk/family?acc=PF00055
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00055%3E
http://bio2rdf.org/pfam:PF00052
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00052%3E
regulation of cell motility
receptor binding
extracellular matrix (sensu Metazoa)
laminin complex
AL354836
regulation of embryonic development
LAMA5_HUMAN
http://bio2rdf.org/pfam:PF00055
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00055%3E
http://pfam.sanger.ac.uk/family?acc=PF00052
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00052%3E
regulation of cell migration
20q13.2-q13.3
regulation of cellular process
extracellular matrix
>Laminin subunit alpha-5	MAKRLCAGSALCVRGPRGPAPLLLVGLALLGAARAREEAGGGFSLHPPYFNLAEGARIAA	SATCGEEAPARGSPRPTEDLYCKLVGGPVAGGDPNQTIQGQYCDICTAANSNKAHPASNA	IDGTERWWQSPPLSRGLEYNEVNVTLDLGQVFHVAYVLIKFANSPRPDLWVLERSMDFGR	TYQPWQFFASSKRDCLERFGPQTLERITRDDAAICTTEYSRIVPLENGEIVVSLVNGRPG	AMNFSYSPLLREFTKATNVRLRFLRTNTLLGHLMGKALRDPTVTRRYYYSIKDISIGGRC	VCHGHADACDAKDPTDPFRLQCTCQHNTCGGTCDRCCPGFNQQPWKPATANSANECQSCN	CYGHATDCYYDPEVDRRRASQSLDGTYQGGGVCIDCQHHTTGVNCERCLPGFYRSPNHPL	DSPHVCRRCNCESDFTDGTCEDLTGRCYCRPNFSGERCDVCAEGFTGFPSCYPTPSSSND	TREQVLPAGQIVNCDCSAAGTQGNACRKDPRVGRCLCKPNFQGTHCELCAPGFYGPGCQP	CQCSSPGVADDRCDPDTGQCRCRVGFEGATCDRCAPGYFHFPLCQLCGCSPAGTLPEGCD	EAGRCLCQPEFAGPHCDRCRPGYHGFPNCQACTCDPRGALDQLCGAGGLCRCRPGYTGTA	CQECSPGFHGFPSCVPCHCSAEGSLHAACDPRSGQCSCRPRVTGLRCDTCVPGAYNFPYC	EAGSCHPAGLAPVDPALPEAQVPCMCRAHVEGPSCDRCKPGFWGLSPSNPEGCTRCSCDL	RGTLGGVAECQPGTGQCFCKPHVCGQACASCKDGFFGLDQADYFGCRSCRCDIGGALGQS	CEPRTGVCRCRPNTQGPTCSEPARDHYLPDLHHLRLELEEAATPEGHAVRFGFNPLEFEN	FSWRGYAQMAPVQPRIVARLNLTSPDLFWLVFRYVNRGAMSVSGRVSVREEGRSATCANC	TAQSQPVAFPPSTEPAFITVPQRGFGEPFVLNPGTWALRVEAEGVLLDYVVLLPSAYYEA	ALLQLRVTEACTYRPSAQQSGDNCLLYTHLPLDGFPSAAGLEALCRQDNSLPRPCPTEQL	SPSHPPLITCTGSDVDVQLQVAVPQPGRYALVVEYANEDARQEVGVAVHTPQRAPQQGLL	SLHPCLYSTLCRGTARDTQDHLAVFHLDSEASVRLTAEQARFFLHGVTLVPIEEFSPEFV	EPRVSCISSHGAFGPNSAACLPSRFPKPPQPIILRDCQVIPLPPGLPLTHAQDLTPATSP	AGPRPRPPTAVDPDAEPTLLREPQATVVFTTHVPTLGRYAFLLHGYQPAHPTFPVEVLIN	AGRVWQGHANASFCPHGYGCRTLVVCEGQALLDVTHSELTVTVRVPKGRWLWLDYVLVVP	ENVYSFGYLREEPLDKSYDFISHCAAQGYHISPSSSSLFCRNAAASLSLFYNNAARPCGC	HEVGATGPTCEPFGGQCPCHAHVIGRDCSRCATGYWGFPNCRPCDCGARLCDELTGQCIC	PPRTIPPDCLLCQPQTFGCHPLVGCEECNCSGPGIQELTDPTCDTDSGQCKCRPNVTGRR	CDTCSPGFHGYPRCRPCDCHEAGTAPGVCDPLTGQCYCKENVQGPKCDQCSLGTFSLDAA	NPKGCTRCFCFGATERCRSSSYTRQEFVDMEGWVLLSTDRQVVPHERQPGTEMLRADLRH	VPEAVPEAFPELYWQAPPSYLGDRVSSYGGTLRYELHSETQRGDVFVPMESRPDVVLQGN	QMSITFLEPAYPTPGHVHRGQLQLVEGNFRHTETRNTVSREELMMVLASLEQLQIRALFS	QISSAVFLRRVALEVASPAGQGALASNVELCLCPASYRGDSCQECAPGFYRDVKGLFLGR	CVPCQCHGHSDRCLPGSGVCVDCQHNTEGAHCERCQAGFMSSRDDPSAPCVSCPCPLSVP	SNNFAEGCVLRGGRTQCLCKPGYAGASCERCAPGFFGNPLVLGSSCQPCDCSGNGDPNLL	FSDCDPLTGACRGCLRHTTGPRCEICAPGFYGNALLPGNCTRCDCTPCGTEACDPHSGHC	LCKAGVTGRRCDRCQEGHFGFDGCGGCRPCACGPAAEGSECHPQSGQCHCRPGTMGPQCR	ECAPGYWGLPEQGCRRCQCPGGRCDPHTGRCNCPPGLSGERCDTCSQQHQVPVPGGPVGH	SIHCEVCDHCVVLLLDDLERAGALLPAIHEQLRGINASSMAWARLHRLNASIADLQSQLR	SPLGPRHETAQQLEVLEQQSTSLGQDARRLGGQAVGTRDQASQLLAGTEATLGHAKTLLA	AIRAVDRTLSELMSQTGHLGLANASAPSGEQLLRTLAEVERLLWEMRARDLGAPQAAAEA	ELAAAQRLLARVQEQLSSLWEENQALATQTRDRLAQHEAGLMDLREALNRAVDATREAQE	LNSRNQERLEEALQRKQELSRDNATLQATLHAARDTLASVFRLLHSLDQAKEELERLAAS	LDGARTPLLQRMQTFSPAGSKLRLVEAAEAHAQQLGQLALNLSSIILDVNQDRLTQRAIE	ASNAYSRILQAVQAAEDAAGQALQQADHTWATVVRQGLVDRAQQLLANSTALEEAMLQEQ	QRLGLVWAALQGARTQLRDVRAKKDQLEAHIQAAQAMLAMDTDETSKKIAHAKAVAAEAQ	DTATRVQSQLQAMQENVERWQGQYEGLRGQDLGQAVLDAGHSVSTLEKTLPQLLAKLSIL	ENRGVHNASLALSASIGRVRELIAQARGAASKVKVPMKFNGRSGVQLRTPRDLADLAAYT	ALKFYLQGPEPEPGQGTEDRFVMYMGSRQATGDYMGVSLRDKKVHWVYQLGEAGPAVLSI	DEDIGEQFAAVSLDRTLQFGHMSVTVERQMIQETKGDTVAPGAEGLLNLRPDDFVFYVGG	YPSTFTPPPLLRFPGYRGCIEMDTLNEEVVSLYNFERTFQLDTAVDRPCARSKSTGDPWL	TDGSYLDGTGFARISFDSQISTTKRFEQELRLVSYSGVLFFLKQQSQFLCLAVQEGSLVL	LYDFGAGLKKAVPLQPPPPLTSASKAIQVFLLGGSRKRVLVRVERATVYSVEQDNDLELA	DAYYLGGVPPDQLPPSLRWLFPTGGSVRGCVKGIKALGKYVDLKRLNTTGVSAGCTADLL	VGRAMTFHGHGFLRLALSNVAPLTGNVYSGFGFHSAQDSALLYYRASPDGLCQVSLQQGR	VSLQLLRTEVKTQAGFADGAPHYVAFYSNATGVWLYVDDQLQQMKPHRGPPPELQPQPEG	PPRLLLGGLPESGTIYNFSGCISNVFVQRLLGPQRVFDLQQNLGSVNVSTGCAPALQAQT	PGLGPRGLQATARKASRRSRQPARHPACMLPPHLRTTRDSYQFGGSLSSHLEFVGILARH	RNWPSLSMHVLPRSSRGLLLFTARLRPGSPSLALFLSNGHFVAQMEGLGTRLRAQSRQRS	RPGRWHKVSVRWEKNRILLVTDGARAWSQEGPHRQHQGAEHPQPHTLFVGGLPASSHSSK	LPVTVGFSGCVKRLRLHGRPLGAPTRMAGVTPCILGPLEAGLFFPGSGGVITLDLPGATL	PDVGLELEVRPLAVTGLIFHLGQARTPPYLQLQVTEKQVLLRADDGAGEFSTSVTRPSVL	CDGQWHRLAVMKSGNVLRLEVDAQSNHTVGPLLAAAAGAPAPLYLGGLPEPMAVQPWPPA	YCGCMRRLAVNRSPVAMTRSVEVHGAVGASGCPAA
http://www.uniprot.org/uniprot/O15230
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FO15230%3E
http://bio2rdf.org/pfam:PF02210
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF02210%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10964957
regulation of development
http://bio2rdf.org/pfam:PF00053
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00053%3E
http://bio2rdf.org/uniprot:O15230
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AO15230%3E
http://pfam.sanger.ac.uk/family?acc=PF00053
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00053%3E
regulation of locomotion
1-35
http://pfam.sanger.ac.uk/family?acc=PF06008
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF06008%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AL354836
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAL354836%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=12274842
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D12274842%3E
regulation of cell adhesion
http://pfam.sanger.ac.uk/family?acc=PF02210
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF02210%3E
http://bio2rdf.org/hgnc:6485
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A6485%3E
basement membrane
laminin-1
LAMA5
Laminin subunit alpha-5 precursor
>11073 bp	ATGGCGAAGCGGCTCTGCGCGGGGAGCGCACTGTGTGTTCGCGGCCCCCGGGGCCCCGCG	CCGCTGCTGCTGGTCGGGCTGGCGCTGCTGGGCGCGGCGCGGGCGCGGGAGGAGGCGGGC	GGCGGCTTCAGCCTGCACCCGCCCTACTTCAACCTGGCCGAGGGCGCCCGCATCGCCGCC	TCCGCGACCTGCGGAGAGGAGGCCCCGGCGCGCGGCTCCCCGCGCCCCACCGAGGACCTT	TACTGCAAGCTGGTAGGGGGCCCCGTGGCCGGCGGCGACCCCAACCAGACCATCCGGGGC	CAGTACTGTGACATCTGCACGGCTGCCAACAGCAACAAGGCACACCCCGCGAGCAATGCC	ATCGATGGCACGGAGCGCTGGTGGCAGAGTCCACCGCTGTCCCGCGGCCTGGAGTACAAC	GAGGTCAACGTCACCCTGGACCTGGGCCAGGTCTTCCACGTGGCCTACGTCCTCATCAAG	TTTGCCAACTCACCCCGGCCGGACCTCTGGGTGCTGGAGCGGTCCATGGACTTCGGCCGC	ACCTACCAGCCCTGGCAGTTCTTTGCCTCCTCCAAGAGGGACTGTCTGGAGCGGTTCGGG	CCACAGACGCTGGAGCGCATCACACGGGACGACGCGGCCATCTGCACCACCGAGTACTCA	CGCATCGTGCCCCTGGAGAACGGAGAGATCGTGGTGTCCCTGGTGAACGGACGTCCGGGC	GCCATGAATTTCTCCTACTCGCCGCTGCTACGTGAGTTCACCAAGGCCACCAACGTCCGC	CTGCGCTTCCTGCGTACCAACACGCTGCTGGGCCATCTCATGGGGAAGGCGCTGCGGGAC	CCCACGGTCACCCGCCGGTATTATTACAGCATCAAGGATATCAGCATCGGAGGCCGCTGT	GTCTGCCACGGCCACGCGGATGCCTGCGATGCCAAAGACCCCACGGACCCGTTCAGGCTG	CAGTGCACCTGCCAGCACAACACCTGCGGGGGCACCTGCGACCGCTGCTGCCCCGGCTTC	AATCAGCAGCCGTGGAAGCCTGCGACTGCCAACAGTGCCAACGAGTGCCAGTCCTGTAAC	TGCTACGGCCATGCCACCGACTGTTACTACGACCCTGAGGTGGACCGGCGCCGCGCCAGC	CAGAGCCTGGATGGCACCTATCAGGGTGGGGGTGTCTGTATCGACTGCCAGCACCACACC	ACCGGCGTCAACTGTGAGCGCTGCCTGCCCGGCTTCTACCGCTCTCCCAACCACCCTCTC	GACTCGCCCCACGTCTGCCGCCGCTGCAACTGCGAGTCCGACTTCACGGATGGCACCTGC	GAGGACCTGACGGGTCGATGCTACTGCCGGCCCAACTTCTCTGGGGAGCGGTGTGACGTG	TGTGCCGAGGGCTTCACGGGCTTCCCAAGCTGCTACCCGACGCCCTCGTCCTCCAATGAC	ACCAGGGAGCAGGTGCTGCCAGCCGGCCAGATTGTGAATTGTGACTGCAGCGCGGCAGGG	ACCCAGGGCAACGCCTGCCGGAAGGACCCAAGGGTGGGACGCTGTCTGTGCAAACCCAAC	TTCCAAGGCACCCATTGTGAGCTCTGCGCGCCAGGGTTCTACGGCCCCGGCTGCCAGCCC	TGCCAGTGTTCCAGCCCTGGAGTGGCCGATGACCGCTGTGACCCTGACACAGGCCAGTGC	AGGTGCCGAGTGGGCTTCGAGGGGGCCACATGTGATCGCTGTGCCCCCGGCTACTTTCAC	TTCCCTCTCTGCCAGTTGTGTGGCTGCAGCCCTGCAGGAACCTTGCCCGAGGGCTGCGAT	GAGGCCGGCCGCTGCCTATGCCAGCCTGAGTTTGCTGGACCTCATTGTGACCGGTGCCGC	CCTGGCTACCATGGTTTCCCCAACTGCCAAGCATGCACCTGCGACCCTCGGGGAGCCCTG	GACCAGCTCTGTGGGGCGGGAGGTTTGTGCCGCTGCCGCCCCGGCTACACAGGCACTGCC	TGCCAGGAATGCAGCCCCGGCTTTCACGGCTTCCCCAGCTGTGTCCCCTGCCACTGCTCT	GCTGAAGGCTCCCTGCACGCAGCCTGTGACCCCCGGAGTGGGCAGTGCAGCTGCCGGCCC	CGTGTGACGGGGCTGCGGTGTGACACATGTGTGCCCGGTGCCTACAACTTCCCCTACTGC	GAAGCTGGCTCTTGCCACCCTGCCGGTCTGGCCCCAGTGGATCCTGCCCTTCCTGAGGCA	CAGGTTCCCTGTATGTGCCGGGCTCACGTGGAGGGGCCGAGCTGTGACCGCTGCAAACCT	GGGTTCTGGGGACTGAGCCCCAGCAACCCCGAGGGCTGTACCCGCTGCAGCTGCGACCTC	AGGGGCACACTGGGTGGAGTTGCTGAGTGCCAGCCGGGCACCGGCCAGTGCTTCTGCAAG	CCCCACGTGTGCGGCCAGGCCTGCGCGTCCTGCAAGGATGGCTTCTTTGGACTGGATCAG	GCTGACTATTTTGGCTGCCGCAGCTGCCGGTGTGACATTGGCGGTGCACTGGGCCAGAGC	TGTGAACCGAGGACGGGCGTCTGCCGGTGCCGCCCCAACACCCAGGGCCCCACCTGCAGC	GAGCCTGCGAGGGACCACTACCTCCCGGACCTGCACCACCTGCGCCTGGAGCTGGAGGAG	GCTGCCACACCTGAGGGTCACGCCGTGCGCTTTGGCTTCAACCCCCTCGAGTTCGAGAAC	TTCAGCTGGAGGGGCTACGCGCAGATGGCACCTGTCCAGCCCAGGATCGTGGCCAGGCTG	AACCTGACCTCCCCTGACCTTTTCTGGCTCGTCTTCCGATACGTCAACCGGGGGGCCATG	AGTGTGAGCGGGCGGGTCTCTGTGCGAGAGGAGGGCAGGTCGGCCACCTGCGCCAACTGC	ACAGCACAGAGTCAGCCCGTGGCCTTCCCACCCAGCACGGAGCCTGCCTTCATCACCGTG	CCCCAGAGGGGCTTCGGAGAGCCCTTTGTGCTGAACCCTGGCACCTGGGCCCTGCGTGTG	GAGGCCGAAGGGGTGCTCCTGGACTACGTGGTTCTGCTGCCTAGCGCATACTACGAGGCG	GCGCTCCTGCAGCTGCGGGTGACTGAGGCCTGCACATACCGTCCCTCTGCCCAGCAGTCT	GGCGACAACTGCCTCCTCTACACACACCTCCCCCTGGATGGCTTCCCCTCGGCCGCCGGG	CTGGAGGCCCTGTGTCGCCAGGACAACAGCCTGCCCCGGCCCTGCCCCACGGAGCAGCTC	AGCCCGTCGCACCCGCCACTGATCACCTGCACGGGCAGTGATGTGGACGTCCAGCTTCAA	GTGGCAGTGCCACAGCCAGGCCGCTATGCCCTAGTGGTGGAGTACGCCAATGAGGATGCC	CGCCAGGAGGTGGGCGTGGCCGTGCACACCCCACAGCGGGCCCCCCAGCAGGGGCTGCTC	TCCCTGCACCCCTGCCTGTACAGCACCCTGTGCCGGGGCACTGCCCGGGATACCCAGGAC	CACCTGGCTGTCTTCCACCTGGACTCGGAGGCCAGCGTGAGGCTCACAGCCGAACAGGCA	CGCTTCTTCCTGCACGGGGTCACTCTGGTGCCCATTGAGGAGTTCAGCCCGGAGTTCGTG	GAGCCCCGGGTCAGCTGCATCAGCAGCCACGGCGCCTTTGGCCCCAACAGTGCCGCCTGT	CTGCCCTCGCGCTTCCCAAAGCCGCCCCAGCCCATCATCCTCAGGGACTGCCAGGTGATC	CCGCTGCCGCCCGGCCTCCCGCTGACCCACGCGCAGGATCTCACTCCAGCCATGTCCCCA	GCTGGACCCCGACCTCGGCCCCCCACCGCTGTGGACCCTGATGCAGAGCCCACCCTGCTG	CGTGAGCCCCAGGCCACCGTGGTCTTCACCACCCATGTGCCCACGCTGGGCCGCTATGCC	TTCCTGCTGCACGGCTACCAGCCAGCCCACCCCACCTTCCCCGTGGAAGTCCTCATCAAC	GCCGGCCGCGTGTGGCAGGGCCACGCCAACGCCAGCTTCTGTCCACATGGCTACGGCTGC	CGCACCCTGGTGGTGTGTGAGGGCCAGGCCCTGCTGGACGTGACCCACAGCGAGCTCACT	GTGACCGTGCGTGTGCCCAAGGGCCGGTGGCTCTGGCTGGATTATGTACTCGTGGTCCCT	GAGAACGTCTACAGCTTTGGCTACCTCCGGGAGGAGCCCCTGGATAAATCCTATGACTTC	ATCAGCCACTGCGCAGCCCAGGGCTACCACATCAGCCCCAGCAGCTCATCCCTGTTCTGC	CGAAACGCTGCTGCTTCCCTCTCCCTCTTCTATAACAACGGAGCCCGTCCATGTGGCTGC	CACGAAGTAGGTGCTACAGGCCCCACGTGTGAGCCCTTCGGGGGCCAGTGTCCCTGCCAT	GCCCATGTCATTGGCCGTGACTGCTCCCGCTGTGCCACCGGATACTGGGGCTTCCCCAAC	TGCAGGCCCTGTGACTGCGGTGCCCGCCTCTGTGACGAGCTCACGGGCCAGTGCATCTGC	CCGCCACGCACCATCCCGCCCGACTGCCTGCTGTGCCAGCCCCAGACCTTTGGCTGCCAC	CCCCTGGTCGGCTGTGAGGAGTGTAACTGCTCAGGGCCCGGCATCCAGGAGCTCACAGAC	CCTACCTGTGACACAGACAGCGGCCAGTGCAAGTGCAGACCCAACGTGACTGGGCGCCGC	TGTGATACCTGCTCTCCGGGCTTCCATGGCTACCCCCGCTGCCGCCCCTGTGACTGTCAC	GAGGCGGGCACTGCGCCTGGCGTGTGTGACCCCCTCACAGGGCAGTGCTACTGTAAGGAG	AACGTGCAGGGCCCCAAATGTGACCAGTGCAGCCTTGGGACCTTCTCACTGGATGCTGCC	AACCCCAAAGGTTGCACCCGCTGCTTCTGCTTTGGGGCCACGGAGCGCTGCCGGAGCTCG	TCCTACACCCGCCAGGAGTTCGTGGATATGGAGGGATGGGTGCTGCTGAGCACTGACCGG	CAGGTGGTGCCCCACGAGCGGCAGCCAGGGACGGAGATGCTCCGTGCAGACCTGCGGCAC	GTGCCTGAGGCTGTGCCCGAGGCTTTCCCCGAGCTGTACTGGCAGGCCCCACCCTCCTAC	CTGGGGGACCGGGTGTCATCCTACGGTGGGACCCTCCGTTATGAACTGCACTCAGAGACC	CAGCGGGGAGATGTCTTTGTCCCCATGGAGAGCAGGCCGGATGTGGTGCTGCAGGGCAAC	CAGATGAGCATCACATTCCTGGAGCCGGCATACCCCACGCCTGGCCACGTTCACCGTGGG	CAGCTGCAGCTGGTGGAGGGGAACTTCCGGCATACGGAGACGCGCAACACTGTGTCCCGC	GAGGAGCTCATGATGGTGCTGGCCAGCCTGGAGCAGCTGCAGATCCGTGCCCTCTTCTCA	CAGATCTCCTCGGCTGTCTTCCTGCGCAGGGTGGCACTGGAGGTGGCCAGCCCAGCAGGC	CAGGGGGCCCTGGCCAGCAATGTGGAGCTGTGCCTGTGCCCCGCCAGCTACCGGGGGGAC	TCATGCCAGGAATGTGCCCCCGGCTTCTATCGGGACGTCAAAGGTCTCTTCCTGGGCCGA	TGTGTCCCTTGTCAGTGCCATGGACACTCAGACCGCTGCCTCCCTGGCTCTGGCGTCTGT	GTGGACTGCCAGCACAACACCGAAGGGGCCCACTGTGAGCGCTGCCAGGCTGGCTTCGTG	AGCAGCAGGGACGACCCCAGCGCCCCCTGTGTCAGCTGCCCCTGCCCCCTCTCAGTGCCT	TCCAACAACTTCGCCGAGGGCTGTGTCCTGCGAGGCGGCCGCACCCAGTGCCTCTGCAAA	CCTGGTTATGCAGGTGCCTCCTGCGAGCGGTGTGCGCCCGGATTCTTTGGGAACCCACTG	GTGCTGGGCAGCTCCTGCCAGCCATGCGACTGCAGCGGCAACGGTGACCCCAACTTGCTC	TTCAGCGACTGCGACCCCCTGACGGGCGCCTGCCGTGGCTGCCTGCGCCACACCACTGGG	CCCCGCTGCGAGATCTGTGCCCCCGGCTTCTACGGCAACGCCCTGCTGCCCGGCAACTGC	ACCCGGTGCGACTGTACCCCATGTGGGACAGAGGCCTGCGACCCCCACAGCGGGCACTGC	CTGTGCAAGGCGGGCGTGACTGGGCGGCGCTGTGACCGCTGCCAGGAGGGACATTTTGGT	TTCGATGGCTGCGGGGGCTGCCGCCCGTGTGCTTGTGGACCGGCCGCCGAGGGCTCCGAG	TGCCACCCCCAGAGCGGACAGTGCCACTGCCGACCAGGGACCATGGGACCCCAGTGCCGC	GAGTGTGCCCCTGGCTACTGGGGGCTCCCTGAGCAGGGCTGCAGGCGCTGCCAGTGCCCT	GGGGGCCGCTGTGACCCTCACACGGGCCGCTGCAACTGCCCCCCGGGGCTCAGCGGGGAG	CGCTGCGACACCTGCAGCCAGCAGCATCAGGTGCCTGTTCCAGGCGGGCCTGTGGGCCAC	AGCATCCACTGTGAAGTGTGTGACCACTGTGTGGTCCTGCTCCTGGATGACCTGGAACGG	GCCGGCGCCCTCCTCCCCGCCATTCACGAGCAACTGCGTGGCATCAATGCCAGCTCCATG	GCCTGGGCCCGTCTGCACAGGCTGAACGCCTCCATCGCTGACCTGCAGAGCCAGCTCCGG	AGCCCCCTGGGCCCCCGCCATGAGACGGCACAGCAGCTGGAGGTGCTGGAGCAGCAGAGC	ACAAGCCTCGGGCAGGACGCACGGCGGCTAGGCGGCCAGGCCGTGGGGACCCGAGACCAG	GCGAGCCAATTGCTGGCCGGCACCGAGGCCACACTGGGCCATGCGAAGACGCTGTTGGCG	GCCATCCGGGCTGTGGACCGCACCCTGAGCGAGCTCATGTCCCAGACGGGCCACCTGGGG	CTGGCCAATGCCTCGGCTCCATCAGGTGAGCAGCTGCTCCGGACACTGGCCGAGGTGGAG	CGGCTGCTCTGGGAGATGCGGGCCCGGGACCTGGGGGCCCCGCAGGCAGCAGCTGAGGCT	GAGTTGGCTGCAGCACAGAGATTGCTGGCCCGGGTGCAGGAGCAGCTGAGCAGCCTCTGG	GAGGAGAACCAGGCACTGGCCACACAAACCCGCGACCGGCTGGCCCAGCACGAGGCCGGC	CTCATGGACCTGCGAGAGGCTTTGAACCGGGCAGTGGACGCCACACGGGAGGCCCAGGAG	CTCAACAGCCGCAACCAGGAGCGCCTGGAGGAAGCCCTGCAAAGGAAGCAGGAGCTGTCC	CGGGACAATGCCACCCTGCAGGCCACTCTGCATGCGGCTAGGGACACCCTGGCCAGCGTC	TTCAGATTGCTGCACAGCCTGGACCAGGCTAAGGAGGAGCTGGAGCGCCTCGCCGCCAGC	CTGGATGGGGCTCGGACCCCACTGCTGCAGAGGATGCAGACCTTCTCCCCGGCGGGCAGC	AAGCTGCGTCTAGTGGAGGCCGCCGAGGCCCACGCACAGCAGCTGGGCCAGCTGGCACTC	AATCTGTCCAGCATCATCCTGGACGTCAACCAGGACCGCCTCACCCAGAGGGCCATCGAG	GCCTCCAACGCCTACAGCCGCATCCTGCAGGCCGTGCAGGCTGCCGAGGATGCTGCTGGC	CAGGCCCTGCAGCAGGCGGACCACACGTGGGCGACGGTGGTGCGGCAGGGCCTGGTGGAC	CGAGCCCAGCAGCTCCTGGCCAACAGCACTGCACTAGAAGAGGCCATGCTCCAGGAACAG	CAGAGGCTGGGCCTTGTGTGGGCTGCCCTCCAGGGTGCCAGGACCCAGCTCCGAGATGTC	CGGGCCAAGAAGGACCAGCTGGAGGCGCACATCCAGGCGGCGCAGGCCATGCTTGCCATG	GACACAGACGAGACAAGCAAGAAGATCGCACATGCCAAGGCTGTGGCTGCTGAAGCCCAG	GACACCGCCACCCGTGTGCAGTCCCAGCTGCAGGCCATGCAGGAGAATGTGGAGCGGTGG	CAGGGCCAGTACGAGGGCCTGCGGGGCCAGGACCTGGGCCAGGCAGTGCTTGACGCAGGC	CACTCAGTGTCCACCCTGGAGAAGACGCTGCCCCAGCTGCTGGCCAAGCTGAGCATCCTG	GAGAACCGTGGGGTGCACAACGCCAGCCTGGCCCTGTCCGCCAGCATTGGCCGCGTGCGA	GAGCTCATTGCCCAGGCCCGGGGGGCTGCCAGTAAGGTCAAGGTGCCCATGAAGTTCAAC	GGGCGCTCAGGGGTGCAGCTGCGCACCCCACGGGATCTTGCCGACCTTGCTGCCTACACT	GCCCTCAAGTTCTACCTGCAGGGCCCAGAGCCTGAGCCTGGGCAGGGTACCGAGGATCGC	TTTGTGATGTACATGGGCAGCCGCCAGGCCACTGGGGACTACATGGGTGTGTCTCTGCGT	GACAAGAAGGTGCACTGGGTGTATCAGCTGGGTGAGGCGGGCCCTGCAGTCCTAAGCATC	GATGAGGACATTGGGGAGCAGTTCGCAGCTGTCAGCCTGGACAGGACTCTCCAGTTTGGC	CACATGTCCGTCACAGTGGAGAGACAGATGATCCAGGAAACCAAGGGTGACACGGTGGCC	CCTGGGGCAGAGGGGCTGCTCAACCTGCGGCCAGACGACTTCGTCTTCTACGTCGGGGGG	TACCCCAGTACCTTCACGCCCCCTCCCCTGCTTCGCTTCCCCGGCTACCGGGGCTGCATC	GAGATGGACACGCTGAATGAGGAGGTGGTCAGCCTCTACAACTTCGAGAGGACCTTCCAG	CTGGACACGGCTGTGGACAGGCCTTGTGCCCGCTCCAAGTCGACCGGGGACCCGTGGCTC	ACGGACGGCTCCTACCTGGACGGCACCGGCTTCGCCCGCATCAGCTTCGACAGTCAGATC	AGCACCACCAAGCGCTTCGAGCAGGAGCTGCGGCTCGTGTCCTACAGCGGGGTGCTCTTC	TTCCTGAAGCAGCAGAGCCAGTTCCTGTGCTTGGCCGTGCAAGAAGGCAGCCTCGTGCTG	TTGTATGACTTTGGGGCTGGCCTGAAAAAGGCCGTCCCACTGCAGCCCCCACCGCCCCTG	ACCTCGGCCAGCAAGGCGATCCAGGTGTTCCTGCTGGGGGGCAGCCGCAAGCGTGTGCTG	GTGCGTGTGGAGCGGGCCACGGTGTACAGCGTGGAGCAGGACAATGATCTGGAGCTGGCC	GACGCCTACTACCTGGGGGGCGTGCCGCCCGACCAGCTGCCCCCGAGCCTGCGACGGCTC	TTCCCCACCGGAGGCTCAGTCCGTGGCTGCGTCAAAGGCATCAAGGCCCTGGGCAAGTAT	GTGGACCTCAAGCGGCTGAACACGACAGGCGTGAGCGCCGGCTGCACCGCCGACCTGCTG	GTGGGGCGCGCCATGACTTTCCATGGCCACGGCTTCCTTCGCCTGGCGCTCTCGAACGTG	GCACCGCTCACTGGCAACGTCTACTCCGGCTTCGGCTTCCACAGCGCCCAGGACAGTGCC	CTGCTCTACTACCGGGCGTCCCCGGATGGGCTATGCCAGGTGTCCCTGCAGCAGGGCCGT	GTGAGCCTACAGCTCCTGAGGACTGAAGTGAAAACTCAAGCGGGCTTCGCCGATGGTGCC	CCCCATTACGTCGCCTTCTACAGCAATGCCACGGGAGTCTGGCTGTATGTCGATGACCAG	CTCCAGCAGATGAAGCCCCACCGGGGACCACCCCCCGAGCTCCAGCCGCAGCCTGAGGGG	CCCCCGAGGCTCCTCCTGGGAGGCCTGCCTGAGTCTGGCACCATTTACAACTTCAGTGGC	TGCATCAGCAACGTCTTCGTGCAGCGGCTCCTGGGCCCACAGCGCGTATTTGATCTGCAG	CAGAACCTGGGCAGCGTCAATGTGAGCACGGGCTGTGCACCCGCCCTGCAAGCCCAGACC	CCGGGCCTGGGGCCTAGAGGACTGCAGGCCTCCCGCCGCAGCCGTCAGCCCGCCCGGCAT	CCTGCCTGCATGCTGCCCCCACACCTCAGGACCACCCGAGACTCCTACCAGTTTGGGGGT	TCCCTGTCCAGTCACCTGGAGTTTGTGGGCATCCTGGCCCGACATAGGAACTGGCCCAGT	CTCTCCATGCACGTCCTCCCGCGAAGCTCCCGAGGCCTCCTCCTCTTCACTGCCCGTCTG	AGGCCCGGCAGCCCCTCCCTGGCGCTCTTCCTGAGCAATGGCCACTTCGTTGCACAGATG	GAAGGCCTCGGGACTCGGCTCCGCGCCCAGAGCCGCCAGCGCTCCCGGCCTGGCCGCTGG	CACAAGGTCTCCGTGCGCTGGGAGAAGAACCGGATCCTGCTGGTGACGGACGGGGCCCGG	GCCTGGAGCCAGGAGGGGCCGCACCGGCAGCACCAGGGGGCAGAGCACCCCCAGCCCCAC	ACCCTCTTTGTGGGCGGCCTCCCGGCCAGCAGCCACAGCTCCAAACTTCCGGTGACCGTC	GGGTTCAGCGGCTGTGTGAAGAGACTGAGGCTGCACGGGAGGCCCCTGGGGGCCCCCACA	CGGATGGCAGGGGTCACACCCTGCATCTTGGGCCCCCTGGAGGCGGGCCTGTTCTTCCCA	GGCAGCGGGGGAGTTATCACTTTAGACCTCCCAGGAGCTACACTGCCTGATGTGGGCCTG	GAACTGGAGGTGCGGCCCCTGGCAGTCACCGGACTGATCTTCCACTTGGGCCAGGCCCGG	ACGCCCCCCTACTTGCAGTTGCAGGTGACCGAGAAGCAAGTCCTGCTGCGGGCGGATGAC	GGAGCAGGGGAGTTCTCCACGTCAGTGACCCGCCCCTCAGTGCTGTGTGATGGCCAGTGG	CACCGGCTAGCGGTGATGAAAAGCGGGAATGTGCTCCGGCTGGAGGTGGACGCGCAGAGC	AACCACACCGTGGGCCCCTTGCTGGCGGCTGCAGCTGGTGCCCCAGCCCCTCTGTACCTC	GGGGGCCTGCCTGAGCCCATGGCCGTGCAGCCCTGGCCCCCCGCCTACTGCGGCTGCATG	AGGAGGCTGGCGGTGAACCGGTCCCCCGTCGCCATGACTCGCTCTGTGGAGGTCCACGGG	GCAGTGGGGGCCAGTGGCTGCCCAGCCGCCTAG
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9628581
http://bio2rdf.org/pfam:PF06008
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF06008%3E
http://symbol.bio2rdf.org/symbol:LAMA5
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ALAMA5%3E
RDF Description of Laminin subunit alpha-5
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00029
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00031
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00015
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/958
_:header487937081335206446248
Mon, 23 Apr 2012 18:34:01 GMT
RDF Description of Properdin deficiency
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/958
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PFC
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseaseClass/Immunological
Properdin deficiency
http://www.dbpedia.org/resource/Properdin_deficiency
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FProperdin_deficiency%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3652
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/4659569
_:header18628475111335206446791
RDF Description of Tasmar
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0917816
http://www.fda.gov/medwatch/SAFETY/2006/Feb_PI/Tasmar_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2006%2FFeb_PI%2FTasmar_PI.pdf%3E
http://dbpedia.org/resource/Tolcapone
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FTolcapone%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00323
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00323%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0042134
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0085583
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0034063
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0917798
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0152020
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0085632
Tasmar
http://www.fda.gov/cder/foi/label/2007/020697s012lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2007%2F020697s012lbl.pdf%3E
http://www.fda.gov/medwatch/SAFETY/2007/Jan_PI/Tasmar_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2007%2FJan_PI%2FTasmar_PI.pdf%3E
http://sideeffects.embl.de/drugs/4659569
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F4659569%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0242422
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0011253
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0152029
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0007784
http://www.fda.gov/cder/foi/label/2006/020697s010lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2006%2F020697s010lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0018991
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0003850
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0013384
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0023418
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0011206
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0003507
CID0004659569
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0022904
TASMAR
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0004659569
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0004659569%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0600139
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0004659569&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0004659569%26input_query_species%3D9606%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2470
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2470%3E
tolcapone
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0042721
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/1719
_:header16750479691335206447270
Mon, 23 Apr 2012 18:34:02 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/1719
Heparanase
Endo- glucoronidase
peripheralMembraneProtein.SecretedProtein.Note=secreted,Internal
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17629845
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10405343
http://www.dbpedia.org/resource/Heparanase
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FHeparanase%3E
AF152376
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10395326
http://bio2rdf.org/hgnc:5164
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A5164%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=5616197
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D5616197%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17557930
http://www.uniprot.org/uniprot/Q9Y251
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ9Y251%3E
HPSE
HPSE_HUMAN
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17041566
4q21.3
>Heparanase precursor	MLLRSKPALPPPLMLLLLGPLGPLSPGALPRPAQAQDVVDLDFFTQEPLHLVSPSFLSVT	IDANLATDPRFLILLGSPKLRTLARGLSPAYLRFGGTKTDFLIFDPKKESTFEERSYWQS	QVNQDICKYGSIPPDVEEKLRLEWPYQEQLLLREHYQKKFKNSTYSRSSVDVLYTFANCS	GLDLIFGLNALLRTADLQWNSSNAQLLLDYCSSKGYNISWELGNEPNSFLKKADIFINGS	QLGEDFIQLHKLLRKSTFKNAKLYGPDVGQPRRKTAKMLKSFLKAGGEVIDSVTWHHYYL	NGRTATREDFLNPDVLDIFISSVQKVFQVVESTRPGKKVWLGETSSAYGGGAPLLSDTFA	AGFMWLDKLGLSARMGIEVVMRQVFFGAGNYHLVDENFDPLPDYWLSLLFKKLVGTKVLM	ASVQGSKRRKLRVYLHCTNTDNPRYKEGDLTLYAINLHNVTKYLRLPYPFSNKQVDKYLL	RPLGPHGLLSKSVQLNGLTLKMVDDQTLPPLMEKPLRPGSSLGLPAFSYSFFVIRNAKVA	ACI
http://pfam.sanger.ac.uk/family?acc=PF03662
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF03662%3E
http://symbol.bio2rdf.org/symbol:HPSE
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AHPSE%3E
lysosome
http://bio2rdf.org/uniprot:Q9Y251
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ9Y251%3E
Hpa1
Heparanase precursor
Involved in beta-glucuronidase activity
http://bio2rdf.org/pfam:PF03662
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF03662%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AF152376
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAF152376%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/16951194
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10764835
Endoglycosidase which is a cell surface and extracellular matrix-degrading enzyme. Cleaves heparan sulfate proteoglycans (HSPGs) into heparan sulfate side chains and core proteoglycans. Also implicated in the extravasation of leukocytes and tumor cell lines. Due to its contribution to metastasis and angiogenesis, it is considered to be a potential target for anti- cancer therapies
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10446189
http://www.genenames.org/data/hgnc_data.php?hgnc_id=5164
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D5164%3E
Heparanase-1
>1632 bp	ATGCTGCTGCGCTCGAAGCCTGCGCTGCCGCCGCCGCTGATGCTGCTGCTCCTGGGGCCG	CTGGGTCCCCTCTCCCCTGGCGCCCTGCCCCGACCTGCGCAAGCACAGGACGTCGTGGAC	CTGGACTTCTTCACCCAGGAGCCGCTGCACCTGGTGAGCCCCTCGTTCCTGTCCGTCACC	ATTGACGCCAACCTGGCCACGGACCCGCGGTTCCTCATCCTCCTGGGTTCTCCAAAGCTT	CGTACCTTGGCCAGAGGCTTGTCTCCTGCGTACCTGAGGTTTGGTGGCACCAAGACAGAC	TTCCTAATTTTCGATCCCAAGAAGGAATCAACCTTTGAAGAGAGAAGTTACTGGCAATCT	CAAGTCAACCAGGATATTTGCAAATATGGATCCATCCCTCCTGATGTGGAGGAGAAGTTA	CGGTTGGAATGGCCCTACCAGGAGCAATTGCTACTCCGAGAACACTACCAGAAAAAGTTC	AAGAACAGCACCTACTCAAGAAGCTCTGTAGATGTGCTATACACTTTTGCAAACTGCTCA	GGACTGGACTTGATCTTTGGCCTAAATGCGTTATTAAGAACAGCAGATTTGCAGTGGAAC	AGTTCTAATGCTCAGTTGCTCCTGGACTACTGCTCTTCCAAGGGGTATAACATTTCTTGG	GAACTAGGCAATGAACCTAACAGTTTCCTTAAGAAGGCTGATATTTTCATCAATGGGTCG	CAGTTAGGAGAAGATTTTATTCAATTGCATAAACTTCTAAGAAAGTCCACCTTCAAAAAT	GCAAAACTCTATGGTCCTGATGTTGGTCAGCCTCGAAGAAAGACGGCTAAGATGCTGAAG	AGCTTCCTGAAGGCTGGTGGAGAAGTGATTGATTCAGTTACATGGCATCACTACTATTTG	AATGGACGGACTGCTACCAGGGAAGATTTTCTAAACCCTGATGTATTGGACATTTTTATT	TCATCTGTGCAAAAAGTTTTCCAGGTGGTTGAGAGCACCAGGCCTGGCAAGAAGGTCTGG	TTAGGAGAAACAAGCTCTGCATATGGAGGCGGAGCGCCCTTGCTATCCGACACCTTTGCA	GCTGGCTTTATGTGGCTGGATAAATTGGGCCTGTCAGCCCGAATGGGAATAGAAGTGGTG	ATGAGGCAAGTATTCTTTGGAGCAGGAAACTACCATTTAGTGGATGAAAACTTCGATCCT	TTACCTGATTATTGGCTATCTCTTCTGTTCAAGAAATTGGTGGGCACCAAGGTGTTAATG	GCAAGCGTGCAAGGTTCAAAGAGAAGGAAGCTTCGAGTATACCTTCATTGCACAAACACT	GACAATCCAAGGTATAAAGAAGGAGATTTAACTCTGTATGCCATAAACCTCCATAATGTC	ACCAAGTACTTGCGGTTACCCTATCCTTTTTCTAACAAGCAAGTGGATAAATACCTTCTA	AGACCTTTGGGACCTCATGGATTACTTTCCAAATCTGTCCAACTCAATGGTCTAACTCTA	AAGATGGTGGATGATCAAACCTTGCCACCTTTAATGGAAAAACCTCTCCGGCCAGGAAGT	TCACTGGGCTTGCCAGCTTTCTCATATAGTTTTTTTGTGATAAGAAATGCCAAAGTTGCT	GCTTGCATCTGA
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17609509
lysosomalMembrane
EC 3.2.-.-
RDF Description of Heparanase
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Cox_Kenyon_1856-1919
_:header13074506401335206447647
RDF Description of Cox, Kenyon, 1856-1919
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Cox_Kenyon_1856-1919
Cox, Kenyon, 1856-1919
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext16655
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Pumpurs_Andrejs_1841-1902
_:header11044306491335206448181
Mon, 23 Apr 2012 18:34:03 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Pumpurs_Andrejs_1841-1902
Pumpurs, Andrejs, 1841-1902
RDF Description of Pumpurs, Andrejs, 1841-1902
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17445
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Wodehouse_P_G_(Pelham_Grenville)_1881-1975
_:header2712243471335206448493
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Wodehouse_P_G_(Pelham_Grenville)_1881-1975
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6753
Wodehouse, P. G. (Pelham Grenville), 1881-1975
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7423
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8178
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext20532
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3756
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7464
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6836
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext20533
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6768
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8713
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6879
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext4075
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6877
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6837
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext10586
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6984
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6684
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8190
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7028
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6683
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2005
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7230
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7050
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6880
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7471
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8931
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6955
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6985
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2607
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7298
RDF Description of Wodehouse, P. G. (Pelham Grenville), 1881-1975
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2233
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8176
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8164
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2042
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3829
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6927
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6980
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext10554
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/HPS7
_:header13231345651335206448945
RDF Description of HPS7
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/HPS7
http://symbol.bio2rdf.org/symbol:HPS7
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AHPS7%3E
HPS7
http://www.dbpedia.org/resource/Dysbindin
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FDysbindin%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2599
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/DYSF
_:header13133032331335206449332
Mon, 23 Apr 2012 18:34:04 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/DYSF
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3303
http://symbol.bio2rdf.org/symbol:DYSF
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ADYSF%3E
DYSF
http://www.dbpedia.org/resource/Dysferlin
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FDysferlin%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/785
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3179
RDF Description of DYSF
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/802
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/767
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3236
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/360
_:header7509795501335206449843
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/360
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01073
oxidoreductase activity, acting on CH2 groups, disulfide as acceptor
http://symbol.bio2rdf.org/symbol:RRM1
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ARRM1%3E
http://bio2rdf.org/hgnc:10451
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A10451%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1627826
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17065054
http://pfam.sanger.ac.uk/family?acc=PF03477
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF03477%3E
DNA replication
http://bio2rdf.org/pfam:PF03477
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF03477%3E
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/gene/RRM1
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fgene%2FRRM1%3E
http://bio2rdf.org/uniprot:P23921
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP23921%3E
RRM1
http://www.genenames.org/data/hgnc_data.php?hgnc_id=10451
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D10451%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17131328
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1840662
ribonucleoside-diphosphate reductase complex
Ribonucleoside-diphosphate reductase large subunit
X59543
Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides
DNA metabolism
ribonucleoside-diphosphate reductase activity
>Ribonucleoside-diphosphate reductase large subunit	MHVIKRDGRQERVMFDKITSRIQKLCYGLNMDFVDPAQITMKVIQGLYSGVTTVELDTLA	AETAATLTTKHPDYAILAARIAVSNLHKETKKVFSDVMEDLYNYINPHNGKHSPMVAKST	LDIVLANKDRLNSAIIYDRDFSYNYFGFKTLERSYLLKINGKVAERPQHMLMRVSVGIHK	EDIDAAIETYNLLSERWFTHASPTLFNAGTNRPQLSSCFLLSMKDDSIEGIYDTLKQCAL	ISKSAGGIGVAVSCIRATGSYIAGTNGNSNGLVPMLRVYNNTARYVDQGGNKRPGAFAIY	LEPWHLDIFEFLDLKKNTGKEEQRARDLFFALWIPDLFMKRVETNQDWSLMCPNECPGLD	EVWGEEFEKLYASYEKQGRVRKVVKAQQLWYAIIESQTETGTPYMLYKDSCNRKSNQQNL	GTIKCSNLCTEIVEYTSKDEVAVCNLASLALNMYVTSEHTYDFKKLAEVTKVVVRNLNKI	IDINYYPVPEACLSNKRHRPIGIGVQGLADAFILMRYPFESAEAQLLNKQIFETIYYGAL	EASCDLAKEQGPYETYEGSPVSKGILQYDMWNVTPTDLWDWKVLKEKIAKYGIRNSLLIA	PMPTASTAQILGNNESIEPYTSNIYTRRVLSGEFQIVNPHLLKDLTERGLWHEEMKNQII	ACNGSIQSIPEIPDDLKQLYKTVWEISQKTVLKMAAERGAFIDQSQSLNIHIAEPNYGKL	TSMHFYGWKQGLKTGMYYLRTRPAANPIQFTLNKEKLKDKEKVSKEEEEKERNTAAMVCS	LENRDECLMCGS
map00230	Purine metabolism	map00240	Pyrimidine metabolism
http://bio2rdf.org/pfam:PF02867
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF02867%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9933563
EC 1.17.4.1
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=X59543
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DX59543%3E
http://bio2rdf.org/pfam:PF00317
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00317%3E
Ribonucleoside-diphosphate reductase M1 subunit
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/16807441
RIR1_HUMAN
oxidoreductase activity, acting on CH2 groups
>2379 bp	ATGCATGTGATCAAGCGAGATGGCCGCCAAGAACGAGTCATGTTTGACAAAATTACATCT	CGAATCCAGAAGCTTTGTTATGGACTCAATATGGATTTTGTTGATCCTGCTCAGATCACC	ATGAAAGTAATCCAAGGCTTGTACAGTGGGGTCACCACAGTGGAACTAGATACTTTGGCT	GCTGAAACAGCTGCAACCTTGACTACTAAGCACCCTGACTATGCTATCCTGGCAGCCAGG	ATCGCTGTCTCTAACTTGCACAAAGAAACAAAGAAAGTGTTCAGTGATGTGATGGAAGAC	CTCTATAACTACATAAATCCACATAATGGCAAACACTCTCCCATGGTGGCCAAGTCAACA	TTGGATATTGTTCTGGCCAATAAAGATCGCCTGAATTCTGCTATTATCTATGACCGAGAT	TTCTCTTACAATTACTTCGGCTTTAAGACGCTAGAGCGGTCTTATTTGTTGAAGATCAAT	GGAAAAGTGGCTGAAAGACCACAACATATGTTGATGAGAGTATCTGTTGGGATCCACAAA	GAAGACATTGATGCAGCAATTGAAACATATAATCTTCTTTCTGAGAGGTGGTTTACTCAT	GCTTCGCCCACTCTCTTCAATGCTGGTACCAACCGCCCACAACTTTCTAGCTGTTTTCTT	CTGAGTATGAAAGATGACAGCATTGAAGGCATTTATGACACTCTAAAGCAATGTGCATTG	ATTTCTAAGTCTGCTGGAGGAATTGGTGTTGCTGTGAGTTGTATTCGGGCTACTGGCAGC	TACATTGCTGGGACTAATGGCAATTCCAATGGCCTTGTACCGATGCTGAGAGTATATAAC	AACACAGCTCGATATGTGGATCAAGGTGGGAACAAGCGTCCTGGGGCATTTGCTATTTAC	CTGGAGCCTTGGCATTTAGACATCTTTGAATTCCTTGATTTAAAGAAGAACACAGGAAAG	GAAGAGCAGCGTGCCAGAGATCTTTTCTTTGCTCTTTGGATTCCGGATCTCTTCATGAAA	CGAGTGGAGACTAATCAGGACTGGTCTTTGATGTGTCCAAATGAGTGTCCTGGTCTGGAT	GAGGTTTGGGGAGAGGAATTTGAGAAACTATATGCAAGTTATGAGAAACAAGGTCGTGTC	CGCAAAGTTGTAAAAGCTCAGCAGCTTTGGTATGCCATCATTGAGTCTCAGACGGAAACA	GGCACCCCGTATATGCTCTACAAAGATTCCTGTAATCGAAAGAGCAACCAGCAGAACCTG	GGAACCATCAAATGCAGCAACCTGTGCACAGAAATAGTGGAGTACACCAGCAAAGATGAG	GTTGCTGTTTGTAATTTGGCTTCCCTGGCCCTGAATATGTATGTCACATCAGAACACACA	TACGACTTTAAGAAGTTGGCTGAAGTCACTAAAGTCGTTGTCCGAAACTTGAATAAAATT	ATTGATATAAACTACTATCCTGTACCAGAGGCATGCCTATCAAATAAACGCCATCGCCCC	ATTGGAATTGGGGTACAAGGTCTGGCAGATGCTTTTATCCTGATGAGATACCCTTTTGAG	AGTGCAGAAGCCCAGTTACTGAATAAGCAGATCTTTGAAACTATTTATTATGGTGCTCTG	GAAGCCAGCTGTGACCTTGCCAAGGAGCAGGGCCCATACGAAACCTATGAGGGCTCTCCA	GTTAGCAAAGGAATTCTTCAGTATGATATGTGGAATGTTACTCCTACAGACCTATGGGAC	TGGAAGGTTCTCAAGGAGAAGATTGCAAAGTATGGTATAAGAAACAGTTTACTTATTGCC	CCGATGCCTACAGCTTCCACTGCTCAGATCCTGGGGAATAATGAGTCCATTGAACCTTAC	ACCAGCAACATCTATACTCGCAGAGTCTTGTCAGGAGAATTTCAGATTGTAAATCCTCAC	TTATTGAAAGATCTTACCGAGCGGGGCCTATGGCATGAAGAGATGAAAAACCAGATTATT	GCATGCAATGGCTCTATTCAGAGCATACCAGAAATTCCTGATGACCTGAAGCAACTTTAT	AAAACTGTGTGGGAAATCTCTCAGAAAACTGTTCTCAAGATGGCAGCTGAGAGAGGTGCT	TTCATTGATCAAAGCCAATCTTTGAACATCCACATTGCTGAGCCTAACTATGGCAAACTC	ACTAGTATGCACTTCTACGGCTGGAAGCAGGGTTTGAAGACTGGGATGTATTATTTAAGG	ACGAGACCAGCAGCTAATCCAATCCAGTTCACTCTAAATAAGGAGAAGCTAAAAGATAAA	GAAAAGGTATCAAAAGAGGAAGAAGAGAAGGAGAGGAACACAGCAGCCATGGTGTGCTCT	TTGGAGAATAGAGATGAATGTCTGATGTGTGGATCCTGA
http://pfam.sanger.ac.uk/family?acc=PF02867
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF02867%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=36065
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D36065%3E
2'-deoxyribonucleoside diphosphate + thioredoxin disulfide + H2O = ribonucleoside diphosphate + thioredoxin
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/16708051
http://pfam.sanger.ac.uk/family?acc=PF00317
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00317%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/14583450
11p15.5
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/15075397
Ribonucleotide reductase large chain
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/16966686
http://www.uniprot.org/uniprot/P23921
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP23921%3E
RDF Description of Ribonucleoside-diphosphate reductase large subunit
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01005
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00441
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00631
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/32797
_:header9535324431335206450245
Mon, 23 Apr 2012 18:34:05 GMT
RDF Description of TEMOVATE
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/32797
http://www.fda.gov/cder/foi/label/2004/21644_clobex_lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2004%2F21644_clobex_lbl.pdf%3E
http://www.fda.gov/cder/foi/label/2000/21142lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2000%2F21142lbl.pdf%3E
http://www.fda.gov/cder/foi/label/2003/21142slr009_olux_lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2003%2F21142slr009_olux_lbl.pdf%3E
http://www.fda.gov/cder/foi/label/2007/022013lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2007%2F022013lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0152030
http://www.fda.gov/medwatch/SAFETY/2003/03APR_PI/TemovateE_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2003%2F03APR_PI%2FTemovateE_PI.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0014335
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0011615
http://www.fda.gov/cder/foi/anda/2001/75733_Clobetasol+Propionate_Prntlbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Fanda%2F2001%2F75733_Clobetasol+Propionate_Prntlbl.pdf%3E
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=BjIGNw7HEzQ=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DBjIGNw7HEzQ%3D%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0162834
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0039446
http://www.fda.gov/cder/foi/label/2003/20337slr005_temovate_lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2003%2F20337slr005_temovate_lbl.pdf%3E
OLUX
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=cUB6A6bcWJU=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DcUB6A6bcWJU%3D%3E
http://www.fda.gov/cder/foi/label/2003/21142scs010_olux_lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2003%2F21142scs010_olux_lbl.pdf%3E
http://www.fda.gov/cder/foi/label/2003/020340s006lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2003%2F020340s006lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01013
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01013%3E
http://dbpedia.org/resource/Clobetasol_propionate
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FClobetasol_propionate%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020555
http://www.fda.gov/cder/foi/label/2003/19322slr018,19323slr019_temovate_lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2003%2F19322slr018%2C19323slr019_temovate_lbl.pdf%3E
Temovate E
TEMOVATE
http://sideeffects.embl.de/drugs/32797
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F32797%3E
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000032797
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000032797%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0027441
http://www.fda.gov/cder/foi/label/2002/21142se1-004_Olux_lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2002%2F21142se1-004_Olux_lbl.pdf%3E
clobetasol
http://www.fda.gov/cder/foi/label/2003/19966slr008_temovate_lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2003%2F19966slr008_temovate_lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0036689
CID0000032797
http://www.fda.gov/cder/foi/label/2003/20340slr006_temovate_lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2003%2F20340slr006_temovate_lbl.pdf%3E
http://www.fda.gov/cder/foi/label/2005/021835lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2005%2F021835lbl.pdf%3E
http://www.fda.gov/cder/foi/label/2003/21535_clobex_lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2003%2F21535_clobex_lbl.pdf%3E
CLOBETASOL PROPIONATE (EMOLLIENT)
OLUX E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0034212
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2030
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2030%3E
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=18q1pQ2PRyo=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3D18q1pQ2PRyo%3D%3E
http://www.fda.gov/cder/foi/label/2003/019966s008lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2003%2F019966s008lbl.pdf%3E
CLOBEX
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=uqWiJQp5wFE=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DuqWiJQp5wFE%3D%3E
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=Wa654mN+jA8=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DWa654mN%2BjA8%3D%3E
CLOBETASOL PROPIONATE
http://www.fda.gov/medwatch/SAFETY/2003/03APR_PI/Temovate_Scalp_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2003%2F03APR_PI%2FTemovate_Scalp_PI.pdf%3E
http://www.fda.gov/cder/foi/label/2003/020337s005lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2003%2F020337s005lbl.pdf%3E
http://www.fda.gov/cder/foi/label/2003/019322s018lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2003%2F019322s018lbl.pdf%3E
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=D4RchFwjmVc=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DD4RchFwjmVc%3D%3E
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000032797&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000032797%26input_query_species%3D9606%3E
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=SVhF0AexjYU=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DSVhF0AexjYU%3D%3E
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=vk8Bw0e4EhU=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3Dvk8Bw0e4EhU%3D%3E
http://www.fda.gov/medwatch/SAFETY/2003/03APR_PI/Temovate_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2003%2F03APR_PI%2FTemovate_PI.pdf%3E
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=Ri%2F1LG4OmWQ=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DRi%252F1LG4OmWQ%3D%3E
http://www4.wiwiss.fu-berlin.de/factbook/data/Albania
_:header496127631335206450774
https://www.cia.gov/library/publications/the-world-factbook/flags/al-lgflag.gif
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Flibrary%2Fpublications%2Fthe-world-factbook%2Fflags%2Fal-lgflag.gif%3E
http://www4.wiwiss.fu-berlin.de/factbook/resource/Albania
http://www4.wiwiss.fu-berlin.de/factbook/resource/Greece
Albanian
28 November 1912 (from the Ottoman Empire)
has a civil law system; has not accepted compulsory ICJ jurisdiction; has accepted jurisdiction of the International Criminal Court for its citizens
Council of Ministers proposed by the prime minister, nominated by the president, and approved by parliament
adopted by popular referendum on 22 November 1998; promulgated 28 November 1998
lek (ALL)
red with a black two-headed eagle in the center
19 years of age
.al
Adriatic Sea
President of the Republic Alfred MOISIU (since 24 June 2002)
http://www4.wiwiss.fu-berlin.de/factbook/resource/Serbia
mild temperate; cool, cloudy, wet winters; hot, clear, dry summers; interior is cooler and wetter
1 (Turkey 1)
al
24.5% of GDP
last held 3 July 2005 (next to be held in 2009)
185500000 bbl (1 January 2002)
Maja e Korabit (Golem Korab)
$56500000 (FY02)
president elected by the Peoples Assembly for a five-year term (eligible for a second term); election last held 24 June 2002 (next to be held in June 2007); prime minister appointed by the president
Durres, Sarande, Shengjin, Vlore
2.03 children born/woman
percent of vote by party - NA; seats by party - PD 56, PS 42, PR 11, PSD 7, LSI 5, other 19
65 (3 national, 62 local); 2 cable networks
1 (Georgia 1)
Albania
Independence Day, 28 November
Albanian(s)
http://www4.wiwiss.fu-berlin.de/factbook/resource/Montenegro
ALL
https://www.cia.gov/library/publications/the-world-factbook/maps/al-map.gif
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Flibrary%2Fpublications%2Fthe-world-factbook%2Fmaps%2Fal-map.gif%3E
Republika e Shqiperise
the plural of lek is leke
12 counties (qarqe, singular - qark); Qarku i Beratit, Qarku i Dibres, Qarku i Durresit, Qarku i Elbasanit, Qarku i Fierit, Qarku i Gjirokastres, Qarku i Korces, Qarku i Kukesit, Qarku i Lezhes, Qarku i Shkodres, Qarku i Tiranes, Qarku i Vlores
Lagging behind its Balkan neighbors, Albania is making the difficult transition to a more modern open-market economy. The government has taken measures to curb violent crime and reduce the large gray economy. The economy is bolstered by annual remittances from abroad of $600-$800000000, mostly from Albanians residing in Greece and Italy; this helps offset the towering trade deficit. Agriculture, which accounts for about one-quarter of GDP, is held back because of lack of modern equipment, unclear property rights, and the prevalence of small, inefficient plots of land. Energy shortages and antiquated and inadequate infrastructure contribute to Albanias poor business environment, which make it difficult to attract and sustain foreign investment. The planned construction of a new thermal power plant near Vlore and improved transmission and distribution facilities eventually will help relieve the energy shortages. Also, the government is moving slowly to improve the poor national road and rail network, a long-standing barrier to sustained economic growth. On the positive side, growth was strong in 2003-06 and inflation is low and stable.
Prime Minister Sali BERISHA (since 10 September 2005)
Constitutional Court, Supreme Court (chairman is elected by the Peoples Assembly for a four-year term), and multiple appeals and district courts
Republic of Albania
Tirana (Tirane)
emerging democracy
41 20 N, 19 50 E
https://www.cia.gov/library/publications/the-world-factbook/flags/al-flag.gif
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Flibrary%2Fpublications%2Fthe-world-factbook%2Fflags%2Fal-flag.gif%3E
age 9 and over can read and write
despite new investment in fixed lines, the density of main lines remains the lowest in Europe with roughly 7 lines per 100 people; however, cellular telephone use is widespread and generally effective
AM 13, FM 46, shortwave 1
http://www4.wiwiss.fu-berlin.de/factbook/resource/Macedonia
2832000000 cu m (1 January 2005 est.)
deforestation; soil erosion; water pollution from industrial and domestic effluents
mostly mountains and hills; small plains along coast
offsetting the shortage of fixed line capacity, mobile phone service has been available since 1996; by 2003 two companies were providing mobile services at a greater density than some of Albanias Balkan neighbors
Shqiperia
slightly smaller than Maryland
447 km 1.435-m gauge
the Albanian Government calls for the protection of the rights of ethnic Albanians in neighboring countries, and the peaceful resolution of interethnic disputes; some ethnic Albanian groups in neighboring countries advocate for a "greater Albania," but the idea has little appeal among Albanian nationals; the mass emigration of unemployed Albanians remains a problem for developed countries, chiefly Greece and Italy
Between 1990 and 1992 Albania ended 46 years of xenophobic Communist rule and established a multiparty democracy. The transition has proven challenging as successive governments have tried to deal with high unemployment, widespread corruption, a dilapidated physical infrastructure, powerful organized crime networks, and combative political opponents. Albania has made progress in its democratic development since first holding multiparty elections in 1991, but deficiencies remain. International observers judged elections to be largely free and fair since the restoration of political stability following the collapse of pyramid schemes in 1997. In the 2005 general elections, the Democratic Party and its allies won a decisive victory on pledges of reducing crime and corruption, promoting economic growth, and decreasing the size of government. The election, and particularly the orderly transition of power, was considered an important step forward. Although Albanias economy continues to grow, the country is still one of the poorest in Europe, hampered by a large informal economy and an inadequate energy and transportation infrastructure. Albania has played a largely helpful role in managing inter-ethnic tensions in southeastern Europe, and is continuing to work toward joining NATO and the EU. Albania, with troops in Iraq and Afghanistan, has been a strong supporter of the global war on terrorism.
country code - 355; inadequate fixed main lines; adequate cellular connections; international traffic carried by fiber optic cable and, when necessary, by microwave radio relay from the Tirana exchange to Italy and Greece
$3100000000; including capital expenditures of $3100000000
Southeastern Europe, bordering the Adriatic Sea and Ionian Sea, between Greece and Serbia and Montenegro
unicameral Assembly or Kuvendi (140 seats; 100 are elected by direct popular vote and 40 by proportional vote for four-year terms)
https://www.cia.gov/cia/publications/factbook/geos/al.html
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Fcia%2Fpublications%2Ffactbook%2Fgeos%2Fal.html%3E
Alfred MOISIU elected president; Peoples Assembly vote by number - total votes 134: for 97, against 19, abstained 14, invalid votes 4
RDF Description of Albania
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/2540
_:header20500290721335206451612
Mon, 23 Apr 2012 18:34:06 GMT
RDF Description of Choloylglycine hydrolase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2540
http://www.pdb.org/pdb/explore/explore.do?structureId=2BJF
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D2BJF%3E
U20191
Choloylglycine hydrolase
http://bio2rdf.org/pdb:2BJF
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A2BJF%3E
The enzyme catalyzes the degradation of conjugated bile acids in the mammalian gut
EC 3.5.1.24
Conjugated bile acid hydrolase
CBAH
CBH_CLOPE
http://pfam.sanger.ac.uk/family?acc=PF02275
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF02275%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11792842
http://bio2rdf.org/pfam:PF02275
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF02275%3E
map00120	Bile acid biosynthesis
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=882252
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D882252%3E
http://bio2rdf.org/uniprot:P54965
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP54965%3E
3alpha,7alpha,12alpha-trihydroxy-5beta-cholan-24-oylglycine + H2O = 3alpha,7alpha,12alpha-trihydroxy-5beta-cholanate + glycine
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=U20191
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DU20191%3E
>990 bp	ATGTGTACAGGATTAGCCTTAGAAACAAAAGATGGATTACATTTGTTTGGAAGAAATATG	GATATTGAATATTCATTTAATCAATCTATTATATTTATTCCTAGGAATTTTAAATGTGTA	AACAAATCAAACAAAAAAGAATTAACAACAAAATATGCTGTTCTTGGAATGGGAACTATT	TTTGATGATTATCCTACCTTTGCAGATGGTATGAATGAAAAGGGATTAGGGTGTGCTGGC	TTAAATTTCCCTGTTTATGTTAGCTATTCTAAAGAAGATATAGAAGGTAAAACTAATATT	CCAGTATATAATTTCTTATTATGGGTTTTAGCTAATTTTAGCTCAGTAGAAGAGGTAAAG	GAAGCATTAAAAAATGCTAATATAGTGGATATACCTATTAGCGAAAATATTCCTAATACA	ACTCTTCATTGGATGATAAGCGATATAACAGGAAAGTCTATTGTGGTTGAACAAACAAAG	GAAAAATTAAATGTATTTGATAATAATATTGGAGTATTAACTAATTCACCTACTTTTGAT	TGGCATGTAGCAAATTTAAATCAATATGTAGGTTTGAGATATAATCAAGTTCCAGAATTT	AAGTTAGGAGATCAATCTTTAACTGCTTTAGGTCAAGGAACTGGTTTAGTAGGATTACCA	GGGGACTTTACACCTGCATCTAGATTTATAAGAGTAGCATTTTTAAGAGATGCAATGATA	AAAAATGATAAAGATTCAATAGACTTAATTGAATTTTTCCATATATTAAATAATGTTGCT	ATGGTAAGAGGATCAACTAGAACTGTAGAAGAAAAAAGTGATCTTACTCAATATACAAGT	TGCATGTGTTTAGAAAAAGGAATTTATTATTATAATACCTATGAAAATAATCAAATTAAT	GCAATAGACATGAATAAAGAAAACTTAGATGGAAATGAAATTAAAACATATAAATACAAC	AAAACTTTAAGTATTAATCATGTAAATTAG
Bile salt hydrolase
cbh
http://www.uniprot.org/uniprot/P54965
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP54965%3E
>Choloylglycine hydrolase	MCTGLALETKDGLHLFGRNMDIEYSFNQSIIFIPRNFKCVNKSNKKELTTKYAVLGMGTI	FDDYPTFADGMNEKGLGCAGLNFPVYVSYSKEDIEGKTNIPVYNFLLWVLANFSSVEEVK	EALKNANIVDIPISENIPNTTLHWMISDITGKSIVVEQTKEKLNVFDNNIGVLTNSPTFD	WHVANLNQYVGLRYNQVPEFKLGDQSLTALGQGTGLVGLPGDFTPASRFIRVAFLRDAMI	KNDKDSIDLIEFFHILNNVAMVRGSTRTVEEKSDLTQYTSCMCLEKGIYYYNTYENNQIN	AIDMNKENLDGNEIKTYKYNKTLSINHVN
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7618863
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01956
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/1503
_:header2440256561335206452099
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/1503
http://bio2rdf.org/pdb:5GAL
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A5GAL%3E
cytoplasm.Nucleus.SecretedProtein(potential).Note=mayBeSecretedByANon-classicalSecretory
>Galectin-7	MSNVPHKSSLPEGIRPGTVLRIRGLVPPNASRFHVNLLCGEEQGSDAALHFNPRLDTSEV	VFNSKEQGSWGREERGPGVPFQRGQPFEVLIIASDDGFKAVVGDAQYHHFRHRLPLARVR	LVEVGGDVQLDSVRIF
Involved in sugar binding
p53-induced protein 1
http://www.pdb.org/pdb/explore/explore.do?structureId=5GAL
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D5GAL%3E
http://symbol.bio2rdf.org/symbol:LGALS7
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ALGALS7%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7534301
sugar binding
carbohydrate binding
http://pfam.sanger.ac.uk/family?acc=PF00337
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00337%3E
Galectin-7
Gal-7
>411 bp	ATGTCCAACGTCCCCCACAAGTCCTCGCTGCCCGAGGGCATCCGCCCTGGCACGGTGCTG	AGAATTCGCGGCTTGGTTCCTCCCAATGCCAGCAGGTTCCATGTAAACCTGCTGTGCGGG	GAGGAGCAGGGCTCCGATGCCGCCCTGCATTTCAACCCCCGGCTGGACACGTCGGAGGTG	GTCTTCAACAGCAAGGAGCAAGGCTCCTGGGGCCGCGAGGAGCGCGGGCCGGGCGTTCCT	TTCCAGCGCGGGCAGCCCTTCGAGGTGCTCATCATCGCGTCAGACGACGGCTTCAAGGCC	GTGGTTGGGGACGCCCAGTACCACCACTTCCGCCACCGCCTGCCGCTGGCGCGCGTGCGC	CTGGTGGAGGTGGGCGGGGACGTGCAGCTGGACTCCGTGAGGATCTTCTGA
Could be involved in cell-cell and/or cell-matrix interactions necessary for normal growth control. Pro-apoptotic protein that functions intracellularly upstream of JNK activation and cytochrome c release
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7729568
http://bio2rdf.org/hgnc:6568
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A6568%3E
http://www.uniprot.org/uniprot/P47929
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP47929%3E
LGALS7
HKL-14
http://bio2rdf.org/pfam:PF00337
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00337%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11706006
19q13.2
http://bio2rdf.org/uniprot:P47929
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP47929%3E
LEG7_HUMAN
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=L07769
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DL07769%3E
PI7
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9760227
http://www.genenames.org/data/hgnc_data.php?hgnc_id=6568
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D6568%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=182132
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D182132%3E
L07769
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02678
RDF Description of Galectin-7
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/100
_:header2285226891335206452389
Mon, 23 Apr 2012 18:34:07 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/100
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1469
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/4
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F4%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/FGFR2
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02491
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB02491%3E
Apert syndrome
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00039%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02058
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB02058%3E
http://www.dbpedia.org/resource/Apert_syndrome
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FApert_syndrome%3E
RDF Description of Apert syndrome
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/LHCGR
_:header8890591051335206452857
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/LHCGR
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/966
http://symbol.bio2rdf.org/symbol:LHCGR
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ALHCGR%3E
LHCGR
http://www.dbpedia.org/resource/choriogonadotropin_receptor
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2Fchoriogonadotropin_receptor%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3636
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2738
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2957
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/676
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/762
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/948
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3675
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3159
RDF Description of LHCGR
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/580
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/4033
_:header9402273471335206453476
Mon, 23 Apr 2012 18:34:08 GMT
RDF Description of S-formylglutathione hydrolase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4033
S-formylglutathione + H2O = glutathione + formate
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3164702
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3462714
http://www.uniprot.org/uniprot/P10768
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP10768%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=3465
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D3465%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12904537
ESD
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=182265
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D182265%3E
map00680	Methane metabolism
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7397203
S-formylglutathione hydrolase
ESTD_HUMAN
FGH
http://bio2rdf.org/pfam:PF00756
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00756%3E
http://bio2rdf.org/uniprot:P10768
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP10768%3E
http://symbol.bio2rdf.org/symbol:ESD
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AESD%3E
http://pfam.sanger.ac.uk/family?acc=PF00756
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00756%3E
>894 bp	GAATTCGGGGCAAAAAGCAATCAGCAATTGGACAGGAAAAGAATGGCATTGAAGCAGATT	TCCAGCAACAAGTGCTTTGGGGGATTGCAGAAAGTTTTTGAACATGACAGTGTTGAACTA	AACTGCAAAATGAAATTTGCTGTCTACTTACCACCAAAGGCAGAAACAGGAAAGTGCCCT	GCATGTATTGGCTCTCCAGGTTTAACTTGCACAGAGCCAAAATTTTATCATCAAAATCTG	GTTATCATCAGTCTGCTTCAGAACCATTTGTCTTGTTGTCATTGCTCCAGATACAGCCCT	CGTGCGTGCAATATTAAAGGTGAAGATGAGAGCTGGGACTTTGCGACTGGTCGTGGATTT	TATGTTGATGCCACTGAAGATCCTTGGAAAACCAACTACAGAATGTACTCTTATGTCACA	GAGGAGCTTCCCCAACTCATAAATGCCAATTTTCCAGTGGATCCCCAAAGGATGTCTATT	TTTGGCCACTCCATGGGAGGTCATGGAGCTCTGATCTGTGCTTTGAAAAATCCTGGAAAA	TACAAATCTGTGTCAGCATTTGCTCCAATTTGCAACCCTGTACTCTGTCCCTGGGGCAAA	AAAGCCTTTAGTGGATATTTGGGAACAGATCAAAGTAAATGGAAGGCTTATGATGCTACC	CACCTTGTGAAATCCTATCCAGGATCTCAGCTGGACATACTAATTGATCAAGGGAAAGAT	GACCAGTTTCTTTTAGATGGACAGTTACTCCCTGATAACTTCATAGCTGCCTGTACAGAA	AAGAAAATCCCCGTTGTTTTTCGATTGCAAGAGGGTTATGATCATAGCTACTACTTCATT	GCAACCTTTATTACTGACCACATCAGACATCATGCTAAATACCTGAATGCATGA
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10931946
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2554783
>S-formylglutathione hydrolase	MALKQISSNKCFGGLQKVFEHDSVELNCKMKFAVYLPPKAETGKCPALYWLSGLTCTEQN	FISKSGYHQSASEHGLVVIAPDTSPRGCNIKGEDESWDFGTGAGFYVDATEDPWKTNYRM	YSYVTEELPQLINANFPVDPQRMSIFGHSMGGHGALICALKNPGKYKSVSAFAPICNPVL	CPWGKKAFSGYLGTDQSKWKAYDATHLVKSYPGSQLDILIDQGKDDQFLLDGQLLPDNFI	AACTEKKIPVVFRLQEGYDHSYYFIATFITDHIRHHAKYLNA
13q14.1-q14.2
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=M13450
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DM13450%3E
Esterase D
http://bio2rdf.org/hgnc:3465
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A3465%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7907313
EC 3.1.2.12
M13450
Serine hydrolase involved in the detoxification of formaldehyde
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3462698
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00143
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/159
_:header11313931791335206453733
RDF Description of Bleeding disorder
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/159
http://www.dbpedia.org/resource/Coagulopathy
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FCoagulopathy%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01207
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01207%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C1458140
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fsider%2Fresource%2Fside_effects%2FC1458140%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/P2RX1
Bleeding disorder
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/TBXA2R
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1614
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1613
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0002896
_:header4643880381335206454223
Mon, 23 Apr 2012 18:34:09 GMT
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0002896
http://dbpedia.org/resource/Sideroblastic_anemia
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FSideroblastic_anemia%3E
http://sideeffects.embl.de/se/C0002896
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0002896%3E
sideroblastic anemia
C0002896
RDF Description of sideroblastic anemia
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/674
_:header12398613471335206454624
RDF Description of Leukocyte adhesion deficiency
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/674
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/ITGB2
http://www.dbpedia.org/resource/Leukocyte_adhesion_deficiency
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FLeukocyte_adhesion_deficiency%3E
Leukocyte adhesion deficiency
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2951
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/RLBP1
_:header13966007261335206455230
Mon, 23 Apr 2012 18:34:10 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/RLBP1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/837
http://symbol.bio2rdf.org/symbol:RLBP1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ARLBP1%3E
RLBP1
http://www.dbpedia.org/resource/RLBP1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FRLBP1%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/169
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1652
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3372
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2419
RDF Description of RLBP1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/427
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3758
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3776
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Demosthenes_384_BC-322_BC
_:header11032558641335206455568
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Demosthenes_384_BC-322_BC
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6878
Demosthenes, 384 BC-322 BC
RDF Description of Demosthenes, 384 BC-322 BC
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9060
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9061
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0014118
_:header18959240241335206456043
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0014118
http://dbpedia.org/resource/Endocarditis
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FEndocarditis%3E
http://sideeffects.embl.de/se/C0014118
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0014118%3E
ENDOCARDITIS
C0014118
RDF Description of ENDOCARDITIS
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3467
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2173
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/166548
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5651
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3366
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0042384
_:header17428436761335206456482
Mon, 23 Apr 2012 18:34:11 GMT
http://dbpedia.org/resource/Vasculitis
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FVasculitis%3E
http://sideeffects.embl.de/se/C0042384
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0042384%3E
Vasculitis
C0042384
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/disease/Vasculitis
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fdisease%2FVasculitis%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5472
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5267
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3440
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4893
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4870
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3715
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3639
RDF Description of Vasculitis
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4053
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/1065
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4121
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2022
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3647
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5381226
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3698
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5717
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2156
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2315
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/31378
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2732
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2720
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5362070
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/27686
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5344
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/657298
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5039
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3463
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4170
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4138
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/83786
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/4825
_:header17277210001335206457820
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4825
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02857
Q5SID9_THET8
>708 bp	TCAAACCTCCAGGACGGCCTCGAGGGCCACCTCCACCATACGCCGAACGCCCTCTTGGAG	CACCTCAGGGGGAGCGAGCTCCGGATCGCCGATGCGGTTGGAGACGGCCAGGATGGCCCC	CGTCCGCACCCCCCGCATCCTTCCGAGGAGGAAGAGGGCGCTGGCCTCCATCTCAAAGGC	GAGGACGCCGTAGCGGGCCCAGGCCCGGGCCTCCTCGGGGGTGGTGGCGTAGAAGGCGTC	CTCGCTGGCCACGAGCCCCACCCGGTGGGGGTAGCCCAAGGCCTCCGCCCGGCGCCAGAG	GGCCCGGAAGACCTCGGGGTCGGGCACCGGGGCGTAGGGGCGCCCCTCCAGGTACTGCCG	GGTGGTGCCGTCCAAGGGCACGGCCCCCTGGGCCACGATGAGCTCCCCCGGGGCGAGGTC	CGAAGAAGCGGCCCCCGCCGTCCCCACCCGGACGAGGACCCGGGCGCCAAGCCGGACCAG	CTCCTCCACCACGATGGCCGCCGAGGGGGTGCCCATCCCCGTGGTCTGGACGGAGACGGG	CACGCCCTTGTAAAGGCCCGTGTACCCCCAAAGCCCCCGGTGGTCGTTGTACCGCCTGGG	GTTTTGCAAAAAGGTCTTGGCGATCCACTCGGCCCGGCCCGGATCCCCGGGAAGAAGGAC	GCGCTCCGCCACGTCCCCGGGGTGGGCGCGCACGTGGATGGGGCTCAT
http://bio2rdf.org/uniprot:Q5SID9
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ5SID9%3E
http://www.pdb.org/pdb/explore/explore.do?structureId=1ODL
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1ODL%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AP008226
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAP008226%3E
Purine nucleoside phosphorylase
Involved in catalytic activity
http://pfam.sanger.ac.uk/family?acc=PF01048
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF01048%3E
AP008226
http://bio2rdf.org/pfam:PF01048
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF01048%3E
http://bio2rdf.org/pdb:1ODL
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1ODL%3E
http://www.uniprot.org/uniprot/Q5SID9
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ5SID9%3E
>Purine nucleoside phosphorylase	MSPIHVRAHPGDVAERVLLPGDPGRAEWIAKTFLQNPRRYNDHRGLWGYTGLYKGVPVSV	QTTGMGTPSAAIVVEELVRLGARVLVRVGTAGAASSDLAPGELIVAQGAVPLDGTTRQYL	EGRPYAPVPDPEVFRALWRRAEALGYPHRVGLVASEDAFYATTPEEARAWARYGVLAFEM	EASALFLLGRMRGVRTGAILAVSNRIGDPELAPPEVLQEGVRRMVEVALEAVLEV
RDF Description of Purine nucleoside phosphorylase
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/MPDU1
_:header10095268701335206457875
Mon, 23 Apr 2012 18:34:12 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/MPDU1
http://symbol.bio2rdf.org/symbol:MPDU1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AMPDU1%3E
MPDU1
http://www.dbpedia.org/resource/MPDU1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FMPDU1%3E
RDF Description of MPDU1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1973
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/3613
_:header7271863901335206458357
Mon, 23 Apr 2012 18:34:13 GMT
RDF Description of Delta-aminolevulinic acid dehydratase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3613
HEM2_CHLVI
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=U38348
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DU38348%3E
Delta-aminolevulinic acid dehydratase
http://bio2rdf.org/uniprot:Q59334
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ59334%3E
porphyrin biosynthesis
http://bio2rdf.org/pdb:1W1Z
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1W1Z%3E
ALAD
2 5-aminolevulinate = porphobilinogen + 2 H2O
2 5-aminolevulinate = porphobilinogen + 2 H(2)O
http://pfam.sanger.ac.uk/family?acc=PF00490
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00490%3E
http://bio2rdf.org/pfam:PF00490
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00490%3E
ALADH
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=1033198
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D1033198%3E
heme biosynthesis
porphobilinogen synthase activity
map00860	Porphyrin and chlorophyll metabolism
Porphobilinogen synthase
EC 4.2.1.24
>987 bp	ATGAGCCAGCTCGACCTCCTCAATATTGTGCATCGCCCGAGAAGACTTCGCAGAACCGCA	GCGCTCCGCAACCTTGTGCAGGAAAACACGCTGACGGTCAACGATCTTGTGTTCCCCCTG	TTCGTCATGCCCGGCACCAACGCCGTTGAAGAGGTTTCATCCATGCCCGGCAGCTTCCGC	TTCACCATCGACCGCGCTGTCGAAGAGTGCAAGGAGCTTTACGATCTCGGCATCCAGGGC	ATCGATCTGTTCGGCATTCCGGAGCAGAAAACCGAAGACGGCAGCGAAGCCTACAACGAC	AACGGCATTCTTCAGCAGGCCATCCGCGCCATCAAGAAAGCCGTGCCGGAGCTGTGCATC	ATGACCGACGTTGCACTTGACCCGTTCACCCCATTCGGCCACGATGGCCTGGTCAAGGAC	GGCATCATCCTCAACGACGAAACCGTCGAAGTACTCCAGAAAATGGCCGTTTCTCACGCC	GAAGCTGGCGCAGACTTCGTCTCCCCGAGCGACATGATGGACGGCCGCATCGGCGCCATC	CGCGAAGCACTCGACGAAACCGACCACTCCGACGTGGGCATTCTCTCCTACGCTGCCAAG	TACGCTTCGAGCTTCTACGGCCCGTTCCGTGACGCGCTGCACTCAGCACCGCAGTTCGGC	GACAAAAGCACCTACCAGATGAACCCGGCCAACACCGAAGAGGCGATGAAAGAGGTCGAA	CTCGACATCGTCGAAGGCGCTGACATCGTCATGGTCAAACCTGGCCTGGCCTACCTCGAC	ATCGTCTGGCGCACCAAGGAGCGCTTCGACGTGCCGGTCGCCATCTACCACGTTTCCGGC	GAATACGCCATGGTGAAAGCTGCCGCCGCCAAGGGCTGGATCGACGAAGATCGCGTCATG	ATGGAGTCGCTGCTCTGCATGAAGCGCGCAGGTGCTGACATCATCTTCACCTACTACGCC	AAAGAAGCCGCCAAAAAGCTGCGCTGA
>Delta-aminolevulinic acid dehydratase	MSQLDLLNIVHRPRRLRRTAALRNLVQENTLTVNDLVFPLFVMPGTNAVEEVSSMPGSFR	FTIDRAVEECKELYDLGIQGIDLFGIPEQKTEDGSEAYNDNGILQQAIRAIKKAVPELCI	MTDVALDPFTPFGHDGLVKDGIILNDETVEVLQKMAVSHAEAGADFVSPSDMMDGRIGAI	REALDETDHSDVGILSYAAKYASSFYGPFRDALHSAPQFGDKSTYQMNPANTEEAMKEVE	LDIVEGADIVMVKPGLAYLDIVWRTKERFDVPVAIYHVSGEYAMVKAAAAKGWIDEDRVM	MESLLCMKRAGADIIFTYYAKEAAKKLR
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8626508
http://www.pdb.org/pdb/explore/explore.do?structureId=1W1Z
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1W1Z%3E
U38348
http://www.uniprot.org/uniprot/Q59334
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ59334%3E
hemB
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04344
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB02703
_:header496903681335206458764
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02703
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01319_DB02703
Fusidine
C[C@@H]1[C@H](O)CC[C@@]2(C)[C@H]1CC[C@@]1(C)[C@H]2[C@H](O)C[C@H]2C([C@H](C[C@]12C)OC(C)=O)=C(/CCC=C(C)C)C(O)=O
An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed) It acts by inhibiting translocation during protein synthesis.
http://www.dbpedia.org/resource/Fusidic_acid
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FFusidic_acid%3E
Fusidate Sodium
C31H48O6
InChI=1/C31H48O6/c1-17(2)9-8-10-20(28(35)36)26-22-15-24(34)27-29(5)13-12-23(33)18(3)21(29)11-14-30(27,6)31(22,7)16-25(26)37-19(4)32/h9,18,21-25,27,33-34H,8,10-16H2,1-7H3,(H,35,36)/b26-20-/t18-,21-,22-,23+,24+,25-,27-,29-,30-,31-/m0/s1/f/h35H
1QCA
expt01507
For the treatment of bacterial infections.
http://www.drugbank.ca/drugs/DB02703
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB02703%3E
Metabolites include dicarboxylic ester/acid, 3-keto fusidic acid, hydroxy fusidic acid, glucuronide fusidic acid and a glycol metabolite.
2008-08-26 15:00:56 UTC
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/antibacterialAgents
Fucibet (Fusidic acid + betamethasone)
Fucidic acid
Fucidin Cream 2%
Fucithalmic
Approximately 5 to 6 hours in adults.
http://205.193.93.51/dpdonline/searchRequest.do?din=00586668
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D00586668%3E
Fusidic acid is a bacteriostatic antibiotic that is often used topically in creams and eyedrops, but may also be given systemically as tablets or injections.
http://bio2rdf.org/cpd:C06694
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC06694%3E
Fusidic Acid
http://en.wikipedia.org/wiki/Fusidic_acid
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FFusidic_acid%3E
http://bio2rdf.org/cas:6990-06-3
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A6990-06-3%3E
5.21e-03 mg/mL
(2Z)-2-[(3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoic acid
http://bio2rdf.org/kegg:D04281
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD04281%3E
97 to 99%
FUA
192.5 oC
Diethanolamine fusidate
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/proteinSynthesisInhibitors
Sodium fusidic acid tablets have a 91% oral bioavailability. Absorption of the film-coated tablets is complete when compared to a solution, however oral absorption is variable. Oral fusidic acid hemihydrate (suspension) achieved a 22.5% bioavailability in pediatric patients following a 20 milligram/kilogram dose.
Take with food to reduce irritation.
Fucidine
Fucidin acid
Fusidic acid works by interfering with bacterial protein synthesis, specifically by preventing the translocation of the elongation factor G (EF-G) from the ribosome.
PA10087
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3278
DB02703
Fucicort (Fusidic acid + hydrocortisone)
Fusidate
http://dbpedia.org/resource/Fusidic_acid
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FFusidic_acid%3E
CC1C(O)CCC2(C)C1CCC1(C)C2C(O)CC2C(C(CC12C)OC(C)=O)=C(CCC=C(C)C)C(O)=O
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/anti-bacterialAgents
Fucidate Sodium
http://dbpedia.org/page/Fusidic_acid
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FFusidic_acid%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2808
Ramycin
Fucidin
Fucidate
IECPWNUMDGFDKC-YLSUCPHCDU
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB02703_DB00701
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB02703_DB00641
RDF Description of Fusidic Acid
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00220_DB02703
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB02703_DB01232
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB02703_DB00224
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00224_DB02703
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB02703_DB00220
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB02703_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB02703_DB01319
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB02703_DB01076
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/647
_:header7898588071335206459151
Mon, 23 Apr 2012 18:34:14 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/647
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2858
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/AGGF1
Klippel-Trenaunay syndrome
RDF Description of Klippel-Trenaunay syndrome
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0027947
_:header6937856541335206459652
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F833%3E
http://dbpedia.org/resource/Neutropenia
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FNeutropenia%3E
http://sideeffects.embl.de/se/C0027947
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0027947%3E
Neutropenia
C0027947
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/disease/Neutropenia
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fdisease%2FNeutropenia%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/216239
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5282044
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/6323497
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/51634
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3365
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/60843
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3040
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4178
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5361912
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5412
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4915
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2654
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/104758
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2656
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4609
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/6918453
RDF Description of Neutropenia
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/54688
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2637
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3279
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2610
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5281007
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5582
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/6436173
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3928
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4607
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2130
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/65027
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2719
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2179
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/143
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4163
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4834
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2082
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3657
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2708
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5578
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/30623
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2646
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2631
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/131536
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4030
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5493381
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5462337
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3956
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2622
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/38904
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3324
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4036
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2274
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/1971
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2650
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/50614
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2019
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/119182
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3929
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2629
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3278
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/1134
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3877
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2145
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5396
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0042907
_:header18420212371335206460021
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0042907
http://dbpedia.org/resource/Posterior_vitreous_detachment
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FPosterior_vitreous_detachment%3E
http://sideeffects.embl.de/se/C0042907
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0042907%3E
vitreous detachment
C0042907
RDF Description of vitreous detachment
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Shen_Kuo_1031-1095
_:header1002211971335206460450
Mon, 23 Apr 2012 18:34:15 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Shen_Kuo_1031-1095
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7312
Shen, Kuo, 1031-1095
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7316
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7313
RDF Description of Shen, Kuo, 1031-1095
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7317
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7314
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7315
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/41
_:header19814036931335206460989
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/41
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1351
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PEX10
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseaseClass/Neurological
Adrenoleukodystrophy
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PEX13
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PEX26
http://data.linkedct.org/resource/condition/501
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fcondition%2F501%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PEX5
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/ABCD1
http://www.dbpedia.org/resource/Adrenoleukodystrophy
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FAdrenoleukodystrophy%3E
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/disease/Adrenoleukodystrophy
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fdisease%2FAdrenoleukodystrophy%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PEX1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1348
RDF Description of Adrenoleukodystrophy
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1350
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1347
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1349
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1352
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00560
_:header6593342631335206461467
Mon, 23 Apr 2012 18:34:16 GMT
RDF Description of Tigecycline
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00560
http://dbpedia.org/page/Tigecycline
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FTigecycline%3E
http://129.128.185.122/drugbank2/drugs/DB00560/inserts/1283/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00560%2Finserts%2F1283%2Ffull%3E
http://data.linkedct.org/resource/intervention/50453
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F50453%3E
CN(C)C1C2CC3CC4=C(C=C(NC(=O)CNC(C)(C)C)C(O)=C4C(O)=C3C(=O)C2(O)C(=O)C(C1=O)=C(N)O)N(C)C
http://www.drugbank.ca/drugs/DB00560
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00560%3E
71% to 89%
http://data.linkedct.org/resource/intervention/23227
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F23227%3E
http://bio2rdf.org/kegg:D01079
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD01079%3E
InChI=1/C29H39N5O8/c1-28(2,3)31-11-17(35)32-15-10-16(33(4)5)13-8-12-9-14-21(34(6)7)24(38)20(27(30)41)26(40)29(14,42)25(39)18(12)23(37)19(13)22(15)36/h10,12,14,21,31,36-37,41-42H,8-9,11,30H2,1-7H3,(H,32,35)/b27-20-/t12-,14-,21-,29-/m0/s1/f/h32H
Tigecycline
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/22
http://129.128.185.122/drugbank2/drugs/DB00560/inserts/399/full
http://129.128.185.122/drugbank2/drugs/DB00560/inserts/2283/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00560%2Finserts%2F2283%2Ffull%3E
ZXGBRIBPJBHLMO-WCTWHVKXDK
08:12.24
Tigecycline, a glycylcycline, inhibits protein translation in bacteria by binding to the 30S ribosomal subunit and blocking entry of amino-acyl tRNA molecules into the A site of the ribosome. This prevents incorporation of amino acid residues into elongating peptide chains. Tigecycline carries a glycylamido moiety attached to the 9-position of minocycline. The substitution pattern is not present in any naturally occurring or semisynthetic tetracycline and imparts certain microbiologic properties to tigecycline. Tigecycline is not affected by the two major tetracycline resistance mechanisms, ribosomal protection and efflux. Accordingly, tigecycline has demonstrated in vitro and in vivo activity against a broad spectrum of bacterial pathogens. There has been no cross resistance observed between tigecycline and other antibiotics. Tigecycline is not affected by resistance mechanisms such as beta-lactamases (including extended spectrum beta-lactamases), target site modifications, macrolide efflux pumps or enzyme target changes (e.g. gyrase/topoisomerase). In vitro studies have not demonstrated antagonism between tigecycline and other commonly used antibacterial drugs. In general, tigecycline is considered bacteriostatic.
CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=C(NC(=O)CNC(C)(C)C)C(O)=C4C(O)=C3C(=O)[C@]2(O)C(=O)C(C1=O)=C(N)O)N(C)C
http://bio2rdf.org/cas:220620-09-7
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A220620-09-7%3E
http://data.linkedct.org/resource/intervention/14263
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F14263%3E
http://data.linkedct.org/resource/intervention/36684
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F36684%3E
http://data.linkedct.org/resource/intervention/20724
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F20724%3E
Since glycylcyclines are similar to tetracyclines, they share many of the same side effects and contraindications as tetracyclines. These side effects may include nausea/vomiting, headache, photosensitivity, discoloration of growing teeth, and fetal damage.
Tigecycline is not extensively metabolized. In vitro studies with tigecycline using human liver microsomes, liver slices, and hepatocytes led to the formation of only trace amounts of metabolites. A glucuronide, an N-acetyl metabolite, and a tigecycline epimer (each at no more than 10% of the administered dose) are the primary metabolites.
http://data.linkedct.org/resource/intervention/24234
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F24234%3E
Tigecycline is the first clinically-available drug in a new class of antibiotics called the glycylcyclines. Glycylcyclines are a new class of antibiotics derived from tetracycline. These tetracycline analogues are specifically designed to overcome two common mechanisms of tetracycline resistance, namely resistance mediated by acquired efflux pumps and/or ribosomal protection. Glycylcycline antibiotics have a similar mechanism of action as tetracycline antibiotics. Both classes of antibiotics bind to the 30S ribosomal subunit to prevent the amino-acyl tRNA from binding to the A site of the ribosome. However, the glycylcyclines appear to bind more effectively than the tetracyclines.
2005-06-01	/drugs/560/fda_labels/1057
2008-08-26 16:52:25 UTC
http://www.dbpedia.org/resource/Tigecycline
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FTigecycline%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/140
WAY-GAR-936
4.51e-01 mg/mL
For the treatment of infections caused by susceptible strains of the designated microorganisms in the following conditions: Complicated skin and skin structure infections caused by <i>Escherichia coli</i>, <i>Enterococcus faecalis</i> (vancomycin-susceptible isolates only), <i>Staphylococcus aureus</i> (methicillin-susceptible and -resistant isolates), <i>Streptococcus agalactiae</i>, <i>Streptococcus anginosus</i> grp. (includes <i>S. anginosus</i>, <i>S. intermedius</i>, and <i>S. constellatus</i>), <i>Streptococcus pyogenes</i> and <i>Bacteroides fragilis</i>. Complicated intra-abdominal infections caused by <i>Citrobacter freundii</i>, <i>Enterobacter cloacae</i>, <i>Escherichia coli</i>, <i>Klebsiella oxytoca</i>, <i>Klebsiella pneumoniae</i>, <i>Enterococcus faecalis</i> (vancomycin-susceptible isolates only), <i>Staphylococcus aureus</i> (methicillin-susceptible isolates only), <i>Streptococcus anginosus</i> grp. (includes <i>S. anginosus</i>, <i>S. intermedius</i>, and <i>S. constellatus</i>), <i>Bacteroides fragilis</i>, <i>Bacteroides thetaiotaomicron</i>, <i>Bacteroides uniformis</i>, <i>Bacteroides vulgatus</i>, <i>Clostridium perfringens</i>, and <i>Peptostreptococcus micros</i>.
http://www.rxlist.com/cgi/generic4/tygacil.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric4%2Ftygacil.htm%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/883
Tigecycline is an glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was given a U.S. Food and Drug Administration (FDA) fast-track approval and was approved on June 17, 2005. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus.
C29H39N5O8
J01AA12
27-43 hours
http://bio2rdf.org/cpd:C12012
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC12012%3E
aprd01307
http://dbpedia.org/resource/Tigecycline
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FTigecycline%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/662
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F662%3E
N-[(5aR,6aS,7S,9Z,10aS)-9-(amino-hydroxymethylidene)-4,7-bis(dimethylamino)-1,10a,12-trihydroxy-8,10,11-trioxo-5a,6,6a,7-tetrahydro-5H-tetracen-2-yl]-2-(tert-butylamino)acetamide
GAR-936,Tigecycline
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/powderForSolutionIntravenous
Tygacil
GAR-936
http://data.linkedct.org/resource/intervention/54965
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F54965%3E
http://en.wikipedia.org/wiki/Tigecycline
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FTigecycline%3E
DB00560
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00560_DB00682
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00560_DB01418
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00560_DB00266
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00560_DB01125
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Belasco_David_1853-1931
_:header14800875381335206461934
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Belasco_David_1853-1931
Belasco, David, 1853-1931
RDF Description of Belasco, David, 1853-1931
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext16551
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13319
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/772
_:header10279223611335206462466
Mon, 23 Apr 2012 18:34:17 GMT
RDF Description of Potassium voltage-gated channel subfamily H member 7
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/772
Pore-forming (alpha) subunit of voltage-gated potassium channel. Channel properties may be modulated by cAMP and subunit assembly
http://www.uniprot.org/uniprot/Q9NS40
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ9NS40%3E
KCNH7
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AF032897
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAF032897%3E
http://pfam.sanger.ac.uk/family?acc=PF00027
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00027%3E
http://symbol.bio2rdf.org/symbol:KCNH7
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AKCNH7%3E
http://bio2rdf.org/hgnc:18863
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A18863%3E
>Potassium voltage-gated channel subfamily H member 7	MPVRRGHVAPQNTFLGTIIRKFEGQNKKFIIANARVQNCAIIYCNDGFCEMTGFSRPDVM	QKPCTCDFLHGPETKRHDIAQIAQALLGSEERKVEVTYYHKNGSTFICNTHIIPVKNQEG	VAMMFIINFEYVTDNENAATPERVNPILPIKTVNRKFFGFKFPGLRVLTYRKQSLPQEDP	DVVVIDSSKHSDDSVAMKHFKSPTKESCSPSEADDTKALIQPSKCSPLVNISGPLDHSSP	KRQWDRLYPDMLQSSSQLSHSRSRESLCSIRRASSVHDIEGFGVHPKNIFRDRHASEDNG	RNVKGPFNHIKSSLLGSTSDSNLNKYSTINKIPQLTLNFSEVKTEKKNSSPPSSDKTIIA	PKVKDRTHNVTEKVTQVLSLGADVLPEYKLQTPRINKFTILHYSPFKAVWDWLILLLVIY	TAIFTPYSAAFLLNDREEQKRRECGYSCSPLNVVDLIVDIMFIIDILINFRTTYVNQNEE	VVSDPAKIAIHYFKGWFLIDMVAAIPFDLLIFGSGSDETTTLIGLLKTARLLRLVRVARK	LDRYSEYGAAVLMLSMCIFALNAHWLACIWYAIGNVERPYLTDKIGWLDSLGQQIGKRYN	DSDSSSGPSIKDKYVTALYFTFSSLTSVGFGNVSPNTNSEKIFSICVMLIGSLMYASIFG	NVSAIIQRLYSGTARYHMQMLRVKEFIRFHQIPNPLRQRLEEYFQHAWTYTNGIDMNMVL	KGFPECLQADICLHLNQTLLQNCKAFRGASKGCLRALAMKFKTTHALQGDTLVHCGDVLT	ALYFLSRGSIEISKNDMVVAILGKNDIFGEMVHLYAKPGKSNADVRALTYCDLHKIQRED	LLEVLDMYPEFSDHFLTNLELTFNLRHESAKADLLRSQSMNDSEGDNCKLRRRKLSFESE	GEKENSTNDPEDSADTIRHYQSSKRHFEEKKSRSSSFISSIDDEQKPLFSGIVDSSPGIG	KASGLDFEETVPTSGRMHIDKRSHSCKDITDMRSWERENAHPQPEDSSPSALQRAAWGIS	ETESDLTYGEVEQRLDLLQEQLNRLESQMTTDIQTILQLLQKQTTVVPPAYSMVTAGSEY	QRPIIQLMRTSQPEASIKTDRSFSPSSQCPEFLDLEKSKLKSKESLSSGVHLNTASEDNL	TSLLKQDSDLSLELHLRQRKTYVHPIRHPSLPDSSLSTVGIVGLHRHVSDPGLPGK
550-570
642-662
522-542
413-433
KCNH7_HUMAN
Ether-a-go-go-related protein 3
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=4104136
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D4104136%3E
Signal transduction mechanisms
Ether-a-go-go-related gene potassium channel 3
protein histidine kinase activity
2q24.2
Eag- related protein 3
two-component sensor molecule activity
Voltage-gated potassium channel subunit Kv11.3
AF032897
495-515
http://www.genenames.org/data/hgnc_data.php?hgnc_id=18863
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D18863%3E
450-470
two-component signal transduction system (phosphorelay)
Potassium voltage-gated channel subfamily H member 7
HERG-3
http://bio2rdf.org/uniprot:Q9NS40
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ9NS40%3E
http://bio2rdf.org/pfam:PF00027
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00027%3E
>3591 bp	ATGCCTGTGCGCAGGGGGCATGTGGCACCACAAAATACATTTCTGGGGACCATCATTCGG	AAATTTGAAGGGCAAAATAAAAAATTTATCATTGCAAATGCCAGAGTGCAGAACTGTGCC	ATCATTTATTGCAACGATGGGTTCTGTGAGATGACTGGTTTCTCCAGGCCAGATGTCATG	CAAAAGCCATGCACCTGCGACTTTCTCCATGGACCCGAGACCAAGAGGCATGATATTGCC	CAAATTGCCCAGGCATTGCTGGGGTCAGAAGAGAGGAAAGTGGAGGTCACCTACTATCAC	AAAAATGGGTCCACTTTTATTTGTAACACTCACATAATTCCAGTGAAAAACCAAGAGGGC	GTGGCTATGATGTTCATCATTAATTTTGAATATGTGACGGATAATGAAAACGCTGCCACC	CCAGAGAGGGTAAACCCAATATTACCAATCAAAACTGTAAACCGGAAATTTTTTGGGTTC	AAATTCCCTGGTCTGAGAGTTCTCACTTACAGAAAGCAGTCCTTACCACAAGAAGACCCC	GATGTGGTGGTCATCGATTCATCTAAACACAGTGATGATTCAGTAGCCATGAAGCATTTT	AAGTCTCCTACAAAAGAAAGCTGCAGCCCCTCTGAAGCAGATGACACAAAAGCTTTGATA	CAGCCCAGCAAATGTTCTCCCTTGGTGAATATATCCGGACCTCTTGACCATTCCTCTCCC	AAAAGGCAATGGGACCGACTCTACCCTGACATGCTGCAGTCAAGTTCCCAGCTGTCCCAT	TCCAGATCAAGGGAAAGCTTATGTAGTATACGGAGAGCATCTTCGGTCCATGATATAGAA	GGATTCGGCGTCCACCCCAAGAACATATTTAGAGACCGACATGCCAGCGAAGACAATGGT	CGCAATGTCAAAGGGCCTTTTAATCATATCAAGTCAAGCCTCCTGGGATCCACATCAGAT	TCAAACCTCAACAAATACAGCACCATTAACAAGATTCCACAGCTCACTCTGAATTTTTCA	GAGGTCAAAACTGAGAAAAAGAATTCATCACCTCCTTCTTCAGATAAAACCATTATTGCA	CCCAAGGTTAAAGATCGAACACACAATGTGACTGAGAAAGTGACCCAGGTTCTCTCTTTA	GGAGCAGATGTCCTACCTGAATACAAACTGCAGACACCACGCATCAACAAGTTTACGATA	TTGCACTACAGCCCTTTCAAGGCAGTCTGGGACTGGCTTATCCTGCTGTTGGTCATATAC	ACTGCTATATTTACTCCCTACTCTGCAGCCTTCCTCCTCAATGACAGAGAAGAACAGAAG	AGACGAGAATGTGGCTATTCTTGTAGCCCTTTGAATGTGGTAGACTTGATTGTGGATATT	ATGTTTATCATAGATATTTTAATAAACTTCAGAACAACATATGTTAATCAGAATGAAGAA	GTGGTAAGTGATCCCGCCAAAATAGCAATACACTACTTCAAAGGCTGGTTCCTGATTGAC	ATGGTTGCAGCAATTCCTTTTGACTTGCTGATTTTTGGATCAGGTTCTGATGAGACAACA	ACATTAATTGGTCTTTTGAAGACTGCCCGACTCCTCCGTCTTGTGCGCGTGGCCAGGAAA	CTGGATCGATATTCAGAATATGGCGCTGCTGTTCTAATGCTCTCAATGTGCATCTTTGCC	CTGAATGCACACTGGCTGGCTTGCATTTGGTATGCGATTGGGAATGTAGAAAGGCCTTAC	CTGACTGACAAAATCGGATGGTTGGATTCCTTAGGACAGCAAATTGGGAAACGTTACAAT	GACAGTGACTCAAGTTCTGGACCATCCATTAAAGACAAATACGTCACAGCACTTTATTTT	ACCTTCAGCAGTTTAACCAGTGTAGGATTCGGGAATGTGTCTCCTAACACGAATTCGGAG	AAAATCTTTTCAATTTGTGTCATGTTGATTGGCTCACTAATGTATGCAAGCATTTTTGGG	AATGTATCTGCAATTATCCAAAGACTATACTCGGGAACTGCCAGGTACCACATGCAGATG	CTGCGAGTAAAAGAGTTCATTCGCTTTCACCAAATCCCCAACCCTCTGAGGCAACGTCTT	GAAGAATATTTCCAGCACGCATGGACTTACACCAATGGCATTGACATGAACATGGTCCTA	AAGGGTTTCCCAGAATGCTTACAAGCAGACATTTGTCTACATCTCAACCAGACATTGCTG	CAAAACTGCAAAGCCTTTCGGGGGGCAAGTAAAGGTTGCCTTAGAGCTTTGGCAATGAAG	TTCAAAACCACCCATGCACTCCAAGGAGACACCCTCGTTCACTGTGGGGATGTCCTCACT	GCACTTTATTTCTTATCCAGAGGCTCCATTGAAATCTCAAAGAATGACATGGTGGTGGCT	ATTCTGGGAAAAAATGATATATTTGGAGAAATGGTTCATCTTTATGCCAAACCTGGAAAG	TCTAATGCAGATGTAAGAGCCCTCACATACTGTGACTTGCATAAGATTCAGCGAGAAGAC	TTGTTAGAGGTTTTGGATATGTATCCTGAGTTTTCTGATCACTTTCTAACAAACCTAGAG	TTGACTTTCAACCTAAGGCATGAGAGCGCAAAGGCTGATCTCCTACGATCACAATCCATG	AATGATTCAGAAGGAGACAACTGTAAACTAAGAAGAAGGAAATTGTCATTTGAAAGTGAA	GGAGAGAAAGAAAACAGTACAAATGATCCTGAAGACTCTGCAGATACCATAAGACATTAT	CAGAGTTCCAAGAGACACTTTGAAGAGAAAAAAAGCAGATCCTCATCTTTCATCTCCTCC	ATTGATGATGAACAAAAGCCGCTCTTCTCAGGAATAGTAGACTCTTCTCCAGGAATAGGG	AAAGCATCTGGGCTCGATTTTGAAGAAACAGTGCCCACCTCAGGAAGAATGCACATAGAT	AAAAGAAGTCACTCTTGCAAAGATATCACTGACATGCGAAGCTGGGAACGAGAAAATGCA	CATCCCCAGCCTGAAGACTCCAGTCCATCTGCACTTCAGCGAGCTGCCTGGGGTATCTCT	GAAACCGAAAGCGACCTCACCTACGGGGAAGTGGAACAAAGATTAGATCTGCTCCAGGAG	CAACTTAACAGGCTTGAATCCCAAATGACCACTGACATCCAGACCATCTTACAGTTGCTG	CAGAAACAAACCACTGTGGTCCCCCCAGCCTACAGTATGGTAACAGCAGGATCAGAATAT	CAGAGACCCATCATCCAGCTGATGAGAACCAGTCAACCGGAAGCATCCATCAAAACTGAC	CGAAGTTTCAGCCCTTCCTCACAATGTCCTGAATTTCTAGACCTTGAAAAATCTAAACTT	AAATCCAAAGAATCCCTTTCAAGTGGGGTGCATCTGAACACAGCTTCAGAAGACAACTTG	ACTTCACTTTTAAAACAAGACAGTGATCTCTCTTTAGAGCTTCACCTGCGGCAAAGAAAA	ACTTACGTTCATCCAATTAGGCATCCTTCTTTGCCAGATTCATCCCTAAGCACTGTAGGA	ATCGTGGGTCTTCATAGGCATGTTTCTGATCCTGGTCTTCCAGGGAAATAA
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00308
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01074
_:header2036119561335206462821
RDF Description of Perhexiline
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01074
DB01074
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/451
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/vasodilatorAgents
2-(2,2-Dicyclohexylethyl)piperidine. Coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis. [PubChem]
0.0608 mg/L
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/cardiovascularAgents
2-(2,2-Dicyclohexylethyl)piperidine
http://bio2rdf.org/cas:6621-47-2
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A6621-47-2%3E
PA13015043
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2020
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2020%3E
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F802%3E
C19H35N
Oral LD<sub>50</sub> rat: 2150 mg/kg; Oral LD<sub>50</sub> Mouse: 2641 mg/kg. Short term adverse effects include nausea, transient dizziness, hypoglycaemia in diabetic patients, and torsade de pointes (rare).
(-)-2-(2,2-Dicyclohexylethyl)piperidine
Well absorbed (>80%) from the gastrointestinal tract following oral administration.
2008-08-26 15:30:05 UTC
CYXKNKQEMFBLER-UHFFFAOYAN
Perhexiline
Perhexiline and its metabolites are highly protein bound (>90%).
C08EX02
Perhexilina [INN-Spanish]
2.72e-05 mg/mL
http://dbpedia.org/resource/Perhexiline
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FPerhexiline%3E
The principal metabolites of perhexiline in man are monohydroxyperhexiline (which is excreted, in part, conjugated with glucuronic acid) and dihydroxyperhexiline that accounts for a relatively small proportion of the total metabolites. Two unidentified metabolites have also been found in the faeces. The pharmacological activity of the metabolites is not known. Hydroxylation of perhexiline is controlled by cytochrome P450 2D6 (CY P450 2D6).
C1CCC(CC1)C(C[C@H]1CCCCN1)C1CCCCC1
http://en.wikipedia.org/wiki/Perhexiline
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FPerhexiline%3E
C1CCC(CC1)C(CC1CCCCN1)C1CCCCC1
http://www.dbpedia.org/resource/Perhexiline
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FPerhexiline%3E
Perhexilline
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2021
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2021%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2022
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2022%3E
2-(2,2-dicyclohexylethyl)piperidine
(+)-2-(2,2-Dicyclohexylethyl)piperidine
/drugs/1074/safety_sheets/961
For the management of severe angina pectoris.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/200
InChI=1/C19H35N/c1-3-9-16(10-4-1)19(17-11-5-2-6-12-17)15-18-13-7-8-14-20-18/h16-20H,1-15H2
http://dbpedia.org/page/Perhexiline
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FPerhexiline%3E
Perhexilinum [INN-Latin]
http://www.drugbank.ca/drugs/DB01074
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01074%3E
aprd00107
Perhexiline binds to the mitochondrial enzyme carnitine palmitoyltransferase (CPT)-1 and CPT-2. It acts by shifting myocardial substrate utilisation from long chain fatty acids to carbohydrates through inhibition of CPT-1 and, to a lesser extent, CPT-2, resulting in increased glucose and lactate utilization.
Perhexilene
Used in the treatment of unresponsive or refractory angina. Perhexiline increases glucose metabolism at the expense of free-fatty-acid metabolism, enhancing oxygen efficiency during myocardial ischaemia. Perhexiline also potentiates platelet responsiveness to nitric oxide both in patients with angina and patients with acute coronary syndrome. The predominant mechanism of this particular perhexiline effect is an increase in platelet cGMP responsiveness. Perhexiline also may reduce the potential for nitric oxide clearance by neutrophil-derived oxygen. Perhexiline relieves symptoms of angina, improves exercise tolerance, and increases the workload needed to induce ischaemia when used as monotherapy. The primary therapeutic roles for perhexiline are as short-term therapy (less than 3 months duration) in patients with severe ischaemia awaiting coronary revascularisation or long-term therapy in patients with ischaemic symptoms refractory to other therapeutic measures.
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/277
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F277%3E
http://bio2rdf.org/chebi:35553
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fchebi%3A35553%3E
Variable and non-linear. Some reports show a half-life of 2-6 days, others indicate it could be as high as 30 days.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/calciumChannelBlockers
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3305
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3305%3E
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Miller_Alice_Duer_1874-1942
_:header6104397181335206463297
Mon, 23 Apr 2012 18:34:18 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Miller_Alice_Duer_1874-1942
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext12789
Miller, Alice Duer, 1874-1942
Miller, Alice Duer, 1874-1942 
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8435
RDF Description of Miller, Alice Duer, 1874-1942
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext14835
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext11325
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13146
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext11689
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00439
_:header19103540781335206463824
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00439
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00559_DB00439
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/hydroxymethylglutaryl-coaReductaseInhibitors
Cerivastatin sodium
Cerivastatin
2008-08-26 13:53:23 UTC
Cerivastatin, sodium salt
http://en.wikipedia.org/wiki/Cerivastatin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FCerivastatin%3E
Cerivastatin, a competitive HMG-CoA reductase inhibitor effective in lowering LDL cholesterol and triglycerides, is used to treat primary hypercholesterolemia and mixed dyslipidemia (Fredrickson types IIa and IIb).
PA448897
More than 99% of the circulating drug is bound to plasma proteins (80% to albumin).
Used as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Types IIa and IIb) when the response to dietary restriction of saturated fat and cholesterol and other non-pharmacological measures alone has been inadequate.
C26H34FNO5
4.19e-03 mg/mL
http://www.dbpedia.org/resource/Cerivastatin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FCerivastatin%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3977
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3977%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/631
DB00439
aprd00102
COCC1=C(C2=CC=C(F)C=C2)C(C=C[C@@H](O)C[C@@H](O)CC(O)=O)=C(N=C1C(C)C)C(C)C
http://129.128.185.122/drugbank2/drugs/DB00439/inserts/182/full
Rivastatin
SEERZIQQUAZTOL-CMHQMAEVDV
Highly solubility
Hepatic. Biotransformation pathways for cerivastatin in humans include the following: demethylation of the benzylic methyl ether to form Ml and hydroxylation of the methyl group in the 6'-isopropyl moiety to form M23.
InChI=1/C26H34FNO5/c1-15(2)25-21(11-10-19(29)12-20(30)13-23(31)32)24(17-6-8-18(27)9-7-17)22(14-33-5)26(28-25)16(3)4/h6-11,15-16,19-20,29-30H,12-14H2,1-5H3,(H,31,32)/b11-10+/t19-,20-/m1/s1/f/h31H
http://205.193.93.51/dpdonline/searchRequest.do?din=02237325
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02237325%3E
2-3 hours
The mean absolute oral bioavailability 60% (range 39 - 101%).
On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal Rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Canadian market.
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1092
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1092%3E
Rhabdomyolysis, liver concerns
2001-03-01	/drugs/439/fda_labels/535
Baycol
Lipobay
http://dbpedia.org/resource/Cerivastatin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FCerivastatin%3E
http://129.128.185.122/drugbank2/drugs/DB00439/inserts/1978/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00439%2Finserts%2F1978%2Ffull%3E
http://129.128.185.122/drugbank2/drugs/DB00439/inserts/962/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00439%2Finserts%2F962%2Ffull%3E
http://bio2rdf.org/cpd:C07966
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC07966%3E
COCC1=C(C2=CC=C(F)C=C2)C(C=CC(O)CC(O)CC(O)=O)=C(N=C1C(C)C)C(C)C
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/anticholesteremicAgents
http://www.rxlist.com/cgi/generic/cerivastat.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric%2Fcerivastat.htm%3E
http://dbpedia.org/page/Cerivastatin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FCerivastatin%3E
C10AA06
Cerivastatin competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the hepatic enzyme responsible for converting HMG-CoA to mevalonate. As mevalonate is a precursor of sterols such as cholesterol, this results in a decrease in cholesterol in hepatic cells, upregulation of LDL-receptors, and an increase in hepatic uptake of LDL-cholesterol from the circulation.
(E,3R,5S)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-di(propan-2-yl)pyridin-3-yl]-3,5-dihydroxyhept-6-enoic acid
http://bio2rdf.org/cas:145599-86-6
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A145599-86-6%3E
http://www.drugbank.ca/drugs/DB00439
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00439%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/antilipemicAgents
Grapefruit and grapefruit juice should be avoided throughout treatment as grapefruit can significantly increase serum levels of this product.
Angerbauer R, Bischoff H, Steinke W and Ritter W (1994) BAY w 6228. Drugs Fut 19: 537-541.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01149_DB00439
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00439_DB01369
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00199_DB00439
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00439_DB00559
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01241_DB00439
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00439_DB01241
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00439_DB01045
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00439_DB00199
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00439_DB00619
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00439_DB00091
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01211_DB00439
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01026_DB00439
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00439_DB00615
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01045_DB00439
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00439_DB01149
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00439_DB00343
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00439_DB01039
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00439_DB01211
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00439_DB01026
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00439_DB01167
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01394_DB00439
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00343_DB00439
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00439_DB01393
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00615_DB00439
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00439_DB01394
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01039_DB00439
RDF Description of Cerivastatin
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00619_DB00439
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00439_DB01321
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00091_DB00439
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01369_DB00439
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01167_DB00439
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Clarendon_Edward_Hyde_Earl_of_1609-1674
_:header13366925151335206464090
Mon, 23 Apr 2012 18:34:19 GMT
RDF Description of Clarendon, Edward Hyde, Earl of, 1609-1674
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Clarendon_Edward_Hyde_Earl_of_1609-1674
Clarendon, Edward Hyde, Earl of, 1609-1674
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6671
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Barlow_Joel_1754-1812
_:header15439836181335206464507
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Barlow_Joel_1754-1812
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8683
Barlow, Joel, 1754-1812
RDF Description of Barlow, Joel, 1754-1812
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/2253
_:header15545133911335206465029
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2253
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01638
http://www.uniprot.org/uniprot/P12070
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP12070%3E
http://pfam.sanger.ac.uk/family?acc=PF01261
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF01261%3E
>Xylose isomerase	MSVQPTPADHFTFGLWTVGWTGADPFGVATRKNLDPVEAVHKLAELGAYGITFHDNDLIP	FDATEAEREKILGDFNQALKDTGLKVPMVTTNLFSHPVFKDGGFTSNDRSIRRFALAKVL	HNIDLAAEMGAETFVMWGGREGSEYDGSKDLAAALDRMREGVDTAAGYIKDKGYNLRIAL	EPKPNEPRGDIFLPTVGHGLAFIEQLEHGDIVGLNPETGHEQMAGLNFTHGIAQALWAEK	LFHIDLNGQRGIKYDQDLVFGHGDLTSAFFTVDLLENGFPNGGPKYTGPRHFDYKPSRTD	GYDGVWDSAKANMSMYLLLKERALAFRADPEVQEAMKTSGVFELGETTLNAGESAADLMN	DSASFAGFDAEAAAERNFAFIRLNQLAIEHLLGSR
>1188 bp	ATGAGCGTTCAGCCGACCCCTGCAGACCACTTCACCTTTGGCCTCTGGACCGTAGGATGG	ACCGGCGCCGACCCATTCGGTGTCGCCACCCGCAAGAACCTGGACCCGGTAGAAGCCGTC	CACAAGCTGGCCGAGCTCGGCGCCTACGGCATCACCTTCCACGACAATGACCTGATTCCT	TTTGACGCCACCGAGGCAGAGCGCGAAAAGATCCTTGGTGACTTCAACCAGGCGCTGAAG	GACACCGGCCTGAAGGTCCCAATGGTGACCACCAACCTGTTCAGCCACCCGGTCTTCAAG	GACGGCGGCTTCACCTCTAACGACCGCTCGATCCGTCGTTTTGCACTGGCTAAGGTCCTG	CACAACATCGACTTGGCAGCCGAGATGGGCGCCGAAACCTTCGTCATGTGGGGCGGGCGC	GAAGGCAGCGAATACGACGGTTCCAAGGACCTGGCCGCAGCACTTGATCGCATGCGCGAA	GGCGTGGACACGGCAGCTGGCTACATCAAGGACAAGGGTTACAACCTGCGCATCGCGCTG	GAGCCAAAGCCAAATGAACCACGCGGCGACATCTTCCTGCCTACCGTCGGCCACGGCCTG	GCCTTCATCGAGCAGCTGGAGCACGGCGACATCGTCGGCCTGAACCCAGAAACCGGCCAC	GAGCAGATGGCCGGCCTGAACTTCACCCACGGCATCGCTCAGGCACTGTGGGCCGAGAAG	CTGTTCCACATTGACCTCAACGGCCAGCGCGGCATCAAGTACGACCAGGACCTGGTCTTC	GGCCACGGCGATCTGACCAGCGCGTTCTTCACCGTAGACCTGCTGGAAAACGGCTTCCCT	AACGGCGGACCAAAGTACACCGGCCCACGCCACTTCGACTACAAGCCATCGCGCACCGAC	GGCTACGACGGCGTGTGGGACTCGGCCAAGGCCAACATGTCCATGTACCTGCTGCTCAAG	GAACGTGCCCTGGCCTTCCGTGCGGATCCAGAGGTACAGGAAGCCATGAAGACCTCGGGC	GTCTTCGAACTGGGCGAAACCACCCTGAACGCCGGGGAAAGCGCAGCGGATCTGATGAAT	GATTCCGCGAGCTTCGCAGGCTTTGACGCCGAGGCCGCCGCAGAGCGCAACTTCGCGTTC	ATCCGCCTGAACCAGCTGGCCATCGAGCACCTGCTCGGCTCCCGCTAA
X59466
intramolecular oxidoreductase activity
EC 5.3.1.5
XYLA_ARTS7
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=39059
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D39059%3E
xylA
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2319597
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2304904
D-xylose = D-xylulose
http://www.pdb.org/pdb/explore/explore.do?structureId=1XLL
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1XLL%3E
intramolecular oxidoreductase activity, interconverting aldoses and ketoses
Xylose isomerase
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=X59466
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DX59466%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3508294
http://bio2rdf.org/pfam:PF01261
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF01261%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2769749
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1854339
http://bio2rdf.org/pdb:1XLL
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1XLL%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1854338
xylose isomerase activity
http://bio2rdf.org/uniprot:P12070
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP12070%3E
RDF Description of Xylose isomerase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02172
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03206
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01904
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/337
_:header17953648121335206465527
Mon, 23 Apr 2012 18:34:20 GMT
RDF Description of NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/337
NADH + H+ + ubiquinone = NAD+ + ubiquinol
mitochondrial electron transport, NADH to ubiquinone
http://pfam.sanger.ac.uk/family?acc=PF01058
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF01058%3E
http://bio2rdf.org/uniprot:O75251
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AO75251%3E
Transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone
http://bio2rdf.org/hgnc:7714
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A7714%3E
CI-20kD
http://www.genenames.org/data/hgnc_data.php?hgnc_id=7714
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D7714%3E
ATP synthesis coupled electron transport (sensu Eukaryota)
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8938450
map00190	Oxidative phosphorylation
http://www.uniprot.org/uniprot/O75251
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FO75251%3E
EC 1.6.99.3
monovalent inorganic cation transporter activity
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10360771
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=3342734
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D3342734%3E
ATP synthesis coupled electron transport
NDUFS7
PSST subunit
EC 1.6.5.3
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10097178
>NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial precursor	MAVLSAPGLRGFRILGLRSSVGPAVQARGVHQSVATDGPSSTQPALPKARAVAPKPSSRG	EYVVAKLDDLVNWARRSSLWPMTFGLACCAVEMMHMAAPRYDMDRFGVVFRASPRQSDVM	IVAGTLTNKMAPALRKVYDQMPEPRYVVSMGSCANGGGYYHYSYSVVRGCDRIVPVDIYI	PGCPPTAEALLYGILQLQRKIKRERRLQIWYRR
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AC005329
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAC005329%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8369340
http://symbol.bio2rdf.org/symbol:NDUFS7
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ANDUFS7%3E
NADH dehydrogenase (ubiquinone) activity
NADH dehydrogenase iron-sulfur protein 7, mitochondrial precursor
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10330338
NADH-ubiquinone oxidoreductase 20 kDa subunit
Complex I-20kD
http://bio2rdf.org/pfam:PF01058
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF01058%3E
19p13.3
cation transporter activity
hydrogen ion transporter activity
AC005329
NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial
NDUS7_HUMAN
>642 bp	ATGGCGGTGCTGTCAGCTCCTGGCCTGCGCGGCTTCCGGATCCTTGGTCTGCGCTCCAGC	GTGGGCCTGGCTGTGCAGGCACGAGGTGTCCATCAGAGCGTGGCCACCGATGGCCCAAGC	AGCACCCAGCCTGCCCTGCCAAAGGCCAGAGCCGTGGCTCCCAAACCCAGCAGCCGGGGC	GAGTATGTGGTGGCCAAGCTGGATGACCTCGTCAACTGGGCCCGCCGGAGTTCTCTGTGG	CCCATGACCTTCGGCCTGGCCTGCTGCGCCGTGGAGATGATGCACATGGCAGCACCCCGC	TACGACATGGACCGCTTTGGCGTGGTCTTCCGCGCCAGCCCGCGCCAGTCCGACGTCATG	ATCGTGGCCGGCACACTCACCAACAAGATGGCCCCAGCGCTTCGCAAGGTCTACGACCAG	ATGCCGGAGCCGCGCTACGTGGTCTCCATGGGGAGCTGCGCCAACGGAGGAGGCTACTAC	CACTATTCCTACTCGGTGGTGAGGGGCTGCGACCGCATCGTGCCCGTGGACATCTACATC	CCAGGCTGCCCACCTACGGCCGAGGCCCTGCTCTACGGCATCCTGCAGCTGCAGAGGAAG	ATCAAGCGGGAGCGGAGGCTGCAGATCTGGTACCGCAGGTAG
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0016867
_:header20317252091335206465952
http://sideeffects.embl.de/se/C0016867
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0016867%3E
furunculosis
C0016867
RDF Description of furunculosis
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4264
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB03462
_:header9259407791335206466378
Mon, 23 Apr 2012 18:34:21 GMT
RDF Description of Thymine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03462
1IQU
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3639
InChI=1/C5H6N2O2/c1-3-2-6-5(9)7-4(3)8/h2H,1H3,(H2,6,7,8,9)/f/h6-7H
Thymine
2008-08-26 15:08:47 UTC
CC1=CNC(=O)NC1=O
C5H6N2O2
DB03462
http://bio2rdf.org/cpd:C00178
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC00178%3E
RWQNBRDOKXIBIV-ZDKSUBDRCY
http://bio2rdf.org/cas:65-71-4
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A65-71-4%3E
http://www.drugbank.ca/drugs/DB03462
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB03462%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3594
TDR
http://bio2rdf.org/chebi:17821
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fchebi%3A17821%3E
1.08e+01 mg/mL
expt03032
-1.52 [ADME Research, USCD]
5-methyl-1H-pyrimidine-2,4-dione
http://www4.wiwiss.fu-berlin.de/dblp/data/person/114413
_:header9788112881335206467062
http://www4.wiwiss.fu-berlin.de/dblp/resource/person/114413
George Varghese
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/podc/ChandranmenonV98
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/jacm/VargheseJ00
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tocs/AdiseshuVP99
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/focs/AwerbuchV91
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigcomm/PerlmanV88
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigcomm/BonomiMPSV06
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/wdag/AwerbuchPVD94
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/ton/VargheseL97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/cn/WarkhedeSV04
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/ccr/PerlmanV87
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/infocom/PapadopoulosPV98
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigcomm/NarayanGV03
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/wss/Varghese97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/cjtcs/VargheseAG97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/infocom/LampsonSV98
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/podc/Varghese98
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/icdcs/AroraGV94
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/homepages/v/GeorgeVarghese
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/micro/TuckCV04
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/hpca/NarayanasamySSCV03
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/fpga/TsuMJHWTRVWD99
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/imw/EstanV01
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/stoc/AwerbuchKMPV93
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigcomm/SrinivasanVSW98
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/ccr/EstanVF02
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/phsn/SrinivasanV99
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigcomm/ChandranmenonV95
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/jsac/VargheseP90
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/spaa/ChungGV04
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigcomm/BaboescuV01
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/soda/SuriV99
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/focs/AwerbuchPV91
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/ton/PapadopoulosPV04
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/podc/JayaramV96
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tocs/WaldvogelVTP01
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigcomm/EstanSV03
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigcomm/ShreedharV95
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/podc/MurphyRV97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/podc/CostelloV96
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigcomm/SikkaV00
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigcomm/AdiseshuPV96
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/infocom/SnoeyinkSV01
RDF Description of George Varghese
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigcomm/WaldvogelVTP97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigcomm/VargheseFB06
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigmetrics/SrinivasanV98
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/podc/SuriVC97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/osdi/SinghEVS04
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigcomm/EstanKMV04
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/ipl/VargheseCW95
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/ccr/EstanV02
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/ccr/EathertonVD04
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/imc/EstanVF03
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/infocom/SuriVC97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/icnp/BaboescuV02
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tcbb/RaphaelLV04
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/spe/CostelloV98
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/imc/FiskV02
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/ton/ChandranmenonV96
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tse/MurphyRV02
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigcomm/OzverenSV94
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/imc/KompellaSV04
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/siamcomp/Varghese00
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/ton/ShreedharV96
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tocs/SrinivasanV99
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/infocom/TuckSCV04
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/icnp/QiuVS01
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/nossdav/KompellaV04
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigcomm/MaoGVK02
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/ton/LampsonSV99
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tocs/EstanV03
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/podc/JayaramV97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/podc/WeldvolgelVTP98
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigcomm/SrinivasanSV99
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/infocom/AwerbuchPV94
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/wss/CostelloV99
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/spaa/Varghese98
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/iandc/VargheseL96
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/imc/EstanSV02
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/infocom/WarkhedeSV01
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/infocom/BaboescuSV03
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/ton/BaboescuV05
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/podc/PapadopoulosPV98
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/cn/BaboescuV03
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/ccr/VargheseE04
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/cn/SnoeyinkSV05
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/podc/Varghese94
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/jsac/OzverenSV95
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigcomm/SinghBVW03
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sosp/VargheseL87
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/infocom/ChandranmenonV01
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/ccs/LevchenkoPV04
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigmetrics/QiuVS01
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/isca/SherwoodVC03
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/podc/VargheseL92
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigmetrics/RamabhadranV03
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigcomm/EstanV02
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00781
_:header5673925681335206467318
Mon, 23 Apr 2012 18:34:22 GMT
RDF Description of Polymyxin B Sulfate
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00781
Band-Aid-S-1 (Bacitracin Zinc + Polymyxin B sulfate)
Bacitracin-Neomycin Polymyxin Ont (Bacitracin Zinc + Neomycin sulfate + Polymyxin B sulfate)
2008-08-26 21:12:48 UTC
Polymyxin B Sulfate
Forte Topical Suspension (Hydrocortisone Acetate + Hydrocortisone Sodium Succinate + Neomycin sulfate + Penicillin G Procaine + Polymyxin B sulfate)
Polycidin Ophthalmic Ointment (Bacitracin (Bacitracin Zinc) + Polymyxin B sulfate)
25 mg/mL
Overdose can cause stomach pains, vomiting, and diarrhea.
HFMDLUQUEXNBOP-VTFLQOHRCV
Neosporin Ophthalmic Ointment (Bacitracin (Bacitracin Zinc) + Neomycin sulfate + Polymyxin B sulfate)
Polymyxin B sulfate is a mixture of polymyxins B1 and B2, obtained from <i>Bacillus polymyxa</i> strains. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxic. All gram-positive bacteria, fungi, and the gram-negative cocci, <i>N. gonorrhea</i> and <i>N. menigitidis</i>, are resistant.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/injectionSolutionIntramuscular
http://129.128.185.122/drugbank2/drugs/DB00781/inserts/2275/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00781%2Finserts%2F2275%2Ffull%3E
Polysporin Topical First Aid Antibiotic Ointment (Bacitracin + Polymyxin B sulfate)
Polytracin Ont (Bacitracin Zinc + Polymyxin B sulfate)
http://www.drugbank.ca/drugs/DB00781
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00781%3E
OS(O)(=O)=O.CC[C@@H](C)CCCCC(=O)N[C@H](CCN)C(=O)N[C@H]([C@@H](C)O)C(=O)N[C@H](CCN)C(=O)N[C@@H]1CCNC(=O)[C@H](NC(=O)[C@@H](CCN)NC(=O)[C@@H](CCN)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O
S03AA03
First Aid Antibiotic Ointment (Bacitracin Zinc + Polymyxin B sulfate)
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3772
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3772%3E
Neosporin Antibiotic Cream (Gramicidin + Neomycin sulfate + Polymyxin B sulfate)
Gercillin (Bacitracin + Benzocaine + Polymyxin B sulfate + Tyrothricin)
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/injectionSolutionIntravenousDrip
Neosporin Ointment (Bacitracin (Bacitracin Zinc) + Neomycin sulfate + Polymyxin B sulfate)
Septomixine Forte (Dexamethasone + Halethazole Tartrate + Neomycin sulfate + Polymyxin B sulfate + Tyrothricin)
Band-Aid Brand Antibiotic (Bacitracin Zinc + Polymyxin B sulfate)
Polysporin Cream (Gramicidin + Polymyxin B sulfate)
Not absorbed from the normal alimentary tract.
Polyderm Antibiotic Ointment (Bacitracin + Lidocaine Hydrochloride + Polymyxin B sulfate)
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/powderForSolutionIntrathecal
Polycidin Eye, Ear Drops (Gramicidin + Polymyxin B sulfate)
http://129.128.185.122/drugbank2/drugs/DB00781/inserts/1276/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00781%2Finserts%2F1276%2Ffull%3E
Neotopic Ointment (Bacitracin (Bacitracin Zinc) + Neomycin sulfate + Polymyxin B sulfate)
Lidosporin Ear Drops (Lidocaine Hydrochloride + Polymyxin B sulfate)
J01XB02
Polysporin Eye and Ear Drops Sterile (Gramicidin + Polymyxin B sulfate)
Polyderm Ointment Usp (Bacitracin Zinc + Polymyxin B sulfate)
Aerosporin
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2480
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2480%3E
InChI=1/C56H98N16O13.H2O4S/c1-7-32(4)13-11-12-16-44(75)63-36(17-23-57)51(80)72-46(34(6)74)56(85)68-39(20-26-60)48(77)67-41-22-28-62-55(84)45(33(5)73)71-52(81)40(21-27-61)65-47(76)37(18-24-58)66-53(82)42(29-31(2)3)69-54(83)43(30-35-14-9-8-10-15-35)70-49(78)38(19-25-59)64-50(41)79;1-5(2,3)4/h8-10,14-15,31-34,36-43,45-46,73-74H,7,11-13,16-30,57-61H2,1-6H3,(H,62,84)(H,63,75)(H,64,79)(H,65,76)(H,66,82)(H,67,77)(H,68,85)(H,69,83)(H,70,78)(H,71,81)(H,72,80);(H2,1,2,3,4)/f/h62-72H;1-2H
Lidosporin Cream (Gramicidin + Lidocaine Hydrochloride + Polymyxin B sulfate)
/drugs/781/safety_sheets/756
Neo Bace Ophthalmic Ointment (Bacitracin + Polymyxin B sulfate)
http://dbpedia.org/page/Polymyxin_B
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FPolymyxin_B%3E
aprd01190
Mycitracin OPH ONT (Bacitracin + Neomycin sulfate + Polymyxin B sulfate)
Laryngets Loz (Benzocaine + Cetylpyridinium Chloride + Polymyxin B sulfate + Tyrothricin)
OS(O)(=O)=O.CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CCN)NC1=O)C(C)O
PA451028
Neosporin Irrigating Solution (Neomycin sulfate + Polymyxin B sulfate)
Polysporin Burn Formula Cream (Gramicidin + Lidocaine Hydrochloride + Polymyxin B sulfate)
http://dbpedia.org/resource/Polymyxin_B
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FPolymyxin_B%3E
For treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of <i>Pseudomonas aeruginosa</i>.
A07AA05
Ophthocort Ont (Chloramphenicol + Hydrocortisone Acetate + Polymyxin B sulfate)
Antibiotic Cream (Gramicidin + Polymyxin B sulfate)
Optiprime Oph Gel (Neomycin sulfate + Polymyxin B sulfate)
C56H100N16O17S
Synalar Bi-Otic Solution (Fluocinolone Acetonide + Neomycin sulfate + Polymyxin B sulfate)
Antibiotic Ointment (Bacitracin + Polymyxin B sulfate)
Surolan Drops (Miconazole Nitrate + Polymyxin B sulfate + Prednisolone Acetate)
Polymyxin B sulfate salt
Poly-RX
Polymixin B sulfate
Polysporin Triple Antibiotic Ointment (Bacitracin + Gramicidin + Polymyxin B sulfate)
http://bio2rdf.org/cas:1405-20-5
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A1405-20-5%3E
Pms-Polytrimethoprim (Polymyxin B sulfate + Trimethoprim (Trimethoprim sulfate))
Polysporin Antibiotic Ointment (Bacitracin + Polymyxin B sulfate)
http://bio2rdf.org/cpd:C11613
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC11613%3E
http://205.193.93.51/dpdonline/searchRequest.do?din=02242485
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02242485%3E
Ozonol Antibiotic Plus - Ointment (Bacitracin + Lidocaine Hydrochloride + Polymyxin B sulfate)
http://www.dbpedia.org/resource/Polymyxin_B
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FPolymyxin_B%3E
N-[4-amino-1-[[1-[[4-amino-1-oxo-1-[[6,9,18-tris(2-aminoethyl)-15-benzyl-3-(1-hydroxyethyl)-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide; sulfuric acid
Lidomyxin (Lidocaine Hydrochloride + Polymyxin B sulfate)
Bacitracin-Neomycin-Polymyxin Oph Ont (Bacitracin Zinc + Neomycin sulfate + Polymyxin B sulfate)
http://www.rxlist.com/cgi/generic3/polymyxin.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric3%2Fpolymyxin.htm%3E
Lanabiotic Ont (Bacitracin + Polymyxin B sulfate)
Polysporin Antibiotic Burn Cream (Gramicidin + Lidocaine Hydrochloride + Polymyxin B sulfate)
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/139
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F139%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/powderForSolutionOphthalmic
Ozonol Antibiotic Plus Ont (Bacitracin + Lidocaine Hydrochloride + Polymyxin B sulfate)
Polysporin Sterile Ophthalmic Ointment (Bacitracin (Bacitracin Zinc) + Polymyxin B sulfate)
Sandoz Cortimyxin (Bacitracin (Bacitracin Zinc) + Hydrocortisone + Neomycin sulfate + Polymyxin B sulfate)
Anaprime OPH Gel (Flumethasone + Neomycin sulfate + Polymyxin B sulfate)
Polymyxin B sulphate
First Aid Antibiotic (Bacitracin Zinc + Polymyxin B sulfate)
Polymyxin B sulfate is a mixture of polymyxins B1 and B2, obtained from Bacillus polymyxa strains. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxic. All gram-positive bacteria, fungi, and the gram-negative cocci, N. gonorrhea and N. menigitidis, are resistant. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosa.
Polytopic Ont (Bacitracin + Polymyxin B sulfate)
DB00781
S01AA18
Neosporin Eye-Ear Solution (Gramicidin + Neomycin sulfate + Polymyxin B sulfate)
Cortisporin (Bacitracin Zinc + Hydrocortisone + Neomycin sulfate + Polymyxin B sulfate)
Polymyxin B sulfate has a bactericidal action against almost all gram-negative bacilli except the Proteus group. Polymyxin B sulfate binds to and interferes with the permeability of the bacterial cytoplasmic membrane.
Antibiotic Lozenges (Benzocaine + Cetylpyridinium Chloride + Polymyxin B sulfate + Tyrothricin)
Neospan Mastitis Treatment (Neomycin sulfate + Penicillin G Potassium + Polymyxin B sulfate + Streptomycin sulfate)
S02AA11
http://en.wikipedia.org/wiki/Polymyxin_B
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FPolymyxin_B%3E
Pulmosirum Pastille (Benzocaine + Cetylpyridinium Chloride + Polymyxin B sulfate + Tyrothricin)
http://bio2rdf.org/kegg:D01066
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD01066%3E
Mastitis Care (Neomycin sulfate + Penicillin G Potassium + Polymyxin B sulfate + Streptomycin sulfate)
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Major_Charles_1856-1913
_:header6882845911335206467780
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Major_Charles_1856-1913
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext14242
Major, Charles, 1856-1913
RDF Description of Major, Charles, 1856-1913
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext14671
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17498
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext12057
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Toulet_Paul_Jean_1867-1920
_:header19069642081335206468167
Mon, 23 Apr 2012 18:34:23 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Toulet_Paul_Jean_1867-1920
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext15882
Toulet, Paul Jean, 1867-1920
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext15815
RDF Description of Toulet, Paul Jean, 1867-1920
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/62
_:header13071322371335206468692
RDF Description of Glycine receptor subunit beta
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/62
GLRB
http://symbol.bio2rdf.org/symbol:GLRB
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AGLRB%3E
http://pfam.sanger.ac.uk/family?acc=PF02931
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF02931%3E
postsynaptic membrane
479-496
GLRB_HUMAN
neurotransmitter receptor activity
extracellular ligand-gated ion channel activity
Glycine receptor 58 kDa subunit
299-316
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9676428
http://www.genenames.org/data/hgnc_data.php?hgnc_id=4329
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D4329%3E
>1494 bp	ATGAAGTTTTTATTGACAACTGCCTTTTTAATTTTAATTTCCTTGTGGGTGGAAGAAGCC	TATTCTAAGGAAAAGTCTTCAAAGAAAGGGAAGGGGAAAAAGAAGCAGTATCTATGCCCA	TCTCAGCAGTCAGCAGAGGACCTTGCCCGAGTACCTGCCAACTCCACTAGCAATATCTTG	AACAGGTTATTGGTCAGTTATGATCCCAGGATAAGACCAAACTTCAAAGGCATTCCTGTT	GATGTAGTAGTCAACATTTTTATTAACAGTTTTGGATCCATTCAAGAAACAACAATGGAC	TATAGAGTTAACATCTTCCTGAGACAAAAATGGAATGACCCCAGGCTGAAGCTCCCCAGT	GATTTTAGGGGTTCAGATGCACTGACAGTGGATCCAACAATGTACAAGTGTTTATGGAAA	CCTGATTTATTTTTTGCAAATGAAAAAAGTGCCAATTTTCATGATGTGACCCAGGAAAAC	ATCCTCCTCTTTATTTTTCGTGATGGAGATGTCCTTGTCAGCATGAGGTTATCTATTACT	CTTTCATGCCCTTTGGACTTGACATTGTTTCCCATGGATACACAACGTTGCAAGATGCAA	CTGGAGAGCTTTGGTTACACAACTGATGATTTACGATTTATCTGGCAGTCAGGAGATCCT	GTGCAATTAGAAAAAATTGCCTTGCCTCAATTTGATATCAAAAAGGAAGATATTGAATAT	GGTAACTGTACAAAATACTATAAAGGCACGGGCTACTACACATGCGTGGAAGTCATCTTC	ACCCTGAGGAGGCAGGTCGGCTTTTACATGATGGGGGTCTACGCCCCAACCCTGCTCATT	GTTGTTCTCTCCTGGCTTTCCTTCTGGATCAACCCGGACGCGAGTGCTGCCAGAGTGCCC	CTGGGTATCTTCTCAGTCCTCAGCTTGGCCTCTGAGTGCACAACCCTTGCCGCTGAGCTT	CCCAAAGTTTCCTATGTGAAGGCTCTTGATGTTTGGCTTATTGCTTGCCTTCTCTTTGGG	TTTGCTTCCCTGGTGGAGTATGCAGTTGTCCAGGTGATGCTGAACAACCCCAAAAGGGTT	GAAGCTGAAAAAGCCAGAATTGCTAAGGCTGAGCAAGCAGATGGAAAAGGTGGAAATGTG	GCTAAAAAGAATACTGTGAATGGAACAGGGACTCCTGTTCATATTAGCACTTTGCAGGTT	GGTGAGACCAGATGCAAAAAAGTTTGTACTTCTAAGTCTGATCTGAGATCTAATGACTTC	AGCATTGTTGGAAGCTTACCAAGAGATTTTGAACTATCCAATTATGACTGCTATGGAAAA	CCCATTGAAGTTAACAACGGACTTGGGAAATCTCAGGCTAAGAACAACAAGAAGCCTCCC	CCTGCGAAACCTGTTATTCCAACAGCAGCAAAGCGAATTGATCTTTATGCAAGAGCATTG	TTTCCTTTCTGCTTCTTGTTCTTCAATGTTATATATTGGTCTATATATTTATGA
331-354
http://www.uniprot.org/uniprot/P48167
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP48167%3E
1-22
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/16884688
http://www.pdb.org/pdb/explore/explore.do?structureId=1T3E
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1T3E%3E
anion channel activity
The glycine receptor is a neurotransmitter-gated ion channel. Binding of glycine to its receptor increases the chloride conductance and thus produces hyperpolarization (inhibition of neuronal firing)
chloride transport
Glycine receptor subunit beta
Glycine receptor subunit beta precursor
4q31.3
http://bio2rdf.org/hgnc:4329
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A4329%3E
>Glycine receptor subunit beta precursor	MKFLLTTAFLILISLWVEEAYSKEKSSKKGKGKKKQYLCPSQQSAEDLARVPANSTSNIL	NRLLVSYDPRIRPNFKGIPVDVVVNIFINSFGSIQETTMDYRVNIFLRQKWNDPRLKLPS	DFRGSDALTVDPTMYKCLWKPDLFFANEKSANFHDVTQENILLFIFRDGDVLVSMRLSIT	LSCPLDLTLFPMDTQRCKMQLESFGYTTDDLRFIWQSGDPVQLEKIALPQFDIKKEDIEY	GNCTKYYKGTGYYTCVEVIFTLRRQVGFYMMGVYAPTLLIVVLSWLSFWINPDASAARVP	LGIFSVLSLASECTTLAAELPKVSYVKALDVWLIACLLFGFASLVEYAVVQVMLNNPKRV	EAEKARIAKAEQADGKGGNVAKKNTVNGTGTPVHISTLQVGETRCKKVCTSKSDLRSNDF	SIVGSLPRDFELSNYDCYGKPIEVNNGLGKSQAKNNKKPPPAKPVIPTAAKRIDLYARAL	FPFCFLFFNVIYWSIYL
266-290
U33267
ligand-gated ion channel activity
Involved in extracellular-glycine-gated chloride channel activity
http://bio2rdf.org/uniprot:P48167
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP48167%3E
inorganic anion transport
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=U33267
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DU33267%3E
http://pfam.sanger.ac.uk/family?acc=PF02932
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF02932%3E
chloride channel activity
http://bio2rdf.org/pfam:PF02931
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF02931%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8717357
glycine-gated chloride channel activity
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=992687
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D992687%3E
anion transport
http://bio2rdf.org/pfam:PF02932
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF02932%3E
http://bio2rdf.org/pdb:1T3E
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1T3E%3E
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/5483
_:header14883760851335206469082
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/5483
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03994
35-alpha calcimedin
4q13-q22
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8639653
Placental anticoagulant protein III
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2975506
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2159184
http://www.uniprot.org/uniprot/P12429
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP12429%3E
calcium-dependent phospholipid binding
phospholipase inhibitor activity
>Annexin A3	MASIWVGHRGTVRDYPDFSPSVDAEAIQKAIRGIGTDEKMLISILTERSNAQRQLIVKEY	QAAYGKELKDDLKGDLSGHFEHLMVALVTPPAVFDAKQLKKSMKGAGTNEDALIEILTTR	TSRQMKDISQAYYTVYKKSLGDDISSETSGDFRKALLTLADGRRDESLKVDEHLAKQDAQ	ILYKAGENRWGTDEDKFTEILCLRSFPQLKLTFDEYRNISQKDIVDSIKGELSGHFEDLL	LAIVNCVRNTPAFLAERLHRALKGIGTDEFTLNRIMVSRSEIDLLDIRTEFKKHYGYSLY	SAIKSDTSGDYEITLLKICGGDD
phospholipid binding
http://bio2rdf.org/hgnc:541
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A541%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=541
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D541%3E
Annexin A3
http://bio2rdf.org/uniprot:P12429
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP12429%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1830024
Lipocortin III
enzyme regulator activity
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2138632
>972 bp	ATGGCATCTATCTGGGTTGGACACCGAGGAACAGTAAGAGATTATCCAGACTTTAGCCCA	TCAGTGGATGCTGAAGCTATTCAGAAAGCAATCAGAGGAATTGGAACTGATGAGAAAATG	CTCATCAGCATTCTGACTGAGAGGTCAAATGCACAGCGGCAGCTGATTGTTAAGGAATAT	CAAGCAGCATATGGAAAGGAGCTGAAAGATGACTTGAAGGGTGATCTCTCTGGCCACTTT	GAGCATCTCATGGTGGCCCTAGTGACTCCACCAGCAGTCTTTGATGCAAAGCAGCTAAAG	AAATCCATGAAGGGCGCGGGAACAAACGAAGATGCCTTGATTGAAATCTTAACTACCAGG	ACAAGCAGGCAAATGAAGGATATCTCTCAAGCCTATTATACAGTATACAAGAAGAGTCTT	GGAGATGACATTAGTTCCGAAACATCTGGTGACTTCCGGAAAGCTCTGTTGACTTTGGCA	GATGGCAGAAGAGATGAAAGTCTGAAAGTGGATGAGCATCTGGCCAAACAAGATGCCCAG	ATTCTCTATAAAGCTGGTGAGAACAGATGGGGCACGGATGAAGACAAATTCACTGAGATC	CTGTGTTTAAGGAGCTTTCCTCAATTAAAACTAACATTTGATGAATACAGAAATATCAGC	CAAAAGGACATTGTGGACAGCATAAAAGGAGAATTATCTGGGCATTTTGAAGACTTACTG	TTGGCCATAGTTAATTGTGTGAGGAACACGCCGGCCTTTTTAGCCGAAAGACTGCATCGA	GCCTTGAAGGGTATTGGAACTGATGAGTTTACTCTGAACCGAATAATGGTGTCCAGATCA	GAAATTGACCTTTTGGACATTCGAACAGAGTTCAAGAAGCATTATGGCTATTCCCTATAT	TCAGCAATTAAATCGGATACTTCTGGAGACTATGAAATCACACTCTTAAAAATCTGTGGT	GGAGATGACTGA
M20560
ANXA3
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8276419
ANXA3_HUMAN
Annexin III
lipid binding
http://bio2rdf.org/pfam:PF00191
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00191%3E
http://pfam.sanger.ac.uk/family?acc=PF00191
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00191%3E
PAP-III
Involved in calcium ion binding
enzyme inhibitor activity
Non Essential
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=M20560
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DM20560%3E
http://www.pdb.org/pdb/explore/explore.do?structureId=1AII
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1AII%3E
Inhibitor of phospholipase A2, also possesses anti- coagulant properties. Also cleaves the cyclic bond of inositol 1,2-cyclic phosphate to form inositol 1-phosphate
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2968983
Inositol 1,2-cyclic phosphate 2-phosphohydrolase
http://bio2rdf.org/pdb:1AII
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1AII%3E
RDF Description of Annexin A3
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00597
_:header9031698291335206469550
Mon, 23 Apr 2012 18:34:24 GMT
RDF Description of Gadoteridol
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00597
InChI=1/C17H32N4O7.Gd/c1-14(22)10-18-2-4-19(11-15(23)24)6-8-21(13-17(27)28)9-7-20(5-3-18)12-16(25)26;/h14,22H,2-13H2,1H3,(H,23,24)(H,25,26)(H,27,28);/q;+3/p-3/fC17H29N4O7.Gd/q-3;m
[Gd+3].C[C@H](O)CN1CCN(CCN(CCN(CC1)CC([O-])=O)CC([O-])=O)CC([O-])=O
1.12e+01 mg/mL
DB00597
http://bio2rdf.org/kegg:D01137
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD01137%3E
/drugs/597/safety_sheets/1129
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/contrastMedia
http://205.193.93.51/dpdonline/searchRequest.do?din=02229056
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02229056%3E
Gadoteridol provides contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. Gadoteridol can also be used for whole body contrast enhanced MRI including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies. n MRI, visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in T2. When placed in a magnetic field, gadoteridol shortens the T1 relaxation time in tissues where it accumulates. Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadoteridol in lesions such as neoplasms, abscesses, and subacute infarcts.
V08CA04
ProHance
Gadoteridol
PA449723
2008-08-26 14:29:50 UTC
C17H29GdN4O7
DPNNNPAKRZOSMO-IBOKPTKACE
http://bio2rdf.org/cas:120066-54-8
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A120066-54-8%3E
Based on the behavior of protons when placed in a strong magnetic field, which is interpreted and transformed into images by magnetic resonance (MR) instruments. Paramagnetic agents have unpaired electrons that generate a magnetic field about 700 times larger than the proton's field, thus disturbing the proton's local magnetic field. When the local magnetic field around a proton is disturbed its relaxation process is altered. MR images are based on proton density and proton relaxation dynamics. MR instruments can record two different relaxation processes, the T1 (spin-lattice or longitudinal relaxation time) and T2 (spin-spin or transverse relaxation time). In MRI, visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in T2. When placed in a magnetic field, gadoteridol shortens the T1 relaxation time in tissues where it accumulates. Gadoteridol does not cross the intact blood-brain barrier; therefore, it does not accumulate in normal brain tissue or in central nervous system (CNS) lesions that have not caused an abnormal blood-brain barrier (e.g., cysts, mature post-operative scars). Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadoteridol in lesions such as neoplasms, abscesses, and subacute infarcts.
Gadoteridol provides contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. Gadoteridol can also be used for whole body contrast enhanced MRI including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies.
2003-10-01	/drugs/597/fda_labels/91
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/contrastAgents
[Gd+3].CC(O)CN1CCN(CCN(CCN(CC1)CC([O-])=O)CC([O-])=O)CC([O-])=O
aprd00992
Distribution 12 minutes (mean), elimination 100 minutes (mean).
gadolinium(+3) cation; 2-[4-(2-hydroxypropyl)-7,10-bis(2-oxido-2-oxoethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate
Prohance Multipack
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3951
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3951%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1853
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F1853%3E
http://www.drugbank.ca/drugs/DB00597
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00597%3E
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Johnson_Lyndon_B_(Lyndon_Baines)_1908-1973
_:header14923022771335206469909
RDF Description of Johnson, Lyndon B. (Lyndon Baines), 1908-1973
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Johnson_Lyndon_B_(Lyndon_Baines)_1908-1973
Johnson, Lyndon B. (Lyndon Baines), 1908-1973
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5042
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Young_E_H_(Emily_Hilda)_1880-1949
_:header1999935691335206470310
Mon, 23 Apr 2012 18:34:25 GMT
RDF Description of Young, E. H. (Emily Hilda), 1880-1949
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Young_E_H_(Emily_Hilda)_1880-1949
Young, E. H. (Emily Hilda), 1880-1949
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8131
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/4919
_:header5160295701335206470836
RDF Description of Catalase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4919
antioxidant activity
Occurs in almost all aerobically respiring organisms and serves to protect cells from the toxic effects of hydrogen peroxide
http://pfam.sanger.ac.uk/family?acc=PF00199
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00199%3E
http://bio2rdf.org/uniprot:P00432
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP00432%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7082009
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=BC103066
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DBC103066%3E
Catalase
http://bio2rdf.org/pfam:PF00199
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00199%3E
http://www.uniprot.org/uniprot/P00432
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP00432%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10417406
CAT
>1584 bp	ATGGCGGACAACCGGGATCCAGCCAGCGACCAGATGAAACACTGGAAGGAGCAGAGGGCC	GCGCAGAAACCTGATGTCCTGACCACTGGAGGTGGTAATCCAGTAGGAGACAAACTCAAT	AGTCTGACAGTAGGGCCCCGAGGGCCCCTTCTCGTCCAGGATGTGGTTTTCACTGATGAA	ATGGCTCACTTTGACCGGGAGAGAATTCCTGAGAGAGTCGTGCACGCCAAAGGAGCAGGG	GCTTTTGGCTACTTTGAGGTCACACATGACATTACCAGATACTCCAAGGCGAAGGTGTTT	GAGCATATTGGAAAGAGGACGCCCATTGCAGTTCGCTTCTCCACTGTTGCTGGAGAATCG	GGCTCAGCTGACACAGTTCGTGACCCTCGTGGCTTTGCAGTGAAATTTTACACAGAAGAT	GGTAATTGGGATCTTGTTGGAAATAATACTCCCATTTTCTTCATCAGGGATGCTCTATTG	TTTCCATCCTTTATCCACAGCCAGAAGAGAAACCCTCAAACGCACCTGAAGGATCCGGAC	ATGGTCTGGGACTTCTGGAGCCTGCGTCCTGAGTCTCTGCATCAGGTTTCCTTCCTGTTC	AGTGATCGAGGGATTCCAGATGGACACAGGCACATGAATGGATATGGATCGCATACTTTC	AAGCTGGTTAATGCAAATGGAGAGGCAGTTTATTGCAAATTCCATTATAAGACTGATCAG	GGCATCAAAAACCTTTCTGTTGAAGATGCAGCAAGACTTGCCCACGAAGATCCTGACTAT	GGCCTCCGCGATCTTTTCAATGCCATTGCCACAGGCAACTACCCCTCCTGGACTTTATAC	ATCCAGGTCATGACATTTAGTGAGGCAGAAATTTTTCCATTTAATCCATTTGATCTTACC	AAGGTTTGGCCTCACGGCGACTATCCTCTTATTCCAGTTGGTAAATTGGTCTTAAACCGG	AACCCAGTTAATTACTTTGCTGAGGTTGAACAGTTGGCTTTTGACCCAAGCAACATGCCG	CCCGGCATCGAGCCCAGCCCTGACAAAATGCTCCAGGGCCGCCTTTTTGCCTATCCTGAC	ACTCACCGCCACCGCCTGGGACCCAACTATCTCCAGATACCTGTGAACTGTCCCTACCGT	GCTCGAGTGGCCAACTACCAGCGTGACGGCCCCATGTGCATGATGGACAATCAGGGTGGG	GCTCCAAATTACTACCCCAATAGCTTTAGTGCTCCCGAGCATCAGCCTTCTGCCCTGGAA	CACAGGACCCACTTCTCTGGGGATGTACAGCGCTTCAACAGTGCCAACGATGACAATGTC	ACTCAGGTGCGGACTTTCTATTTGAAAGTGCTGAATGAGGAGCAGAGGAAACGCCTGTGT	GAGAACATTGCGGGCCATCTGAAAGACGCACAGCTTTTTATCCAGAAGAAAGCGGTTAAG	AACTTCAGCGATGTCCATCCTGAATATGGCTCCCGCATCCAGGCTCTTTTGGACAAATAC	AATGAGGAGAAACCTAAGAACGCAGTTCACACCTATGTGCAGCATGGGTCTCACTTGTCT	GCAAGGGAGAAAGCTAATCTCTGA
Involved in catalase activity
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7328661
CATA_BOVIN
BC103066
oxygen and reactive oxygen species metabolism
http://www.pdb.org/pdb/explore/explore.do?structureId=4BLC
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D4BLC%3E
response to oxidative stress
http://bio2rdf.org/pdb:4BLC
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A4BLC%3E
EC 1.11.1.6
peroxidase activity
peroxisome
>Catalase	MADNRDPASDQMKHWKEQRAAQKPDVLTTGGGNPVGDKLNSLTVGPRGPLLVQDVVFTDE	MAHFDRERIPERVVHAKGAGAFGYFEVTHDITRYSKAKVFEHIGKRTPIAVRFSTVAGES	GSADTVRDPRGFAVKFYTEDGNWDLVGNNTPIFFIRDALLFPSFIHSQKRNPQTHLKDPD	MVWDFWSLRPESLHQVSFLFSDRGIPDGHRHMNGYGSHTFKLVNANGEAVYCKFHYKTDQ	GIKNLSVEDAARLAHEDPDYGLRDLFNAIATGNYPSWTLYIQVMTFSEAEIFPFNPFDLT	KVWPHGDYPLIPVGKLVLNRNPVNYFAEVEQLAFDPSNMPPGIEPSPDKMLQGRLFAYPD	THRHRLGPNYLQIPVNCPYRARVANYQRDGPMCMMDNQGGAPNYYPNSFSAPEHQPSALE	HRTHFSGDVQRFNSANDDNVTQVRTFYLKVLNEEQRKRLCENIAGHLKDAQLFIQKKAVK	NFSDVHPEYGSRIQALLDKYNEEKPKNAVHTYVQHGSHLSAREKANL
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3712444
catalase activity
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03014
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/SLC5A1
_:header15297483961335206471114
Mon, 23 Apr 2012 18:34:26 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/SLC5A1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/455
http://symbol.bio2rdf.org/symbol:SLC5A1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ASLC5A1%3E
SLC5A1
http://www.dbpedia.org/resource/SLC5A1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FSLC5A1%3E
RDF Description of SLC5A1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2480
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Tesla_Nikola_1856-1943
_:header659650761335206471518
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Tesla_Nikola_1856-1943
Tesla, Nikola, 1856-1943
RDF Description of Tesla, Nikola, 1856-1943
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13476
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0023470
_:header15606806711335206472001
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0023470
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F791%3E
http://dbpedia.org/resource/Myeloid_leukemia
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FMyeloid_leukemia%3E
http://sideeffects.embl.de/se/C0023470
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0023470%3E
myelogenous leukemia
C0023470
myeloid leukemia
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5473385
RDF Description of myelogenous leukemia
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01614
_:header14922099201335206472462
Mon, 23 Apr 2012 18:34:27 GMT
RDF Description of Acepromazine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01614
CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(C)=O
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/sedativesAndHypnotics
C19H22N2OS
2007-08-29 20:12:05 UTC
Acetylpromazine
http://www.drugbank.ca/drugs/DB01614
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01614%3E
Ace
http://en.wikipedia.org/wiki/Acepromazine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FAcepromazine%3E
Acepromazine
http://bio2rdf.org/chebi:44932
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fchebi%3A44932%3E
InChI=1/C19H22N2OS/c1-14(22)15-9-10-19-17(13-15)21(12-6-11-20(2)3)16-7-4-5-8-18(16)23-19/h4-5,7-10,13H,6,11-12H2,1-3H3
< 25 oC
Acepromazine is one of the phenothiazine derivative psychotropic drugs, used little in humans, however frequently in animals as a sedative and antiemetic.
ACP
http://dbpedia.org/resource/Acepromazine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FAcepromazine%3E
PMZ
2008-08-26 15:37:01 UTC
10-(3-dimethylaminopropyl)phenothiazin-3-yl methyl ketone
Atravet
Acezine 2
http://bio2rdf.org/cas:61-00-7
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A61-00-7%3E
10-(3-dimethylaminopropyl)phenothiazine-3-ethylone
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/dopamineAntagonists
NOSIYYJFMPDDSA-UHFFFAOYAJ
1-[10-(3-dimethylaminopropyl)phenothiazin-2-yl]ethanone
http://dbpedia.org/page/Acepromazine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FAcepromazine%3E
DB01614
9.80e-03 mg/mL
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00843_DB01614
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00674_DB01614
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01239
_:header2066486391335206472882
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00674_DB01239
C18H18ClNS
Chlorprotixene
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1025
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1025%3E
http://dbpedia.org/page/Chlorprothixene
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FChlorprothixene%3E
Chlorprothixine
Symptoms of overdose include difficulty in breathing (severe), dizziness (severe), drowsiness (severe), muscle trembling, jerking, stiffness, or uncontrolled movements (severe), small pupils, unusual excitement, and unusual tiredness or weakness (severe).
3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine
WSPOMRSOLSGNFJ-UHFFFAOYAR
DB01239
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1377
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1377%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/94
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F94%3E
Chlothixen
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/502
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3841
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3841%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3423
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3423%3E
http://en.wikipedia.org/wiki/Chlorprothixene
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FChlorprothixene%3E
Chlorprotixen
InChI=1/C18H18ClNS/c1-20(2)11-5-7-14-15-6-3-4-8-17(15)21-18-10-9-13(19)12-16(14)18/h3-4,6-10,12H,5,11H2,1-2H3
3.66e-04 mg/mL
Chlorprothixene blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/54
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F54%3E
aprd00718
Traquilan
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3852
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3852%3E
http://bio2rdf.org/cpd:C07953
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC07953%3E
http://bio2rdf.org/cas:113-59-7
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A113-59-7%3E
CPX
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1032
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1032%3E
Paxyl
0.295 mg/L
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/436
Rentovet
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/concentrateOral
For treatment of psychotic disorders (e.g. schizophrenia) and of acute mania occuring as part of bipolar disorders.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/antipsychotics
http://129.128.185.122/drugbank2/drugs/DB01239/inserts/1503/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB01239%2Finserts%2F1503%2Ffull%3E
8 to 12 hours
http://129.128.185.122/drugbank2/drugs/DB01239/inserts/556/full
/drugs/1239/safety_sheets/1137
CN(C)CCC=C1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
N05AF03
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/590
http://www.drugbank.ca/drugs/DB01239
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01239%3E
Tardan
Chlorprotixine
Truxaletten
2008-08-26 16:53:44 UTC
97.5 oC
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1460
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1460%3E
http://bio2rdf.org/kegg:D00790
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD00790%3E
Chlorprothixene
CN(C)CCC=C1/C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
Tarasan
Chlorprothixene is a typical antipsychotic drug of the thioxanthine class. It has a low antipsychotic potency (half to 2/3 of chlorpromazine). An intrinsic antidepressant effect of chlorprothixene has been discussed, but not proven yet. Likewise, it is unclear, if chlorprothixene has genuine analgesic effects. An antiemetic effect, as with most antipsychotics, exists. It is used in the treatment of nervous, mental, and emotional conditions. Improvement in such conditions is thought to result from the effect of the medicine on nerve pathways in specific areas of the brain. Chlorprothixene has a strong sedative activity with a high incidence of anticholinergic side-effects. Chlorprothixene is structurally related to chlorpromazine, with which it shares in principal all side effects. Allergic side-effects and liver damage seem to appear with an appreciable lower frequency.
Chloroprothixene
Incomplete bioavailability.
http://www.dbpedia.org/resource/Chlorprothixene
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FChlorprothixene%3E
CPT
Taractan
Truxil
http://data.linkedct.org/resource/intervention/2617
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F2617%3E
Trictal
Cis-Chlorprothixene
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/852
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F852%3E
http://dbpedia.org/resource/Chlorprothixene
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FChlorprothixene%3E
Alpha-Chlorprothixene
Chlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors.
Iaractan
Vetacalm
PA448967
Chlorprothixen
http://129.128.185.122/drugbank2/drugs/DB01239/inserts/2500/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB01239%2Finserts%2F2500%2Ffull%3E
Tactaran
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/638
Truxal
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01239_DB00989
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01170_DB01239
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01239_DB00674
RDF Description of Chlorprothixene
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00843_DB01239
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01239_DB00843
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01239_DB01170
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/ACVRL1
_:header17631931241335206473273
Mon, 23 Apr 2012 18:34:28 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/ACVRL1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/507
http://symbol.bio2rdf.org/symbol:ACVRL1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AACVRL1%3E
ACVRL1
http://www.dbpedia.org/resource/ACVRL1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FACVRL1%3E
RDF Description of ACVRL1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2591
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Holmes_John_Haynes_1879-1964
_:header4763901011335206473684
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Holmes_John_Haynes_1879-1964
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17939
Holmes, John Haynes, 1879-1964
RDF Description of Holmes, John Haynes, 1879-1964
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01072
_:header630633461335206474164
Mon, 23 Apr 2012 18:34:29 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00458_DB01072
http://129.128.185.122/drugbank2/drugs/DB01072/inserts/461/full
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/proteaseInhibitors
http://data.linkedct.org/resource/intervention/32512
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F32512%3E
http://dbpedia.org/resource/Atazanavir
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FAtazanavir%3E
Atazanavir is rapidly absorbed with a T<sub>max</sub> of approximately 2.5 hours. Administration of atazanavir with food enhances bioavailability and reduces pharmacokinetic variability. Oral bioavailability is 60-68%.
For use, in combination with other antiretroviral agents, in the treatment of HIV-1 infection.
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/rey1671.shtml
86% bound to human serum proteins (alpha-1-acid glycoprotein and albumin). Protein binding is independent of concentration.
ATZ
Elimination half-life in adults (healthy and HIV infected) is approximately 7 hours (following a 400 mg daily dose with a light meal). Elimination half-life in hepatically impaired is 12.1 hours (following a single 400 mg dose).
COC(=O)NC(C(=O)NC(CC1=CC=CC=C1)C(O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)C(NC(=O)OC)C(C)(C)C)C(C)(C)C
2003-07-01	/drugs/1072/fda_labels/1032
Latazanavir
atazanavir
Zrivada
Food increases product absorption.
http://dbpedia.org/page/Atazanavir
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FAtazanavir%3E
Atazanavir
C38H52N6O7
http://www.drugbank.ca/drugs/DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01072%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/1588
http://129.128.185.122/drugbank2/drugs/DB01072/inserts/2377/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB01072%2Finserts%2F2377%2Ffull%3E
http://data.linkedct.org/resource/intervention/1550
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F1550%3E
DB01072
AXRYRYVKAWYZBR-NASIUOTHDQ
Reyataz
COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C
http://data.linkedct.org/resource/intervention/33777
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F33777%3E
Atazanavir selectively inhibits the virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1 infected cells, thus preventing formation of mature virions.
BMS-232632
http://bio2rdf.org/kegg:D01276
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD01276%3E
methyl N-[(2S)-1-[[(2S,3S)-3-hydroxy-4-[[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-[(4-pyridin-2-ylphenyl)methyl]amino]-1-phenylbutan-2-yl]amino]-3,3-dimethyl-1-oxobutan-2-yl]carbamate
J05AE08
Atazanavir (ATV) is an azapeptide HIV-1 protease inhibitor (PI). It is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Atazanavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.
ATV
Atazanavir is extensively metabolized in humans, primarily by the liver. The major biotransformation pathways of atazanavir in humans consisted of monooxygenation and dioxygenation. Other minor biotransformation pathways for atazanavir or its metabolites consisted of glucuronidation, N-dealkylation, hydrolysis, and oxygenation with dehydrogenation. In vitro studies using human liver microsomes suggested that atazanavir is metabolized by CYP3A.
http://bio2rdf.org/cas:198904-31-3
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A198904-31-3%3E
aprd00804
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/251
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F251%3E
Administration with food reduces pharmacokinetic variability.
Atazanavir sulfate
2008-08-26 16:06:25 UTC
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1907
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1907%3E
http://data.linkedct.org/resource/intervention/27699
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F27699%3E
http://data.linkedct.org/resource/intervention/30750
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F30750%3E
08:18.08.08
http://en.wikipedia.org/wiki/Atazanavir
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FAtazanavir%3E
http://129.128.185.122/drugbank2/drugs/DB01072/inserts/1379/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB01072%2Finserts%2F1379%2Ffull%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/731
http://205.193.93.51/dpdonline/searchRequest.do?din=02248610
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02248610%3E
InChI=1/C38H52N6O7/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47)/t29-,30-,31+,32+/m0/s1/f/h40-43H
Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once-daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003. [Wikipedia]
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/hivProteaseInhibitors
PA10251
Free base slightly soluble (4-5 mg/mL)
http://www.rxlist.com/cgi/generic/reyataz.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric%2Freyataz.htm%3E
3.27e-03 mg/mL
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00203
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00908
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00281
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00300_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00736_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01118_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01129_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00696
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00338_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00343_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB01341
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00530
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00653
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00458
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00300
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB01418
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01211_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00682
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB01244
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01244_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB01151
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01242_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00227
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01142_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00585_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00980_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB01076
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00344
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01378_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00604_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00897_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00696_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00908_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00224
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB01375
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB01373
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00213_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB01294
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00321_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00736
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00540_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00927
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00864
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00343
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00353
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00238
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00604
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB01378
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00585
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00321
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01076_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00897
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01373_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00266
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00927_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00641
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00625
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00683_DB01072
RDF Description of Atazanavir
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00320_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00863
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00683
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB01142
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB01346
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB01129
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00615
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00320
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00615_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00213
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB01045
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00227_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00091_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00877
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01151_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01048_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00540
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01045_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00625_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00238_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB01390
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB01323
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00501
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00448_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00338
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00543_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB01370
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB01242
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB01377
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00448
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB01118
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00501_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00224_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00243
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB01100
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00091
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00530_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00543
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00762
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00863_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB01268
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB01125
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00243_DB01072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB00726
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01072_DB01211
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01100_DB01072
http://www4.wiwiss.fu-berlin.de/eurostat/data/countries/Norway
_:header4789023061335206474487
RDF Description of Norway
http://www4.wiwiss.fu-berlin.de/eurostat/resource/countries/Norway
http://www4.wiwiss.fu-berlin.de/eurostat/resource/eurostat/countries
no
http://estatwrap.ontologycentral.com/dic/geo#NO
http://www4.wiwiss.fu-berlin.de/eurostat/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Festatwrap.ontologycentral.com%2Fdic%2Fgeo%23NO%3E
Norway
http://ec.europa.eu/eurostat/ramon/rdfdata/countries/NO
http://www4.wiwiss.fu-berlin.de/eurostat/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fec.europa.eu%2Feurostat%2Framon%2Frdfdata%2Fcountries%2FNO%3E
http://dbpedia.org/resource/Norway
http://www4.wiwiss.fu-berlin.de/eurostat/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FNorway%3E
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Pessoa_Fernando_1888-1935
_:header7384073911335206474916
RDF Description of Pessoa, Fernando, 1888-1935
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Pessoa_Fernando_1888-1935
Pessoa, Fernando, 1888-1935
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19978
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Irving_Washington_1783-1859
_:header9909572051335206475328
Mon, 23 Apr 2012 18:34:30 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Irving_Washington_1783-1859
Irving, Washington, 1783-1859
Irving, Washington, 1783-1859 
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1371
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3293
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8571
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2043
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext20656
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext877
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1850
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext21195
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7994
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19293
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13042
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7993
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext10135
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2048
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8519
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7002
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext41
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13515
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13514
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext14228
RDF Description of Irving, Washington, 1783-1859
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7948
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1372
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB04825
_:header6050387831335206475784
RDF Description of Prenylamine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04825
http://bio2rdf.org/cas:390-64-7
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A390-64-7%3E
Carditin
2008-08-26 15:16:36 UTC
Corpax
36.5 oC
0.05 mg/mL at 37 oC [YALKOWSKY,SH & DANNENFELSER,RM (1992)]
IFFPICMESYHZPQ-UHFFFAOYAV
N-(1-Methyl-2-phenylethyl)-gamma-phenylbenzenepropanamine
DL-prenylamine
Hostaginan
InChI=1/C24H27N/c1-20(19-21-11-5-2-6-12-21)25-18-17-24(22-13-7-3-8-14-22)23-15-9-4-10-16-23/h2-16,20,24-25H,17-19H2,1H3
3,3-di(phenyl)-N-(1-phenylpropan-2-yl)propan-1-amine
N-(3,3-Diphenylpropyl)-alpha-methylphenethylamine
3.54e-05 mg/mL
Prenylamine
Bismethin
2007-09-11 20:28:54 UTC
DB04825
1-Phenyl-2-(1',1'-diphenylpropyl-3'-amino)propane
N-(1-Methyl-2-phenylethyl)-3,3-diphenyl-1-propanamine
Prenylaminum [inn-latin]
http://www.dbpedia.org/resource/Prenylamine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FPrenylamine%3E
Prenilamina [inn-spanish]
N-(3'-Phenyl-2-propyl)-1,1-diphenyl-3-propyloamine
Segontin
Prenylamine was withdrawn from the Canadian, US, and UK markets in 1988 due to concerns regarding cardiac arrhythmias.
C[C@@H](CC1=CC=CC=C1)NCCC(C1=CC=CC=C1)C1=CC=CC=C1
C24H27N
N-(3,3-Diphenylpropyl)-alpha-methylphenaethylamin [German]
Falliocor
Valecor
Synadrin
Elecor
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/adrenergicAgents
CC(CC1=CC=CC=C1)NCCC(C1=CC=CC=C1)C1=CC=CC=C1
http://www.drugbank.ca/drugs/DB04825
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB04825%3E
Corontin
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/937
_:header10248856781335206476709
Mon, 23 Apr 2012 18:34:31 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/937
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01254
http://bio2rdf.org/uniprot:P06239
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP06239%3E
Tyrosine kinase that plays an essential role for the selection and maturation of developing T-cell in the thymus and in mature T-cell function. Is constitutively associated with the cytoplasmic portions of the CD4 and CD8 surface receptors and plays a key role in T-cell antigen receptor(TCR)-linked signal transduction pathways. Association of the TCR with a peptide antigen-bound MHC complex facilitates the interaction of CD4 and CD8 with MHC class II and class I molecules, respectively, and thereby recruits the associated LCK to the vicinity of the TCR/CD3 complex. LCK then phosphorylates tyrosines residues within the immunoreceptor tyrosines-based activation motifs (ITAMs) in the cytoplasmic tails of the TCRgamma chains and CD3 subunits, initiating the TCR/CD3 signaling pathway. In addition, contributes to signaling by other receptor molecules. Associates directly with the cytoplasmic tail of CD2, and upon engagement of the CD2 molecule, LCK undergoes hyperphosphorylation and activation. Also plays a role in the IL2 receptor-linked signaling pathway that controls T-cell proliferative response. Binding of IL2 to its receptor results in increased activity of LCK. Is expressed at all stages of thymocyte development and is required for the regulation of maturation events that are governed by both pre-TCR and mature alpha beta TCR
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2558056
http://pfam.sanger.ac.uk/family?acc=PF00018
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00018%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=X05027
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DX05027%3E
http://bio2rdf.org/hgnc:6524
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A6524%3E
http://pfam.sanger.ac.uk/family?acc=PF07714
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF07714%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7512222
>1524 bp	ATGGGCTGTGGCTGCAGCTCACACCCGGAAGATGACTGGATGGAAAACATCGATGTGTGT	GAGAACTGCCATTATCCCATAGTCCCACTGGATGGCAAGGGCACGCTGCTCATCCGAAAT	GGCTCTGAGGTGCGGGACCCACTGGTTACCTACGAAGGCTCCAATCCGCCGGCTTCCCCA	CTGCAAGACAACCTGGTTATCGCTCTGCACAGCTATGAGCCCTCTCACGACGGAGATCTG	GGCTTTGAGAAGGGGGAACAGCTCCGCATCCTGGAGCAGAGCGGCGAGTGGTGGAAGGCG	CAGTCCCTGACCACGGGCCAGGAAGGCTTCATCCCCTTCAATTTTGTGGCCAAAGCGAAC	AGCCTGGAGCCCGAACCCTGGTTCTTCAAGAACCTGAGCCGCAAGGACGCGGAGCGGCAG	CTCCTGGCGCCCGGGAACACTCACGGCTCCTTCCTCATCCGGGAGAGCGAGAGCACCGCG	GGATCGTTTTCACTGTCGGTCCGGGACTTCGACCAGAACCAGGGAGAGGTGGTGAAACAT	TACAAGATCCGTAATCTGGACAACGGTGGCTTCTACATCTCCCCTCGAATCACTTTTCCC	GGCCTGCATGAACTGGCCTCCGCCATTACACCAATCGCTTCAGATGGGCTGTGCACACGG	TTGAGCCGCCCCTGCCAGACCCAGAAGCCCCAGAAGCCGTGGTGGGAGGACGAGTGGGAG	GTTCCCAGGGAGACGCTGAAGCTGGTGGAGCGGCTGGGGGCTGGACAGTTCGGGAGGTGT	GGATGGGGTACTACAACGGGCACAACGAAGGTGGCGGTGAAGAGCCTGAAGCAGGGCAGC	ATGTCCGCCGGACGCCTTCCTGCCGAGGCCAACCTCATGAAGCAGCTGCAACACCAGCGG	CTGGTTCGGCTCTACGCTGTGGTCACCCAGGAGCCCATCTACATCATCACTGAATACATG	GAGAATGGGAGTCTAGTGGATTTTCTCAAGACCCCTTCAGGCATCAAGTTGACCATCAAC	AAACTCCTGGACATGGCAGCCCAAATTGCAGAAGGCATGGCATTCATTGAAGAGCGGAAT	TATATTCATCGTGACCTTCGGGCTGCCAACATTCTGGTGTCTGACACCCTGAGCTGCAAG	ATTGCAGACTTTGGCCTAGCACGCCTCATTGAGGACAACGAGTACACAGCCAGGGAGGGG	GCCAAGTTTCCCATTAAGTGGACAGCGCCAGAAGCCATTAACTACGGGACATTCACCATC	AAGTCAGATGTGTGGTCTTTTGGGATCCTGCTGACGGAAATTGTCACCCACGGCCGCATC	CCTTACCCAGGGATGACCAACCCGGAGGTGATTCAGAACCTGGAGCGAGGCTACCGCATG	GTGCGCCCTGACAACTGTCCAGAGGAGCTGTACCAACTCATGAGGCTGTGCTGGAAGGAG	CGCCCAGAGGACCGGCCCACCTTTGACTACCTGCGCAGTGTGCTGGAGGACTTCTTCACG	GCCACAGAGGGCAGTACAGCCTAG
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3489486
LCK
http://bio2rdf.org/pfam:PF00017
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00017%3E
LSK
http://www.genenames.org/data/hgnc_data.php?hgnc_id=6524
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D6524%3E
Proto-oncogene tyrosine-protein kinase LCK
1p34.3
T cell- specific protein-tyrosine kinase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11840567
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7504174
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2835736
cytoplasm.CellMembrane
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3493153
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2850479
EC 2.7.10.2
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3265417
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8604142
http://www.uniprot.org/uniprot/P06239
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP06239%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11009097
ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate
http://bio2rdf.org/pfam:PF00018
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00018%3E
http://symbol.bio2rdf.org/symbol:LCK
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ALCK%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2787474
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=36808
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D36808%3E
protein-tyrosine kinase activity
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8945479
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7495859
p56-LCK
http://pfam.sanger.ac.uk/family?acc=PF00017
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00017%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17154512
Lymphocyte cell-specific protein-tyrosine kinase
http://bio2rdf.org/pfam:PF07714
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF07714%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1639064
LCK_HUMAN
Involved in protein kinase activity
>Proto-oncogene tyrosine-protein kinase LCK	GCGCSSHPEDDWMENIDVCENCHYPIVPLDGKGTLLIRNGSEVRDPLVTYEGSNPPASPL	QDNLVIALHSYEPSHDGDLGFEKGEQLRILEQSGEWWKAQSLTTGQEGFIPFNFVAKANS	LEPEPWFFKNLSRKDAERQLLAPGNTHGSFLIRESESTAGSFSLSVRDFDQNQGEVVKHY	KIRNLDNGGFYISPRITFPGLHELVRHYTNASDGLCTRLSRPCQTQKPQKPWWEDEWEVP	RETLKLVERLGAGQFGEVWMGYYNGHTKVAVKSLKQGSMSPDAFLAEANLMKQLQHQRLV	RLYAVVTQEPIYIITEYMENGSLVDFLKTPSGIKLTINKLLDMAAQIAEGMAFIEERNYI	HRDLRAANILVSDTLSCKIADFGLARLIEDNEYTAREGAKFPIKWTAPEAINYGTFTIKS	DVWSFGILLTEIVTHGRIPYPGMTNPEVIQNLERGYRMVRPDNCPEELYQLMRLCWKERP	EDRPTFDYLRSVLEDFFTATEGQYQPQP
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7852312
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8139546
X05027
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9685372
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7532720
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8794306
cytoplasmicSide.PresentInLipidRaftsInAnUnactiveForm
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01830
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04003
RDF Description of Proto-oncogene tyrosine-protein kinase LCK
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04395
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02010
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03023
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/1108
_:header1614668141335206476960
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1108
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3998
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/ABCA3
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/SFTPC
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseaseClass/Respiratory
Surfactant deficiency
RDF Description of Surfactant deficiency
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3999
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Dutt_Toru_1856-1877
_:header5106126761335206477382
Mon, 23 Apr 2012 18:34:32 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Dutt_Toru_1856-1877
Dutt, Toru, 1856-1877
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13268
RDF Description of Dutt, Toru, 1856-1877
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/589
_:header14868449861335206477758
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/589
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2756
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/CLCN5
Hypophosphatemia
http://data.linkedct.org/resource/condition/6311
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fcondition%2F6311%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PHEX
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0085682
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fsider%2Fresource%2Fside_effects%2FC0085682%3E
RDF Description of Hypophosphatemia
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2755
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/4052
_:header11990216101335206478296
Mon, 23 Apr 2012 18:34:33 GMT
RDF Description of Sphingomyelin phosphodiesterase 4
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4052
http://www.uniprot.org/uniprot/Q9NXE4
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ9NXE4%3E
2q21.1
sphingomyelin + H2O = N-acylsphingosine + choline phosphate
Neutral sphingomyelinase III
http://symbol.bio2rdf.org/symbol:SMPD4
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ASMPD4%3E
nSMase- 3
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10718198
EC 3.1.4.12
Sphingomyelin phosphodiesterase 4
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/16517606
NSMA3_HUMAN
SMPD4
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11230166
>2397 bp	ATGGCGTTCCCTCACCTGCAGCAGCCCAGCTTTCTACTGGCTAGCCTGAAAGCTGACTCT	ATAAATAAGCCCTTTGCACAGCAGTGCCAAGACTTGGTTAAAGTCATTGAGGACTTTCCA	GCAAAGGAGCTGCACACCATCTTCCCATGGCTGGTAGAAAGCATTTTTGGCAGCCTAGAT	GGTGTCCTCGTTGGCTGGAACCTCCGCTGCTTACAGGGGCGCGTGAATCCTGTGGAGTAC	AGCATCGTGATGGAATTTCTCGACCCTGGTGGCCCAATGATGAAGTTGGTTTATAAGCTT	CAAGCTGAAGACTATAAGTTCGACTTTCCTGTCTCCTACTTGCCTGGTCCTGTGAAGGCG	TCCATCCAGGAGTGCATCCTCCCTGACAGTCCTCTGTACCACAACAAGGTCCAGTTCACC	CCTACTGGGGGCCTTGGTCTGAACTTGGCCCTGAATCCGTTCGAGTATTACATATTCTTC	TTTGCCTTGAGCCTCATCACTCAGAAGCCACTTCCTGTGTCCCTCCACGTCCGTACTTCA	GACTGTGCCTATTTCATCCTGGTGGACAGGTACCTGTCATGGTTCCTGCCCACCGAAGGC	AGTGTGCCCCCACCACTCTCCTCCAGCCCAGGGGGGACCAGCCCCTCACCACCTCCCAGG	ACACCAGCCATACCCTTTGCTTCCTATGGCCTCCACCACACTAGCCTCCTAAAGCGACAC	ATCTCTCATCAGACGTCTGTGAATGCAGACCCCGCCTCCCACGAGATCTGGAGGTCAGAA	ACTCTGCTCCAGGTTTTTGTTGAAATGTGGCTTCATCACTATTCCTTGGAGATGTATCAA	AAAATGCAGTCCCCTCATGCCAAGGAGTCGTTCACGCCTACTGAGGAGCATGTGTTGGTG	GTGCGCCTGCTGCTGAAGCACCTGCACGCCTTTGCCAACAGCCTGAAGCCAGAGCAGGCC	TCACCCTCCGCCCACTCCCACGCCACCAGCCCCCTGGAGGAGTTCAAACGGGCTGCTGTC	CCGAGGTTCGTCCAGCAGAAACTCTACCTCTTCTTGCAGCATTGCTTTGGCCACTGGCCC	CTGGACGCATCGTTCAGAGCTGTCCTGGAGATGTGGCTGAGCTACCTGCAGCCGTGGCGG	TACGCGCCTGACAAGCAGGCTCCGGGCAGCGACTCCCAGCCCCGGTGTGTGTCGGAGAAA	TGGGCACCCTTTGTCCAGGAGAACCTGCTGATGTACACCAAGTTGTTTGTGGGCTTTCTG	AACCGCGCGCTCCGCACAGACCTGGTCAGCCCCAAGCACGCGCTCATGGTGTTCCGAGTG	GCCAAAGTCTTTGCCCAGCCCAACCTGGCTGAGATGATTCAGAAAGGTGAGCAGCTATTC	CTGGAGCCAGAGCTGGTCATCCCCCACCGCCAGCACCGACTCTTCACGGCCCCCACATTC	ACTGGGAGCTTCCTGTCACCCTGGCCACCAGCGGTCACTGATGCCTCCTTCAAGGTGAAG	AGCCACGTCTACAGCCTGGAGGGCCAGGACTGCAAGTACACCCCGATGTTTGGGCCCGAG	GCCCGCACCCTGGTCCTGCGCCTCGCTCAGCTCATCACACAGGCCAAACACACAGCCAAG	TCCATCTCCGACCAGTGTGCGGAGAGCCCGGCTGGCCACTCCTTCCTCTCATGGCTGGGC	TTTAGCTCCATGGACACCAATGGCTCCTACACAGCCAACGACCTGGACGAGATGGGGCAA	GACAGTGTCCGGAAGACAGATGAATACCTGGAGAAGGCCCTGGAGTACCTGCGCCAGATA	TTCCGGCTCAGCGAAGCGCAGCTCAGGCAGTTCACACTCGCCTTGGGCACCACCCAGGAT	GAGAATGGAAAAAAGCAACTCCCCGACTGCATCGTGGGTGAGGACGGACTCATCCTTACG	CCCCTGGGGCGGTACCAGATCATCAATGGGCTGCGAAGGTTTGAAATTGAGTACCAGGGG	GACCCGGAGCTGCAGCCCATCCGGAGCTATGAGATCGCCAGCTTGGTCCGCACACTCTTT	AGGCTGTCGTCTGCCATCAACCACAGATTTGCAGGACAGATGGCGGCTCTGTGTTCCCGG	GATGACTTCCTCGGCAGCTTCTGTCGCTACCACCTCACAGAACCTGGGCTGGCCAGCAGG	CACCTGCTGAGCCCTGTGGGGCGGAGGCAGGTGGCCGGCCACACCCGCGGCCCCAGGCTC	AGCCTGCGCTTCCTGGGCAGTTACCGGACGCTGGTCTCGCTGCTGCTGGCCTTCTTCGTG	GCCTCTCTGTTCTGCGTCGGGCCCCTCCCATGCACGCTGCTGCTCACCCTGGGCTATGTC	CTCTACGCCTCTGCCATGACACTGCTGACCGAGCGGGGGAAGCTGCACCAGCCCTGA
AB037839
783-803
http://bio2rdf.org/hgnc:32949
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A32949%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=7243217
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D7243217%3E
map00600	Sphingolipid metabolism
nSMase3
>Sphingomyelin phosphodiesterase 4	MAFPHLQQPSFLLASLKADSINKPFAQQCQDLVKVIEDFPAKELHTIFPWLVESIFGSLD	GVLVGWNLRCLQGRVNPVEYSIVMEFLDPGGPMMKLVYKLQAEDYKFDFPVSYLPGPVKA	SIQECILPDSPLYHNKVQFTPTGGLGLNLALNPFEYYIFFFALSLITQKPLPVSLHVRTS	DCAYFILVDRYLSWFLPTEGSVPPPLSSSPGGTSPSPPPRTPAIPFASYGLHHTSLLKRH	ISHQTSVNADPASHEIWRSETLLQVFVEMWLHHYSLEMYQKMQSPHAKLEVLHYRLSVSS	ALYSPAQPSLQALHAYQESFTPTEEHVLVVRLLLKHLHAFANSLKPEQASPSAHSHATSP	LEEFKRAAVPRFVQQKLYLFLQHCFGHWPLDASFRAVLEMWLSYLQPWRYAPDKQAPGSD	SQPRCVSEKWAPFVQENLLMYTKLFVGFLNRALRTDLVSPKHALMVFRVAKVFAQPNLAE	MIQKGEQLFLEPELVIPHRQHRLFTAPTFTGSFLSPWPPAVTDASFKVKSHVYSLEGQDC	KYTPMFGPEARTLVLRLAQLITQAKHTAKSISDQCAESPAGHSFLSWLGFSSMDTNGSYT	ANDLDEMGQDSVRKTDEYLEKALEYLRQIFRLSEAQLRQFTLALGTTQDENGKKQLPDCI	VGEDGLILTPLGRYQIINGLRRFEIEYQGDPELQPIRSYEIASLVRTLFRLSSAINHRFA	GQMAALCSRDDFLGSFCRYHLTEPGLASRHLLSPVGRRQVAGHTRGPRLSLRFLGSYRTL	VSLLLAFFVASLFCVGPLPCTLLLTLGYVLYASAMTLLTERGKLHQP
Catalyzes the hydrolysis of membrane sphingomyelin to form phosphorylcholine and ceramide
http://www.genenames.org/data/hgnc_data.php?hgnc_id=32949
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D32949%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AB037839
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAB037839%3E
Neutral sphingomyelinase 3
http://bio2rdf.org/uniprot:Q9NXE4
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ9NXE4%3E
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Tarkington_Booth_1869-1946
_:header20264969271335206478676
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Tarkington_Booth_1869-1946
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6401
Tarkington, Booth, 1869-1946
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext15855
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6554
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8740
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8867
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13275
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1611
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5756
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1983
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3428
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6552
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext980
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5949
RDF Description of Tarkington, Booth, 1869-1946
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1158
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5798
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2595
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext483
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext402
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1098
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext18259
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2326
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9659
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6547
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext297
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C1510472
_:header21152495051335206479198
Mon, 23 Apr 2012 18:34:34 GMT
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C1510472
http://sideeffects.embl.de/se/C1510472
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC1510472%3E
drug dependence
C1510472
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4736
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/7029
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4095
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2441
RDF Description of drug dependence
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Davis_Jefferson_1808-1889
_:header20122715121335206479544
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Davis_Jefferson_1808-1889
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19831
Davis, Jefferson, 1808-1889
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5205
RDF Description of Davis, Jefferson, 1808-1889
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/4110
_:header18960077891335206480074
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4110
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00661
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting
http://bio2rdf.org/uniprot:Q08289
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ08289%3E
http://symbol.bio2rdf.org/symbol:CACNB2
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ACACNB2%3E
CAB2
voltage-gated calcium channel activity
di-, tri-valent inorganic cation transport
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=S60415
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DS60415%3E
CACNB2
>Voltage-dependent L-type calcium channel subunit beta-2	MVQRDMSKSPPTAAAAVAQEIQMELLENVAPAGALGAAAQSYGKGARRKNRFKGSDGSTS	SDTTSNSFVRQGSADSYTSRPSDSDVSLEEDREAVRREAERQAQAQLEKAKTKPVAFAVR	TNVSYSAAHEDDVPVPGMAISFEAKDFLHVKEKFNNDWWIGRLVKEGCEIGFIPSPVKLE	NMRLQHEQRAKQGKFYSSKSGGNSSSSLGDIVPSSRKSTPPSSAIDIDATGLDAEENDIP	ANHRSPKPSANSVTSPHSKEKRMPFFKKTEHTPPYDVVPSMRPVVLVGPSLKGYEVTDMM	QKALFDFLKHRFEGRISITRVTADISLAKRSVLNNPSKHAIIERSNTRSSLAEVQSEIER	IFELARTLQLVVLDADTINHPAQLSKTSLAPIIVYVKISSPKVLQRLIKSRGKSQAKHLN	VQMVAADKLAQCPPELFDVILDENQLEDACEHLADYLEAYWKATHPPSSSLPNPLLSRTL	ATSSLPLSPTLASNSQGSQGDQRTDRSAPIRSASQAEEEPSVEPVKKSQHRSSSSAPHHN	HRSGTSRGLSRQETFDSETQESRDSAYVEPKEDYSHDHVDHYASHRDHNHRDETHGSSDH	RHRESRHRSRDVDREQDHNECNKQRSRHKSKDRYCEKDGEVISKKRNEAGEWNRDVYIRQ
>1983 bp	ATGGTCCAAAGGGACATGTCCAAGTCGCCTCCCACAGCGGCGGCGGCGGTGGCGCAGGAG	ATCCAGATGGAACTGCTAGAGAACGTGGCTCCCGCGGGGGCGCTCGGAGCCGCCGCACAG	TCATATGGAAAAGGAGCCAGAAGGAAAAACAGATTTAAAGGATCTGATGGAAGCACGTCA	TCTGATACTACCTCAAATAGTTTTCTTCGCCAGGGTTCGGCAGACTCCTACACTAGCCGT	CCATCCGATTCCGATGTATCTCTGGAGGAGGACCGGGAGGCAGTGCGCAGAGAAGCGCAG	CAGGCCCAGGCACAGTTGGAAAAAGCAAAGACAAAGCCCGTTGCATTTGCGGTTCGGACA	GATGTCAGCTACAGTGCGGCCCATGAAGATGATGTTCCAGTGCCTGGCATGGCCATCTCA	TTCGAAGCAAAAGATTTTCTGCATGTTAAGGAAAAATTTAACAATGACTGGTGGATAGGG	CGATTGGTAAAAGAAGGCTGTGAAATCGGATTCATTCCAAGCCCAGTCAAACTAGAAAAC	ATGAGGCTGCAGCATGAACAGAGAGCCAAGCAAGGGAAATTCTACTCCAGTAAATCAGGA	GGAAATTCATCATCCAGTTTGGGTGACATAGTACCTAGTTCCAGAAAATCAACACCTCCA	TCATCTGCTATAGACATAGATGCTACTGGCTTAGATGCAGAAGAAAATGATATTCCAGCA	AACCACCGCTCCCCTAAACCCAGTGCAAACAGTGTAACGTCACCCCACTCCAAAGAGAAA	AGAATGCCCTTCTTTAAGAAGACAGAGCACACTCCTCCGTATGATGTGGTACCTTCCATG	CGACCAGTGGTCCTAGTGGGCCCTTCTCTGAAGGGCTACGAGGTCACAGATATGATGCAA	AAAGCGCTGTTTGATTTTTTAAAACACAGATTTGAAGGGCGGATATCCATCACAAGGGTC	ACCGCTGACATCTCGCTTGCCAAACGCTCGGTATTAAACAATCCCAGTAAGCACGCAATA	ATAGAAAGATCCAACACAAGGTCAAGCTTAGCGGAAGTTCAGAGTGAAATCGAAAGGATT	TTTGAAGTTGCAAGAACATTGCAGTTGGTGGTCCTTGACGCGGATACAATTAATCATCCA	GCTCAACTCAGTAAAACCTCCTTGGCCCCTATTATAGTATATGTAAAGATTTCTTCTCCT	AAGGTTTTACAAACCTTAATAAAATCTCGAGGGAAATCTCAAGCTAAACACCTCAACGTC	CAGATGGTAGCAGCTGATAAACTGGCTCAGTGTCCTCCAGAGCTGTTCGATGTGATCTTG	GATGAGAACCAGCTTGAGGATGCCTGTGAGCACCTTGCCGACTATCTGGAGGCCTACTGG	AAGGCCACCCATCCTCCCAGCAGTAGCCTCCCCAACCCTCTCCTTAGCCGTACATTAGCC	ACTTCAAGTCTGCCTCTTAGCCCCACCCTAGCCTCTAATTCACAGGGTTCTCAAGGTCAT	CAGAGGACTGATCGCTCCGCTCCTATCCGTTCTGCTTCCCAAGCTGAAGAAGAACCTAGT	GTGGAAGGAGTCAAGAAATCCCAGCACCGCTCTTCCTCCTCAGCCCCACACCACAACCAT	CGCAGTGGGACAAGTCGCGGCCTCTCCAGGCAAGAGACATTTGACTCGGAAACCCAGGAG	AGTCGAGACTCTGCCTACGTAGAGCCAAAGGAAGATTATTCCCATGACCACGTGGACCAC	TATGCCTCACACCGTGACCACAACCACAGAGACGAGACCCACGGGAGCAGTGACCACAGA	CACAGGGAGTCCCGGCACCGTTCCCGGGACGTGGATCGAGAGCAGGACCACAACGAGTGC	AACAAGCAGCAGCGCAGCCGTCATAAATCCAAGGATCGCTACTGTGAAAAGGATGGAGAA	GTGATATCAAAAAAACGGAATGAGGCTGGGGAGTGGAACAGGGATGTTTACATCCGCCAA	TGA
http://bio2rdf.org/pfam:PF00774
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00774%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=300417
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D300417%3E
Lambert-Eaton myasthenic syndrome antigen B
CACB2_HUMAN
calcium ion transport
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9254841
MYSB
Voltage-dependent L-type calcium channel subunit beta-2
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8494331
Calcium channel voltage-dependent subunit beta 2
http://pfam.sanger.ac.uk/family?acc=PF00774
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00774%3E
http://bio2rdf.org/hgnc:1402
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A1402%3E
S60415
http://www.uniprot.org/uniprot/Q08289
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ08289%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=1402
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D1402%3E
RDF Description of Voltage-dependent L-type calcium channel subunit beta-2
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00653
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/2180
_:header16723477681335206480482
Mon, 23 Apr 2012 18:34:35 GMT
RDF Description of 3-phosphoinositide-dependent protein kinase 1
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2180
>3-phosphoinositide-dependent protein kinase 1	MARTTSQLYDAVPIQSSVVLCSCPSPSMVRTQTESSTPPGIPGGSRQGPAMDGTAAEPRP	GAGSLQHAQPPPQPRKKRPEDFKFGKILGEGSFSTVVLARELATSREYAIKILEKRHIIK	ENKVPYVTRERDVMSRLDHPFFVKLYFTFQDDEKLYFGLSYAKNGELLKYIRKIGSFDET	CTRFYTAEIVSALEYLHGKGIIHRDLKPENILLNEDMHIQITDFGTAKVLSPESKQARAN	SFVGTAQYVSPELLTEKSACKSSDLWALGCIIYQLVAGLPPFRAGNEYLIFQKIIKLEYD	FPEKFFPKARDLVEKLLVLDATKRLGCEEMEGYGPLKAHPFFESVTWENLHQQTPPKLTA	YLPAMSEDDEDCYGNYDNLLSQFGCMQVSSSSSSHSLSASDTGLPQRSGSNIEQYIHDLD	SNSFELDLQFSEDEKRLLLEKQAGGNPWHQFVENNLILKMGPVDKRKGLFARRRQLLLTE	GPHLYYVDPVNKVLKGEIPWSQELRPEAKNFKTFFVHTPNRTYYLMDPSGNAHKWCRKIQ	EVWRQRYQSHPDAAVQ
PDPK1
http://bio2rdf.org/uniprot:O15530
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AO15530%3E
3-phosphoinositide-dependent protein kinase 1
http://www.uniprot.org/uniprot/O15530
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FO15530%3E
http://www.pdb.org/pdb/explore/explore.do?structureId=2BIY
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D2BIY%3E
http://symbol.bio2rdf.org/symbol:PDPK1
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3APDPK1%3E
EC 2.7.11.1
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10364160
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9094314
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/16887935
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/16455452
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11481331
http://bio2rdf.org/hgnc:8816
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A8816%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AF017995
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAF017995%3E
Phosphorylates and activates not only PKB/AKT, but also PKA, PKC-zeta, RPS6KA1 and RPS6KB1. May play a general role in signaling processes and in development. Isoform 3 is catalytically inactive
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9637919
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/15205346
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/14973075
http://bio2rdf.org/pdb:2BIY
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A2BIY%3E
peripheralMembraneProtein.Note=membrane-associatedAfterCellStimulationLe
AF017995
>1671 bp	ATGGCCAGGACCACCAGCCAGCTGTATGACGCCGTGCCCATCCAGTCCAGCGTGGTGTTA	TGTTCCTGCCCATCCCCATCAATGGTGAGGACCCAGACTGAGTCCAGCACGCCCCCTGGC	ATTCCTGGTGGCAGCAGGCAGGGCCCCGCCATGGACGGCACTGCAGCCGAGCCTCGGCCC	GGCGCCGGCTCCCTGCAGCATGCCCAGCCTCCGCCGCAGCCTCGGAAGAAGCGGCCTGAG	GACTTCAAGTTTGGGAAAATCCTTGGGGAAGGCTCTTTTTCCACGGTTGTCCTGGCTCGA	GAACTGGCAACCTCCAGAGAATATGCGATTAAAATTCTGGAGAAGCGACATATCATAAAA	GAGAACAAGGTCCCCTATGTAACCAGAGAGCGGGATGTCATGTCGCGCCTGGATCACCCC	TTCTTTGTTAAGCTTTACTTCACATTTCAGGACGACGAGAAGCTGTATTTCGGCCTTAGT	TATGCCAAAAATGGAGAACTACTTAAATATATTCGCAAAATCGGTTCATTCGATGAGACC	TGTACCCGATTTTACACGGCTGAGATCGTGTCTGCTTTAGAGTACTTGCACGGCAAGGGC	ATCATTCACAGGGACCTTAAACCGGAAAACATTTTGTTAAATGAAGATATGCACATCCAG	ATCACAGATTTTGGAACAGCAAAAGTCTTATCCCCAGAGAGCAAACAAGCCAGGGCCAAC	TCATTCGTGGGAACAGCGCAGTACGTTTCTCCAGAGCTGCTCACGGAGAAGTCCGCCTGT	AAGAGTTCAGACCTTTGGGCTCTTGGATGCATAATATACCAGCTTGTGGCAGGACTCCCA	CCATTCCGAGCTGGAAACGAGTATCTTATATTTCAGAAGATCATTAAGTTGGAATATGAC	TTTCCAGAAAAATTCTTCCCTAAGGCAAGAGACCTCGTGGAGAAACTTTTGGTTTTAGAT	GCCACAAAGCGGTTAGGCTGTGAGGAAATGGAAGGATACGGACCTCTTAAAGCACACCCG	TTCTTCGAGTCCGTCACGTGGGAGAACCTGCACCAGCAGACGCCTCCGAAGCTCACCGCT	TACCTGCCGGCTATGTCGGAAGACGACGAGGACTGCTATGGCAATTATGACAATCTCCTG	AGCCAGTTTGGCTGCATGCAGGTGTCTTCGTCCTCCTCCTCACACTCCCTGTCAGCCTCC	GACACGGGCCTGCCCCAGAGGTCAGGCAGCAACATAGAGCAGTACATTCACGATCTGGAC	TCGAACTCCTTTGAACTGGACTTACAGTTTTCCGAAGATGAGAAGAGGTTGTTGTTGGAG	AAGCAGGCTGGCGGAAACCCTTGGCACCAGTTTGTAGAAAATAATTTAATACTAAAGATG	GGCCCAGTGGATAAGCGGAAGGGTTTATTTGCAAGACGACGACAGCTGTTGCTCACAGAA	GGACCACATTTATATTATGTGGATCCTGTCAACAAAGTTCTGAAAGGTGAAATTCCTTGG	TCACAAGAACTTCGACCAGAGGCCAAGAATTTTAAAACTTTCTTTGTCCACACGCCTAAC	AGGACGTATTATCTGATGGACCCCAGCGGGAACGCACACAAGTGGTGCAGGAAGATCCAG	GAGGTTTGGAGGCAGCGATACCAGAGCCACCCGGACGCCGCTGTGCAGTGA
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=2407613
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D2407613%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9445477
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10455013
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/16060857
PDPK1_HUMAN
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9368760
http://www.genenames.org/data/hgnc_data.php?hgnc_id=8816
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D8816%3E
hPDK1
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04522
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03265
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01946
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01933
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Maturin_Charles_Robert_1782-1824
_:header11172337081335206480951
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Maturin_Charles_Robert_1782-1824
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1831
Maturin, Charles Robert, 1782-1824 
RDF Description of Maturin, Charles Robert, 1782-1824 
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/3958
_:header8723064861335206481447
Mon, 23 Apr 2012 18:34:36 GMT
RDF Description of LORAZEPAM
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0037315
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3209
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3209%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/128
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F128%3E
Ativan
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0002884
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1455
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F1455%3E
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=VqSnnEMeJPs=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DVqSnnEMeJPs%3D%3E
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000003958&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000003958%26input_query_species%3D9606%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0233795
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0017086
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=QIuSHN1Q8AE=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DQIuSHN1Q8AE%3D%3E
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=otHi%2FU9J3fk=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DotHi%252FU9J3fk%3D%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1071
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F1071%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0151849
LORAZEPAM
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2804
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2804%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/838
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F838%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/497
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F497%3E
http://www.fda.gov/medwatch/SAFETY/2007/Apr_PI/Ativan_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2007%2FApr_PI%2FAtivan_PI.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0001122
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2931
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2931%3E
http://dbpedia.org/resource/Lorazepam
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FLorazepam%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0162297
http://sideeffects.embl.de/drugs/3958
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F3958%3E
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000003958
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000003958%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2972
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2972%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/658
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F658%3E
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=bQkaM1coYHE=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DbQkaM1coYHE%3D%3E
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=ME9niixBdYY=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DME9niixBdYY%3D%3E
CID0000003958
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C1279420
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0038220
http://www.fda.gov/cder/foi/anda/98/74496_Lorazepam_Prntlbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Fanda%2F98%2F74496_Lorazepam_Prntlbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2665
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2665%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020672
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0021141
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2473
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2473%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0086132
http://www.fda.gov/cder/foi/label/2006/018140s028lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2006%2F018140s028lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020542
http://www.fda.gov/cder/foi/anda/2000/74-793_Lorazepam_prntlbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Fanda%2F2000%2F74-793_Lorazepam_prntlbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2016
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2016%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/999
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F999%3E
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=u5NwiRT+dDw=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3Du5NwiRT%2BdDw%3D%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1164
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F1164%3E
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=xe4mExqGPAc=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3Dxe4mExqGPAc%3D%3E
http://www.fda.gov/cder/foi/label/1998/96989s35s36lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F1998%2F96989s35s36lbl.pdf%3E
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=S5dqAXyQvlM=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DS5dqAXyQvlM%3D%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0917799
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0233796
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/4264
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F4264%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0031511
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00186
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00186%3E
http://www.fda.gov/cder/foi/label/2007/017794s034s035lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2007%2F017794s034s035lbl.pdf%3E
lorazepam
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1468
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F1468%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0522224
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=6MeCfgLrEC8=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3D6MeCfgLrEC8%3D%3E
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01600
_:header11800928931335206481840
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01600
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00091_DB01600
Novo-Tiaprofenic
Apo-Tiaprofenic Tablets
http://dbpedia.org/page/Tiaprofenic_acid
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FTiaprofenic_acid%3E
DB01600
Tiaprofenic acid is a non-steroidal anti-inflammatory drug of the arylpropionic acid (profen) class, used to treat pain, especially arthritic pain.
PMS-tiaprofenic
2007-08-29 18:44:06 UTC
http://bio2rdf.org/cas:33005-95-7
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A33005-95-7%3E
Nu-Tiaprofenic
InChI=1/C14H12O3S/c1-9(14(16)17)11-7-8-12(18-11)13(15)10-5-3-2-4-6-10/h2-9H,1H3,(H,16,17)/f/h16H
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/capsuleExtendedReleaseOral
2-(5-Benzyl-2-thienyl)propionsaeure
Hepatic (10%). Sparingly metabolised in the liver to two inactive metabolites.
Tiaprofenic acid
Acide tiaprofenique [inn-french]
2-[5-(benzoyl)thiophen-2-yl]propanoic acid
Surgam
Acidum tiaprofenicum [inn-latin]
Dom-tiaprofenic
Acido tiaprofenico [inn-spanish]
http://www.drugbank.ca/drugs/DB01600
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01600%3E
PA10212
C14H12O3S
Surgam SR
5-Benzoyl-alpha-methyl-2-thiopheneacetic acid
2008-08-26 14:54:04 UTC
Tiaprofenic-200 - Tab
96 oC
Bioavailability is 90% following oral administration.
http://www.dbpedia.org/resource/Tiaprofenic_acid
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FTiaprofenic_acid%3E
Tiaprofensaeure
GUHPRPJDBZHYCJ-WYUMXYHSCF
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/290
Tiaprofenic acid is a non-steroidal anti-inflammatory drug of the arylpropionic acid (profen) class, used to treat pain, especially arthritic pain. The typical adult dose is 300mg twice daily. It is not recommended in children.
3.24e-02 mg/mL
Tiaprofenic-300 - Tab
CC(C(O)=O)C1=CC=C(S1)C(=O)C1=CC=CC=C1
1.5-2.5 hours
http://en.wikipedia.org/wiki/Tiaprofenic_acid
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FTiaprofenic_acid%3E
http://205.193.93.51/dpdonline/searchRequest.do?din=02136112
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02136112%3E
C[C@H](C(O)=O)C1=CC=C(S1)C(=O)C1=CC=CC=C1
Tiaprofenic acid belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). It works by blocking the production of a chemical (prostaglandin) which the body produces in response to injury or certain diseases. This prostaglandin would otherwise go on to cause swelling, pain and inflammation.
Used to treat pain, especially arthritic pain.
http://dbpedia.org/resource/Tiaprofenic_acid
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FTiaprofenic_acid%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/anti-inflammatoryAgents,Non-steroidal
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00563_DB01600
RDF Description of Tiaprofenic acid
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0038506
_:header21462208411335206482354
Mon, 23 Apr 2012 18:34:37 GMT
RDF Description of stuttering
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0038506
http://sideeffects.embl.de/se/C0038506
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0038506%3E
stuttering
C0038506
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Martorell_Joanot_1415-1480
_:header14838267351335206482702
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Martorell_Joanot_1415-1480
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext378
Martorell, Joanot, 1415-1480
RDF Description of Martorell, Joanot, 1415-1480
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C1621958
_:header7928592211335206483169
Mon, 23 Apr 2012 18:34:38 GMT
RDF Description of glioblastoma multiforme
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C1621958
http://sideeffects.embl.de/se/C1621958
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC1621958%3E
glioblastoma multiforme
C1621958
http://www4.wiwiss.fu-berlin.de/factbook/data/Zimbabwe
_:header15026480161335206483565
https://www.cia.gov/library/publications/the-world-factbook/flags/zi-flag.gif
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Flibrary%2Fpublications%2Fthe-world-factbook%2Fflags%2Fzi-flag.gif%3E
http://www4.wiwiss.fu-berlin.de/factbook/resource/Zimbabwe
http://www4.wiwiss.fu-berlin.de/factbook/resource/South_Africa
3.08 children born/woman
AM 7, FM 20 (plus 17 repeater stations), shortwave 1
parliamentary democracy
system was once one of the best in Africa, but now suffers from poor maintenance; more than 100000 outstanding requests for connection despite an equally large number of installed but unused main lines
8 provinces and 2 cities* with provincial status; Bulawayo*, Harare*, Manicaland, Mashonaland Central, Mashonaland East, Mashonaland West, Masvingo, Matabeleland North, Matabeleland South, Midlands
Zimbabwean
https://www.cia.gov/library/publications/the-world-factbook/flags/zi-lgflag.gif
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Flibrary%2Fpublications%2Fthe-world-factbook%2Fflags%2Fzi-lgflag.gif%3E
mixture of Roman-Dutch and English common law
21 December 1979
Senate - percent of vote by party - ZANU-PF 73.7%, MDC 20.3%, other 4.4%, independents 1.6%; seats by party - ZANU-PF 43, MDC 7; House of Assembly - percent of vote by party - ZANU-PF 59.6%, MDC 39.5%, other 0.9%; seats by party - ZANU-PF 78, MDC 41, independents 1
ZWD
Inyangani
The UK annexed Southern Rhodesia from the [British] South Africa Company in 1923. A 1961 constitution was formulated that favored whites in power. In 1965 the government unilaterally declared its independence, but the UK did not recognize the act and demanded more complete voting rights for the black African majority in the country (then called Rhodesia). UN sanctions and a guerrilla uprising finally led to free elections in 1979 and independence (as Zimbabwe) in 1980. Robert MUGABE, the nations first prime minister, has been the countrys only ruler (as president since 1987) and has dominated the countrys political system since independence. His chaotic land redistribution campaign, which began in 2000, caused an exodus of white farmers, crippled the economy, and ushered in widespread shortages of basic commodities. Ignoring international condemnation, MUGABE rigged the 2002 presidential election to ensure his reelection. Opposition and labor strikes in 2003 were unsuccessful in pressuring MUGABE to retire early; security forces continued their brutal repression of regime opponents. The ruling ZANU-PF party used fraud and intimidation to win a two-thirds majority in the March 2005 parliamentary election, allowing it to amend the constitution at will and recreate the Senate, which had been abolished in the late 1980s. In April 2005, Harare embarked on Operation Restore Order, ostensibly an urban rationalization program, which resulted in the destruction of the homes or businesses of 700000 mostly poor supporters of the opposition, according to UN estimates. ZANU-PF announced in December 2006 that they would seek to extend MUGABEs term in office until 2010 when presidential and parliamentary elections would be "harmonized."
tropical; moderated by altitude; rainy season (November to March)
UTC+2 (7 hours ahead of Washington, DC during Standard Time)
108.4% of GDP
The government of Zimbabwe faces a wide variety of difficult economic problems as it struggles with an unsustainable fiscal deficit, an overvalued exchange rate, soaring inflation, and bare shelves. Its 1998-2002 involvement in the war in the Democratic Republic of the Congo drained hundreds of millions of dollars from the economy. The governments land reform program, characterized by chaos and violence, has badly damaged the commercial farming sector, the traditional source of exports and foreign exchange and the provider of 400000 jobs, turning Zimbabwe into a net importer of food products. Badly needed support from the IMF has been suspended because of the governments arrears on past loans, which it began repaying in 2005. The official annual inflation rate rose from 32% in 1998, to 133% in 2004, 585% in 2005, and approached 1000% in 2006, although private sector estimates put the figure much higher. Meanwhile, the official exchange rate fell from approximately 1 (revalued) Zimbabwean dollar per US dollar in 2003 to 160 per US dollar in 2006.
slightly larger than Montana
age 15 and over can read and write English
.zw
http://www4.wiwiss.fu-berlin.de/factbook/resource/Mozambique
18 years of age (est.)
Executive President Robert Gabriel MUGABE (since 31 December 1987); Vice President Joseph MSIKA (since December 1999) and Vice President Joyce MUJURU (since 6 December 2004); note - the president is both the chief of state and head of government
Harare
Zimbabwean(s)
Republic of Zimbabwe
Cabinet appointed by the president; responsible to the House of Assembly
mostly high plateau with higher central plateau (high veld); mountains in east
16.1% of GDP
Botswana built electric fences and South Africa has placed military along the border to stem the flow of thousands of Zimbabweans fleeing to find work and escape political persecution; Namibia has supported, and in 2004 Zimbabwe dropped objections to, plans between Botswana and Zambia to build a bridge over the Zambezi River, thereby de facto recognizing a short, but not clearly delimited, Botswana-Zambia boundary in the river
zi
Executive President Robert Gabriel MUGABE (since 31 December 1987); Vice President Joseph MSIKA (since December 1999) and Vice President Joyce MUJURU (since 6 December 2004)
https://www.cia.gov/cia/publications/factbook/geos/zi.html
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Fcia%2Fpublications%2Ffactbook%2Fgeos%2Fzi.html%3E
junction of the Runde and Save rivers
Zimbabwe
seven equal horizontal bands of green, yellow, red, black, red, yellow, and green with a white isosceles triangle edged in black with its base on the hoist side; a yellow Zimbabwe bird representing the long history of the country is superimposed on a red five-pointed star in the center of the triangle, which symbolizes peace; green symbolizes agriculture, yellow - mineral wealth, red - blood shed to achieve independence, and black stands for the native people
Senate last held 26 November 2005 (next to be held in 2010; House of Assembly last held 31 March 2005 (next to be held in 2010)
https://www.cia.gov/library/publications/the-world-factbook/maps/zi-map.gif
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Flibrary%2Fpublications%2Fthe-world-factbook%2Fmaps%2Fzi-map.gif%3E
18 April 1980 (from UK)
presidential candidates nominated with a nomination paper signed by at least 10 registered voters (at least one from each province) and elected by popular vote for a six-year term (no term limits); election last held 9-11 March 2002 (next to be held in March 2008); co-vice presidents appointed by the president
bicameral Parliament consists of a Senate (66 seats - 50 elected by popular vote for a five-year term, 6 nominated by the president, 10 nominated by the Council of Chiefs) and a House of Assembly (150 seats - 120 elected by popular vote for five-year terms, 12 nominated by the president, 10 occupied by traditional chiefs chosen by their peers, and 8 occupied by provincial governors appointed by the president)
$1924000000; including capital expenditures of $NA
consists of microwave radio relay links, open-wire lines, radiotelephone communication stations, fixed wireless local loop installations, and a substantial mobile cellular network; Internet connection is available in Harare and planned for all major towns and for some of the smaller ones
Southern Africa, between South Africa and Zambia
Supreme Court; High Court
Binga, Kariba
deforestation; soil erosion; land degradation; air and water pollution; the black rhinoceros herd - once the largest concentration of the species in the world - has been significantly reduced by poaching; poor mining practices have led to toxic waste and heavy metal pollution
Zimbabwean dollar (ZWD)
Independence Day, 18 April
http://www4.wiwiss.fu-berlin.de/factbook/resource/Botswana
Robert Gabriel MUGABE reelected president; percent of vote - Robert Gabriel MUGABE 56.2%, Morgan TSVANGIRAI 41.9%
country code - 263; satellite earth stations - 2 Intelsat; 2 international digital gateway exchanges (in Harare and Gweru)
17 50 S, 31 03 E
RDF Description of Zimbabwe
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/4659568
_:header3549104421335206484075
RDF Description of ENTACAPONE
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0004659568&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0004659568%26input_query_species%3D9606%3E
CID0004659568
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0278008
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0012813
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0235198
ENTACAPONE
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0015393
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0085635
http://dbpedia.org/resource/Entacapone
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FEntacapone%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0035410
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0014130
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0028084
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0018824
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0004659568
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0004659568%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0008311
http://sideeffects.embl.de/drugs/4659568
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F4659568%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00494
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00494%3E
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=UANl+kwySSg=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DUANl%2BkwySSg%3D%3E
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/1036
_:header8476363921335206484451
Mon, 23 Apr 2012 18:34:39 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1036
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3857
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fsider%2Fresource%2Fside_effects%2FC0036572%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/SCN2A1
http://www.dbpedia.org/resource/Seizure
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FSeizure%3E
http://data.linkedct.org/resource/condition/11913
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fcondition%2F11913%3E
Seizures
http://data.linkedct.org/resource/condition/11907
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fcondition%2F11907%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3856
RDF Description of Seizures
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/4057
_:header5970905131335206485010
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4057
AF023466
http://bio2rdf.org/uniprot:Q6IB77
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ6IB77%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17143481
http://www.uniprot.org/uniprot/Q6IB77
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ6IB77%3E
>489 bp	ATGTTACCATTGCAAGGTGCCCAGATGCTGCAGATGCTGGAGAAATCCTTGAGGAAGAGC	CTCCCAGCATCCTTAAAGGTTTATGGAACTGTCTTTCACATAAACCATGGAAATCCATTC	AATCTGAAGGCTGTGGTGGACAAGTGGCCTGATTTTAATACAGTGGTTGTCTGCCCTCAG	GAGCAGGATATGACAGATGACCTTGATCACTATACCAATACTTACCAAATCTACTCCAAA	GATCCCCAAAACTGTCAGGAATTCCTTGGATCACCAGAACTCATCAACTGGAAACAGCAT	TTACAGATTCAAAGTTCACAGCCTAGCCTGAATGAGGCTATACAAAATCTTGCAGCCATT	AAGTCCTTCAAAGTCAAACAAACACAACGCATTCTCTATATGGCAGCTGAAACAGCCAAG	GAACTGACTCCTTTCCTGCTGAAATCAAAGATTTTATCTCCCAGTGGTGGCAAACCCAAG	GCCATGTGA
HRP-1(CLP)
Glycine N-acyltransferase
http://bio2rdf.org/hgnc:13734
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A13734%3E
GLYAT
Mitochondrial acyltransferase which transfers the acyl group to the N-terminus of glycine. Can conjugate a multitude of substrates to form a variety of N-acylglycines
http://symbol.bio2rdf.org/symbol:GLYAT
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AGLYAT%3E
AAc
http://www.genenames.org/data/hgnc_data.php?hgnc_id=13734
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D13734%3E
Aralkyl acyl-CoA N-acyltransferase
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AF023466
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAF023466%3E
EC 2.3.1.13
GLYAT_HUMAN
acyl-CoA + glycine = CoA + N-acylglycine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17146584
Acyl-CoA:glycine N- acyltransferase
11q12.1
Aralkyl acyl-CoA:amino acid N-acyltransferase
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=2554941
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D2554941%3E
>Glycine N-acyltransferase	MMLPLQGAQMLQMLEKSLRKSLPASLKVYGTVFHINHGNPFNLKAVVDKWPDFNTVVVCP	QEQDMTDDLDHYTNTYQIYSKDPQNCQEFLGSPELINWKQHLQIQSSQPSLNEAIQNLAA	IKSFKVKQTQRILYMAAETAKELTPFLLKSKILSPSGGKPKAINQEMFKLSSMDVTHAHL	VNKFWHFGGNERSQRFIERCIQTFPTCCLLGPEGTPVCWDLMDQTGEMRMAGTLPEYRLH	GLVTYVIYSHAQKLGKLGFPVYSHVDYSNEAMQKMSYTLQHVPIPRSWNQWNCVPL
RDF Description of Glycine N-acyltransferase
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/939
_:header20904552491335206485268
Mon, 23 Apr 2012 18:34:40 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/939
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3617
Polycythemia
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04716
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB04716%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/JAK2
http://www.dbpedia.org/resource/Polycythemia_vera
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FPolycythemia_vera%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/VHL
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0032461
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fsider%2Fresource%2Fside_effects%2FC0032461%3E
RDF Description of Polycythemia
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3616
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/SUR1
_:header14185302781335206485678
RDF Description of SUR1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/SUR1
http://symbol.bio2rdf.org/symbol:SUR1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ASUR1%3E
SUR1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2147
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2732
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2733
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Turner_Frederick_Jackson_1861-1932
_:header7462787981335206486064
Mon, 23 Apr 2012 18:34:41 GMT
RDF Description of Turner, Frederick Jackson, 1861-1932
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Turner_Frederick_Jackson_1861-1932
Turner, Frederick Jackson, 1861-1932
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3826
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext20643
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/3
_:header16925723281335206486590
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3
http://symbol.bio2rdf.org/symbol:HDC
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AHDC%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/16960050
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17227057
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/15070923
DCHS_HUMAN
http://www.uniprot.org/uniprot/P19113
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP19113%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/16790022
http://bio2rdf.org/uniprot:P19113
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP19113%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1425659
X54297
>Histidine decarboxylase	MMEPEEYRERGREMVDYICQYLSTVRERRVTPDVQPGYLRAQLPESAPEDPDSWDSIFGD	IERIIMPGVVHWQSPHMHAYYPALTSWPSLLGDMLADAINCLGFTWASSPACTELEMNVM	DWLAKMLGLPEHFLHHHPSSQGGGVLQSTVSESTLIALLAARKNKILEMKTSEPDADESC	LNARLVAYASDQAHSSVEKAGLISLVKMKFLPVDDNFSLRGEALQKAIEEDKQRGLVPVF	VCATLGTTGVCAFDCLSELGPICAREGLWLHIDAAYAGTAFLCPEFRGFLKGIEYADSFT	FNPSKWMMVHFDCTGFWVKDKYKLQQTFSVNPIYLRHANSGVATDFMHWQIPLSRRFRSV	KLWFVIRSFGVKNLQAHVRHGTEMAKYFESLVRNDPSFEIPAKRHLGLVVFRLKGPNCLT	ENVLKEIAKAGRLFLIPATIQDKLIIRFTVTSQFTTRDDILRDWNLIRDAATLILSQHCT	SQPSPRVGNLISQIRGARAWACGTSLQSVSGAGDDPVQARKIIKQPQRVGAGPMKRENGL	HLETLLDPVDDCFSEEAPDATKHKLSSFLFSYLSVQTKKKTVRSLSCNSVPVSAQKPLPT	EASVKNGGSSRVRIFSRFPEDMMMLKKSAFKKLIKFYSVPSFPECSSQCGLQLPCCPLQA	MV
15q21-q22
http://pfam.sanger.ac.uk/family?acc=PF00282
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00282%3E
http://bio2rdf.org/hgnc:4855
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A4855%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=32109
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D32109%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12679420
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=X54297
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DX54297%3E
Histidine decarboxylase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1768863
HDC
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8288622
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2216786
carboxy-lyase activity
>1989 bp	ATGATGGAGCCTGAGGAGTACAGAGAGAGAGGGAGAGAGATGGTGGATTACATCTGCCAG	TACCTGAGCACTGTGCGGGAGAGACGTGTGACGCCAGACGTGCAGCCTGGCTACCTGCGA	GCCCAGCTGCCTGAGAGTGCTCCTGAGGACCCCGACAGCTGGGACAGCATCTTTGGGGAC	ATTGAACGAATCATCATGCCTGGGGTGGTACATTGGCAGAGCCCCCATATGCACGCCTAC	TACCCAGCCCTCACCTCTTGGCCCTCCCTGCTAGGAGACATGCTGGCTGATGCCATCAAC	TGCTTGGGATTCACCTGGGCATCCAGCCCTGCGTGTACAGAGCTGGAGATGAACGTCATG	GACTGGTTGGCAAAAATGCTGGGACTTCCAGAGCACTTCTTGCACCACCACCCCAGCAGC	CAGGGCGGAGGCGTCCTGCAGCAGACGGTCAGTGAATCCACTTTGATTGCCCTGCTGGCA	GCAAGGAAGAACAAAATCCTGGAAATGAAAACGTCTGAGCCCGATGCTGATGAGTCCTGC	CTAAATGCCCGACTCGTGGCCTATGCCTCTGACCAGGCTCACTCCTCTGTGGAAAAGGCT	GGTTTGATTTCCCTTGTGAAGATGAAATTTCTGCCTGTGGATGACAACTTCTCACTCCGA	GGGGAAGCTCTTCAGAAGGCCATCGAGGAAGACAAGCAGCGGGGCTTGGTGCCCGTCTTT	GTCTGTGCAACACTAGGGACCACTGGGGTCTGTGCATTTGACTGCCTGTCAGAGCTGGGC	CCCATCTGTGCCCGTGAGGGGCTGTGGCTCCACATCGATGCTGCTTATGCAGGCACTGCC	TTCCTGTGCCCCGAGTTCCGGGGGTTTCTGAAGGGGATTGAGTATGCCGACTCCTTCACC	TTTAATCCTTCCAAGTGGATGATGGTGCATTTTGACTGTACTGGGTTCTGGGTCAAGGAC	AAGTACAAGCTGCAGCAGACCTTCAGTGTGAATCCCATCTACCTCAGGCATGCCAACTCA	GGCGTGGCCACCGACTTCATGCACTGGCAGATCCCCCTGAGCCGACGGTTTCGCTCTGTT	AAACTCTGGTTCGTGATTCGGTCCTTCGGGGTGAAGAATCTTCAAGCACATGTCAGACAT	GGTACTGAAATGGCTAAATATTTTGAATCTCTGGTCAGAAACGACCCTTCCTTTGAAATT	CCTGCCAAGAGGCACCTTGGCCTGGTGGTTTTTCGTCTAAAGGGTCCTAATTGTCTCACA	GAAAATGTGTTAAAGGAAATAGCTAAAGCTGGCCGTCTCTTCCTCATCCCGGCCACTATC	CAGGACAAGTTAATCATCCGTTTCACTGTGACATCCCAGTTTACCACTAGGGATGACATC	CTGAGAGACTGGAATCTCATTCGAGATGCTGCCACTCTCATCCTGAGTCAGCACTGTACT	TCCCAACCCAGCCCTCGGGTTGGGAACCTCATCTCCCAAATCAGGGGTGCCAGAGCCTGG	GCCTGTGGAACGTCCCTTCAGTCTGTCAGTGGGGCAGGAGATGATCCAGTCCAGGCCAGG	AAGATCATCAAGCAGCCTCAGCGTGTGGGAGCCGGTCCCATGAAAAGGGAAAATGGCCTC	CATCTTGAAACCCTGCTGGACCCAGTTGATGACTGCTTTTCAGAAGAGGCCCCAGATGCC	ACCAAGCACAAGCTGTCCTCCTTCCTGTTCAGTTACTTGTCTGTGCAGACTAAGAAGAAG	ACGGTGCGCTCCCTCAGTTGCAACAGTGTGCCAGTGAGTGCTCAGAAGCCACTGCCCACA	GAGGCCTCTGTGAAGAATGGGGGCTCCTCCAGGGTCAGAATCTTTTCCAGGTTTCCAGAA	GACATGATGATGCTGAAGAAAAGTGCCTTCAAAAAACTCATCAAATTCTACAGCGTCCCC	AGCTTTCCTGAATGCAGCTCTCAATGTGGACTCCAGCTGCCCTGTTGCCCTCTGCAGGCC	ATGGTTTAG
http://bio2rdf.org/pfam:PF00282
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00282%3E
L-histidine = histamine + CO2
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/16547811
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11980912
carbon-carbon lyase activity
map00340	Histidine metabolism
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17075268
EC 4.1.1.22
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17191019
http://www.genenames.org/data/hgnc_data.php?hgnc_id=4855
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D4855%3E
RDF Description of Histidine decarboxylase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00117
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/3092
_:header15778373831335206487052
RDF Description of 3-isopropylmalate dehydrogenase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3092
http://bio2rdf.org/pdb:1A05
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1A05%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8282728
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9739088
3-isopropylmalate dehydrogenase
IMDH
EC 1.1.1.85
leucine biosynthesis
leucine metabolism
Beta-IPM dehydrogenase
>3-isopropylmalate dehydrogenase	MKKIAIFAGDGIGPEIVAAARQVLDAVDQAAHLGLRCTEGLVGGAALDASDDPLPAASLQ	LAMAADAVILGAVGGPRWDAYPPAKRPEQGLLRLRKGLDLYANLRPAQIFPQLLDASPLR	PELVRDVDILVVRELTGDIYFGQPRGLEVIDGKRRGFNTMVYDEDEIRRIAHVAFRAAQG	RRKQLCSVDKANVLETTRLWREVVTEVARDYPDVRLSHMYVDNAAMQLIRAPAQFDVLLT	GNMFGDILSDEASQLTGSIGMLPSASLGEGRAMYEPIHGSAPDIAGQDKANPLATILSVA	MMLRHSLNAEPWAQRVEAAVQRVLDQGLRTADIAAPGTPVIGTKAMGAAVVNALNLKD
map00290	Valine, leucine and isoleucine biosynthesis
http://www.uniprot.org/uniprot/Q56268
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ56268%3E
3-isopropylmalate dehydrogenase activity
oxidoreductase activity, acting on CH-OH group of donors
leuB
>1077 bp	ATGAAAAAAATAGCCATCTTCGCCGGTGACGGCATCGGTCCGGAAATCGTGGCAGCCGCC	CGGCAAGTGCTGGATGCAGTGGATCAGGCCGCCCACCTTGGCCTGCGTTGTACCGAAGGC	CTGGTGGGCGGGGCCGCGCTGGATGCCAGCGATGATCCCTTGCCGGCGGCTTCTTTGCAG	TTGGCCATGGCGGCGGATGCAGTCATTTTGGGTGCGGTGGGCGGCCCCCGCTGGGACGCG	TATCCACCCGCCAAGCGCCCGGAACAGGGACTGCTGCGTCTGCGCAAAGGCCTGGACCTT	TATGCGAACCTGCGTCCCGCACAGATTTTTCCGCAGTTGCTGGATGCCTCGCCCCTACGC	CCGGAGCTGGTGCGCGACGTCGATATCCTGGTGGTGCGCGAGCTGACCGGGGATATCTAC	TTCGGCCAGCCACGCGGTCTGGAGGTCATCGACGGCAAGCGCCGCGGCTTTAACACCATG	GTCTATGACGAGGATGAAATTCGCCGTATCGCTCATGTGGCCTTCCGCGCTGCCCAGGGG	CGTCGCAAGCAGTTGTGCTCGGTGGACAAGGCCAATGTCCTGGAGACCACGCGTCTGTGG	CGCGAGGTGGTCACCGAGGTAGCGCGGGACTATCCCGATGTGCGGCTCAGCCACATGTAT	GTGGATAATGCCGCCATGCAACTGATCCGCGCCCCGGCACAGTTCGACGTGCTGTTGACC	GGCAATATGTTCGGCGACATTCTTTCCGACGAGGCCAGTCAATTGACTGGTTCCATCGGT	ATGCTGCCCTCGGCCTCGCTGGGCGAGGGACGGGCGATGTATGAACCCATCCATGGCTCG	GCGCCGGATATTGCCGGGCAGGACAAGGCGAATCCCCTGGCCACGATTCTATCCGTGGCG	ATGATGCTGCGGCATTCCCTCAACGCCGAACCCTGGGCGCAACGGGTGGAGGCGGCAGTG	CAGCGAGTGCTGGATCAGGGCCTGCGCACTGCGGATATTGCAGCGCCGGGAACGCCGGTA	ATCGGCACCAAAGCCATGGGTGCCGCGGTGGTCAACGCCCTGAACCTGAAGGATTGA
http://bio2rdf.org/uniprot:Q56268
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ56268%3E
branched chain family amino acid metabolism
http://pfam.sanger.ac.uk/family?acc=PF00180
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00180%3E
D14585
3-IPM-DH
http://bio2rdf.org/pfam:PF00180
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00180%3E
LEU3_THIFE
oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=414355
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D414355%3E
http://www.pdb.org/pdb/explore/explore.do?structureId=1A05
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1A05%3E
(1) (1a) (2R,3S)-3-isopropylmalate + NAD+ = (2S)-2-isopropyl-3-oxosuccinate + NADH + H+
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=D14585
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DD14585%3E
Catalyzes the oxidation of 3-carboxy-2-hydroxy-4- methylpentanoate (3-isopropylmalate) to 3-carboxy-4-methyl-2- oxopentanoate. The product decarboxylates to 4-methyl-2 oxopentanoate
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04279
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Kirby_William_1817-1906
_:header15606096011335206487472
Mon, 23 Apr 2012 18:34:42 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Kirby_William_1817-1906
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2735
Kirby, William, 1817-1906
RDF Description of Kirby, William, 1817-1906
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/2684
_:header8781477591335206487856
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2684
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02183
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8812426
HINT1
Histidine triad nucleotide-binding protein 1
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17337452
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17158446
http://www.genenames.org/data/hgnc_data.php?hgnc_id=4912
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D4912%3E
http://symbol.bio2rdf.org/symbol:HINT1
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AHINT1%3E
Hydrolyzes adenosine 5'-monophosphoramidate substrates such as AMP-morpholidate, AMP-N-alanine methyl ester, AMP-alpha- acetyl lysine methyl ester and AMP-NH2
5q31.2
http://bio2rdf.org/pfam:PF01230
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF01230%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=862933
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D862933%3E
http://bio2rdf.org/hgnc:4912
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A4912%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17217311
cytoplasm.Nucleus.Note=interactionWithCdk7LeadsToAMoreNuclearLocalization
EC 3.-.-.-
HINT1_HUMAN
Protein kinase C-interacting protein 1
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7644499
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9323207
>Histidine triad nucleotide-binding protein 1	MADEIAKAQVARPGGDTIFGKIIRKEIPAKIIFEDDRCLAFHDISPQAPTHFLVIPKKHI	SQISVAEDDDESLLGHLMIVGKKCAADLGLNKGYRMVVNEGSDGGQSVYHVHLHVLGGRQ	MHWPPG
Protein kinase C inhibitor 1
U27143
http://www.pdb.org/pdb/explore/explore.do?structureId=1KPF
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1KPF%3E
http://bio2rdf.org/pdb:1KPF
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1KPF%3E
>381 bp	ATGGCAGATGAGATTGCCAAGGCTCAGGTCGCTCGGCCTGGTGGCGACACGATCTTTGGG	AAGATCATCCGCAAGGAAATACCAGCCAAAATCATTTTTGAGGATGACCGGTGCCTTGCT	TTCCATGACATTTCCCCTCAAGCACCAACACATTTTCTGGTGATACCCAAGAAACATATA	TCCCAGATTTCTGTGGCAGAAGATGATGATGAAAGTCTTCTTGGACACTTAATGATTGTT	GGCAAGAAATGTGCTGCTGATCTGGGCCTGAATAAGGGTTATCGAATGGTGGTGAATGAA	GGTTCAGATGGTGGACAGTCTGTCTATCACGTTCATCTCCATGTTCTTGGAGGTCGGCAA	ATGCATTGGCCTCCTGGTTAA
http://pfam.sanger.ac.uk/family?acc=PF01230
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF01230%3E
http://www.uniprot.org/uniprot/P49773
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP49773%3E
Adenosine 5'-monophosphoramidase
PKCI-1
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8643579
http://bio2rdf.org/uniprot:P49773
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP49773%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=U27143
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DU27143%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00131
RDF Description of Histidine triad nucleotide-binding protein 1
http://www4.wiwiss.fu-berlin.de/eurostat/data/countries/European_Free_Trade_Association
_:header5673374351335206488234
Mon, 23 Apr 2012 18:34:43 GMT
RDF Description of European Free Trade Association
http://www4.wiwiss.fu-berlin.de/eurostat/resource/countries/European_Free_Trade_Association
http://dbpedia.org/resource/EFTA
http://www4.wiwiss.fu-berlin.de/eurostat/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FEFTA%3E
European Free Trade Association
http://estatwrap.ontologycentral.com/dic/geo#EFTA
http://www4.wiwiss.fu-berlin.de/eurostat/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Festatwrap.ontologycentral.com%2Fdic%2Fgeo%23EFTA%3E
European_Free_Trade_Association
http://ec.europa.eu/eurostat/ramon/rdfdata/countries/EFTA
http://www4.wiwiss.fu-berlin.de/eurostat/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fec.europa.eu%2Feurostat%2Framon%2Frdfdata%2Fcountries%2FEFTA%3E
efta
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/May_Karl_Friedrich_1842-1912
_:header11999505201335206488640
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/May_Karl_Friedrich_1842-1912
May, Karl Friedrich, 1842-1912
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2780
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2779
RDF Description of May, Karl Friedrich, 1842-1912
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0005758
_:header12449662321335206489111
Mon, 23 Apr 2012 18:34:44 GMT
http://dbpedia.org/resource/Blister
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FBlister%3E
http://sideeffects.embl.de/se/C0005758
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0005758%3E
blistering
C0005758
blister
blisters
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2762
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4421
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5408
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/72938
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4865
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/157922
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2812
RDF Description of blistering
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Benton_Thomas_Hart_1782-1858
_:header16826621701335206489451
RDF Description of Benton, Thomas Hart, 1782-1858
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Benton_Thomas_Hart_1782-1858
Benton, Thomas Hart, 1782-1858
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext741
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB02061
_:header18545163371335206489893
RDF Description of Cellobiose
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02061
(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol
OC[C@@H]1O[C@@H](O[C@@H]2[C@H](CO)O[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O
OCC1OC(OC2C(CO)OC(O)C(O)C2O)C(O)C(O)C1O
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2252
A disaccharide consisting of two glucose units in beta (1-4) glycosidic linkage. Obtained from the partial hydrolysis of cellulose. [PubChem]
http://bio2rdf.org/chebi:17057
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fchebi%3A17057%3E
http://www.drugbank.ca/drugs/DB02061
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB02061%3E
CBI
expt00844
http://dbpedia.org/page/Cellobiose
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FCellobiose%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2802
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4595
Cellobiose
2008-08-26 16:45:55 UTC
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2807
http://dbpedia.org/resource/Cellobiose
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FCellobiose%3E
InChI=1/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2
GUBGYTABKSRVRQ-UHFFFAOYAN
5.86e+02 mg/mL
http://bio2rdf.org/cas:16462-44-5
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A16462-44-5%3E
C12H22O11
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2645
1K72
http://en.wikipedia.org/wiki/Cellobiose
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FCellobiose%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4583
http://bio2rdf.org/cpd:C00185
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC00185%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3236
DB02061
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/823
_:header7902323931335206490305
Mon, 23 Apr 2012 18:34:45 GMT
RDF Description of Netherton syndrome
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/823
http://data.linkedct.org/resource/condition/8713
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fcondition%2F8713%3E
Netherton syndrome
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseaseClass/Dermatological
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/SPINK5
http://www.dbpedia.org/resource/Netherton_syndrome
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FNetherton_syndrome%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3345
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Pliny_the_Younger_62?-113
_:header20851388301335206490719
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Pliny_the_Younger_62?-113
Pliny, the Younger, 62?-113
Pliny, the Younger, 62?-113 
RDF Description of Pliny, the Younger, 62?-113
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2811
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3234
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext12758
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Chekhov_Anton_Pavlovich_1860-1904
_:header16786588881335206491120
Mon, 23 Apr 2012 18:34:46 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Chekhov_Anton_Pavlovich_1860-1904
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13414
Chekhov, Anton Pavlovich, 1860-1904
Chekhov, Anton Pavlovich, 1860-1904 
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13413
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1754
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13409
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13418
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext12494
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13412
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1883
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6408
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1756
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1732
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1944
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1552
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13417
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1753
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13416
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7986
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13505
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13415
RDF Description of Chekhov, Anton Pavlovich, 1860-1904
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13437
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13419
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1755
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Meyer_Conrad_Ferdinand_1825-1898
_:header16616938371335206491513
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Meyer_Conrad_Ferdinand_1825-1898
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9632
Meyer, Conrad Ferdinand, 1825-1898
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6421
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9494
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3675
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5801
RDF Description of Meyer, Conrad Ferdinand, 1825-1898
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9495
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9496
http://www4.wiwiss.fu-berlin.de/eurostat/data/regions/Marche
_:header2587865651335206491895
RDF Description of Marche
http://www4.wiwiss.fu-berlin.de/eurostat/resource/regions/Marche
http://www4.wiwiss.fu-berlin.de/eurostat/resource/eurostat/regions
http://dbpedia.org/resource/Marche
http://www4.wiwiss.fu-berlin.de/eurostat/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FMarche%3E
http://ec.europa.eu/eurostat/ramon/rdfdata/nuts2008/ITE3
http://www4.wiwiss.fu-berlin.de/eurostat/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fec.europa.eu%2Feurostat%2Framon%2Frdfdata%2Fnuts2008%2FITE3%3E
Marche
http://www4.wiwiss.fu-berlin.de/eurostat/resource/countries/Italia
ite3
http://estatwrap.ontologycentral.com/dic/geo#ITE3
http://www4.wiwiss.fu-berlin.de/eurostat/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Festatwrap.ontologycentral.com%2Fdic%2Fgeo%23ITE3%3E
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/646
_:header18014985791335206492430
Mon, 23 Apr 2012 18:34:47 GMT
RDF Description of Malate dehydrogenase, cytoplasmic
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/646
main pathways of carbohydrate metabolism
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=D55654
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DD55654%3E
MDH1
http://bio2rdf.org/hgnc:6970
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A6970%3E
(S)-malate + NAD+ = oxaloacetate + NADH + H+
>Malate dehydrogenase, cytoplasmic	SEPIRVLVTGAAGQIAYSLLYSIGNGSVFGKDQPIILVLLDITPMMGVLDGVLMELQDCA	LPLLKDVIATDKEDVAFKDLDVAILVGSMPRREGMERKDLLKANVKIFKSQGAALDKYAK	KSVKVIVVGNPANTNCLTASKSAPSIPKENFSCLTRLDHNRAKAQIALKLGVTANDVKNV	IIWGNHSSTQYPDVNHAKVKLQGKEVGVYEALKDDSWLKGEFVTTVQQRGAAVIKARKLS	SAMSAAKAICDHVRDIWFGTPEGEFVSMGVISDGNSYGVPDDLLYSFPVVIKNKTWKFVE	GLPINDFSREKMDLTAKELTEEKESAFEFLSSA
>1005 bp	ATGTCTGAACCAATCAGAGTCCTTGTGACTGGAGCAGCTGGTCAAATTGCATATTCACTG	CTGTACAGTATTGGAAATGGATCTGTCTTTGGTAAAGATCAGCCTATAATTCTTGTGCTG	TTGGATATCACCCCCATGATGGGTGTCCTGGACGGTGTCCTAATGGAACTGCAAGACTGT	GCCCTTCCCCTCCTGAAAGATGTCATCGCAACAGATAAAGAAGACGTTGCCTTCAAAGAC	CTGGATGTGGCCATTCTTGTGGGCTCCATGCCAAGAAGGGAAGGCATGGAGAGAAAAGAT	TTACTGAAAGCAAATGTGAAAATCTTCAAATCCCAGGGTGCAGCCTTAGATAAATACGCC	AAGAAGTCAGTTAAGGTTATTGTTGTGGGTAATCCAGCCAATACCAACTGCCTGACTGCT	TCCAAGTCAGCTCCATCCATCCCCAAGGAGAACTTCAGTTGCTTGACTCGTTTGGATCAC	AACCGAGCTAAAGCTCAAATTGCTCTTAAACTTGGTGTGACTGCTAATGATGTAAAGAAT	GTCATTATCTGGGGAAACCATTCCTCGACTCAGTATCCAGATGTCAACCATGCCAAGGTG	AAATTGCAAGGAAAGGAAGTTGGTGTTTATGAAGCTCTGAAAGATGACAGCTGGCTCAAG	GGAGAATTTGTCACGACTGTGCAGCAGCGTGGCGCTGCTGTCATCAAGGCTCGAAAACTA	TCCAGTGCCATGTCTGCTGCAAAAGCCATCTGTGACCACGTCAGGGACATCTGGTTTGGA	ACCCCAGAGGGAGAGTTTGTGTCCATGGGTGTTATCTCTGATGGCAACTCCTATGGTGTT	CCTGATGATCTGCTCTACTCATTCCCTGTTGTAATCAAGAATAAGACCTGGAAGTTTGTT	GAAGGTCTCCCTATTAATGATTTCTCACGTGAGAAGATGGATCTTACTGCAAAGGAACTG	ACAGAAGAAAAAGAAAGTGCTTTTGAATTTCTTTCCTCTGCCTGA
Malate dehydrogenase, cytoplasmic
http://bio2rdf.org/pfam:PF00056
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00056%3E
http://symbol.bio2rdf.org/symbol:MDH1
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AMDH1%3E
http://bio2rdf.org/pfam:PF02866
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF02866%3E
MDHC_HUMAN
http://www.pdb.org/pdb/explore/explore.do?structureId=5MDH
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D5MDH%3E
energy derivation by oxidation of organic compounds
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8786100
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7895732
http://bio2rdf.org/pdb:5MDH
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A5MDH%3E
L-malate dehydrogenase activity
malate metabolism
http://pfam.sanger.ac.uk/family?acc=PF02866
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF02866%3E
malate dehydrogenase activity
http://www.genenames.org/data/hgnc_data.php?hgnc_id=6970
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D6970%3E
tricarboxylic acid cycle intermediate metabolism
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/16983536
lactate dehydrogenase activity
map00020	Citrate cycle (TCA cycle)	map00620	Pyruvate metabolism	map00630	Glyoxylate and dicarboxylate metabolism	map00710	Carbon fixation	map00720	Reductive carboxylate cycle (CO2 fixation)
http://pfam.sanger.ac.uk/family?acc=PF00056
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00056%3E
http://bio2rdf.org/uniprot:P40925
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP40925%3E
http://www.uniprot.org/uniprot/P40925
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP40925%3E
L-lactate dehydrogenase activity
Cytosolic malate dehydrogenase
2p13.3
D55654
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=1255604
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D1255604%3E
EC 1.1.1.37
http://www4.wiwiss.fu-berlin.de/dblp/data/person/154635
_:header15820670381335206493003
http://www4.wiwiss.fu-berlin.de/dblp/resource/person/154635
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/avmfss/CleavelandH89
Matthew Hennessy
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/entcs/Hennessy98
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/iandc/HennessyS85
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/jacm/AcetoH92
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/mscs/HennessyR04
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/mfcs/FerreiraH95
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/jar/RielyH03
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/iandc/YoshidaH02
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/ecoopw/HennessyR98
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tcs/Hennessy02
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/iandc/HennessyI93
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/scp/HennessyLR01
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/toplas/HennessyR02
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/mfcs/HennessyP80
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/concur/FrancalanzaH05
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/icalp/Hennessy94
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/entcs/HennessyR98
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/icalp/AcetoH91
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/acta/Hennessy84
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/icalp/NicolaH83
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/acta/HennessyL95
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/jlp/Hennessy05
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/jacm/CastellaniH89
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/lmcs/GorlaHS05
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/fuin/KiehnH97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tcs/RielyH01
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/ifip/Hennessy83
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/fac/HennessyI93
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/tacs/RathkeH97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/concur/BoudolCHK92
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/entcs/HennessyR02
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/entcs/GorlaHS05
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tcs/HennessyA80
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/jacm/Hennessy85
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/mfcs/HennessyP79
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/lics/CleavelandH88
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/concur/Hennessy92
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/mfcs/BoudolCHK91
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/stoc/HennessyA77
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/toplas/MerroH06
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/fac/BoudolCHK94
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/jacm/HennessyM85
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/concur/HennessyR95
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/icalp/RielyH97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/acta/Arun-KumarH92
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/ifm/Hennessy99
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/icalp/Hennessy85
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/stoc/Hennessy84
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/icdcs/HennessyLP81
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/iandc/HartonasH98
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/mfcs/HennessyS84
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/popl/MerroH02
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/lics/Hennessy93
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/ibm/Hennessy86
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/icfp/FerreiraHJ96
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/iandc/Hennessy94
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/concur/HennessyL93
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tcs/HennessyL95
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/rex/Hennessy88
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/fossacs/HennessyMR03
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/acta/HennessyRY05
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/toplas/Hennessy86
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/fsttcs/Hennessy89
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tcs/NicolaH84
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/entcs/HymH06
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/fct/Hennessy99
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/iandc/HennessyR95
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/fac/CleavelandH93
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/jcss/Hennessy80
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/siamcomp/Hennessy80
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/icalp/HennessyM80
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/popl/RielyH98
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/tacs/Arun-KumarH91
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/acta/Hennessy95
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/csl/HartonasH97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/mfps/AcetoH89
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/programm/Hennessy82
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/forte/HennessyR90
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/concur/Hennessy90
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/icalp/HennessyA76
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/siamcomp/Hennessy88
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/tapsoft/NicolaH87
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/lics/YoshidaH00
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/fossacs/FrancalanzaH06
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tcs/EidenbenzHBRWC04
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/iandc/AcetoH94
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tcs/BoudolCHK93
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tcs/FerreiraH99
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/iandc/AcetoH93
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/forte/CiaffaglioneHR05
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/iandc/HennessyR02
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/fsttcs/CastellaniH98
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tcs/Hennessy87
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/lics/AcetoH89
RDF Description of Matthew Hennessy
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tcs/HennessyR98
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/iandc/Hennessy83
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/concur/YoshidaH99
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tcs/HennessyMR04
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/cav/HennessyL93
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/icalp/2002
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/popl/RielyH99
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/fac/HennessyL96
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/iandc/CleavelandH90
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/fac/Hennessy91
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/iandc/Hennessy81
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/fossacs/HennessyRY04
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/ecoopw/HennessyR99
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/jfp/FerreiraHJ98
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/icalp/HennessyR00
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/mfcs/Hennessy93
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/icalp/HennessyI90
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Kanada_Yasumasa
_:header17389290961335206493308
Mon, 23 Apr 2012 18:34:48 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Kanada_Yasumasa
Kanada, Yasumasa
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext745
RDF Description of Kanada, Yasumasa
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Grimke_Archibald_H_1849-1930
_:header13649510151335206493707
RDF Description of Grimke, Archibald H., 1849-1930
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Grimke_Archibald_H_1849-1930
Grimke, Archibald H., 1849-1930
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext14555
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/2566
_:header17612527801335206494257
Mon, 23 Apr 2012 18:34:49 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2566
Ya1
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles
http://bio2rdf.org/pfam:PF00043
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00043%3E
Involved in glutathione transferase activity
>Glutathione S-transferase A1	MAGKPVLHYFNARGRMECIRWLLAAAGVEFEEKFIQSPEDLEKLKKDGNLMFDQVPMVEI	DGMKLAQTRAILNYIATKYDLYGKDMKERALIDMYSEGILDLTEMIGQLVLCPPDQREAK	TALAKDRTKNRYLPAFEKVLKSHGQDYLVGNRLTRVDIHLLEVLLYVEEFDASLLTPFPL	LKAFKSRISSLPNVKKFLQPGSQRKPPMDAKQIQEARKAFKIQ
http://bio2rdf.org/uniprot:P13745
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP13745%3E
Glutathione S-transferase Ya
http://bio2rdf.org/pfam:PF02798
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF02798%3E
http://pfam.sanger.ac.uk/family?acc=PF00043
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00043%3E
GST class-alpha member 1
GSTA1_MOUSE
http://www.uniprot.org/uniprot/P13745
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP13745%3E
Gsta1
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3652905
M19256
glutathione transferase activity
http://bio2rdf.org/pdb:1F3A
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1F3A%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2049074
>672 bp	ATGGCCGGGAAGCCCGTGCTTCACTACTTCAATGCCCGGGGCAGAATGGAGTGCATCAGG	TGGCTCCTAGCTGCAGGAGGGGTGGAGTTTGAAGAGAAGTTTATACAGAGTCCGGAAGAT	TTGGAAAAGCTAAAAAAAGATGGGAATTTGATGTTTGACCAAGTGCCCATGGTGGAGATT	GATGGGATGAAGCTGGCGCAGACCAGAGCCATTCTCAACTACATCGCCACCAAATATGAC	CTCTATGGGAAGGACATGAAGGAGAGAGCCCTGATTGACATGTATTCAGAAGGTATTTTA	GATCTGACTGAAATGATTGGGCAATTGGTATTATGTCCCCCAGACCAAAGAGAAGCCAAG	ACTGCCTTGGCAAAAGATAGGACCAAAAACCGTTACTTGCCTGCCTTTGAAAAGGTGTTG	AAGAGCCATGGCCAAGACTACCTTGTGGGCAACAGGCTGACCAGGGTGGACATCCACCTA	CTGGAAGTTCTCCTCTATGTTGAAGAGTTTGATGCCAGCCTTCTGACCCCTTTCCCTCTG	CTGAAGGCCTTCAAGAGCAGAATCAGCAGCCTCCCCAATGTGAAGAAGTTTCTACAGCCT	GGCAGCCAGAGAAAGCCTCCCATGGATGCAAAACAAATTCAAGAAGCAAGGAAGGCTTTC	AAGATTCAGTGA
Glutathione S-transferase A1
transferase activity, transferring alkyl or aryl (other than methyl) groups
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=387179
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D387179%3E
map00480	Glutathione metabolism
RX + glutathione = HX + R-S-glutathione
http://pfam.sanger.ac.uk/family?acc=PF02798
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF02798%3E
http://www.pdb.org/pdb/explore/explore.do?structureId=1F3A
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1F3A%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=M19256
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DM19256%3E
EC 2.5.1.18
RDF Description of Glutathione S-transferase A1
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01915
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/863
_:header9143116211335206494713
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/863
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3440
http://data.linkedct.org/resource/condition/9203
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fcondition%2F9203%3E
Omenn syndrome
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/DCLRE1C
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/RAG1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/RAG2
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3439
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3438
RDF Description of Omenn syndrome
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0085576
_:header19968569821335206495143
Mon, 23 Apr 2012 18:34:50 GMT
RDF Description of microcytic anemia
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0085576
http://sideeffects.embl.de/se/C0085576
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0085576%3E
microcytic anemia
C0085576
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/190
_:header5077009521335206495506
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/190
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1719
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/RASA1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseaseClass/Cardiovascular
Capillary malformations
RDF Description of Capillary malformations
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0002963
_:header10253639291335206495984
RDF Description of Variant Angina
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0002963
http://dbpedia.org/resource/Prinzmetal%27s_angina
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FPrinzmetal%2527s_angina%3E
http://sideeffects.embl.de/se/C0002963
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0002963%3E
Variant Angina
C0002963
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/3890
_:header5402663171335206496469
Mon, 23 Apr 2012 18:34:51 GMT
RDF Description of Glutamate decarboxylase 2
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3890
>Glutamate decarboxylase 2	MASPGSGFWSFGSEDGSGDSENPGTARAWCQVAQKFTGGIGNKLCALLYGDAEKPAESGG	SQPPRAAARKAACACDQKPCSCSKVDVNYAFLHATDLLPACDGERPTLAFLQDVMNILLQ	YVVKSFDRSTKVIDFHYPNELLQEYNWELADQPQNLEEILMHCQTTLKYAIKTGHPRYFN	QLSTGLDMVGLAADWLTSTANTNMFTYEIAPVFVLLEYVTLKKMREIIGWPGGSGDGIFS	PGGAISNMYAMMIARFKMFPEVKEKGMAALPRLIAFTSEHSHFSLKKGAAALGIGTDSVI	LIKCDERGKMIPSDLERRILEAKQKGFVPFLVSATAGTTVYGAFDPLLAVADICKKYKIW	MHVDAAWGGGLLMSRKHKWKLSGVERANSVTWNPHKMMGVPLQCSALLVREEGLMQNCNQ	MHASYLFQQDKHYDLSYDTGDKALQCGRHVDVFKLWLMWRAKGTTGFEAHVDKCLELAEY	LYNIIKNREGYEMVFDGKPQHTNVCFWYIPPSLRTLEDNEERMSRLSKVAPVIKARMMEY	GTTMVSYQPLGDKVNFFRMVISNPAATHQDIDFLIEEIERLGQDL
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AL162503
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAL162503%3E
>1758 bp	ATGGCATCTCCGGGCTCTGGCTTTTGGTCTTTCGGGTCGGAAGATGGCTCTGGGGATTCC	GAGAATCCCGGCACAGCGCGAGCCTGGTGCCAAGTGGCTCAGAAGTTCACGGGCGGCATC	GGAAACAAACTGTGCGCCCTGCTCTACGGAGACGCCGAGAAGCCGGCGGAGAGCGGCGGG	AGCCAACCCCCGCGGGCCGCCGCCCGGAAGGCCGCCTGCGCCTGCGACCAGAAGCCCTGC	AGCTGCTCCAAAGTGGATGTCAACTACGCGTTTCTCCATGCAACAGACCTGCTGCCGGCG	TGTGATGGAGAAAGGCCCACTTTGGCGTTTCTGCAAGATGTTATGAACATTTTACTTCAG	TATGTGGTGAAAAGTTTCGATAGATCAACCAAAGTGATTGATTTCCATTATCCTAATGAG	CTTCTCCAAGAATATAATTGGGAATTGGCAGACCAACCACAAAATTTGGAGGAAATTTTG	ATGCATTGCCAAACAACTCTAAAATATGCAATTAAAACAGGGCATCCTAGATACTTCAAT	CAACTTTCTACTGGTTTGGATATGGTTGGATTAGCAGCAGACTGGCTGACATCAACAGCA	AATACTAACATGTTCACCTATGAAATTGCTCCAGTATTTGTGCTTTTGGAATATGTCACA	CTAAAGAAAATGAGAGAAATCATTGGCTGGCCAGGGGGCTCTGGCGATGGGATATTTTCT	CCCGGTGGCGCCATATCTAACATGTATGCCATGATGATCGCACGCTTTAAGATGTTCCCA	GAAGTCAAGGAGAAAGGAATGGCTGCTCTTCCCAGGCTCATTGCCTTCACGTCTGAACAT	AGTCATTTTTCTCTCAAGAAGGGAGCTGCAGCCTTAGGGATTGGAACAGACAGCGTGATT	CTGATTAAATGTGATGAGAGAGGGAAAATGATTCCATCTGATCTTGAAAGAAGGATTCTT	GAAGCCAAACAGAAAGGGTTTGTTCCTTTCCTCGTGAGTGCCACAGCTGGAACCACCGTG	TACGGAGCATTTGACCCCCTCTTAGCTGTCGCTGACATTTGCAAAAAGTATAAGATCTGG	ATGCATGTGGATGCAGCTTGGGGTGGGGGATTACTGATGTCCCGAAAACACAAGTGGAAA	CTGAGTGGCGTGGAGAGGGCCAACTCTGTGACGTGGAATCCACACAAGATGATGGGAGTC	CCTTTGCAGTGCTCTGCTCTCCTGGTTAGAGAAGAGGGATTGATGCAGAATTGCAACCAA	ATGCATGCCTCCTACCTCTTTCAGCAAGATAAACATTATGACCTGTCCTATGACACTGGA	GACAAGGCCTTACAGTGCGGACGCCACGTTGATGTTTTTAAACTATGGCTGATGTGGAGG	GCAAAGGGGACTACCGGGTTTGAAGCGCATGTTGATAAATGTTTGGAGTTGGCAGAGTAT	TTATACAACATCATAAAAAACCGAGAAGGATATGAGATGGTGTTTGATGGGAAGCCTCAG	CACACAAATGTCTGCTTCTGGTACATTCCTCCAAGCTTGCGTACTCTGGAAGACAATGAA	GAGAGAATGAGTCGCCTCTCGAAGGTGGCTCCAGTGATTAAAGCCAGAATGATGGAGTAT	GGAACCACAATGGTCAGCTACCAACCCTTGGGAGACAAGGTCAATTTCTTCCGCATGGTC	ATCTCAAACCCAGCGGCAACTCACCAAGACATTGACTTCCTGATTGAAGAAATAGAACGC	CTTGGACAAGATTTATAA
http://bio2rdf.org/uniprot:Q5VZ30
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ5VZ30%3E
GAD2
http://bio2rdf.org/hgnc:4093
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A4093%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10978228
Glutamate decarboxylase 2
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/16075246
http://www.uniprot.org/uniprot/Q5VZ30
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ5VZ30%3E
Pancreatic islets and brain, 65kDa
10p11.23
http://symbol.bio2rdf.org/symbol:GAD2
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AGAD2%3E
AL162503
Q5VZ30_HUMAN
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=55662653
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D55662653%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=4093
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D4093%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8499653
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00393
_:header11874722131335206496855
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00393
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00393_DB00313
http://129.128.185.122/drugbank2/drugs/DB00393/inserts/2109/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00393%2Finserts%2F2109%2Ffull%3E
C21H26N2O7
http://www.drugbank.ca/drugs/DB00393
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00393%3E
COCCOC(=O)C1=C(C)NC(C)=C([C@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1627
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F1627%3E
http://bio2rdf.org/cpd:C07267
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC07267%3E
InChI=1/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3
Take at the same time each day, with or without food, but always in the same manner.
1.20e-02 mg/mL
Although the precise mechanism of action is not known, nimodipine blocks intracellular influx of calcium that is thought to be a central to ischaemic neuronal damage. Nimodipine binds specifically to L-type voltage-gated calcium channels.
Nimodipine
95%
COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/750
8-9 hours
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4497
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fsider%2Fresource%2Fdrugs%2F4497%3E
http://dbpedia.org/page/Nimodipine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FNimodipine%3E
UIAGMCDKSXEBJQ-UHFFFAOYAP
Bioavailability is 100% following intravenous administration and 13% following oral administration.
http://en.wikipedia.org/wiki/Nimodipine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FNimodipine%3E
http://www.dbpedia.org/resource/Nimodipine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FNimodipine%3E
Nimodipino [INN-Spanish]
2008-10-23 19:42:25 UTC
http://dbpedia.org/resource/Nimodipine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FNimodipine%3E
Periplum
O5-(2-methoxyethyl) O3-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
2000-08-01	/drugs/393/fda_labels/370
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3662
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3662%3E
Nimodipine belongs to the class of pharmacological agents known as calcium channel blockers. Nimodipine is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured congenital aneurysms who are in good neurological condition post-ictus (e.g., Hunt and Hess Grades I-III). The contractile processes of smooth muscle cells are dependent upon calcium ions, which enter these cells during depolarization as slow ionic transmembrane currents. Nimodipine inhibits calcium ion transfer into these cells and thus inhibits contractions of vascular smooth muscle. In animal experiments, nimodipine had a greater effect on cerebral arteries than on arteries elsewhere in the body perhaps because it is highly lipophilic, allowing it to cross the blood brain barrier.
Nimotop
A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure. [PubChem]
C08CA06
http://bio2rdf.org/kegg:D00438
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD00438%3E
DB00393
Nimodipinum [INN-Latin]
Grapefruit and grapefruit juice should be avoided throughout treatment. Grapefruit can increase serum levels of this product.
http://data.linkedct.org/resource/intervention/19099
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F19099%3E
125 oC
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2057
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2057%3E
PA450633
http://www.rxlist.com/cgi/generic2/nimodip.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric2%2Fnimodip.htm%3E
http://bio2rdf.org/cas:66085-59-4
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A66085-59-4%3E
http://129.128.185.122/drugbank2/drugs/DB00393/inserts/1100/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00393%2Finserts%2F1100%2Ffull%3E
http://data.linkedct.org/resource/intervention/9905
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F9905%3E
aprd00612
24:12.92
/drugs/393/safety_sheets/876
For the treatment of subarachnoid bleeding.
http://205.193.93.51/dpdonline/searchRequest.do?din=02155923
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02155923%3E
Symptoms of overdosage would be expected to be related to cardiovascular effects such as excessive peripheral vasodilation with marked systemic hypotension.
RDF Description of Nimodipine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00393_DB00510
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01369_DB00393
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00393_DB01369
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00510_DB00393
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00501_DB00393
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00393_DB00501
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00022
_:header1627008561335206497357
Mon, 23 Apr 2012 18:34:52 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00022
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00022_DB01223
PA10153
PEG-Intron	(Schering Corp)
For the treatment of chronic hepatitis C in patients not previously treated with interferon alpha who have compensated liver disease and are at least 18 years of age.
http://www.rxlist.com/cgi/generic2/peginterferon.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric2%2Fpeginterferon.htm%3E
http://dbpedia.org/resource/Peginterferon_alfa-2b
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FPeginterferon_alfa-2b%3E
2004-03-01	/drugs/22/fda_labels/621
Unitron PEG
http://dbpedia.org/page/Peginterferon_alfa-2b
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FPeginterferon_alfa-2b%3E
http://en.wikipedia.org/wiki/Peginterferon_alfa-2b
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FPeginterferon_alfa-2b%3E
biod00048
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/728
61 oC (Beldarrain, A. et al., Biochemistry 38:7865-7873 (1999)) Davis JM, Narachi MA, Levine HL, Alton NK, Arakawa T. Conformation and stability of two recombinant human interferon-alpha analogs.
http://129.128.185.122/drugbank2/drugs/DB00022/inserts/2622/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00022%2Finserts%2F2622%2Ffull%3E
http://www.uniprot.org/uniprot/P01563
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP01563%3E
IFNA2_HUMAN
2008-03-17 16:05:29 UTC
1RH2
http://129.128.185.122/drugbank2/drugs/DB00022/inserts/1636/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00022%2Finserts%2F1636%2Ffull%3E
L03AB10
The mean elimination half-life is approximately 40 hours (range 22 to 60 hours) in patients with HCV infection.
http://bio2rdf.org/uniprot:P01563
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP01563%3E
http://data.linkedct.org/resource/intervention/22678
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F22678%3E
http://205.193.93.51/dpdonline/searchRequest.do?din=02242966
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02242966%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/428
Peginterferon alfa-2b
http://data.linkedct.org/resource/intervention/10985
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F10985%3E
http://data.linkedct.org/resource/intervention/47392
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F47392%3E
DB00022
http://bio2rdf.org/cas:99210-65-8
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A99210-65-8%3E
btd00048
Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.
Following a single subcutaneous dose of peginterferon alfa-2b, the mean absorption half-life (t&frac12; k<sub>a</sub>) was 4.6 hours.
http://data.linkedct.org/resource/intervention/47363
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F47363%3E
Peginterferon alfa-2b is a covalent conjugate of recombinant alfa-2b interferon with monomethoxy polyethylene glycol (PEG). The average molecular weight of the PEG portion of the molecule is 12,000 daltons. The average molecular weight of the PEG-Intron molecule is approximately 31,000 daltons. The specific activity of peginterferon alfa-2b is approximately 0.7 x 108 IU/mg protein. Interferon alfa-2b is a water-soluble protein with a molecular weight of 19,271 daltons produced by recombinant DNA techniques. It is obtained from the bacterial fermentation of a strain of <i>Escherichia coli</i> bearing a genetically engineered plasmid containing an interferon gene from human leukocytes. The PEG strand protects the molecule in vivo from proteolytic breakdown, substantially increases its in vivo half-life, and reduces immunogenicity by wrapping around and physically hindering access to the protein portion of the molecule.
Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.
>DB00022 sequence	CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI	QQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVR	KYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE
08:18.20
http://www.drugbank.ca/drugs/DB00022
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00022%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00022_DB01303
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01303_DB00022
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00277_DB00022
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00022_DB00277
RDF Description of Peginterferon alfa-2b
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01223_DB00022
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00022_DB00651
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/1256
_:header1274107971335206497679
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/1256
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB06144
http://bio2rdf.org/hgnc:5301
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A5301%3E
http://symbol.bio2rdf.org/symbol:HTR6
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AHTR6%3E
5-HT-6
65-85
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8522988
L41147
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/270770
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17239595
1p36-p35
101-122
5-hydroxytryptamine 6 receptor
http://www.uniprot.org/uniprot/P50406
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP50406%3E
>5-hydroxytryptamine 6 receptor	MVPEPGPTANSTPAWGAGPPSAPGGSGWVAAALCVVIALTAAANSLLIALICTQPALRNT	SNFFLVSLFTSDLMVGLVVMPPAMLNALYGRWVLARGLCLLWTAFDVMCCSASILNLCLI	SLDRYLLILSPLRYKLRMTPLRALALVLGAWSLAALASFLPLLLGWHELGHARPPVPGQC	RLLASLPFVLVASGLTFFLPSGAICFTYCRILLAARKQAVQVASLTTGMASQASETLQVP	RTPRPGVESADSRRLATKHSRKALKASLTLGILLGMFFVTWLPFFVANIVQAVCDCISPG	LFDVLTWLGYCNSTMNPIIYPLFMRDFKRALGRFLPCPRCPRERQASLASPSLRTSHSGP	RPGLSLQQVLPLPLPPDSDSDSDAGSGGSSGLRLTAQLLLPGEATQDPPLPTRAAAAVNF	FNIDPAEPELRPHPLGIPTN
Involved in rhodopsin-like receptor activity
Serotonin receptor 6
http://bio2rdf.org/uniprot:P50406
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP50406%3E
296-320
>1323 bp	ATGGTCCCAGAGCCGGGCCCAACCGCCAATAGCACCCCGGCCTGGGGGGCAGGGCCGCCG	TCGGCCCCGGGGGGCAGCGGCTGGGTGGCGGCCGCGCTGTGCGTGGTCATCGCGCTGACG	GCGGCGGCCAACTCGCTGCTGATCGCGCTCATCTGCACTCAGCCCGCGCTGCGCAACACG	TCCAACTTCTTCCTGGTGTCGCTCTTCACGTCTGACCTGATGGTGGGGCTGGTGGTGATG	CCGCCGGCCATGCTGAACGCGCTGTACGGGCGCTGGGTGCTGGCGCGCGGCCTCTGCCTG	CTCTGGACCGCCTTCGACGTGATGTGCTGCAGCGCCTCCATCCTCAACCTCTGCCTCATC	AGCCTGGACCGCTACCTGCTCATCCTCTCGCCGCTGCGCTACAAGCTGCGCATGACGCCC	CTGCGTGCCCTGGCCCTAGTCCTGGGCGCCTGGAGCCTCGCCGCTCTCGCCTCCTTCCTG	CCCCTGCTGCTGGGCTGGCACGAGCTGGGCCACGCACGGCCACCCGTCCCTGGCCAGTGC	CGCCTGCTGGCCAGCCTGCCTTTTGTCCTTGTGGCGTCGGGCCTCACCTTCTTCCTGCCC	TCGGGTGCCATATGCTTCACCTACTGCAGGATCCTGCTAGCTGCCCGCAAGCAGGCCGTG	CAGGTGGCCTCCCTCACCACCGGCATGGCCAGTCAGGCCTCGGAGACGCTGCAGGTGCCC	AGGACCCCACGCCCAGGGGTGGAGTCTGCTGACAGCAGGCGTCTAGCCACGAAGCACAGC	AGGAAGGCCCTGAAGGCCAGCCTGACGCTGGGCATCCTGCTGGGCATGTTCTTTGTGACC	TGGTTGCCCTTCTTTGTGGCCAACATAGTCCAGGCCGTGTGCGACTGCATCTCCCCAGGC	CTCTTCGATGTCCTCACATGGCTGGGTTACTGTAACAGCACCATGAACCCCATCATCTAC	CCACTCTTCATGCGGGACTTCAAGCGGGCGCTGGGCAGGTTCCTGCCATGTCCACGCTGT	CCCCGGGAGCGCCAGGCCAGCCTGGCCTCGCCATCACTGCGCACCTCTCACAGCGGCCCC	CGGCCCGGCCTTAGCCTACAGCAGGTGCTGCCGCTGCCCCTGCCGCCGGACTCAGATTCG	GACTCAGACGCAGGCTCAGGCGGCTCCTCGGGCCTGCGGCTCACGGCCCAGCTGCTGCTT	CCTGGCGAGGCCACCCAGGACCCCCCGCTGCCCACCAGGGCCGCTGCCGCCGTCAATTTC	TTCAACATCGACCCCGCGGAGCCCGAGCTGCGGCCGCATCCACTTGGCATCCCCACGAAC	TGA
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=1162924
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D1162924%3E
This is one of the several different receptors for 5- hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11888555
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=L41147
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DL41147%3E
145-166
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/278843
HTR6
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10715164
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7656980
http://www.genenames.org/data/hgnc_data.php?hgnc_id=5301
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D5301%3E
35-57
5HT6R_HUMAN
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/gene/HTR6
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fgene%2FHTR6%3E
185-208
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00889
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00904
RDF Description of 5-hydroxytryptamine 6 receptor
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01488
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Summerhayes_Martha_1844-1926
_:header483286451335206498098
Mon, 23 Apr 2012 18:34:53 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Summerhayes_Martha_1844-1926
Summerhayes, Martha, 1844-1926
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1049
RDF Description of Summerhayes, Martha, 1844-1926
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/FitzGerald_Edward_1809-1883
_:header13449409131335206498503
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/FitzGerald_Edward_1809-1883
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext246
FitzGerald, Edward, 1809-1883
FitzGerald, Edward, 1809-1883 
RDF Description of FitzGerald, Edward, 1809-1883
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext20539
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2587
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext20452
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0007642
_:header11262483201335206499004
http://dbpedia.org/resource/Cellulitis
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FCellulitis%3E
http://sideeffects.embl.de/se/C0007642
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0007642%3E
cellulitis
C0007642
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/145068
RDF Description of cellulitis
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/8953
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5746
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0027709
_:header16944229901335206499417
Mon, 23 Apr 2012 18:34:54 GMT
RDF Description of nephrocalcinosis
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0027709
http://sideeffects.embl.de/se/C0027709
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0027709%3E
nephrocalcinosis
C0027709
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/1003
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3249
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/1934
_:header9235934411335206499830
RDF Description of Colorectal cancer
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1934
http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=116806
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fdispomim.cgi%3Fid%3D116806%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/chromosomalLocation/3p22-p21.3
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/CTNNB1
Colorectal cancer
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01356
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01356%3E
http://bio2rdf.org/omim:116806
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fomim%3A116806%3E
http://data.linkedct.org/resource/condition/3060
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fcondition%2F3060%3E
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/IL12B
_:header15973310291335206500201
Mon, 23 Apr 2012 18:34:55 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/IL12B
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1503
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/gene/IL12B
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fgene%2FIL12B%3E
http://symbol.bio2rdf.org/symbol:IL12B
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AIL12B%3E
IL12B
RDF Description of IL12B
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/68740
_:header12900845541335206500717
RDF Description of ZOLEDRONIC ACID
http://www.fda.gov/cder/foi/label/2008/021223s016lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2008%2F021223s016lbl.pdf%3E
http://www.fda.gov/medwatch/SAFETY/2005/Jan_PI/Zometa_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2005%2FJan_PI%2FZometa_PI.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0175677
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020453
ZOLEDRONIC ACID
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0232493
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000068740&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000068740%26input_query_species%3D9606%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0029408
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0036416
http://www.fda.gov/cder/foi/label/2002/21386lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2002%2F21386lbl.pdf%3E
http://sideeffects.embl.de/drugs/68740
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F68740%3E
http://www.fda.gov/medwatch/SAFETY/2007/Nov_PI/Zometa_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2007%2FNov_PI%2FZometa_PI.pdf%3E
http://www.fda.gov/cder/foi/label/2008/021817s001lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2008%2F021817s001lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00399
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00399%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0037011
http://www.fda.gov/medwatch/SAFETY/2004/feb_PI/Zometa_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2004%2Ffeb_PI%2FZometa_PI.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0520474
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0029456
http://www.fda.gov/medwatch/SAFETY/2008/Jun_PI/Reclast_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2008%2FJun_PI%2FReclast_PI.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0026858
http://www.fda.gov/medwatch/SAFETY/2005/Oct_PI/Zometa_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2005%2FOct_PI%2FZometa_PI.pdf%3E
Zometa
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0014583
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020502
zoledronic acid
http://www.fda.gov/medwatch/SAFETY/2008/Mar_PI/Zometa_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2008%2FMar_PI%2FZometa_PI.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0022661
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/910
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F910%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0019557
http://www.fda.gov/cder/foi/label/2003/21223scf004_zometa_lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2003%2F21223scf004_zometa_lbl.pdf%3E
http://dbpedia.org/resource/Zoledronic_acid
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FZoledronic_acid%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0001430
http://www.fda.gov/cder/foi/label/2007/022080lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2007%2F022080lbl.pdf%3E
http://www.fda.gov/medwatch/SAFETY/2006/May_PIs/Zometa_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2006%2FMay_PIs%2FZometa_PI.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0031090
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020437
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=5zFUzYOYUUY=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3D5zFUzYOYUUY%3D%3E
http://www.fda.gov/cder/foi/label/2004/21223slr008_zometa_lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2004%2F21223slr008_zometa_lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0080179
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000068740
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000068740%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0242528
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/4070
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F4070%3E
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=WpMfs24iNz8=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DWpMfs24iNz8%3D%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0016658
http://www.fda.gov/cder/foi/label/2007/021223s014lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2007%2F021223s014lbl.pdf%3E
http://www.fda.gov/cder/foi/label/2005/021223s011lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2005%2F021223s011lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020488
http://www.fda.gov/cder/foi/label/2001/21223lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2001%2F21223lbl.pdf%3E
http://www.fda.gov/medwatch/SAFETY/2004/mar_PI/Zometa_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2004%2Fmar_PI%2FZometa_PI.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0221247
CID0000068740
http://www.fda.gov/cder/foi/label/2006/021223s012lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2006%2F021223s012lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0026764
Reclast
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0022081
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C1378703
http://www.fda.gov/cder/foi/label/2007/021817lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2007%2F021817lbl.pdf%3E
http://www.fda.gov/cder/foi/label/2004/021223s006lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2004%2F021223s006lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00590
_:header7523936841335206501097
Mon, 23 Apr 2012 18:34:56 GMT
RDF Description of Doxazosin
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00590
http://129.128.185.122/drugbank2/drugs/DB00590/inserts/2620/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00590%2Finserts%2F2620%2Ffull%3E
Supressin
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/alpha-adrenergicBlockingAgents
http://dbpedia.org/resource/Doxazosin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FDoxazosin%3E
Cardura-4
http://129.128.185.122/drugbank2/drugs/DB00590/inserts/649/full
Alfadil
RUZYUOTYCVRMRZ-PECIQRARCR
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/789
http://data.linkedct.org/resource/intervention/55078
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F55078%3E
289-290oC
InChI=1/C23H25N5O5/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26)/f/h24H2
http://data.linkedct.org/resource/intervention/27363
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F27363%3E
C23H25N5O5
2004-06-01	/drugs/590/fda_labels/741	2005-02-01	/drugs/590/fda_labels/757
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/adrenergicAlpha-antagonists
24 mg/L
A selective alpha-1-adrenergic blocker that lowers serum cholesterol. It is also effective in the treatment of hypertension. [PubChem]
http://data.linkedct.org/resource/intervention/17156
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F17156%3E
http://www.rxlist.com/cgi/generic/doxazo.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric%2Fdoxazo.htm%3E
Carduran
Doxazosin
http://129.128.185.122/drugbank2/drugs/DB00590/inserts/1634/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00590%2Finserts%2F1634%2Ffull%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/632
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/556
Cardenalin
22 hours
Cardura-2
Normothen
Diblocin
Doxazosin acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.
DB00590
http://bio2rdf.org/cpd:C06970
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC06970%3E
S. F. Campbell, U.S. Pat. 4,188,390 (1980)
aprd00474
http://bio2rdf.org/cas:74191-85-8
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A74191-85-8%3E
http://data.linkedct.org/resource/intervention/46965
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F46965%3E
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/car1069.shtml
Cardura
http://www.drugbank.ca/drugs/DB00590
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00590%3E
Cardura-1
Doxazosin is an alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Accordingly, Doxazosin is a selective inhibitor of the alpha1 subtype of alpha adrenergic receptors. In the human prostate, Doxazosin antagonizes phenylephrine (alpha1 agonist)-induced contractions, <i>in vitro</i>, and binds with high affinity to the alpha1c adrenoceptor, which is thought to be the predominant functional type in the prostate. Studies in normal human subjects have shown that Doxazosin competitively antagonized the pressor effects of phenylephrine (an alpha1 agonist) and the systolic pressor effect of norepinephrine. The antihypertensive effect of Doxazosin results from a decrease in systemic vascular resistance and the parent compound Doxazosin is primarily responsible for the antihypertensive activity.
C02CA04
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-2-yl)methanone
7.90e-01 mg/mL
http://data.linkedct.org/resource/intervention/40560
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F40560%3E
Cardular
98%
http://dbpedia.org/page/Doxazosin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FDoxazosin%3E
COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1
COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)[C@H]1COC2=CC=CC=C2O1
http://205.193.93.51/dpdonline/searchRequest.do?din=02243217
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02243217%3E
http://en.wikipedia.org/wiki/Doxazosin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FDoxazosin%3E
Symptoms of overdose include hypotension. Oral LD<sub>50</sub> is greater than 1000 mg/kg in mice and rats.
For treatment and management of Hypertension and urinary obstruction symptoms of BPH.
PA449407
24:20.00
2008-08-26 16:45:17 UTC
65%
Doxazosin mesylate
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00590_DB00862
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00590_DB00820
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01073
_:header20141459971335206501591
RDF Description of Fludarabine
19-29%
http://129.128.185.122/drugbank2/drugs/DB01073/inserts/1066/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB01073%2Finserts%2F1066%2Ffull%3E
http://data.linkedct.org/resource/intervention/17548
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F17548%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3957
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1091
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1091%3E
aprd00594
http://www.drugbank.ca/drugs/DB01073
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01073%3E
http://data.linkedct.org/resource/intervention/26181
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F26181%3E
/drugs/1073/safety_sheets/768
For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1046
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1046%3E
http://205.193.93.51/dpdonline/searchRequest.do?din=02246226
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02246226%3E
http://data.linkedct.org/resource/intervention/26754
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F26754%3E
Fludarabine 5'-monophosphate
http://data.linkedct.org/resource/intervention/27605
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F27605%3E
http://bio2rdf.org/cas:75607-67-9
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A75607-67-9%3E
Bioavailability is 55% following oral administration.
Fludara
http://data.linkedct.org/resource/intervention/38491
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F38491%3E
http://data.linkedct.org/resource/intervention/26738
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F26738%3E
NC1=C2N=CN(C3OC(COP(O)(O)=O)C(O)C3O)C2=NC(F)=N1
http://dbpedia.org/resource/Fludarabine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FFludarabine%3E
http://129.128.185.122/drugbank2/drugs/DB01073/inserts/2078/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB01073%2Finserts%2F2078%2Ffull%3E
http://data.linkedct.org/resource/intervention/25980
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F25980%3E
http://data.linkedct.org/resource/intervention/61251
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F61251%3E
http://data.linkedct.org/resource/intervention/32140
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F32140%3E
http://data.linkedct.org/resource/intervention/26751
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F26751%3E
Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis. The mechanism of action of this antimetabolite is not completely characterized and may be multi-faceted.
2.96e+00 mg/mL
C10H13FN5O7P
Fludura
http://data.linkedct.org/resource/intervention/25973
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F25973%3E
DB01073
http://data.linkedct.org/resource/intervention/27602
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F27602%3E
Fludarabine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/603
http://data.linkedct.org/resource/intervention/27598
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F27598%3E
http://data.linkedct.org/resource/intervention/37745
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F37745%3E
http://data.linkedct.org/resource/intervention/38731
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F38731%3E
http://data.linkedct.org/resource/intervention/5602
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F5602%3E
20 hours
NC1=C2N=CN([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]3O)C2=NC(F)=N1
InChI=1/C10H13FN5O7P/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(18)5(17)3(23-9)1-22-24(19,20)21/h2-3,5-6,9,17-18H,1H2,(H2,12,14,15)(H2,19,20,21)/t3-,5-,6+,9-/m1/s1/f/h19-20H,12H2
http://data.linkedct.org/resource/intervention/39141
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F39141%3E
http://data.linkedct.org/resource/intervention/35334
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35334%3E
http://129.128.185.122/drugbank2/drugs/DB01073/inserts/253/full
L01BB05
Fludarabine is a chemotherapy drug used in the treatment of chronic lymphocytic leukemia. It acts at DNA polymerase alpha, ribonucleotide reductase and DNA primase, results in the inhibition of DNA synthesis, and destroys the cancer cells.
Fludarabine monophosphate
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3266
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3266%3E
http://dbpedia.org/page/Fludarabine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FFludarabine%3E
FAMP
3.53 mg/ml
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3976
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3976%3E
J. A. Montgomery, U.S. pat. 4,210,745 (1980 to U.S. Dept. Health, Education and Welfare)
http://data.linkedct.org/resource/intervention/26740
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F26740%3E
Fludarabine (marketed as fludarabine phosphate under the trade name Fludara) is a chemotherapy drug used in the treatment of hematological malignancies. [Wikipedia]
http://data.linkedct.org/resource/intervention/30612
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F30612%3E
http://data.linkedct.org/resource/intervention/37748
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F37748%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1335
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1335%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/984
http://bio2rdf.org/kegg:D01907
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD01907%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/788
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F788%3E
http://data.linkedct.org/resource/intervention/26742
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F26742%3E
Food slightly increases product bioavailability.
http://data.linkedct.org/resource/intervention/38769
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F38769%3E
http://data.linkedct.org/resource/intervention/27010
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F27010%3E
http://data.linkedct.org/resource/intervention/5343
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F5343%3E
http://data.linkedct.org/resource/intervention/37743
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F37743%3E
http://data.linkedct.org/resource/intervention/35293
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35293%3E
http://en.wikipedia.org/wiki/Fludarabine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FFludarabine%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/35
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F35%3E
http://data.linkedct.org/resource/intervention/25982
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F25982%3E
http://data.linkedct.org/resource/intervention/38786
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F38786%3E
Fludarabine phosphate
http://data.linkedct.org/resource/intervention/38384
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F38384%3E
http://data.linkedct.org/resource/intervention/37750
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F37750%3E
http://data.linkedct.org/resource/intervention/26749
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F26749%3E
[(2R,3S,4S,5R)-5-(6-amino-2-fluoropurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
GIUYCYHIANZCFB-DOXDFKSTDC
http://data.linkedct.org/resource/intervention/29130
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F29130%3E
260 oC
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3873
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3873%3E
PA449655
http://www.dbpedia.org/resource/Fludarabine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FFludarabine%3E
http://data.linkedct.org/resource/intervention/57935
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F57935%3E
2008-08-26 15:52:23 UTC
http://data.linkedct.org/resource/intervention/57728
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F57728%3E
http://www.rxlist.com/cgi/generic/fludarabine.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric%2Ffludarabine.htm%3E
http://data.linkedct.org/resource/intervention/35349
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35349%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01073_DB00552
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00975_DB01073
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01073_DB00975
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0152169
_:header5248383271335206502001
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0152169
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4911
http://dbpedia.org/resource/Renal_colic
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FRenal_colic%3E
http://sideeffects.embl.de/se/C0152169
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0152169%3E
renal colic
C0152169
RDF Description of renal colic
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/SBF2
_:header6638071481335206502413
Mon, 23 Apr 2012 18:34:57 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/SBF2
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1845
http://symbol.bio2rdf.org/symbol:SBF2
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ASBF2%3E
SBF2
http://www.dbpedia.org/resource/SBF2
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FSBF2%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1844
RDF Description of SBF2
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00665
_:header1751638431335206502846
RDF Description of Nilutamide
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00665
XWXYUMMDTVBTOU-WYUMXYHSCQ
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3934
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3934%3E
L02BB02
http://en.wikipedia.org/wiki/Nilutamide
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FNilutamide%3E
5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione
Rapidly and completely absorbed, yielding high and persistent plasma concentrations.
Nilutamide competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue.
aprd00150
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/84
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F84%3E
Nilutamida [Spanish]
Nilandron
http://www.rxlist.com/cgi/generic2/nilutam.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric2%2Fnilutam.htm%3E
For use in combination with surgical castration for the treatment of metastatic prostate cancer (Stage D2)
Take before breakfast.
InChI=1/C12H10F3N3O4/c1-11(2)9(19)17(10(20)16-11)6-3-4-8(18(21)22)7(5-6)12(13,14)15/h3-5H,1-2H3,(H,16,20)/f/h16H
PA450632
http://129.128.185.122/drugbank2/drugs/DB00665/inserts/2615/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00665%2Finserts%2F2615%2Ffull%3E
http://205.193.93.51/dpdonline/searchRequest.do?din=02221861
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02221861%3E
http://data.linkedct.org/resource/intervention/19098
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F19098%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/146
http://129.128.185.122/drugbank2/drugs/DB00665/inserts/643/full
Nilutamide
http://bio2rdf.org/cas:63612-50-0
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A63612-50-0%3E
DB00665
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
C12H10F3N3O4
http://129.128.185.122/drugbank2/drugs/DB00665/inserts/1627/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00665%2Finserts%2F1627%2Ffull%3E
38.0-59.1 hours
Nilandrone
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/androgenAntagonists
http://dbpedia.org/resource/Nilutamide
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FNilutamide%3E
Anandron
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3658
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3658%3E
Nilutamide [Usan:Ban:Inn]
http://dbpedia.org/page/Nilutamide
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FNilutamide%3E
http://bio2rdf.org/kegg:D00965
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD00965%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1439
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1439%3E
http://bio2rdf.org/cpd:C08164
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC08164%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/910
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F910%3E
http://www.drugbank.ca/drugs/DB00665
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00665%3E
2008-08-26 16:51:15 UTC
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1677
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F1677%3E
Symptoms of overdose include dizziness, general discomfort, headache, nausea, and vomiting.
The results of a human metabolism study using 14C-radiolabelled tablets show that nilutamide is extensively metabolized and less than 2% of the drug is excreted unchanged in urine after 5 days.
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1676
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1676%3E
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/nil1294.shtml
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3559
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3559%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1080
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1080%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3664
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3664%3E
CC1(C)NC(=O)N(C1=O)C1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/173
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F173%3E
Nilutamidum [Latin]
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/960
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F960%3E
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Sinclair_Upton_1878-1968
_:header323313811335206503242
Mon, 23 Apr 2012 18:34:58 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Sinclair_Upton_1878-1968
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7774
Sinclair, Upton, 1878-1968
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5806
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5677
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5776
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5961
RDF Description of Sinclair, Upton, 1878-1968
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3302
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1558
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext16470
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1157
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5774
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3301
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3304
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext140
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3303
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext4923
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5829
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6556
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5807
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7522
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5421
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5964
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/NEU
_:header12269617711335206503657
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/NEU
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1327
http://symbol.bio2rdf.org/symbol:NEU
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ANEU%3E
NEU
http://www.dbpedia.org/resource/neu
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2Fneu%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3890
RDF Description of NEU
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3889
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2435
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2470
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3489
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/3049
_:header2328251651335206504178
Mon, 23 Apr 2012 18:34:59 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3049
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02756
http://bio2rdf.org/pdb:1G0O
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1G0O%3E
http://www.pdb.org/pdb/explore/explore.do?structureId=1G0O
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1G0O%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=431103
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D431103%3E
http://pfam.sanger.ac.uk/family?acc=PF00106
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00106%3E
T4HR_MAGGR
scytalone + NADP+ = 1,3,6,8-tetrahydroxynaphthalene + NADPH + H+
EC 1.1.1.252
Tetrahydroxynaphthalene reductase
L22309
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=L22309
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DL22309%3E
http://www.uniprot.org/uniprot/Q12634
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ12634%3E
THNR
>852 bp	ATGCCTGCCGTCACTCAACCCCGCGGCGAGAGCAAGTATGACGCGATCCCAGGCCCCTTG	GGTCCTCAGTCAGCCTCTCTTGAGGGCAAGGTTGCCCTCGTGACTGGCGCTGGCCGTGGT	ATCGGCAGGGAAATGGCCATGGAGCTCGGTCGTCGTGGCTGCAAGGTCATTGTCAACTAC	GCCAACAGCACCGAGTCCGCCGAGGAGGTCGTCGCCGCCATCAAGAAGAACGGCTCTGAC	GCTGCCTGCGTCAAGGCCAACGTTGGTGTCGTCGAGGACATCGTCAGGATGTTCGAGGAG	GCCGTCAAGATCTTTGGCAAGCTCGACATCGTTTGCTCCAACAGCGGCGTCGTCTCCTTC	GGCCACGTCAAGGACGTCACCCCTGAGGAATTTGACCGTGTCTTTACCATCAACACCCGT	GGCCAGTTCTTTGTCGCCCGCGAGGCCTACAAGCACCTCGAGATTGGTGGTCGCCTGATT	CTGATGGGCTCCATCACTGGCCAGGCCAAGGCTGTGCCCAAGCACGCCGTCTACTCAGGA	TCAAAGGGTGCCATCGAGACATTTGCTCGCTGCATGGCTATCGACATGGCCGACAAGAAG	ATTACTGTTAATGTGGTTGCTCCTGGTGGTATCAAGACCGATATGTACCATGCAGTCTGC	AGGGAATACATTCCAAACGGCGAGAATCTCTCCAACGAGGAGGTTGACGAGTATGCCGCG	AGCGCTTGGAGCCCTCTACATCGTGTGGGCCTGCCGATCGATATTGCCCGTGTGGTCTGC	TTTCTGGCCTCGAACGATGGCGGCTGGGTCACTGGGAAAGTGATCGGTATCGACGGCGGT	GCTTGCATGTAA
http://bio2rdf.org/pfam:PF00106
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00106%3E
T4HN reductase
>Tetrahydroxynaphthalene reductase	MPAVTQPRGESKYDAIPGPLGPQSASLEGKVALVTGAGRGIGREMAMELGRRGCKVIVNY	ANSTESAEEVVAAIKKNGSDAACVKANVGVVEDIVRMFEEAVKIFGKLDIVCSNSGVVSF	GHVKDVTPEEFDRVFTINTRGQFFVAREAYKHLEIGGRLILMGSITGQAKAVPKHAVYSG	SKGAIETFARCMAIDMADKKITVNVVAPGGIKTDMYHAVCREYIPNGENLSNEEVDEYAA	SAWSPLHRVGLPIDIARVVCFLASNDGGWVTGKVIGIDGGACM
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8939741
Catalyzes the NADPH-dependent reduction of 1,3,6,8- tetrahydroxynaphthalene (T4HN) into (+)-scytalone and 1,3,8- trihydroxynaphthalene into (-)-vermelone. This enzyme is the biochemical target of several commercially important fungicides which are used to prevent blast disease in rice plants
http://bio2rdf.org/uniprot:Q12634
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ12634%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8112349
RDF Description of Tetrahydroxynaphthalene reductase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04479
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02891
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03302
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Cobb_Irvin_S_(Irvin_Shrewsbury)_1876-1944
_:header19879803631335206504440
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Cobb_Irvin_S_(Irvin_Shrewsbury)_1876-1944
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext18526
Cobb, Irvin S. (Irvin Shrewsbury), 1876-1944
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1222
RDF Description of Cobb, Irvin S. (Irvin Shrewsbury), 1876-1944
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1891
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext16197
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext10798
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext4551
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1890
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19479
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Carr_Terry_Gene_1937-1987
_:header3185648251335206504882
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Carr_Terry_Gene_1937-1987
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17958
Carr, Terry Gene, 1937-1987
RDF Description of Carr, Terry Gene, 1937-1987
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Newman_Francis_William_1805-1897
_:header610578531335206505287
Mon, 23 Apr 2012 18:35:00 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Newman_Francis_William_1805-1897
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext12056
Newman, Francis William, 1805-1897
RDF Description of Newman, Francis William, 1805-1897
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00964
_:header4919202551335206505732
RDF Description of Apraclonidine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00964
2008-08-26 16:08:42 UTC
http://129.128.185.122/drugbank2/drugs/DB00964/inserts/1452/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00964%2Finserts%2F1452%2Ffull%3E
P-Aminoclonidine Hydrochloride
52:92.00
http://www.rxlist.com/cgi/generic2/apraclonidine.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric2%2Fapraclonidine.htm%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/eentDrugs
http://en.wikipedia.org/wiki/Apraclonidine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FApraclonidine%3E
DB00964
Apraclonidine
/drugs/964/safety_sheets/1366
4.09e-01 mg/mL
2002-03-01	/drugs/964/fda_labels/300	2004-06-01	/drugs/964/fda_labels/1054
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/liquidOphthalmic
http://bio2rdf.org/cpd:C07668
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC07668%3E
Topical use of apraclonidine ophthalmic solution leads to systemic absorption. Studies of apraclonidine (0.5% ophthalmic solution) dosed one drop three times a day in both eyes for 10 days in normal volunteers yielded mean peak and trough concentrations of 0.9 ng/mL and 0.5 ng/mL, respectively.
Accidental or intentional ingestion of oral apraclonidine has been reported to cause apnea, arrhythmias, asthenia, bradycardia, conduction defects, diminished or absent reflexes, dryness of the mouth, hypotension, hypothermia, hypoventilation, irritability, lethargy, miosis, pallor, respiratory depression, sedation or coma, seizure, somnolence, transient hypertension, and vomiting.
Iopidine Eye
PA448468
http://www.dbpedia.org/resource/Apraclonidine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FApraclonidine%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/antiglaucomicAgents
Apraclonidine is an alpha adrenergic receptor agonist. It has a peak ocular hypotensive effect occurring at two hours post-dosing. Fluorophotometric studies in animals and humans suggest that Apraclonidine has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow.
aprd00012
Apraclonidina [INN-Spanish]
NC1=CC(Cl)=C(NC2=NCCN2)C(Cl)=C1
98.7%
8 hours
Apraclonidine significantly lowers intraocular pressure with minimal effects on cardiovascular and pulmonary parameters. It lowers intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow.
http://dbpedia.org/page/Apraclonidine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FApraclonidine%3E
S01EA03
http://www.drugbank.ca/drugs/DB00964
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00964%3E
http://dbpedia.org/resource/Apraclonidine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FApraclonidine%3E
http://129.128.185.122/drugbank2/drugs/DB00964/inserts/2451/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00964%2Finserts%2F2451%2Ffull%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3791
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3791%3E
Apraclonidinum [INN-Latin]
InChI=1/C9H10Cl2N4/c10-6-3-5(12)4-7(11)8(6)15-9-13-1-2-14-9/h3-4H,1-2,12H2,(H2,13,14,15)/f/h13,15H
http://205.193.93.51/dpdonline/searchRequest.do?din=02076306
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02076306%3E
For short-term adjunctive therapy in patients on maximally tolerated medical therapy who require additional Intra Ocular Pressure (IOP) reduction.
http://bio2rdf.org/cas:66711-21-5
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A66711-21-5%3E
IEJXVRYNEISIKR-YENFCIRVCF
C9H10Cl2N4
Apraclonidine, also known as iopidine, is a sympathomimetic used in glaucoma therapy. It is an alpha2-adrenergic agonist.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/solution/DropsOphthalmic
2,6-dichloro-N-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/adrenergicAlpha-agonists
Iopidine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/318
Aplonidine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/ophthalmics
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/ALG1
_:header15340492021335206506106
Mon, 23 Apr 2012 18:35:01 GMT
RDF Description of ALG1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/ALG1
http://symbol.bio2rdf.org/symbol:ALG1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AALG1%3E
ALG1
http://bio2rdf.org/hgnc:18294
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A18294%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=18294
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D18294%3E
http://bio2rdf.org/geneid:56052
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fgeneid%3A56052%3E
http://www.dbpedia.org/resource/ALG1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FALG1%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1982
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/4259
_:header13456159011335206506648
RDF Description of Vigamox
CID0000004259
http://www.fda.gov/cder/foi/label/2003/21598_vigamox_lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2003%2F21598_vigamox_lbl.pdf%3E
http://www.fda.gov/medwatch/SAFETY/2005/Jun_PI/Avelox_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2005%2FJun_PI%2FAvelox_PI.pdf%3E
Vigamox
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0151826
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0008677
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0031212
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000004259
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000004259%3E
http://www.fda.gov/medwatch/SAFETY/2004/mar_PI/Avelox_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2004%2Fmar_PI%2FAvelox_PI.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0022575
VIGAMOX
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0034880
Avelox
http://www.fda.gov/cder/foi/label/2003/21085slr014,21277slr006,21277se1-007,21085slr015,21277slr009,21085slr017_avelox_lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2003%2F21085slr014%2C21277slr006%2C21277se1-007%2C21085slr015%2C21277slr009%2C21085slr017_avelox_lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0036130
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0024225
http://www.fda.gov/cder/foi/label/2002/21085s12lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2002%2F21085s12lbl.pdf%3E
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=B94mNHVTgJE=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DB94mNHVTgJE%3D%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0030794
http://www.fda.gov/medwatch/SAFETY/2003/03Oct_PI/Avelox_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2003%2F03Oct_PI%2FAvelox_PI.pdf%3E
http://www.fda.gov/cder/foi/label/2003/021085s014lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2003%2F021085s014lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0042594
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=maQmGW2ilN0=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DmaQmGW2ilN0%3D%3E
http://www.fda.gov/cder/foi/label/2001/21277lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2001%2F21277lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0042998
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0009768
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0151754
http://www.fda.gov/cder/foi/nda/2001/21-085S010_Avelox_prntlbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Fnda%2F2001%2F21-085S010_Avelox_prntlbl.pdf%3E
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000004259&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000004259%26input_query_species%3D9606%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020624
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0034359
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0151632
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/206
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F206%3E
http://www.fda.gov/medwatch/SAFETY/2003/03Feb_PI/Avelox_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2003%2F03Feb_PI%2FAvelox_PI.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0024282
http://www.fda.gov/cder/foi/label/2004/21277slr018,21085slr023_avelox_lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2004%2F21277slr018%2C21085slr023_avelox_lbl.pdf%3E
http://sideeffects.embl.de/drugs/4259
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F4259%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0004690
MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE)
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0151479
http://www.fda.gov/medwatch/SAFETY/2007/May_PI/Avelox_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2007%2FMay_PI%2FAvelox_PI.pdf%3E
http://www.fda.gov/cder/foi/label/1999/21085lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F1999%2F21085lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0042376
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00218
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00218%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0003126
http://www.fda.gov/medwatch/SAFETY/2004/jul_PI/Avelox_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2004%2Fjul_PI%2FAvelox_PI.pdf%3E
moxifloxacin
http://www.fda.gov/medwatch/SAFETY/2008/Feb_PI/Avelox_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2008%2FFeb_PI%2FAvelox_PI.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0007785
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=xTvgdxio5%2Fs=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DxTvgdxio5%252Fs%3D%3E
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER
http://www.fda.gov/cder/foi/label/2002/21085s6s7lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2002%2F21085s6s7lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0031154
http://www.fda.gov/cder/foi/label/2004/21598slr002_vigamox_lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2004%2F21598slr002_vigamox_lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0004239
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0085614
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0740394
http://dbpedia.org/resource/Moxifloxacin
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FMoxifloxacin%3E
http://www.fda.gov/cder/foi/label/2004/21598slr008_vigamox_lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2004%2F21598slr008_vigamox_lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0038534
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Sabatini_Rafael_1875-1950
_:header3391353621335206506900
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Sabatini_Rafael_1875-1950
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3423
Sabatini, Rafael, 1875-1950
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7949
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3294
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3530
RDF Description of Sabatini, Rafael, 1875-1950
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2640
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1965
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2687
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2783
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3430
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3030
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2389
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3467
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2702
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1947
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6548
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1457
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2636
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3408
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/FGF10
_:header6848855191335206507311
Mon, 23 Apr 2012 18:35:02 GMT
RDF Description of FGF10
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/FGF10
http://symbol.bio2rdf.org/symbol:FGF10
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AFGF10%3E
FGF10
http://bio2rdf.org/hgnc:3666
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A3666%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=3666
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D3666%3E
http://bio2rdf.org/geneid:2255
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fgeneid%3A2255%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1470
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/101
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/4132
_:header20985960131335206507856
RDF Description of Chloride channel protein ClC-Ka
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4132
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=Z30643
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DZ30643%3E
Chloride channel protein ClC-Ka
CLCKA_HUMAN
>Chloride channel protein ClC-Ka	MEELVGLREGFSGDPVTLQELWGPCPHIRRAIQGGLEWLKQKVFRLGEDWYFLMTLGVLM	ALVSYAMNFAIGCVVRAHQWLYREIGDSHLLRYLSWTVYPVALVSFSSGFSQSITPSSGG	SGIPELKTMLAGVILEDYLDIKNFGAKVVGLSCTLATGSTLFLGKVGPFVHLSVMIAAYL	GRVRTTTIGEPENKSKQNEMLVAAAAVGVATVFAAPFSGVLFSIEVMSSHFSVRDYWRGF	FAATCGAFIFRLLAVFNSEQETITSLYKTSFRVDVPFDLPEIFFFVALGGICGVLSCAYL	FCQRTFLSFIKTNRYSSKLLATSKPVYSALATLLLASITYPPGVGHFLASRLSMKQHLDS	LFDNHSWALMTQNSSPPWPEELDPQHLWWEWYHPRFTIFGTLAFFLVMKFWMLILATTIP	MPAGYFMPIFILGAAIGRLLGEALAVAFPEGIVTGGVTNPIMPGGYALAGAAAFSGAVTH	TISTALLAFELTGQIVHALPVLMAVLAANAIAQSCQPSFYDGTIIVKKLPYLPRILGRNI	GSHHVRVEHFMNHSITTLAKDTPLEEVVKVVTSTDVTEYPLVESTESQILVGIVQRAQLV	QALQAEPPSRAPGHQQCLQDILARGCPTEPVTLTLFSETTLHQAQNLFKLLNLQSLFVTS	RGRAVGCVSWVEMKKAISNLTNPPAPK
Chloride channel Ka
http://symbol.bio2rdf.org/symbol:CLCNKA
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ACLCNKA%3E
282-302
52-72
329-349
http://pfam.sanger.ac.uk/family?acc=PF00571
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00571%3E
voltage-gated chloride channel activity
CLCNKA
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8041726
http://www.uniprot.org/uniprot/P51800
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP51800%3E
ClC-K1
http://pfam.sanger.ac.uk/family?acc=PF00654
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00654%3E
http://bio2rdf.org/hgnc:2026
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A2026%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=2026
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D2026%3E
http://bio2rdf.org/uniprot:P51800
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP51800%3E
Z30643
http://bio2rdf.org/pfam:PF00571
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00571%3E
417-437
486-506
452-472
Involved in voltage-gated chloride channel activity
>2064 bp	ATGGAGGAGTTGGTGGGGCTGCGTGAGGGCTTCTCAGGGGACCCTGTGACTCTGCAGGAG	CTGTGGGGCCCCTGTCCCCACATCCGCCGAGCCATCCAAGGTGGCCTGGAGTGGCTAAAG	CAGAAGGTGTTCCGCCTGGGAGAAGACTGGTACTTCCTGATGACCCTCGGGGTGCTCATG	GCCCTGGTCAGCTATGCCATGAACTTTGCCATCGGGTGTGTGGTCCGAGCACACCAGTGG	CTGTACAGGGAGATTGGGGACAGCCACCTGCTCCGGTATCTTTCCTGGACTGTGTACCCT	GTGGCCCTCGTCTCTTTCTCCTCAGGCTTCTCCCAGAGCATCACGCCCTCCTCTGGAGGT	TCTGGAATCCCGGAGCTGAAGACCATGTTGGCGGGTGTGATCTTGGAGGACTACCTGGAT	ATCAAGAACTTTGGGGCCAAGGTGGTGGGCCTCTCCTGCACCCTGGCCACCGGCAGCACC	CTGTTCCTGGGCAAAGTGGGCCCTTTCGTGCACCTGTCTGTAATGATCGCTGCCTACCTG	GGCCGTGTGCGCACCACGACCATCGGGGAGCCTGAGAACAAGAGCAAGCAAAACGAAATG	CTGGTGGCAGCGGCGGCAGTGGGCGTGGCCACAGTCTTTGCAGCTCCCTTCAGCGGCGTC	CTGTTCAGCATCGAGGTCATGTCTTCCCACTTCTCTGTCCGGGATTACTGGAGGGGCTTC	TTTGCGGCCACCTGCGGGGCCTTCATATTCCGGCTCCTGGCAGTCTTCAACAGCGAGCAG	GAGACCATCACCTCCCTCTACAAGACCAGTTTCCGGGTGGACGTTCCCTTCGACCTGCCT	GAGATCTTCTTTTTTGTGGCGCTGGGTGGCATCTGCGGCGTCCTGAGCTGTGCTTACCTC	TTCTGTCAGCGAACCTTCCTCAGCTTCATCAAGACCAATCGGTACAGCTCCAAACTGCTG	GCTACTAGCAAGCCTGTGTACTCCGCTCTGGCCACCTTGCTTCTCGCCTCCATCACCTAC	CCGCCTGGTGTGGGCCACTTCCTAGCTTCTCGGCTGTCCATGAAGCAGCATCTGGACTCG	CTGTTCGACAACCACTCCTGGGCGCTGATGACCCAGAACTCCAGCCCACCCTGGCCCGAG	GAGCTCGACCCCCAGCACCTTTGGTGGGAATGGTACCACCCGCGGTTCACCATCTTTGGG	ACCCTTGCCTTCTTCCTGGTTATGAAGTTCTGGATGCTGATTCTGGCCACCACCATCCCC	ATGCCTGCCGGGTACTTCATGCCCATCTTTATCCTTGGAGCTGCCATCGGGCGCCTCTTG	GGAGAGGCTCTTGCCGTCGCCTTCCCTGAGGGCATTGTGACTGGAGGGGTTACCAATCCC	ATCATGCCCGGGGGGTATGCTCTGGCAGGGGCTGCAGCCTTCTCAGGGGCTGTGACCCAC	ACCATCTCCACGGCGCTGCTGGCCTTTGAGCTGACCGGCCAGATAGTGCATGCACTGCCC	GTGCTGATGGCGGTGCTGGCAGCCAACGCCATTGCACAGAGCTGCCAGCCCTCCTTCTAT	GATGGCACCATCATTGTCAAGAAGCTGCCATACCTGCCACGGATTCTGGGCCGCAACATC	GGCTCCCACCATGTGAGGGTGGAGCACTTCATGAACCACAGCATCACCACACTGGCCAAG	GACACGCCGCTGGAGGAGGTGGTCAAGGTTGTGACCTCCACAGACGTGACCGAGTATCCC	CTGGTGGAGAGCACAGAGTCCCAGATCCTGGTAGGCATCGTGCAGAGGGCCCAGCTGGTG	CAGGCCCTCCAGGCTGAGCCTCCTTCCAGGGCTCCAGGACACCAGCAGTGTCTCCAGGAC	ATCTTGGCCAGGGGCTGCCCCACGGAACCAGTGACCCTGACGCTATTCTCAGAGACCACC	TTGCACCAGGCACAAAACCTCTTTAAGCTGTTGAACCTTCAGTCCCTCTTCGTGACATCG	CGGGGCAGAGCTGTGGGCTGCGTGTCCTGGGTGGAGATGAAGAAAGCAATTTCCAACCTG	ACAAATCCGCCAGCTCCAAAGTGA
161-181
396-416
http://bio2rdf.org/pfam:PF00654
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00654%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17659402
236-256
202-222
1p36
Voltage-gated chloride channel. Chloride channels have several functions including the regulation of cell volume; membrane potential stabilization, signal transduction and transepithelial transport. May be important in urinary concentrating mechanisms
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04552
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/5543
_:header6508412961335206508813
Mon, 23 Apr 2012 18:35:03 GMT
RDF Description of Platelet-activating factor acetylhydrolase IB alpha subunit
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/5543
http://pfam.sanger.ac.uk/family?acc=PF08513
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF08513%3E
Lissencephaly-1 protein
LIS-1
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11163260
Platelet-activating factor acetylhydrolase IB alpha subunit
PAF acetylhydrolase 45 kDa subunit
>1233 bp	ATGGTGCTGTCCCAGAGACAACGAGATGAACTAAATCGAGCTATAGCAGATTATCTTCGT	TCAAATGGCTATGAAGAGGCATATTCCGTTTTTAAAAAGGAAGCTGAACTAGATATGAAT	GAAGAATTAGATAAGAAGTATGCTGGTCTTTTGGAAAAAAAATGGACATCTGTTATTAGA	TTACAAAAAAAGGTAATGGAATTAGAATCAAAACTAAATGAAGCAAAAGAAGAATTTACG	TCAGGTGGTCCTCTTGGTCAGAAACGAGACCCAAAAGAATGGATTCCCCGTCCACCTGAG	AAATATGCATTGAGTGGTCATAGGAGTCCAGTTACTCGAGTCATTTTCCATCCTGTGTTC	AGTGTTATGGTCTCTGCTTCAGAGGATGCTACAATTAAGGTGTGGGATTATGAGACTGGA	GATTTTGAGCGAACTCTCAAGGGGCATACAGACTCTGTACAGGACATTTCCTTTGACCAC	AGTGGCAAGCTTCTGGCTTCCTGTTCTGCAGATATGACGATTAAATTATGGGATTTTCAG	GGTTTTGAATGCATCAGAACCATGCACGGCCACGACCACAATGTCTCTTCAGTAGCCATC	ATGCCTAATGGAGATCATATAGTGTCTGCCTCAAGGGATAAAACTATAAAAATGTGGGAA	GTGCAAACTGGCTACTGTGTGAAGACATTCACAGGACACAGAGAATGGGTACGTATGGTG	CGGCCAAATCAGGACGGCACTCTGATAGCCAGCTGTTCCAATGACCAGACTGTGCGTGTA	TGGGTTGTAGCAACAAAGGAATGCAAAGCTGAGCTCCGAGAACACGAACATGTGGTAGAA	TGCATTTCCTGGGCTCCAGAAAGTTCATATTCTTCCATCTCTGAAGCAACAGGATCTGAG	ACTAAAAAAAGTGGCAAGCCTGGACCCTTCTTGCTATCTGGTTCCAGAGACAAAACTATT	AAGATGTGGGACGTCAGTACTGGCATGTGCCTTATGACTCTGGTGGGTCATGATAATTGG	GTACGTGGAGTTCTGTTCCATTCTGGGGGGAAGTTTATTTTGAGTTGTGCTGATGACAAG	ACCCTCCGTGTATGGGATTACAAGAACAAGCGATGCATGAAGACCCTCAATGCGCATGAA	CACTTTGTTACCTCCTTGGATTTCCATAAGACGGCACCCTATGTGGTTACTGGCAGTGTA	GATCAAACAGTAAAGGTGTGGGAGTGCCGTTGA
Pafah1b1
http://bio2rdf.org/pfam:PF08513
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF08513%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9459487
cytoplasm(bySimilarity).Centrosome(bySimilarity).Spindle(bySimilarity).Nucleus
http://pfam.sanger.ac.uk/family?acc=PF00400
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00400%3E
http://bio2rdf.org/pfam:PF00400
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00400%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AF016049
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAF016049%3E
LIS1_RAT
Required for proper activation of Rho GTPases and actin polymerization at the leading edge of locomoting cerebellar neurons and postmigratory hippocampal neurons in response to calcium influx triggered via NMDA receptors. Non-catalytic subunit of an acetylhydrolase complex which inactivates platelet- activating factor (PAF) by removing the acetyl group at the SN-2 position (By similarity). Positively regulates the activity of the minus-end directed microtubule motor protein dynein. May enhance dynein-mediated microtubule sliding by targeting dynein to the microtubule plus end. Required for several dynein- and microtubule-dependent processes such as the maintenance of Golgi integrity, the peripheral transport of microtubule fragments and the coupling of the nucleus and centrosome. Required during brain development for the proliferation of neuronal precursors and the migration of newly formed neurons from the ventricular/subventricular zone toward the cortical plate. Neuronal migration involves a process called nucleokinesis, whereby migrating cells extend an anterior process into which the nucleus subsequently translocates. During nucleokinesis dynein at the nuclear surface may translocate the nucleus towards the centrosome by exerting force on centrosomal microtubules. May also play a role in other forms of cell locomotion including the migration of fibroblasts during wound healing
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11056532
PAFAH alpha
AF016049
PAF-AH 45 kDa subunit
http://bio2rdf.org/uniprot:P63004
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP63004%3E
http://www.pdb.org/pdb/explore/explore.do?structureId=1UUJ
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1UUJ%3E
http://bio2rdf.org/pdb:1UUJ
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1UUJ%3E
>Platelet-activating factor acetylhydrolase IB alpha subunit	MVLSQRQRDELNRAIADYLRSNGYEEAYSVFKKEAELDMNEELDKKYAGLLEKKWTSVIR	LQKKVMELESKLNEAKEEFTSGGPLGQKRDPKEWIPRPPEKYALSGHRSPVTRVIFHPVF	SVMVSASEDATIKVWDYETGDFERTLKGHTDSVQDISFDHSGKLLASCSADMTIKLWDFQ	GFECIRTMHGHDHNVSSVAIMPNGDHIVSASRDKTIKMWEVQTGYCVKTFTGHREWVRMV	RPNQDGTLIASCSNDQTVRVWVVATKECKAELREHEHVVECISWAPESSYSSISEATGSE	TKKSGKPGPFLLSGSRDKTIKMWDVSTGMCLMTLVGHDNWVRGVLFHSGGKFILSCADDK	TLRVWDYKNKRCMKTLNAHEHFVTSLDFHKTAPYVVTGSVDQTVKVWECR
PAF-AH alpha
http://www.uniprot.org/uniprot/P63004
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP63004%3E
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB02315
_:header5703892771335206509103
Mon, 23 Apr 2012 18:35:04 GMT
RDF Description of Cyclic Guanosine Monophosphate
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02315
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1759
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1759%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/197
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F197%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2766
1MC0
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4060
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F4060%3E
Cyclic Guanosine Monophosphate
InChI=1/C10H12N5O7P/c11-10-13-7-4(8(17)14-10)12-2-15(7)9-5(16)6-3(21-9)1-20-23(18,19)22-6/h2-3,5-6,9,16H,1H2,(H,18,19)(H3,11,13,14,17)/f/h14,18H,11H2
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1132
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1132%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3588
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3588%3E
ZOOGRGPOEVQQDX-LNTCFBCGCM
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1345
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1345%3E
http://bio2rdf.org/cas:7665-99-8
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A7665-99-8%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1247
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1247%3E
2-amino-9-[(1S,6R,8R,9R)-3,9-dihydroxy-3-oxo-2,4,7-trioxa-3$l^{5}-phosphabicyclo[4.3.0]nonan-8-yl]-3H-purin-6-one
expt02518
http://www.drugbank.ca/drugs/DB02315
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB02315%3E
3.79e+00 mg/mL
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2494
PCG
http://bio2rdf.org/cpd:C00942
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC00942%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/808
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F808%3E
Guanosine cyclic 3&#39;,5&#39;-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3&#39;- and 5&#39;-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed)
http://bio2rdf.org/chebi:16356
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fchebi%3A16356%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2628
NC1=NC2=C(N=CN2[C@H]2O[C@@H]3CO[P@](O)(=O)O[C@@H]3[C@@H]2O)C(=O)N1
DB02315
NC1=NC2=C(N=CN2C2OC3COP(O)(=O)OC3C2O)C(=O)N1
2008-08-26 16:17:17 UTC
C10H12N5O7P
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/39
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F39%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3319
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3319%3E
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Bergman_Hjalmar_1883-1931
_:header51203611335206509566
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Bergman_Hjalmar_1883-1931
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext15724
Bergman, Hjalmar, 1883-1931
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext12613
RDF Description of Bergman, Hjalmar, 1883-1931
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17015
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB04594
_:header145447241335206510044
RDF Description of 3-hydroxyglutaric acid
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04594
3-hydroxypentanedioic acid
1.72e+02 mg/mL
ZQHYXNSQOIDNTL-AUDIXQRPCD
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/5713
OC(CC(O)=O)CC(O)=O
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2621
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2621%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/517
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F517%3E
3-hydroxyglutaric acid
C5H8O5
InChI=1/C5H8O5/c6-3(1-4(7)8)2-5(9)10/h3,6H,1-2H2,(H,7,8)(H,9,10)/f/h7,9H
2008-08-26 17:05:23 UTC
3HG
http://bio2rdf.org/cas:638-18-6
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A638-18-6%3E
DB04594
2007-09-11 17:48:55 UTC
http://www.drugbank.ca/drugs/DB04594
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB04594%3E
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00167
_:header5477180221335206510414
Mon, 23 Apr 2012 18:35:05 GMT
RDF Description of L-Isoleucine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00167
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/546
Absorbed from the small intestine by a sodium-dependent active-transport process
CC[C@H](C)[C@H](N)C(O)=O
An essential branched-chain aliphatic amino acid found in many proteins. It is an isomer of leucine. It is important in hemoglobin synthesis and regulation of blood sugar and energy levels. [PubChem]
DB00167
(2S,3S)-2-amino-3-methylpentanoic acid
C6H13NO2
2S,3S-Isoleucine
(S)-Isoleucine
Symptoms of hypoglycemia, increased mortality in ALS patients taking large doses of BCAAs
AGPKZVBTJJNPAG-JOOMIXNWDU
http://www.drugbank.ca/drugs/DB00167
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00167%3E
34.4 mg/mL at 25 oC [YALKOWSKY,SH & DANNENFELSER,RM (1992)]
(S,S)-Isoleucine
(Applies to Valine, Leucine and Isoleucine) <br/>This group of essential amino acids are identified as the branched-chain amino acids, BCAAs. Because this arrangement of carbon atoms cannot be made by humans, these amino acids are an essential element in the diet. The catabolism of all three compounds initiates in muscle and yields NADH and FADH2 which can be utilized for ATP generation. The catabolism of all three of these amino acids uses the same enzymes in the first two steps. The first step in each case is a transamination using a single BCAA aminotransferase, with a-ketoglutarate as amine acceptor. As a result, three different a-keto acids are produced and are oxidized using a common branched-chain a-keto acid dehydrogenase, yielding the three different CoA derivatives. Subsequently the metabolic pathways diverge, producing many intermediates. <br/>The principal product from valine is propionylCoA, the glucogenic precursor of succinyl-CoA. Isoleucine catabolism terminates with production of acetylCoA and propionylCoA; thus isoleucine is both glucogenic and ketogenic. Leucine gives rise to acetylCoA and acetoacetylCoA, and is thus classified as strictly ketogenic. <br/>There are a number of genetic diseases associated with faulty catabolism of the BCAAs. The most common defect is in the branched-chain a-keto acid dehydrogenase. Since there is only one dehydrogenase enzyme for all three amino acids, all three a-keto acids accumulate and are excreted in the urine. The disease is known as Maple syrup urine disease because of the characteristic odor of the urine in afflicted individuals. Mental retardation in these cases is extensive. Unfortunately, since these are essential amino acids, they cannot be heavily restricted in the diet; ultimately, the life of afflicted individuals is short and development is abnormal The main neurological problems are due to poor formation of myelin in the CNS.
(2S,3S)-2-Amino-3-methylpentanoic acid
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/630
(2S,3S)-a-Amino-b-methyl-n-valeric acid
2008-08-26 16:17:43 UTC
L-(+)-Isoleucine
2-Amino-3-methylvaleric acid
1H74
CCC(C)C(N)C(O)=O
They provide ingredients for the manufacturing of other essential biochemical components in the body, some of which are utilized for the production of energy, stimulants to the upper brain and helping you to be more alert.
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2%3E
erythro-L-Isoleucine
(2S,3S)-a-Amino-b-methylvaleric acid
http://bio2rdf.org/chebi:17191
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fchebi%3A17191%3E
http://bio2rdf.org/cpd:C00407
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC00407%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/701
http://129.128.185.122/drugbank2/drugs/DB00167/inserts/1530/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00167%2Finserts%2F1530%2Ffull%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/574
L-Isoleucine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/powderOral
1.14e+02 mg/mL
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/795
http://bio2rdf.org/cas:73-32-5
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A73-32-5%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/essentialAminoAcids
168-170 oC
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4080
Isoleucine
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1287
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1287%3E
http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/bra_0042.shtml
/drugs/167/safety_sheets/658
ILE
http://bio2rdf.org/kegg:D00065
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD00065%3E
L-Ile
The branched-chain amino acids may have antihepatic encephalopathy activity in some. They may also have anticatabolic and antitardive dyskinesia activity.
InChI=1/C6H13NO2/c1-3-4(2)5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t4-,5-/m0/s1/f/h8H
nutr00031
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/PLA2G2A
_:header11556478501335206510847
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PLA2G2A
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/gene/PLA2G2A
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fgene%2FPLA2G2A%3E
http://symbol.bio2rdf.org/symbol:PLA2G2A
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3APLA2G2A%3E
PLA2G2A
http://bio2rdf.org/hgnc:9031
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A9031%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=9031
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D9031%3E
http://bio2rdf.org/geneid:5320
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fgeneid%3A5320%3E
RDF Description of PLA2G2A
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/3871
_:header15989826401335206511355
Mon, 23 Apr 2012 18:35:06 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3871
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00102
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=1136584
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D1136584%3E
http://bio2rdf.org/hgnc:14634
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A14634%3E
7q22.1
PDGF-associated protein
PAP1
PAP
Enhances PDGFA-stimulated cell growth in fibroblasts, but inhibits the mitogenic effect of PDGFB
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8780057
28 kDa heat- and acid-stable phosphoprotein
U41745
>28 kDa heat- and acid-stable phosphoprotein	MPKGGRKGGHKGRARQYTSPEEIDAQLQAEKQKAREEEEQKEGGDGAAGDPKKEKKSLDS	DESEDEEDDYQQKRKGVEGLIDIENPNRVAQTTKKVTQLDLDGPKELSRREREEIEKQKA	KERYMKMHLAGKTEQAKADLARLAIIRKQREEAARKKEEERKAKDDATLSGKRMQSLSLN	K
http://bio2rdf.org/uniprot:Q13442
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ13442%3E
>546 bp	ATGCCTAAAGGAGGAAGAAAGGGAGGCCACAAAGGCCGGGCGAGGCAGTATACAAGCCCT	GAGGAGATCGACGCGCAGCTGCAGGCTGAGAAGCAGAAGGCCAGGGAAGAAGAGGAGCAA	AAAGAAGGTGGAGATGGGGCTGCAGGTGACCCCAAAAAGGAGAAGAAATCTCTAGACTCA	GATGAGAGTGAGGATGAAGAAGATGACTACCAGCAAAAGCGCAAAGGCGTTGAAGGGCTC	ATCGACATCGAGAACCCCAACCGGGTGGCACAGACAACCAAAAAGGTCACACAACTGGAT	CTGGACGGGCCAAAGGAGCTTTCGAGGAGAGAACGAGAAGAGATTGAGAAGCAGAAGGCA	AAAGAGCGTTACATGAAAATGCACTTGGCCGGGAAGACAGAGCAAGCCAAGGCTGACCTG	GCCCGGCTGGCCATCATCCGGAAACAGCGGGAGGAGGCTGCCCGGAAGAAGGAAGAGGAA	AGGAAAGCAAAAGACGATGCCACATTGTCAGGAAAACGAATGCAGTCACTCTCCCTGAAT	AAGTAA
PDAP1
http://symbol.bio2rdf.org/symbol:PDAP1
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3APDAP1%3E
HAP28_HUMAN
http://www.uniprot.org/uniprot/Q13442
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ13442%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=14634
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D14634%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=U41745
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DU41745%3E
PDGFA-associated protein 1
RDF Description of 28 kDa heat- and acid-stable phosphoprotein
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0030920
_:header9189715391335206511753
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0030920
http://sideeffects.embl.de/se/C0030920
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0030920%3E
PEPTIC ULCER
C0030920
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/disease/Peptic_Ulcer
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fdisease%2FPeptic_Ulcer%3E
peptic ulcer disease
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4934
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2088
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/20585
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4057
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/222786
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3342
RDF Description of PEPTIC ULCER
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3059
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5508
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4775
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4900
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5342
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00181
_:header9073242381335206512232
Mon, 23 Apr 2012 18:35:07 GMT
RDF Description of Baclofen
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00181
Baclon
http://data.linkedct.org/resource/intervention/61820
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F61820%3E
Nu-Baclofen
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3566
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3566%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/muscleRelaxants,Central
12:20.00
Novo-Baclofen
http://129.128.185.122/drugbank2/drugs/DB00181/inserts/176/full
7.12e-01 mg/mL
30%
206-208 oC
KPYSYYIEGFHWSV-NDKGDYFDCG
Kemstro
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/616
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F616%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/skeletalMuscleRelaxants
Baclofen is a muscle relaxant and antispastic. Baclofen is useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Although Baclofen is an analog of the putative inhibitory neurotransmitter gamma-aminobutyric acid (GABA), there is no conclusive evidence that actions on GABA systems are involved in the production of its clinical effects. In studies with animals, Baclofen has been shown to have general CNS depressant properties as indicated by the production of sedation with tolerance, somnolence, ataxia, and respiratory and cardiovascular depression. Baclofen is rapidly and extensively absorbed and eliminated. Absorption may be dose-dependent, being reduced with increasing doses. Baclofen is excreted primarily by the kidney in unchanged form and there is relatively large intersubject variation in absorption and/or elimination.
2003-11-01	/drugs/181/fda_labels/234
http://dbpedia.org/page/Baclofen
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FBaclofen%3E
NCC(CC(O)=O)C1=CC=C(Cl)C=C1
A gamma-aminobutyric acid derivative that is a specific agonist at GABA-B receptors (receptors, GABA-B). It is used in the treatment of spasticity, especially that due to spinal cord damage. Its therapeutic effects result from actions at spinal and supraspinal sites, generally the reduction of excitatory transmission. [PubChem]
For the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity
http://205.193.93.51/dpdonline/searchRequest.do?din=02242151
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02242151%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4094
http://bio2rdf.org/cas:1134-47-0
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A1134-47-0%3E
DB00181
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1332
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F1332%3E
http://129.128.185.122/drugbank2/drugs/DB00181/inserts/955/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00181%2Finserts%2F955%2Ffull%3E
1.51 hours
http://data.linkedct.org/resource/intervention/36225
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F36225%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/solutionIntrathecal
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/gabaAgonists
http://bio2rdf.org/kegg:D00241
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD00241%3E
LD<sub>50</sub>=45 mg/kg (male mice, IV); LD<sub>50</sub>=78 mg/kg (male rat, IV)
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3327
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3327%3E
Lioresal
Baclofen
NC[C@@H](CC(O)=O)C1=CC=C(Cl)C=C1
2008-08-26 14:46:35 UTC
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/muscleRelaxants
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/4180
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F4180%3E
Rapidly and extensively absorbed
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/804
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F804%3E
http://en.wikipedia.org/wiki/Baclofen
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FBaclofen%3E
InChI=1/C10H12ClNO2/c11-9-3-1-7(2-4-9)8(6-12)5-10(13)14/h1-4,8H,5-6,12H2,(H,13,14)/f/h13H
http://data.linkedct.org/resource/intervention/1819
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F1819%3E
http://www.rxlist.com/cgi/generic/baclofen.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric%2Fbaclofen.htm%3E
http://data.linkedct.org/resource/intervention/47177
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F47177%3E
Neth. pat. Appl. 6,407,755; H. Keberle et al., U.S. pat. 3,471,548 (1965, 1969 both to Ciba)
M03BX01
Lioresal Intrathecal
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/240
http://data.linkedct.org/resource/intervention/50668
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F50668%3E
http://data.linkedct.org/resource/intervention/7913
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F7913%3E
Apo-Baclofen
Baclofen is a direct agonist at GABAB receptors. The precise mechanism of action of Baclofen is not fully known. It is capable of inhibiting both monosynaptic and polysynaptic reflexes at the spinal level, possibly by hyperpolarization of afferent terminals, although actions at supraspinal sites may also occur and contribute to its clinical effect.
/drugs/181/safety_sheets/648
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3394
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3394%3E
http://dbpedia.org/resource/Baclofen
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FBaclofen%3E
2090 mg/L
http://129.128.185.122/drugbank2/drugs/DB00181/inserts/1971/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00181%2Finserts%2F1971%2Ffull%3E
http://data.linkedct.org/resource/intervention/32728
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F32728%3E
aprd00551
4-amino-3-(4-chlorophenyl)butanoic acid
http://www.drugbank.ca/drugs/DB00181
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00181%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/4082
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F4082%3E
C10H12ClNO2
PA448533
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/791
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F791%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3375
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3375%3E
Pms-Baclofen
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/KCNH2
_:header5384164351335206512580
RDF Description of KCNH2
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/KCNH2
http://symbol.bio2rdf.org/symbol:KCNH2
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AKCNH2%3E
KCNH2
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Aneurin
_:header19392539231335206513020
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Aneurin
Aneurin
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9842
RDF Description of Aneurin
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0038238
_:header5050131791335206513491
Mon, 23 Apr 2012 18:35:08 GMT
http://dbpedia.org/resource/Steatorrhea
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FSteatorrhea%3E
http://sideeffects.embl.de/se/C0038238
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0038238%3E
steatorrhea
C0038238
RDF Description of steatorrhea
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01146
_:header12127151621335206513901
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01146
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00843_DB01146
Histryl
Diphenylpyraline
Protectosil Plus Efa (Diphenylpyraline Hydrochloride + Silicone)
For use in the treatment of allergic rhinitis, hay fever, and allergic skin disorders.
Oradrine 2 Tab (Acetaminophen + Caffeine + Diphenylpyraline Hydrochloride + Phenylpropanolamine Hydrochloride)
Oradrine Tablets (Acetaminophen + Caffeine + Codeine Phosphate + Diphenylpyraline Hydrochloride + Phenylpropanolamine Hydrochloride)
Hystryl
> 99% in human serum albumin
http://205.193.93.51/dpdonline/searchRequest.do?din=00777285
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D00777285%3E
Biohisdex Dm Decongestant (Dextromethorphan Hydrobromide + Diphenylpyraline Hydrochloride + Phenylephrine Hydrochloride)
Lyssipoll
Belfene
Diphenylpyraline is an antihistamine that prevents, but does not reverse, responses mediated by histamine alone. Diphenylpyraline antagonizes most of the pharmacological effects of histamine, including urticaria and pruritus. Also, diphenylpyraline may exhibit anticholinergic actions (as do most of the antihistamines) and may thus provide a drying effect on the nasal mucosa.
Diafen
http://www.drugbank.ca/drugs/DB01146
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01146%3E
Allergen
Diphenylpyraline Hydrochloride
http://129.128.185.122/drugbank2/drugs/DB01146/inserts/383/full
4-[di(phenyl)methoxy]-1-methylpiperidine
http://dbpedia.org/resource/Diphenylpyraline
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FDiphenylpyraline%3E
Diphenylpyralamine
Neargal
CN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
http://bio2rdf.org/kegg:D01172
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD01172%3E
Vito Bronches Sirop (Dextromethorphan Hydrobromide + Diphenylpyraline Hydrochloride + Potassium Iodide + Sodium Citrate)
http://www.dbpedia.org/resource/Diphenylpyraline
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FDiphenylpyraline%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/liquidSubcutaneous
Dayfen
Chemhisdine Dm Decongestant (Dextromethorphan Hydrobromide + Diphenylpyraline Hydrochloride + Phenylephrine Hydrochloride)
Creo-Rectal Nourrisson (Camphor + Diphenylpyraline Hydrochloride + Guaiacol Carbonate)
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/liquidIntradermal
Well absorbed after oral administration.
aprd00719
V01AA02
Emercreme No4 Ont Efa (Bacitracin + Benzocaine + Cetylpyridinium Chloride + Diphenylpyraline Hydrochloride + Tyrothricin)
V01AA20
Histyn
1.88e-02 mg/mL
Sinugex 38 (Acetaminophen + Caffeine + Diphenylpyraline Hydrochloride)
C19H23NO
Metrate (Dextromethorphan Hydrobromide + Diphenylpyraline Hydrochloride + Potassium Iodide + Sodium Citrate)
http://129.128.185.122/drugbank2/drugs/DB01146/inserts/1257/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB01146%2Finserts%2F1257%2Ffull%3E
http://dbpedia.org/page/Diphenylpyraline
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FDiphenylpyraline%3E
Diphenylpyraline is an antihistamine. Antihistamines used in the treatment of allergy act by competing with histamine for H 1-receptor sites on effector cells. Antihistamines prevent, but do not reverse, responses mediated by histamine alone. Antihistamines antagonize, in varying degrees, most of the pharmacological effects of histamine, including urticaria and pruritus.
Emercidin D Tab (Acetaminophen + Caffeine + Diphenylpyraline Hydrochloride + Phenylpropanolamine Hydrochloride)
Diphenylpyrilene
Dafen
Antihistamines such as diphenylpyraline used in the treatment of allergy act by competing with histamine for H1-receptor sites on effector cells. This reduces the effects of histamine, leading to a temporary reduction of allergy symptoms.
OWQUZNMMYNAXSL-UHFFFAOYAE
2008-08-26 15:39:25 UTC
InChI=1/C19H23NO/c1-20-14-12-18(13-15-20)21-19(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-19H,12-15H2,1H3
Oradrine-2 Tab (Acetaminophen + Caffeine + Diphenylpyraline Hydrochloride + Phenylpropanolamine Hydrochloride)
Creo-Rectal Enfant (Camphor + Diphenylpyraline Hydrochloride + Guaiacol Carbonate)
Chemhisdex Dm Decongestant (Dextromethorphan Hydrobromide + Diphenylpyraline Hydrochloride + Phenylephrine Hydrochloride)
Mepiben
Creo-Rectal Adulte (Camphor + Diphenylpyraline Hydrochloride + Guaiacol Carbonate)
http://bio2rdf.org/cas:147-20-6
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A147-20-6%3E
Nezger Tab (Acetylsalicylic Acid + Diphenylpyraline Hydrochloride + Guaifenesin + Phenylephrine Hydrochloride)
Hispril
Solucodan-H (Diphenylpyraline Hydrochloride + Hydrocodone Bitartrate + Menthol + Potassium Guaiacol Sulphonate + Sodium Citrate)
Corytab (Acetaminophen + Caffeine + Diphenylpyraline Hydrochloride)
R06AA07
92:04.00*
DB01146
Codalin (Codeine Phosphate + Diphenylpyraline Hydrochloride + Phenylephrine Hydrochloride)
http://en.wikipedia.org/wiki/Diphenylpyraline
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FDiphenylpyraline%3E
Biohisdine Dm Decongestant (Dextromethorphan Hydrobromide + Diphenylpyraline Hydrochloride + Phenylephrine Hydrochloride)
http://129.128.185.122/drugbank2/drugs/DB01146/inserts/2259/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB01146%2Finserts%2F2259%2Ffull%3E
RDF Description of Diphenylpyraline
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00674_DB01146
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Sidney_Margaret_1844-1924
_:header9252807441335206514282
Mon, 23 Apr 2012 18:35:09 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Sidney_Margaret_1844-1924
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext594
Sidney, Margaret, 1844-1924
Sidney, Margaret, 1844-1924 
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7498
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2770
RDF Description of Sidney, Margaret, 1844-1924
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7434
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext20037
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6418
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6987
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5632
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Stoddard_Charles_Warren_1843-1909
_:header844392681335206514725
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Stoddard_Charles_Warren_1843-1909
Stoddard, Charles Warren, 1843-1909
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3313
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13321
RDF Description of Stoddard, Charles Warren, 1843-1909
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0016736
_:header10091893041335206515234
Mon, 23 Apr 2012 18:35:10 GMT
RDF Description of frostbite
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0016736
http://dbpedia.org/resource/Frostbite
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FFrostbite%3E
http://sideeffects.embl.de/se/C0016736
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0016736%3E
frostbite
C0016736
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/disease/Frostbite
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fdisease%2FFrostbite%3E
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/PARK2
_:header12138539631335206515545
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PARK2
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1329
http://symbol.bio2rdf.org/symbol:PARK2
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3APARK2%3E
PARK2
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3548
RDF Description of PARK2
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/670
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/902
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2902
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1328
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/32
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/GDI1
_:header21034064021335206515952
RDF Description of GDI1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/GDI1
http://symbol.bio2rdf.org/symbol:GDI1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AGDI1%3E
GDI1
http://www.dbpedia.org/resource/GDI1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FGDI1%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3119
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/746
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Pina_Rui_de_1440-1521
_:header17045099501335206516444
Mon, 23 Apr 2012 18:35:11 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Pina_Rui_de_1440-1521
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext16571
Pina, Rui de, 1440-1521
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext15674
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext18167
RDF Description of Pina, Rui de, 1440-1521
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Bok_Edward_William_1863-1930
_:header12618304181335206517244
Mon, 23 Apr 2012 18:35:12 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Bok_Edward_William_1863-1930
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext15930
Bok, Edward William, 1863-1930
RDF Description of Bok, Edward William, 1863-1930
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3538
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/FTH1
_:header6212327201335206518004
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/FTH1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2823
http://symbol.bio2rdf.org/symbol:FTH1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AFTH1%3E
FTH1
http://www.dbpedia.org/resource/FTH1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FFTH1%3E
RDF Description of FTH1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/622
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Marcantonio_Vito_1902-1954
_:header4393865801335206518798
Mon, 23 Apr 2012 18:35:13 GMT
RDF Description of Marcantonio, Vito, 1902-1954
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Marcantonio_Vito_1902-1954
Marcantonio, Vito, 1902-1954
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext11009
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01190
_:header9461683671335206519433
Mon, 23 Apr 2012 18:35:14 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01190
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01190_DB01199
Clindamycine [French]
/drugs/1190/safety_sheets/1240
http://data.linkedct.org/resource/intervention/26848
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F26848%3E
Cleocin Hcl
http://bio2rdf.org/cpd:C06914
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC06914%3E
84:04.04
3.10e+00 mg/mL
http://205.193.93.51/dpdonline/searchRequest.do?din=02258331
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02258331%3E
Clindesse
Clindamicina [INN-Spanish]
Cleocin Pediatric
Clindamycin
30.6 mg/L
http://bio2rdf.org/cas:18323-44-9
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A18323-44-9%3E
http://data.linkedct.org/resource/intervention/16631
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F16631%3E
D10AF01
Cleocin T
http://bio2rdf.org/chebi:3745
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fchebi%3A3745%3E
aprd00566
Clinimycin
Chlolincocin
Clindamycin Phosphate
Birkenmeyer, U.S. Pat. 3,475,407(1970)
Clindets
(2S,4R)-N-[2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide
Cleocin T Gel
clindamycin
2008-08-26 16:31:45 UTC
InChI=1/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9?,10-,11+,12?,13+,14-,15-,16-,18-/m1/s1/f/h20H
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/powderForSolutionOral
DB01190
An antibacterial agent that is a semisynthetic analog of lincomycin. [PubChem]
J01FF01
Systemic/Vaginal-Clindamycin inhibits protein synthesis of bacteria by binding to the 50 S ribosomal subunits of the bacteria. Topical-Clindamycin reduces free fatty acid concentrations on the skin and to suppress the growth of Propionibacterium acnes (Corynebacterium acnes) , an anaerobe found in sebaceous glands and follicles.
PA449035
Clindamycin Hydrochloride
Dalacin C Phosphate
G01AA10
2.4 hours
08:12.28.20
255 oC
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/lincomycins
http://data.linkedct.org/resource/intervention/26891
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F26891%3E
Sobelin
KDLRVYVGXIQJDK-MUUPOQBDDB
http://data.linkedct.org/resource/intervention/16634
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F16634%3E
http://data.linkedct.org/resource/intervention/3142
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F3142%3E
CCCC1CC(N(C)C1)C(=O)NC(C(C)Cl)C1OC(SC)C(O)C(O)C1O
Cleocin T Topical Solution
Dalacin C Flavored Granules
Dalacin
Dalacin T Topical Solution
1999-08-01	/drugs/1190/fda_labels/522	2002-07-01	/drugs/1190/fda_labels/384	2003-05-01	/drugs/1190/fda_labels/221	2003-08-01	/drugs/1190/fda_labels/301	2004-10-01	/drugs/1190/fda_labels/979	2004-12-01	/drugs/1190/fda_labels/754
C18H33ClN2O5S
Cleocin Phosphate
http://bio2rdf.org/kegg:D00277
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD00277%3E
Cleocin T Lotion
Cleocin
Orally and parenterally administered clindamycin has been associated with severe colitis (pseudomembranous colitis) which may result in patient death. Use of the topical formulation of clindamycin results in absorption of the antibiotic from the skin surface. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin.
Clindagel
Zindaclin
http://data.linkedct.org/resource/intervention/54680
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F54680%3E
Clindamycine [INN-French]
http://129.128.185.122/drugbank2/drugs/DB01190/inserts/764/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB01190%2Finserts%2F764%2Ffull%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/creamIntravaginal
http://data.linkedct.org/resource/intervention/61605
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F61605%3E
http://dbpedia.org/resource/Clindamycin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FClindamycin%3E
CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O
http://www.rxlist.com/cgi/generic2/clindam.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric2%2Fclindam.htm%3E
Evoclin
http://129.128.185.122/drugbank2/drugs/DB01190/inserts/44/full
92-94%
http://129.128.185.122/drugbank2/drugs/DB01190/inserts/1788/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB01190%2Finserts%2F1788%2Ffull%3E
Clindamycinum [INN-Latin]
Clinda-Derm
Clindamycin is an antibiotic, similar to and a derivative of lincomycin. Clindamycin can be used in topical or systemic treatment. It is effective as an anti-anaerobic antibiotic and antiprotozoal.
Dalacin C
CLY
http://dbpedia.org/page/Clindamycin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FClindamycin%3E
For the treatment of serious infections caused by susceptible anaerobic bacteria (anaerobes, streptococci, pneumococci, and staphylococci)
http://en.wikipedia.org/wiki/Clindamycin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FClindamycin%3E
ResiDerm A
Rapidly absorbed after oral administration. Absorption of an oral dose is virtually complete (90%), and the concomitant administration of food does not appreciably modify the serum concentrations; serum levels have been uniform and predictable from person to person and dose to dose.
Clindamycin Hcl
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/818
http://www.drugbank.ca/drugs/DB01190
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01190%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/solutionTopical
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01190_DB00483
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01190_DB00091
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01190_DB01336
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01190_DB00732
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01190_DB01337
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01190_DB01226
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01190_DB00728
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01190_DB01575
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01190_DB01339
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01190_DB01574
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01190_DB01370
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00091_DB01190
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01190_DB01375
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01190_DB01334
RDF Description of Clindamycin
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01190_DB00202
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/LAMB2
_:header4835745071335206519867
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/LAMB2
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/761
http://symbol.bio2rdf.org/symbol:LAMB2
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ALAMB2%3E
LAMB2
http://www.dbpedia.org/resource/Laminin%2C_beta_2
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FLaminin%252C_beta_2%3E
RDF Description of LAMB2
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3158
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Millet_F_D_(Francis_Davis)_1846-1912
_:header21057664981335206520336
Mon, 23 Apr 2012 18:35:15 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Millet_F_D_(Francis_Davis)_1846-1912
Millet, F. D. (Francis Davis), 1846-1912 
RDF Description of Millet, F. D. (Francis Davis), 1846-1912 
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext11437
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/3834
_:header6352446951335206520787
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3834
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00013
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2471408
http://pfam.sanger.ac.uk/family?acc=PF00086
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00086%3E
Sulfated glycoprotein widely distributed in basement membranes and tightly associated with laminin. Also binds to collagen IV and perlecan. It probably has a role in cell- extracellular matrix interactions
http://bio2rdf.org/pfam:PF07645
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF07645%3E
M30269
http://bio2rdf.org/uniprot:P14543
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP14543%3E
cell-matrix adhesion
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9328311
http://bio2rdf.org/pfam:PF06119
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF06119%3E
NID1
NID1_HUMAN
http://www.genenames.org/data/hgnc_data.php?hgnc_id=7821
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D7821%3E
http://bio2rdf.org/pfam:PF00058
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00058%3E
Entactin
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/14672920
>3744 bp	ATGTTGGCCTCGAGCAGCCGGATCCGGGCTGCGTGGACGCGGGCGCTGCTGCTGCCGCTG	CTGCTGGCGGGGCCTGTGGGCTGCCTGAGCCGCCAGGAGCTCTTTCCCTTCGGCCCCGGA	CAGGGGGACCTGGAGCTGGAGGACGGGGATGACTTCGTCTCTCCTGCCCTGGAGCTGAGT	GGGGCGCTCCGCTTCTACGACAGATCCGACATCGACGCAGTCTACGTCACCACAAATGGC	ATCATTGCTACGAGTGAACCCCCGGCCAAAGAATCCCATCCCGGGCTCTTCCCACCAACA	TTCGGTGCAGTCGCCCCTTTCCTGGCGGACTTGGACACGACCGATGGCCTGGGGAAGGTT	TATTATCGAGAAGACTTATCCCCCTCCATCACTCAGCGAGCAGCAGAGTGTGTCCACAGA	GGGTTCCCGGAGATCTCTTTCCAGCCTAGTAGCGCGGTGGTTGTCACTTGGGAATCCGTG	GCCCCCTACCAAGGGCCCAGCAGGGACCCAGACCAGAAAGGCAAGAGAAACACGTTCCAG	GCTGTTCTAGCCTCCTCTGATTCCAGCTCCTATGCCATTTTCCTTTATCCTGAGGATGGT	CTGCAGTTCCATACGACATTCTCAAAGAAGGAAAACAACCAAGTTCCTGCCGTGGTTGCA	TTCAGTCAAGGTTCAGTGGGATTCTTATGGAAGAGCAACGGAGCTTATAACATATTTGCT	AATGACAGGGAATCAATTGAAAATTTGGCCAAGAGTAGTAACTCTGGGCAGCAGGGTGTC	TGGGTGTTTGAGATTGGGAGTCCAGCCACCACCAATGGCGTGGTGCCTGCAGACGTGATC	CTCGGAACTGAAGATGGGGCAGAGTATGATGATGAGGATGAAGATTATGACCTGGCGACC	ACTCGTCTGGGCCTGGAGGATGTGGGCACCACGCCCTTCTCCTACAAGGCTCTGAGAAGG	GGAGGTGCTGACACATACAGTGTGCCCAGCGTCCTCTCCCCGCGCCGGGCAGCTACCGAA	AGGCCCCTTGGACCTCCCACAGAGAGAACCAGGTCTTTCCAGTTGGCAGTGGAGACTTTT	CACCAGCAGCACCCTCAGGTCATAGATGTGGATGAAGTTGAGGAAACAGGAGTTGTTTTC	AGCTATAACACGGATTCCCGCCAGACGTGTGCTAACAACAGACACCAGTGCTCGGTGCAC	GCAGAGTGCAGGGACTACGCCACGGGCTTCTGCTGCAGCTGTGTCGCTGGCTATACGGGC	AATGGCAGGCAATGTGTTGCAGAAGGTTCCCCCCAGCGAGTCAATGGCAAGGTGAAAGGA	AGGATCTTTGTGGGGAGCAGCCAGGTCCCCATTGTCTTTGAGAACACTGACCTCCACTCT	TACGTAGTAATGAACCACGGGCGCTCCTACACAGCCATCAGCACCATTCCCGAGACCGTT	GGATATTCTCTGCTTCCACTGGCCCCAGTTGGAGGCATCATTGGATGGATGTTTGCAGTG	GAGCAGGACGGATTCAAGAATGGGTTCAGCATCACCGGGGGTGAGTTCACTCGCCAGGCT	GAGGTGACCTTCGTGGGGCACCCGGGCAATCTGGTCATTAAGCAGCGGTTCAGCGGCATC	GATGAGCATGGGCACCTGACCATCGACACGGAGCTGGAGGGCCGCGTGCCGCAGATTCCG	TTCGGCTCCTCCGTGCACATTGAGCCCTACACGGAGCTGTACCACTACTCCACCTCAGTG	ATCACTTCCTCCTCCACCCGGGAGTACACGGTGACTGAGCCCGAGCGAGATGGGGCATCT	CCTTCACGCATCTACACTTACCAGTGGCGCCAGACCATCACCTTCCAGGAATGCGTCCAC	GATGACTCCCGGCCAGCCCTGCCCAGCACCCAGCAGCTCTCGGTGGACAGCGTGTTCGTC	CTGTACAACCAGGAGGAGAAGATCTTGCGCTACGCTTTCAGCAACTCCATTGGGCCTGTG	AGGGAAGGCTCCCCTGATGCTCTTCAGAATCCCTGCTACATCGGCACTCATGGGTGTGAC	ACCAACGCGGCCTGTCGCCCTGGTCCCAGGACACAGTTCACCTGCGAGTGCTCCATCGGC	TTCCGAGGAGACGGGCGAACCTGCTATGATATTGATGAATGTTCAGAACAACCCTCAGTG	TGTGGGAGCCACACAATCTGCAATAATCACCCAGGAACCTTCCGCTGCGAGTGTGTGGAG	GGCTACCAGTTTTCAGATGAGGGAACGTGTGTGGCTGTCGTGGACCAGCGCCCCATCAAC	TACTGTGAAACTGGCCTTCATAACTGCGACATACCCCAGCGGGCCCAGTGTATCTACACA	GGAGGCTCCTCCTACACCTGTTCCTGCTTGCCAGGCTTTTCTGGGGATGGCCAAGCCTGC	CAAGATGTAGATGAATGCCAGCCAAGCCGATGTCACCCTGACGCCTTCTGCTACAACACT	CCAGGCTCTTTCACGTGCCAGTGCAAACCTGGTTATCAGGGAGACGGCTTCCGTTGCGTG	CCCGGAGAGGTGGAGAAAACCCGGTGCCAGCACGAGCGAGAACACATTCTCGGGGCAGCG	GGGGCGACAGACCCACAGCGACCCATTCCTCCGGGGCTGTTCGTTCCTGAGTGCGATGCG	CACGGGCACTACGCGCCCACCCAGTGCCACGGCAGCACCGGCTACTGCTGGTGCGTGGAT	CGCGACGGCCGCGAGGTGGAGGGCACCAGGACCAGGCCCGGGATGACGCCCCCGTGTCTG	AGTACAGTGGCTCCCCCGATTCACCAAGGACCTGCGGTGCCTACCGCCGTGATCCCCTTG	CCTCCTGGGACCCATTTACTCTTTGCCCAGACTGGGAAGATTGAGCGCCTGCCCCTGGAG	GGAAATACCATGAGGAAGACAGAAGCAAAGGCGTTCCTTCATGTCCCGGCTAAAGTCATC	ATTGGACTGGCCTTTGACTGCGTGGACAAGATGGTTTACTGGACGGACATCACTGAGCCT	TCCATTGGGAGAGCTAGTCTACATGGTGGAGAGCCAACCACCATCATTAGACAAGATCTT	GGAAGTCCAGAAGGTATCGCTGTTGATCACCTTGGCCGCAACATCTTCTGGACAGACTCT	AACCTGGATCGAATAGAAGTGGCGAAGCTGGACGGCACGCAGCGCCGGGTGCTCTTTGAG	ACTGACCTGGTGAATCCCAGAGGCATTGTAACGGATTCCGTGAGAGGGAACCTTTACTGG	ACAGACTGGAACAGAGATAACCCCAAGATTGAAACTTCCTACATGGACGGCACGAACCGG	AGGATCCTTGTGCAGGATGACCTGGGCTTGCCCAATGGACTGCACTTCGATGCGTTCTCA	TCTCAGCTCTGCTGGGTGGATGCAGGCACCAATCGGGCGGAATGCCTGAACCCCAGTCAG	CCCAGCAGACGCAAGGCTCTCGAAGGGCTCCAGTATCCTTTTGCTGTGACGAGCTACGGG	AAGAATCTGTATTTCACAGACTGGAAGATGAATTCCGTGGTTGCTCTCGATCTTGCAATT	TCCAAGGAGACGGATGCTTTCCAACCCCACAAGCAGACCCGGCTGTATGGCATCACCACG	GCCCTGTCTCAGTGTCCGCAAGGCCATAACTACTGCTCAGTGAACAATGGCGGCTGCACC	CACCTATGCTTGGCCACCCCAGGGAGCAGGACCTGCCGTTGCCCTGACAACACCTTGGGA	GTTGACTGTATCGAACGGAAATGA
Nidogen-1 precursor
Nidogen-1
http://pfam.sanger.ac.uk/family?acc=PF06119
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF06119%3E
http://bio2rdf.org/pfam:PF07474
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF07474%3E
http://www.pdb.org/pdb/explore/explore.do?structureId=1GL4
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1GL4%3E
1q43
1-28
http://bio2rdf.org/hgnc:7821
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A7821%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=189209
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D189209%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2574658
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7557988
http://www.uniprot.org/uniprot/P14543
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP14543%3E
cell-substrate adhesion
http://bio2rdf.org/pfam:PF00086
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00086%3E
http://symbol.bio2rdf.org/symbol:NID1
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ANID1%3E
http://pfam.sanger.ac.uk/family?acc=PF07645
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF07645%3E
http://pfam.sanger.ac.uk/family?acc=PF07474
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF07474%3E
>Nidogen-1	MLASSSRIRAAWTRALLLPLLLAGPVGCLSRQELFPFGPGQGDLELEDGDDFVSPALELS	GALRFYDRSDIDAVYVTTNGIIATSEPPAKESHPGLFPPTFGAVAPFLADLDTTDGLGKV	YYREDLSPSITQRAAECVHRGFPEISFQPSSAVVVTWESVAPYQGPSRDPDQKGKRNTFQ	AVLASSDSSSYAIFLYPEDGLQFHTTFSKKENNQVPAVVAFSQGSVGFLWKSNGAYNIFA	NDRESIENLAKSSNSGQQGVWVFEIGSPATTNGVVPADVILGTEDGAEYDDEDEDYDLAT	TRLGLEDVGTTPFSYKALRRGGADTYSVPSVLSPRRAATERPLGPPTERTRSFQLAVETF	HQQHPQVIDVDEVEETGVVFSYNTDSRQTCANNRHQCSVHAECRDYATGFCCSCVAGYTG	NGRQCVAEGSPQRVNGKVKGRIFVGSSQVPIVFENTDLHSYVVMNHGRSYTAISTIPETV	GYSLLPLAPVGGIIGWMFAVEQDGFKNGFSITGGEFTRQAEVTFVGHPGNLVIKQRFSGI	DEHGHLTIDTELEGRVPQIPFGSSVHIEPYTELYHYSTSVITSSSTREYTVTEPERDGAS	PSRIYTYQWRQTITFQECVHDDSRPALPSTQQLSVDSVFVLYNQEEKILRYAFSNSIGPV	REGSPDALQNPCYIGTHGCDTNAACRPGPRTQFTCECSIGFRGDGRTCYDIDECSEQPSV	CGSHTICNNHPGTFRCECVEGYQFSDEGTCVAVVDQRPINYCETGLHNCDIPQRAQCIYT	GGSSYTCSCLPGFSGDGQACQDVDECQPSRCHPDAFCYNTPGSFTCQCKPGYQGDGFRCV	PGEVEKTRCQHEREHILGAAGATDPQRPIPPGLFVPECDAHGHYAPTQCHGSTGYCWCVD	RDGREVEGTRTRPGMTPPCLSTVAPPIHQGPAVPTAVIPLPPGTHLLFAQTGKIERLPLE	GNTMRKTEAKAFLHVPAKVIIGLAFDCVDKMVYWTDITEPSIGRASLHGGEPTTIIRQDL	GSPEGIAVDHLGRNIFWTDSNLDRIEVAKLDGTQRRVLFETDLVNPRGIVTDSVRGNLYW	TDWNRDNPKIETSYMDGTNRRILVQDDLGLPNGLTFDAFSSQLCWVDAGTNRAECLNPSQ	PSRRKALEGLQYPFAVTSYGKNLYFTDWKMNSVVALDLAISKETDAFQPHKQTRLYGITT	ALSQCPQGHNYCSVNNGGCTHLCLATPGSRTCRCPDNTLGVDCIERK
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=M30269
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DM30269%3E
http://pfam.sanger.ac.uk/family?acc=PF00058
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00058%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8441232
http://bio2rdf.org/pdb:1GL4
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1GL4%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1906509
RDF Description of Nidogen-1
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Smith_Logan_Pearsall_1865-1949
_:header8714147741335206521106
Mon, 23 Apr 2012 18:35:16 GMT
RDF Description of Smith, Logan Pearsall, 1865-1949
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Smith_Logan_Pearsall_1865-1949
Smith, Logan Pearsall, 1865-1949
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext12390
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8544
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Bonner_Geraldine_1870-1930
_:header117324281335206521514
RDF Description of Bonner, Geraldine, 1870-1930
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Bonner_Geraldine_1870-1930
Bonner, Geraldine, 1870-1930
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9775
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19113
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Blackmore_R_D_(Richard_Doddridge)_1825-1900
_:header11744762771335206521924
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Blackmore_R_D_(Richard_Doddridge)_1825-1900
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7112
Blackmore, R. D. (Richard Doddridge), 1825-1900
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7435
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6824
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext840
RDF Description of Blackmore, R. D. (Richard Doddridge), 1825-1900
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17460
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/OPA1
_:header14400236061335206522346
Mon, 23 Apr 2012 18:35:17 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/OPA1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3443
http://symbol.bio2rdf.org/symbol:OPA1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AOPA1%3E
OPA1
http://bio2rdf.org/hgnc:8140
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A8140%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=8140
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D8140%3E
http://bio2rdf.org/geneid:4976
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fgeneid%3A4976%3E
http://www.dbpedia.org/resource/Optic_atrophy_1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FOptic_atrophy_1%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/866
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/449
RDF Description of OPA1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2464
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/2283
_:header11647292201335206523281
Mon, 23 Apr 2012 18:35:18 GMT
RDF Description of Bacitracin
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2283
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00626
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00626%3E
CID0000002283
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000002283&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000002283%26input_query_species%3D9606%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0014009
http://sideeffects.embl.de/drugs/2283
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F2283%3E
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000002283
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000002283%3E
Bacitracin
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3340
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3340%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2916
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2916%3E
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00599
_:header7626212191335206523609
RDF Description of Thiopental
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00599
DB00599
InChI=1/C11H18N2O2S/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)/f/h12-13H
Intraval
CCC[C@H](C)C1(CC)C(=O)NC(=S)NC1=O
Trapanal
A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration. It is also used for hypnosis and for the control of convulsive states. It has been used in neurosurgical patients to reduce increased intracranial pressure. It does not produce any excitation but has poor analgesic and muscle relaxant properties. Small doses have been shown to be anti-analgesic and lower the pain threshold. (From Martindale, The Extra Pharmacopoeia, 30th ed, p920)
N05CA19
http://data.linkedct.org/resource/intervention/30281
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F30281%3E
http://www.drugbank.ca/drugs/DB00599
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00599%3E
N01AF03
Thiopentobarbituric acid
Thiothal
Thiopental
Tiopentale [Italian]
Farmotal
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2193
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2193%3E
http://bio2rdf.org/cpd:C07521
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC07521%3E
http://205.193.93.51/dpdonline/searchRequest.do?din=00038393
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D00038393%3E
Nesdonal
http://bio2rdf.org/chebi:30490
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fchebi%3A30490%3E
1OED_A
http://dbpedia.org/resource/Thiopental
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FThiopental%3E
Primarily hepatic. Biotransformation products of thiopental are pharmacologically inactive and mostly excreted in the urine.
Pentothal
Thiopentobarbitone
http://www.rxlist.com/cgi/generic3/thiopental.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric3%2Fthiopental.htm%3E
Thiopental binds at a distinct binding site associated with a Cl<sup>-</sup> ionopore at the GABA<sub>A</sub> receptor, increasing the duration of time for which the Cl<sup>-</sup> ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
CCCC(C)C1(CC)C(=O)NC(=S)NC1=O
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/anesthetics,Intravenous
Thiopental, a barbiturate, is used for the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli. Thiopental is an ultrashort-acting depressant of the central nervous system which induces hypnosis and anesthesia, but not analgesia. It produces hypnosis within 30 to 40 seconds of intravenous injection. Recovery after a small dose is rapid, with some somnolence and retrograde amnesia. Repeated intravenous doses lead to prolonged anesthesia because fatty tissues act as a reservoir; they accumulate Pentothal in concentrations 6 to 12 times greater than the plasma concentration, and then release the drug slowly to cause prolonged anesthesia
http://dbpedia.org/page/Thiopental
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FThiopental%3E
Thiopentone
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/333
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F333%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/gabaModulators
http://bio2rdf.org/cas:76-75-5
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A76-75-5%3E
Overdosage may occur from too rapid or repeated injections. Too rapid injection may be followed by an alarming fall in blood pressure even to shock levels. Apnea, occasional laryngospasm, coughing and other respiratory difficulties with excessive or too rapid injections may occur. Lethal blood levels may be as low as 1 mg/100 mL for short-acting barbiturates; less if other depressant drugs or alcohol are also present.
http://en.wikipedia.org/wiki/Thiopental
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FThiopental%3E
http://www.dbpedia.org/resource/Sodium_thiopental
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FSodium_thiopental%3E
-3.36 [ADME Research, USCD]
5-ethyl-5-pentan-2-yl-2-sulfanylidene-1,3-diazinane-4,6-dione
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3937
http://129.128.185.122/drugbank2/drugs/DB00599/inserts/1804/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00599%2Finserts%2F1804%2Ffull%3E
C11H18N2O2S
Thiopentobarbital
Thiotal 5g (Thiopental Sodium + Water)
aprd00660
Penthiobarbital
Approximately 80% of the drug in the blood is bound to plasma protein.
IUJDSEJGGMCXSG-BAINRFMOCL
http://129.128.185.122/drugbank2/drugs/DB00599/inserts/781/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00599%2Finserts%2F781%2Ffull%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/hypnoticsAndSedatives
3.98e-02 mg/mL
For use as the sole anesthetic agent for brief (15 minute) procedures, for induction of anesthesia prior to administration of other anesthetic agents, to supplement regional anesthesia, to provide hypnosis during balanced anesthesia with other agents for analgesia or muscle relaxation, for the control of convulsive states during or following inhalation anesthesia or local anesthesia, in neurosurgical patients with increased intracranial pressure, and for narcoanalysis and narcosynthesis in psychiatric disorders.
2008-08-26 16:00:50 UTC
Pentothiobarbital
Thionembutal
Thiomebumal
PA451664
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/CHRNB1
_:header14127603431335206524115
Mon, 23 Apr 2012 18:35:19 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/CHRNB1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3251
http://symbol.bio2rdf.org/symbol:CHRNB1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ACHRNB1%3E
CHRNB1
http://www.dbpedia.org/resource/CHRNB1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FCHRNB1%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/787
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3260
RDF Description of CHRNB1
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB03687
_:header7367852541335206524499
RDF Description of 4-Diphosphocytidyl-2-C-Methyl-D-Erythritol
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03687
DB03687
InChI=1/C14H25N3O14P2/c1-14(23,6-18)8(19)5-29-33(26,27)31-32(24,25)28-4-7-10(20)11(21)12(30-7)17-3-2-9(15)16-13(17)22/h2-3,7-8,10-12,18-21,23H,4-6H2,1H3,(H,24,25)(H,26,27)(H2,15,16,22)/f/h24,26H,15H2
YFAUKWZNPVBCFF-PRXKNGJVCZ
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2383
4-Diphosphocytidyl-2-C-Methyl-D-Erythritol
[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl [hydroxy-[(2R,3S)-2,3,4-trihydroxy-3-methylbutoxy]phosphoryl] hydrogen phosphate
1OJ4
expt00873
2008-08-26 14:20:47 UTC
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2867
C14H25N3O14P2
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3019
CDM
CC(O)(CO)C(O)COP(O)(=O)OP(O)(=O)OCC1OC(C(O)C1O)N1C=CC(N)=NC1=O
C[C@@](O)(CO)[C@@H](O)CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H]1O[C@H]([C@H](O)[C@H]1O)N1C=CC(N)=NC1=O
http://www.drugbank.ca/drugs/DB03687
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB03687%3E
1.29e+01 mg/mL
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01078
_:header4847091761335206524968
RDF Description of Deslanoside
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01078
Deacetyllanatoside C
C47H74O19
4.68e-01 mg/mL
20%
Deslanoside is a cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation.
InChI=1/C47H74O19/c1-20-41(64-36-16-30(50)42(21(2)60-36)65-37-17-31(51)43(22(3)61-37)66-44-40(56)39(55)38(54)32(18-48)63-44)29(49)15-35(59-20)62-25-8-10-45(4)24(13-25)6-7-27-28(45)14-33(52)46(5)26(9-11-47(27,46)57)23-12-34(53)58-19-23/h12,20-22,24-33,35-44,48-52,54-57H,6-11,13-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27-,28-,29+,30+,31+,32-,33-,35+,36+,37+,38-,39+,40-,41-,42-,43-,44+,45+,46+,47+/m1/s1
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/806
Deslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Deslanoside also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential.
Cedilanid-d
Little absorption from the gastrointestinal tract (40%).
Deacetyllanatoside C. A cardiotonic glycoside from the leaves of Digitalis lanata. [PubChem]
http://www.drugbank.ca/drugs/DB01078
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01078%3E
http://bio2rdf.org/kegg:D01240
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD01240%3E
Deslanoside
2008-08-26 15:31:27 UTC
Symptoms of overdose include ventricular tachycardia, ventricular fibrillation, progressive bradyarrhythmias, or heart block.
http://dbpedia.org/page/Deslanoside
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FDeslanoside%3E
For the treatment and management of Congestive cardiac insufficiency, arrhythmias and heart failure.
aprd00909
C01AA07
DB01078
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/anti-arrhythmiaAgents
http://bio2rdf.org/cas:17598-65-1
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A17598-65-1%3E
http://en.wikipedia.org/wiki/Deslanoside
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FDeslanoside%3E
OBATZBGFDSVCJD-CPSYTWHUBI
4-[(3S,5R,8R,9R,10S,12R,13S,14S,17R)-12,14-dihydroxy-3-[(2R,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-6-methyl-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-5H-furan-2-one
CC1OC(CC(O)C1OC1CC(O)C(OC2CC(O)C(OC3OC(CO)C(O)C(O)C3O)C(C)O2)C(C)O1)OC1CCC2(C)C(CCC3C2CC(O)C2(C)C(CCC32O)C2=CC(=O)OC2)C1
PA449235
36 hours
http://dbpedia.org/resource/Deslanoside
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FDeslanoside%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/cardiotonicAgents
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/enzymeInhibitors
C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00887_DB01078
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00999_DB01078
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00695_DB01078
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00310_DB01078
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00524_DB01078
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00808_DB01078
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00903_DB01078
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00436_DB01078
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/PHKA1
_:header6286379681335206525354
Mon, 23 Apr 2012 18:35:20 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PHKA1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3227
http://symbol.bio2rdf.org/symbol:PHKA1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3APHKA1%3E
PHKA1
http://www.dbpedia.org/resource/PHKA1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FPHKA1%3E
RDF Description of PHKA1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/784
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/House_Edward_Mandell_1858-1938
_:header6836457821335206525757
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/House_Edward_Mandell_1858-1938
House, Edward Mandell, 1858-1938
RDF Description of House, Edward Mandell, 1858-1938
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6711
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/41744
_:header6120349131335206526263
Mon, 23 Apr 2012 18:35:21 GMT
RDF Description of VALSTAR PRESERVATIVE FREE
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/41744
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000041744
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000041744%3E
VALSTAR PRESERVATIVE FREE
CID0000041744
http://sideeffects.embl.de/drugs/41744
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F41744%3E
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000041744&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000041744%26input_query_species%3D9606%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00385
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00385%3E
http://www.fda.gov/cder/foi/label/1998/20892lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F1998%2F20892lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/24486
_:header10876948591335206526699
RDF Description of Calcium Chloride
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/24486
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000024486
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000024486%3E
http://sideeffects.embl.de/drugs/24486
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F24486%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3375
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3375%3E
Calcium Chloride
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01164
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01164%3E
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000024486&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000024486%26input_query_species%3D9606%3E
CID0000024486
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Dempster_George_1732-1818
_:header5478087741335206527093
Mon, 23 Apr 2012 18:35:22 GMT
RDF Description of Dempster, George, 1732-1818
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Dempster_George_1732-1818
Dempster, George, 1732-1818
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext15857
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00797
_:header10200582051335206527540
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00797
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00501_DB00797
Priscoline
Benzazoline
Tolazoline
/drugs/797/safety_sheets/1197
InChI=1/C10H12N2/c1-2-4-9(5-3-1)8-10-11-6-7-12-10/h1-5H,6-8H2,(H,11,12)/f/h11H
C04AB02
PA451716
C1CN=C(CC2=CC=CC=C2)N1
Olitensol
http://en.wikipedia.org/wiki/Tolazoline
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FTolazoline%3E
Tolazoline is a pulmonary vasodilator indicated used to decrease pulmonary vascular resistance (PVR) in persistent pulmonary hypertension of the newborn (PPHN).
Vasodilatan
174 oC
2008-08-26 15:08:05 UTC
http://bio2rdf.org/cas:59-98-3
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A59-98-3%3E
1.36e+00 mg/mL
http://bio2rdf.org/cpd:C07147
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC07147%3E
Prefaxil
M02AX02
Dilatol Asi
Imidaline
Vasimid
Priscol
Benzolin
Tolazolin
For the treatment of pulmonary artery anomalies
373 mg/L
Benzidazol
Artonil
DB00797
Lambril
2-(phenylmethyl)-4,5-dihydro-1H-imidazole
Benzylimidazoline
Divascol
Phenylmethylimidazoline
http://205.193.93.51/dpdonline/searchRequest.do?din=02195887
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02195887%3E
C10H12N2
http://dbpedia.org/resource/Tolazoline
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FTolazoline%3E
Kasimid
Peripherine
JIVZKJJQOZQXQB-WXRBYKJCCZ
Imidalin
http://dbpedia.org/page/Tolazoline
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FTolazoline%3E
A vasodilator that apparently has direct actions on blood vessels and also increases cardiac output. Tolazoline can interact to some degree with histamine, adrenergic, and cholinergic receptors, but the mechanisms of its therapeutic effects are not clear. It is used in treatment of persistent pulmonary hypertension of the newborn. [PubChem]
http://www.drugbank.ca/drugs/DB00797
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00797%3E
Vasodilation by means of a direct effect on peripheral vascular smooth muscle and indirect effects produced, in part, by release of endogenous histamine; tolazoline has moderate alpha-adrenergic blocking activity and has histamine agonist activity. Tolazoline usually reduces pulmonary arterial pressure and vascular resistance.
aprd00170
Vasodil
RDF Description of Tolazoline
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00863_DB00797
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/5579
_:header1361360451335206527995
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/5579
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04272
proteolysis
3q24
http://www.uniprot.org/uniprot/P15086
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP15086%3E
exopeptidase activity
Carboxypeptidase B precursor
CPB1
http://pfam.sanger.ac.uk/family?acc=PF00246
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00246%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2920728
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=M81057
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DM81057%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1370825
CBPB1_HUMAN
http://www.genenames.org/data/hgnc_data.php?hgnc_id=2299
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D2299%3E
http://bio2rdf.org/pdb:1KWM
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1KWM%3E
http://pfam.sanger.ac.uk/family?acc=PF02244
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF02244%3E
carboxypeptidase A activity
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9524066
PASP
carboxypeptidase activity
metallocarboxypeptidase activity
peptidase activity
Involved in carboxypeptidase A activity
http://bio2rdf.org/uniprot:P15086
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP15086%3E
Carboxypeptidase B
>Carboxypeptidase B	MLALLVLVTVALASAHHGGEHFEGEKVFRVNVEDENHINIIRELASTTQIDFWKPDSVTQ	IKPHSTVDFRVKAEDTVTVENVLKQNELQYKVLISNLRNVVEAQFDSRVRATGHSYEKYN	KWETIEAWTQQVATENPALISRSVIGTTFEGRAIYLLKVGKAGQNKPAIFMDCGFHAREW	ISPAFCQWFVREAVRTYGREIQVTELLDKLDFYVLPVLNIDGYIYTWTKSRFWRKTRSTH	TGSSCIGTDPNRNFDAGWCEIGASRNPCDETYCGPAAESEKETKALADFIRNKLSSIKAY	LTIHSYSQMMIYPYSYAYKLGENNAELNALAKATVKELASLHGTKYTYGPGATTIYPAAG	GSDDWAYDQGIRYSFTFELRDTGRYGFLLPESQIRATCEETFLAIKYVASYVLEHLY
Pancreas-specific protein
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12162965
>1251 bp	ATGTTGGCACTCTTGGTTCTGGTGACTGTGGCCCTGGCATCTGCTCATCATGGTGGTGAG	CACTTTGAAGGCGAGAAGGTGTTCCGTGTTAACGTTGAAGATGAAAATCACATTAACATA	ATCCGCGAGTTGGCCAGCACGACCCAGATTGACTTCTGGAAGCCAGATTCTGTCACACAA	ATCAAACCTCACAGTACAGTTGACTTCCGTGTTAAAGCAGAAGATACTGTCACTGTGGAG	AATGTTCTAAAGCAGAATGAACTACAATACAAGGTACTGATAAGCAACCTGAGAAATGTG	GTGGAGGCTCAGTTTGATAGCCGGGTTCGTGCAACAGGACACAGTTATGAGAAGTACAAC	AAGTGGGAAACGATAGAGGCTTGGACTCAACAAGTCGCCACTGAGAATCCAGCCCTCATC	TCTCGCAGTGTTATCGGAACCACATTTGAGGGACGCGCTATTTACCTCCTGAAGGTTGGC	AAAGCTGGACAAAATAAGCCTGCCATTTTCATGGACTGTGGTTTCCATGCCAGAGAGTGG	ATTTCTCCTGCATTCTGCCAGTGGTTTGTAAGAGAGGCTGTTCGTACCTATGGACGTGAG	ATCCAAGTGACAGAGCTTCTCGACAAGTTAGACTTTTATGTCCTGCCTGTGCTCAATATT	GATGGCTACATCTACACCTGGACCAAGAGCCGATTTTGGAGAAAGACTCGCTCCACCCAT	ACTGGATCTAGCATTGGCACAGACCCCAACAGAAATTTTGATGCTGGTTGGTGTGAAATT	GGAGCCTCTCGAAACCCCTGTGATGAAACTTACTGTGGACCTGCCGCAGAGTCTGAAAAG	GAGACCAAGGCCCTGGCTGATTTCATCCGCAACAAACTCTCTTCCATCAAGGCATATCTG	ACAATCCACTCGTACTCCCAAATGATGATCTACCCTTACTCATATGCTTACAAACTCGGT	GAGAACAATGCTGAGTTGAATGCCCTGGCTAAAGCTACTGTGAAAGAACTTGCCTCACTG	CACGGCACCAAGTACACATATGGCCCGGGAGCTACAACAATCTATCCTGCTGCTGGGGGC	TCTGACGACTGGGCTTATGACCAAGGAATCAGATATTCCTTCACCTTTGAACTTCGAGAT	ACAGGCAGATATGGCTTTCTCCTTCCAGAATCCCAGATCCGGGCTACCTGCGAGGAGACC	TTCCTGGCAATCAAGTATGTTGCCAGCTACGTCCTGGAACACCTGTACTAG
Preferential release of a C-terminal lysine or arginine amino acid
http://bio2rdf.org/pfam:PF02244
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF02244%3E
http://bio2rdf.org/pfam:PF00246
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00246%3E
http://www.pdb.org/pdb/explore/explore.do?structureId=1KWM
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1KWM%3E
http://bio2rdf.org/hgnc:2299
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A2299%3E
EC 3.4.17.2
M81057
RDF Description of Carboxypeptidase B
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/3412
_:header8811676991335206528481
Mon, 23 Apr 2012 18:35:23 GMT
RDF Description of FK506-binding protein 3
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3412
FKBP-25
FK506-binding protein 3
>FK506-binding protein 3	MAAAVPQRAWTVEQLRSEQLPKKDIIKFLQEHGSDSFLAEHKLLGNIKNVAKTANKDHLV	TAYNHLFETKRFKGTESISKVSEQVKNVKLNEDKPKETKSEETLDEGPPKYTKSVLKKGD	KTNFPKKGDVVHCWYTGTLQDGTVFDTNIQTSAKKKKNAKPLSFKVGVGKVIRGWDEALL	TMSKGEKARLEIEPEWAYGKKGQPDAKIPPNAKLTFEVELVDID
14q21.3
>675 bp	ATGGCGGCGGCCGTTCCACAGCGGGCGTGGACCGTGGAGCAGCTGCGCAGTGAGCAGCTG	CCCAAGAAGGATATTATCAAGTTTCTGCAGGAACACGGTTCAGATTCGTTTCTTGCAGAA	CATAAATTATTAGGAAACATTAAAAATGTGGCCAAGACAGCTAACAAGGACCACTTGGTT	ACAGCCTATAACCATCTTTTTGAAACTAAGCGTTTTAAGGGTACTGAAAGTATAAGTAAA	GTGTCTGAGCAAGTAAAAAATGTGAAGCTTAATGAAGATAAACCCAAAGAAACCAAGTCT	GAAGAGACCCTGGATGAGGGTCCACCAAAATATACTAAATCTGTTCTGAAAAAGGGAGAT	AAAACCAACTTTCCCAAAAAGGGAGATGTTGTTCACTGCTGGTATACAGGAACACTACAA	GATGGGACTGTTTTTGATACTAATATTCAAACAAGTGCAAAGAAGAAGAAAAATGCCAAG	CCTTTAAGTTTTAAGGTCGGAGTAGGCAAAGTTATCAGAGGATGGGATGAAGCTCTCTTG	ACTATGAGTAAAGGAGAAAAGGCTCGACTGGAGATTGAACCAGAATGGGCTTACGGAAAG	AAAGGACAGCCTGATGCCAAAATTCCACCAAATGCAAAACTCACTTTTGAAGTGGAATTA	GTGGATATTGATTGA
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/gene/FKBP3
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fgene%2FFKBP3%3E
http://bio2rdf.org/uniprot:Q00688
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ00688%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=182626
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D182626%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=3719
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D3719%3E
http://bio2rdf.org/hgnc:3719
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A3719%3E
FKBP3_HUMAN
FKBP3
http://www.pdb.org/pdb/explore/explore.do?structureId=1PBK
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1PBK%3E
http://symbol.bio2rdf.org/symbol:FKBP3
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AFKBP3%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=M96256
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DM96256%3E
25 kDa FKBP
FK506- and rapamycin-binding proteins (FKBPs) constitute a family of receptors for the two immunosuppressants which inhibit T-cell proliferation by arresting two distinct cytoplasmic signal transmission pathways. PPIases accelerate the folding of proteins
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1374240
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1375932
http://www.uniprot.org/uniprot/Q00688
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ00688%3E
M96256
Rapamycin- selective 25 kDa immunophilin
http://bio2rdf.org/pdb:1PBK
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1PBK%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1376117
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02439
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Penrose_Margaret
_:header7385411231335206528791
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Penrose_Margaret
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext20870
Penrose, Margaret
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7210
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext15653
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext16091
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2789
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5629
RDF Description of Penrose, Margaret
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext4914
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7081
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00385
_:header12970010161335206529256
Mon, 23 Apr 2012 18:35:24 GMT
RDF Description of Valrubicin
http://www.drugbank.ca/drugs/DB00385
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00385%3E
Valrubicin is a semisynthetic analog of the anthracycline doxorubicin, and is administered by infusion directly into the bladder.
http://www.rxlist.com/cgi/generic2/rubicin.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric2%2Frubicin.htm%3E
aprd00662
http://dbpedia.org/resource/Valrubicin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FValrubicin%3E
116-117oC
ZOCKGBMQLCSHFP-BFKABFATDD
http://129.128.185.122/drugbank2/drugs/DB00385/inserts/1331/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00385%2Finserts%2F1331%2Ffull%3E
http://dbpedia.org/page/Valrubicin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FValrubicin%3E
The primary anticipated complications of overdosage associated with intravesical administration would be consistent with irritable bladder symptoms. Myelosuppression is possible if valrubicin is inadvertently administered systemically or if significant systemic exposure occurs following intravesical administration (e.g., in patients with bladder/rupture perforation). The maximum tolerated dose in humans by either intraperitoneal or intravenous administration is 600 mg/m<sup>2</sup>.
CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@@H]2C[C@H](NC(=O)C(F)(F)F)[C@@H](O)[C@H](C)O2)C2=C(C1)C(O)=C1C(=O)C3=C(C(=O)C1=C2O)C(OC)=CC=C3
Valstar
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/327
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F327%3E
Valrubicin (N-trifluoroacetyladriamycin-14-valerate, Valstar&reg;) is a chemotherapy drug used to treat bladder cancer. Valrubicin is a semisynthetic analog of the anthracycline doxorubicin, and is administered by infusion directly into the bladder. [Wikipedia]
[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate
CCCCC(=O)OCC(=O)C1(O)CC(OC2CC(NC(=O)C(F)(F)F)C(O)C(C)O2)C2=C(C1)C(O)=C1C(=O)C3=C(C(=O)C1=C2O)C(OC)=CC=C3
DB00385
C34H36F3NO13
http://129.128.185.122/drugbank2/drugs/DB00385/inserts/2330/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00385%2Finserts%2F2330%2Ffull%3E
Valrubicin
>99%
http://en.wikipedia.org/wiki/Valrubicin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FValrubicin%3E
Antibiotic Ad 32
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/liquidIntravesical
InChI=1/C34H36F3NO13/c1-4-5-9-21(40)49-13-20(39)33(47)11-16-24(19(12-33)51-22-10-17(27(41)14(2)50-22)38-32(46)34(35,36)37)31(45)26-25(29(16)43)28(42)15-7-6-8-18(48-3)23(15)30(26)44/h6-8,14,17,19,22,27,41,43,45,47H,4-5,9-13H2,1-3H3,(H,38,46)/t14?,17?,19-,22?,27?,33-/m0/s1/f/h38H
Valrubicin is metabolized to two primary metabolites: N-trifluoroacetyladriamycin and N-trifluoroacetyladriamycinol.
http://129.128.185.122/drugbank2/drugs/DB00385/inserts/429/full
Valrubicin is an anthracycline that affects a variety of inter-related biological functions, most of which involve nucleic acid metabolism. It readily penetrates into cells, where it inhibits the incorporation of nucleosides into nucleic acids, causes extensive chromosomal damage, and arrests cell cycle in G2. Although valrubicin does not bind strongly to DNA, a principal mechanism of its action, mediated by valrubicin metabolites, is interference with the normal DNA breaking-resealing action of DNA topoisomerase II.
Valstar Preservative Free
2008-08-26 15:48:07 UTC
3.25e-02 mg/mL
http://bio2rdf.org/cas:56124-62-0
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A56124-62-0%3E
L01DB09
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2186
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2186%3E
http://205.193.93.51/dpdonline/searchRequest.do?din=02242466
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02242466%3E
1998-09-01	/drugs/385/fda_labels/1063
insoluble
For the treatment of cancer of the bladder.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/817
PA451847
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/454
_:header4607118801335206529833
RDF Description of Peroxisomal multifunctional enzyme type 2
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/454
HSD17B4
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9880674
17-beta-hydroxysteroid dehydrogenase 4
Bifunctional enzyme acting on the peroxisomal beta- oxidation pathway for fatty acids. Catalyzes the formation of 3- ketoacyl-CoA intermediates from both straight-chain and 2-methyl- branched-chain fatty acids
http://pfam.sanger.ac.uk/family?acc=PF02036
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF02036%3E
http://www.uniprot.org/uniprot/P51659
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP51659%3E
Peroxisomal multifunctional enzyme type 2
http://www.pdb.org/pdb/explore/explore.do?structureId=1ZBQ
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1ZBQ%3E
>2211 bp	ATGGGCTCACCGCTGAGGTTCGACGGGCGGGTGGTACTGGTCACCGGCGCGGGGGCAGGA	TTGGGCCGAGCCTATGCCCTGGCTTTTGCAGAAAGAGGAGCGTTAGTTGTTGTGAATGAT	TTGGGAGGGGACTTCAAAGGAGTTGGTAAAGGCTCCTTAGCTGCTGATAAGGTTGTTGAA	GAAATAAGAAGGAGAGGTGGAAAAGCAGTGGCCAACTATGATTCAGTGGAAGAAGGAGAG	AAGGTTGTGAAGACAGCCCTGGATGCTTTTGGAAGAATAGATGTTGTGGTCAACAATGCT	GGAATTCTGAGGGATCGTTCCTTTGCTAGGATAAGTGATGAAGACTGGGATATAATCCAC	AGAGTTCATTTGCGGGGTTCATTCCAAGTGACACGGGCAGCATGGGAACACATGAAGAAA	CAGAAGTATGGAAGGATTATTATGACTTCATCAGCTTCAGGAATATATGGCAACTTTGGC	CAGGCCAATTATAGTGCTGCAAAGTTGGGTCTTCTGGGCCTTGCAAATTCTCTTGCAATT	GAAGGCAGGAAAAGCAACATTCATTGTAACACCATTGCTCCTAATGCGGGATCACGGATG	ACTCAGACAGTTATGCCTGAAGATCTTGTGGAAGCCCTGAAGCCAGAGTATGTGGCACCT	CTTGTCCTTTGGCTTTGTCACGAGAGTTGTGAGGAGAATGGTGGCTTGTTTGAGGTTGGA	GCAGGATGGATTGGAAAATTACGCTGGGAGCGGACTCTTGGAGCTATTGTAAGACAAAAG	AATCACCCAATGACTCCTGAGGCAGTCAAGGCTAACTGGAAGAAGATCTGTGACTTTGAG	AATGCCAGCAAGCCTCAGAGTATCCAAGAATCAACTGGCAGTATAATTGAAGTTCTGAGT	AAAATAGATTCAGAAGGAGGAGTTTCAGCAAATCATACTAGTCGTGCAACGTCTACAGCA	ACATCAGGATTTGCTGGAGCTATTGGCCAGAAACTCCCTCCATTTTCTTATGCTTATACG	GAACTGGAAGCTATTATGTATGCCCTTGGAGTGGGAGCGTCAATCAAGGATCCAAAAGAT	TTGAAATTTATTTATGAAGGAAGTTCTGATTTCTCCTGTTTGCCCACCTTCGGAGTTATC	ATAGGTCAGAAATCTATGATGGGTGGAGGATTAGCAGAAATTCCTGGACTTTCAATCAAC	TTTGCAAAGGTTCTTCATGGAGAGCAGTACTTAGAGTTATATAAACCACTTCCCAGAGCA	GGAAAATTAAAATGTGAAGCAGTTGTTGCTGATGTCCTAGATAAAGGATCCGGTGTAGTG	ATTATTATGGATGTCTATTCTTATTCTGAGAAGGAACTTATATGCCACAATCAGTTCTCT	CTCTTTCTTGTTGGCTCTGGAGGCTTTGGTGGAAAACGGACATCAGACAAAGTCAAGGTA	GCTGTAGCCATACCTAATAGACCTCCTGATGCTGTACTTACAGATACCACCTCTCTTAAT	CAGGCTGCTTTGTACCGCCTCAGTGGAGACTGGAATCCCTTACACATTGATCCTAACTTT	GCTAGTCTAGCAGGTTTTGACAAGCCCATATTACATGGATTATGTACATTTGGATTTTCT	GCCAGGCGTGTGTTACAGCAGTTTGCAGATAATGATGTGTCAAGATTCAAGGCAATTAAG	GCTCGTTTTGCAAAACCAGTATATCCAGGACAAACTCTACAAACTGAGATGTGGAAGGAA	GGAAACAGAATTCATTTTCAAACCAAGGTCCAAGAAACTGGAGACATTGTCATTTCAAAT	GCATATGTGGATCTTGCACCAACATCTGGTACTTCAGCTAAGACACCCTCTGAGGGCGGG	AAGCTTCAGAGTACCTTTGTATTTGAGGAAATAGGACGCCGCCTAAAGGATATTGGGCCT	GAGGTGGTGAAGAAAGTAAATGCTGTATTTGAGTGGCATATAACCAAAGGCGGAAATATT	GGGGCTAAGTGGACTATTGACCTGAAAAGTGGTTCTGGAAAAGTGTACCAAGGCCCTGCA	AAAGGTGCTGCTGATACAACAATCATACTTTCAGATGAAGATTTCATGGAGGTGGTCCTG	GGCAAGCTTGACCCTCAGAAGGCATTCTTTAGTGGCAGGCTGAAGGCCAGAGGGAACATC	ATGCTGAGCCAGAAACTTCAGATGATTCTTAAAGACTACGCCAAGCTCTGA
DHB4_HUMAN
sterol carrier activity
DBP
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9089413
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8902629
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=X87176
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DX87176%3E
3- hydroxyacyl-CoA dehydrogenase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12517343
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7487879
MFE-2
5q21
http://bio2rdf.org/pfam:PF02036
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF02036%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11700068
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=1050517
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D1050517%3E
http://bio2rdf.org/pdb:1ZBQ
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1ZBQ%3E
EC 4.2.1.107
X87176
http://pfam.sanger.ac.uk/family?acc=PF01575
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF01575%3E
D-bifunctional protein
http://bio2rdf.org/uniprot:P51659
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP51659%3E
http://bio2rdf.org/hgnc:5213
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A5213%3E
3-alpha,7- alpha,12-alpha-trihydroxy-5-beta-cholest-24-enoyl-CoA hydratase
(S)-3-hydroxyacyl-CoA + NAD+ = 3-oxoacyl-CoA + NADH + H+
map00062	Fatty acid biosynthesis (path 2)	map00071	Fatty acid metabolism	map00280	Valine, leucine and isoleucine degradation	map00310	Lysine degradation	map00380	Tryptophan metabolism	map00632	Benzoate degradation via CoA ligation	map00650	Butanoate metabolism	map00930	Caprolactam degradation
D-3-hydroxyacyl-CoA dehydratase
EC 1.1.1.35
http://www.genenames.org/data/hgnc_data.php?hgnc_id=5213
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D5213%3E
17-beta-HSD 4
steroid binding
http://symbol.bio2rdf.org/symbol:HSD17B4
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AHSD17B4%3E
>Peroxisomal multifunctional enzyme type 2	GSPLRFDGRVVLVTGAGAGLGRAYALAFAERGALVVVNDLGGDFKGVGKGSLAADKVVEE	IRRRGGKAVANYDSVEEGEKVVKTALDAFGRIDVVVNNAGILRDRSFARISDEDWDIIHR	VHLRGSFQVTRAAWEHMKKQKYGRIIMTSSASGIYGNFGQANYSAAKLGLLGLANSLAIE	GRKSNIHCNTIAPNAGSRMTQTVMPEDLVEALKPEYVAPLVLWLCHESCEENGGLFEVGA	GWIGKLRWERTLGAIVRQKNHPMTPEAVKANWKKICDFENASKPQSIQESTGSIIEVLSK	IDSEGGVSANHTSRATSTATSGFAGAIGQKLPPFSYAYTELEAIMYALGVGASIKDPKDL	KFIYEGSSDFSCLPTFGVIIGQKSMMGGGLAEIPGLSINFAKVLHGEQYLELYKPLPRAG	KLKCEAVVADVLDKGSGVVIIMDVYSYSEKELICHNQFSLFLVGSGGFGGKRTSDKVKVA	VAIPNRPPDAVLTDTTSLNQAALYRLSGDWNPLHIDPNFASLAGFDKPILHGLCTFGFSA	RRVLQQFADNDVSRFKAIKARFAKPVYPGQTLQTEMWKEGNRIHFQTKVQETGDIVISNA	YVDLAPTSGTSAKTPSEGGKLQSTFVFEEIGRRLKDIGPEVVKKVNAVFEWHITKGGNIG	AKWTIDLKSGSGKVYQGPAKGAADTTIILSDEDFMEVVLGKLDPQKAFFSGRLKARGNIM	LSQKLQMILKDYAKL
http://bio2rdf.org/pfam:PF01575
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF01575%3E
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01591
_:header15795522041335206530133
Mon, 23 Apr 2012 18:35:25 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01591
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01167_DB01591
http://129.128.185.122/drugbank2/drugs/DB01591/inserts/4778/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB01591%2Finserts%2F4778%2Ffull%3E
Overdosage with solifenacin can potentially result in severe anticholinergic effects and should be treated accordingly. The highest solifenacin dose given to human volunteers was a single 100 mg dose. Intolerable anticholinergic side effects (fixed and dilated pupils, blurred vision, failure of heel-to-toe exam, tremors and dry skin) occurred on day 3 in normal volunteers taking 50 mg daily (5 times the maximum recommended therapeutic dose).
http://www.drugbank.ca/drugs/DB01591
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01591%3E
http://129.128.185.122/drugbank2/drugs/DB01591/inserts/4777/full
The elimination half-life of solifenacin following chronic dosing is approximately 45-68 hours.
Solifenacin is extensively metabolized in the liver. The primary pathway for elimination is by way of CYP3A4; however, alternate metabolic pathways exist. The primary metabolic routes of solifenacin are through N-oxidation of the quinuclidin ring and 4R-hydroxylation of tetrahydroisoquinoline ring. One pharmacologically active metabolite (4R-hydroxy solifenacin), occurring at low concentrations and unlikely to contribute significantly to clinical activity, and three pharmacologically inactive metabolites (N-glucuronide and the N-oxide and 4R-hydroxy-N-oxide of solifenacin) have been found in human plasma after oral dosing.
DB01591
http://en.wikipedia.org/wiki/Solifenacin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FSolifenacin%3E
2004-12-01	/drugs/1591/fda_labels/477
For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Solifenacin is a competitive muscarinic receptor antagonist. Muscarinic receptors play an important role in several major cholinergically mediated functions, including contractions of urinary bladder smooth muscle and stimulation of salivary secretion.
[(8R)-1-azabicyclo[2.2.2]octan-8-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; butanedioic acid
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/103
aprd00168
http://data.linkedct.org/resource/intervention/56802
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F56802%3E
http://129.128.185.122/drugbank2/drugs/DB01591/inserts/4779/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB01591%2Finserts%2F4779%2Ffull%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/anti-incontinenceAgents
Vesikur
http://dbpedia.org/resource/Solifenacin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FSolifenacin%3E
http://bio2rdf.org/cas:242478-37-1
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A242478-37-1%3E
http://dbpedia.org/page/Solifenacin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FSolifenacin%3E
Solifenacin (rINN), marketed as solifenacin succinate under the trade name Vesicare, is a urinary antispasmodic of the anticholinergic class. It is used in the treatment of overactive bladder with urge incontinence. [Wikipedia]
Solifenacin
OC(=O)CCC(O)=O.O=C(O[C@H]1C[N@@]2CC[C@H]1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/antispasmodics
http://205.193.93.51/dpdonline/searchRequest.do?din=02277263
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02277263%3E
http://data.linkedct.org/resource/intervention/13260
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F13260%3E
http://data.linkedct.org/resource/intervention/55910
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F55910%3E
RXZMMZZRUPYENV-JAIDUIOBDC
2008-08-26 20:30:42 UTC
C27H32N2O6
http://data.linkedct.org/resource/intervention/45417
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F45417%3E
G04BD08
Solifenacin is a competitive muscarinic acetylcholine receptor antagonist. The binding of acetylcholine to these receptors, particularly the M3 receptor subtype, plays a critical role in the contraction of smooth muscle. By preventing the binding of acetylcholine to these receptors, solifenacin reduces smooth muscle tone in the bladder, allowing the bladder to retain larger volumes of urine and reducing the number of incontinence episodes.
solifenacin succinate
http://www.rxlist.com/cgi/generic/vesicare.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric%2Fvesicare.htm%3E
http://data.linkedct.org/resource/intervention/45080
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F45080%3E
Solifenacin is approximately 98% (in vivo) bound to human plasma proteins, principally to alpha1-acid glycoprotein.
Vesicare
http://www.dbpedia.org/resource/Solifenacin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FSolifenacin%3E
http://data.linkedct.org/resource/intervention/60171
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F60171%3E
http://data.linkedct.org/resource/intervention/20336
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F20336%3E
OC(=O)CCC(O)=O.O=C(OC1CN2CCC1CC2)N1CCC2=CC=CC=C2C1C1=CC=CC=C1
InChI=1/C23H26N2O2.C4H6O4/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19;5-3(6)1-2-4(7)8/h1-9,18,21-22H,10-16H2;1-2H2,(H,5,6)(H,7,8)/t21-,22-;/m0./s1/f/h;5,7H
The absolute bioavailability of solifenacin is approximately 90%, and plasma concentrations of solifenacin are proportional to the dose administered.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01026_DB01591
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00843_DB01591
RDF Description of Solifenacin
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01211_DB01591
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00209_DB01591
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00674_DB01591
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00220_DB01591
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00382_DB01591
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00662_DB01591
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00427_DB01591
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01149_DB01591
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Common_Thomas
_:header18197102131335206530658
RDF Description of Common, Thomas 
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Common_Thomas
Common, Thomas 
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1998
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01228
_:header20421291211335206531121
Mon, 23 Apr 2012 18:35:26 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01228
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00604_DB01228
4-methoxy-N-[2-(1-piperidin-1-ylpropan-2-yl)phenyl]benzamide
Encainide is a sodium channel blocker, binding to voltage gated sodium channels. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole.
aprd00613
Encainide
Encainida [Spanish]
COC1=CC=C(C=C1)C(=O)NC1=CC=CC=C1[C@H](C)CN1CCCCC1
VOVAEUFPROBLAL-MPIMZMORCE
2008-08-26 14:36:57 UTC
Used to treat irregular heartbeats, encainide decreases excitability, conduction velocity, and automaticity as a result of slowed atrial, atrioventricular (AV) nodal, His-Purkinje, and intraventricular conduction. It causes a slight but significant prolongation of refractory periods in these tissues. The greatest effect is on the His-Purkinje system. Encainide decreases the rate of rise of the action potential without markedly affecting its duration.
http://en.wikipedia.org/wiki/Encainide
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FEncainide%3E
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fsider%2Fresource%2Fdrugs%2F48041%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/sodiumChannelBlockers
http://bio2rdf.org/cas:66778-36-7
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A66778-36-7%3E
For management of irregular heartbeats to a normal rhythm.
All drug products containing encainide hydrochloride. Encainide hydrochloride, formerly marketed as Enkaid capsules, was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack. The manufacturer of Enkaid capsules voluntarily withdrew the product from the US market on December 16, 1991.
COC1=CC=C(C=C1)C(=O)NC1=CC=CC=C1C(C)CN1CCCCC1
Encainide [French]
4.77e-03 mg/mL
http://dbpedia.org/resource/Encainide
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FEncainide%3E
DB01228
Enkaid
Encainidum [Latin]
1-2 hours
http://dbpedia.org/page/Encainide
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FEncainide%3E
C01BC08
InChI=1/C22H28N2O2/c1-17(16-24-14-6-3-7-15-24)20-8-4-5-9-21(20)23-22(25)18-10-12-19(26-2)13-11-18/h4-5,8-13,17H,3,6-7,14-16H2,1-2H3,(H,23,25)/f/h23H
http://www.dbpedia.org/resource/Encainide
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FEncainide%3E
http://www.drugbank.ca/drugs/DB01228
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01228%3E
http://bio2rdf.org/cpd:C06978
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC06978%3E
RDF Description of Encainide
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/70
_:header1888650711335206531487
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1398
Alport syndrome
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/COL4A5
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/COL4A4
http://data.linkedct.org/resource/condition/809
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fcondition%2F809%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseaseClass/Renal
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1396
RDF Description of Alport syndrome
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/484
_:header5537713011335206532035
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/484
phosphoinositide 3-kinase complex
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2198571
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=M35296
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DM35296%3E
Abelson murine leukemia viral oncogene homolog 2
ABL2_HUMAN
Abelson-related gene protein
phosphatidylinositol 3-kinase activity
Tyrosine-protein kinase ABL2
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12522270
http://www.genenames.org/data/hgnc_data.php?hgnc_id=77
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D77%3E
ABL2
lipid kinase activity
>Tyrosine-protein kinase ABL2	MGQQVGRVGEAPGLQQPQPRGIRGSSAARPSGRRRDPAGRTTETGFNIFTQHDHFASCVE	DGFEGDKTGGSSPEALHRPYGCDVEPQALNEAIRWSSKENLLGATESDPNLFVALYDFVA	SGDNTLSITKGEKLRVLGYNQNGEWSEVRSKNGQGWVPSNYITPVNSLEKHSWYHGPVSR	SAAEYLLSSLINGSFLVRESESSPGQLSISLRYEGRVYHYRINTTADGKVYVTAESRFST	LAELVHHHSTVADGLVTTLHYPAPKCNKPTVYGVSPIHDKWEMERTDITMKHKLGGGQYG	EVYVGVWKKYSLTVAVKTLKEDTMEVEEFLKEAAVMKEIKHPNLVQLLGVCTLEPPFYIV	TEYMPYGNLLDYLRECNREEVTAVVLLYMATQISSAMEYLEKKNFIHRDLAARNCLVGEN	HVVKVADFGLSRLMTGDTYTAHAGAKFPIKWTAPESLAYNTFSIKSDVWAFGVLLWEIAT	YGMSPYPGIDLSQVYDLLEKGYRMEQPEGCPPKVYELMRACWKWSPADRPSFAETHQAFE	TMFHDSSISEEVAEELGRAASSSSVVPYLPRLPILPSKTRTLKKQVENKENIEGAQDATE	NSASSLAPGFIRGAQASSGSPALPRKQRDKSPSSLLEDAKETCFTRDRKGGFFSSFMKKR	NAPTPPKRSSSFREMENQPHKKYELTGNFSSVASLQHADGFSFTPAQQEANLVPPKCYGG	SFAQRNLCNDDGGGGGGSGTAGGGWSGITGFFTPRLIKKTLGLRAGKPTASDDTSKPFPR	SNSTSSMSSGLPEQDRMAMTLPRNCQRSKLQLERTVSTSSQPEENVDRANDMLPKKSEES	AAPSRERPKAKLLPRGATALPLRTPSGDLAITEKDPPGVGVAGVAAAPKGKEKNGGARLG	MAGVPEDGEQPGWPSPAKAAPVLPTTHNHKVPVLISPTLKHTPADVQLIGTDSQGNKFKL	LSEHQVTSSGDKDRPRRVKPKCAPPPPPVMRLLQHPSICSDPTEEPTALTAGQSTSETQE	GGKKAALGAVPISGKAGRPVMPPPQVPLPTSSISPAKMANGTAGTKVALRKTKQAAEKIS	ADKISKEALLECADLLSSALTEPVPNSQLVDTGHQLLDYCSGYVDCIPQTRNKFAFREAV	SKLELSLQELQVSSAAAGVPGTNPVLNNLLSCVQEISDVVQR
Tyrosine kinase ARG
http://bio2rdf.org/hgnc:77
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A77%3E
http://bio2rdf.org/uniprot:P42684
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP42684%3E
http://www.uniprot.org/uniprot/P42684
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP42684%3E
phosphoinositide 3-kinase activity
>3549 bp	ATGGGGCAGCAGGTGGGCCGCGTCGGGGAAGCTCCGGGGCTCCAGCAGCCTCAGCCCCGC	GGGATCCGGGGCAGCAGTGCAGCCAGGCCCTCCGGCCGCAGGCGGGACCCGGCGGGGCGC	ACCACAGAGACCGGCTTCAATATCTTCACCCAGCATGATCACTTTGCCAGCTGTGTGGAG	GATGGATTTGAGGGAGACAAGACTGGAGGCAGTAGTCCAGAAGCTTTGCATCGTCCCTAT	GGTTGTGATGTTGAACCCCAGGCACTAAATGAGGCTATCAGGTGGAGCTCCAAGGAGAAC	TTGCTCGGAGCCACTGAGAGTGACCCTAATCTCTTCGTTGCACTTTATGATTTTGTAGCA	AGTGGTGATAACACACTCAGCATCACTAAAGGTGAAAAGCTACGAGTCCTTGGTTACAAC	CAGAATGGTGAGTGGAGTGAAGTTCGCTCTAAGAATGGGCAGGGCTGGGTGCCAAGCAAC	TACATCACCCCAGTGAACAGCCTGGAAAAACACTCCTGGTACCATGGACCTGTGTCACGC	AGTGCAGCTGAGTATCTGCTCAGCAGTCTAATCAATGGCAGCTTCCTGGTGCGAGAAAGT	GAGAGTAGCCCTGGGCAGCTGTCCATCTCGCTCAGGTACGAGGGACGTGTGTATCACTAC	AGGATCAATACCACTGCAGATGGCAAGGTGTATGTGACTGCTGAGAGCCGCTTCAGCACC	TTGGCAGAGCTTGTACACCATCACTCCACAGTGGCTGATGGGCTGGTGACAACATTACAC	TACCCAGCACCCAAGTGTAATAAGCCTACAGTCTATGGTGTGTCCCCCATCCACGACAAA	TGGGAAATGGAGCGAACAGATATTACCATGAAGCACAAACTTGGGGGCGGTCAGTATGGA	GAGGTTTACGTTGGCGTCTGGAAGAAATACAGCCTTACAGTTGCTGTGAAAACATTGAAG	GAAGATACCATGGAGGTAGAAGAATTCCTGAAAGAAGCTGCAGTAATGAAGGAAATCAAG	CATCCTAATCTGGTACAACTTTTAGGTGTGTGTACTTTGGAGCCACCATTTTACATTGTG	ACTGAATACATGCCATACGGGAATTTGCTGGATTACCTCCGAGAATGCAACCGAGAAGAG	GTGACTGCAGTTGTGCTGCTCTACATGGCCACTCAGATTTCTTCTGCAATGGAGTACTTA	GAGAAGAAGAATTTCATCCATAGAGATCTTGCAGCTCGTAACTGCCTAGTGGGAGAAAAC	CATGTGGTAAAAGTGGCTGACTTTGGCTTAAGTAGATTGATGACTGGAGACACTTATACT	GCTCATGCTGGAGCCAAATTTCCTATTAAGTGGACAGCACCAGAGAGTCTTGCCTACAAT	ACCTTCTCAATTAAATCTGACGTCTGGGCTTTTGGGGTATTGTTGTGGGAAATTGCTACC	TATGGAATGTCACCATATCCAGGTATTGACCTGTCTCAGGTCTATGACCTACTAGAAAAA	GGATATCGAATGGAACAGCCTGAGGGATGCCCCCCTAAGGTTTATGAACTTATGAGAGCA	TGCTGGAAGTGGAGCCCTGCCGATAGGCCCTCTTTTGCTGAAACACACCAAGCTTTTGAA	ACCATGTTCCATGACTCCAGCATTTCTGAAGAGGTAGCTGAGGAGCTTGGGAGAGCCGCC	TCCTCGTCATCTGTTGTTCCATACCTGCCCCGGCTACCTATACTTCCTTCCAAGACTCGG	ACACTGAAGAAACAGGTGGAGAACAAGGAGAACATTGAAGGGGCACAAGATGCCACAGAA	AATTCTGCTTCCAGTTTAGCACCAGGGTTCATCAGAGGTGCACAGGCCTCTAGTGGATCC	CCAGCACTGCCTCGAAAGCAAAGAGACAAGTCACCCAGCAGCCTCTTGGAAGATGCCAAA	GAGACATGCTTCACCAGGGATAGGAAGGGGGGCTTCTTCAGCTCCTTCATGAAGAAGAGA	AATGCTCCTACACCCCCCAAACGCAGCAGCTCCTTCCGAGAAATGGAGAATCAGCCCCAT	AAGAAATACGAACTCACGGGTAACTTCTCATCTGTTGCTTCTCTACAGCATGCTGATGGG	TTCTCTTTCACTCCTGCCCAGCAAGAGGCGAATCTGGTGCCACCCAAGTGCTATGGGGGG	AGCTTTGCACAGAGGAACCTCTGTAATGACGACGGTGGTGGGGGTGGGGGCAGTGGCACT	GCTGGGGGTGGGTGGTCTGGCATCACAGGCTTCTTTACACCACGCTTAATCAAAAAGACA	CTGGGCTTACGAGCAGGTAAACCCACAGCCAGTGATGACACTTCCAAGCCTTTTCCAAGG	TCAAACTCTACATCTTCCATGTCCTCAGGGCTTCCAGAGCAGGATAGGATGGCAATGACC	CTTCCCAGGAACTGCCAGAGGTCCAAACTCCAGCTGGAAAGGACAGTGTCCACCTCTTCT	CAGCCAGAAGAGAATGTGGACAGGGCCAATGACATGCTTCCAAAAAAATCAGAGGAAAGT	GCTGCTCCAAGCAGGGAGAGACCAAAAGCCAAGTTATTGCCCAGAGGAGCCACAGCTCTT	CCTCTCAGAACACCCTCTGGGGATCTAGCCATTACAGAGAAGGACCCTCCAGGGGTGGGA	GTGGCTGGAGTGGCAGCTGCCCCCAAGGGTAAAGAGAAGAATGGTGGGGCACGACTTGGG	ATGGCTGGAGTTCCAGAGGATGGAGAGCAGCCGGGCTGGCCTTCTCCAGCCAAGGCTGCC	CCCGTCCTCCCAACCACTCACAACCACAAAGTGCCAGTCCTTATCTCACCCACTCTGAAA	CACACTCCAGCTGACGTGCAGCTCATTGGCACAGACTCTCAGGGGAATAAATTCAAGCTC	TTATCTGAGCATCAGGTCACATCCTCTGGAGACAAGGACCGACCCCGACGGGTAAAACCA	AAGTGTGCCCCACCCCCACCACCAGTGATGAGACTACTGCAGCATCCGTCCATCTGCTCA	GACCCTACAGAAGAGCCAACTGCCCTAACTGCAGGACAGTCCACATCAGAAACACAGGAA	GGAGGAAAGAAGGCAGCTCTGGGCGCAGTGCCCATCAGTGGGAAAGCTGGGAGGCCAGTG	ATGCCTCCACCTCAAGTGCCTCTGCCCACATCTTCCATCTCGCCAGCCAAAATGGCCAAT	GGCACAGCAGGTACTAAAGTGGCTCTGAGAAAAACCAAACAGGCCGCTGAGAAAATCTCA	GCAGACAAAATCAGCAAAGAGGCCCTGCTGGAATGTGCTGACCTACTGTCCAGTGCACTC	ACGGAACCTGTGCCCAACAGCCAGCTGGTAGACACTGGACACCAGCTGCTTGACTACTGC	TCAGGCTATGTGGACTGCATCCCTCAAACTCGCAACAAATTTGCCTTCCGAGAGGCTGTG	AGCAAACTGGAACTCAGCCTGCAGGAGCTACAGGTTTCTTCAGCAGCTGCTGGTGTGCCC	GGGACAAACCCTGTCCTTAATAACTTATTGTCATGTGTACAGGAAATCAGTGATGTGGTG	CAGAGGTAG
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=178993
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D178993%3E
http://symbol.bio2rdf.org/symbol:ABL2
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AABL2%3E
Involved in phosphoinositide 3-kinase regulator activity
1q24-q25
M35296
RDF Description of Tyrosine-protein kinase ABL2
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00171
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0040156
_:header11858578651335206532391
Mon, 23 Apr 2012 18:35:27 GMT
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0040156
http://sideeffects.embl.de/se/C0040156
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0040156%3E
thyrotoxicosis
C0040156
RDF Description of thyrotoxicosis
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/3983
_:header4658002061335206532939
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3983
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00130
http://symbol.bio2rdf.org/symbol:TGM5
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ATGM5%3E
AF035960
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=2895530
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D2895530%3E
map04610	Huntington's disease
http://bio2rdf.org/pfam:PF01841
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF01841%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AF035960
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAF035960%3E
TGM5
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11390390
http://pfam.sanger.ac.uk/family?acc=PF01841
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF01841%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=11781
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D11781%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9452468
Protein-glutamine gamma-glutamyltransferase 5
TGX
TGase 5
TGM5_HUMAN
peptide cross-linking
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/15038793
>Protein-glutamine gamma-glutamyltransferase 5	MAQGLEVALTDLQSSRNNVRHHTEEITVDHLLVRRGQAFNLTLYFRNRSFQPGLDNIIFV	VETGPLPDLALGTRAVFSLARHHSPSPWIAWLETNGATSTEVSLCAPPTAAVGRYLLKIH	IDSFQGSVTAYQLGEFILLFNPWCPEDAVYLDSEPQRQEYVMNDYGFIYQGSKNWIRPCP	WNYGQFEDKIIDICLKLLDKSLHFQTDPATDCALRGSPVYVSRVVCAMINSNDDNGVLNG	NWSENYTDGANPAEWTGSVAILKQWNATGCQPVRYGQCWVFAAVMCTVMRCLGIPTRVIT	NFDSGHDTDGNLIIDEYYDNTGRILGNKKKDTIWNFHVWNECWMARKDLPPAYGGWQVLD	ATPQEMSNGVYCCGPASVRAIKEGEVDLNYDTPFVFSMVNADCMSWLVQGGKEQKLHQDT	SSVGNFISTKSIQSDERDDITENYKYEEGSLQERQVFLKALQKLKARSFHGSQRGAELQP	SRPTSLSQDSPRSLHTPSLRPSDVVQVSLKFKLLDPPNMGQDICFVLLALNMSSQFKDLK	VNLSAQSLLHDGSPLSPFWQDTAFITLSPKEAKTYPCKISYSQYSQYLSTDKLIRISALG	EEKSSPEKILVNKIITLSYPSITINVLGAAVVNQPLSIQVIFSNPLSEQVEDCVLTVEGS	GLFKKQQKVFLGVLKPQHQASIILETVPFKSGQRQIQANMRSNKFKDIKGYRNVYVDFAL
http://bio2rdf.org/hgnc:11781
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A11781%3E
http://www.uniprot.org/uniprot/O43548
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FO43548%3E
Catalyzes the cross-linking of proteins and the conjugation of polyamines to proteins. Contributes to the formation of the cornified cell envelope of keratinocytes
protein glutamine + alkylamine = protein N5-alkylglutamine + NH3
http://bio2rdf.org/pfam:PF00927
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00927%3E
Transglutaminase-5
Transglutaminase X
http://pfam.sanger.ac.uk/family?acc=PF00868
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00868%3E
EC 2.3.2.13
http://bio2rdf.org/uniprot:O43548
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AO43548%3E
TG(X)
15q15.2
http://bio2rdf.org/pfam:PF00868
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00868%3E
TGase X
http://pfam.sanger.ac.uk/family?acc=PF00927
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00927%3E
>2163 bp	ATGGCCCAAGGGCTAGAAGTGGCCCTCACAGACCTCCAGAGCTCCAGAAATAATGTGCGG	CACCACACGGAGGAGATCACTGTGGACCACCTGCTTGTTCGCCGGGGCCAGGCCTTCAAC	CTCACCCTGTACTTCAGGAACCGGAGCTTCCAGCCAGGCCTGGACAACATCATCTTCGTG	GTTGAAACTGGACCGCTGTCAGACCTGGCCTTGGGGACTCGGGCTGTGTTCAGCCTGGCA	CGCCATCACAGCCCCAGCCCCTGGATTGCCTGGCTGGAGACCAATGGGGCCACCTCCACA	GAGGTGAGCTTGTGCGCTCCTCCCACGGCGGCCGTGGGTCGGTACCTCTTGAAAATCCAC	ATCGACTCCTTCCAGGGGTCTGTGACGGCCTACCAGCTAGGGGAGTTCATCCTGCTTTTC	AATCCCTGGTGCCCAGAGGATGCTGTCTACTTGGACAGTGAACCCCAGAGGCAGGAGTAT	GTCATGAATGATTATGGCTTCATCTACCAAGGCAGCAAGAACTGGATCCGCCCATGTCCC	TGGAACTATGGACAGTTTGAAGACAAAATCATAGACATCTGCCTGAAGCTGCTAGACAAG	AGCCTGCACTTCCAGACTGACCCAGCCACAGACTGTGCTCTGCGGGGAAGCCCCGTCTAC	GTCAGCAGAGTGGTGTGTGCCATGATCAACAGCAATGATGATAATGGGGTGCTCAATGGA	AACTGGAGTGAGAATTACACAGACGGCGCCAACCCTGCGGAGTGGACGGGCAGCGTGGCC	ATCCTGAAGCAGTGGAACGCCACAGGCTGCCAGCCCGTGCGCTACGGGCAATGCTGGGTC	TTTGCTGCCGTCATGTGCACAGTGATGAGGTGTCTGGGGATCCCTACCCGTGTGATCACC	AACTTCGACTCTGGCCACGATACAGATGGAAACCTGATCATAGATGAGTATTATGACAAC	ACAGGCAGGATTTTGGGGAATAAGAAGAAGGATACTATCTGGAACTTCCATGTCTGGAAT	GAGTGCTGGATGGCCCGGAAGGATCTGCCCCCTGCATATGGAGGCTGGCAGGTGCTGGAC	GCCACACCTCAGGAGATGAGCAACGGCGTCTACTGCTGTGGCCCTGCCTCTGTCAGAGCC	ATCAAAGAAGGAGAAGTGGACCTGAACTATGACACGCCCTTTGTGTTTTCGATGGTGAAT	GCTGACTGCATGTCCTGGCTCGTCCAGGGAGGGAAGGAGCAGAAGCTTCACCAGGACACG	AGTTCTGTTGGCAATTTTATCAGCACAAAGAGCATCCAGAGTGACGAGCGGGATGACATC	ACAGAGAACTACAAGTATGAAGAAGGATCCCTCCAGGAGAGGCAGGTGTTTCTGAAGGCT	CTGCAGAAGCTGAAGGCTAGAAGCTTCCATGGCTCCCAAAGAGGAGCAGAGTTGCAACCT	TCCAGGCCCACATCACTGAGCCAGGACAGCCCTCGGAGCCTGCATACACCTTCCCTTCGA	CCCAGTGATGTGGTGCAAGTCTCCCTGAAATTCAAGCTGCTCGACCCGCCCAACATGGGC	CAGGATATATGCTTTGTCCTGCTGGCCCTCAACATGTCCTCCCAGTTCAAGGACCTCAAA	GTGAACCTGAGTGCCCAGTCTCTGCTGCACGATGGCAGCCCCCTGTCCCCATTCTGGCAG	GACACAGCGTTCATCACACTCTCTCCTAAAGAAGCAAAGACCTACCCCTGCAAAATCTCC	TATTCCCAGTACAGCCAGTACCTGTCAACAGACAAGCTGATCCGCATCAGTGCCCTGGGT	GAAGAGAAAAGCAGTCCTGAGAAAATCCTGGTGAACAAGATCATCACCTTATCTTATCCA	AGCATCACGATTAATGTTCTAGGAGCAGCCGTTGTGAACCAGCCACTCTCCATACAGGTG	ATATTTTCAAACCCCCTCTCGGAGCAGGTTGAGGACTGTGTGCTGACTGTGGAAGGAAGT	GGCCTCTTCAAGAAACAGCAGAAAGTCTTCCTTGGAGTCCTCAAACCCCAACACCAAGCA	AGCATCATTCTGGAGACCGTCCCCTTCAAGAGTGGACAAAGGCAGATCCAAGCTAATATG	AGAAGCAACAAGTTTAAGGACATTAAGGGTTACAGGAATGTTTATGTAGACTTTGCATTA	TAA
RDF Description of Protein-glutamine gamma-glutamyltransferase 5
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/293
_:header4673457641335206533288
Mon, 23 Apr 2012 18:35:28 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/293
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2048
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/FBLN5
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/ELN
Cutis laxa
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/ATP7A
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00533
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00533%3E
http://www.dbpedia.org/resource/Cutis_laxa
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FCutis_laxa%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2047
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2049
RDF Description of Cutis laxa
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2046
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/LYP
_:header17202420001335206533702
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/LYP
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2150
http://symbol.bio2rdf.org/symbol:LYP
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ALYP%3E
LYP
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4010
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3023
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3793
RDF Description of LYP
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0027424
_:header6677326761335206534211
Mon, 23 Apr 2012 18:35:29 GMT
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0027424
http://dbpedia.org/resource/Nasal_congestion
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FNasal_congestion%3E
http://sideeffects.embl.de/se/C0027424
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0027424%3E
nasal congestion
C0027424
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3372
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/6049
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3125
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/39860
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3518
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5452
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2725
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3742
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2913
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4740
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4748
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4845
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2781
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5052
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3100
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2949
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2431
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4927
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3637
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2564
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3964
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/62867
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3382
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5775
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5454
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3042
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3737
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3373
RDF Description of nasal congestion
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4768
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/4513
_:header9935010921335206534676
RDF Description of AXID
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000004513&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000004513%26input_query_species%3D9606%3E
http://www.fda.gov/cder/foi/nda/98/20555-S3_AxidAr_prntlbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Fnda%2F98%2F20555-S3_AxidAr_prntlbl.pdf%3E
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=%2FHPDmNdweVo=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3D%252FHPDmNdweVo%3D%3E
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=Si84OB3bhyk=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DSi84OB3bhyk%3D%3E
AXID AR
AXID
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00585
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00585%3E
CID0000004513
http://www.fda.gov/cder/foi/label/2005/019508s033lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2005%2F019508s033lbl.pdf%3E
http://sideeffects.embl.de/drugs/4513
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F4513%3E
http://www.fda.gov/cder/foi/label/2005/21494s001lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2005%2F21494s001lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0262465
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0018834
http://dbpedia.org/resource/Nizatidine
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FNizatidine%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/48
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F48%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0018418
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000004513
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000004513%3E
NIZATIDINE
http://www.fda.gov/cder/foi/label/2004/21494_axid_lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2004%2F21494_axid_lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Urquhart_of_Cromarty_Thomas_Sir
_:header14761050931335206535079
Mon, 23 Apr 2012 18:35:30 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Urquhart_of_Cromarty_Thomas_Sir
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8170
Urquhart of Cromarty, Thomas, Sir 
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8167
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8169
RDF Description of Urquhart of Cromarty, Thomas, Sir 
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8166
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8168
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/3202
_:header10730801421335206535726
RDF Description of Actin, alpha skeletal muscle
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3202
http://bio2rdf.org/pfam:PF00022
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00022%3E
http://bio2rdf.org/uniprot:P68136
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP68136%3E
actin cytoskeleton
http://www.pdb.org/pdb/explore/explore.do?structureId=1IJJ
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1IJJ%3E
motor activity
Alpha-actin-1
Actin, alpha skeletal muscle
>1134 bp	ATGTGTGACGAGGACGAGACCACCGCTCTTGTGTGTGACAACGGCTCTGGCCTGGTGAAA	GCTGGCTTTGCCGGGGATGATGCCCCCAGGGCTGTGTTCCCATCCATCGTGGGTCGGCCC	CGTCACCAGGGTGTCATGGTCGGTATGGGTCAGAAGGATTCCTACGTGGGCGACGAGGCC	CAGAGCAAGCGAGGTATCCTGACCCTGAAGTACCCCATTGAACACGGCATTATCACCAAC	TGGGACGACATGGAGAAGATCTGGCACCACACCTTCTACAATGAGCTGCGTGTGGCCCCC	GAGGAGCACCCGACCCTGCTCACTGAGGCCCCTTTGAACCCCAAAGCTAACCGGGAGAAG	ATGACTCAAATCATGTTTGAGACCTTCAACGTGCCTGCTATGTATGTGGCTATTCAGGCG	GTGCTGTCTCTCTATGCCTCCGGCCGAACCACCGGCATCGTGTTGGATTCTGGGGACGGT	GTCACCCACAACGTGCCCATCTATGAGGGTTATGCCCTGCCACACGCCATCATGCGTCTG	GACCTCGCTGGTCGCGACCTTACTGACTACCTGATGAAAATCCTCACCGAGCGTGGCTAT	TCCTTCGTGACCACAGCTGAACGTGAGATTGTGCGCGACATCAAAGAGAAGCTGTGCTAC	GTGGCCCTGGACTTCGAGAATGAGATGGCCACCGCTGCCTCTTCCTCCTCCCTGGAAAAG	AGCTATGAGCTGCCTGACGGGCAGGTCATCACCATCGGCAATGAGCGCTTCCGTTGCCCG	GAGACGCTCTTCCAGCCTTCCTTTATCGGTATGGAGTCTGCGGGGATCCATGAGACCACC	TACAACAGCATCATGAAGTGCGACATCGACATCAGGAAGGACCTGTACGCCAACAACGTC	ATGTCAGGGGGCACTACCATGTACCCCGGTATCGCTGACCGCATGCAGAAGGAGATCACA	GCTCTGGCTCCCAGCACCATGAAGATCAAGATCATCGCCCCCCCTGAGCGCAAGTACTCA	GTGTGGATCGGCGGCTCCATCCTGGCCTCGCTGTCCACCTTCCAGCAGATGTGGATCACC	AAGCAGGAGTACGACGAGGCCGGCCCCTCCATTGTGCACCGCAAATGCTTCTAG
http://pfam.sanger.ac.uk/family?acc=PF00022
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00022%3E
>Actin, alpha skeletal muscle	MCDEDETTALVCDNGSGLVKAGFAGDDAPRAVFPSIVGRPRHQGVMVGMGQKDSYVGDEA	QSKRGILTLKYPIEHGIITNWDDMEKIWHHTFYNELRVAPEEHPTLLTEAPLNPKANREK	MTQIMFETFNVPAMYVAIQAVLSLYASGRTTGIVLDSGDGVTHNVPIYEGYALPHAIMRL	DLAGRDLTDYLMKILTERGYSFVTTAEREIVRDIKEKLCYVALDFENEMATAASSSSLEK	SYELPDGQVITIGNERFRCPETLFQPSFIGMESAGIHETTYNSIMKCDIDIRKDLYANNV	MSGGTTMYPGIADRMQKEITALAPSTMKIKIIAPPERKYSVWIGGSILASLSTFQQMWIT	KQEYDEAGPSIVHRKCF
V01218
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=V01218
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DV01218%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/6287276
ACTS_RAT
Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=55577
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D55577%3E
http://bio2rdf.org/pdb:1IJJ
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1IJJ%3E
Cytoskeleton
http://www.uniprot.org/uniprot/P68136
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP68136%3E
Acta1
actin filament
structural constituent of cytoskeleton
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/6894330
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03021
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03431
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02621
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03616
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03850
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04151
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02772
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03903
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C1306341
_:header9581004751335206536049
http://dbpedia.org/resource/Developmental_disability
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FDevelopmental_disability%3E
http://sideeffects.embl.de/se/C1306341
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC1306341%3E
Mental impairment
C1306341
RDF Description of Mental impairment
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/SNAP29
_:header6566001061335206536456
Mon, 23 Apr 2012 18:35:31 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/SNAP29
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1806
http://symbol.bio2rdf.org/symbol:SNAP29
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ASNAP29%3E
SNAP29
http://www.dbpedia.org/resource/SNAP29
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FSNAP29%3E
RDF Description of SNAP29
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1273
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/POU1F1
_:header8289280631335206536826
RDF Description of POU1F1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/POU1F1
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/gene/POU1F1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fgene%2FPOU1F1%3E
http://symbol.bio2rdf.org/symbol:POU1F1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3APOU1F1%3E
POU1F1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3595
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1269
http://www4.wiwiss.fu-berlin.de/eurostat/data/regions/Arnsberg
_:header1143891451335206537272
Mon, 23 Apr 2012 18:35:32 GMT
RDF Description of Arnsberg
http://www4.wiwiss.fu-berlin.de/eurostat/resource/regions/Arnsberg
Arnsberg
http://www4.wiwiss.fu-berlin.de/eurostat/resource/countries/Deutschland
http://estatwrap.ontologycentral.com/dic/geo#DEA5
http://www4.wiwiss.fu-berlin.de/eurostat/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Festatwrap.ontologycentral.com%2Fdic%2Fgeo%23DEA5%3E
http://ec.europa.eu/eurostat/ramon/rdfdata/nuts2008/DEA5
http://www4.wiwiss.fu-berlin.de/eurostat/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fec.europa.eu%2Feurostat%2Framon%2Frdfdata%2Fnuts2008%2FDEA5%3E
http://dbpedia.org/resource/Arnsberg
http://www4.wiwiss.fu-berlin.de/eurostat/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FArnsberg%3E
dea5
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00738
_:header12432699801335206537653
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00738
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00933_DB00738
http://205.193.93.51/dpdonline/searchRequest.do?din=02183080
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02183080%3E
Pentamidine
aprd00303
http://bio2rdf.org/cpd:C07420
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC07420%3E
08:30.92
Pentamidine is an antiprotozoal agent. It is an aromatic diamidine, and is known to have activity against <i>Pneumocystis carinii</i>. The exact nature of its antiprotozoal action is unknown. <i>in vitro</i> studies with mammalian tissues and the protozoan <i>Crithidia oncopelti</i> indicate that the drug interferes with nuclear metabolism producing inhibition of the synthesis of DNA, RNA, phospholipids and proteins. Little is known about the drug's pharmacokinetics. The medication is also useful in Leishmaniasis and in prophylaxis against sleeping sickness caused by <i>Trypanosoma brucei gambiense</i>. Hydration before treatment lessens the incidence and severity of side effects, which include liver or kidney dysfunction, hypertension, hypotension, hypoglycemia, hypocalemia, leukopenia, thrombcytopenia, anemia, and allergic reaction. It is generally well-tolerated.
NebuPent
4-[5-(4-carbamimidoylphenoxy)pentoxy]benzenecarboximidamide
InChI=1/C19H24N4O2/c20-18(21)14-4-8-16(9-5-14)24-12-2-1-3-13-25-17-10-6-15(7-11-17)19(22)23/h4-11H,1-3,12-13H2,(H3,20,21)(H3,22,23)/f/h20,22H,21,23H2/b20-18-,22-19-
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2331
9.1-13.2 hours
2.36e-02 mg/mL
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/trypanocidalAgents
DB00738
For the treatment of pneumonia due to <i>Pneumocystis carinii</i>.
Pentam 300
http://129.128.185.122/drugbank2/drugs/DB00738/inserts/1611/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00738%2Finserts%2F1611%2Ffull%3E
1,3-bis(4-amidinophenoxy)pentane
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/antifungalAgents
Pentamide
69%
PNT
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/8813
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fsider%2Fresource%2Fdrugs%2F8813%3E
P01CX01
Symptoms of overdose include pain, nausea, anorexia, hypotension, fever, rash, bad taste in mouth, confusion/hallucinations, dizziness, and diarrhea.
http://dbpedia.org/page/Pentamidine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FPentamidine%3E
/drugs/738/safety_sheets/757
expt02625
186.0 oC (decomposes)
Pentacarinat
Pentam
The mode of action of pentamidine is not fully understood. It is thought that the drug interferes with nuclear metabolism producing inhibition of the synthesis of DNA, RNA, phospholipids, and proteins.
http://dbpedia.org/resource/Pentamidine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FPentamidine%3E
Pneumocystis carinii
Absorbed poorly through the gastrointestinal tract and is usually administered parenterally.
C19H24N4O2
XDRYMKDFEDOLFX-QJSOSZRSDA
[H]N=C(/N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N[H])C=C1
PA450850
1RKW
http://en.wikipedia.org/wiki/Pentamidine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FPentamidine%3E
http://bio2rdf.org/cas:100-33-4
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A100-33-4%3E
http://www.drugbank.ca/drugs/DB00738
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00738%3E
2008-08-26 15:04:06 UTC
4, 4'-Diamidinodiphenoxypentane
[H]N=C(N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N[H])C=C1
http://www.rxlist.com/cgi/generic3/pentam.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric3%2Fpentam.htm%3E
http://www.dbpedia.org/resource/Pentamidine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FPentamidine%3E
Pentamidine Isethionate
Complete
Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. [PubChem]
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/antiprotozoalAgents
Pneumopent
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00738_DB00246
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00738_DB00933
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01369_DB00738
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00679_DB00738
RDF Description of Pentamidine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00738_DB01369
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00738_DB00679
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Traill_Catharine_Parr_1802-1899
_:header3953245071335206538069
Mon, 23 Apr 2012 18:35:33 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Traill_Catharine_Parr_1802-1899
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8607
Traill, Catharine Parr, 1802-1899
RDF Description of Traill, Catharine Parr, 1802-1899
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6479
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13559
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8382
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6813
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/4445
_:header12171701581335206538605
RDF Description of Aldehyde dehydrogenase, dimeric NADP-preferring
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4445
ALDH class 3
J03637
http://bio2rdf.org/uniprot:P11883
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP11883%3E
http://bio2rdf.org/pdb:1AD3
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1AD3%3E
Involved in aldehyde dehydrogenase [NAD(P)+] activity
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=J03637
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DJ03637%3E
HTC-ALDH
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2831537
AL3A1_RAT
http://bio2rdf.org/pfam:PF00171
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00171%3E
http://www.uniprot.org/uniprot/P11883
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP11883%3E
http://pfam.sanger.ac.uk/family?acc=PF00171
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00171%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8509394
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2091023
Tumor-associated aldehyde dehydrogenase
Aldehyde dehydrogenase, dimeric NADP-preferring
ALDHs play a major role in the detoxification of alcohol-derived acetaldehyde. They are involved in the metabolism of corticosteroids, biogenic amines, neurotransmitters, and lipid peroxidation. This protein preferentially oxidizes aromatic aldehyde substrates. It may play a role in the oxidation of toxic aldehydes
>1362 bp	ATGAGCAGTATCAGTGACACCGTGAAACGGGCCAGGGAGGCCTTTAACTCCGGCAAGACT	CGATCGCTGCAGTTCCGAATCCAGCAGTTGGAGGCGCTGCAGCGCATGATCAATGAGAAC	CTGAAAAGCATCTCTGGGGCGCTGGCCTCTGACCTGGGCAAGAACGAATGGACCTCCTAC	TATGAGGAAGTGGCTCACGTACTGGAGGAGCTTGATACCACAATTAAGGAGCTCCCTGAT	TGGGCTGAGGATGAGCCTGTGGCCAAGACTCGCCAGACCCAGCAGGATGACCTCTACATC	CACTCGGAGCCCCTGGGTGTGGTCCTTGTCATAGGTGCTTGGAACTACCCCTTCAACCTC	ACCATCCAGCCCATGGTGGGTGCCGTTGCTGCAGGAAACGCAGTGATCCTCAAGCCCTCA	GAAGTGAGCGGGCACATGGCAGACCTGCTAGCGACACTCATCCCTCAGTATATGGACCAG	AATCTGTACCTAGTGGTCAAAGGGGGTGTCCCTGAAACCACGGAGCTGCTCAAAGAGAGG	TTTGACCACATCATGTACACTGGGAGCACAGCCGTAGGGAAGATTGTTATGGCCGCTGCC	GCCAAGCATCTGACTCCTGTCACCCTGGAGCTTGGAGGGAAAAGCCCTTGTTACGTGGAC	AAGGACTGTGATCTAGATGTGGCTTGCAGGCGTATCGCCTGGGGGAAATTTATGAACAGT	GGCCAGACCTGTGTGGCCCCAGACTACATCCTCTGTGACCCCTCGATTCAGAACCAAATC	GTGGAGAAGCTCAAGAAGTCACTCAAAGATTTCTATGGGGAAGATGCTAAGCAGTCCCGT	GATTATGGGAGGATCATCAATGACCGTCACTTCCAGCGGGTCAAAGGCCTGATTGACAAC	CAGAAAGTAGCCCATGGAGGCACTTGGGACCAGTCCTCACGATACATAGCTCCAACCATC	CTGGTGGATGTGGACCCCCAGTCCCCAGTGATGCAGGAGGAGATCTTTGGGCCGGTGATG	CCCATTGTGTGTGTTCGAAGCTTGGAGGAGGCCATTCAATTTATCAACCAGCGTGAGAAG	CCCCTGGCACTCTATGTGTTCTCCAACAATGAGAAGGTGATCAAGAAAATGATCGCAGAG	ACATCCAGCGGTGGAGTGACAGCCAATGACGTCATTGTTCACATCACCGTGCCCACTTTG	CCCTTTGGTGGTGTGGGGAACAGCGGCATGGGGGCCTACCATGGCAAGAAAAGCTTCGAG	ACCTTCTCCCACCGCCGCTCTTGCCTGGTGAAGTCTCTGTTGAATGAAGAAGCTCACAAG	GCCAGGTATCCCCCAAGCCCAGCCAAGATGCCCCGGCACTGA
Aldh3a1
EC 1.2.1.5
http://www.pdb.org/pdb/explore/explore.do?structureId=1AD3
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1AD3%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9095201
>Aldehyde dehydrogenase, dimeric NADP-preferring	MSSISDTVKRAREAFNSGKTRSLQFRIQQLEALQRMINENLKSISGALASDLGKNEWTSY	YEEVAHVLEELDTTIKELPDWAEDEPVAKTRQTQQDDLYIHSEPLGVVLVIGAWNYPFNL	TIQPMVGAVAAGNAVILKPSEVSGHMADLLATLIPQYMDQNLYLVVKGGVPETTELLKER	FDHIMYTGSTAVGKIVMAAAAKHLTPVTLELGGKSPCYVDKDCDLDVACRRIAWGKFMNS	GQTCVAPDYILCDPSIQNQIVEKLKKSLKDFYGEDAKQSRDYGRIINDRHFQRVKGLIDN	QKVAHGGTWDQSSRYIAPTILVDVDPQSPVMQEEIFGPVMPIVCVRSLEEAIQFINQREK	PLALYVFSNNEKVIKKMIAETSSGGVTANDVIVHITVPTLPFGGVGNSGMGAYHGKKSFE	TFSHRRSCLVKSLLNEEAHKARYPPSPAKMPRH
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2713359
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/5432
_:header4337342231335206539018
RDF Description of Trafficking protein particle complex subunit 3
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/5432
TRAPPC3
Trafficking protein particle complex subunit 3
BET3 homolog
http://bio2rdf.org/uniprot:O43617
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AO43617%3E
http://www.pdb.org/pdb/explore/explore.do?structureId=1SZ7
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1SZ7%3E
AJ224335
http://www.uniprot.org/uniprot/O43617
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FO43617%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9564032
May play a role in vesicular transport from endoplasmic reticulum to Golgi
http://pfam.sanger.ac.uk/family?acc=PF04051
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF04051%3E
http://bio2rdf.org/hgnc:19942
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A19942%3E
TPPC3_HUMAN
>543 bp	ATGTCGAGGCAGGCGAACCGTGGCACCGAGAGCAAGAAAATGAGCTCTGAGCTCTTCACC	CTGACCTATGGTGCCCTGGTCACCCAGCTATGTAAGGACTATGAAAATGATGAAGATGTG	AATAAACAGCTGGACAAAATGGGCTTTAACATTGGAGTCCGGCTGATTGAAGATTTCTTG	GCTCGGTCAAATGTTGGGAGGTGCCATGACTTTCGGGAAACTGCGGATGTCATTGCCAAG	GTGGCGTTCAAGATGTACTTGGGCATCACTCCAAGCATTACTAATTGGAGCCCAGCTGGT	GATGAATTCTCCCTCATTTTGGAAAATAACCCCTTGGTGGACTTTGTGGAACTTCCTGAT	AACCACTCATCCCTTATTTATTCCAATCTCTTGTGTGGGGTGTTGCGGGGAGCTTTGGAG	ATGGTCCAGATGGCTGTGGAGGCCAAGTTTGTCCAGGACACCCTGAAAGGAGACGGTGTG	ACAGAAATCCGGATGAGATTCATCAGGCGGATTGAGGACAATCTTCCAGCTGGAGAGGAA	TAA
http://www.genenames.org/data/hgnc_data.php?hgnc_id=19942
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D19942%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11805826
http://bio2rdf.org/pdb:1SZ7
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1SZ7%3E
>Trafficking protein particle complex subunit 3	MSRQANRGTESKKMSSELFTLTYGALVTQLCKDYENDEDVNKQLDKMGFNIGVRLIEDFL	ARSNVGRCHDFRETADVIAKVAFKMYLGITPSITNWSPAGDEFSLILENNPLVDFVELPD	NHSSLIYSNLLCGVLRGALEMVQMAVEAKFVQDTLKGDGVTEIRMRFIRRIEDNLPAGEE
http://bio2rdf.org/pfam:PF04051
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF04051%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AJ224335
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAJ224335%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03796
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/4768
_:header12757160381335206539587
Mon, 23 Apr 2012 18:35:34 GMT
RDF Description of DIBENZYLINE
Phenoxybenzamine
http://www.fda.gov/cder/foi/label/2008/008708s025lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2008%2F008708s025lbl.pdf%3E
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000004768&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000004768%26input_query_species%3D9606%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00925
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00925%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1231
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F1231%3E
DIBENZYLINE
CID0000004768
http://sideeffects.embl.de/drugs/4768
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F4768%3E
http://dbpedia.org/resource/Phenoxybenzamine
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FPhenoxybenzamine%3E
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000004768
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000004768%3E
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB03856
_:header11243745941335206539863
RDF Description of Alpha-Difluoromethylornithine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03856
C6H12F2N2O2
2008-08-26 14:58:25 UTC
DB03856
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2438
VLCYCQAOQCDTCN-WXRBYKJCCY
pentane-1,4-diamine
5.00e+01 mg/mL
InChI=1/C6H12F2N2O2/c7-4(8)6(10,5(11)12)2-1-3-9/h4H,1-3,9-10H2,(H,11,12)/f/h11H
Alpha-Difluoromethylornithine
NCCC[C@@](N)(C(F)F)C(O)=O
2TOD
DMO
http://www.drugbank.ca/drugs/DB03856
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB03856%3E
expt01229
NCCCC(N)(C(F)F)C(O)=O
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00229
_:header4303653771335206540333
Mon, 23 Apr 2012 18:35:35 GMT
RDF Description of Cefotiam
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00229
Cefotiam
40%
Cefotiam hydrochloride
For treatment of severe infections caused by susceptible bacteria.
Adverse effects following overdosage include nausea, vomiting, epigastric distress, diarrhea, and convulsions.
Cefotiamum [INN-Latin]
One of the cephalosporins that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms. [PubChem]
http://bio2rdf.org/kegg:D01819
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD01819%3E
2008-08-26 14:06:42 UTC
J01DC07
Approximately 1 hour.
1.29e+00 mg/mL
InChI=1/C18H23N9O4S3/c1-25(2)3-4-26-18(22-23-24-26)34-7-9-6-32-15-12(14(29)27(15)13(9)16(30)31)21-11(28)5-10-8-33-17(19)20-10/h8,12,15H,3-7H2,1-2H3,(H2,19,20)(H,21,28)(H,30,31)/t12-,15-/m1/s1/f/h21,30H,19H2
http://dbpedia.org/resource/Cefotiam
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FCefotiam%3E
http://www.drugbank.ca/drugs/DB00229
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00229%3E
CN(C)CCN1N=NN=C1SCC1=C(N2C(SC1)C(NC(=O)CC1=CSC(N)=N1)C2=O)C(O)=O
Cefotiam is a third generation beta-lactam cephalosporin antibiotic. It has broad spectrum activity against Gram positive and Gram negative bacteria. It does not have activity against <i>Pseudomonas aeruginosa</i>. Cefotiam works by inhibiting bacterial cell wall biosynthesis.
Rapidly absorbed following intramuscular injection. Bioavailability is 60% following intramuscular injection.
C18H23N9O4S3
aprd00855
The bactericidal activity of cefotiam results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs).
http://en.wikipedia.org/wiki/Cefotiam
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FCefotiam%3E
http://bio2rdf.org/cas:61622-34-2
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A61622-34-2%3E
(6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)acetyl]amino]-3-[[1-(2-dimethylaminoethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Soluble
CTM
CN(C)CCN1N=NN=C1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)CC1=CSC(N)=N1)C2=O)C(O)=O
DB00229
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/633
QYQDKDWGWDOFFU-WDAPPIQIDK
http://bio2rdf.org/cpd:C13289
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC13289%3E
Ceradon
http://dbpedia.org/page/Cefotiam
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FCefotiam%3E
http://www4.wiwiss.fu-berlin.de/eurostat/data/regions/Unterfranken
_:header3909635081335206540767
RDF Description of Unterfranken
http://www4.wiwiss.fu-berlin.de/eurostat/resource/regions/Unterfranken
Unterfranken
de26
http://dbpedia.org/resource/Lower_Franconia
http://www4.wiwiss.fu-berlin.de/eurostat/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FLower_Franconia%3E
http://estatwrap.ontologycentral.com/dic/geo#DE26
http://www4.wiwiss.fu-berlin.de/eurostat/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Festatwrap.ontologycentral.com%2Fdic%2Fgeo%23DE26%3E
http://ec.europa.eu/eurostat/ramon/rdfdata/nuts2008/DE26
http://www4.wiwiss.fu-berlin.de/eurostat/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fec.europa.eu%2Feurostat%2Framon%2Frdfdata%2Fnuts2008%2FDE26%3E
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0017677
_:header1162973151335206541245
Mon, 23 Apr 2012 18:35:36 GMT
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0017677
http://sideeffects.embl.de/se/C0017677
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0017677%3E
erythema migrans
C0017677
RDF Description of erythema migrans
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00849
_:header19671217971335206541634
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00849
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB00849
Mebaral
For the relief of anxiety, tension, and apprehension, also used as an anticonvulsant for the treatment of epilepsy.
Mephobarbitone
Approximately 50% of an oral dose of mephobarbital is absorbed from the gastrointestinal tract.
CC[C@@]1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1
Mephobarbital
http://en.wikipedia.org/wiki/Mephobarbital
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FMephobarbital%3E
InChI=1/C13H14N2O3/c1-3-13(9-7-5-4-6-8-9)10(16)14-12(18)15(2)11(13)17/h4-8H,3H2,1-2H3,(H,14,16,18)/f/h14H
Meberal
Hepatic, primarily by the hepatic microsomal enzyme system. About 75% of a single oral dose of mephobarbital is metabolized to phenobarbital in 24 hours.
http://129.128.185.122/drugbank2/drugs/DB00849/inserts/1950/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00849%2Finserts%2F1950%2Ffull%3E
Metylfenemal
Methylphenobarbital, a barbiturate, is used in combination with acetaminophen or aspirin and caffeine for its sedative and relaxant effects in the treatment of tension headaches, migraines, and pain. Barbiturates act as nonselective depressants of the central nervous system (CNS), capable of producing all levels of CNS mood alteration from excitation to mild sedation, hypnosis, and deep coma. In sufficiently high therapeutic doses, barbiturates induce anesthesia.
Methylphenobarbital binds at a distinct binding site associated with a Cl<sup>-</sup> ionopore at the GABA<sub>A</sub> receptor, increasing the duration of time for which the Cl<sup>-</sup> ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
http://www.rxlist.com/cgi/generic2/mephobarbital.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric2%2Fmephobarbital.htm%3E
Prominal
N-Methylphenobarbital
Isonal
Enfenemal
70-76%
Enphenemalum
aprd00047
Metilfenobarbitale [Dcit]
1.84 [HANSCH,C ET AL. (1995)]
34 (range 11-67) hours
Phemiton
A barbiturate that is metabolized to phenobarbital. It has been used for similar purposes, especially in epilepsy, but there is no evidence mephobarbital offers any advantage over phenobarbital. [PubChem]
Phemetone
DB00849
2008-08-26 14:01:56 UTC
http://dbpedia.org/page/Mephobarbital
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FMephobarbital%3E
Phemitone
http://dbpedia.org/resource/Mephobarbital
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FMephobarbital%3E
Methylphenolbarbital
Metilfenobarbital [INN-Spanish]
Mebroin
176 oC
Methylphenobarbitonum
N-Ethylmethylphenylbarbituric acid
Methyl-Calminal
Methylphenobarbital
Slightly soluble
http://bio2rdf.org/chebi:6758
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fchebi%3A6758%3E
5-ethyl-1-methyl-5-phenyl-1,3-diazinane-2,4,6-trione
Enphenemal
Phenmiton
N-Methylethylphenylbarbituric acid
N03AA01
CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1
http://bio2rdf.org/cpd:C07829
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC07829%3E
Methyl Phenobarbitone
http://bio2rdf.org/cas:115-38-8
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A115-38-8%3E
Morbusan
http://129.128.185.122/drugbank2/drugs/DB00849/inserts/933/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00849%2Finserts%2F933%2Ffull%3E
7.10e-01 mg/mL
ALARQZQTBTVLJV-YHMJCDSICC
N-Methylphenolbarbitol
http://www.dbpedia.org/resource/Methylphenobarbital
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FMethylphenobarbital%3E
Methylphenylbarbituric acid
C13H14N2O3
http://www.drugbank.ca/drugs/DB00849
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00849%3E
Methylphenobarbitalum [INN-Latin]
Menta-Bal
Metyna
http://bio2rdf.org/kegg:D00700
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD00700%3E
Mephytal
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00977_DB00849
RDF Description of Methylphenobarbital
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00908_DB00849
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00264_DB00849
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01223_DB00849
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00860_DB00849
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00254_DB00849
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00333_DB00849
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01023_DB00849
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00687_DB00849
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00603_DB00849
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00400_DB00849
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00255_DB00849
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00091_DB00849
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01115_DB00849
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00510_DB00849
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00443_DB00849
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00717_DB00849
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00705_DB00849
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00158_DB00849
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01234_DB00849
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00741_DB00849
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00367_DB00849
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00277_DB00849
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00571_DB00849
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00916_DB00849
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00635_DB00849
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00317_DB00849
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00783_DB00849
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00286_DB00849
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00882_DB00849
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00351_DB00849
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01303_DB00849
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/952
_:header8332660591335206542186
Mon, 23 Apr 2012 18:35:37 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/952
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02004
http://www.genenames.org/data/hgnc_data.php?hgnc_id=3009
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D3009%3E
Dipeptidyl peptidase 4
serine-type endopeptidase activity
DPP4_HUMAN
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1352530
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=535388
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D535388%3E
DPP IV
endopeptidase activity
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/16490580
Release of an N-terminal dipeptide, Xaa-Yaa!Zaa-, from a polypeptide, preferentially when Yaa is Pro, provided Zaa is neither Pro nor hydroxyproline INHIBITOR L-Pro-L-boroPro
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7927537
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7487939
Removes N-terminal dipeptides sequentially from polypeptides having unsubstituted N-termini provided that the penultimate residue is proline. Plays a role in T-cell activation
http://www.pdb.org/pdb/explore/explore.do?structureId=2BGR
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D2BGR%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8094732
http://bio2rdf.org/hgnc:3009
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A3009%3E
TP103
http://symbol.bio2rdf.org/symbol:DPP4
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ADPP4%3E
EC 3.4.14.5
prolyl oligopeptidase activity
http://bio2rdf.org/pfam:PF00930
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00930%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/16855072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1347043
>2301 bp	ATGAAGACACCGTGGAAGGTTCTTCTGGGACTGCTGGGTGCTGCTGCGCTTGTCACCATC	ATCACCGTGCCCGTGGTTCTGCTGAACAAAGGCACAGATGATGCTACAGCTGACAGTCGC	AAAACTTACACTCTAACTGATTACTTAAAAAATACTTATAGACTGAAGTTATACTCCTTA	AGATGGATTTCAGATCATGAATATCTCTACAAACAAGAAAATAATATCTTGGTATTCAAT	GCTGAATATGGAAACAGCTCAGTTTTCTTGGAGAACAGTACATTTGATGAGTTTGGACAT	TCTATCAATGATTATTCAATATCTCCTGATGGGCAGTTTATTCTCTTAGAATACAACTAC	GTGAAGCAATGGAGGCATTCCTACACAGCTTCATATGACATTTATGATTTAAATAAAAGG	CAGCTGATTACAGAAGAGAGGATTCCAAACAACACACAGTGGGTCACATGGTCACCAGTG	GGTCATAAATTGGCATATGTTTGGAACAATGACATTTATGTTAAAATTGAACCAAATTTA	CCAAGTTACAGAATCACATGGACGGGGAAAGAAGATATAATATATAATGGAATAACTGAC	TGGGTTTATGAAGAGGAAGTCTTCAGTGCCTACTCTGCTCTGTGGTGGTCTCCAAACGGC	ACTTTTTTAGCATATGCCCAATTTAACGACACAGAAGTCCCACTTATTGAATACTCCTTC	TACTCTGATGAGTCACTGCAGTACCCAAAGACTGTACGGGTTCCATATCCAAAGGCAGGA	GCTGTGAATCCAACTGTAAAGTTCTTTGTTGTAAATACAGACTCTCTCAGCTCAGTCACC	AATGCAACTTCCATACAAATCACTGCTCCTGCTTCTATGTTGATAGGGGATCACTACTTG	TGTGATGTGACATGGGCAACACAAGAAAGAATTTCTTTGCAGTGGCTCAGGAGGATTCAG	AACTATTCGGTCATGGATATTTGTGACTATGATGAATCCAGTGGAAGATGGAACTGCTTA	GTGGCACGGCAACACATTGAAATGAGTACTACTGGCTGGGTTGGAAGATTTAGGCCTTCA	GAACCTCATTTTACCCTTGATGGTAATAGCTTCTACAAGATCATCAGCAATGAAGAAGGT	TACAGACACATTTGCTATTTCCAAATAGATAAAAAAGACTGCACATTTATTACAAAAGGC	ACCTGGGAAGTCATCGGGATAGAAGCTCTAACCAGTGATTATCTATACTACATTAGTAAT	GAATATAAAGGAATGCCAGGAGGAAGGAATCTTTATAAAATCCAACTTAGTGACTATACA	AAAGTGACATGCCTCAGTTGTGAGCTGAATCCGGAAAGGTGTCAGTACTATTCTGTGTCA	TTCAGTAAAGAGGCGAAGTATTATCAGCTGAGATGTTCCGGTCCTGGTCTGCCCCTCTAT	ACTCTACACAGCAGCGTGAATGATAAAGGGCTGAGAGTCCTGGAAGACAATTCAGCTTTG	GATAAAATGCTGCAGAATGTCCAGATGCCCTCCAAAAAACTGGACTTCATTATTTTGAAT	GAAACAAAATTTTGGTATCAGATGATCTTGCCTCCTCATTTTGATAAATCCAAGAAATAT	CCTCTACTATTAGATGTGTATGCAGGCCCATGTAGTCAAAAAGCAGACACTGTCTTCAGA	CTGAACTGGGCCACTTACCTTGCAAGCACAGAAAACATTATAGTAGCTAGCTTTGATGGC	AGAGGAAGTGGTTACCAAGGAGATAAGATCATGCATGCAATCAACAGAAGACTGGGAACA	TTTGAAGTTGAAGATCAAATTGAAGCAGCCAGACAATTTTCAAAAATGGGATTTGTGGAC	AACAAACGAATTGCAATTTGGGGCTGGTCATATGGAGGGTACGTAACCTCAATGGTCCTG	GGATCGGGAAGTGGCGTGTTCAAGTGTGGAATAGCCGTGGCGCCTGTATCCCGGTGGGAG	TACTATGACTCAGTGTACACAGAACGTTACATGGGTCTCCCAACTCCAGAAGACAACCTT	GACCATTACAGAAATTCAACAGTCATGAGCAGAGCTGAAAATTTTAAACAAGTTGAGTAC	CTCCTTATTCATGGAACAGCAGATGATAACGTTCACTTTCAGCAGTCAGCTCAGATCTCC	AAAGCCCTGGTCGATGTTGGAGTGGATTTCCAGGCAATGTGGTATACTGATGAAGACCAT	GGAATAGCTAGCAGCACAGCACACCAACATATATATACCCACATGAGCCACTTCATAAAA	CAATGTTTCTCTTTACCTTAG
7-28
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1977364
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/16682937
http://bio2rdf.org/uniprot:P27487
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP27487%3E
http://pfam.sanger.ac.uk/family?acc=PF00326
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00326%3E
>Dipeptidyl peptidase 4	MKTPWKVLLGLLGAAALVTIITVPVVLLNKGTDDATADSRKTYTLTDYLKNTYRLKLYSL	RWISDHEYLYKQENNILVFNAEYGNSSVFLENSTFDEFGHSINDYSISPDGQFILLEYNY	VKQWRHSYTASYDIYDLNKRQLITEERIPNNTQWVTWSPVGHKLAYVWNNDIYVKIEPNL	PSYRITWTGKEDIIYNGITDWVYEEEVFSAYSALWWSPNGTFLAYAQFNDTEVPLIEYSF	YSDESLQYPKTVRVPYPKAGAVNPTVKFFVVNTDSLSSVTNATSIQITAPASMLIGDHYL	CDVTWATQERISLQWLRRIQNYSVMDICDYDESSGRWNCLVARQHIEMSTTGWVGRFRPS	EPHFTLDGNSFYKIISNEEGYRHICYFQIDKKDCTFITKGTWEVIGIEALTSDYLYYISN	EYKGMPGGRNLYKIQLSDYTKVTCLSCELNPERCQYYSVSFSKEAKYYQLRCSGPGLPLY	TLHSSVNDKGLRVLEDNSALDKMLQNVQMPSKKLDFIILNETKFWYQMILPPHFDKSKKY	PLLLDVYAGPCSQKADTVFRLNWATYLASTENIIVASFDGRGSGYQGDKIMHAINRRLGT	FEVEDQIEAARQFSKMGFVDNKRIAIWGWSYGGYVTSMVLGSGSGVFKCGIAVAPVSRWE	YYDSVYTERYMGLPTPEDNLDHYRNSTVMSRAENFKQVEYLLIHGTADDNVHFQQSAQIS	KALVDVGVDFQAMWYTDEDHGIASSTAHQHIYTHMSHFIKQCFSLP
Adenosine deaminase complexing protein 2
http://www.uniprot.org/uniprot/P27487
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP27487%3E
http://pfam.sanger.ac.uk/family?acc=PF00930
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00930%3E
Dipeptidyl peptidase IV
DPP4
http://bio2rdf.org/pfam:PF00326
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00326%3E
ADABP
2q24.3
dipeptidyl-peptidase IV activity
U13735
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1677636
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/16338283
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=U13735
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DU13735%3E
single-passTypeIiMembraneProtein.ProcessedForm:secretedProtein.Note=alsoExis
http://bio2rdf.org/pdb:2BGR
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A2BGR%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8096237
T-cell activation antigen CD26
serine-type peptidase activity
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/16868220
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1352704
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01261
RDF Description of Dipeptidyl peptidase 4
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01884
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04491
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/HLA-DRB1
_:header21283298301335206542447
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/HLA-DRB1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1019
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/gene/HLA-DRB1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fgene%2FHLA-DRB1%3E
http://symbol.bio2rdf.org/symbol:HLA-DRB1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AHLA-DRB1%3E
HLA-DRB1
http://www.dbpedia.org/resource/HLA-DRB1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FHLA-DRB1%3E
RDF Description of HLA-DRB1
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB04077
_:header17977088841335206542906
RDF Description of Glycerol
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04077
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/633
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F633%3E
http://data.linkedct.org/resource/intervention/6284
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F6284%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2985
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2985%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/solvents
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2394
Glycerol
CRY
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3221
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3313
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2838
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2838%3E
PEDCQBHIVMGVHV-UHFFFAOYAF
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/5489
OCC(O)CO
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3833
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3833%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2343
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2343%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3194
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2852
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3173
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3834
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3834%3E
http://www.drugbank.ca/drugs/DB04077
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB04077%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/5140
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2933
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4692
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4311
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3306
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3393
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3709
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/cryoprotectiveAgents
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3234
1.17e+03 mg/mL
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/904
1V40
A trihydroxy sugar alcohol that is an intermediate in carbohydrate and lipid metabolism. It is used as a solvent, emollient, pharmaceutical agent, and sweetening agent. [PubChem]
http://data.linkedct.org/resource/intervention/58523
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F58523%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1943
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1943%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/381
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F381%3E
DB04077
2008-08-26 13:59:56 UTC
expt01027
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3116
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/689
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F689%3E
InChI=1/C3H8O3/c4-1-3(6)2-5/h3-6H,1-2H2
C3H8O3
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3336
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3238
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3232
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3345
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2547
propane-1,2,3-triol
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3191
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2101
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1023
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1023%3E
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F254%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1916
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1916%3E
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Feuillet_Octave_1821-1890
_:header16990292381335206543363
Mon, 23 Apr 2012 18:35:38 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Feuillet_Octave_1821-1890
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7576
Feuillet, Octave, 1821-1890
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext16403
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3943
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3946
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3945
RDF Description of Feuillet, Octave, 1821-1890
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3944
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Burnett_Frances_Hodgson_1849-1924
_:header59778171335206543793
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Burnett_Frances_Hodgson_1849-1924
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2514
Burnett, Frances Hodgson, 1849-1924
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5303
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext384
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext506
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6491
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5304
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1550
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext137
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8574
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext459
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext15651
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext10466
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext113
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5302
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8812
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19514
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17226
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext460
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext18945
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17396
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9487
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext479
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext146
RDF Description of Burnett, Frances Hodgson, 1849-1924
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6027
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/932
_:header4348917361335206544210
Mon, 23 Apr 2012 18:35:39 GMT
RDF Description of Placental abruption
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/932
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04018
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB04018%3E
http://data.linkedct.org/resource/condition/10154
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fcondition%2F10154%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02048
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB02048%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04534
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB04534%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00360
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00360%3E
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB04184%3E
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01867%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03707
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB03707%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01997
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01997%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02141
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB02141%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02044
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB02044%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02994
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB02994%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03332
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB03332%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01098
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01098%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01821
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01821%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04399
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB04399%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02692
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB02692%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03910
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB03910%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03974
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB03974%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02589
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB02589%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02335
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB02335%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02979
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB02979%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04223
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB04223%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01686
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01686%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00155
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00155%3E
Placental abruption
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03963
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB03963%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04402
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB04402%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02207
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB02207%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02911
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB02911%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01833
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01833%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04559
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB04559%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/NOS3
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03684
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB03684%3E
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB03014%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03918
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB03918%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03100
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB03100%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03065
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB03065%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02234
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB02234%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03144
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB03144%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02027
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB02027%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03305
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB03305%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02077
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB02077%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00125
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00125%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3600
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/739
_:header14874021941335206544704
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/739
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01212
Gamma-glutamyltranspeptidase precursor
EC 2.3.2.2
Gamma-glutamyltranspeptidase
GGT_ECOLI
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1360205
>Gamma-glutamyltranspeptidase precursor	MIKPTFLRRVAIAALLSGSCFSAAAAPPAPPVSYGVEEDVFHPVRAKQGMVASVDATATQ	VGVDILKEGGNAVDAAVAVGYALAVTHPQAGNLGGGGFMLIRSKNGNTTAIDFREMAPAK	ATRDMFLDDQGNPDSKKSLTSHLASGTPGTVAGFSLALDKYGTMPLNKVVQPAFKLARDG	FIVNDALADDLKTYGSEVLPNHENSKAIFWKEGEPLKKGDTLVQANLAKSLEMIAENGPD	EFYKGTIAEQIAQEMQKNGGLITKEDLAAYKAVERTPISGDYRGYQVYSMPPPSSGGIHI	VQILNILENFDMKKYGFGSADAMQIMAEAEKYAYADRSEYLGDPDFVKVPWQALTNKAYA	KSIADQIDINKAKPSSEIRPGKLAPYESNQTTHYSVVDKDGNAVAVTYTLNTTFGTGIVA	GESGILLNNQMDDFSAKPGVPNVYGLVGGDANAVGPNKRPLSSMSPTIVVKDGKTWLVTG	SPGGSRIITTVLQMVVNSIDYGLNVAEATNAPRFHHQWLPDELRVEKGFSPDTLKLLEAK	GQKVALKEAMGSTQSIMVGPDGELYGASDPRSVDDLTAGY
http://bio2rdf.org/pfam:PF01019
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF01019%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=146133
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D146133%3E
http://pfam.sanger.ac.uk/family?acc=PF01019
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF01019%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=M28722
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DM28722%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2570061
transferase activity, transferring acyl groups
http://bio2rdf.org/uniprot:P18956
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP18956%3E
gamma-glutamyltransferase activity
ggt
M28722
(5-L-glutamyl)-peptide + an amino acid = peptide + 5-L-glutamyl amino acid
>1743 bp	ATGATAAAACCGACGTTTTTACGCCGGGTGGCCATTGCTGCTCTGCTCTCAGGAAGTTGT	TTTAGCGCCGCCGCCGCGCCTCCTGCGCCGCCCGTCTCGTATGGTGTGGAGGAAGATGTC	TTCCACCCGGTACGCGCGAAACAGGGAATGGTAGCGTCTGTGGACGCCACTGCCACTCAG	GTGGGGGTGGATATTCTCAAGGAGGGCGGGAATGCCGTTGATGCCGCCGTGGCGGTGGGC	TACGCGCTGGCGGTAACGCATCCGCAGGCAGGGAATCTGGGCGGTGGTGGTTTTATGTTA	ATCCGCTCGAAAAATGGCAATACCACGGCTATCGATTTCCGCGAAATGGCACCCGCCAAA	GCGACCCGCGATATGTTCCTCGATGATCAGGGCAACCCGGACAGCAAAAAATCACTCACT	TCGCATCTGGCTTCCGGCACACCGGGTACGGTAGCAGGTTTCTCGCTGGCGCTGGATAAA	TACGGCACCATGCCGCTGAACAAAGTCGTGCAGCCCGCGTTTAAACTGGCACGCGATGGT	TTTATCGTTAACGACGCGCTGGCTGACGATCTCAAAACCTACGGTAGCGAAGTGTTGCCG	AATCACGAAAACAGTAAAGCTATCTTCTGGAAAGAGGGCGAGCCGCTGAAAAAGGGCGAC	ACGCTGGTGCAGGCGAACCTGGCAAAGAGCCTGGAGATGATTGCTGAAAACGGCCCGGAC	GAATTCTATAAAGGCACGATTGCGGAACAGATCGCCCAGGAGATGCAGAAAAACGGTGGC	TTGATCACTAAAGAAGATTTAGCAGCCTATAAAGCGGTCGAACGCACTCCGATAAGCGGC	GATTATCGCGGGTATCAGGTTTACTCCATGCCACCGCCATCCTCCGGCGGGATCCATATC	GTACAAATCCTCAATATTCTGGAAAACTTCGATATGAAGAAATACGGCTTTGGCAGCGCC	GATGCGATGCAAATCATGGCAGAAGCGGAGAAATACGCCTACGCCGACCGCTCGGAATAT	CTTGGCGACCCGGATTTTGTCAAAGTACCGTGGCAGGCGCTGACCAATAAAGCCTATGCC	AAATCTATTGCCGATCAAATTGATATCAATAAAGCGAAGCCATCCAGCGAAATTCGCCCC	GGCAAGCTTGCGCCTTATGAGAGTAATCAAACTACCCATTACTCAGTGGTGGATAAAGAT	GGTAACGCGGTGGCGGTGACCTATACGCTGAACACCACCTTCGGTACGGGCATTGTCGCG	GGCGAGAGCGGTATTCTGCTTAATAACCAGATGGATGATTTCTCCGCCAAACCGGGCGTA	CCGAACGTTTACGGGCTGGTGGGCGGTGATGCCAACGCCGTCGGGCCGAACAAACGCCCG	CTGTCGTCGATGTCGCCGACCATTGTGGTGAAAGACGGTAAAACCTGGCTGGTTACCGGT	AGCCCAGGCGGTAGCCGGATCATCACTACAGTGCTGCAAATGGTGGTGAATAGCATCGAT	TATGGCTTGAACGTCGCCGAAGCGACCAATGCGCCGCGTTTCCACCATCAGTGGTTGCCG	GACGAGCTGCGTGTCGAAAAAGGGTTTAGCCCGGATACGCTCAAGCTGCTGGAAGCAAAA	GGTCAGAAAGTGGCGCTGAAAGAGGCGATGGGCAGTACACAAAGCATTATGGTTGGGCCG	GACGGTGAGTTGTACGGCGCATCCGACCCGCGCTCGGTGGATGATTTAACGGCGGGGTAC	TAA
http://www.uniprot.org/uniprot/P18956
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP18956%3E
map00430	Taurine and hypotaurine metabolism	map00450	Selenoamino acid metabolism	map00460	Cyanoamino acid metabolism	map00480	Glutathione metabolism	map00590	Prostaglandin and leukotriene metabolism
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8041620
transferase activity, transferring amino-acyl groups
periplasm
RDF Description of Gamma-glutamyltranspeptidase
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/1236
_:header10755916421335206545049
Mon, 23 Apr 2012 18:35:40 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1236
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2973
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/ECM1
Lipoid proteinosis
http://www.dbpedia.org/resource/Lipoid_proteinosis
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FLipoid_proteinosis%3E
RDF Description of Lipoid proteinosis
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Monnier_Marc_1827-1885
_:header21176041671335206545474
RDF Description of Monnier, Marc, 1827-1885
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Monnier_Marc_1827-1885
Monnier, Marc, 1827-1885
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17290
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0023370
_:header5990666541335206545977
RDF Description of Leriche syndrome
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0023370
http://dbpedia.org/resource/Aortoiliac_occlusive_disease
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FAortoiliac_occlusive_disease%3E
http://sideeffects.embl.de/se/C0023370
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0023370%3E
Leriche syndrome
C0023370
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/435
_:header14103120381335206546265
Mon, 23 Apr 2012 18:35:41 GMT
RDF Description of Gardner syndrome
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/435
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/APC
Gardner syndrome
http://www.dbpedia.org/resource/Gardner%27s_syndrome
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FGardner%2527s_syndrome%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2428
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/PCBD1
_:header19307885531335206546659
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PCBD1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/556
http://symbol.bio2rdf.org/symbol:PCBD1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3APCBD1%3E
PCBD1
http://www.dbpedia.org/resource/PCBD1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FPCBD1%3E
RDF Description of PCBD1
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/468
_:header7728289071335206547212
Mon, 23 Apr 2012 18:35:42 GMT
RDF Description of Cytochrome P450 4A11
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/468
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=181397
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D181397%3E
CYPIVA11
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1739747
EC 1.14.15.3
15-32; 118-140
http://www.genenames.org/data/hgnc_data.php?hgnc_id=2642
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D2642%3E
http://www.uniprot.org/uniprot/Q02928
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ02928%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8363569
Cytochrome P450 4A11
http://pfam.sanger.ac.uk/family?acc=PF00067
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00067%3E
>Cytochrome P450 4A11 precursor	MSVSVLSPSRLLGDVSGILQAASLLILLLLLIKAVQLYLHRQWLLKALQQFPCPPSHWLF	GHIQELQQDQELQRIQKWVETFPSACPHWLWGGKVRVQLYDPDYMKVILGRSDPKSHGSY	RFLAPWIGYGLLLLNGQTWFQHRRMLTPAFHYDILKPYVGLMADSVRVMLDKWEELLGQD	SPLEVFQHVSLMTLDTIMKCAFSHQGSIQVDRNSQSYIQAISDLNNLVFSRVRNAFHQND	TIYSLTSAGRWTHRACQLAHQHTDQVIQLRKAQLQKEGELEKIKRKRHLDFLDILLLAKM	ENGSILSDKDLRAEVDTFMFEGHDTTASGISWILYALATHPKHQERCREEIHSLLGDGAS	ITWNHLDQMPYTTMCIKEALRLYPPVPGIGRELSTPVTFPDGRSLPKGIMVLLSIYGLHH	NPKVWPNPEVFDPFRFAPGSAQHSHAFLPFSGGSRNCIGKQFAMNELKVATALTLLRFEL	LPDPTRIPIPIARLVLKSKNGIHLRLRRLPNPCEDKDQL
octane + reduced rubredoxin + O2 = 1-octanol + oxidized rubredoxin + H2O
Catalyzes the omega- and (omega-1)-hydroxylation of various fatty acids such as laurate, myristate and palmitate. Has little activity towards prostaglandins A1 and E1
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8274222
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7679927
http://bio2rdf.org/hgnc:2642
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A2642%3E
CYP4A11
http://bio2rdf.org/uniprot:Q02928
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ02928%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12464262
1p33
CYP4AII
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11821421
http://symbol.bio2rdf.org/symbol:CYP4A11
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ACYP4A11%3E
Lauric acid omega-hydroxylase
Fatty acid omega-hydroxylase
map00071	Fatty acid metabolism
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=L04751
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DL04751%3E
peripheralMembraneProtein
heme binding
P450-HL-omega
iron ion binding
L04751
tetrapyrrole binding
>1560 bp	ATGAGTGTCTCTGTGCTGAGCCCCAGCAGACTCCTGGGTGATGTCTCTGGAATCCTCCAA	GCGGCCTCCCTGCTCATTCTGCTTCTGCTGCTGATCAAGGCAGTTCAGCTCTACCTGCAC	AGGCAGTGGCTGCTCAAAGCCCTCCAGCAGTTCCCGTGCCCTCCCTCCCACTGGCTCTTC	GGGCACATCCAGGAGCTCCAACAGGACCAGGAGCTACAACGGATTCAGAAATGGGTGGAG	ACATTCCCAAGTGCCTGTCCTCATTGGCTATGGGGAGGCAAAGTTCGTGTCCAGCTCTAT	GACCCTGACTATATGAAGGTGATTCTGGGGAGATCAGACCCGAAATCCCATGGTTCCTAC	AGATTCCTGGCTCCATGGATTGGGTACGGCTTGCTCCTGTTGAATGGGCAGACATGGTTC	CAGCATCGACGGATGCTGACCCCAGCCTTCCACTATGACATCCTGAAGCCCTATGTGGGG	CTCATGGCAGACTCTGTACGAGTGATGCTGGACAAATGGGAAGAGCTCCTTGGCCAGGAT	TCCCCTCTGGAGGTCTTTCAGCACGTCTCCTTGATGACCCTGGACACCATCATGAAGTGT	GCCTTCAGCCATCAGGGCAGCATCCAGGTGGACAGGAATTCTCAGTCCTACATACAGGCC	ATTAGTGACCTGAACAACCTGGTTTTTTCCCGTGTGAGGAATGCCTTTCACCAGAATGAC	ACCATCTACAGCCTGACCTCTGCTGGCCGCTGGACACACCGCGCCTGCCAGCTGGCCCAT	CAGCACACAGACCAAGTGATCCAACTGAGGAAGGCTCAACTACAGAAGGAGGGGGAGCTG	GAGAAGATCAAGAGGAAGAGGCATTTGGATTTTCTGGATATCCTCCTCTTGGCCAAAATG	GAGAATGGGAGCATCTTGTCAGACAAGGACCTCCGTGCTGAGGTGGACACGTTCATGTTT	GAGGGCCACGACACCACAGCCAGTGGGATCTCCTGGATCCTCTATGCTCTGGCCACACAC	CCCAAGCATCAGGAGAGGTGCCGGGAGGAGATCCACAGCCTCCTGGGTGATGGAGCCTCC	ATCACCTGGAACCACCTGGACCAGATGCCCTACACCACCATGTGCATTAAGGAGGCACTG	AGGCTCTACCCACCGGTGCCAGGCATTGGCAGAGAGCTCAGCACTCCCGTCACCTTCCCT	GATGGGCGCTCCTTGCCCAAAGGTATCATGGTCCTCCTCTCCATTTATGGCCTTCACCAC	AACCCAAAAGTGTGGCCCAACCCAGAGGTGTTTGACCCTTTCCGTTTTGCACCGGGTTCT	GCTCAACACAGCCACGCTTTCCTGCCCTTCTCAGGAGGATCAAGGAACTGCATTGGGAAA	CAATTTGCCATGAACGAGCTGAAGGTGGCCACGGCCCTGACCCTGCTCCGCTTTGAGCTG	CTGCCTGATCCCACCAGGATCCCCATCCCCATTGCACGACTTGTGTTGAAATCCAAAAAT	GGAATCCACCTGCGTCTCAGGAGGCTCCCTAACCCTTGTGAAGACAAGGACCAGCTTTGA
Cytochrome P450 4A11 precursor
P-450 HK omega
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11246504
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11139583
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7798189
Secondary metabolites biosynthesis, transport and catabolism
http://bio2rdf.org/pfam:PF00067
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00067%3E
CP4AB_HUMAN
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/SBDS
_:header5542783451335206547516
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/SBDS
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1052
http://symbol.bio2rdf.org/symbol:SBDS
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ASBDS%3E
SBDS
http://www.dbpedia.org/resource/SBDS
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FSBDS%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3887
RDF Description of SBDS
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0033246
_:header6591407431335206547991
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0033246
http://dbpedia.org/resource/Proctitis
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FProctitis%3E
http://sideeffects.embl.de/se/C0033246
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0033246%3E
proctitis
C0033246
RDF Description of proctitis
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2099
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2021
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4064
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3397
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Bottomley_Gordon_1874-1948
_:header4082252521335206548403
Mon, 23 Apr 2012 18:35:43 GMT
RDF Description of Bottomley, Gordon, 1874-1948 
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Bottomley_Gordon_1874-1948
Bottomley, Gordon, 1874-1948 
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext16435
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/5137
_:header477473451335206548904
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/5137
http://bio2rdf.org/uniprot:P26361
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP26361%3E
http://bio2rdf.org/pfam:PF00005
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00005%3E
>4431 bp	ATGCAGAAGTCGCCTTTGGAGAAAGCCAGCTTTATCTCCAAACTCTTCTTCAGCTGGACC	ACACCAATTTTGAGGAAAGGGTACAGACACCACTTGGAGTTGTCAGACATATACCAAGCC	CCTTCTGCTGATTCAGCTGACCACTTGTCTGAAAAACTAGAAAGAGAATGGGACAGAGAA	CAAGCTTCAAAAAAGAATCCCCAGCTTATCCACGCCCTTCGGCGATGCTTTTTCTGGAGA	TTCCTCTTCTATGGAATTTTGCTATACCTAGGGGAAGTCACCAAGGCTGTCCAGCCTGTC	TTGCTAGGAAGAATCATAGCATCCTATGATCCAGAAAACAAGGTGGAACGTTCCATTGCC	ATTTACCTTGGCATAGGCTTATGCCTTCTCTTCATTGTCAGGACACTGCTTCTTCACCCA	GCTATTTTTGGCCTTCATCGCATTGGAATGCAGATGAGAACAGCTATGTTTAGCTTGATT	TATAAGAAGACTTTAAAGTTGTCAAGCCGCGTTCTTGATAAAATAAGTATTGGACAACTT	GTTAGTCTTCTTTCCAACAACCTGAACAAATTTGATGAAGGACTTGCCTTGGCACATTTT	ATATGGATTGCTCCTTTACAAGTGACTCTTCTGATGGGGCTTCTCTGGGACTTGTTACAG	TTCTCAGCCTTCTGTGGCCTTGGTTTACTGATAATCCTGGTTATTTTTCAAGCTATCCTA	GGGAAGATGATGGTGAAGTACAGAGATCAAAGAGCTGCAAAGATCAATGAAAGACTCGTG	ATCACATCAGAAATTATTGATAATATCTATTCTGTTAAGGCATATTGTTGGGAATCAGCG	ATGGAGAAAATGATTGAAAACTTGAGAGAGGTGGAGCTGAAAATGACCCGGAAGGCGGCC	TATATGAGGTTCTTCACTAGCTCTGCCTTCTTCTTTTCAGGGTTCTTTGTAGTCTTTCTA	TCTGTGCTTCCCTACACAGTCATCAACGGAATCGTCCTACGAAAAATATTCACAACCATT	TCATTCTGCATTGTCCTACGTATGTCAGTCACGCGGCAGTTCCCCACTGCCGTACAGATA	TGGTATGATTCTTTTGGAATGATAAGAAAAATACAGGATTTCCTGCAGAAACAAGAGTAT	AAAGTACTGGAGTATAACTTAATGACCACAGGCATAATCATGGAAAATGTAACAGCATTT	TGGGAGGAGGGATTTGGGGAATTACTGCAGAAAGCACAACAAAGCAATGGTGACAGAAAA	CATTCCAGTGATGAGAACAATGTCAGTTTCAGTCATCTCTGCCTTGTGGGAAATCCTGTG	CTGAAAAACATCAATTTGAATATAGAGAAAGGAGAGATGTTGGCTATTACTGGATCTACT	GGACTAGGAAAGACATCACTCCTGATGTTGATTTTGGGAGAACTGGAAGCTTCAGAGGGA	ATTATTAAGCACAGTGGAAGAGTTTCATTCTGCTCTCAATTTTCTTGGATTATGCCGGGT	ACTATCAAAGAAAATATCATCTTTGGTGTTTCCTATGATGAGTACAGATATAAGAGTGTT	GTCAAAGCTTGCCAACTACAGCAGGACATCACCAAGTTTGCAGAACAAGACAACACAGTT	CTTGGAGAAGGTGGAGTCACACTGAGTGGAGGTCAGCGTGCAAGGATTTCTTTAGCAAGA	GCAGTATATAAAGATGCTGATTTGTACCTATTAGATTCCCCTTTTGGATATCTAGATGTT	TTTACTGAAGAACAAGTATTTGAAAGCTGTGTTTGTAAATTGATGGCCAACAAAACTAGG	ATTTTGGTTACATCTAAAATGGAACACTTAAGGAAAGCTGACAAAATACTAATTTTGCAT	CAGGGGACTAGCTATTTTTATGGGACATTTTCTGAGCTACAAAGTCTACGTCCGAGCTTC	AGTTCGAAACTCATGGGGTATGATACTTTTGACCAGTTTACTGAGGAAAGAAGAAGTTCA	ATTCTAACTGAGACCTTACGCAGGTTCTCAGTAGACGATTCCTCTGCCCCGTGGAGCAAA	CCCAAACAGTCGTTTAGACAGACTGGAGAGGTGGGAGAAAAAAGGAAGAACTCTATTCTA	AATTCATTCAGCTCTGTAAGGAAAATTTCCATTGTGCAAAAGACTCCATTATGTATCGAT	GGAGAGTCTGATGATCTCCAAGAAAAGAGACTGTCCCTAGTTCCGGATTCTGAACAGGGG	GAGGCTGCTCTGCCGCGCAGCAACATGATCGCCACCGGCCCCACATTTCCAGGCAGAAGA	AGACAGTCTGTTTTGGATCTGATGACGTTCACACCCAACTCAGGCTCCAGCAATCTTCAG	AGGACCAGAACTTCTATTCGAAAAATCTCCTTAGTCCCTCAGATAAGCTTAAATGAAGTG	GATGTATATTCAAGGAGATTATCGCAAGATAGCACACTGAACATCACTGAAGAAATTAAC	GAAGAAGATTTAAAGGAGTGTTTTCTTGATGATGTGATCAAGATACCCCCGGTGACAACA	TGGAACACATACCTACGATATTTTACTCTCCATAAAGGCTTACTGCTAGTGCTGATTTGG	TGCGTACTGGTTTTTCTGGTTGAGGTGGCTGCTTCTTTATTTGTGTTATGGTTGCTTAAA	AACAACCCTGTTAACAGTGGAAACAATGGTACTAAAATTTCCAATAGCTCCTACGTTGTG	ATCATCACCAGTACCAGTTTCTATTATATTTTTTACATTTACGTGGGAGTGGCTGACACT	TTGCTTGCCCTGAGCCTCTTCAGAGGTTTGCCGCTGGTGCATACGTTAATCACAGCATCA	AAAATTTTGCACAGGAAAATGTTACACTCCATTCTTCACGCCCCTATGTCGACCATCAGC	AAGCTGAAAGCAGGTGGGATTCTTAACAGATTCTCCAAAGATATAGCAATTTTGGATGAC	TTTCTGCCTCTTACCATTTTTGACTTCATTCAGTTGGTGTTCATTGTGATTGGAGCTATA	ATAGTCGTCTCGGCATTACAACCCTACATCTTCCTAGCAACGGTGCCAGGGCTAGTAGTC	TTTATTTTACTGAGGGCCTACTTCCTTCATACAGCACAGCAGCTCAAACAACTGGAATCT	GAAGGCAGGAGTCCAATTTTCACCCACCTTGTGACAAGCTTAAAAGGACTCTGGACACTT	CGAGCCTTCCGACGCCAGACTTACTTTGAAACTCTGTTCCACAAAGCTCTGAATTTGCAC	ACTGCCAACTGGTTTATGTATCTGGCAACCTTGCGCTGGTTCCAAATGAGAATAGACATG	ATATTTGTCCTCTTCTTCATTGTTGTTACCTTCATCTCCATTTTAACAACAGGTGAAGGA	GAAGGAACAGCTGGTATTATTCTAACTTTAGCTATGAATATCATGAGTACTTTGCAGTGG	GCTGTGAACTCAAGCATTGATACAGATAGCTTGATGCGATCTGTGAGCAGAGTGTTTAAG	TTTATTGATATACAAACAGAAGAAAGTATGTACACACAGATAATTAAAGAACTACCTAGA	GAAGGATCATCTGACGTTTTAGTCATTAAGAATGAGCATGTGAAGAAAAGTGATATCTGG	CCCTCTGGAGGCGAAATGGTTGTCAAAGACCTTACTGTGAAATACATGGATGATGGAAAT	GCCGTATTAGAGAACATTTCTTTTTCAATAAGTCCTGGACAGAGGGTGGGGCTCTTAGGA	AGAACTGGATCAGGAAAAAGTACTTTGCTTTCAGCATTTTTACGAATGTTGAACATTAAA	GGTGATATAGAGATTGATGGTGTCTCATGGAATTCAGTGACCTTACAAGAATGGAGGAAA	GCTTTCGGAGTGATAACACAGAAAGTATTTATCTTTTCTGGAACATTCAGACAAAACCTG	GATCCCAATGGAAAATGGAAAGATGAAGAAATATGGAAAGTTGCAGATGAGGTTGGACTC	AAGTCTGTAATAGAGCAGTTTCCTGGACAGCTCAACTTTACCCTTGTGGATGGGGGTTAT	GTGCTAAGCCATGGCCATAAGCAATTAATGTGCTTGGCCCGATCAGTTCTCAGTAAGGCC	AAGATCATACTGCTTGATGAGCCCAGTGCCCATCTAGACCCCATAACATACCAAGTCATT	CGACGAGTTCTAAAACAAGCCTTCGCTGGTTGCACAGTCATCCTCTGTGAACACAGGATA	GAAGCGATGTTGGATTGCCAGCGATTTTTGGTCATAGAAGAGAGCAATGTCTGGCAGTAC	GACTCCCTTCAGGCACTTCTGAGTGAGAAGAGTATCTTCCAGCAGGCCATTAGCTCCTCG	GAAAAGATGAGGTTCTTCCAGGGCCGCCACTCCAGCAAGCACAAGCCTCGGACGCAAATT	ACTGCTCTGAAAGAGGAGACAGAAGAAGAAGTTCAAGAAACCCGTCTCTAG
986-1006
221-241
http://www.pdb.org/pdb/explore/explore.do?structureId=1R10
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1R10%3E
http://pfam.sanger.ac.uk/family?acc=PF00005
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00005%3E
Cystic fibrosis transmembrane conductance regulator
81-103
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=M69298
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DM69298%3E
1009-1029
CFTR_MOUSE
308-328
hydrolase activity, acting on acid anhydrides, catalyzing transmembrane movement of substances
cAMP- dependent chloride channel
http://bio2rdf.org/pdb:1R10
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1R10%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7691356
ATPase activity, coupled to transmembrane movement of substances
Cftr
M69298
1124-1144
Involved in the transport of chloride ions. May regulate bicarbonate secretion and salvage in epithelial cells by regulating the SLC4A7 transporter
331-350
907-927
http://www.uniprot.org/uniprot/P26361
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP26361%3E
http://pfam.sanger.ac.uk/family?acc=PF00664
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00664%3E
118-138
CFTR
>Cystic fibrosis transmembrane conductance regulator	MQKSPLEKASFISKLFFSWTTPILRKGYRHHLELSDIYQAPSADSADHLSEKLEREWDRE	QASKKNPQLIHALRRCFFWRFLFYGILLYLGEVTKAVQPVLLGRIIASYDPENKVERSIA	IYLGIGLCLLFIVRTLLLHPAIFGLHRIGMQMRTAMFSLIYKKTLKLSSRVLDKISIGQL	VSLLSNNLNKFDEGLALAHFIWIAPLQVTLLMGLLWDLLQFSAFCGLGLLIILVIFQAIL	GKMMVKYRDQRAAKINERLVITSEIIDNIYSVKAYCWESAMEKMIENLREVELKMTRKAA	YMRFFTSSAFFFSGFFVVFLSVLPYTVINGIVLRKIFTTISFCIVLRMSVTRQFPTAVQI	WYDSFGMIRKIQDFLQKQEYKVLEYNLMTTGIIMENVTAFWEEGFGELLEKVQQSNGDRK	HSSDENNVSFSHLCLVGNPVLKNINLNIEKGEMLAITGSTGSGKTSLLMLILGELEASEG	IIKHSGRVSFCSQFSWIMPGTIKENIIFGVSYDEYRYKSVVKACQLQQDITKFAEQDNTV	LGEGGVTLSGGQRARISLARAVYKDADLYLLDSPFGYLDVFTEEQVFESCVCKLMANKTR	ILVTSKMEHLRKADKILILHQGSSYFYGTFSELQSLRPDFSSKLMGYDTFDQFTEERRSS	ILTETLRRFSVDDSSAPWSKPKQSFRQTGEVGEKRKNSILNSFSSVRKISIVQKTPLCID	GESDDLQEKRLSLVPDSEQGEAALPRSNMIATGPTFPGRRRQSVLDLMTFTPNSGSSNLQ	RTRTSIRKISLVPQISLNEVDVYSRRLSQDSTLNITEEINEEDLKECFLDDVIKIPPVTT	WNTYLRYFTLHKGLLLVLIWCVLVFLVEVAASLFVLWLLKNNPVNSGNNGTKISNSSYVV	IITSTSFYYIFYIYVGVADTLLALSLFRGLPLVHTLITASKILHRKMLHSILHAPMSTIS	KLKAGGILNRFSKDIAILDDFLPLTIFDFIQLVFIVIGAIIVVSALQPYIFLATVPGLVV	FILLRAYFLHTAQQLKQLESEGRSPIFTHLVTSLKGLWTLRAFRRQTYFETLFHKALNLH	TANWFMYLATLRWFQMRIDMIFVLFFIVVTFISILTTGEGEGTAGIILTLAMNIMSTLQW	AVNSSIDTDSLMRSVSRVFKFIDIQTEESMYTQIIKELPREGSSDVLVIKNEHVKKSDIW	PSGGEMVVKDLTVKYMDDGNAVLENISFSISPGQRVGLLGRTGSGKSTLLSAFLRMLNIK	GDIEIDGVSWNSVTLQEWRKAFGVITQKVFIFSGTFRQNLDPNGKWKDEEIWKVADEVGL	KSVIEQFPGQLNFTLVDGGYVLSHGHKQLMCLARSVLSKAKIILLDEPSAHLDPITYQVI	RRVLKQAFAGCTVILCEHRIEAMLDCQRFLVIEESNVWQYDSLQALLSEKSIFQQAISSS	EKMRFFQGRHSSKHKPRTQITALKEETEEEVQETRL
http://bio2rdf.org/pfam:PF00664
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00664%3E
195-215
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1716243
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7526924
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10655503
855-875
Involved in nucleotide binding
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1712752
ATP-binding cassette transporter sub- family C member 7
1098-1118
ATPase activity
RDF Description of Cystic fibrosis transmembrane conductance regulator
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/1133
_:header20506383581335206549150
Mon, 23 Apr 2012 18:35:44 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1133
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4066
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/60
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F60%3E
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00661%3E
Thyrotoxic periodic paralysis
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3636
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3636%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseaseClass/Endocrine
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/CACNA1S
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00653%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/538
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F538%3E
RDF Description of Thyrotoxic periodic paralysis
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/662
_:header10682929301335206549571
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/662
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2875
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/RDH12
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/RPGRIP1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseaseClass/Ophthamological
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/AIPL1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00162%3E
http://www.dbpedia.org/resource/Leber%27s_congenital_amaurosis
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FLeber%2527s_congenital_amaurosis%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/RPE65
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/CRB1
Leber congenital amaurosis
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/CRX
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/GUCY2D
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2878
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2880
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2877
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2879
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2876
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2874
RDF Description of Leber congenital amaurosis
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Hume_David_1711-1776
_:header407078181335206549999
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Hume_David_1711-1776
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19216
Hume, David, 1711-1776
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19213
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19214
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19215
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19211
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext4320
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext4583
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19212
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9662
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext10574
RDF Description of Hume, David, 1711-1776
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext4705
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Todhunter_Isaac_1820-1884
_:header5834390221335206550438
Mon, 23 Apr 2012 18:35:45 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Todhunter_Isaac_1820-1884
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19770
Todhunter, Isaac, 1820-1884
RDF Description of Todhunter, Isaac, 1820-1884
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/ATP6V0A4
_:header9497996491335206550833
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/ATP6V0A4
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1278
http://symbol.bio2rdf.org/symbol:ATP6V0A4
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AATP6V0A4%3E
ATP6V0A4
http://www.dbpedia.org/resource/ATP6V0A4
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FATP6V0A4%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3724
RDF Description of ATP6V0A4
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Sully_Prudhomme_1839-1907
_:header3624113521335206551239
Mon, 23 Apr 2012 18:35:46 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Sully_Prudhomme_1839-1907
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19075
Sully Prudhomme, 1839-1907
Sully Prudhomme, 1839-1907 
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext20664
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17916
RDF Description of Sully Prudhomme, 1839-1907
http://www4.wiwiss.fu-berlin.de/factbook/data/Hong_Kong
_:header14656861811335206551715
RDF Description of Hong Kong
http://www4.wiwiss.fu-berlin.de/factbook/resource/Hong_Kong
Xianggang
55 (2 TV networks, each broadcasting on 2 channels)
Hong Kong
https://www.cia.gov/library/publications/the-world-factbook/maps/hk-map.gif
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Flibrary%2Fpublications%2Fthe-world-factbook%2Fmaps%2Fhk-map.gif%3E
1% of GDP
.hk
$472900000000 (30 June 2006 est.)
Basic Law, approved in March 1990 by Chinas National Peoples Congress, is Hong Kongs "mini-constitution"
Hong Kong Special Administrative Region
South China Sea
0.98 children born/woman
subtropical monsoon; cool and humid in winter, hot and rainy from spring through summer, warm and sunny in fall
18 years of age
limited democracy
Chinese/Hong Kong
https://www.cia.gov/cia/publications/factbook/geos/hk.html
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Fcia%2Fpublications%2Ffactbook%2Fgeos%2Fhk.html%3E
21.1% of GDP
HKD
less than 200
air and water pollution from rapid urbanization
National Day (Anniversary of the Founding of the Peoples Republic of China), 1 October (1949); note - 1 July 1997 is celebrated as Hong Kong Special Administrative Region Establishment Day
1 April - 31 March
hk
https://www.cia.gov/library/publications/the-world-factbook/flags/hk-flag.gif
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Flibrary%2Fpublications%2Fthe-world-factbook%2Fflags%2Fhk-flag.gif%3E
modern facilities provide excellent domestic and international services
Chinese/Hong Konger
Hong Kong has a free market economy highly dependent on international trade. The territory has become more closely linked to mainland China over the past few years. Even before Hong Kong reverted to Chinese administration on 1 July 1997, it had extensive trade and investment ties with China. Hong Kongs service industry over the past decade has grown rapidly as its manufacturing industry has moved to the mainland. Hong Kong also has stepped up its efforts to gain approval to offer more mainland financial services in a bid to remain competitive with Chinas growing financial centers. Hong Kongs natural resources are limited, and food and raw materials must be imported. Gross imports and exports (including reexports to and from third countries) each exceed GDP in dollar value. Per capita GDP exceeds that of the four big economies of Western Europe. GDP growth averaged a strong 5% from 1989 to 2006, but Hong Kong suffered two recessions in the past eight years because of the Asian financial crisis in 1997-98 and the global downturn in 2001-02. Although the Severe Acute Respiratory Syndrome (SARS) outbreak in 2003 also battered Hong Kongs economy, a solid rise in exports, a boom in tourism from the mainland because of Chinas easing of travel restrictions, and a return of consumer confidence resulted in the resumption of strong growth from late 2003 through 2006. Moreover, several large initial public offerings of Chinese companies on the Hong Kong stock exchange since late 2005 have helped to boost Hong Kongs status as a financial hub and have contributed to the improved performance of the market in late 2006.
none (special administrative region of China)
President of China HU Jintao (since 15 March 2003)
based on English common law
unicameral Legislative Council or LEGCO (60 seats; in 2004 30 seats indirectly elected by functional constituencies, 30 elected by popular vote; members serve four-year terms)
percent of vote by party - pro-democracy 63%, pro-Beijing 37%; seats by party - (pro-Beijing 34) DAB 12, Liberal Party 10, FTU 1, independents 11; (pro-democracy 25) Democratic Party 9, CTU 2, ADPL 1, Frontier Party 1, NWSC 1, independents 11; non-voting LEGCO president 1
https://www.cia.gov/library/publications/the-world-factbook/flags/hk-lgflag.gif
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Flibrary%2Fpublications%2Fthe-world-factbook%2Fflags%2Fhk-lgflag.gif%3E
Hong Kong dollar (HKD)
Court of Final Appeal in the Hong Kong Special Administrative Region
Executive Council consists of 14 official members and 15 non-official members
chief executive elected for five-year term by 800-member electoral committee; last held on 25 March 2007 (next to be held in 2012)
562 (Australia 1, Belgium 3, Canada 28, China 274, Denmark 6, Germany 6, Greece 27, Indonesia 4, Japan 67, South Korea 6, Norway 26, Philippines 16, Portugal 1, Singapore 24, Syria 1, Taiwan 6, UAE 2, UK 43, US 21)
red with a stylized, white, five-petal bauhinia flower in the center
Donald TSANG elected chief executive receiving 84.1% of the vote; Alan LEONG received 15.9%
417 (Bahamas 8, Belize 8, Bermuda 10, Cambodia 15, China 7, Cyprus 1, France 1, French Southern and Antarctic Lands 2, Greece 1, Honduras 2, India 1, Liberia 37, Malaysia 14, Malta 2, Marshall Islands 7, Norway 55, Panama 169, Philippines 3, Saint Vincent and the Grenadines 6, Singapore 50, Taiwan 3, Tuvalu 8, unknown 7)
Tai Mo Shan
Chief Executive Donald TSANG (since 24 June 2005)
Xianggang Tebie Xingzhengqu
direct election 18 years of age; universal for permanent residents living in the territory of Hong Kong for the past seven years; indirect election limited to about 200000 members of functional constituencies and an 800-member election committee drawn from broad regional groupings, municipal organizations, and central government bodies
age 15 and over has ever attended school
Occupied by the UK in 1841, Hong Kong was formally ceded by China the following year; various adjacent lands were added later in the 19th century. Pursuant to an agreement signed by China and the UK on 19 December 1984, Hong Kong became the Hong Kong Special Administrative Region (SAR) of China on 1 July 1997. In this agreement, China has promised that, under its "one country, two systems" formula, Chinas socialist economic system will not be imposed on Hong Kong and that Hong Kong will enjoy a high degree of autonomy in all matters except foreign and defense affairs for the next 50 years.
AM 5, FM 9, shortwave 0
microwave radio relay links and extensive fiber-optic network
Eastern Asia, bordering the South China Sea and China
six times the size of Washington, DC
hilly to mountainous with steep slopes; lowlands in north
$33020000000; including capital expenditures of $33020000000
last held 12 September 2004 (next to be held in September 2008)
Hong Kong garrison is funded by China; figures are NA
country code - 852; satellite earth stations - 3 Intelsat (1 Pacific Ocean and 2 Indian Ocean); coaxial cable to Guangzhou, China; access to 5 international submarine cables providing connections to ASEAN member nations, Japan, Taiwan, Australia, Middle East, and Western Europe
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Blaine_James_Gillespie_1830-1893
_:header20958399111335206552021
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Blaine_James_Gillespie_1830-1893
Blaine, James Gillespie, 1830-1893
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext21128
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext20065
RDF Description of Blaine, James Gillespie, 1830-1893
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00949
_:header13662314821335206552492
Mon, 23 Apr 2012 18:35:47 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00949
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00949_DB01174
20-23 hours
http://en.wikipedia.org/wiki/Felbamate
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FFelbamate%3E
http://dbpedia.org/resource/Felbamate
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FFelbamate%3E
http://129.128.185.122/drugbank2/drugs/DB00949/inserts/871/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00949%2Finserts%2F871%2Ffull%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/antiepilepticAgents
http://bio2rdf.org/cas:25451-15-4
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A25451-15-4%3E
NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
Slightly soluble in water
http://www.drugbank.ca/drugs/DB00949
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00949%3E
LD<sub>50</sub>=5000 mg/kg (Orally in rats)
DB00949
>90%
The mechanism by which felbamate exerts its anticonvulsant activity is unknown, but in animal test systems designed to detect anticonvulsant activity, felbamate has properties in common with other marketed anticonvulsants. <i>In vitro</i> receptor binding studies suggest that felbamate may be an antagonist at the strychnine-insensitive glycine-recognition site of the N-methyl-D-aspartate (NMDA) receptor-ionophore complex. Antagonism of the NMDA receptor glycine binding site may block the effects of the excitatory amino acids and suppress seizure activity. Animal studies indicate that felbamate may increase the seizure threshold and may decrease seizure spread.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/464
Felbamate
Felbamate is an anticonvulsant drug used in the treatment of epilepsy. It is used to treat partial seizures (with and without generalization) in adults and partial and generalized seizures associated with Lennox-Gastaut syndrome in children. It has a weak inhibitory effect on GABA receptor binding sites.
http://dbpedia.org/page/Felbamate
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FFelbamate%3E
InChI=1/C11H14N2O4/c12-10(14)16-6-9(7-17-11(13)15)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H2,12,14)(H2,13,15)/f/h12-13H2
/drugs/949/safety_sheets/936
Felbatol
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/706
http://129.128.185.122/drugbank2/drugs/DB00949/inserts/1892/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00949%2Finserts%2F1892%2Ffull%3E
http://bio2rdf.org/cpd:C07501
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC07501%3E
N03AX10
151.5 oC
http://data.linkedct.org/resource/intervention/5443
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F5443%3E
7.40e-01 mg/mL
Felbamate is an antiepileptic indicated as monotherapy or as an adjunct to other anticonvulsants for the treatment of partial seizures resulting from epilepsy. Receptor-binding studies <i>in vitro</i> indicate that felbamate has weak inhibitory effects on GABA-receptor binding, benzodiazepine receptor binding, and is devoid of activity at the MK-801 receptor binding site of the NMDA receptor-ionophore complex. However, felbamate does interact as an antagonist at the strychnine-insensitive glycine recognition site of the NMDA receptor-ionophore complex.
Taloxa
PA449590
aprd00505
Taking it after a meal may reduce the incidence of adverse effects.
(3-carbamoyloxy-2-phenylpropyl) carbamate
20-36%
http://129.128.185.122/drugbank2/drugs/DB00949/inserts/119/full
http://www.rxlist.com/cgi/generic3/felbamate.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric3%2Ffelbamate.htm%3E
http://bio2rdf.org/kegg:D00536
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD00536%3E
C11H14N2O4
Felbamyl
WKGXYQFOCVYPAC-KGJHZMDYCN
For use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use.
2008-08-26 17:02:10 UTC
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/837
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01174_DB00949
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00510_DB00949
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01320_DB00949
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00564_DB00949
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00949_DB00532
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00949_DB00510
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00949_DB01320
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00949_DB00754
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00794_DB00949
RDF Description of Felbamate
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00949_DB00564
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00949_DB00794
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01369_DB00949
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00949_DB01369
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB02345
_:header6634486981335206552952
RDF Description of Selenocysteine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02345
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2748
http://dbpedia.org/page/Selenocysteine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FSelenocysteine%3E
http://en.wikipedia.org/wiki/Selenocysteine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FSelenocysteine%3E
2-amino-3-selanylpropanoic acid
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2638
http://bio2rdf.org/cpd:C05688
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC05688%3E
expt01033
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2730
392 mg/mL at 0 oC [STEPHEN,H & STEPHEN,T (1963)]
http://www.drugbank.ca/drugs/DB02345
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB02345%3E
Selenocysteine
ZKZBPNGNEQAJSX-JSWHHWTPCO
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2657
N[C@@H](C[SeH])C(O)=O
NC(C[SeH])C(O)=O
3.25e+02 mg/mL
C3H7NO2Se
InChI=1/C3H7NO2Se/c4-2(1-7)3(5)6/h2,7H,1,4H2,(H,5,6)/f/h5H
1PFP
http://bio2rdf.org/chebi:9093
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fchebi%3A9093%3E
2008-08-26 13:55:09 UTC
http://bio2rdf.org/cas:4408-78-0
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A4408-78-0%3E
CSE
DB02345
A naturally occurring amino acid in both eukaryotic and prokaryotic organisms. It is found in tRNAs and in the catalytic site of some enzymes. The genes for glutathione peroxidase and formate dehydrogenase contain the TGA codon, which codes for this amino acid. [PubChem]
143-146 oC
http://dbpedia.org/resource/Selenocysteine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FSelenocysteine%3E
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Wren_Percival_Christopher_1885-1941
_:header18197082851335206553331
Mon, 23 Apr 2012 18:35:48 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Wren_Percival_Christopher_1885-1941
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext11691
Wren, Percival Christopher, 1885-1941
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext10667
RDF Description of Wren, Percival Christopher, 1885-1941
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01396
_:header10039250651335206553786
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01396
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00524_DB01396
Avoid avocado.
C01AA01
Avoid excess salt/sodium unless otherwise instructed by your physician.
Digitoxin
2008-08-26 16:05:41 UTC
Unidigin
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/liquidOral
Digitoxinum
Avoid bran and high fiber foods within 2 hours of taking this medication.
Digitoxoside
Crystodigin
0.0039 mg/mL at 25 oC [YALKOWSKY,SH & DANNENFELSER,RM (1992)]
Digitalin
http://bio2rdf.org/cpd:C06955
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC06955%3E
/drugs/1396/safety_sheets/1371
http://www.dbpedia.org/resource/Digitoxin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FDigitoxin%3E
http://bio2rdf.org/kegg:D00297
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD00297%3E
A cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665)
For the treatment and management of congestive cardiac insufficiency, arrhythmias and heart failure.
2.88e-02 mg/mL
C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H](CC[C@]43O)C3=CC(=O)OC3)C2)O[C@@H]1C
Tardigal
PA449316
255.5 oC
http://en.wikipedia.org/wiki/Digitoxin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FDigitoxin%3E
C41H64O13
DB01396
http://bio2rdf.org/cas:71-63-6
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A71-63-6%3E
WDJUZGPOPHTGOT-XUDUSOBPBI
2007-07-08 17:03:56 UTC
http://dbpedia.org/resource/Digitoxin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FDigitoxin%3E
1.85 [SANGSTER (1993)]
Digitoxin is a cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting (From Martindale, The Extra Pharmacopoeia, 30th ed, p665). Unlike digoxin (which is eliminated from the body via the kidneys), it is eliminated via the liver, so could be used in patients with poor or erratic kidney function. However, it is now rarely used in current UK medical practice. While there have been several controlled trials which have shown digoxin to be effective in a proportion of patients treated for heart failure, there is not the same strong evidence base for digitoxin, although it is presumed to be similarly effective.
http://dbpedia.org/page/Digitoxin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FDigitoxin%3E
CC1OC(CC(O)C1O)OC1C(O)CC(OC1C)OC1C(O)CC(OC2CCC3(C)C(CCC4C3CCC3(C)C(CCC43O)C3=CC(=O)OC3)C2)OC1C
http://bio2rdf.org/chebi:28544
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fchebi%3A28544%3E
C01AA04
4-[(3S,5R,8R,9S,10S,13R,14S,17R)-3-[(2R,4S,5S,6R)-5-[(2S,4S,5S,6R)-5-[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-5H-furan-2-one
Limit garlic, ginger, gingko, and horse chestnut.
http://www.drugbank.ca/drugs/DB01396
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01396%3E
Digitoksin
Digitoxin inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Digitoxin also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential.
Avoid milk, calcium containing dairy products, iron, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication.
92:02.00*
Digitoxin exhibits similar toxic effects to the more-commonly used digoxin, namely: anorexia, nausea, vomiting, diarrhoea, confusion, visual disturbances, and cardiac arrhythmias.
InChI=1/C41H64O13/c1-20-36(46)29(42)16-34(49-20)53-38-22(3)51-35(18-31(38)44)54-37-21(2)50-33(17-30(37)43)52-25-8-11-39(4)24(15-25)6-7-28-27(39)9-12-40(5)26(10-13-41(28,40)47)23-14-32(45)48-19-23/h14,20-22,24-31,33-38,42-44,46-47H,6-13,15-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27+,28-,29+,30+,31+,33+,34+,35+,36-,37-,38-,39+,40-,41+/m1/s1
http://205.193.93.51/dpdonline/searchRequest.do?din=02236621
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02236621%3E
RDF Description of Digitoxin
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00903_DB01396
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00887_DB01396
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00908_DB01396
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00999_DB01396
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00695_DB01396
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00436_DB01396
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00468_DB01396
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00310_DB01396
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00808_DB01396
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0019045
_:header21015006121335206554168
Mon, 23 Apr 2012 18:35:49 GMT
RDF Description of hemoglobinopathy
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0019045
http://dbpedia.org/resource/Hemoglobinopathy
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FHemoglobinopathy%3E
http://sideeffects.embl.de/se/C0019045
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0019045%3E
hemoglobinopathy
C0019045
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/885
_:header19719492701335206554749
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/885
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00918
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10458598
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10101238
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=219679
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D219679%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/15311727
348-373
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8622623
5HT1B_HUMAN
5-hydroxytryptamine 1B receptor
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7768274
5- HT1B
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12028320
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/15138762
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10188968
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3141589
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1565658
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10704941
HTR1B
Serotonin receptor 1B
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1328844
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11594437
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2566947
206-229
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10884561
5-HT-1D-beta
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9700983
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10844127
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11050304
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12093318
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7944828
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11735616
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17190530
http://bio2rdf.org/hgnc:5287
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A5287%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/14744615
http://www.uniprot.org/uniprot/P28222
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP28222%3E
D10995
166-187
S12
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/gene/HTR1B
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fgene%2FHTR1B%3E
>1173 bp	ATGGAGGAACCGGGTGCTCAGTGCGCTCCACCGCCGCCCGCGGGCTCCGAGACCTGGGTT	CCTCAAGCCAACTTATCCTCTGCTCCCTCCCAAAACTGCAGCGCCAAGGACTACATTTAC	CAGGACTCCATCTCCCTACCCTGGAAAGTACTGCTGGTTATGCTATTGGCGCTCATCACC	TTGGCCACCACGCTCTCCAATGCCTTTGTGATTGCCACAGTGTACCGGACCCGGAAACTG	CACACCCCGGCTAACTACCTGATCGCCTCTCTGGCGGTCACCGACCTGCTTGTGTCCATC	CTGGTGATGCCCATCAGCACCATGTACACTGTCACCGGCCGCTGGACACTGGGCCAGGTG	GTCTGTGACTTCTGGCTGTCGTCGGACATCACTTGTTGCACTGCCTCCATCCTGCACCTC	TGTGTCATCGCCCTGGACCGCTACTGGGCCATCACGGACGCCGTGGAGTACTCAGCTAAA	AGGACTCCCAAGAGGGCGGCGGTCATGATCGCGCTGGTGTGGGTCTTCTCCATCTCTATC	TCGCTGCCGCCCTTCTTCTGGCGTCAGGCTAAGGCCGAAGAGGAGGTGTCGGAATGCGTG	GTGAACACCGACCACATCCTCTACACGGTCTACTCCACGGTGGGTGCTTTCTACTTCCCC	ACCCTGCTCCTCATCGCCCTCTATGGCCGCATCTACGTAGAAGCCCGCTCCCGGATTTTG	AAACAGACGCCCAACAGGACCGGCAAGCGCTTGACCCGAGCCCAGCTGATAACCGACTCC	CCCGGGTCCACGTCCTCGGTCACCTCTATTAACTCGCGGGTTCCCGACGTGCCCAGCGAA	TCCGGATCTCCTGTGTATGTGAACCAAGTCAAAGTGCGAGTCTCCGACGCCCTGCTGGAA	AAGAAGAAACTCATGGCCGCTAGGGAGCGCAAAGCCACCAAGACCCTAGGGATCATTTTG	GGAGCCTTTATTGTGTGTTGGCTACCCTTCTTCATCATCTCCCTAGTGATGCCTATCTGC	AAAGATGCCTGCTGGTTCCACCTAGCCATCTTTGACTTCTTCACATGGCTGGGCTATCTC	AACTCCCTCATCAACCCCATAATCTATACCATGTCCAATGAGGACTTTAAACAAGCATTC	CATAAACTGATACGTTTTAAGTGCACAAGTTGA
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10727715
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11198050
87-109
316-340
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12010764
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10824628
http://www.genenames.org/data/hgnc_data.php?hgnc_id=5287
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D5287%3E
Serotonin 1D beta receptor
http://bio2rdf.org/uniprot:P28222
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP28222%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9650800
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/14725972
5-HT-1B
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/15056946
50-73
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7802650
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10454495
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10455274
120-145
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10193663
>5-hydroxytryptamine 1B receptor	MEEPGAQCAPPPPAGSETWVPQANLSSAPSQNCSAKDYIYQDSISLPWKVLLVMLLALIT	LATTLSNAFVIATVYRTRKLHTPANYLIASLAVTDLLVSILVMPISTMYTVTGRWTLGQV	VCDFWLSSDITCCTASILHLCVIALDRYWAITDAVEYSAKRTPKRAAVMIALVWVFSISI	SLPPFFWRQAKAEEEVSECVVNTDHILYTVYSTVGAFYFPTLLLIALYGRIYVEARSRIL	KQTPNRTGKRLTRAQLITDSPGSTSSVTSINSRVPDVPSESGSPVYVNQVKVRVSDALLE	KKKLMAARERKATKTLGIILGAFIVCWLPFFIISLVMPICKDACWFHLAIFDFFTWLGYL	NSLINPIIYTMSNEDFKQAFHKLIRFKCTS
http://symbol.bio2rdf.org/symbol:HTR1B
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AHTR1B%3E
6q13
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8218242
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1348246
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/14574404
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11015308
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/14728705
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1315531
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11069595
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2512511
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7871045
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11134654
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/15096229
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11834247
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1610347
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2664084
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11513839
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12384251
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7881730
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10225363
This is one of the several different receptors for 5- hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that inhibit adenylate cyclase activity
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10884562
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9760032
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1351684
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1559993
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/15224175
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1660351
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10513577
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=D10995
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DD10995%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12269863
RDF Description of 5-hydroxytryptamine 1B receptor
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00669
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00571
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00696
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00952
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01191
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00960
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00998
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00216
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00320
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00315
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00953
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Lawrence_George_A_(George_Alfred)_1827-1876
_:header14685669641335206555022
RDF Description of Lawrence, George A. (George Alfred), 1827-1876
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Lawrence_George_A_(George_Alfred)_1827-1876
Lawrence, George A. (George Alfred), 1827-1876
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19121
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17084
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19705
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00375
_:header12659812091335206555470
Mon, 23 Apr 2012 18:35:50 GMT
RDF Description of Colestipol
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00375
ClCC1CO1.NCCNCCNCCNCCN
http://dbpedia.org/page/Colestipol
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FColestipol%3E
http://205.193.93.51/dpdonline/searchRequest.do?din=00642975
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D00642975%3E
Not applicable (not hydrolyzed by digestive enzymes and not absorbed).
Colestipol
http://www.drugbank.ca/drugs/DB00375
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00375%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/granuleOral
24:06.04
http://dbpedia.org/resource/Colestipol
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FColestipol%3E
Highly crosslinked and insoluble basic anion exchange resin used as anticholesteremic. It may also may reduce triglyceride levels. [PubChem]
Colestipol is a non-absorbed, lipid-lowering polymer that binds bile acids in the intestine, impeding their reabsorption. As the bile acid pool becomes depleted, the hepatic enzyme, cholesterol 7-(alpha)-hydroxylase, is upregulated, which increases the conversion of cholesterol to bile acids. This causes an increased demand for cholesterol in the liver cells, resulting in the dual effect of increasing transcription and activity of the cholesterol biosynthetic enzyme, hydroxymethyl-glutaryl-coenzyme A (HMG-CoA) reductase, and increasing the number of hepatic low-density lipoprotein (LDL) receptors. These compensatory effects result in increased clearance of LDL cholesterol (LDL-C) from the blood, resulting in decreased serum LDL-C levels. Serum triglyceride levels may increase or remain unchanged. The end result is increased clearance of LDL-cholesterol from the blood with decreased serum LDL-cholesterol.
aprd00884
N'-(2-aminoethyl)-N-[2-(2-aminoethylamino)ethyl]ethane-1,2-diamine; 2-(chloromethyl)oxirane
Not absorbed from the gastrointestinal tract.
Cholestabyl
http://www.rxlist.com/cgi/generic/colestipol.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric%2Fcolestipol.htm%3E
Colestipolum [INN-Latin]
C10AC02
InChI=1/C8H23N5.C3H5ClO/c9-1-3-11-5-7-13-8-6-12-4-2-10;4-1-3-2-5-3/h11-13H,1-10H2;3H,1-2H2
http://bio2rdf.org/cpd:C06925
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC06925%3E
2008-08-26 20:35:40 UTC
Cholesterol is the major, and probably the sole precursor of bile acids. During normal digestion, bile acids are secreted via the bile from the liver and gall bladder into the intestines. Bile acids emulsify the fat and lipid materials present in food, thus facilitating absorption. A major portion of the bile acids secreted is reabsorbed from the intestines and returned via the portal circulation to the liver, thus completing the enterohepatic cycle. Only very small amounts of bile acids are found in normal serum. Colestipol hydrochloride binds bile acids in the intestine forming a complex that is excreted in the feces. This nonsystemic action results in a partial removal of the bile acids from the enterohepatic circulation, preventing their reabsorption. Since colestipol hydrochloride is an anion exchange resin, the chloride anions of the resin can be replaced by other anions, usually those with a greater affinity for the resin than the chloride ion.
http://data.linkedct.org/resource/intervention/16681
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F16681%3E
Oral LD<sub>50</sub> in rats is > 1000 mg/kg. Symptoms of overdose may include eye irritation, constipation, abdominal cramps, nausea, vomiting, diarrhea, and hypersensitivity. However, as colestipol is not absorbed, the risk of systemic toxicity is low.
http://129.128.185.122/drugbank2/drugs/DB00375/inserts/2265/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00375%2Finserts%2F2265%2Ffull%3E
http://129.128.185.122/drugbank2/drugs/DB00375/inserts/1266/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00375%2Finserts%2F1266%2Ffull%3E
PA449096
http://www.dbpedia.org/resource/Colestipol
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FColestipol%3E
C11H28ClN5O
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/anionExchangeResins
ClC[C@@H]1CO1.NCCNCCNCCNCCN
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/col1094.shtml
http://en.wikipedia.org/wiki/Colestipol
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FColestipol%3E
DB00375
Colestid
http://bio2rdf.org/cas:50925-79-6
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A50925-79-6%3E
http://129.128.185.122/drugbank2/drugs/DB00375/inserts/389/full
/drugs/375/safety_sheets/904
GMRWGQCZJGVHKL-UHFFFAOYAD
For use, as adjunctive therapy to diet, for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00375_DB01583
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00375_DB00390
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00375_DB00266
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00375_DB01418
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00375_DB00481
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01095_DB00375
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00375_DB00682
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00375_DB00451
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00375_DB01586
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00375_DB00279
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00390_DB00375
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00481_DB00375
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00375_DB01125
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00375_DB01095
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00451_DB00375
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00741_DB00375
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00375_DB01584
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00375_DB00741
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0740858
_:header4530171091335206556084
Mon, 23 Apr 2012 18:35:51 GMT
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0740858
http://sideeffects.embl.de/se/C0740858
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0740858%3E
Substance Abuse
C0740858
RDF Description of Substance Abuse
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0014534
_:header17314744381335206556419
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0014534
http://dbpedia.org/resource/Epididymitis
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FEpididymitis%3E
http://sideeffects.embl.de/se/C0014534
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0014534%3E
epididymitis
C0014534
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/disease/Epididymitis
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fdisease%2FEpididymitis%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4638
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/9904
RDF Description of epididymitis
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01907
_:header18855958651335206556917
RDF Description of Nicotinamide-Adenine-Dinucleotide
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/368
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4500
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4507
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4477
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/12
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2967
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4490
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2302
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1699
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1699%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/327
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2680
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2680%3E
http://www.drugbank.ca/drugs/DB01907
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01907%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4448
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4474
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/419
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4423
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/431
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F431%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3401
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2683
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4442
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4459
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4485
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/545
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F545%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2827
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2672
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2672%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4433
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4427
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4453
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2630
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3735
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/147
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3618
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2799
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/328
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4456
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4318
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4428
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/551
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F551%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2393
Nicotinamide-Adenine-Dinucleotide
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3333
NC(=O)C1=CC=C[N+](=C1)C1OC(COP([O-])(=O)OP(O)(=O)OCC2OC(C(O)C2O)N2C=NC3=C2N=CN=C3N)C(O)C1O
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/579
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4450
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4424
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2591
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2341
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2881
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4486
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4471
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4461
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2318
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4497
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4454
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2424
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2424%3E
2008-08-26 14:16:42 UTC
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2629
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F4%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4465
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3445
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3598
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2863
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2863%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2308
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2308%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4300
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4478
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3297
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4468
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3362
2.14e+00 mg/mL
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4489
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2919
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4462
1OG3
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4437
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4498
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4483
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4419
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/385
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F385%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4504
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/302
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F302%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/77
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4466
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4431
http://bio2rdf.org/kegg:D00002
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD00002%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4421
DB01907
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2701
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3316
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/251
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4434
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4480
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/599
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4508
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4501
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4491
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4510
http://bio2rdf.org/cpd:C00003
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC00003%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3487
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4438
NAD
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2770
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2365
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3250
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2434
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2350
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4495
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4505
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4449
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4475
C21H27N7O14P2
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/63
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3604
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4422
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2063
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2063%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4443
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3228
InChI=1/C21H27N7O14P2/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(32)14(30)11(41-21)6-39-44(36,37)42-43(34,35)38-5-10-13(29)15(31)20(40-10)27-3-1-2-9(4-27)18(23)33/h1-4,7-8,10-11,13-16,20-21,29-32H,5-6H2,(H5-,22,23,24,25,33,34,35,36,37)/f/h36H,22-23H2
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3615
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/217
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2350
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2350%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3328
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2336
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4446
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4472
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3736
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3350
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/166
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1378
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1378%3E
http://bio2rdf.org/cas:53-84-9
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A53-84-9%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3729
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4457
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4414
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4440
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4429
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4476
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2641
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3059
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4425
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4451
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3575
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3575%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4487
[[(2R,3R)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-2,3-dihydrofuran-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/796
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3671
http://bio2rdf.org/chebi:15846
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fchebi%3A15846%3E
expt02287
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4455
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2018
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3036
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3148
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4458
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4484
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2623
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3387
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/714
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2826
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3070
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2316
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4479
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4426
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4432
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4469
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4452
NC(=O)C1=CC=C[N+](=C1)[C@@H]1O[C@@H](CO[P@]([O-])(=O)O[P@@](O)(=O)OC[C@@H]2O[C@H]([C@H](O)[C@H]2O)N2C=NC3=C2N=CN=C3N)[C@H](O)[C@H]1O
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3081
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3468
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4488
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4463
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4343
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3672
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4509
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4499
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/919
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F919%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4470
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4460
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2507
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3678
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4435
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/444
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/652
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F652%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4496
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4481
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1286
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1286%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2538
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4351
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4444
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4464
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4502
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2424
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3367
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2762
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4439
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3501
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/597
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2910
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/350
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4506
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/517
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3177
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2831
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1289
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1289%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4436
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4482
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3726
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4418
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2329
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4430
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4447
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4473
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4467
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4420
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3545
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4441
BAWFJGJZGIEFAR-QRPVTFOWCF
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1216
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1216%3E
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/610
_:header19787634661335206557380
Mon, 23 Apr 2012 18:35:52 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/610
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01021
KCNMA1
U13913
http://pfam.sanger.ac.uk/family?acc=PF03493
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF03493%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=U13913
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DU13913%3E
179-199
Calcium-activated potassium channel subunit alpha 1
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2541731
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7993625
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/16446048
K(VCA)alpha
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12726817
301-321
MaxiK
http://bio2rdf.org/hgnc:6284
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A6284%3E
368-388
http://www.genenames.org/data/hgnc_data.php?hgnc_id=6284
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D6284%3E
http://www.uniprot.org/uniprot/Q12791
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ12791%3E
Slo homolog
KCMA1_HUMAN
240-260
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=537439
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D537439%3E
cation channel activity
Maxi K channel
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7573516
Slo-alpha
KCa1.1
>Calcium-activated potassium channel subunit alpha 1	MANGGGGGGGSSGGGGGGGGSSLRMSSNIHANHLSLDASSSSSSSSSSSSSSSSSSSSSS	VHEPKMDALIIPVTMEVPCDSRGQRMWWAFLASSMVTFFGGLFIILLWRTLKYLWTVCCH	CGGKTKEAQKINNGSSQADGTLKPVDEKEEAVAAEVGWMTSVKDWAGVMISAQTLTGRVL	VVLVFALSIGALVIYFIDSSNPIESCQNFYKDFTLQIDMAFNVFFLLYFGLRFIAANDKL	WFWLEVNSVVDFFTVPPVFVSVYLNRSWLGLRFLRALRLIQFSEILQFLNILKTSNSIKL	VNLLSIFISTWLTAAGFIHLVENSGDPWENFQNNQALTYWECVYLLMVTMSTVGYGDVYA	KTTLGRLFMVFFILGGLAMFASYVPEIIELIGNRKKYGGSYSAVSGRKHIVVCGHITLES	VSNFLKDFLHKDRDDVNVEIVFLHNISPNLELEALFKRHFTQVEFYQGSVLNPHDLARVK	IESADACLILANKYCADPDAEDASNIMRVISIKNYHPKIRIITQMLQYHNKAHLLNIPSW	NWKEGDDAICLAELKLGFIAQSCLAQGLSTMLANLFSMRSFIKIEEDTWQKYYLEGVSNE	MYTEYLSSAFVGLSFPTVCELCFVKLKLLMIAIEYKSANRESRILINPGNHLKIQEGTLG	FFIASDAKEVKRAFFYCKACHDDITDPKRIKKCGCKRPKMSIYKRMRRACCFDCGRSERD	CSCMSGRVRGNVDTLERAFPLSSVSVNDCSTSFRAFEDEQPSTLSPKKKQRNGGMRNSPN	TSPKLMRHDPLLIPGNDQIDNMDSNVKKYDSTGMFHWCAPKEIEKVILTRSEAAMTVLSG	HVVVCIFGDVSSALIGLRNLVMPLRASNFHYHELKHIVFVGSIEYLKREWETLHNFPKVS	ILPGTPLSRADLRAVNINLCDMCVILSANQNNIDDTSLQDKECILASLNIKSMQFDDSIG	VLQANSQGFTPPGMDRSSPDNSPVHGMLRQPSITTGVNIPIITELVNDTNVQFLDQDDDD	DPDTELYLTQPFACGTAFAVSVLDSLMSATYFNDNILTLIRTLVTGGATPELEALIAEEN	ALRGGYSTPQTLANRDRCRVAQLALLDGPFADLGDGGCYGDLFCKALKTYNMLCFGIYRL	RDAHLSTPSQCTKRYVITNPPYEFELVPTDLIFCLMQFDHNAGQSRASLSHSSHSSQSSS	KKSSSVHSIPSTANRQNRPKSRESRDKQKYVQEERL
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1446749
http://bio2rdf.org/uniprot:Q12791
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ12791%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8962157
Slo1
>3639 bp	ATGAGTAGCAATATCCACGCGAACCATCTCAGCCTAGACGCGTCCTCCTCCTCCTCCTCC	TCCTCTTCCTCTTCTTCTTCTTCCTCCTCCTCTTCCTCCTCGTCCTCGGTCCACGAGCCC	AAGATGGATGCGCTCATCATCCCGGTGACCATGGAGGTGCCGTGCGACAGCCGGGGCCAA	CGCATGTGGTGGGCTTTCCTGGCCTCCTCCATGGTGACTTTCTTCGGGGGCCTCTTCATC	ATCTTGCTCTGGCGGACGCTCAAGTACCTGTGGACCGTGTGCTGCCACTGCGGGGGCAAG	ACGAAGGAGGCCCAGAAGATTAACAATGGCTCAAGCCAGGCGGATGGCACTCTCAAACCA	GTGGATGAAAAAGAGGAGGCAGTGGCCGCCGAGGTCGGCTGGATGACCTCCGTGAAGGAC	TGGGCGGGGGTGATGATATCCGCCCAGACACTGACTGGCAGAGTCCTGGTTGTCTTAGTC	TTTGCTCTCAGCATCGGTGCACTTGTAATATACTTCATAGATTCATCAAACCCAATAGAA	TCCTGCCAGAATTTCTACAAAGATTTCACATTACAGATCGACATGGCTTTCAACGTGTTC	TTCCTTCTCTACTTCGGCTTGCGGTTTATTGCAGCCAACGATAAATTGTGGTTCTGGCTG	GAAGTGAACTCTGTAGTGGATTTCTTCACGGTGCCCCCCGTGTTTGTGTCTGTGTACTTA	AACAGAAGTTGGCTTGGTTTGAGATTTTTAAGAGCTCTGAGACTGATACAGTTTTCAGAA	ATTTTGCAGTTTCTGAATATTCTTAAAACAAGTAATTCCATCAAGCTGGTGAATCTGCTC	TCCATATTTATCAGCACGTGGCTGACTGCAGCCGGGTTCATCCATTTGGTGGAGAATTCA	GGGGACCCATGGGAAAATTTCCAAAACAACCAGGCTCTCACCTACTGGGAATGTGTCTAT	TTACTCATGGTCACAATGTCCACCGTTGGTTATGGGGATGTTTATGCAAAAACCACACTT	GGGCGCCTCTTCATGGTCTTCTTCATCCTCGGGGGACTGGCCATGTTTGCCAGCTACGTC	CCTGAAATCATAGAGTTAATAGGAAACCGCAAGAAATACGGGGGCTCCTATAGTGCGGTT	AGTGGAAGAAAGCACATTGTGGTCTGCGGACACATCACTCTGGAGAGTGTTTCCAACTTC	CTGAAGGACTTTCTGCACAAGGACCGGGATGACGTCAATGTGGAGATCGTTTTTCTTCAC	AACATCTCCCCCAACCTGGAGCTTGAAGCTCTGTTCAAACGACATTTTACTCAGGTGGAA	TTTTATCAGGGTTCCGTCCTCAATCCACATGATCTTGCAAGAGTCAAGATAGAGTCAGCA	GATGCATGCCTGATCCTTGCCAACAAGTACTGCGCTGACCCGGATGCGGAGGATGCCTCG	AATATCATGAGAGTAATCTCCATAAAGAACTACCATCCGAAGATAAGAATCATCACTCAA	ATGCTGCAGTATCACAACAAGGCCCATCTGCTAAACATCCCGAGCTGGAATTGGAAAGAA	GGTGATGACGCAATCTGCCTCGCAGAGTTGAAGTTGGGCTTCATAGCCCAGAGCTGCCTG	GCTCAAGGCCTCTCCACCATGCTTGCCAACCTCTTCTCCATGAGGTCATTCATAAAGATT	GAGGAAGACACATGGCAGAAATACTACTTGGAAGGAGTCTCAAATGAAATGTACACAGAA	TATCTCTCCAGTGCCTTCGTGGGTCTGTCCTTCCCTACTGTTTGTGAGCTGTGTTTTGTG	AAGCTCAAGCTCCTAATGATAGCCATTGAGTACAAGTCTGCCAACCGAGAGAGCCGTATA	TTAATTAATCCTGGAAACCATCTTAAGATCCAAGAAGGTACTTTAGGATTTTTCATCGCA	AGTGATGCCAAAGAAGTTAAAAGGGCATTTTTTTACTGCAAGGCCTGTCATGATGACATC	ACAGATCCCAAAAGAATAAAAAAATGTGGCTGCAAACGGCCCAAGATGTCCATCTACAAG	AGAATGAGACGGGCATGTTGTTTTGATTGCGGACGTTCTGAGCGTGACTGCTCATGCATG	TCAGGCCGTGTGCGTGGTAACGTGGACACCCTTGAGAGAGCCTTCCCACTTTCTTCTGTC	TCTGTTAATGATTGCTCCACCAGTTTCCGTGCCTTTGAAGATGAGCAGCCGTCAACACTA	TCACCAAAAAAAAAGCAACGGAATGGAGGCATGCGGAACTCACCCAACACCTCGCCTAAG	CTGATGAGGCATGACCCCTTGTTAATTCCTGGCAATGATCAGATTGACAACATGGACTCC	AATGTGAAGAAGTACGACTCTACTGGGATGTTTCACTGGTGTGCACCCAAGGAGATAGAG	AAAGTCATCCTGACTCGAAGTGAAGCTGCCATGACCGTCCTGAGTGGCCATGTCGTGGTC	TGCATCTTTGGCGACGTCAGCTCAGCCCTGATCGGCCTCCGGAACCTGGTGATGCCGCTC	CGTGCCAGCAACTTTCATTACCATGAGCTCAAGCACATTGTGTTTGTGGGCTCTATTGAG	TACCTCAAGCGGGAATGGGAGACGCTTCATAACTTCCCCAAAGTGTCCATATTGCCTGGT	ACGCCATTAAGTCGGGCTGATTTAAGGGCTGTCAACATCAACCTCTGTGACATGTGCGTT	ATCCTGTCAGCCAATCAGAATAATATTGATGATACTTCGCTGCAGGACAAGGAATGCATC	TTGGCGTCACTCAACATCAAATCTATGCAGTTTGATGACAGCATCGGAGTCTTGCAGGCT	AATTCCCAAGGGTTCACACCTCCAGGAATGGATAGATCCTCTCCAGATAACAGCCCAGTG	CACGGGATGTTACGTCAACCATCCATCACAACTGGGGTCAACATCCCCATCATCACTGAA	CTAGTGAACGATACTAATGTTCAGTTTTTGGACCAAGACGATGATGATGACCCTGATACA	GAACTGTACCTCACGCAGCCCTTTGCCTGTGGGACAGCATTTGCCGTCAGTGTCCTGGAC	TCACTCATGAGCGCGACGTACTTCAATGACAATATCCTCACCCTGATACGGACCCTGGTG	ACCGGAGGAGCCACGCCGGAGCTGGAGGCTCTGATTGCTGAGGAAAACGCCCTTAGAGGT	GGCTACAGCACCCCGCAGACACTGGCCAATAGGGACCGCTGCCGCGTGGCCCAGTTAGCT	CTGCTCGATGGGCCATTTGCGGACTTAGGGGATGGTGGTTGTTATGGTGATCTGTTCTGC	AAAGCTCTGAAAACATATAATATGCTTTGTTTTGGAATTTACCGGCTGAGAGATGCTCAC	CTCAGCACCCCCAGTCAGTGCACAAAGAGGTATGTCATCACCAACCCGCCCTATGAGTTT	GAGCTCGTGCCGACGGACCTGATCTTCTGCTTAATGCAGTTTGACCACAATGCCGGCCAG	TCCCGGGCCAGCCTGTCCCATTCCTCCCACTCGTCGCAGTCCTCCAGCAAGAAGAGCTCC	TCTGTTCACTCCATCCCATCCACAGCAAACCGACAGAACCGGCCCAAGTCCAGGGAGTCC	CGGGACAAACAGAAGTACGTGCAGGAAGAGCGGCTTTGA
265-285
10q22.3
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10097176
Slowpoke homolog
hSlo
calcium-activated potassium channel activity
http://bio2rdf.org/pfam:PF03493
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF03493%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7877450
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7987297
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10692449
potassium channel activity
http://symbol.bio2rdf.org/symbol:KCNMA1
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AKCNMA1%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10794813
Potassium channel activated by both membrane depolarization or increase in cytosolic Ca(2+) that mediates export of K(+). It is also activated by the concentration of cytosolic Mg(2+). Its activation dampens the excitatory events that elevate the cytosolic Ca(2+) concentration and/or depolarize the cell membrane. It therefore contributes to repolarization of the membrane potential. Plays a key role in controlling excitability in a number of systems, such as regulation of the contraction of smooth muscle, the tuning of hair cells in the cochlea, regulation of transmitter release, and innate immunity. In smooth muscles, its activation by high level of Ca(2+), caused by ryanodine receptors in the sarcoplasmic reticulum, regulates the membrane potential. In cochlea cells, its number and kinetic properties partly determine the characteristic frequency of each hair cell and thereby helps to establish a tonotopic map. Kinetics of KCNMA1 channels are determined by alternative splicing, phosphorylation status and its combination with modulating beta subunits. Highly sensitive to both iberiotoxin (IbTx) and charybdotoxin (CTX)
Calcium-activated potassium channel, subfamily M subunit alpha 1
215-235
87-107
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8821792
BK channel
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9391153
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/14766795
BKCA alpha
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00232
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01003
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01119
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00562
RDF Description of Calcium-activated potassium channel subunit alpha 1
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00606
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00436
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00228
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00880
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01325
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00999
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00774
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Lear_Edward_1812-1888
_:header5672401281335206557768
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Lear_Edward_1812-1888
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13650
Lear, Edward, 1812-1888
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13648
RDF Description of Lear, Edward, 1812-1888
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext20113
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13649
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13647
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext982
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13646
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/1245
_:header11111465041335206558182
Mon, 23 Apr 2012 18:35:53 GMT
RDF Description of Paroxysmal nocturnal hemoglobinuria
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1245
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PIGA
http://data.linkedct.org/resource/condition/9710
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fcondition%2F9710%3E
Paroxysmal nocturnal hemoglobinuria
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3551
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Simms_William_Gilmore_1806-1870
_:header968544591335206558603
RDF Description of Simms, William Gilmore, 1806-1870
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Simms_William_Gilmore_1806-1870
Simms, William Gilmore, 1806-1870
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext843
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6059
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6012
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext16303
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/1374
_:header7556942241335206559089
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/1374
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01136
http://www.uniprot.org/uniprot/P16860
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP16860%3E
extracellular region
1p36.2
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=179515
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D179515%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2136732
http://bio2rdf.org/uniprot:P16860
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP16860%3E
>Natriuretic peptides B precursor [Contains: Gamma-brain natriuretic peptide; Brain natriuretic peptide 32	MDPQTAPSRALLLLLFLHLAFLGGRSHPLGSPGSASDLETSGLQEQRNHLQGKLSELQVE	QTSLEPLQESPRPTGVWKSREVATEGIRGHRKMVLYTLRAPRSPKMVQGSGCFGRKMDRI	SSSSGLGCKVLRRH
http://bio2rdf.org/pfam:PF00212
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00212%3E
Natriuretic peptides B precursor
NPPB
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/14692707
ANFB_HUMAN
http://pfam.sanger.ac.uk/family?acc=PF00212
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00212%3E
Natriuretic peptides B
1-26
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2522777
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17207730
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/15325927
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=M31776
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DM31776%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2597152
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11206715
Acts as a cardiac hormone with a variety of biological actions including natriuresis, diuresis, vasorelaxation, and inhibition of renin and aldosterone secretion. It is thought to play a key role in cardiovascular homeostasis. Helps restore the body's salt and water balance. Improves heart function
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2138890
hormone activity
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/15864245
http://www.genenames.org/data/hgnc_data.php?hgnc_id=7940
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D7940%3E
M31776
http://symbol.bio2rdf.org/symbol:NPPB
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ANPPB%3E
>405 bp	ATGGATCCCCAGACAGCACCTTCCCGGGCGCTCCTGCTCCTGCTCTTCTTGCATCTGGCT	TTCCTGGGAGGTCGTTCCCACCCGCTGGGCAGCCCCGGTTCAGCCTCGGACTTGGAAACG	TCCGGGTTACAGGAGCAGCGCAACCATTTGCAGGGCAAACTGTCGGAGCTGCAGGTGGAG	CAGACATCCCTGGAGCCCCTCCAGGAGAGCCCCCGTCCCACAGGTGTCTGGAAGTCCCGG	GAGGTAGCCACCGAGGGCATCCGTGGGCACCGCAAAATGGTCCTCTACACCCTGCGGGCA	CCACGAAGCCCCAAGATGGTGCAAGGGTCTGGCTGCTTTGGGAGGAAGATGGACCGGATC	AGCTCCTCCAGTGGCCTGGGCTGCAAAGTGCTGAGGCGGCATTAA
Involved in hormone activity
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11401111
http://bio2rdf.org/hgnc:7940
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A7940%3E
RDF Description of Natriuretic peptides B
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB04076
_:header4200490691335206559422
Mon, 23 Apr 2012 18:35:54 GMT
RDF Description of Hypoxanthine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04076
A purine and a reaction intermediate in the metabolism of adenosine and in the formation of nucleic acids by the salvage pathway. [PubChem]
Hypoxanthine
expt01767
3.94e+00 mg/mL
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2816
2008-08-26 15:40:57 UTC
C5H3N4O
-2.29 [ADME Research, USCD]
http://www.drugbank.ca/drugs/DB04076
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB04076%3E
http://bio2rdf.org/chebi:17368
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fchebi%3A17368%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3397
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3397%3E
http://bio2rdf.org/cpd:C00262
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC00262%3E
O=C1NC=Nc2ncnc12
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/850
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F850%3E
1A9T
DB04076
HPA
3,7-dihydropurin-6-one
http://bio2rdf.org/cas:68-94-0
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A68-94-0%3E
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/APOA5
_:header9117080331335206559837
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/APOA5
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2712
http://symbol.bio2rdf.org/symbol:APOA5
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AAPOA5%3E
APOA5
http://www.dbpedia.org/resource/APOA5
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FAPOA5%3E
RDF Description of APOA5
http://www4.wiwiss.fu-berlin.de/dblp/data/person/213108
_:header8278572751335206560264
Mon, 23 Apr 2012 18:35:55 GMT
http://www4.wiwiss.fu-berlin.de/dblp/resource/person/213108
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/homepages/h/JamesJHorning
Jim Horning
RDF Description of Jim Horning
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/cacm/SimonsH05
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/cacm/DenningHPW05
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0848558
_:header10694680971335206560724
RDF Description of hypospadias
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0848558
http://sideeffects.embl.de/se/C0848558
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0848558%3E
hypospadias
C0848558
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB03205
_:header6769810921335206561081
Mon, 23 Apr 2012 18:35:56 GMT
RDF Description of Pyrroloquinoline Quinone
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03205
expt02652
http://bio2rdf.org/cas:72909-34-3
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A72909-34-3%3E
1KB0
Pyrroloquinoline Quinone
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3153
PQQ
4,5-dioxo-1H-pyrrolo[5,4-f]quinoline-2,7,9-tricarboxylic acid
http://bio2rdf.org/cpd:C00113
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC00113%3E
OC(=O)C1=CC(C(O)=O)=C2C(=N1)C(=O)C(=O)c1cc(nc21)C(O)=O
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3405
DB03205
http://bio2rdf.org/chebi:18315
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fchebi%3A18315%3E
C14H5N2O8
2008-08-26 15:02:48 UTC
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/5164
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/5165
A pyrrolo-quinoline having two adjacent keto-groups at the 4 and 5 positions and three acidic carboxyl groups. It is a coenzyme of some DEHYDROGENASES. [PubChem]
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4956
http://www.drugbank.ca/drugs/DB03205
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB03205%3E
9.66e-02 mg/mL
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Hodgson_William_Hope_1877-1918
_:header5248612081335206561505
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Hodgson_William_Hope_1877-1918
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext10002
Hodgson, William Hope, 1877-1918
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext10966
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext10662
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext10542
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext10832
RDF Description of Hodgson, William Hope, 1877-1918
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Ian_Janis_1951-
_:header12211558031335206561889
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Ian_Janis_1951-
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3002
Ian, Janis, 1951- 
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3001
RDF Description of Ian, Janis, 1951- 
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/GLC1A
_:header8081617651335206562301
Mon, 23 Apr 2012 18:35:57 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/GLC1A
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2458
http://symbol.bio2rdf.org/symbol:GLC1A
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AGLC1A%3E
GLC1A
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2463
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2459
RDF Description of GLC1A
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00686
_:header21046337241335206562705
RDF Description of Pentosan Polysulfate
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00686
FCCNSUIJIOOXEZ-OEMNPTGHDX
http://bio2rdf.org/cas:37300-21-3
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A37300-21-3%3E
A sulfated pentosyl polysaccharide with heparin-like properties. [PubChem]
For the relief of bladder pain or discomfort associated with interstitial cystitis.
Pentosan polysulfate sodium is a low molecular weight heparin-like compound. It has anticoagulant and fibrinolytic effects.
InChI=1/C10H18O21S4/c11-3-1-26-10(8(31-35(22,23)24)5(3)28-32(13,14)15)27-4-2-25-9(12)7(30-34(19,20)21)6(4)29-33(16,17)18/h3-12H,1-2H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)/t3-,4-,5+,6+,7-,8-,9-,10+/m1/s1/f/h13,16,19,22H
[(2R,3R,4S,5R)-2-hydroxy-5-[(2S,3R,4S,5R)-5-hydroxy-3,4-disulfooxyoxan-2-yl]oxy-3-sulfooxyoxan-4-yl] hydrogen sulfate
http://129.128.185.122/drugbank2/drugs/DB00686/inserts/2453/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00686%2Finserts%2F2453%2Ffull%3E
4.8 hours
C10H18O21S4
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/anticoagulants
Slow
Pentosan Polysulfate
Take on an empty stomach, 1 hour before or 2 hours after meals.
Pentosan polysulfate is a polymer of xylose hydrogen sulfate and contains two sulfate groups per carbohydrate monomer. It binds Fibroblast growth factors (FGFs) as well as other heparin-binding growth factors. It has been shown to interact also with the heparin-binding site of FGFR-1. It inhibits the growth of SW13 adrenocortical cells transfected with FGF-4 and tumorigenicity of MCF-7 breast carcinoma cells transfected with FGF-1 or FGF-4.
2008-08-26 17:07:39 UTC
http://129.128.185.122/drugbank2/drugs/DB00686/inserts/519/full
http://205.193.93.51/dpdonline/searchRequest.do?din=02082101
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02082101%3E
O[C@@H]1CO[C@@H](O[C@@H]2CO[C@@H](O)[C@H](OS(O)(=O)=O)[C@H]2OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O
OC1COC(OC2COC(O)C(OS(O)(=O)=O)C2OS(O)(=O)=O)C(OS(O)(=O)=O)C1OS(O)(=O)=O
http://www.drugbank.ca/drugs/DB00686
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00686%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/760
3.49e+00 mg/mL
http://www.rxlist.com/cgi/generic2/pento.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric2%2Fpento.htm%3E
Elmiron
DB00686
C05BA04
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/361
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/1525
http://129.128.185.122/drugbank2/drugs/DB00686/inserts/1455/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00686%2Finserts%2F1455%2Ffull%3E
aprd01175
2004-08-01	/drugs/686/fda_labels/1090
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Cooper_Courtney_Ryley_1886-1940
_:header5696004221335206563080
Mon, 23 Apr 2012 18:35:58 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Cooper_Courtney_Ryley_1886-1940
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext20155
Cooper, Courtney Ryley, 1886-1940
RDF Description of Cooper, Courtney Ryley, 1886-1940
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext20104
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/773
_:header162825891335206563474
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/773
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3195
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/ZFHX1B
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseaseClass/Developmental
Mowat-Wilson syndrome
http://www.dbpedia.org/resource/Mowat-Wilson_syndrome
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FMowat-Wilson_syndrome%3E
RDF Description of Mowat-Wilson syndrome
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00602
_:header15753780481335206563931
RDF Description of Ivermectin
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00602
http://129.128.185.122/drugbank2/drugs/DB00602/inserts/798/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00602%2Finserts%2F798%2Ffull%3E
http://129.128.185.122/drugbank2/drugs/DB00602/inserts/66/full
Parasitic nematodes and other roundworms
Ivermectin is a semisynthetic, anthelminitic agent. It is an avermectin which a group of pentacyclic sixteen-membered lactone (i.e. a macrocyclic lactone disaccharide) derived from the soil bacterium Streptomyces avermitilis. Avermectins are potent anti-parasitic agents. Ivermectin is the most common avermectin. It is a broad spectrum antiparasitic drug for oral administration. It is sometimes used to treat human onchocerciasis (river blindness). It is the mixture of 22,23-dihydro-avermectin B1a (at least 90%) and 22,23-dihydro-avermectin B1b (less than 10%).
P02CF01
LD<sub>50</sub> = 29.5 mg/kg (Mouse, oral). LD<sub>50</sub> = 10 mg/kg (Rat, oral). Adverse effects include muscle or joint pain, dizziness, fever, headache, skin rash, fast heartbeat.
Ivermectin
http://www.drugbank.ca/drugs/DB00602
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00602%3E
Ivermectin B1
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/348
16 hours (also reported at 22-28 hours)
22,23-Dihydroxy-avermectin B
Ivermectin binds selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate muscle and nerve cells of the microfilaria. This binding causes an increase in the permeability of the cell membrane to chloride ions and results in hyperpolarization of the cell, leading to paralysis and death of the parasite. Ivermectin also is believed to act as an agonist of the neurotransmitter gamma-aminobutyric acid (GABA), thereby disrupting GABA-mediated central nervous system (CNS) neurosynaptic transmission. Ivermectin may also impair normal intrauterine development of O. volvulus microfilariae and may inhibit their release from the uteri of gravid female worms.
Stromectol
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/538
http://bio2rdf.org/kegg:D00804
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD00804%3E
http://bio2rdf.org/cas:70288-86-7
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A70288-86-7%3E
Moderately well absorbed. Improved absorption with high fat meal.
Primarily hepatic. Ivermectin and/or its metabolites are excreted almost exclusively in the feces over an estimated 12 days, with less than 1 % of the administered dose excreted in the urine.
aprd01058
DB00602
2008-08-26 21:14:57 UTC
5-O-demethyl-22,23-dihydro-avermectin A1a
InChI=1/C48H74O14.C47H72O14/c1-11-25(2)43-28(5)17-18-47(62-43)23-34-20-33(61-47)16-15-27(4)42(26(3)13-12-14-32-24-55-45-40(49)29(6)19-35(46(51)58-34)48(32,45)52)59-39-22-37(54-10)44(31(8)57-39)60-38-21-36(53-9)41(50)30(7)56-38;1-24(2)41-27(5)16-17-46(61-41)22-33-19-32(60-46)15-14-26(4)42(25(3)12-11-13-31-23-54-44-39(48)28(6)18-34(45(50)57-33)47(31,44)51)58-38-21-36(53-10)43(30(8)56-38)59-37-20-35(52-9)40(49)29(7)55-37/h12-15,19,25-26,28,30-31,33-45,49-50,52H,11,16-18,20-24H2,1-10H3;11-14,18,24-25,27,29-30,32-44,48-49,51H,15-17,19-23H2,1-10H3/b13-12+,27-15+,32-14+;12-11+,26-14+,31-13+/t25?,26-,28-,30-,31-,33+,34-,35-,36-,37-,38-,39-,40+,41-,42-,43+,44-,45+,47+,48+;25-,27-,29-,30-,32+,33-,34-,35-,36-,37-,38-,39+,40-,41+,42-,43-,44+,46+,47+/m00/s1
Mectizan
http://www.dbpedia.org/resource/Ivermectin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FIvermectin%3E
For the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite <i>Strongyloides stercoralis</i>. Also for the treatment of onchocerciasis (river blindness) due to the nematode parasite <i>Onchocerca volvulus</i>. Can be used to treat scabies caused by <i>Sarcoptes scabiei</i>.
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1594
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F1594%3E
/drugs/602/safety_sheets/997
Ivermectin (22,23-dihydroavermectin B1a + 22,23-dihydroavermectin B1b) is a broad-spectrum anti-parasite medication, traditionally used against worms (except tapeworms), but more recently found to be effective against most mites and some lice too. It is mainly used in humans in the treatment of onchocerciasis, but is also effective against other worm infestations (such as strongyloidiasis, ascariasis, trichuriasis and enterobiasis).
CO[C@H]1C[C@@H](O[C@@H](C)[C@@H]1O)O[C@H]1[C@H](C)O[C@H](C[C@@H]1OC)O[C@H]1[C@@H](C)C=CC=C2/CO[C@@H]3[C@H](O)C(C)=C[C@@H](C(=O)O[C@H]4C[C@@H](CC=C1/C)O[C@@]1(CC[C@H](C)[C@H](O1)C(C)C)C4)[C@]23O.CC[C@@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](CC=C(C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)C=CC=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/anthelmintics
PA450133
http://www.rxlist.com/cgi/generic3/ivermectin.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric3%2Fivermectin.htm%3E
Ivermectin-luminol
http://205.193.93.51/dpdonline/searchRequest.do?din=02248882
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02248882%3E
COC1CC(OC(C)C1O)OC1C(C)OC(CC1OC)OC1C(C)C=CC=C2COC3C(O)C(C)=CC(C(=O)OC4CC(CC=C1C)OC1(CCC(C)C(O1)C(C)C)C4)C23O.CCC(C)C1OC2(CCC1C)CC1CC(CC=C(C)C(OC3CC(OC)C(OC4CC(OC)C(O)C(C)O4)C(C)O3)C(C)C=CC=C3COC4C(O)C(C)=CC(C(=O)O1)C34O)O2
155 oC
Heel 170 Tab (Calcium Iodide + Fucus Vesiculosus + Ivermectin B1b + Silicon Dioxide)
SPBDXSGPUHCETR-MVGRHBATBN
93%
http://en.wikipedia.org/wiki/Ivermectin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FIvermectin%3E
22,23-Dihyroavermectin B1
http://dbpedia.org/resource/Ivermectin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FIvermectin%3E
http://dbpedia.org/page/Ivermectin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FIvermectin%3E
2003-01-01	/drugs/602/fda_labels/489
http://data.linkedct.org/resource/intervention/43480
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F43480%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/antinematodalAgents
http://data.linkedct.org/resource/intervention/41711
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F41711%3E
C95H146O28
http://bio2rdf.org/cpd:C07970
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC07970%3E
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/3219
_:header12149585841335206564549
Mon, 23 Apr 2012 18:35:59 GMT
RDF Description of Emadine
Emadine
EMADINE
CID0000003219
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01084
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01084%3E
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000003219
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000003219%3E
http://sideeffects.embl.de/drugs/3219
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F3219%3E
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000003219&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000003219%26input_query_species%3D9606%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2313
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2313%3E
emedastine
http://www.fda.gov/cder/foi/label/2003/20706slr011_emadine_lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2003%2F20706slr011_emadine_lbl.pdf%3E
http://dbpedia.org/resource/Emedastine
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FEmedastine%3E
http://www.fda.gov/medwatch/SAFETY/2003/03May_PI/Emadine_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2003%2F03May_PI%2FEmadine_PI.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/2092
_:header9797281041335206565462
Mon, 23 Apr 2012 18:36:00 GMT
RDF Description of Uroxatral
http://www.fda.gov/medwatch/SAFETY/2007/Mar_PI/Uroxatral_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2007%2FMar_PI%2FUroxatral_PI.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0149746
Uroxatral
http://www.fda.gov/cder/foi/label/2006/021287s005lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2006%2F021287s005lbl.pdf%3E
ALFUZOSIN HYDROCHLORIDE
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=mCFmDrfZMSM=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DmCFmDrfZMSM%3D%3E
UROXATRAL
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3799
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3799%3E
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000002092
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000002092%3E
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000002092&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000002092%26input_query_species%3D9606%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0023895
http://www.fda.gov/cder/foi/label/2007/021287s008lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2007%2F021287s008lbl.pdf%3E
http://www.fda.gov/medwatch/SAFETY/2006/Mar+PIs/Uroxatral_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2006%2FMar+PIs%2FUroxatral_PI.pdf%3E
http://www.fda.gov/cder/foi/label/2008/021287s011lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2008%2F021287s011lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00346
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00346%3E
http://dbpedia.org/resource/Alfuzosin
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FAlfuzosin%3E
http://www.fda.gov/cder/foi/label/2006/021287s007lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2006%2F021287s007lbl.pdf%3E
http://www.fda.gov/medwatch/SAFETY/2008/May_PI/Uroxatral_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2008%2FMay_PI%2FUroxatral_PI.pdf%3E
http://sideeffects.embl.de/drugs/2092
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F2092%3E
http://www.fda.gov/cder/foi/label/2003/21287_uroxatral_lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2003%2F21287_uroxatral_lbl.pdf%3E
alfuzosin
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=78hXvj5uD54=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3D78hXvj5uD54%3D%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0005001
CID0000002092
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/5205
_:header7757533311335206566436
Mon, 23 Apr 2012 18:36:01 GMT
RDF Description of Pyridoxamine 5'-phosphate oxidase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/5205
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7896706
EC 1.4.3.5
PDX3_YEAST
>Pyridoxamine 5'-phosphate oxidase	MTKQAEETQKPIIFAPETYQYDKFTLNEKQLTDDPIDLFTKWFNEAKEDPRETLPEAITF	SSAELPSGRVSSRILLFKELDHRGFTIYSNWGTSRKAHDIATNPNAAIVFFWKDLQRQVR	VEGITEHVNRETSERYFKTRPRGSKIGAWASRQSDVIKNREELDELTQKNTERFKDAEDI	PCPDYWGGLRIVPLEIEFWQGRPSRLHDRFVYRRKTENDPWKVVRLAP
X76078
FMN binding
http://bio2rdf.org/pdb:1CI0
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1CI0%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=X76078
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DX76078%3E
water-soluble vitamin metabolism
http://www.uniprot.org/uniprot/P38075
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP38075%3E
http://bio2rdf.org/pfam:PF01243
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF01243%3E
oxidoreductase activity, acting on the CH-NH2 group of donors
oxidoreductase activity, acting on the CH-NH2 group of donors, oxygen as acceptor
Oxidizes PNP and PMP into pyridoxal 5'-phosphate (PLP)
http://pfam.sanger.ac.uk/family?acc=PF01243
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF01243%3E
PNP/PMP oxidase
Pyridoxamine 5'-phosphate oxidase
vitamin B6 metabolism
PDX3
vitamin metabolism
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8091864
PNPOx
pyridoxine biosynthesis
http://bio2rdf.org/uniprot:P38075
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP38075%3E
>687 bp	TCATGGGGCTAGTCTAACGACTTTCCATGGATCGTTTTCTGTTTTTCTTCTGTAAACGAA	TCTATCATGCAATCTCGAGGGTCTACCTTGCCAGAACTCAATTTCCAGTGGAACGATTCT	CAAGCCACCCCAATAATCTGGACATGGGATGTCTTCAGCATCCTTGAAACGTTCGGTGTT	TTTTTGGGTCAACTCGTCTAGTTCTTCTCTGTTCTTGATAACATCCGATTGGCGGGAAGC	CCATGCACCGATCTTGGATCCACGAGGTCTCGTCTTAAAGTATCTTTCAGAAGTTTCTCT	GTTAACATGCTCTGTGATACCTTCAACTCTCACCTGCCTTTGCAGATCCTTCCAAAAGAA	TACGATTGCCGCATTCGGGTTGGTAGCAATATCATGAGCCTTTCTAGAGGTTCCCCAGTT	AGAATAAATAGTAAAACCTCTATGGTCGAGCTCCTTAAAAAGAAGAATCCTGGACGACAC	CCTCCCACTAGGTAGTTCCGCGGATGAAAAAGTAATTGCTTCTGGCAACGTTTCCCTTGG	GTCTTCCTTGGCTTCGTTGAACCATTTGGTGAAAAGATCGATTGGGTCGTCAGTAAGTTG	TTTTTCATTCAAAGTAAATTTATCATATTGATACGTCTCAGGAGCAAATATGATTGGCTT	TTGGGTCTCCTCAGCTTGTTTAGTCAT
http://www.pdb.org/pdb/explore/explore.do?structureId=1CI0
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1CI0%3E
pyridoxine metabolism
Involved in FMN binding
pyridoxamine-phosphate oxidase activity
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7813418
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03247
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/4425
_:header12792097721335206567438
Mon, 23 Apr 2012 18:36:02 GMT
nicotinamide-nucleotide adenylyltransferase activity
http://www.uniprot.org/uniprot/O26253
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FO26253%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9371463
NADM_METTH
NMN adenylyltransferase
http://bio2rdf.org/pdb:1EJ2
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1EJ2%3E
NAD(+) pyrophosphorylase
>Nicotinamide-nucleotide adenylyltransferase	MRGLLVGRMQPFHRGHLQVIKSILEEVDELIICIGSAQLSHSIRDPFTAGERVMMLTKAL	SENGIPASRYYIIPVQDIECNALWVGHIKMLTPPFDRVYSGNPLVQRLFSEDGYEVTAPP	LFYRDRYSGTEVRRRMLDDGDWRSLLPESVVEVIDEINGVERIKHLAKKEVSELGGIS
Nicotinamide-nucleotide adenylyltransferase
NAD(+) diphosphorylase
http://www.pdb.org/pdb/explore/explore.do?structureId=1EJ2
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1EJ2%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11017201
cytoplasm(bySimilarity)
http://bio2rdf.org/uniprot:O26253
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AO26253%3E
RDF Description of Nicotinamide-nucleotide adenylyltransferase
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/SLC2A1
_:header1196231511335206567646
RDF Description of SLC2A1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/SLC2A1
http://symbol.bio2rdf.org/symbol:SLC2A1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ASLC2A1%3E
SLC2A1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2481
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/456
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/NPHP5
_:header6389382161335206568060
Mon, 23 Apr 2012 18:36:03 GMT
RDF Description of NPHP5
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/NPHP5
http://symbol.bio2rdf.org/symbol:NPHP5
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ANPHP5%3E
NPHP5
http://www.dbpedia.org/resource/IQCB1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FIQCB1%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3863
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Propertius_Sextus_circa_50-16_BC
_:header12480036881335206568555
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Propertius_Sextus_circa_50-16_BC
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext237
Propertius, Sextus, circa 50-16 BC
RDF Description of Propertius, Sextus, circa 50-16 BC
http://www4.wiwiss.fu-berlin.de/factbook/data/Pakistan
_:header10826432901335206568996
https://www.cia.gov/library/publications/the-world-factbook/flags/pk-flag.gif
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Flibrary%2Fpublications%2Fthe-world-factbook%2Fflags%2Fpk-flag.gif%3E
https://www.cia.gov/library/publications/the-world-factbook/maps/pk-map.gif
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Flibrary%2Fpublications%2Fthe-world-factbook%2Fmaps%2Fpk-map.gif%3E
RDF Description of Pakistan
http://www4.wiwiss.fu-berlin.de/factbook/resource/Pakistan
UTC+5 (10 hours ahead of Washington, DC during Standard Time)
Islamabad
federal republic
15.6% of GDP
President General Pervez MUSHARRAF (since 20 June 2001)
the president is elected by an electoral college drawn from the national parliament and provincial assemblies for a five-year term; note - Musharraf was last sworn in as President in November 2002; the prime minister is selected by the National Assembly (next elections to be held in late 2007)
https://www.cia.gov/library/publications/the-world-factbook/flags/pk-lgflag.gif
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Flibrary%2Fpublications%2Fthe-world-factbook%2Fflags%2Fpk-lgflag.gif%3E
Senate results - percent of vote by party - NA; seats by party - PML 39, MMA 18, PPPP 9, MQM 6, PML/N 4, PkMAP 3, PPP/S 3, ANP 2, BNP/A 1, BNP/M 1, JWP 1, PML/F 1, independents 12; National Assembly results - percent of votes by party - NA; seats by party - PML/Q 126, PPPP 81, MMA 63, PML/N 19, MQM 17, NA 16, PML/F 5, PML/J 3, PPP/S 2, BNP/A 1, JWP 1, PAT 1, PkMAP 1, PML/Z 1, PTI 1, independents 4
Islamic Republic of Pakistan
http://www4.wiwiss.fu-berlin.de/factbook/resource/Afghanistan
slightly less than twice the size of California
bicameral Parliament or Majlis-e-Shoora consists of the Senate (100 seats; members indirectly elected by provincial assemblies and the territories representatives in the National Assembly to serve six-year terms; half of the Senates seats turn over every three years) and the National Assembly (342 seats; 272 seats filled by popular vote; 60 seats reserved for women; 10 seats reserved for non-Muslims; members serve five-year terms)
K
167146 km (includes 711 km of expressways)
green with a vertical white band (symbolizing the role of religious minorities) on the hoist side; a large white crescent and star are centered in the green field; the crescent, star, and color green are traditional symbols of Islam
Pakistani rupee (PKR)
AZIZ elected by the National Assembly on 27 August 2004
20 (5 state-run channels and 15 privately-owned satellite channels)
based on English common law with provisions to accommodate Pakistans status as an Islamic state; accepts compulsory ICJ jurisdiction, with reservations
Republic Day, 23 March
Pakistani(s)
various talks and confidence-building measures cautiously have begun to defuse tensions over Kashmir, particularly since the October 2005 earthquake in the region; Kashmir nevertheless remains the site of the worlds largest and most militarized territorial dispute with portions under the de facto administration of China (Aksai Chin), India (Jammu and Kashmir), and Pakistan (Azad Kashmir and Northern Areas); UN Military Observer Group in India and Pakistan (UNMOGIP) has maintained a small group of peacekeepers since 1949; India does not recognize Pakistans ceding historic Kashmir lands to China in 1964; India and Pakistan have maintained their 2004 cease fire in Kashmir and initiated discussions on defusing the armed stand-off in the Siachen glacier region; Pakistan protests Indias fencing the highly militarized Line of Control and construction of the Baglihar Dam on the Chenab River in Jammu and Kashmir, which is part of the larger dispute on water sharing of the Indus River and its tributaries; to defuse tensions and prepare for discussions on a maritime boundary, India and Pakistan seek technical resolution of the disputed boundary in Sir Creek estuary at the mouth of the Rann of Kutch in the Arabian Sea; Pakistani maps continue to show the Junagadh claim in Indias Gujarat State; by 2005, Pakistan, with UN assistance, repatriated 2300000 Afghan refugees leaving slightly more than a million, many of whom remain at their own choosing; Pakistan has proposed and Afghanistan protests construction of a fence and laying of mines along portions of their porous border; Pakistan has sent troops into remote tribal areas to monitor and control the border with Afghanistan and to stem terrorist or other illegal activities
flat Indus plain in east; mountains in north and northwest; Balochistan plateau in west
Cabinet appointed by the prime minister
Pakistan, an impoverished and underdeveloped country, has suffered from decades of internal political disputes, low levels of foreign investment, and a costly, ongoing confrontation with neighboring India. However, IMF-approved government policies, bolstered by generous foreign assistance and renewed access to global markets since 2001, have generated solid macroeconomic recovery the last five years. The government has made substantial macroeconomic reforms since 2000, most notably privatizing the banking sector. Poverty levels have decreased by 10% since 2001, and Islamabad has steadily raised development spending in recent years, including a 52% real increase in the budget allocation for development in FY07, a necessary step toward reversing the broad underdevelopment of its social sector. The fiscal deficit - the result of chronically low tax collection and increased spending, including reconstruction costs from the October 2005 earthquake - appears manageable for now. GDP growth, spurred by gains in the industrial and service sectors, remained in the 6-8% range in 2004-06. Inflation remains the biggest threat to the economy, jumping to more than 9% in 2005 before easing to 7.9% in 2006. The central bank is pursuing tighter monetary policy - raising interest rates in 2006 - while trying to preserve growth. Foreign exchange reserves are bolstered by steady worker remittances, but a growing current account deficit - driven by a widening trade gap as import growth outstrips export expansion - could draw down reserves and dampen GDP growth in the medium term.
pk
microwave radio relay, coaxial cable, fiber-optic cable, cellular, and satellite networks
Supreme Court (justices appointed by the president); Federal Islamic or Sharia Court
Pakistan
http://www4.wiwiss.fu-berlin.de/factbook/resource/China
3.71 children born/woman
Jamhuryat Islami Pakistan
mostly hot, dry desert; temperate in northwest; arctic in north
The separation in 1947 of British India into the Muslim state of Pakistan (with two sections West and East) and largely Hindu India was never satisfactorily resolved, and India and Pakistan fought two wars - in 1947-48 and 1965 - over the disputed Kashmir territory. A third war between these countries in 1971 - in which India capitalized on Islamabads marginalization of Bengalis in Pakistani politics - resulted in East Pakistan becoming the separate nation of Bangladesh. In response to Indian nuclear weapons testing, Pakistan conducted its own tests in 1998. The dispute over the state of Kashmir is ongoing, but discussions and confidence-building measures have led to decreased tensions since 2002.
11 (Comoros 2, North Korea 3, Malta 1, Nigeria 1, Panama 3, Saint Vincent and the Grenadines 1)
Indian Ocean
water pollution from raw sewage, industrial wastes, and agricultural runoff; limited natural fresh water resources; a majority of the population does not have access to potable water; deforestation; soil erosion; desertification
Southern Asia, bordering the Arabian Sea, between India on the east and Iran and Afghanistan on the west and China in the north
country code - 92; satellite earth stations - 3 Intelsat (1 Atlantic Ocean and 2 Indian Ocean); 3 operational international gateway exchanges (1 at Karachi and 2 at Islamabad); microwave radio relay to neighboring countries
12 April 1973; suspended 5 July 1977, restored with amendments 30 December 1985; suspended 15 October 1999, restored in stages in 2002; amended 31 December 2003
PKR
33 42 N, 73 10 E
759700000000 cu m (1 January 2005 est.)
4 provinces, 1 territory*, and 1 capital territory**; Balochistan, Federally Administered Tribal Areas*, Islamabad Capital Territory**, North-West Frontier Province, Punjab, Sindh
the Pakistani-administered portion of the disputed Jammu and Kashmir region consists of two administrative entities: Azad Kashmir and Northern Areas
http://www4.wiwiss.fu-berlin.de/factbook/resource/Iran
Senate - last held in March 2006 (next to be held in March 2009); National Assembly - last held 10 October 2002 (next to be held in 2007)
http://www4.wiwiss.fu-berlin.de/factbook/resource/India
https://www.cia.gov/cia/publications/factbook/geos/pk.html
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Fcia%2Fpublications%2Ffactbook%2Fgeos%2Fpk.html%3E
55% of GDP
AM 31, FM 68, shortwave NA
Karachi, Port Muhammad Bin Qasim
18 years of age; universal; joint electorates and reserved parliamentary seats for women and non-Muslims
the telecom infrastructure is improving dramatically with foreign and domestic investments into fixed-line and mobile networks; mobile cellular subscribership has skyrocketed, approaching 50000000 in late 2006, up from only about 300000 in 2000; fiber systems are being constructed throughout the country to aid in network growth; main line availability has risen only marginally over the same period and there are still difficulties getting main line service to rural areas.
16 years of age for voluntary military service; soldiers cannot be deployed for combat until age of 18; the Pakistani Air Force and Pakistani Navy have inducted their first female pilots and sailors
14 August 1947 (from UK)
Prime Minister Shaukat AZIZ (since 28 August 2004)
$25650000000; including capital expenditures of $NA
.pk
Pakistani
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Veblen_Oswald_1880-1960
_:header20368085351335206569325
Mon, 23 Apr 2012 18:36:04 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Veblen_Oswald_1880-1960
Veblen, Oswald, 1880-1960
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext18741
RDF Description of Veblen, Oswald, 1880-1960
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00770
_:header16813851921335206569782
RDF Description of Alprostadil
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00770
Edex
Alprox-TD
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fsider%2Fresource%2Fdrugs%2F214%3E
http://en.wikipedia.org/wiki/Alprostadil
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FAlprostadil%3E
GMVPRGQOIOIIMI-LKSHNYPLDA
The absolute bioavailability of alprostadil has not been determined.
CCCCC[C@H](O)C=C[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O
Prostin VR Pediatric
Alprostadil (prostaglandin E1) is produced endogenously to relax vascular smooth muscle and cause vasodilation. In adult males, the vasodilatory effects of alprostadil on the cavernosal arteries and the trabecular smooth muscle of the corpora cavernosa result in rapid arteriolar inflow and expansion of the lacunar spaces within the corpora.&nbsp;As the expanded corporal sinusoids are compressed against the tunica albuginea, venous outflow through the subtunical vessels is impeded and penile rigidity develops.&nbsp;This is referred to as the corporal veno-occlusive mechanism. In infants, the vasodilatory effects of alprostadil increase pulmonary or systemic blood flow.
http://data.linkedct.org/resource/intervention/27620
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F27620%3E
2008-08-26 16:50:31 UTC
http://dbpedia.org/resource/Alprostadil
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FAlprostadil%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/73
For palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Also for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.
Alprostadil
http://www.drugbank.ca/drugs/DB00770
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00770%3E
2002-06-01	/drugs/770/fda_labels/573	2006-06-01	/drugs/770/fda_labels/394
http://129.128.185.122/drugbank2/drugs/DB00770/inserts/2253/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00770%2Finserts%2F2253%2Ffull%3E
C01EA01
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/plateletAggregationInhibitors
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/fibrinolyticAgents
http://bio2rdf.org/kegg:D00180
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD00180%3E
Caverject Sterile Powder - Kit 11.9mcg /Vial (Alprostadil + Water)
5 to 10 minutes (after a single dose), in healthy adults and neonates.
Alprostadil must be infused continuously because it is very rapidly metabolized. As much as 80% of the circulating alprostadil may be metabolized in one pass through the lungs, primarily by beta- and omega-oxidation.
Alprostadil causes vasodilation by means of a direct effect on vascular and ductus arteriosus (DA) smooth muscle, preventing or reversing the functional closure of the DA that occurs shortly after birth. This results in increased pulmonary or systemic blood flow in infants. In cyanotic congenital heart disease, alprostadil's actions result in an increased oxygen supply to the tissues. In infants with interrupted aortic arch or very severe aortic coarctation, alprostadil maintains distal aortic perfusion by permitting blood flow through the DA from the pulmonary artery to the aorta. In infants with aortic coarctation, alprostadil reduces aortic obstruction either by relaxing ductus tissue in the aortic wall or by increasing effective aortic diameter by dilating the DA. In infants with these aortic arch anomalies, systemic blood flow to the lower body is increased, improving tissue oxygen supply and renal perfusion. When administered by intracavernosal injection or as an intraurethral suppository, alprostadil acts locally to relax the trabecular smooth muscle of the corpora cavernosa and the cavernosal arteries. Swelling, elongation, and rigidity of the penis result when arterial blood rapidly flows into the corpus cavernosum to expand the lacunar spaces. The entrapped blood reduces the venous blood outflow as sinusoids compress against the tunica albuginea.
Befar
26.7 mg/L
PA448334
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/cav1073.shtml
http://data.linkedct.org/resource/intervention/57272
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F57272%3E
DB00770
Prostaglandin E1
7-[(1R,2R,3R)-3-hydroxy-2-[(3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid
http://data.linkedct.org/resource/intervention/15801
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F15801%3E
CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O
http://www.dbpedia.org/resource/Alprostadil
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FAlprostadil%3E
Topiglan
http://bio2rdf.org/cas:745-65-3
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A745-65-3%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/suppositoryUrethral
C20H34O5
/drugs/770/safety_sheets/1354
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/solutionIntra-arterial
Oral, mouse: LD<sub>50</sub> = 186 mg/kg; Oral, rat: LD<sub>50</sub> = 228 mg/kg. Apnea, bradycardia, pyrexia, hypotension, and flushing may be signs of drug overdosage.
Alista
http://www.rxlist.com/cgi/generic/alprostadil.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric%2Falprostadil.htm%3E
l-Prostaglandin E1
115 - 116 oC
http://dbpedia.org/page/Alprostadil
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FAlprostadil%3E
Muse
http://129.128.185.122/drugbank2/drugs/DB00770/inserts/378/full
http://data.linkedct.org/resource/intervention/31667
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F31667%3E
aprd00785
Alprostadil Prostoglandin E1
Femprox
Bound in plasma primarily to albumin (81% bound) and to a lesser extent alpha-globulin IV-4 fraction (55% bound).
Caverject Sterile Powder - Kit 23.2mcg/Vial (Alprostadil + Water)
http://205.193.93.51/dpdonline/searchRequest.do?din=02241680
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02241680%3E
http://bio2rdf.org/chebi:15544
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fchebi%3A15544%3E
7.88e-02 mg/mL
http://bio2rdf.org/cpd:C04741
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC04741%3E
Prostin VR
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/406
Alprostadil is produced endogenously and causes vasodilation by means of a direct effect on vascular and ductus arteriosus (DA) smooth muscle, preventing or reversing the functional closure of the DA that occurs shortly after birth. This results in increased pulmonary or systemic blood flow in infants. In infants, it is used for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. In adults, it is used for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.
InChI=1/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/t15-,16+,17+,19+/m0/s1/f/h24H
G04BE01
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3794
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3794%3E
Caverject
PGE1
alprostadil
http://129.128.185.122/drugbank2/drugs/DB00770/inserts/1251/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00770%2Finserts%2F1251%2Ffull%3E
Prink
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0149654
_:header7229007341335206570278
Mon, 23 Apr 2012 18:36:05 GMT
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0149654
http://sideeffects.embl.de/se/C0149654
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0149654%3E
conduct disorders
C0149654
RDF Description of conduct disorders
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/CEBPE
_:header15163155181335206570599
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/CEBPE
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1252
http://symbol.bio2rdf.org/symbol:CEBPE
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ACEBPE%3E
CEBPE
http://www.dbpedia.org/resource/CEBPE
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FCEBPE%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3923
RDF Description of CEBPE
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0019322
_:header16370047381335206571064
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0019322
http://dbpedia.org/resource/Umbilical_hernia
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FUmbilical_hernia%3E
http://sideeffects.embl.de/se/C0019322
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0019322%3E
umbilical hernia
C0019322
RDF Description of umbilical hernia
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/McGee_W_J_(William_John)_1853-1912
_:header11903165821335206571442
Mon, 23 Apr 2012 18:36:06 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/McGee_W_J_(William_John)_1853-1912
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19628
McGee, W. J. (William John), 1853-1912
RDF Description of McGee, W. J. (William John), 1853-1912
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Heyward_DuBose_1885-1940
_:header8592914321335206571850
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Heyward_DuBose_1885-1940
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext16064
Heyward, DuBose, 1885-1940
RDF Description of Heyward, DuBose, 1885-1940
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Belloc_Hilaire_1870-1953
_:header3769485011335206572297
Mon, 23 Apr 2012 18:36:07 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Belloc_Hilaire_1870-1953
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7352
Belloc, Hilaire, 1870-1953
Belloc, Hilaire, 1870-1953 
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7432
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext18018
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13046
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13367
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7373
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext18839
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext10700
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext18276
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext18042
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7354
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8442
RDF Description of Belloc, Hilaire, 1870-1953
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/5452
_:header4957738371335206572800
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/5452
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03814
Pulmonary surfactant-associated protein A precursor
PSP-A
>747 bp	ATGTCACTGTGTTCTTTGGCCTTCACCCTCTTCTTGACTGTTGTCGCTGGTATCAAGTGC	AATGTGACAGACGTTTGTGCTGGAAGCCCTGGGATCCCTGGAGCTCCTGGAAACCATGGT	CTGCCTGGCAGAGACGGGAGAGACGGTGTCAAAGGAGACCCTGGACCTCCAGGTCCCATG	GGCCCTCCTGGAGGAATGCCAGGTCTTCCTGGACGCGATGGGCTGCCCGGAGGACCTGGT	GCACCTGGAGGACGTGGAGACAAGGGAGAGCCTGGAGAAAGGGGCCTGCCAGGATTTCCA	GCTTACCTGGATGAGGAGCTCCAGACTGAACTCTATGAGATCAAACATCAGATTCTGCAA	ACAATGGGAGTCCTCAGCTTGCAAGGATCCATGCTGTCAGTGGGGGATAAAGTCTTTTCC	ACCAATGGGCAGTCAGTCAACTTTGATACCATTAAAGAGATGTGTACCAGAGCAGGAGGC	AACATTGCTGTCCCGAGGACTCCTGAGGAGAACGAGGCCATTGCAAGTATTGCGAAGAAG	TACAACAACTATGTCTACTTGGGCATGATTGAAGACCAGACTCCTGGAGACTTCCACTAC	CTGGATGGGGCTTCTGTGAACTACACCAACTGGTACCCAGGAGAACCCAGGGGTCAGGGC	AAAGAAAAGTGTGTAGAAATGTATACAGATGGGACATGGAATGATAGGGGCTGCCTGCAG	TACCGGCTGGCTGTTTGTGAATTTTGA
Pulmonary surfactant-associated protein A
PSAP
In presence of calcium ions, it binds to surfactant phospholipids and contributes to lower the surface tension at the air-liquid interface in the alveoli of the mammalian lung and is essential for normal respiration
http://bio2rdf.org/uniprot:P08427
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP08427%3E
Sftpa1
SFTPA_RAT
SP-A
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=M33201
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DM33201%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2901856
http://pfam.sanger.ac.uk/family?acc=PF00059
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00059%3E
>Pulmonary surfactant-associated protein A	MSLCSLAFTLFLTVVAGIKCNVTDVCAGSPGIPGAPGNHGLPGRDGRDGVKGDPGPPGPM	GPPGGMPGLPGRDGLPGAPGAPGERGDKGEPGERGLPGFPAYLDEELQTELYEIKHQILQ	TMGVLSLQGSMLSVGDKVFSTNGQSVNFDTIKEMCTRAGGNIAVPRTPEENEAIASIAKK	YNNYVYLGMIEDQTPGDFHYLDGASVNYTNWYPGEPRGQGKEKCVEMYTDGTWNDRGCLQ	YRLAVCEF
phosphate transport
http://bio2rdf.org/pdb:1R14
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1R14%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7491978
http://bio2rdf.org/pfam:PF00059
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00059%3E
http://www.pdb.org/pdb/explore/explore.do?structureId=1R14
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1R14%3E
http://bio2rdf.org/pfam:PF01391
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF01391%3E
Involved in binding
http://www.uniprot.org/uniprot/P08427
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP08427%3E
M33201
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3579914
http://pfam.sanger.ac.uk/family?acc=PF01391
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF01391%3E
RDF Description of Pulmonary surfactant-associated protein A
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Eggleston_Edward_1837-1902
_:header21232299401335206573111
Mon, 23 Apr 2012 18:36:08 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Eggleston_Edward_1837-1902
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19896
Eggleston, Edward, 1837-1902
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext14051
RDF Description of Eggleston, Edward, 1837-1902
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext15597
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext15099
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext12195
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext10070
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00503
_:header14634453121335206573593
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01215_DB00503
The absolute bioavailability of ritonavir has not been determined.
http://bio2rdf.org/cas:155213-67-5
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A155213-67-5%3E
http://129.128.185.122/drugbank2/drugs/DB00503/inserts/1662/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00503%2Finserts%2F1662%2Ffull%3E
RIT
Ritonavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Ritonavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.
An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. [PubChem]
http://data.linkedct.org/resource/intervention/56266
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F56266%3E
DB00503
Abbott 84538
http://129.128.185.122/drugbank2/drugs/DB00503/inserts/2642/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00503%2Finserts%2F2642%2Ffull%3E
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fsider%2Fresource%2Fdrugs%2F5076%3E
InChI=1/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1/f/h39,41-42H
Ritonavir
http://www.rxlist.com/cgi/generic2/ritonavirsol.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric2%2Fritonavirsol.htm%3E
NCDNCNXCDXHOMX-TYYXQKCWDL
Ritonavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
ritonavir
http://data.linkedct.org/resource/intervention/62909
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F62909%3E
http://bio2rdf.org/cpd:C07240
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC07240%3E
http://dbpedia.org/page/Ritonavir
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FRitonavir%3E
http://dbpedia.org/resource/Ritonavir
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FRitonavir%3E
http://data.linkedct.org/resource/intervention/38054
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F38054%3E
Hepatic. Five metabolites have been identified. The isopropylthiazole oxidation metabolite (M-2) is the major metabolite and has antiviral activity similar to that of ritonavir, however, plasma concentrations are low. The cytochrome P450 enzymes CYP3A and CYP2D6 are primarily involved in the metabolism of ritonavir.
Kaletra (Lopinavir + Ritonavir)
PA451260
http://data.linkedct.org/resource/intervention/49706
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F49706%3E
Human experience of acute overdose with ritonavir is limited. One patient in clinical trials took ritonavir 1500 mg/day for two days. The patient reported paresthesias which resolved after the dose was decreased. A post-marketing case of renal failure with eosinophilia has been reported with ritonavir overdose. The approximate lethal dose was found to be greater than 20 times the related human dose in rats and 10 times the related human dose in mice.
Norvir Sec
Indicated in combination with other antiretroviral agents for the treatment of HIV-infection.
Norvir
http://data.linkedct.org/resource/intervention/43620
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F43620%3E
CC(C)C(NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)NC(CC(O)C(CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
3-5 hours
Practically insoluble
/drugs/503/safety_sheets/1128
CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
http://data.linkedct.org/resource/intervention/61485
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F61485%3E
1ODW
http://205.193.93.51/dpdonline/searchRequest.do?din=02241480
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02241480%3E
Avoid St.John's Wort.
2008-08-26 14:34:45 UTC
http://bio2rdf.org/kegg:D00427
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD00427%3E
http://data.linkedct.org/resource/intervention/23504
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F23504%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/275
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F275%3E
J05AE03
2002-03-01	/drugs/503/fda_labels/501
C37H48N6O5S2
http://www.drugbank.ca/drugs/DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00503%3E
http://data.linkedct.org/resource/intervention/52363
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F52363%3E
http://en.wikipedia.org/wiki/Ritonavir
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FRitonavir%3E
http://data.linkedct.org/resource/intervention/25680
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F25680%3E
1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-di(phenyl)hexan-2-yl]carbamate
1.26e-03 mg/mL
aprd00312
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01244_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01167_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00540_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00637_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00404_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00227_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00604_DB00503
RDF Description of Ritonavir
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00343_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00530_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00317_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01410_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00199_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00543_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00615_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01076_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00475_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00277_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00628_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00683_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00320_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01068_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01303_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00243_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00321_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01223_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00696_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00458_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00472_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00829_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00705_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01151_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00289_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01142_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00363_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00700_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00216_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00908_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01242_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00647_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00977_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01156_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00346_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00673_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00334_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01045_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00510_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00333_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01369_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00554_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01118_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00564_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01048_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00813_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00690_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00091_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00454_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00897_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00390_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00358_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01195_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01100_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01182_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00656_DB00503
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01026_DB00503
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/32800
_:header10034355861335206574176
Mon, 23 Apr 2012 18:36:09 GMT
RDF Description of Sincalide
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/32800
Sincalide
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/286
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F286%3E
http://dbpedia.org/resource/Sincalide
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FSincalide%3E
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000032800
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000032800%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0392680
http://sideeffects.embl.de/drugs/32800
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F32800%3E
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000032800&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000032800%26input_query_species%3D9606%3E
CID0000032800
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00081
_:header18689382551335206574502
RDF Description of Tositumomab
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00081
V10XA53
btd00085
http://bio2rdf.org/uniprot:P01857
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP01857%3E
http://129.128.185.122/drugbank2/drugs/DB00081/inserts/2590/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00081%2Finserts%2F2590%2Ffull%3E
http://dbpedia.org/resource/Tositumomab
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FTositumomab%3E
Ig gamma-1 chain C region
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/kitIntravenous
>Mouse-Human chimeric Anti-CD20 Heavy Chain 1	QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSY	NQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTV	SGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY	SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSV	FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY	RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTK	NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG	NVFSCSVMHEALHNHYTQKSLSLSPGK	>Mouse-Human chimeric Anti-CD20 Heavy Chain 2	QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSY	NQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTV	SGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY	SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSV	FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY	RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTK	NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG	NVFSCSVMHEALHNHYTQKSLSLSPGK	>Mouse-Human chimeric Anti-CD20 Light Chain 1	QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPAR	FSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELKRTVAAPSVFIFPPS	DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL	SKADYEKHKVYACEVTHQGLSSPVTKSFNR	>Mouse-Human chimeric Anti-CD20 Light Chain 2	QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPAR	FSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELKRTVAAPSVFIFPPS	DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL	SKADYEKHKVYACEVTHQGLSSPVTKSFNR
http://www.drugbank.ca/drugs/DB00081
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00081%3E
http://205.193.93.51/dpdonline/searchRequest.do?din=02270471
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02270471%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/75
IGHG1_HUMAN
http://www.dbpedia.org/resource/Tositumomab
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FTositumomab%3E
For treatment of non-Hodgkin's lymphoma (CD20 positive, follicular)
http://bio2rdf.org/cas:192391-48-3
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A192391-48-3%3E
Tositumomab
http://dbpedia.org/page/Tositumomab
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FTositumomab%3E
Tositumomab binds to the CD20 antigen, which is predominantly expressed on mature B cells and on >90% of B-cell non-Hodgkin's lympohomas. The antibody leads to selective killing of B-cells.
http://129.128.185.122/drugbank2/drugs/DB00081/inserts/1598/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00081%2Finserts%2F1598%2Ffull%3E
biod00085
DB00081
Most likely removed by opsonization via the reticuloendothelial system when bound to B lymphocytes, or by human antimurine antibody production
Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine).
Bexxar (Corixa Corp)
0.8 hours (mammalian reticulocytes, in vitro)
2008-02-11 15:02:31 UTC
http://www.uniprot.org/uniprot/P01857
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP01857%3E
http://en.wikipedia.org/wiki/Tositumomab
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FTositumomab%3E
C6416H9874N1688O1987S44
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/196
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F196%3E
Murine anti-CD20 antibody
http://data.linkedct.org/resource/intervention/14395
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F14395%3E
J00228
http://www.rxlist.com/cgi/generic3/bexxar.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric3%2Fbexxar.htm%3E
Binds to the CD20 antigen which is found on mature B lymphocytes. The antibody binding appears to induce apoptosis, complement-dependent cytotoxicity and cell death through ionizing radiation.
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0973461
_:header12751621471335206575013
http://sideeffects.embl.de/se/C0973461
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0973461%3E
dysphasia
C0973461
RDF Description of dysphasia
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Asquith_Margot_1864-1945
_:header14725291891335206575353
Mon, 23 Apr 2012 18:36:10 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Asquith_Margot_1864-1945
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext4321
Asquith, Margot, 1864-1945
RDF Description of Asquith, Margot, 1864-1945
http://www4.wiwiss.fu-berlin.de/dblp/data/person/100665
_:header7714358461335206575920
http://www4.wiwiss.fu-berlin.de/dblp/resource/person/100665
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/coling/CaraballoC98
Eugene Charniak
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/aaai/CharniakC94
RDF Description of Eugene Charniak
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/acl/RoarkC98
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/ai/Charniak00
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/naacl/CharniakJ01
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/uai/ShimonyC90
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/csur/Charniak95
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/acl/BlahetaC99
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/ijcai/Charniak73
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/naacl/Charniak01
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/anlp/Charniak00
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/ijcai/Charniak81
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/pami/GoldmanC93
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/ai/CharniakCACGKLM96
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/uai/GoldmanC90
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/ai/Charniak88
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/aim/Charniak97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/aaai/CharniakHJP93
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/ai/Charniak81
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/ijcai/Charniak77
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/anlp/BlahetaC00
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/aaai/HirstC82
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/ijcai/Charniak75
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/homepages/c/ECharniak
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/ijcai/SchankCWWW77
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/acl/Charniak01
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/aaai/Charniak83
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/aaai/CharniakH91
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/aaai/LeaseCJM06
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/ijcai/CharniakG89
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/aaai/Charniak96
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/aaai/CharniakS90
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/acl/CharniakG88
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/acl/GenzelC02
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/aaai/CharniakS92
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/corr/cs-CL-0008026
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/naacl/GregoryJC04
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/ijcai/Charniak69
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/ijcai/ErsanC95
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/corr/cs-CL-0008027
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/aaai/Charniak86
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/acl/JohnsonC04
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/ai/Charniak78
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/ijcnlp/LeaseC05
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/ai/CharniakS94
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/ai/CharniakG93
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/aaai/Charniak97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/aaai/CharniakG91
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/uai/CharniakG89
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/aim/Charniak91
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/uai/CarrollC91
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/acl/BerlandC99
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00896
_:header2360857311335206576243
Mon, 23 Apr 2012 18:36:11 GMT
RDF Description of Rimexolone
The serum half-life of rimexolone could not be reliably estimated due to the large number of samples below the quantitation limit of the assay (80 pg/mL). However, based on the time required to reach steady-state, the half-life appears to be short (1-2 hours).
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FRimexolone%3E
Rimexolone
http://bio2rdf.org/cas:49697-38-3
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A49697-38-3%3E
Rimexolone is a glucocorticoid corticosteroid for systemic use. Corticosteroids suppress the inflammatory response to a variety of inciting agents of a mechanical, chemical, or immunological nature. They inhibit edema, cellular infiltration, capillary dilatation, fibroblastic proliferation, deposition of collagen and scar formation associated with inflammation.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/corticosteroids
aprd01220
DB00896
http://dbpedia.org/page/Rimexolone
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FRimexolone%3E
For the treatment of postoperative inflammation following ocular surgery and in the treatment of anterior uveitis.
2003-05-01	/drugs/896/fda_labels/1016
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/anti-inflammatoryAgents
http://129.128.185.122/drugbank2/drugs/DB00896/inserts/127/full
1.21e-02 mg/mL
InChI=1/C24H34O3/c1-6-20(27)24(5)14(2)11-18-17-8-7-15-12-16(25)9-10-22(15,3)21(17)19(26)13-23(18,24)4/h9-10,12,14,17-19,21,26H,6-8,11,13H2,1-5H3/t14-,17?,18?,19+,21?,22+,23+,24-/m1/s1
H02AB12
Rimexolone is a glucocorticoid steroid used to treat inflammation in the eye. It is marketed as a 1% eye drop solution under the trade name Vexol
http://en.wikipedia.org/wiki/Rimexolone
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FRimexolone%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/suspensionOphthalmic
S01BA13
C24H34O3
CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C
PA451254
http://www.rxlist.com/cgi/generic3/rimexol.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric3%2Frimexol.htm%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/469
/drugs/896/safety_sheets/752
QTTRZHGPGKRAFB-PAIWTFDUBR
(10R,11S,13S,16R,17S)-11-hydroxy-10,13,16,17-tetramethyl-17-propanoyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
Undergoes extensive metabolism. Following intravenous administration of radiolabeled rimexolone in rats, more than 80% of the dose was excreted in the feces as rimexolone and metabolites. Metabolites have been shown to be either less active than rimexolone or inactive in human glucocorticoid receptor binding assays.
2008-08-26 15:51:27 UTC
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/232
http://www.drugbank.ca/drugs/DB00896
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00896%3E
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3070%3E
CCC(=O)C1(C)C(C)CC2C3CCC4=CC(=O)C=CC4(C)C3C(O)CC12C
http://205.193.93.51/dpdonline/searchRequest.do?din=02163691
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02163691%3E
http://129.128.185.122/drugbank2/drugs/DB00896/inserts/883/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00896%2Finserts%2F883%2Ffull%3E
Betamethasone is a glucocorticoid receptor agonist. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition of arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes.
52:08.08
Symptoms of overdose include retinal toxicity, glaucoma, and subcapsular cataract.
Systemically absorbed.
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/58
_:header16977582601335206576822
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/58
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00129
229-249
197-217
22q11.21
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9598310
365-385
http://bio2rdf.org/pfam:PF00324
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00324%3E
Cationic amino acid transporter 4
amine transporter activity
CAT-4
66-86
270-290
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17329401
amino acid transport
567-587
http://bio2rdf.org/hgnc:11062
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A11062%3E
AJ000730
318-338
539-559
http://www.genenames.org/data/hgnc_data.php?hgnc_id=11062
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D11062%3E
CTR4_HUMAN
CAT4
http://bio2rdf.org/uniprot:O43246
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AO43246%3E
http://symbol.bio2rdf.org/symbol:SLC7A4
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ASLC7A4%3E
508-528
amino acid-polyamine transporter activity
http://pfam.sanger.ac.uk/family?acc=PF00324
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00324%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=4378940
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D4378940%3E
SLC7A4
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/15746185
Involved in the transport of the cationic amino acids (arginine, lysine and ornithine)
>Cationic amino acid transporter 4	MARGLPTIASLARLCQKLNRLKPLEDSTMETSLRRCLSTLDLTLLGVGGMVGSGLYVLTG	AVAKEVAGPAVLLSFGVAAVASLLAALCYAEFGARVPRTGSAYLFTYVSMGELWAFLIGW	NVLLEYIIGGAAVARAWSGYLDSMFSHSIRNFTETHVGSWQVPLLGHYPDFLAAGIILLA	SAFVSCGARVSSWLNHTFSAISLLVILFIVILGFILAQPHNWSADEGGFAPFGFSGVMAG	TASCFYAFVGFDVIAASSEEAQNPRRSVPLAIAISLAIAAGAYILVSTVLTLMVPWHSLD	PDSALADAFYQRGYRWAGFIVAAGSICAMNTVLLSLLFSLPRIVYAMAADGLFFQVFAHV	HPRTQVPVAGTLAFGLLTAFLALLLDLESLVQFLSLGTLLAYTFVATSIIVLRFQKSSPP	SSPGPASPGPLTKQQSSFSDHLQLVGTVHASVPEPGELKPALRPYLGFLDGYSPGAVVTW	ALGVMLASAITIGCVLVFGNSTLHLPHWGYILLLLLTSVMFLLSLLVLGAHQQQYREDLF	QIPMVPLIPALSIVLNICLMLKLSYLTWVRFSIWLLMGLAVYFGYGIRHSKENQRELPGL	NSTHYVVFPRGSLEETVQAMQPPSQAPAQDPGHME
42-62
>1911 bp	ATGGCCCGGGGGCTGCCCACCATTGCTAGCCTGGCACGCTTATGCCAGAAGCTGAACCGC	CTGAAGCCGCTGGAGGACTCCACCATGGAGACGTCACTGCGGCGCTGCCTGTCCACGCTG	GACCTGACTCTTCTGGGCGTGGGTGGCATGGTGGGCTCGGGTCTCTACGTGCTCACAGGT	GCCGTGGCCAAGGAGGTGGCTGGCCCTGCTGTGCTCTTGTCCTTCGGTGTGGCCGCTGTG	GCCTCCCTGCTGGCAGCCCTATGCTATGCAGAATTTGGGGCACGTGTGCCACGCACGGGC	TCTGCCTACCTGTTCACCTACGTATCCATGGGCGAGCTGTGGGCCTTCCTCATCGGCTGG	AATGTTCTCCTCGAATACATCATCGGTGGCGCCGCCGTGGCCCGTGCCTGGAGTGGCTAC	CTGGACTCTATGTTCAGCCACAGCATCCGCAACTTCACTGAAGACCCACGTGGGTTCTTG	GCAGGTGCCCCTCCTGGGCCACTACCCGGACTTCCTGGCTGCTGGCATCATCCTCCCTGG	CCTCTGCCTTTGTCTCCTGTGGAGCCCGCGTGTCCTCCCTGGCTCAATCACACCTTCTCG	GCCATCAGCCTGCTTGTCATTCTCTTCATTGTCATCCTGGGCTTCATCCTGGCCCAGCCT	CACAACTGGAGCGCTGACGAAGGCGGCTTTGCACCCTTCGGCTTCTCCGGCGTCATGGCC	GGCACTGCCTCCTGCTTCTATGCTTTCGTGGGCTTCGACGTCATTGCCGCCTCCAGTGAG	GAGGCCCAGAACCCACGGCGGTCTGTGCCTCTGGCCATCGCCATCTCGCTTGCCATTGCA	GCTGGTGCCTACATCCTTGTCTCCACCGTGCTAACCCTCATGGTGCCCTGGCACAGCCTG	GACCCCGACTCAGCGCTTGCAGATGCCTTCTACCAGCGGGGCTACAGGTGGGCTGGCTTC	ATCGTGGCAGCTGGCTCCATCTGCGCCATGAACACCGTCCTGCTCAGCCTCCTCTTCTCC	CTGCCACGCATTGTCTATGCCATGGCCGCCGATGGGCTCTTCTTCCAGGTGTTTGCCCAT	GTGCACCCCCGGACACAGGTGCCTGTGGCGGGCACCCTGGCGTTCGGGCTCCTCACGGCC	TTCCTGGCACTGCTGCTGGACCTGGAGTCGCTGGTTCAGTTCCTGTCCCTTGGCACACTC	CTGGCCTACACATTCGTGGCCACCAGTATCATTGTGCTGCGCTTCCAGAAGTCTTCCCCG	CCCAGCTCCCCAGGCCCAGCCAGCCCTGGCCCCCTGACCAAGCAGCAGAGCTCCTTCTCA	GACCACCTACAGCTGGTGGGCACTGTACACGCCTCCGTCCCTGAGCCAGGGGAGCTGAAG	CCAGCCCTGAGGCCCTACCTGGGCTTCTTGGATGGGTACAGCCCTGGAGCAGTGGTGACT	TGGGCGCTTGGCGTTATGTTGGCCTCAGCCATCACCATAGGCTGCGTGCTTGTCTTTGGG	AACTCGACCCTGCACCTCCCACACTGGGGTTACATCCTGCTGCTCCTGCTCACCAGTGTC	ATGTTTCTGCTCAGCCTCCTTGTCCTGGGGGCTCACCAGCAACAGTATCGGGAAGACTTA	TTTCAGATCCCCATGGTTCCCCTGATTCCAGCCCTGAGCATCGTCCTCAACATCTGCCTC	ATGCTGAAACTTAGCTATCTGACCTGGGTGCGCTTCTCCATCTGGCTGCTGATGGGACTT	GCAGTGTATTTCGGCTATGGCATCCGGCATAGCAAGGAGAACCAGCGGGAGCTGCCAGGG	CTGAACTCCACACACTACGTGGTATTCCCCAGGGGCAGCCTGGAGGAGACAGTGCAGGCT	ATGCAGCCCCCCAGCCAGGCACCAGCACAGGACCCTGGCCATATGGAGTAG
amine transport
391-411
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AJ000730
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAJ000730%3E
http://www.uniprot.org/uniprot/O43246
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FO43246%3E
113-133
multi-passMembraneProtein(probable)
478-498
amino acid transporter activity
RDF Description of Cationic amino acid transporter 4
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00123
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00954
_:header4609004481335206577200
Mon, 23 Apr 2012 18:36:12 GMT
RDF Description of Dirithromycin
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00954
http://129.128.185.122/drugbank2/drugs/DB00954/inserts/20/full
Dirithromycin
(1S,2R,4R,5R,6S,7S,8R,11R,12R,15R,17S)-5-[(2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-11-ethyl-4,12-dihydroxy-7-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-15-(2-methoxyethoxymethyl)-2,4,6,8,12,17-hexamethyl-10,14-dioxa-16-azabicyclo[11.3.1]heptadecan-9-one
http://129.128.185.122/drugbank2/drugs/DB00954/inserts/725/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00954%2Finserts%2F725%2Ffull%3E
15 to 30% for erythromycylamine, the active compound.
Oral dirithromycin is rapidly absorbed, with an absolute bioavailability of approximately 10%. Dietary fat has little or no effect on the bioavailability of dirithromycin.
DB00954
Dirithromycin is converted by nonenzymatic hydrolysis during absorption to the active compound, erythromycylamine. Sixty to 90% of a dose is hydrolyzed to erythromycylamine within 35 minutes after dosing, and conversion is nearly complete after 1.5 hours. Erythromycylamine undergoes little or no hepatic biotransformation. No other metabolites of dirithromycin have been detected in the serum.
Dynabac
CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(C2O)N(C)C)C(C)(O)CC(C)C2NC(COCCOC)OC(C2C)C1(C)O
http://www.rxlist.com/cgi/generic2/dirthromycin.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric2%2Fdirthromycin.htm%3E
C42H78N2O14
http://www.drugbank.ca/drugs/DB00954
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00954%3E
http://bio2rdf.org/cas:62013-04-1
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A62013-04-1%3E
http://129.128.185.122/drugbank2/drugs/DB00954/inserts/1750/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00954%2Finserts%2F1750%2Ffull%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/884
http://dbpedia.org/page/Dirithromycin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FDirithromycin%3E
2008-08-26 14:34:50 UTC
http://dbpedia.org/resource/Dirithromycin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FDirithromycin%3E
Poor
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/macrolides
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@@H]([C@H]2C)[C@]1(C)O
WLOHNSSYAXHWNR-GETPLZSYBB
2.30e-01 mg/mL
PA449368
InChI=1/C42H78N2O14/c1-15-29-42(10,49)37-24(4)32(43-30(56-37)21-52-17-16-50-13)22(2)19-40(8,48)36(58-39-33(45)28(44(11)12)18-23(3)53-39)25(5)34(26(6)38(47)55-29)57-31-20-41(9,51-14)35(46)27(7)54-31/h22-37,39,43,45-46,48-49H,15-21H2,1-14H3/t22-,23-,24+,25+,26-,27+,28+,29-,30-,31+,32+,33-,34+,35+,36-,37?,39+,40-,41-,42-/m1/s1
J01FA13
http://en.wikipedia.org/wiki/Dirithromycin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FDirithromycin%3E
Dirithromycin is a macrolide glycopeptide antibiotic. It is used to treat many different types of bacterial infections, such as bronchitis, pneumonia, tonsillitis, and even skin infections.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/tabletFilmCoatedOral
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/dyn1151.shtml
Dirithromycin is a pro-drug which is converted non-enzymatically during intestinal absorption into the microbiologically active moiety erythromycylamine. Erythromycylamine exerts its activity by binding to the 50S ribosomal subunits of susceptible mircoorganisms resulting in inhibition of protein synthesis. Dirithromycin/erythromycylamine has been shown to be active against most strains of the following microorganisms both in vitro and in clinical infections: <i>Staphylococcus aureus</i> (methicillin-susceptible strains only), <i>Streptococcus pneumoniae</i>, <i>Streptococcus pyogenes</i>, <i>Haemophilus influenzae</i>, <i>Legionella pneumophila</i>, <i>Moraxella catarrhalis</i>, and <i>Mycoplasma pneumoniae</i>.
For the treatment of the following mild-to-moderate infections caused by susceptible strains of microorganisms: acute bacterial exacerbations of chronic bronchitis, secondary bacterial infection of acute bronchitis, community-acquired pneumonia, pharyngitis/tonsilitis, and uncomplicated skin and skin structure infections.
The mean plasma half-life of erythromycylamine was estimated to be about 8 h (2 to 36 h), with a mean urinary terminal elimination half-life of about 44 h (16 to 65 h) in patients with normal renal function.
The toxic symptoms following an overdose of a macrolide antibiotic may include nausea, vomiting, epigastric distress, and diarrhea.
aprd00931
Dirithromycin prevents bacteria from growing, by interfering with their protein synthesis. Dirithromycin binds to the 50S subunit of the 70S bacterial ribosome, and thus inhibits the translocation of peptides. Dirithromycin has over 10 times higher affinity to the subunit 50S than erythromycin. In addition, dirithromycin binds simultaneously in to two domains of 23S RNA of the ribosomal subunit 50S, where older macrolides bind only in one. Dirithromycin can also inhibit the formation of ribosomal subunits 50S and 30S.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00243_DB00954
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0043167
_:header16245413061335206577701
RDF Description of Pertussis
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0043167
http://dbpedia.org/resource/Pertussis
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FPertussis%3E
http://sideeffects.embl.de/se/C0043167
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0043167%3E
Pertussis
C0043167
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/5447
_:header13313580931335206578144
RDF Description of Lethal(3)malignant brain tumor-like protein
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/5447
http://pfam.sanger.ac.uk/family?acc=PF02820
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF02820%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=15905
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D15905%3E
Lethal(3)malignant brain tumor-like protein
H-L(3)MBT
>2319 bp	ATGAGGCGAAGAGAGGGCCATGGCACCGACTCCGAGATGGGTCAAGGACCCGTACGGGAG	TCGCAATCCTCAGACCCTCCCGCGCTCCAGTTCCGGATAAGCGAGTATAAGCCGCTGAAC	ATGGCGGGAGTGGAGCAGCCCCCGAGCCCCGAGCTGCGGCAGGAAGGCGTGACCGAATAC	GAAGATGGCGGGGCCCCGGCGGGAGATGGCGAGGCGGGCCCCCAACAGGCGGAGGACCAC	CCCCAGAATCCTCCAGAAGATCCCAATCAGGACCCCCCAGAGGATGATAGCACCTGTCAG	TGCCAGGCGTGCGGGCCTCACCAAGCCGCGGGTCCAGATCTTGGTTCCTCTAATGATGGC	TGCCCTCAGCTGTTCCAGGAGCGGTCAGTCATAGTGGAGAACTCCTCAGGCTCTACCAGC	GCTTCTGAGCTCCTCAAACCCATGAAGAAGAGGAAGCGCAGGGAATACCAGAGCCCATCA	GAGGAGGAGTCGGAGCCAGAGGCCATGGAGAAGCAAGAAGAAGGAAAGGACCCAGAGGGA	CAACCCACTGCTAGCACCCCAGAGAGTGAGGAGTGGAGCAGCAGCCAGCCTGCAACAGGT	GAGAAGAAGGAATGCTGGTCGTGGGAGTCCTACCTAGAGGAGCAGAAGGCCATTACTGCT	CCAGTCAGCCTCTTCCAGGACTCCCAGGCAGTCACTCACAACAAGAATGGCTTCAAACTG	GGCATGAAGTTGGAAGGCATTGACCCTCAACACCCGTCCATGTACTTCATCCTCACCGTG	GCTGAGGTATGTGGCTATCGCCTACGCCTGCACTTTGATGGGTATTCTGAGTGCCATGAC	TTCTGGGTCAATGCCAACTCCCCTGACATTCACCCTGCTGGCTGGTTCGAGAAGACGGGC	CACAAGCTGCAGCTTCCCAAAGGTTACAAGGAGGAGGAGTTCAGCTGGAGCCAGTACATG	TGCAGCACAAGAGCTCAGGCTGCCCCCAAGCACATGTTTGTGAGCCAGAGCCACAGTCCC	CCACCCTTGGGCTTCCAGGTGGGCATGAAGCTGGAGGCTGTTGACCGCATGAACCCGTCC	CTTGTCTGCGTGGCCAGTGTGACCGATGTGGTGGACAGCCGCTTCCTGGTGCACTTTGAC	AACTGGGATGATACTTATGACTACTGGTGTGATCCCAGCAGCCCCTACATCCACCCAGTG	GGCTGGTGCCAGAAGCAAGGAAAGCCCCTCACCCCTCCACAAGACTACCCAGACCCTGAT	AACTTCTGTTGGGAGAAATATCTGGAAGAAACTGGGGCCTCTGCTGTCCCCACCTGGGCC	TTCAAGGTGCGACCCCCTCACAGCTTCCTGGTCAATATGAAGCTGGAGGCTGTGGACCGC	AGGAACCCAGCCCTGATTCGCGTGGCCAGCGTGGAGGATGTGGAGGACCATCGGATAAAG	ATCCACTTTGATGGCTGGAGTCATGGCTATGATTTCTGGATCGACGCTGATCACCCAGAC	ATCCACCCTGCCGGCTGGTGCTCCAAGACAGGACATCCCCTGCAGCCTCCTCTCGGACCC	AGAGAGCCCAGCTCTGCCTCCCCTGGGGGCTGTCCCCCTCTCAGCTATAGGAGCCTGCCC	CACACTAGGACCTCCAAATACAGCTTTCACCACCGGAAGTGCCCCACTCCTGGTTGCGAC	GGCTCTGGCCATGTCACAGGCAAGTTCACAGCTCACCATTGCCTCTCAGGCTGCCCACTG	GCTGAGAGGAACCAGAGCCGGCTGAAAGCGGAGCTGTCTGACCCGGAGGCCTCAGCCCGC	AAGAAGAACCTCTCAGGCTTCTCCCCAAGGAAGAAGCCTCGCCATCACGGCCGAATTGGA	CGCCCTCCGAAGTATCGAAAGATTCCGCAGGAAGATTTCCAGACCCTCACGCCCGATGTC	GTGCACCAGTCCCTCTTCATGTCAGCCCTGTCGGCCCACCCTGACCGCTCACTCTCAGTG	TGCTGGGAGCAGCACTGCAAGCTCCTGCCAGGAGTAGCGGGCATCTCAGCCTCGACAGTC	GCCAAGTGGACCATCGATGAGGTCTTCGGCTTTGTTCAGACCCTGACAGGTTGTGAGGAC	CAAGCACGCCTCTTCAAAGACGAGGCAAGAATAGTCAGAGTGACCCATGTATCTGGGAAG	ACTCTAGTCTGGACTGTGGCCCAGCTTGGGGACCTTGTGTGCTCAGATCATCTTCAGGAA	GGAAAAGGCATCCTGGAGACAGGAGTCCATTCACTCCTCTGCTCTCTACCCACTCATTTG	CTTGCCAAACTTAGCTTTGCCAGTGATAGTCAATATTAA
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=U89358
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DU89358%3E
L3MBTL
Polycomb group (PcG) protein. PcG proteins maintain the transcriptionally repressive state of genes, probably via a modification of chromatin, rendering it heritably changed in its expressibility. Participates in the ETV6-mediated repression. Probably plays a role in cell proliferation. Overexpression induces multinucleated cells, suggesting that it is required to accomplish normal mitosis
H-l(3)mbt protein
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12842041
U89358
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10445843
http://bio2rdf.org/pdb:1OZ2
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1OZ2%3E
20q13.12
L(3)mbt protein homolog
http://bio2rdf.org/uniprot:Q9Y468
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ9Y468%3E
http://pfam.sanger.ac.uk/family?acc=PF01530
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF01530%3E
http://www.pdb.org/pdb/explore/explore.do?structureId=1OZ2
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1OZ2%3E
http://bio2rdf.org/pfam:PF02820
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF02820%3E
L(3)mbt-like
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9734811
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12588862
>Lethal(3)malignant brain tumor-like protein	MRRREGHGTDSEMGQGPVRESQSSDPPALQFRISEYKPLNMAGVEQPPSPELRQEGVTEY	EDGGAPAGDGEAGPQQAEDHPQNPPEDPNQDPPEDDSTCQCQACGPHQAAGPDLGSSNDG	CPQLFQERSVIVENSSGSTSASELLKPMKKRKRREYQSPSEEESEPEAMEKQEEGKDPEG	QPTASTPESEEWSSSQPATGEKKECWSWESYLEEQKAITAPVSLFQDSQAVTHNKNGFKL	GMKLEGIDPQHPSMYFILTVAEVCGYRLRLHFDGYSECHDFWVNANSPDIHPAGWFEKTG	HKLQPPKGYKEEEFSWSQYLRSTRAQAAPKHLFVSQSHSPPPLGFQVGMKLEAVDRMNPS	LVCVASVTDVVDSRFLVHFDNWDDTYDYWCDPSSPYIHPVGWCQKQGKPLTPPQDYPDPD	NFCWEKYLEETGASAVPTWAFKVRPPHSFLVNMKLEAVDRRNPALIRVASVEDVEDHRIK	IHFDGWSHGYDFWIDADHPDIHPAGWCSKTGHPLQPPLGPREPSSASPGGCPPLSYRSLP	HTRTSKYSFHHRKCPTPGCDGSGHVTGKFTAHHCLSGCPLAERNQSRLKAELSDSEASAR	KKNLSGFSPRKKPRHHGRIGRPPKYRKIPQEDFQTLTPDVVHQSLFMSALSAHPDRSLSV	CWEQHCKLLPGVAGISASTVAKWTIDEVFGFVQTLTGCEDQARLFKDEARIVRVTHVSGK	TLVWTVAQLGDLVCSDHLQEGKGILETGVHSLLCSLPTHLLAKLSFASDSQY
http://bio2rdf.org/hgnc:15905
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A15905%3E
L3MBTL1
http://bio2rdf.org/pfam:PF01530
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF01530%3E
http://www.uniprot.org/uniprot/Q9Y468
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ9Y468%3E
LMBTL_HUMAN
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/292
_:header16098635791335206578458
Mon, 23 Apr 2012 18:36:13 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/292
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2045
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/HLXB9
Currarino syndrome
http://www.dbpedia.org/resource/Currarino_syndrome
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FCurrarino_syndrome%3E
RDF Description of Currarino syndrome
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Cambrensis_Giraldus_1146-1223
_:header11907055661335206579305
Mon, 23 Apr 2012 18:36:14 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Cambrensis_Giraldus_1146-1223
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1148
Cambrensis, Giraldus, 1146-1223
RDF Description of Cambrensis, Giraldus, 1146-1223
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1092
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Cairns_John_1818-1892
_:header4856599351335206579708
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Cairns_John_1818-1892
Cairns, John, 1818-1892
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext11113
RDF Description of Cairns, John, 1818-1892
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00412
_:header3168301791335206580153
Mon, 23 Apr 2012 18:36:15 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01241_DB00412
http://dbpedia.org/resource/Rosiglitazone
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FRosiglitazone%3E
http://data.linkedct.org/resource/intervention/60200
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F60200%3E
BRL
http://data.linkedct.org/resource/intervention/20115
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F20115%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/450
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F450%3E
http://www.dbpedia.org/resource/Rosiglitazone
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FRosiglitazone%3E
Rosiglizole
http://data.linkedct.org/resource/intervention/36661
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F36661%3E
Crowther, Smith, U.S. Pat. 3,337,628 (1967)
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3407
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3407%3E
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/cx1532.shtml
Avandamet (Metformin hydrochloride + Rosiglitazone maleate)
http://bio2rdf.org/kegg:D00596
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD00596%3E
http://bio2rdf.org/cas:122320-73-4
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A122320-73-4%3E
http://data.linkedct.org/resource/intervention/38901
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F38901%3E
http://data.linkedct.org/resource/intervention/20121
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F20121%3E
aprd00403
For the treatment of Type II diabetes mellitus
http://data.linkedct.org/resource/intervention/27361
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F27361%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/238
A10BG02
PA451283
http://data.linkedct.org/resource/intervention/52723
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F52723%3E
Hepatic. Rosiglitazone is extensively metabolized in the liver to inactive metabolites via N-demethylation, hydroxylation, and conjugation with sulfate and glucuronic acid. In vitro data have shown that Cytochrome (CYP) P450 isoenzyme 2C8 (CYP2C8) and to a minor extent CYP2C9 are involved in the hepatic metabolism of rosiglitazone.
The absolute bioavailability of rosiglitazone is 99%. Peak plasma concentrations are observed about 1 hour after dosing. Administration of rosiglitazone with food resulted in no change in overall exposure (AUC), but there was an approximately 28% decrease in C<sub>max</sub> and a delay in T<sub>max</sub> (1.75 hours). These changes are not likely to be clinically significant; therefore, rosiglitazone may be administered with or without food.
Rosigliazone maleate
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/hypoglycemicAgents
5-[[4-[2-(methyl-pyridin-2-ylamino)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
68:20.28
YASAKCUCGLMORW-UYBDAZJACF
3-4 hours
Rosiglitazone
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2969%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3406
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3406%3E
http://129.128.185.122/drugbank2/drugs/DB00412/inserts/326/full
http://www.drugbank.ca/drugs/DB00412
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00412%3E
InChI=1/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)/f/h20H
122-123 oC
C18H19N3O3S
2008-08-26 16:21:25 UTC
Rosiglitazone, a member of the drug group known as the thiazolidinediones or "insulin sensitizers", is not chemically or functionally related to the alpha-glucosidase inhibitors, the biguanides, or the sulfonylureas. Rosiglitazone targets insulin resistance and, hence, is used alone or with metformine or sulfonylurea to improve glycemic control in patients with type 2 diabetes mellitus.
http://data.linkedct.org/resource/intervention/52557
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F52557%3E
http://data.linkedct.org/resource/intervention/12510
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F12510%3E
Rosiglitazone maleate
http://data.linkedct.org/resource/intervention/62381
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F62381%3E
http://dbpedia.org/page/Rosiglitazone
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FRosiglitazone%3E
rosiglitazone
Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl).	Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPAR��. Rosiglitazone is a selective ligand of PPAR��, and has no PPAR��-binding action.	Apart from its effect on insulin resistance, it appears to have an anti-inflammatory effect: nuclear factor kappa-B (NF��B) levels fall and inhibitor (I��B) levels increase in patients on rosiglitazone.	Recent research has suggested that rosiglitazone may also be of benefit to a subset of patients with Alzheimer's disease not expressing the ApoE4 allele. This is the subject of a clinical trial currently underway.
Side effects include fluid retention, congestive heart failure (CHF), liver disease
http://data.linkedct.org/resource/intervention/27371
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F27371%3E
3.80e-02 mg/mL
DB00412
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2809
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2809%3E
Avandaryl (Glimepiride + Rosiglitazone maleate)
http://data.linkedct.org/resource/intervention/60383
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F60383%3E
99.8% bound to plasma proteins, primarily albumin.
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F683%3E
1999-05-01	/drugs/412/fda_labels/892
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/614
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F614%3E
/drugs/412/safety_sheets/1190
http://data.linkedct.org/resource/intervention/60344
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F60344%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/thazolidinediones
http://129.128.185.122/drugbank2/drugs/DB00412/inserts/1182/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00412%2Finserts%2F1182%2Ffull%3E
http://en.wikipedia.org/wiki/Rosiglitazone
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FRosiglitazone%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/851
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F851%3E
http://data.linkedct.org/resource/intervention/62304
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F62304%3E
Rosiglitazone acts as an agonist at peroxisome proliferator activated receptors (PPAR) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPAR-gamma receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In this way, rosiglitazone enhances tissue sensitivity to insulin.
http://data.linkedct.org/resource/intervention/27378
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F27378%3E
http://data.linkedct.org/resource/intervention/49770
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F49770%3E
http://data.linkedct.org/resource/intervention/38956
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F38956%3E
http://205.193.93.51/dpdonline/searchRequest.do?din=02241113
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02241113%3E
http://129.128.185.122/drugbank2/drugs/DB00412/inserts/2188/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00412%2Finserts%2F2188%2Ffull%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2472
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2472%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2152
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2152%3E
http://data.linkedct.org/resource/intervention/49768
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F49768%3E
CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
CN(CCOC1=CC=C(C[C@H]2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
http://www.rxlist.com/cgi/generic2/rosigl.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric2%2Frosigl.htm%3E
http://data.linkedct.org/resource/intervention/35582
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35582%3E
Avandia
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00230_DB00412
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01045_DB00412
RDF Description of Rosiglitazone
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01026_DB00412
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/PRKN
_:header4291371501335206580486
RDF Description of PRKN
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PRKN
http://symbol.bio2rdf.org/symbol:PRKN
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3APRKN%3E
PRKN
http://www.dbpedia.org/resource/Parkin_%28ligase%29
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FParkin_%2528ligase%2529%3E
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/FREM2
_:header8554689711335206580903
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/FREM2
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/416
http://symbol.bio2rdf.org/symbol:FREM2
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AFREM2%3E
FREM2
http://bio2rdf.org/hgnc:25396
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A25396%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=25396
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D25396%3E
http://bio2rdf.org/geneid:341640
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fgeneid%3A341640%3E
http://www.dbpedia.org/resource/FREM2
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FFREM2%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2406
RDF Description of FREM2
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Oppenheim_James_1882-1932
_:header14165282131335206581749
Mon, 23 Apr 2012 18:36:16 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Oppenheim_James_1882-1932
Oppenheim, James, 1882-1932
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext11372
RDF Description of Oppenheim, James, 1882-1932
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/199
_:header1988042301335206582268
Mon, 23 Apr 2012 18:36:17 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/199
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=458255
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D458255%3E
230-250
172-192
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=U05321
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DU05321%3E
U05321
MCT 7
SLC16A2
Very active and specific thyroid hormone transporter. Stimulates cellular uptake of thyroxine (T4), triiodothyronine (T3), reverse triiodothyronine (rT3) and diidothyronine. Does not transport Leu, Phe, Trp or Tyr
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7981683
387-407
http://bio2rdf.org/hgnc:10923
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A10923%3E
Monocarboxylate transporter 8
http://symbol.bio2rdf.org/symbol:SLC16A2
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ASLC16A2%3E
323-343
Xq13.2
201-221
>1620 bp	ATGGCGCTGCAAAGCCAGGCGAGCGAGGAAGCAAAGGGGCCCTGGCAGGAGGCAGACCAG	GAACAGCAGGAGCCGGTGGGTAGCCCAGAGCCGGAGTCTGAGCCGGAGCCTGAGCCCGAG	CCCGAGCCCGTGCCAGTGCCCCCGCCCGAGCCCCAGCCGGAGCCCCAGCCCCTACCGGAC	CCCGCACCCCTGCCGGAGCTGGAGTTCGAGTCCGAGCGGGTGCACGAACCCGAGCCCACG	CCTACGGTAGAGACCCGCGGCACCGCGCGCGGCTTCCAGCCTCCCGAAGGTGGCTTCGGC	TGGGTGGTGGTGTTCGCTGCCACCTGGTGCAACGGCTCCATCTTCGGCATCCATAACTCT	GTCGGGATCCTCTACTCCATGCTGCTAGAGGAGGAAAAGGAAAAAAATCGCCAAGTGGAG	TTCCAAGCAGCATGGGTCGGAGCCCTCGCGATGGGTATGATCTTCTTCTGTTCTCCCATT	GTGAGTATATTCACTGACCGTTTGGGCTGCCGAATCACAGCAACCGCGGGGGCTGCCGTT	GCTTTCATTGGCCTCCATACCAGCTCCTTCACCAGCTCCCTAAGCCTGCGCTACTTCACC	TACGGGATTCTCTTTGGTTGTGGCTGTTCCTTCGCCTTTCAGCCATCCCTCGTCATCCTG	GGCCACTACTTTCAACGCCGCCTGGGTCTGGCCAATGGTGTGGTGTCTGCTGGGAGTAGC	ATTTTCTCCATGTCCTTCCCCTTCCTCATCAGAATGCTGGGGGATAAGATCAAGCTGGCC	CAAACCTTCCAGGTGCTGAGTACCTTCATGTTTGTTCTTATGCTGCTTTCACTCACCTAC	CGGCCCCTCCTGCCCAGCTCCCAGGACACCCCAAGCAAGAGAGGTGTCCGCACCCTGCAC	CAGCGCTTTCTGGCTCAGCTCAGGAAGTACTTCAACATGCGAGTGTTCCGCCAACGCACT	TACCGCATCTGGGCCTTCGGAATTGCTGCTGCTGCCCTTGGCTACTTTGTTCCCTATGTA	CACCTGATGAAGTATGTGGAGGAGGAGTTCTCAGAAATCAAGGAGACCTGGGTGCTCTTG	GTGTGTATTGGGGCTACCTCAGGCCTTGGGCGTCTTGTGTCAGGCCACATCAGTGACTCC	ATCCCTGGACTTAAGAAGATCTACTTGCAGGTCCTTTCCTTCCTGCTCCTGGGCCTGATG	TCCATGATGATTCCCCTGTGCCGGGACTTCGGGGGCCTTATTGTCGTCTGTCTTTTCCTG	GGCCTTTGCGATGGCTTCTTCATCACCATCATGGCCCCCATTGCATTTGAGCTGGTGGGC	CCAATGCAGGCCTCACAGGCCATTGGCTACCTCCTGGGCATGATGGCCCTGCCAATGATT	GCTGGGCCCCCCATTGCAGGCCTACTCCGCAACTGTTTTGGGGACTACCATGTGGCCTTC	TACTTTGCCGGTGTGCCCCCCATCATCGGGGCTGTAATCCTCTTCTTCGTCCCTCTGATG	CATCAAAGGATGTTCAAGAAAGAGCAGAGAGATTCCAGCAAGGATAAGATGTTGGCCCCT	GACCCAGACCCCAATGGGGAGCTACTGCCGGGCTCCCCCAACCCTGAGGAACCAATCTAA
410-430
259-279
MCT 8
http://www.genenames.org/data/hgnc_data.php?hgnc_id=10923
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D10923%3E
>Monocarboxylate transporter 8	MALQSQASEEAKGPWQEADQEQQEPVGSPEPESEPEPEPEPEPVPVPPPEPQPEPQPLPD	PAPLPELEFESERVHEPEPTPTVETRGTARGFQPPEGGFGWVVVFAATWCNGSIFGIHNS	VGILYSMLLEEEKEKNRQVEFQAAWVGALAMGMIFFCSPIVSIFTDRLGCRITATAGAAV	AFIGLHTSSFTSSLSLRYFTYGILFGCGCSFAFQPSLVILGHYFQRRLGLANGVVSAGSS	IFSMSFPFLIRMLGDKIKLAQTFQVLSTFMFVLMLLSLTYRPLLPSSQDTPSKRGVRTLH	QRFLAQLRKYFNMRVFRQRTYRIWAFGIAAAALGYFVPYVHLMKYVEEEFSEIKETWVLL	VCIGATSGLGRLVSGHISDSIPGLKKIYLQVLSFLLLGLMSMMIPLCRDFGGLIVVCLFL	GLCDGFFITIMAPIAFELVGPMQASQAIGYLLGMMALPMIAGPPIAGLLRNCFGDYHVAF	YFAGVPPIIGAVILFFVPLMHQRMFKKEQRDSSKDKMLAPDPDPNGELLPGSPNPEEPI
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/16604139
Solute carrier family 16 member 2
144-164
X-linked PEST-containing transporter
357-377
X
97-117
http://www.uniprot.org/uniprot/P36021
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP36021%3E
MOT8_HUMAN
http://bio2rdf.org/uniprot:P36021
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP36021%3E
RDF Description of Monocarboxylate transporter 8
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Greg_Percy_1836-1889
_:header11399802401335206582669
RDF Description of Greg, Percy, 1836-1889
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Greg_Percy_1836-1889
Greg, Percy, 1836-1889
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext10165
http://www4.wiwiss.fu-berlin.de/dblp/data/person/286424
_:header10087906281335206583200
Mon, 23 Apr 2012 18:36:18 GMT
http://www4.wiwiss.fu-berlin.de/dblp/resource/person/286424
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/nips/KochLMH87
Carver Mead
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/iscas/DelbruckM94
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tcad/LinM86
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tcad/LinM84
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/nips/HaslerDMM94
RDF Description of Carver Mead
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/homepages/m/CarverMead
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/nips/LazzaroRMM88
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/iscas/DiorioMHMM95
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/computer/HutchinsonKLM88
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/pics/Mead01
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/nips/DelbruckM88
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/iscas/MinchDHM95
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/nips/DeWeerthM89
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/nn/MeadM88
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/iscas/LiuM94
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/nips/MinchHDM94
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/nips/RyckebuschBM88
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/ifip/Mead83
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/iscas/HaslerDMM95
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0019829
_:header15155018341335206583544
RDF Description of Hodgkins Disease
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0019829
http://sideeffects.embl.de/se/C0019829
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0019829%3E
Hodgkins Disease
C0019829
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/632
_:header9752335091335206583941
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/632
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2836
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/KAL1
Kallmann syndrome
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/FGFR1
http://data.linkedct.org/resource/condition/6956
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fcondition%2F6956%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2837
RDF Description of Kallmann syndrome
http://www4.wiwiss.fu-berlin.de/dblp/data/person/198166
_:header8382749351335206584562
Mon, 23 Apr 2012 18:36:19 GMT
http://www4.wiwiss.fu-berlin.de/dblp/resource/person/198166
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigopsE/GefflautJPLEUTDR00
Jochen Liedtke
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/sigops/Liedtke95
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigopsE/JaegerTGPEL00
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/rbac/JaegerGIL97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/sigops/LiedtkeBBHRS91
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/sigops/Liedtke94
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigopsE/LiedtkeIJPP98a
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/mkern/Liedtke92
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/pos/ElphinstoneRHL96
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/sigops/Liedtke96
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/hotos/LiedtkeIJ97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/pos/SkoglundCL00
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigopsE/LiedtkeVE00
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/cacm/Liedtke96
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/wiess/HaeberlenLPRU00
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/sigops/LiedtkeE96
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigopsE/Liedtke94
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/hotos/JaegerELPP99
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/aPcsac/AronLEPJD01
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/sigops/Liedtke95a
RDF Description of Jochen Liedtke
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/dagstuhl/HarigKL91
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sosp/HartigHLSW97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/hotos/LiedtkeW01
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/hotos/LiedtkeUEJP99
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/rtas/LiedtkeHH97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sosp/Liedtke93
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/sigops/Liedtke94a
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sosp/Liedtke95
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/hotos/LiedtkeESHHIJ97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/spe/HeiserEVRL98
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigopsE/JaegerLPPI98
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tissec/JaegerPLI99
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigopsE/LiedtkeIJPP98
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/arcs/Liedtke92
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/97
_:header14046588281335206584806
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/97
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1466
http://www.dbpedia.org/resource/Antley-Bixler_syndrome
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FAntley-Bixler_syndrome%3E
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB03247%3E
Antley-Bixler syndrome
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00865
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00865%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/POR
RDF Description of Antley-Bixler syndrome
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/3381
_:header20810656221335206585350
Mon, 23 Apr 2012 18:36:20 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3381
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03226
ADH3_BACST
Thermophilic NAD(+)-dependent alcohol dehydrogenase. Bears mainly an ethanol-dehydrogenase activity
>Alcohol dehydrogenase	MKAAVVEQFKEPLKIKEVEKPTISYGEVLVRIKACGVCHTDLHAAHGDWPVKPKLPLIPG	HEGVGIVEEVGPGVTHLKVGDRVGIPWLYSACGHCDYCLSGQETLCEHQKNAGYSVDGGY	AEYCRAAADYVVKIPDNLSFEEAAPIFCAGVTTYKALKVTGAKPGEWVAIYGIGGLGHVA	VQYAKAMGLNVVAVDIGDEKLELAKELGADLVVNPLKEDAAKFMKEKVGGVHAAVVTAVS	KPAFQSAYNSIRRGGACVLVGLPPEEMPIPIFDTVLNGIKIIGSIVGTRKDLQEALQFAA	EGKVKTIIEVQPLEKINEVFDRMLKGQINGRVVLTLEDK
http://bio2rdf.org/pdb:1RJW
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1RJW%3E
Involved in zinc ion binding
http://www.uniprot.org/uniprot/P42328
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP42328%3E
Alcohol dehydrogenase
http://www.pdb.org/pdb/explore/explore.do?structureId=1RJW
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1RJW%3E
http://bio2rdf.org/uniprot:P42328
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP42328%3E
>1020 bp	ATGAAAGCCGCTGTAGTTGAACAATTTAAGGAACCATTAAAAATAAAAGAAGTAGAAAAA	CCAACCATTTCATATGGAGAAGTATTAGTCCGCATTAAAGCATGCGGTGTTTGTCATACT	GACTTGCATGCCGCTCACGGCGATTGGCCGGTAAAACCAAAACTTCCTTTAATCCCTGGC	CATGAAGGAGTAGGAATTGTTGAAGAAGTAGGTCCAGGCGTAACCCATTTAAAAGTGGGC	GACCGCGTTGGAATTCCTTGGTTATATTCTGCATGCGGCCATTGTGATTATTGTTTAAGC	GGCCAAGAGACATTATGTGAGCACCAAAAAAACGCTGGCTACTCTGTTGATGGAGGGTAT	GCAGAATATTGCAGAGCGGCAGCAGACTATGTGGTTAAAATTCCTGACAACTTATCATTT	GAAGAAGCTGCCCCAATTTTCTGCGCCGGAGTTACTACCTATAAAGCGTTAAAAGTAACA	GGGGCAAAACCAGGAGAATGGGTAGCAATTTACGGTATCGGCGGCCTTGGACACGTTGCC	GTTCAATACGCGAAGGCGATGGGACTTAATGTCGTTGCTGTTGATATCGGCGACGAAAAA	CTTGAACTTGCAAAAGAACTTGGCGCTGATCTTGTTGTAAACCCTTTGAAAGAAGATGCA	GCGAAATTTATGAAAGAGAAAGTCGGCGGAGTTCACGCAGCAGTCGTAACAGCTGTATCT	AAGCCAGCGTTTCAATCTGCGTACAATTCTATCCGCAGAGGCGGAGCTTGTGTGCTTGTC	GGATTGCCACCGGAAGAAATGCCTATTCCAATTTTTGATACGGTTTTAAATGGAATCAAA	ATCATCGGTTCCATTGTCGGCACGCGGAAAGACCTGCAAGAAGCGCTCCAATTCGCAGCG	GAAGGTAAAGTAAAAACCATTATTGAAGTGCAACCTCTTGAAAAAATTAATGAAGTATTT	GACAGAATGCTAAAAGGTCAAATTAACGGGCGTGTAGTTTTAACGTTAGAAGATAAATAA
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8020473
ADH-HT
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=440138
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D440138%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=Z27089
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DZ27089%3E
Z27089
map00010	Glycolysis / Gluconeogenesis
RDF Description of Alcohol dehydrogenase
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Campbell_John_Douglas_Sutherland_1845-1914
_:header2460040891335206585764
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Campbell_John_Douglas_Sutherland_1845-1914
Campbell, John Douglas Sutherland, 1845-1914
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7212
RDF Description of Campbell, John Douglas Sutherland, 1845-1914
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/PDX1
_:header3642290941335206586157
Mon, 23 Apr 2012 18:36:21 GMT
RDF Description of PDX1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PDX1
http://symbol.bio2rdf.org/symbol:PDX1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3APDX1%3E
PDX1
http://www.dbpedia.org/resource/Pdx1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FPdx1%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2864
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/2781
_:header7921750411335206586658
RDF Description of Clemastine
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0043144
http://sideeffects.embl.de/drugs/2781
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F2781%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0022893
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00283
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00283%3E
Clemastine
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000002781
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000002781%3E
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000002781&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000002781%26input_query_species%3D9606%3E
CID0000002781
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0027813
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0011609
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Vatsyayana
_:header9544223841335206586965
RDF Description of Vatsyayana
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Vatsyayana
Vatsyayana
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext14609
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/75
_:header16072470521335206587360
Mon, 23 Apr 2012 18:36:22 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/75
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1419
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/ENAM
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/DLX3
Amelogenesis imperfecta
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseaseClass/Bone
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/AMELX
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/KLK4
http://www.dbpedia.org/resource/Amelogenesis_imperfecta
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FAmelogenesis_imperfecta%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1420
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1418
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1417
RDF Description of Amelogenesis imperfecta
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1416
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Hughes_Langston_1902-1967
_:header3416604151335206587782
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Hughes_Langston_1902-1967
Hughes, Langston, 1902-1967
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19435
RDF Description of Hughes, Langston, 1902-1967
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Booth_William_1829-1912
_:header11957702781335206588210
Mon, 23 Apr 2012 18:36:23 GMT
RDF Description of Booth, William, 1829-1912
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Booth_William_1829-1912
Booth, William, 1829-1912
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext475
http://www4.wiwiss.fu-berlin.de/drugbank/data/enzymes/39
_:header1404104061335206588591
RDF Description of Cholinesterase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/enzymes/39
http://bio2rdf.org/uniprot:P06276
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP06276%3E
http://www.uniprot.org/uniprot/P06276
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP06276%3E
Cholinesterase
>Cholinesterase	MHSKVTIICIRFLFWFLLLCMLIGKSHTEDDIIIATKNGKVRGMNLTVFGGTVTAFLGIP	YAQPPLGRLRFKKPQSLTKWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDC	LYLNVWIPAPKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGALG	FLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESAGAASVSLHLLSPG	SHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLTGCSRENETEIIKCLRNKDPQEI	LLNEAFVVPYGTPLSVNFGPTVDGDFLTDMPDILLELGQFKKTQILVGVNKDEGTAFLVY	GAPGFSKDNNSIITRKEFQEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDV	VGDYNFICPALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPLER	RDNYTKAEEILSRSIVKRWANFAKYGNPNETQNNSTSWPVFKSTEQKYLTLNTESTRIMT	KLRAQQCRFWTSFFPKVLEMTGNIDEAEWEWKAGFHRWNNYMMDWKNQFNDYTSKKESCV	GL
BCHE
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01927
_:header18235562511335206589069
Mon, 23 Apr 2012 18:36:24 GMT
RDF Description of Duroquinone
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01927
DB01927
Duroquinone
1QRD
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/146
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F146%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2949
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2949%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2388
2.23 [HANSCH,C ET AL. (1995)]
expt01265
WAMKWBHYPYBEJY-UHFFFAOYAK
2008-08-26 14:22:37 UTC
InChI=1/C10H12O2/c1-5-6(2)10(12)8(4)7(3)9(5)11/h1-4H3
C10H12O2
2,3,5,6-tetramethylcyclohexa-2,5-diene-1,4-dione
DQN
1.69e+00 mg/mL
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1593
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1593%3E
111.5 oC
http://bio2rdf.org/cas:527-17-3
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A527-17-3%3E
CC1=C(C)C(=O)C(C)=C(C)C1=O
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2157
http://www.drugbank.ca/drugs/DB01927
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01927%3E
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00822
_:header7343216001335206589472
RDF Description of Disulfiram
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00822
Teturam
Antietanol
TATD
Ancazide Et
Tetraethylthiram Disulphide
http://129.128.185.122/drugbank2/drugs/DB00822/inserts/2533/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00822%2Finserts%2F2533%2Ffull%3E
Tetraethylthiuran Disulfide
2008-08-26 14:37:56 UTC
Disulfram
LD<sub>50</sub>=8.6g/kg (orally in rats). Symptoms of overdose include irritation, slight drowsiness, unpleasant taste, mild GI disturbances, and orthostatic hypotension.
Tetradine
Disulfan
Nocceler Tet-G
TTS X
DB00822
Etyl Tuex
http://dbpedia.org/page/Disulfiram
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FDisulfiram%3E
Teturamin
Perkait Tetd
Tetraetil
Akrochem Tetd
http://data.linkedct.org/resource/intervention/4440
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F4440%3E
Sanceler Tet
http://bio2rdf.org/kegg:D00131
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD00131%3E
Tetraethylthiram Disulfide
http://www.dbpedia.org/resource/Disulfiram
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FDisulfiram%3E
Nocbin
TTS
Antabuse
Thireranide
Tillram
Soxinol Tet
Refusal
Super Rodiatox
Abstensil
C10H20N2S4
Ro-Sulfiram
Usaf B-33
Disetil
Antivitium
Ekagom Teds
http://www.drugbank.ca/drugs/DB00822
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00822%3E
A carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. When alcohol is ingested after administration of disulfiram, blood acetaldehyde concentrations are increased, followed by flushing, systemic vasodilation, respiratory difficulties, nausea, hypotension, and other symptoms (acetaldehyde syndrome). It acts by inhibiting aldehyde dehydrogenase. [PubChem]
http://www.rxlist.com/cgi/generic/disulfiram.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric%2Fdisulfiram.htm%3E
1.26e-02 mg/mL
http://data.linkedct.org/resource/intervention/57835
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F57835%3E
http://data.linkedct.org/resource/intervention/26112
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F26112%3E
Abstinil
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F4070%3E
Stopaethyl
Esperal
Dupont Fungicide 4472
PA449376
Exhoran
Anti-Ethyl
Bonibal
Ekagom Dtet
Ethyl Tuads Rodform
Abstinyl
Stopethyl
N07BB01
Gababentin
CCN(CC)C(=S)SSC(=S)N(CC)CC
Nocceler Tet
Ethyl Thiram
Tetraethylthioperoxydicarbonic Diamide
Dicupral
Etabus
Anthethyl
Hoca
4.09 mg/L
http://data.linkedct.org/resource/intervention/47262
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F47262%3E
Aversan
Stopety
Antaetil
Thiocid
For the treatment and management of chronic alcoholism
http://bio2rdf.org/chebi:4659
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fchebi%3A4659%3E
Antikol
http://en.wikipedia.org/wiki/Disulfiram
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FDisulfiram%3E
Alcophobin
Contralin
Tetraethylthiuram Disulfide
http://bio2rdf.org/cas:97-77-8
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A97-77-8%3E
Noxal
Ethyl Thiurad
Stopetyl
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/811
InChI=1/C10H20N2S4/c1-5-11(6-2)9(13)15-16-10(14)12(7-3)8-4/h5-8H2,1-4H3
Disulfiram
Exhorran
Antaethyl
Averzan
diethylcarbamothioylsulfanyl diethylaminomethanedithioate
Ethyl Tuads
Tetraethylthiuram Sulfide
Espenal
Thiophos
Disulfuram
Krotenal
Anticol
Antalcol
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/alcoholDeterrents
Disulfiram blocks the oxidation of alcohol at the acetaldehyde stage during alcohol metabolism following disulfiram intake causing an accumulation of acetaldehyde in the blood producing highly unpleasant symptoms. Disulfiram blocks the oxidation of alcohol through its irreversible inactivation of aldehyde dehydrogenase, which acts in the second step of ethanol utilization. In addition, disulfiram competitively binds and inhibits the peripheral benzodiazepine receptor, which may indicate some value in the treatment of the symptoms of alcohol withdrawal, however this activity has not been extensively studied.
http://129.128.185.122/drugbank2/drugs/DB00822/inserts/1538/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00822%2Finserts%2F1538%2Ffull%3E
71.5 oC
Antaethan
Accel Tet
Tetraethylthiuram
Ekaland Tetd
Antethyl
Anteyl
Cronetal
P03AA04
http://dbpedia.org/resource/Disulfiram
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FDisulfiram%3E
aprd00767
/drugs/822/safety_sheets/1363
Dupon 4472
Tetradin
Thioscabin
Tetraethylthiuram Disulphide
Disulphuram
http://205.193.93.51/dpdonline/searchRequest.do?din=00002534
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D00002534%3E
Disulfiram produces a sensitivity to alcohol which results in a highly unpleasant reaction when the patient under treatment ingests even small amounts of alcohol. Disulfiram blocks the oxidation of alcohol at the acetaldehyde stage during alcohol metabolism following disulfiram intake, the concentration of acetaldehyde occurring in the blood may be 5 to 10 times higher than that found during metabolism of the same amount of alcohol alone. Accumulation of acetaldehyde in the blood produces a complex of highly unpleasant symptoms referred to hereinafter as the disulfiram-alcohol reaction. This reaction, which is proportional to the dosage of both disulfiram and alcohol, will persist as long as alcohol is being metabolized. Disulfiram does not appear to influence the rate of alcohol elimination from the body. Prolonged administration of disulfiram does not produce tolerance; the longer a patient remains on therapy, the more exquisitely sensitive he becomes to alcohol.
Antadix
http://bio2rdf.org/cpd:C01692
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC01692%3E
-4.86 [ADME Research, USCD]
Antabus
Antaenyl
http://data.linkedct.org/resource/intervention/60789
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F60789%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3117
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fsider%2Fresource%2Fdrugs%2F3117%3E
Tiuram
Tetidis
Ethyl Tuex
Contrapot
Ethyldithiurame
Tenurid
Disulfiram is absorbed slowly from the gastrointestinal tract (80 to 90% of oral dose).
Ethyl Thiudad
Antiaethan
TETD
Antietil
http://data.linkedct.org/resource/intervention/35717
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F35717%3E
Perkacit Tetd
Sanceler Tet-G
TTD
Antetan
Ephorran
Tenutex
Ethyldithiourame
Alk-Aubs
Ekagom Tetds
Avoid alcohol for up to 14 days after treatment has been stopped.
Accel Tet-R
http://data.linkedct.org/resource/intervention/21267
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F21267%3E
Antetil
AUZONCFQVSMFAP-UHFFFAOYAF
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00822_DB00266
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00701_DB00822
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01320_DB00822
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00822_DB00277
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00822_DB00916
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00822_DB00754
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01223_DB00822
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00822_DB00682
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00277_DB00822
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00951_DB00822
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01303_DB00822
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00822_DB00532
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00822_DB01320
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00822_DB00951
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00822_DB00651
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00822_DB01418
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00822_DB00356
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00822_DB01223
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00916_DB00822
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00822_DB01125
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00356_DB00822
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00822_DB00907
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00822_DB01303
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00822_DB00701
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00694
_:header19951049211335206589905
RDF Description of Daunorubicin
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00694
208-209 oC
Daunamycin
http://data.linkedct.org/resource/intervention/38373
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F38373%3E
C27H29NO10
/drugs/694/safety_sheets/719
6.27e-01 mg/mL
Rp 13057 Hydrochloride
Daunomycin, Hydrochloride
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/antibiotics
97% binding-albumin
L01DB02
http://129.128.185.122/drugbank2/drugs/DB00694/inserts/1440/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00694%2Finserts%2F1440%2Ffull%3E
STQGQHZAVUOBTE-VGBVRHCVBQ
http://en.wikipedia.org/wiki/Daunorubicin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FDaunorubicin%3E
Daunorubicin
J. P. Parsh et al. J. Pharm. Sci. 56, 1691 (1967);	E. M. Acton et al., J. Med. Chem. 17, 659 (1974)
http://129.128.185.122/drugbank2/drugs/DB00694/inserts/507/full
aprd00521
Daunorubicin Hcl
Ondena
PA449212
Leukaemomycin C
http://data.linkedct.org/resource/intervention/4103
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F4103%3E
(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O
Daunoblastin
For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
BNR
Antibiotics From Streptomyces Coeruleorubidus
Daunomycin
Daunorubicin Hydrochloride
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. [PubChem]
LD<sub>50</sub>=20 mg/kg (mice, IV); LD<sub>50</sub>=13 mg/kg (rat, IV)
Cerubidine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/862
http://data.linkedct.org/resource/intervention/16929
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F16929%3E
http://data.linkedct.org/resource/intervention/16928
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F16928%3E
Daunoxome
Rubomycin C
Daunorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Daunorubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.
39.2 mg/L
Daunorubicine
InChI=1/C27H29NO10/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3/t10-,14-,16-,17-,22+,27-/m0/s1
Cerubidin
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/antibiotics,Antineoplastic
http://bio2rdf.org/cas:20830-81-3
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A20830-81-3%3E
http://data.linkedct.org/resource/intervention/38503
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F38503%3E
Daunorubicinum [INN-Latin]
Anthracyline
Daunorubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Daunorubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Daunorubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. The anthracyclines are cell cycle-nonspecific.
http://205.193.93.51/dpdonline/searchRequest.do?din=02231420
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02231420%3E
http://dbpedia.org/resource/Daunorubicin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FDaunorubicin%3E
http://bio2rdf.org/chebi:4330
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fchebi%3A4330%3E
Daunorrubicina
2008-08-26 15:51:10 UTC
http://bio2rdf.org/cpd:C01907
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC01907%3E
Daunarubicinum
Daunomycin Hydrochloride
http://data.linkedct.org/resource/intervention/26755
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F26755%3E
http://www.drugbank.ca/drugs/DB00694
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00694%3E
DM1
18.5 hours
Acetyladriamycin
DB00694
http://data.linkedct.org/resource/intervention/26737
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F26737%3E
Rubidomycin Hydrochloride
http://www.rxlist.com/cgi/generic2/daunorubicin.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric2%2Fdaunorubicin.htm%3E
http://129.128.185.122/drugbank2/drugs/DB00694/inserts/2437/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00694%2Finserts%2F2437%2Ffull%3E
COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(CC(O)(CC3OC3CC(N)C(O)C(C)O3)C(C)=O)C(O)=C1C2=O
Rcra Waste No. U059
Rubidomycin
http://data.linkedct.org/resource/intervention/50139
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F50139%3E
http://dbpedia.org/page/Daunorubicin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FDaunorubicin%3E
Daunorubicin, Hydrochloride
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/RAC2
_:header14637440411335206590300
Mon, 23 Apr 2012 18:36:25 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/RAC2
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/834
http://symbol.bio2rdf.org/symbol:RAC2
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ARAC2%3E
RAC2
http://www.dbpedia.org/resource/Rac2
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FRac2%3E
RDF Description of RAC2
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3369
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Napier_James_1810-1884
_:header13944220281335206590709
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Napier_James_1810-1884
Napier, James, 1810-1884
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext15792
RDF Description of Napier, James, 1810-1884
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Ulbach_Louis_1822-1889
_:header14725469021335206591119
Mon, 23 Apr 2012 18:36:26 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Ulbach_Louis_1822-1889
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext18995
Ulbach, Louis, 1822-1889
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17643
RDF Description of Ulbach, Louis, 1822-1889
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/5466
_:header20044111681335206591607
RDF Description of Gabitril
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000005466&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000005466%26input_query_species%3D9606%3E
http://www.fda.gov/cder/foi/label/2005/020646s014lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2005%2F020646s014lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0027932
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0026650
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00906
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00906%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3553
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3553%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0018520
CID0000005466
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0014544
http://www.fda.gov/cder/foi/label/2005/020646s015lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2005%2F020646s015lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000005466
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000005466%3E
Gabitril
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0028259
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0031256
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0009917
http://www.fda.gov/medwatch/SAFETY/2005/Feb_PI/Gabitril_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2005%2FFeb_PI%2FGabitril_PI.pdf%3E
http://dbpedia.org/resource/Tiagabine
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FTiagabine%3E
tiagabine
http://sideeffects.embl.de/drugs/5466
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F5466%3E
GABITRIL
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01505
_:header15776332471335206591942
RDF Description of Etoxeridine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01505
CCOC(=O)C1(CCN(CCOCCO)CC1)C1=CC=CC=C1
http://bio2rdf.org/cas:469-82-9
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A469-82-9%3E
InChI=1/C18H27NO4/c1-2-23-17(21)18(16-6-4-3-5-7-16)8-10-19(11-9-18)12-14-22-15-13-20/h3-7,20H,2,8-15H2,1H3
Etoxeridine
1.37e+00 mg/mL
2007-07-31 13:10:03 UTC
C18H27NO4
DB01505
http://bio2rdf.org/kegg:D02151
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD02151%3E
2008-08-26 16:07:52 UTC
http://www.drugbank.ca/drugs/DB01505
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01505%3E
KJTKYGFGPQSRRA-UHFFFAOYAV
ethyl 1-[2-(2-hydroxyethoxy)ethyl]-4-phenylpiperidine-4-carboxylate
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Aristophanes_446?_BC-385?_BC
_:header17109062491335206592371
Mon, 23 Apr 2012 18:36:27 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Aristophanes_446?_BC-385?_BC
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8688
Aristophanes, 446? BC-385? BC
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2571
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2562
RDF Description of Aristophanes, 446? BC-385? BC
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3012
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7998
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3013
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17814
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7700
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8689
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/4752
_:header6596148631335206592999
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4752
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00173
2q35
Peroxisomal trans-2-enoyl-CoA reductase
PECR_HUMAN
>Peroxisomal trans-2-enoyl-CoA reductase	MASWAKGRSYLAPGLLQGQVAIVTGGATGIGKAIVKELLELGSNVVIASRKLERLKSAAD	ELQANLPPTKQARVIPIQCNIRNEEEVNNLVKSTLDTFGKINFLVNNGGGQFLSPAEHIS	SKGWHAVLETNLTGTFYMCKAVYSSWMKEHGGSIVNIIVPTKAGFPLAVHSGAARAGVYN	LTKSLALEWACSGIRINCVAPGVIYSQTAVENYGSWGQSFFEGSFQKIPAKRIGVPEEVS	SVVCFLLSPAASFITGQSVDVDGGRSLYTHSYEVPDHDNWPKGAGDLSVVKKMKETFKEK	AKL
DCR-RP
EC 1.3.1.38
regulation of programmed cell death
http://bio2rdf.org/uniprot:Q9BY49
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ9BY49%3E
AJ250303
http://www.genenames.org/data/hgnc_data.php?hgnc_id=18281
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D18281%3E
http://bio2rdf.org/pdb:1YXM
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1YXM%3E
regulation of cellular physiological process
http://bio2rdf.org/hgnc:18281
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A18281%3E
>912 bp	ATGGCCTCCTGGGCTAAGGGCAGGAGCTACCTGGCGCCTGGTTTGCTGCAGGGCCAAGTG	GCATTCGTCACCGGCGGGGCCACGGGCATCGGAAAAGCCATCGTGAAGGAGCTCCTGGAG	CTGGGGAGTAATGTGGTCATTGCATCCCGTAAGTTGGAGAGATTGAAGTCTGCGGCAGAT	GAACTGCAGGCCAACCTACCTCCCACAAAGCAGGCACGAGTCATTCCCATACAATGCAAC	ATCCGGAATGAGGAGGAGGTGAATAATTTGGTCAAATCTACCTTAGATACTTTTGGTAAG	ATCAATTTCTTGGTGAACAATGGAGGAGGCCAGTTTCTTTCCCCTGCTGAACACATCAGT	TCTAAGGGATGGCACGCTGTCTTGAGAACCAACCTGACGGGTAGCTTCTACATGTGCAAA	GCAGTTTACAGCTCCTGGATGAAAGAGCATGGAGGATCTATCGTCAATATCATTGTCCCT	ACTAAAGCTGGATTTCCATTAGCTGTGCATTCTGGAGCTGCAAGAGCAGGTGTTTACAAC	CTCACCAAATCTTTAGCTTTGGAATGGGCCTGCAGTGGAATACGGATCAATTGTGTTGCC	CCTGGAGTTATTTATTCCCAGACTGCTGTGGAGAACTATGGTTCCTGGGGACAAAGCTTC	TTTGAAGGGTCTTTTCAGAAAATCCCCGCTAAACGAATTGGTGTTCCTGAGGAGGTCTCC	TCTGTGGTCTGCTTCCTACTGTCTCCTGCAGCTTCCTTCATCACTGGACAGTCGGTGGAT	GTGGATGGGGGCCGGAGTCTCTATACTCACTCGTATGAGGTACCAGATCATGACAACTGG	CCCAAGGGAGCAGGGGACCTTTCTGTTGTCAAAAAGATGAAGGAGACCTTTAAGGAGAAA	GCTAAGCTCTGA
http://www.uniprot.org/uniprot/Q9BY49
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ9BY49%3E
PECR
TERP
HPDHase
Participates in chain elongation of fatty acids. Has no 2,4-dienoyl-CoA reductase activity
2,4-dienoyl-CoA reductase-related protein
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10811639
pVI-ARL
regulation of apoptosis
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11669066
http://www.pdb.org/pdb/explore/explore.do?structureId=1YXM
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1YXM%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AJ250303
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAJ250303%3E
RDF Description of Peroxisomal trans-2-enoyl-CoA reductase
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/2123
_:header19825052171335206593365
Mon, 23 Apr 2012 18:36:28 GMT
RDF Description of altretamine
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2123
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000002123
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000002123%3E
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000002123&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000002123%26input_query_species%3D9606%3E
CID0000002123
altretamine
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2205
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2205%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0525045
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00488
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00488%3E
http://dbpedia.org/resource/Altretamine
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FAltretamine%3E
http://sideeffects.embl.de/drugs/2123
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F2123%3E
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/TNFA
_:header9375208461335206593795
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/TNFA
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3045
http://symbol.bio2rdf.org/symbol:TNFA
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ATNFA%3E
TNFA
http://www.dbpedia.org/resource/Tumor_necrosis_factor-alpha
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FTumor_necrosis_factor-alpha%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3867
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3166
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2129
RDF Description of TNFA
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1507
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01081
_:header21236748001335206594354
Mon, 23 Apr 2012 18:36:29 GMT
RDF Description of Diphenoxylate
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01081
Diphenoxylate is an opiate receptor agonists that stimulate mu receptors in GI to decrease the peristalsis and constrict the sphincters. Diphenoxylate has a direct effect on circular smooth muscle of the bowel, that conceivably results in segmentation and prolongation of gastrointestinal transit time. The clinical antidiarrheal action of diphenoxylate may thus be a consequence of enhanced segmentation that allows increased contact of the intraluminal contents with the intestinal mucosa.
Diphenoxylate
1.46e-03 mg/mL
Janssen, U.S. pat. 2,898,340 (1959)
http://dbpedia.org/page/Diphenoxylate
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FDiphenoxylate%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/antiperistaltic
Diphenoxylatum [INN-Latin]
90%
http://bio2rdf.org/cas:915-30-0
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A915-30-0%3E
http://bio2rdf.org/kegg:D00301
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD00301%3E
http://dbpedia.org/resource/Diphenoxylate
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FDiphenoxylate%3E
http://129.128.185.122/drugbank2/drugs/DB01081/inserts/1346/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB01081%2Finserts%2F1346%2Ffull%3E
DB01081
12-14 hours
HYPPXZBJBPSRLK-UHFFFAOYAG
http://data.linkedct.org/resource/intervention/45442
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F45442%3E
Lomotil (Atropine Sulfate + Diphenoxylate Hcl)
Coma, dry skin and mucous membranes, enlarged pupils of the eyes, extremely high body temperature, flushing, involuntary eyeball movement, lower than normal muscle tone, pinpoint pupils, rapid heartbeat, restlessness, sluggishness, suppressed breathing
Diphenoxylate, an antidiarrheal, is effective as adjunctive therapy in the management of diarrhea. Diphenoxylate is rapidly and extensively metabolized in man by ester hydrolysis to diphenoxylic acid (difenoxine), which is biologically active and the major metabolite in the blood.
C30H32N2O2
Diphenoxalate
InChI=1/C30H32N2O2/c1-2-34-28(33)29(25-12-6-3-7-13-25)18-21-32(22-19-29)23-20-30(24-31,26-14-8-4-9-15-26)27-16-10-5-11-17-27/h3-17H,2,18-23H2,1H3
http://www.dbpedia.org/resource/Diphenoxylate
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FDiphenoxylate%3E
Lomotil
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/antidiarrheals
http://www.drugbank.ca/drugs/DB01081
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01081%3E
74-95%
http://www.rxlist.com/cgi/generic3/diphenoxylate.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric3%2Fdiphenoxylate.htm%3E
http://129.128.185.122/drugbank2/drugs/DB01081/inserts/439/full
/drugs/1081/safety_sheets/732
A meperidine congener used as an antidiarrheal, usually in combination with atropine. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity. This medication is classified as a Schedule V under the Controlled Substances Act by the Food and Drug Administration (FDA) and the DEA in the United States when used in preparations. When diphenoxylate is used alone, it is classified as a Schedule II.
221 oC
A07DA01
Difenossilato [Dcit]
2008-08-26 14:47:39 UTC
http://129.128.185.122/drugbank2/drugs/DB01081/inserts/2346/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB01081%2Finserts%2F2346%2Ffull%3E
0.8 mg/ml
For as adjunctive therapy in the management of diarrhea
ethyl 1-[3-cyano-3,3-di(phenyl)propyl]-4-phenylpiperidine-4-carboxylate
CCOC(=O)C1(CCN(CC1)CCC(C#N)(C1=CC=CC=C1)C1=CC=CC=C1)C1=CC=CC=C1
Difenoxilato [INN-Spanish]
aprd00366
http://en.wikipedia.org/wiki/Diphenoxylate
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FDiphenoxylate%3E
Diphenoxylate Hydrochloride
Dea No. 9170
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/analgesics,Opioid
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00843_DB01081
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00674_DB01081
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00305
_:header10488425601335206594852
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00305
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00305_DB00570
http://en.wikipedia.org/wiki/Mitomycin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FMitomycin%3E
Ametycin
DB00305
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/alkylatingAgents
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/powderForSolutionIntravesical
1.01e+01 mg/mL
http://129.128.185.122/drugbank2/drugs/DB00305/inserts/157/full
http://129.128.185.122/drugbank2/drugs/DB00305/inserts/929/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00305%2Finserts%2F929%2Ffull%3E
Muamycin
http://bio2rdf.org/cpd:C06681
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC06681%3E
For treatment of malignant neoplasm of lip, oral cavity, pharynx, digestive organs, peritoneum, female breast, and urinary bladder.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/nucleicAcidSynthesisInhibitors
Mitomycin (TN)
L01DC03
8-48 min
MMC
http://dbpedia.org/resource/Mitomycin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FMitomycin%3E
PA450524
Mytomycin
CO[C@]12[C@H]3N[C@H]3C[N@]1C1=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O
COC12C3NC3CN1C1=C(C2COC(N)=O)C(=O)C(N)=C(C)C1=O
http://bio2rdf.org/chebi:27504
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fchebi%3A27504%3E
Mutamycin
An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional alkylating agents causing cross-linking of DNA and inhibition of DNA synthesis. [PubChem]
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/cross-linkingReagents
Mito-C
Mytozytrex
http://129.128.185.122/drugbank2/drugs/DB00305/inserts/1945/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00305%2Finserts%2F1945%2Ffull%3E
Mitomycin
Mitocin-C
Erratic.
Mitomycinum C
http://data.linkedct.org/resource/intervention/59545
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F59545%3E
Soluble (8430 mg/L)
InChI=1/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1/f/h17H2
Primarily hepatic, some in various other tissues.
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/303
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F303%3E
http://bio2rdf.org/kegg:D00208
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD00208%3E
NWIBSHFKIJFRCO-XPNHIKBZDF
http://bio2rdf.org/cas:50-07-7
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A50-07-7%3E
> 360 oC
2002-11-01	/drugs/305/fda_labels/850
2008-08-26 16:49:41 UTC
http://www.rxlist.com/cgi/generic3/mitomycin.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric3%2Fmitomycin.htm%3E
/drugs/305/safety_sheets/1039
C15H18N4O5
http://www.dbpedia.org/resource/Mitomycin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FMitomycin%3E
Ametycine
Mitomycyna C [Polish]
http://dbpedia.org/page/Mitomycin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FMitomycin%3E
6-Amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-5-methyl-azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione carbamate (ester)
Mitamycin
http://www.drugbank.ca/drugs/DB00305
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00305%3E
http://205.193.93.51/dpdonline/searchRequest.do?din=02230729
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02230729%3E
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fsider%2Fresource%2Fdrugs%2F5746%3E
Oral, mouse: LD<sub>50</sub> = 23 mg/kg; Oral, rat: LD<sub>50</sub> = 30 mg/kg. Symptoms of overdose include nausea and vomiting.
Mitomycin is one of the older chemotherapy drugs, which has been around and in use for decades. It is an antibiotic which has been shown to have antitumor activity. Mitomycin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of mitomycin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed. Mitomycin has been shown <i>in vitro</i> to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNFa, and IL-2.
http://data.linkedct.org/resource/intervention/18858
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F18858%3E
http://data.linkedct.org/resource/intervention/9335
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F9335%3E
Mitomycin is activated in vivo to a bifunctional and trifunctional alkylating agent. Binding to DNA leads to cross-linking and inhibition of DNA synthesis and function. Mitomycin is cell cycle phase-nonspecific.
Mit-C
Mitomycinum
7-Amino-9&alpha;-methoxymitosane
Uzu et al.; Agric.Biol.Chem.; 28; 394,401(1964)
Mitozytrex
aprd00284
Mitomycin C
Mitomycin-C
RDF Description of Mitomycin
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00305_DB00541
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00305_DB00309
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB04816
_:header15031903671335206595324
Mon, 23 Apr 2012 18:36:30 GMT
RDF Description of Danthron
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04816
193 oC
Dorbantyl
http://bio2rdf.org/chebi:3682
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fchebi%3A3682%3E
Dorbane
2007-09-11 20:07:41 UTC
http://dbpedia.org/page/Danthron
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FDanthron%3E
DHAQ
1,8-Dihydroxyanthra-9,10-quinone
Dantronum [inn-latin]
Chrysazin
http://www.drugbank.ca/drugs/DB04816
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB04816%3E
Danthron
Roydan
1,8-dihydroxyanthracene-9,10-dione
Istan
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/cathartics
Istizin
Dioxyanthrachinonum
Pastomin
1,8-Dihydroanthraquinone
Laxanthreen
Bancon
OC1=CC=CC2=C1C(=O)C1=C(C=CC=C1O)C2=O
Scatron d
http://www.dbpedia.org/resource/Dantron
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FDantron%3E
Regulin
Modane
Danivac
LTAN
3.05e-01 mg/mL
Withdrawn from the Canadian, US, and UK markets in 1998 due to genotoxicity.
Antrapurol
Laxipur
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/mutagens
1,4,5,8-Tetroxyantraquinone
Laxipurin
2008-08-26 15:23:47 UTC
InChI=1/C14H8O4/c15-9-5-1-3-7-11(9)14(18)12-8(13(7)17)4-2-6-10(12)16/h1-6,15-16H
Neokutin s
Dorbanex
PA449206
http://en.wikipedia.org/wiki/Danthron
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FDanthron%3E
Usaf nd-59
1,8-Dihydroxyanthraquinone
Dantrona [inn-spanish]
Diaquone
Criasazin
http://dbpedia.org/resource/Danthron
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FDanthron%3E
Dantrone [inn-french]
C14H8O4
1,8-Dihydroxy-9,10-anthracenedione
Chrysazine
1,8-Dihydroxyanthrachinon
Dihydroxyanthraquinone
Prugol
http://bio2rdf.org/cas:117-10-2
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A117-10-2%3E
Duolax
Zwitsalax
1,8-Dihydroxyanthrachinon [Czech]
QBPFLULOKWLNNW-UHFFFAOYAR
DB04816
Dionone
1,8-Dihydroxy-9,10-anthraquinone
Altan
Laxanorm
http://bio2rdf.org/cpd:C10312
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC10312%3E
Dantron
Istin
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/4759
_:header19797889201335206595805
RDF Description of Adenylate cyclase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4759
http://bio2rdf.org/pfam:PF00989
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00989%3E
http://pfam.sanger.ac.uk/family?acc=PF00211
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00211%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9171404
phosphorus-oxygen lyase activity
nucleotide metabolism
nucleotide biosynthesis
>2583 bp	ATGTCATTGCAACAGCGTAATTTTGGGGAGACTGGCGATTTGATCTTAGGTACGCAAAAC	CAAGAGCAAAACTTGCCAGAAACTTCGGCTCCTGTCGGCACACTAGCCCGCAGAAAAGGT	ACTATTTCGACATTTCTTGCTCCCTTAACTCAGGATACTTTTAAACAAGTTGTTACAGAA	GTCGAGCAAAAACTCCAAATTGTGCATCAAACCCTGTCAATGTTGGATTCTCACGGGTTT	GAAAATATCCTGCAAGAGATGTTGCAGTCAATTACCTTAAAAACTGGGGAATTGTTGGGG	GCAGATCGGACGACTATATTTTTGCTAGATGAAGAAAAACAAGAATTGTGGTCGATTGTC	GCCGCCGGAGAAGGCGATCGCTCCCTAGAAATTCGCATCCCCGCCGACAAGGGGATTGCC	GGTGAAGTCGCTACTTTTAAACAAGTAGTTAATATACCCTTTGACTTTTATCACGATCCT	CGGTCGATATTTGCCCAAAAACAAGAGAAAATCACTGGCTACCGCACATATACAATGCTG	GCTTTACCGCTATTGAGTGAGCAAGGGCGATTAGTCGCGGTGGTACAGTTACTCAACAAA	TTAAAACCTTACAGTCCTCCTGATGCACTGCTAGCAGAACGGATTGATAATCAAGGTTTT	ACCAGTGCAGATGAGCAATTGTTTCAAGAATTTGCGCCCTCAATTCGCTTGATTTTGGAG	TCGTCACGCTCCTTTTATATAGCGACGCAAAAACAAAGGGCGGCGGCGGCGATGATGAAG	GCGGTAAAGTCTCTGAGCCAAAGTAGTCTGGATTTAGAAGATACCCTCAAACGGGTAATG	GATGAAGCCAAGGAACTGATGAACGCCGATCGCAGTACCTTATGGCTGATAGACCGCGAT	CGCCATGAATTATGGACGAAAATTACTCAAGATAATGGTTCTACTAAGGAGTTGCGCGTT	CCCATAGGTAAAGGTTTTGCCGGGATCGTCGCCGCATCCGGTCAAAAACTCAACATCCCT	TTTGATTTATACGACCATCCAGACTCGGCAACTGCCAAACAAATCGACCAGCAAAATGGC	TACCGCACCTGTAGTTTATTATGTATGCCTGTATTTAACGGCGACCAAGAATTAATTGGT	GTGACCCAACTGGTAAATAAAAAGAAAACCGGAGAGTTCCCCCCCTATAATCCAGAAACT	TGGCCGATAGCGCCCGAATGCTTCCAAGCGAGTTTTGACCGCAACGACGAAGAATTCATG	GAAGCTTTTAATATTCAAGCCGGGGTGGCTTTACAAAATGCTCAGTTGTTTGCCACAGTC	AAGCAACAAGAGCAAATGCAACGGGATATTCTGCGGAGTTTGTCCAACGGTGTGATTTCC	ACAGATAAGTCTGGGACAATTATTGCAGCGAATGAAAGCGCCCAGCGTTTGTTGGGGCTG	GAATCAGAAGATCGTTTGGAAGGTAAACTCATCAGTGAGGCGATCGCCATTAAAGAAGGC	GATTTTAGCAAATGGTGTCAAGATGCCTTACATGGGACAGACCTCAAAGGCCGCCAGCAA	TATTACCCAGACCGCACACTAGTAAGCACTGAAGCAGCACAAAATAGCATTAACCTATCG	ATTAATACCATTGCCGATGCTAGCGATCCCCAGCAAGTCTGCGGCGCGTTGGTGGTGATG	GAAGATATTAGCGATGAGAAGCGCCTCAAGAGTACGATGTATCGCTACATGACTCAGGAA	TTAGCCGAGGAATTGCTGAAATTAGACGATGCTAAACTGGGAGGCGATCGCAAAGAAGTT	TCCATCCTCTTTTCGGATATTCGCGGTTACACCACTTTGACGGAAAATCTGGAAGCCGAA	GAAGTCGTAAGTATGCTCAATGAATATTTTGAGTCGATGGTAGAGGCTGTATTCAAACAC	AAAGGCACTCTGGATAAATACATCGGTGATGCGATTATGGCCGTGTTTGGTTCACCTTTG	CCCTTAGAAGAACACGCTTGGATGGCTGTAAAAACATCTATAGAAATGCGTCATCGCTTA	CAAGAATTTAATCAAAAACGTTATGCAGCTAATAAACCCCGAATCAATATCGGTATTGGC	ATCAATTCCGACACCGTAATTAGTGGCAACATTGGCTCTAGTAAACGTATGGAATTTACA	GCTATTGGTGATGGTGTGAATCTGGGTTCCCGCTTAGAAAGTGTGAGTAAGCAGTATGGT	TGCGACATTATTCTCAGTGATAATACTTTTAAACCATGCCAGGAAAATATTTGGGCTAGA	GAACTAGATTTTATCCGTGTTAAAGGCAGAAATGAGCCAGTATCTATATACGAGTTAATT	GGTTTACGTTCTGTCCCCATTGCTAGTGAAAAATTGCAGGTAATTGAGCATTATCACAAG	GGACGGGAATATTACCTGCAACGTCAATTTTCCTTAGCAAGAGCAGAATTTGCCAATGTT	TTAGCAGTTGATAAACATGACAAAGCCGCGATGTTGCATCTGCTACGCTGTCAGCATTGG	TTACAATCACCTCCAACAGATTCAGAATGGGATGAAGGGGTGTGGACGTTTCAGGAGAAG	TGA
http://bio2rdf.org/uniprot:P94182
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP94182%3E
http://bio2rdf.org/pfam:PF01590
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF01590%3E
cyclic nucleotide biosynthesis
Adenylate cyclase
EC 4.6.1.1
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=D89624
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DD89624%3E
http://bio2rdf.org/pdb:1YKD
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1YKD%3E
http://www.uniprot.org/uniprot/P94182
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP94182%3E
http://pfam.sanger.ac.uk/family?acc=PF01590
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF01590%3E
http://pfam.sanger.ac.uk/family?acc=PF00989
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00989%3E
D89624
P94182_9NOST
>Adenylate cyclase	MSLQQRNFGETGDLILGTQNQEQNLPETSAPVGTLARRKGTISTFLAPLTQDTFKQVVTE	VEQKLQIVHQTLSMLDSHGFENILQEMLQSITLKTGELLGADRTTIFLLDEEKQELWSIV	AAGEGDRSLEIRIPADKGIAGEVATFKQVVNIPFDFYHDPRSIFAQKQEKITGYRTYTML	ALPLLSEQGRLVAVVQLLNKLKPYSPPDALLAERIDNQGFTSADEQLFQEFAPSIRLILE	SSRSFYIATQKQRAAAAMMKAVKSLSQSSLDLEDTLKRVMDEAKELMNADRSTLWLIDRD	RHELWTKITQDNGSTKELRVPIGKGFAGIVAASGQKLNIPFDLYDHPDSATAKQIDQQNG	YRTCSLLCMPVFNGDQELIGVTQLVNKKKTGEFPPYNPETWPIAPECFQASFDRNDEEFM	EAFNIQAGVALQNAQLFATVKQQEQMQRDILRSLSNGVISTDKSGTIIAANESAQRLLGL	ESEDRLEGKLISEAIAIKEGDFSKWCQDALHGTDLKGRQQYYPDRTLVSTEAAQNSINLS	INTIADASDPQQVCGALVVMEDISDEKRLKSTMYRYMTQELAEELLKLDDAKLGGDRKEV	SILFSDIRGYTTLTENLEAEEVVSMLNEYFESMVEAVFKHKGTLDKYIGDAIMAVFGSPL	PLEEHAWMAVKTSIEMRHRLQEFNQKRYAANKPRINIGIGINSDTVISGNIGSSKRMEFT	AIGDGVNLGSRLESVSKQYGCDIILSDNTFKPCQENIWARELDFIRVKGRNEPVSIYELI	GLRSVPIASEKLQVIEHYHKGREYYLQRQFSLARAEFANVLAVDKHDKAAMLHLLRCQHW	LQSPPTDSEWDEGVWTFQEK
Involved in phosphorus-oxygen lyase activity
http://bio2rdf.org/pfam:PF00211
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00211%3E
cyaB2
http://www.pdb.org/pdb/explore/explore.do?structureId=1YKD
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1YKD%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02527
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/4655
_:header7370776831335206596284
Mon, 23 Apr 2012 18:36:31 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4655
http://bio2rdf.org/pfam:PF02518
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF02518%3E
http://pfam.sanger.ac.uk/family?acc=PF02518
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF02518%3E
http://bio2rdf.org/pdb:1WC6
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1WC6%3E
>3609 bp	ATGAGTTCCCCCAACAGAAAATTGAAGCCCACCATATTAGTGGTTGATGATGAGCCAGAT	AATTTAGATCTGCTATACCGGACTTTCCATCGGGAATTTAAAGTTCTCAAAGCCGAAAGT	GGGCCGGCTGCATTGAAGATCTTAGAAGAGGTGGGGGAAGTAGCAGTAATTATCTCTGAT	CAGCGGATGCCCTATATGAGTGGCACAGAGTTTCTCAGTTTGACCGCGACTCAATATCCC	GATTCGATCCGCATTATCCTCACTGGTTATACGGATGTTGAAGACCTGGTAGAGGCAATT	AACTCCGGTAAGGTGTTTAAATATGTCACTAAACCTTGGAAATCTGATGAACTCAAGGCG	ATCGTTCAGCAAGGTTTAGAAACTCATAATGTCCTGAAATCTCGCACAGAGGAACTACGC	CTAGCACAAAAACAGGAATCGTTACTTTATGAAGTGACAAGTACCATTCGCGCCTGTCCT	AATTCCCAGGAAATGTTGCAGCGCATAGTTGAAACAGTGGGTAAAATGTTTGAGGTGAGC	TATTGTCTGCTGCGTTCATTCGGTGTGGGTTCAGACCTGATAGGGCTGGGGGCTGGAGTC	AGCCCTACCAAACAGGATATCACTGCTACACAAGGGAAGGAGTGGTTCGCATACTTAGCG	GAAGGTCAGAATCATCAAAATTCCACGACAGACAACATCAGCGTTATCAATAATAATGAT	CTGGAATTGAGATCCCTGGTTTGGGAAACTACGGAAGTAATGATTCTTTCGGAAGGTTTG	GGAAATGATATTTCTGACCACGATGGACCAGAATGGCAGCAGCGACGAGACGTTTACCAA	CGTGCAGATATTCGCTCCAGTTTGATAGTGCCTCTGTATTACCGTCAGGAATTGTTGGCG	GTTTTGGCGCTGCACCACACGGGATCGCCCCGTAATTGGCATGAACATGAAGTGCAGTTA	GCTGCGGGTGTAGCAGATCAGGCGGCTTTGGCATTGTCTCAGGTGCGCGCATACGAGCAG	GTGCGAGAATTGGCTCGTAGGGAAGCGCTGGTTAATACGATTACCAATGCTATTCGGTCT	AGTCTTGACCCTCAGAAAATTTTTGCGGCTATCACTGAGCAATTGGGGGAGGCTTTGGAG	GTTGATGGCTGTGCTTTGTCTCTCTGGAGTCCGGGAGATGAATATATGCAGTGTGTAGGC	CTTTATAATGCGGCGATTAAAGAAACAGTAGTAGAGACTAGACCGGCGGCTTTGTCTGAA	CCTGATACCAGCACGACGACGAATTTGCCCCTATTGGGGGTAGAAACTAATCAATCCATT	GAGTCCGATCAGTCCGATGATTTGCCTCAGTCGGCGGCTCCTATTAGTGGCAACCCGGTG	CTTCAGGAATTGATTAGAACTCGCGCTCCGGTGGCGATCGCTGATATCGAACAGCGACCA	GACTCGATGGTGATGTTGCCTTTGCGATCGCCTTCTAAGGCTCTATTGGTTGTGCCACTA	TTGCTCGATGGTGATATTATTGGCAGCATATCCCTACGCCAAAATCACCAAGTTCGCCAT	TGGCAACCCTCCGAAATTGATATGGTCCTGTTGGTGGCAGCCCAAGCCGCTTTGGCGGTA	CAGCAGGCTCGTCTATACCAAAAAACACGCCAGCAAGCAGAACGCCTATTAGAAGCCGAC	CGCCTCAAAACTGAGTTTTTTCAAAATGTCTCCCACGAGTTTCGCACCCCTTTGACTTTG	ATGATAGGTCCTTTGGAAACGGTGGTTAATCAACAGCAGGATCTGTCATTAGACCAAGCG	AAAATTGCTCTGCGTAACTCCAGGCGACTATTGCGCTTGGTTAATCAATTATTGGATTTG	CAACGGTTTGATGCGGGACGAATGCAGCCCAGTTTTCGCCCCTGTGACCTGGTGGAGTTT	TGTCAGCAAACGGTGGAATCATTTAAGTCTTATTGCGATCGCAAACAAATTAATCTAGTT	ACCAATTTACAGAGTTGCCCCCAACTTTATCTTGATCTGGAAAGGTTTGATAAAGTCCTT	TACAATTTGCTCTCTAATGCCATGAAGTTTACCCCCACCGATGGCACTATTACCGTTAGT	CTCCAGCCCGAAGGGAATTATTGCCGTCTTATGGTCAAAGATACCGGGATTGGTATTAAA	CAAGAACAACTCCCCCATTTATTTGAACGCTTCCGACAAGCTGAAGGTTCAGCCAATCGC	TCCTTTGAGGGGAGTGGCTTGGGATTGGCTCTGGTTAAAGAGTTGGTCGAACTCCATCAT	GGTCGCATTACTGTAGAGTCTGAGTATGGTCAGGGAACTACATTTACCGTCTGGCTACAA	ATGGGGAATCTTCATCTACCACCCTCGCCTCTCCTTGATGTTCCCGCTGAGTTTGATGCA	CGTCGAGCAGCCGTAGAATTGGCTGATGTGGAGGTCGATTTACCAGATGTACAAATTGAC	GACATAAATCTGCCGGAGGTTTTGGTTGCTGACGGTTCGGCTTCCCTCACGGACCACGGA	CAGTTGGGGTCTAATACTGTCCTGGTGGTGGATGATAACCCCGATTTGCGCCGCTATGTG	TCGATGATGTTGCAAAATGCCGGATTTAATGCGGTTTTGGCTAAGAATGGCGCTGATGGT	TTTAACAAGGCTCAGACTTATCATCCTGATGTGATTGTTACTGATTTGATGATGCCCCAG	GTGTCTGGGTTGGAGTTGATTCGCATGATTCGCTCCTCACCTGAACTTAGGGGAACTCCA	ATTATTTTGTTGACTGCTAAGGCTGATGAGGATACCCGCATCGAAGGGGTTGAGCGCGGC	GCTGATGCCTATGTTTCTAAGCCTTTTAATGACCGGGAGTTGATAGCTGAGGTCAGGAAT	TTACAGGCCCTCAAGGCAGAGGAACGACGGGTAGCCCATTTGAATAAGTATCTGACTGAA	TCAGTATTGCGACGGTTTTTGCCGGAGTCTATGGTCAAAAAGGCGGCGGCGGGGGACTTG	ACTCTGGATTTGCGCCCGGAACCGAGGCTGATTACCATTTTATTTAGTGATATTGTCGGT	TTTACTCGGATGTCTAATGCTCTACAGTCTCAGGGGGTGGCGGAATTGCTTAATGAGTAT	TTGGGAGAAATGACTCGGGCGGTTTTTGAGAATCAGGGGACTGTTGACAAGTTTGTAGGA	GATGCGATTATGGCTTTGTATGGAGCCCCGGAGGAGATGAGCCCCTCTGAACAAGTCCGA	CGCGCGATCGCTACGGCTAGACAAATGTTGGTGGCTCTCGAAAAACTTAACCAGGGTTGG	CAGGAACGAGGTTTGGTGGGCCGTAATGAGGTTCCTCCGGTGCGGTTCCGCTGTGGGATT	CACCAGGGTATGGCTGTGGTGGGGTTGTTTGGTTCCCAAGAGCGATCGGATTTTACGGCG	ATCGGTCCTTCGGTTAATATTGCTGCCCGTCTTCAGGAGGCTACTGCCCCCAACAGCATT	ATGGTATCCGCTATGGTGGCTCAGTATGTCCCCGATGAGGAGATTATTAAGCGCGAATTT	CTCGAACTTAAAGGCATTGATGAGCCGGTAATGACTTGTGTGATTAACCCAAATATGCTG	AATCAGTAA
>Adenylate cyclase	MSSPNRKLKPTILVVDDEPDNLDLLYRTFHREFKVLKAESGPAALKILEEVGEVAVIISD	QRMPYMSGTEFLSLTATQYPDSIRIILTGYTDVEDLVEAINSGKVFKYVTKPWKSDELKA	IVQQGLETHNVLKSRTEELRLAQKQESLLYEVTSTIRACPNSQEMLQRIVETVGKMFEVS	YCLLRSFGVGSDLIGLGAGVSPTKQDITATQGKEWFAYLAEGQNHQNSTTDNISVINNND	LELRSLVWETTEVMILSEGLGNDISDHDGPEWQQRRDVYQRADIRSSLIVPLYYRQELLA	VLALHHTGSPRNWHEHEVQLAAGVADQAALALSQVRAYEQVRELARREALVNTITNAIRS	SLDPQKIFAAITEQLGEALEVDGCALSLWSPGDEYMQCVGLYNAAIKETVVETRPAALSE	PDTSTTTNLPLLGVETNQSIESDQSDDLPQSAAPISGNPVLQELIRTRAPVAIADIEQRP	DSMVMLPLRSPSKALLVVPLLLDGDIIGSISLRQNHQVRHWQPSEIDMVLLVAAQAALAV	QQARLYQKTRQQAERLLEADRLKTEFFQNVSHEFRTPLTLMIGPLETVVNQQQDLSLDQA	KIALRNSRRLLRLVNQLLDLQRFDAGRMQPSFRPCDLVEFCQQTVESFKSYCDRKQINLV	TNLQSCPQLYLDLERFDKVLYNLLSNAMKFTPTDGTITVSLQPEGNYCRLMVKDTGIGIK	QEQLPHLFERFRQAEGSANRSFEGSGLGLALVKELVELHHGRITVESEYGQGTTFTVWLQ	MGNLHLPPSPLLDVPAEFDARRAAVELADVEVDLPDVQIDDINLPEVLVADGSASLTDHG	QLGSNTVLVVDDNPDLRRYVSMMLQNAGFNAVLAKNGADGFNKAQTYHPDVIVTDLMMPQ	VSGLELIRMIRSSPELRGTPIILLTAKADEDTRIEGVERGADAYVSKPFNDRELIAEVRN	LQALKAEERRVAHLNKYLTESVLRRFLPESMVKKAAAGDLTLDLRPEPRLITILFSDIVG	FTRMSNALQSQGVAELLNEYLGEMTRAVFENQGTVDKFVGDAIMALYGAPEEMSPSEQVR	RAIATARQMLVALEKLNQGWQERGLVGRNEVPPVRFRCGIHQGMAVVGLFGSQERSDFTA	IGPSVNIAARLQEATAPNSIMVSAMVAQYVPDEEIIKREFLELKGIDEPVMTCVINPNML	NQ
phosphorus metabolism
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=D49692
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DD49692%3E
http://www.uniprot.org/uniprot/O32393
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FO32393%3E
http://bio2rdf.org/pfam:PF00512
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00512%3E
http://www.pdb.org/pdb/explore/explore.do?structureId=1WC6
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1WC6%3E
D49692
http://bio2rdf.org/uniprot:O32393
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AO32393%3E
phosphorylation
two-component response regulator activity
http://pfam.sanger.ac.uk/family?acc=PF00072
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00072%3E
cyaC
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9297847
phosphate metabolism
http://bio2rdf.org/pfam:PF00072
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00072%3E
http://pfam.sanger.ac.uk/family?acc=PF00512
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00512%3E
O32393_SPIPL
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02596
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02355
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/CD151
_:header16227983291335206596617
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/CD151
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/821
http://symbol.bio2rdf.org/symbol:CD151
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ACD151%3E
CD151
http://bio2rdf.org/hgnc:1630
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A1630%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=1630
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D1630%3E
http://bio2rdf.org/geneid:977
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fgeneid%3A977%3E
http://www.dbpedia.org/resource/CD151
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FCD151%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3342
RDF Description of CD151
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0001122
_:header20795251871335206597035
Mon, 23 Apr 2012 18:36:32 GMT
http://dbpedia.org/resource/Acidosis
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FAcidosis%3E
http://sideeffects.embl.de/se/C0001122
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0001122%3E
Acidosis
C0001122
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/175
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3043
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/8612
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4914
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2973
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2519
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/6503
RDF Description of Acidosis
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/453
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5206
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/750
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/3701
_:header15126932531335206597611
RDF Description of Pyruvate dehydrogenase deficiency
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3701
Pyruvate dehydrogenase deficiency
http://www4.wiwiss.fu-berlin.de/diseasome/resource/chromosomalLocation/Xp22.2-p22.1
http://www.dbpedia.org/resource/Pyruvate_dehydrogenase_deficiency
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FPyruvate_dehydrogenase_deficiency%3E
http://bio2rdf.org/omim:312170
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fomim%3A312170%3E
http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=312170
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fdispomim.cgi%3Fid%3D312170%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PDHA1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/978
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PHE1A
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00157%3E
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/5318
_:header13143916861335206598047
RDF Description of Exelderm
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5318
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000005318&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000005318%26input_query_species%3D9606%3E
Exelderm
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C1384589
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0040262
CID0000005318
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1856
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F1856%3E
http://www.fda.gov/medwatch/SAFETY/2003/03May_PI/Exelderm_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2003%2F03May_PI%2FExelderm_PI.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0040259
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0040252
http://www.fda.gov/cder/foi/label/2003/18737slr003_exelderm_lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2003%2F18737slr003_exelderm_lbl.pdf%3E
http://sideeffects.embl.de/drugs/5318
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F5318%3E
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000005318
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000005318%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3398
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3398%3E
EXELDERM
sulconazole
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB03025
_:header17567977841335206598430
Mon, 23 Apr 2012 18:36:33 GMT
RDF Description of 1-Octen-3-Ol
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03025
1-Octen-3-Ol
3OL
1.31e+00 mg/mL
DB03025
http://www.drugbank.ca/drugs/DB03025
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB03025%3E
1GT1
InChI=1/C8H16O/c1-3-5-6-7-8(9)4-2/h4,8-9H,2-3,5-7H2,1H3
2008-08-26 15:10:42 UTC
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2498
(3S)-oct-1-en-3-ol
C8H16O
VSMOENVRRABVKN-UHFFFAOYAB
CCCCCC(O)C=C
expt00184
CCCCC[C@H](O)C=C
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/SCN5A
_:header9713155611335206598841
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/SCN5A
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/gene/SCN5A
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fgene%2FSCN5A%3E
http://symbol.bio2rdf.org/symbol:SCN5A
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ASCN5A%3E
SCN5A
http://bio2rdf.org/hgnc:10593
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A10593%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=10593
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D10593%3E
http://bio2rdf.org/geneid:6331
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fgeneid%3A6331%3E
http://www.dbpedia.org/resource/Nav1.5
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FNav1.5%3E
RDF Description of SCN5A
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/KIF1B
_:header7588799301335206599235
Mon, 23 Apr 2012 18:36:34 GMT
RDF Description of KIF1B
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/KIF1B
http://symbol.bio2rdf.org/symbol:KIF1B
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AKIF1B%3E
KIF1B
http://www.dbpedia.org/resource/KIF1B
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FKIF1B%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1833
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00824
_:header5937729901335206599660
RDF Description of Enprofylline
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00824
C8H10N4O2
http://www.drugbank.ca/drugs/DB00824
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00824%3E
Enprofylline
1200 mg/L
Enprofylline is a derivative of theophylline which shares bronchodilator properties. Enprofylline is used in asthma, chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy. Long-term enprofylline administration may be associated with elevation in liver enzyme levels and unpredictable blood levels.
287-289 oC
5.67e+00 mg/mL
CCCN1C(=O)NC(=O)C2=C1N=CN2
Enprofilina [INN-Spanish]
DB00824
Enprofylline is a synthetic dimethylxanthine derivative structurally related to theophylline and caffeine. It antagonizes erythrocyte phosphodiesterase, increasing cAMP activity.
Rapidly absorbed from the digestive tract
InChI=1/C8H10N4O2/c1-2-3-12-6-5(9-4-10-6)7(13)11-8(12)14/h4H,2-3H2,1H3,(H,9,10)(H,11,13,14)/f/h9,11H
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/1971
1.9 hours
3-Propylxanthine
49%
http://bio2rdf.org/cas:41078-02-8
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A41078-02-8%3E
Used in the management of symptoms of asthma. Also used in the treatment of peripheral vascular diseases and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.
Enprofylline inhibits erythrocyte phosphodiesterase, resulting in an increase in erythrocyte cAMP activity. Subsequently, the erythrocyte membrane becomes more resistant to deformity. Along with erythrocyte activity, enprofylline also decreases blood viscosity by reducing plasma fibrinogen concentrations and increasing fibrinolytic activity.
aprd00273
Nilyph
2008-08-26 16:16:38 UTC
3-n-Propylxanthine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/541
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/268
3-propyl-7H-purine-2,6-dione
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/bronchodilatorAgents
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/anti-asthmaticAgents
Enprofyllinum [INN-Latin]
Oxeze
SIQPXVQCUCHWDI-FLKJISBTCR
http://www4.wiwiss.fu-berlin.de/dblp/data/person/110635
_:header1713935701335206600268
http://www4.wiwiss.fu-berlin.de/dblp/resource/person/110635
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/pe/KleinrockM92
Leonard Kleinrock
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/acm/LuK92
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/pc/HuangK90
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tc/Kleinrock76
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/ifip/KleinrockY80
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/pe/AkaviaK89
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/middleware/EusticeKMPRR03
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/icdcs/KleinrockM81
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/icnp/HuK96
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tpds/KleinrockK93
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/hpdc/TungK93
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/telsys/Kleinrock97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tpds/TungK96
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/cie/Kleinrock04
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/apn/NielsenK94
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/jacm/Kleinrock66
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/jacm/KleinrockN81
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/icpp/HorngK91
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/networking/TewariK05
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/infocom/JiangK98
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/pe/LevyK91
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/cacm/Kleinrock85
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigmetrics/HarinarayanK91
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/nspw/EusticeKMPRR03
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/jcss/KleinrockC67
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/ifip/KleinrockMH71
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/ifip/Kleinrock68
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/jacm/CoffmanK68
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/winet/ShortBK95
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tc/DechterK86
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/monet/Kleinrock96
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tpds/HuangK93
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/pe/LuK92
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tc/KermaniK80
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/infocom/NelsonK83
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/cacm/LeinerCCKKLPRW97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/cn/KleinrockK77
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/adhoc/Kleinrock03
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/cn/KamounK79
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigmetrics/TewariK05
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tse/KleinrockH92
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tomacs/FeldermanK91
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/cacm/Kleinrock01
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/cacm/MartinBDDK85
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/wsc/BagrodiaGKST95
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/jacm/Kleinrock67
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/mobicom/ShortBK95
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/icc/JiangK97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/computer/Kleinrock85
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigmetrics/LinK91
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/ifip/Kleinrock77
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/pc/HuangK90a
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/atmn/LinK93
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/corr/cs-NI-9901011
RDF Description of Leonard Kleinrock
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/cn/Kleinrock90
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/homepages/k/LKleinrock
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/ifip/Kleinrock74
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/icc/KoliasK97
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/pe/RosenbergMK90
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/cn/KermaniK79
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/icccn/HuK95
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/jpdc/JiangK00
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/cacm/KleinrockNO76
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/jsac/AkyldizGK01
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tit/Kleinrock85
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/monet/BadrinathFKPRS00
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/jacm/KleinrockM72
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/icc/HuK97
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/4051
_:header10187363431335206600668
Mon, 23 Apr 2012 18:36:35 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4051
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12361952
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/14984733
PTDSS2
lipid metabolism
314-334
377-397
Serine-exchange enzyme II
127-147
PTSS2_HUMAN
Catalyzes a base-exchange reaction in which the polar head group of phosphatidylethanolamine is replaced by L-serine
phosphatidylserine biosynthesis
AL834357
336-356
Phosphatidylserine synthase 2
http://pfam.sanger.ac.uk/family?acc=PF03034
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF03034%3E
http://www.uniprot.org/uniprot/Q9BVG9
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ9BVG9%3E
http://bio2rdf.org/uniprot:Q9BVG9
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ9BVG9%3E
http://bio2rdf.org/hgnc:15463
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A15463%3E
cellular lipid metabolism
http://bio2rdf.org/pfam:PF03034
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF03034%3E
11p15
63-83
PtdSer synthase 2
glycerophospholipid metabolism
242-262
phosphatidylserine metabolism
404-424
>1464 bp	ATGCGGAGGGGCGAGCGCAGGGACGCCGGAGGTCCGCGGCCCGAGTCCCCGGTGCCCGCG	GGCAGGGCCTCGCTGGAGGAGCCGCCTGACGGGCCGTCTGCCGGCCAAGCCACCGGGCCG	GGCGAGGGCCGCCGCAGCACCGAGTCCGAGGTCTACGACGACGGCACCAACACCTTCTTC	TGGCGAGCCCACACCTTAACCGTGCTCTTCATCCTCACCTGTACGCTTGGCTATGTGACG	CTGCTGGAGGAAACACCTCAGGACACGGCCTACAACACCAAGAGAGGTATTGTGGCCAGT	ATTTTGGTTTTCTTATGTTTTGGAGTCACACAAGCTAAAGACGGGCCATTTTCCAGACCT	CATCCAGCTTACTGGAGGTTTTGGCTCTGCGTGAGTGTGGTCTACGAGCTGTTTCTCATC	TTTATACTCTTCCAGACTGTCCAGGACGGCCGGCAGTTTCTAAAGTATGTTGACCCCAAG	CTGGGAGTCCCACTGCCAGAGAGAGACTACGGGGGAAACTGCCTCATCTACGACCCAGAC	AATGAGACTGACCCCTTTCACAACATCTGGGACAAGTTGGATGGCTTTGTTCCCGCGCAC	TTTCTTGGCTGGTACCTGAAGACCCTGATGATCCGAGACTGGTGGATGTGCATGATCATC	AGCGTGATGTTCGAGTTCCTGGAGTACAGCCTGGAGCACCAGCTGCCCAACTTCAGCGAG	TGCTGGTGGGATCACTGGATCATGGACGTGCTCGTCTGCAACGGGCTGGGCATCTACTGC	GGCATGAAGACCCTTGAGTGGCTGTCCCTGAAGACGTACAAGTGGCAGGGCCTCTGGAAC	ATTCCGACCTACAAGGGCAAGATGAAGAGGATCGCCTTCCAGTTCACGCCGTACAGCTGG	GTTCGCTTCGAGTGGAAGCCGGCCTCCAGCCTGCGTCGCTGGCTGGCCGTGTGCGGCATC	ATCCTGGTGTTCCTGTTGGCAGAACTGAACACGTTCTACCTGAAGTTTGTGCTGTGGATG	CCCCCGGAGCACTACCTGGTCCTCCTGCGGCTCGTCTTCTTCGTGAACGTGGGTGGCGTG	GCCATGCGTGAGATCTACGACTTCATGGATGACCCGAAGCCCCACAAGAAGCTGGGCCCG	CAGGCCTGGCTGGTGGCGGCCATCACGGCCACGGAGCTGCTCATCGTGGTGAAGTACGAC	CCCCACACGCTCACCCTGTCCCTGCCCTTCTACATCTCCCAGTGCTGGACCCTCGGCTCC	GTCCTGGCGCTCACCTGGACCGTCTGGCGCTTCTTCCTGCGGGACATCACATTGAGGTAC	AAGGAGACCCGGTGGCAGAAGTGGCAGAACAAGGATGACCAGGGCAGCACCGTCGGCAAC	GGGGACCAGCACCCACTGGGGCTGGACGAAGACCTGCTGGGGCCTGGGGTGGCCGAGGGC	GAGGGAGCACCAACTCCAAACTGA
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17387686
phospholipid metabolism
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AL834357
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAL834357%3E
EC 2.7.8.-
>Phosphatidylserine synthase 2	MRRGERRDAGGPRPESPVPAGRASLEEPPDGPSAGQATGPGEGRRSTESEVYDDGTNTFF	WRAHTLTVLFILTCTLGYVTLLEETPQDTAYNTKRGIVASILVFLCFGVTQAKDGPFSRP	HPAYWRFWLCVSVVYELFLIFILFQTVQDGRQFLKYVDPKLGVPLPERDYGGNCLIYDPD	NETDPFHNIWDKLDGFVPAHFLGWYLKTLMIRDWWMCMIISVMFEFLEYSLEHQLPNFSE	CWWDHWIMDVLVCNGLGIYCGMKTLEWLSLKTYKWQGLWNIPTYKGKMKRIAFQFTPYSW	VRFEWKPASSLRRWLAVCGIILVFLLAELNTFYLKFVLWMPPEHYLVLLRLVFFVNVGGV	AMREIYDFMDDPKPHKKLGPQAWLVAAITATELLIVVKYDPHTLTLSLPFYISQCWTLGS	VLALTWTVWRFFLRDITLRYKETRWQKWQNKDDQGSTVGNGDQHPLGLDEDLLGPGVAEG	EGAPTPN
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12833164
http://www.genenames.org/data/hgnc_data.php?hgnc_id=15463
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D15463%3E
membrane lipid metabolism
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=21740008
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D21740008%3E
PSS-2
http://symbol.bio2rdf.org/symbol:PTDSS2
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3APTDSS2%3E
primary metabolism
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/15052332
RDF Description of Phosphatidylserine synthase 2
http://www4.wiwiss.fu-berlin.de/eurostat/data/regions/Sur
_:header17962364511335206601051
Mon, 23 Apr 2012 18:36:36 GMT
RDF Description of Sur
http://www4.wiwiss.fu-berlin.de/eurostat/resource/regions/Sur
http://ec.europa.eu/eurostat/ramon/rdfdata/nuts2008/ES6
http://www4.wiwiss.fu-berlin.de/eurostat/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fec.europa.eu%2Feurostat%2Framon%2Frdfdata%2Fnuts2008%2FES6%3E
Sur
http://www4.wiwiss.fu-berlin.de/eurostat/resource/countries/Espa%C3%B1a
http://estatwrap.ontologycentral.com/dic/geo#ES6
http://www4.wiwiss.fu-berlin.de/eurostat/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Festatwrap.ontologycentral.com%2Fdic%2Fgeo%23ES6%3E
es6
http://dbpedia.org/resource/South
http://www4.wiwiss.fu-berlin.de/eurostat/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FSouth%3E
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/48175
_:header15590901601335206601575
RDF Description of Ultravate
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/48175
http://www.fda.gov/cder/foi/label/2003/19967slr004_ultravate_lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2003%2F19967slr004_ultravate_lbl.pdf%3E
http://www.fda.gov/cder/foi/label/2003/019967s004lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2003%2F019967s004lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2239
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2239%3E
http://sideeffects.embl.de/drugs/48175
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F48175%3E
CID0000048175
http://www.fda.gov/cder/foi/label/2004/19968s007lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2004%2F19968s007lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00596
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00596%3E
Ultravate
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000048175
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000048175%3E
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000048175&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000048175%26input_query_species%3D9606%3E
http://www.fda.gov/cder/foi/label/2004/19967s010lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2004%2F19967s010lbl.pdf%3E
ULTRAVATE
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Defauconpret_Auguste_Jean-Baptiste_1767-1843
_:header9267055211335206601866
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Defauconpret_Auguste_Jean-Baptiste_1767-1843
Defauconpret, Auguste Jean-Baptiste, 1767-1843 
RDF Description of Defauconpret, Auguste Jean-Baptiste, 1767-1843 
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext14703
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext18825
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext16236
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/39860
_:header16944947371335206602371
Mon, 23 Apr 2012 18:36:37 GMT
RDF Description of NABILONE
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0037195
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0683416
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0041654
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00486
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00486%3E
http://www.fda.gov/cder/foi/label/2006/018677s011lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2006%2F018677s011lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0030319
CID0000039860
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0220870
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020040
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0270996
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0233459
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C1456784
NABILONE
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=A4MAcWwlDLo=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DA4MAcWwlDLo%3D%3E
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000039860&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000039860%26input_query_species%3D9606%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0349231
Cesamet
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2722
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2722%3E
http://dbpedia.org/resource/Nabilone
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FNabilone%3E
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=xBopEMjajW8=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DxBopEMjajW8%3D%3E
http://sideeffects.embl.de/drugs/39860
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F39860%3E
http://www.fda.gov/medwatch/SAFETY/2006/May_PIs/Cesamet_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2006%2FMay_PIs%2FCesamet_PI.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0015423
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000039860
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000039860%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0085762
nabilone
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=hO5+oe92Ihg=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DhO5%2Boe92Ihg%3D%3E
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/2772
_:header881021591335206602908
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2772
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02085
http://pfam.sanger.ac.uk/family?acc=PF00291
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00291%3E
http://bio2rdf.org/pfam:PF00291
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00291%3E
http://www.pdb.org/pdb/explore/explore.do?structureId=1F2D
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1F2D%3E
http://bio2rdf.org/uniprot:Q7M523
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ7M523%3E
ACC deaminase
map00640	Propanoate metabolism
>1-aminocyclopropane-1-carboxylate deaminase	SGVAKFAKYPLTFGPSPISNLNRLSQHLGSKVNVYAKREDCNSGLAFGGNKLRKLEYIVP	DIVEGDYTHLVSIGGRQSNQTRMVAALAAKLGKKCVLIQEDWVPIPEAEKDVYNRVGNIE	LSRIMGADVRVIEDGFDIGMRKSFANALQELEDAGHKPYPIPAGCSEHKYGGLGFVGFAD	EVINQEVELGIKFDKIVVCCVTGSTTAGILAGMAQYGRQDDVIAIDASFTSEKTKEQTLR	IANNTAKLIGVEHEFKDFTLDTRFAYPCYGVPNEGTIEAIRTCAEQEGVLTDPVYEGKSM	QGLIALIKEDYFKPGANVLYVHLGGAPALSAYSSFFPTKTA
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9604000
ACCD
EC 3.5.99.7
Catalyzes a cyclopropane ring-opening reaction, the irreversible conversion of 1-aminocyclopropane-1-carboxylate (ACC) to ammonia and alpha-ketobutyrate
ethylene biosynthesis
http://www.uniprot.org/uniprot/Q7M523
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ7M523%3E
1A1D_WILSA
1-aminocyclopropane-1-carboxylate deaminase
http://bio2rdf.org/pdb:1F2D
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1F2D%3E
hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds
1-aminocyclopropane-1-carboxylate + H2O = 2-oxobutanoate + NH3
1-aminocyclopropane-1-carboxylate deaminase activity
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02849
RDF Description of 1-aminocyclopropane-1-carboxylate deaminase
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/233
_:header5526535751335206603308
Mon, 23 Apr 2012 18:36:38 GMT
RDF Description of Potassium channel subfamily K member 2
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/233
KCNK2
http://www.genenames.org/data/hgnc_data.php?hgnc_id=6277
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D6277%3E
224-244
multi-passMembraneProtein(potential)
Outward rectifying potassium channel
TREK-1 K(+) channel subunit
>Potassium channel subfamily K member 2	MLPSASRERPGYRAGVAAPDLLDPKSAAQNSKPRLSFSTKPTVLASRVESDTTINVMKWK	TVSTIFLVVVLYLIIGATVFKALEQPHEISQRTTIVIQKQTFISQHSCVNSTELDELIQQ	IVAAINAGIIPLGNTSNQISHWDLGSSFFFAGTVITTIGFGNISPRTEGGKIFCIIYALL	GIPLFGFLLAGVGDQLGTIFGKGIAKVEDTFIKWNVSQTKIRIISTIIFILFGCVLFVAL	PAIIFKHIEGWSALDAIYFVVITLTTIGFGDYVAGGSDIEYLDFYKPVVWFWILVGLAYF	AAVLSMIGRLVRVISKKTKEEVGEFRAHAAEWTANVTAEFKETRRRLSVEIYDKFQRATS	IKRKLSAELAGNHNQELTPCRRTLSVNHLTSERDVLPPLLKTESIYLNGLAPHCAGEEIA	VIENIK
1q41
AF129399
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AF129399
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAF129399%3E
Two-pore potassium channel TPKC1
Two-pore domain potassium channel TREK-1
http://www.uniprot.org/uniprot/O95069
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FO95069%3E
>1236 bp	ATGGCGGCCCCTGACTTGCTGGATCCTAAATCTGCCGCTCAGAACTCCAAACCGAGGCTC	TCGTTTTCCACGAAACCCACAGTGCTTGCTTCCCGGGTGGAGAGTGACACGACCATTAAT	GTTATGAAATGGAAGACGGTCTCCACGATATTCCTGGTGGTTGTCCTCTATCTGATCATC	GGAGCCACCGTGTTCAAAGCATTGGAGCAGCCTCATGAGATTTCACAGAGGACCACCATT	GTGATCCAGAAGCAAACATTCATATCCCAACATTCCTGTGTCAATTCGACGGAGCTGGAT	GAACTCATTCAGCAAATAGTGGCAGCAATAAATGCAGGGATTATACCGTTAGGAAACACC	TCCAATCAAATCAGTCACTGGGATTTGGGAAGTTCCTTCTTCTTTGCTGGCACTGTTATT	ACAACCATAGGATTTGGAAACATCTCACCACGCACAGAAGGCGGCAAAATATTCTGTATC	ATCTATGCCTTACTGGGAATTCCCCTCTTTGGTTTTCTCTTGGCTGGAGTTGGAGATCAG	CTAGGCACCATATTTGGAAAAGGAATTGCCAAAGTGGAAGATACGTTTATTAAGTGGAAT	GTTAGTCAGACCAAGATTCGCATCATCTCAACAATCATATTTATACTATTTGGCTGTGTA	CTCTTTGTGGCTCTGCCTGCGATCATATTCAAACACATAGAAGGCTGGAGTGCCCTGGAC	GCCATTTATTTTGTGGTTATCACTCTAACAACTATTGGATTTGGTGACTACGTTGCAGGT	GGATCCGATATTGAATATCTGGACTTCTATAAGCCTGTCGTGTGGTTCTGGATCCTTGTA	GGGCTTGCTTACTTTGCTGCTGTCCTGAGCATGATTGGAGATTGGCTCCGAGTGATATCT	AAAAAGACAAAAGAAGAGGTGGGAGAGTTCAGAGCACACGCTGCTGAGTGGACAGCCAAC	GTCACAGCCGAATTCAAAGAAACCAGGAGGCGACTGAGTGTGGAGATTTATGACAAGTTC	CAGCGGGCCACCTCCATCAAGCGGAAGCTCTCGGCAGAACTGGCTGGAAACCACAATCAG	GAGCTGACTCCTTGTAGGAGGACCCTGTCAGTGAACCACCTGACCAACGAGAGGGATGTC	TTGCCTCCCTTACTGAAGACTGAGAGTATCTATCTGAATGGTTTGACGCCACACTGTGCT	GGTGAAGAGATTGCTGTGATTGAGAACATCAAATAG
http://pfam.sanger.ac.uk/family?acc=PF07885
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF07885%3E
KCNK2_HUMAN
http://bio2rdf.org/pfam:PF07885
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF07885%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=5712621
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D5712621%3E
Potassium channel subfamily K member 2
http://symbol.bio2rdf.org/symbol:KCNK2
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AKCNK2%3E
http://bio2rdf.org/uniprot:O95069
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AO95069%3E
http://bio2rdf.org/hgnc:6277
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A6277%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10321245
Outward rectifying potassium channel protein TREK-1
288-308
62-82
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00204
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00344
_:header10448361651335206603760
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00344
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00852_DB00344
Triptil
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/98
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F98%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/adrenergicUptakeInhibitors
Novo-Tripramine
DB00344
Rhotrimine
2.31e-04 mg/mL
http://129.128.185.122/drugbank2/drugs/DB00344/inserts/108/full
aprd00441
CNCCCC1C2=CC=CC=C2C=CC2=CC=CC=C12
169-171 oC (Protriptyline HCl)
Engelhardt, Christy Belg. pat. 617,967, C.A. 59, 517f (1963)
Apo-Imipramine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/824
Apo-Amitriptyline
Tofranil
http://www.drugbank.ca/drugs/DB00344
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00344%3E
Protriptyline
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/norepinephrine-reuptakeInhibitors
http://en.wikipedia.org/wiki/Protriptyline
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FProtriptyline%3E
http://129.128.185.122/drugbank2/drugs/DB00344/inserts/1878/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00344%2Finserts%2F1878%2Ffull%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3452
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3452%3E
http://205.193.93.51/dpdonline/searchRequest.do?din=00322741
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D00322741%3E
http://bio2rdf.org/cas:438-60-8
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A438-60-8%3E
Apo-Trimip
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/antidepressiveAgents
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3421
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3421%3E
Protriptyline is a tricyclic antidepressant. It was thought that tricyclic antidepressants work by inhibiting the re-uptake of the neurotransmitters norepinephrine and serotonin by nerve cells. However, this response occurs immediately, yet mood does not lift for around two weeks. It is now thought that changes occur in receptor sensitivity in the cerebral cortex and hippocampus. The hippocampus is part of the limbic system, a part of the brain involved in emotions. Presynaptic receptors are affected: a1 and b1 receptors are sensitized, a2 receptors are desensitised (leading to increased noradrenaline production). Tricyclics are also known as effective analgesics for different types of pain, especially neuropathic or neuralgic pain. A precise mechanism for their analgesic action is unknown, but it is thought that they modulate anti-pain opioid systems in the CNS via an indirect serotonergic route. They are also effective in migraine prophylaxis, but not in abortion of acute migraine attack. The mechanism of their anti-migraine action is also thought to be serotonergic.
Anafranil
Surmontil
http://dbpedia.org/resource/Protriptyline
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FProtriptyline%3E
For the treatment of depression and obsessive-compulsive disorders.
C19H21N
Sinequan
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/540
Amimetilina
http://dbpedia.org/page/Protriptyline
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FProtriptyline%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1467
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1467%3E
2008-08-26 14:27:26 UTC
Pertofrane
BWPIARFWQZKAIA-UHFFFAOYAS
Protryptyline
Asendin
Side effects include anxiety, blood disorders, confusion, decreased libido, dizziness, flushing, headache, impotence, insomnia, low blood pressure, nightmares, rapid or irregular heartbeat, rash, seizures, sensitivity to sunlight, stomach and intestinal problems.
Aventyl
Protriptyline acts by decreasing the reuptake of norepinephrine and serotonin (5-HT).
Novo-Doxepin
InChI=1/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-10,12-13,19-20H,6,11,14H2,1H3
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/872
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F872%3E
Novotriptyn
Levate
Norpramin
1.04 mg/L
PA451168
N06AA11
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/antidepressiveAgents,Tricyclic
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fsider%2Fresource%2Fdrugs%2F4976%3E
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/viv1617.shtml
Triadapin 5
http://www.dbpedia.org/resource/Protriptyline
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FProtriptyline%3E
http://bio2rdf.org/cpd:C07408
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC07408%3E
Novopramine
Vivactil
Impril
Tricyclic antidepressant similar in action and side effects to imipramine. It may produce excitation. [PubChem]
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00668_DB00344
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00575_DB00344
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00674_DB00344
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB00344
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00908_DB00344
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00843_DB00344
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01247_DB00344
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00780_DB00344
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01367_DB00344
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00501_DB00344
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00397_DB00344
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00662_DB00344
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00388_DB00344
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00816_DB00344
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00382_DB00344
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01045_DB00344
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00176_DB00344
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00871_DB00344
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00615_DB00344
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01170_DB00344
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00472_DB00344
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00427_DB00344
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00365_DB00344
RDF Description of Protriptyline
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00209_DB00344
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01171_DB00344
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00604_DB00344
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/1296
_:header12617104841335206604136
Mon, 23 Apr 2012 18:36:39 GMT
RDF Description of Aarskog-Scott syndrome
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1296
http://bio2rdf.org/omim:305400
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fomim%3A305400%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/FGD1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/FGDY
Aarskog-Scott syndrome
http://www4.wiwiss.fu-berlin.de/diseasome/resource/chromosomalLocation/Xp11.21
http://www.dbpedia.org/resource/Aarskog-Scott_syndrome
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FAarskog-Scott_syndrome%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/10
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/AAS
http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=305400
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fdispomim.cgi%3Fid%3D305400%3E
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/3239
_:header16593830621335206604542
RDF Description of Gastrotropin
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3239
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3049572
PIP
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=J05136
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DJ05136%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8805562
http://www.pdb.org/pdb/explore/explore.do?structureId=1EIO
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1EIO%3E
>465 bp	ATGGAGGGGTCCAATCAGAGCTGTAGCTGCCGGCCTACACCACCCTTCGGCTCCTGGACC	TCCCAGCTCTCCGGCGGCATGGCCTTCACTGGCAAGTATGAGATCGAGAGTGAGAAGAAC	TACGATGAGTTCATGAAGCGCTTGGCACTCCCCAGCGACGCCATTGACAAGGCCCGCAAC	CTCAAGATCATCTCGGAGGTGAAGCAGGATGGCCAGAACTTCACCTGGTCCCAGCAATAC	CCCGGGGGCCACTCCATCACCAACACGTTCACCATCGGCAAGGAGTGCGACATAGAGACC	ATCGGGGGCAAGAAGTTCAAGGCCACTGTGCAGATGGAGGGGGGGAAGGTGGTGGTGAAC	AGCCCCAACTACCACCACACCGCGGAGATTGTGGACGGCAAGCTGGTGGAGGTCTCCACT	GTCGGAGGCGTGACGTACGAGCGTGTAAGCAAGAAGCTGGCATGA
http://pfam.sanger.ac.uk/family?acc=PF00061
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00061%3E
Gastrotropin
http://bio2rdf.org/uniprot:P10289
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP10289%3E
ILBP_PIG
Ileal lipid-binding protein
http://www.uniprot.org/uniprot/P10289
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP10289%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=164466
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D164466%3E
FABP6
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10806391
http://bio2rdf.org/pdb:1EIO
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1EIO%3E
http://bio2rdf.org/pfam:PF00061
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00061%3E
Ileal protein which stimulates gastric acid and pepsinogen secretion. Seems to be able to bind to bile salts and bilirubins
ILBP
>Gastrotropin	MAFTGKYEIESEKNYDEFMKRLALPSDAIDKARNLKIISEVKQDGQNFTWSQQYPGGHSI	TNTFTIGKECDIETIGGKKFKATVQMEGGKVVVNSPNYHHTAEIVDGKLVEVSTVGGVTY	ERVSKKLA
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2584215
Involved in lipid and bile salt transporter activity
Porcine ileal peptide
GT
J05136
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02691
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00155
_:header7192864391335206605009
RDF Description of L-Citrulline
2.18e+01 mg/mL
200 g/L (at 20 oC)
1J1Z
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1406
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1406%3E
N5-(Aminocarbonyl)ornithine
http://data.linkedct.org/resource/intervention/22448
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F22448%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3448
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3448%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/291
L-citrulline is converted to L-arginine by argininosuccinate synthase. L-arginine is in turn responsible for citrulline's therapeutic affects. Many of L-arginine's activities, including its possible anti-atherogenic actions, may be accounted for by its role as the precursor to nitric oxide or NO. NO is produced by all tissues of the body and plays very important roles in the cardiovascular system, immune system and nervous system. NO is formed from L-arginine via the enzyme nitric oxide synthase or synthetase (NOS), and the effects of NO are mainly mediated by 3',5' -cyclic guanylate or cyclic GMP. NO activates the enzyme guanylate cyclase, which catalyzes the synthesis of cyclic GMP from guanosine triphosphate or GTP. Cyclic GMP is converted to guanylic acid via the enzyme cyclic GMP phosphodiesterase. <br/><br/>NOS is a heme-containing enzyme with some sequences similar to cytochrome P-450 reductase. Several isoforms of NOS exist, two of which are constitutive and one of which is inducible by immunological stimuli. The constitutive NOS found in the vascular endothelium is designated eNOS and that present in the brain, spinal cord and peripheral nervous system is designated nNOS. The form of NOS induced by immunological or inflammatory stimuli is known as iNOS. iNOS may be expressed constitutively in select tissues such as lung epithelium. <br/><br/>All the nitric oxide synthases use NADPH (reduced nicotinamide adenine dinucleotide phosphate) and oxygen (O<sub>2</sub>) as cosubstrates, as well as the cofactors FAD (flavin adenine dinucleotide), FMN (flavin mononucleotide), tetrahydrobiopterin and heme. Interestingly, ascorbic acid appears to enhance NOS activity by increasing intracellular tetrahydrobiopterin. eNOS and nNOS synthesize NO in response to an increased concentration of calcium ions or in some cases in response to calcium-independent stimuli, such as shear stress. <i>In vitro</i> studies of NOS indicate that the Km of the enzyme for L-arginine is in the micromolar range. The concentration of L-arginine in endothelial cells, as well as in other cells, and in plasma is in the millimolar range. What this means is that, under physiological conditions, NOS is saturated with its L-arginine substrate. In other words, L-arginine would not be expected to be rate-limiting for the enzyme, and it would not appear that supraphysiological levels of L-arginine which could occur with oral supplementation of the amino acid would make any difference with regard to NO production. The reaction would appear to have reached its maximum level. However, <i>in vivo</i> studies have demonstrated that, under certain conditions, e.g. hypercholesterolemia, L-arginine could enhance endothelial-dependent vasodilation and NO production.
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2708
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2708%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2011
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2011%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/108
NC(CCCNC(N)=O)C(O)=O
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/999
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F999%3E
delta-Ureidonorvaline
214 oC
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/1814
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/865
http://bio2rdf.org/cas:372-75-8
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A372-75-8%3E
CIR
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4068
L-Citrulline
Citrulline is an amino acid.  It is made from ornithine and carbamoyl phosphate in one of the central reactions in the urea cycle. It is also produced from arginine as a by-product of the reaction catalyzed by NOS family.  Its name is derived from citrullus, the Latin word for watermelon, from which it was first isolated.
http://www.drugbank.ca/drugs/DB00155
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00155%3E
A non-essential amino acid and a precursor of arginine. Citrulline supplements have been claimed to promote energy levels, stimulate the immune system and help detoxify ammonia (a cell toxin). L-citrulline is made from L-ornithine and carbamoyl phosphate in one of the central reactions in the urea cycle. It is also produced from L-arginine as a by-product of the reaction catalyzed by the enzyme NO synthase. L-citrulline, while being an amino acid, is not involved in protein synthesis and is not one of the amino acids coded for by DNA. Although citrulline cannot be incorporated in proteins during protein synthesis, several proteins are known to contain citrulline as an amino acid. These citrulline residues are generated by a family of enzymes called peptidylarginine deiminases (PADs), which convert the amino acid arginine into citrulline. Proteins that contain citrulline residues include myelin basic protein (MBP), fillagrin and several histone proteins.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4066
(2S)-2-amino-5-(carbamoylamino)pentanoic acid
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/975
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F975%3E
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F932%3E
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3600%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3047
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3047%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/7
N[C@@H](CCCNC(N)=O)C(O)=O
DB00155
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3792
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3792%3E
Sitrulline
Used for nutritional supplementation, also for treating dietary shortage or imbalance.
Citrulline
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/non-essentialAminoAcids
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2706
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2706%3E
http://bio2rdf.org/chebi:16349
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fchebi%3A16349%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/670
2008-08-26 17:01:42 UTC
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/336
N5-Carbamoyl-L-ornithine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4067
N5-carbamylornithine
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/868
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F868%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1894
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1894%3E
http://data.linkedct.org/resource/intervention/47613
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F47613%3E
http://data.linkedct.org/resource/intervention/3120
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F3120%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4065
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1228
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1228%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/740
C6H13N3O3
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/243
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F243%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/710
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F710%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3697
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3697%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/416
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/843
/drugs/155/safety_sheets/908
N5-carbamoylornithine
nutr00021
http://bio2rdf.org/cpd:C00327
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC00327%3E
InChI=1/C6H13N3O3/c7-4(5(10)11)2-1-3-9-6(8)12/h4H,1-3,7H2,(H,10,11)(H3,8,9,12)/t4-/m0/s1/f/h9-10H,8H2
http://data.linkedct.org/resource/intervention/21426
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F21426%3E
2-Amino-5-uredovaleric acid
RHGKLRLOHDJJDR-HOODZTACDX
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/76
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/EGR2
_:header5071223411335206605364
Mon, 23 Apr 2012 18:36:40 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/EGR2
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3357
http://symbol.bio2rdf.org/symbol:EGR2
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AEGR2%3E
EGR2
http://www.dbpedia.org/resource/EGR2
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FEGR2%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2118
RDF Description of EGR2
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1830
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/5215
_:header20055288941335206605885
RDF Description of sulfadiazine
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5215
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/230
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F230%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0040558
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0031036
CID0000005215
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0025637
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0178879
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0271429
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00359
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00359%3E
http://sideeffects.embl.de/drugs/5215
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F5215%3E
sulfadiazine
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000005215&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000005215%26input_query_species%3D9606%3E
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000005215
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000005215%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0025294
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0001175
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0014038
http://dbpedia.org/resource/Sulfadiazine
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FSulfadiazine%3E
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0006826
_:header7716967911335206606297
Mon, 23 Apr 2012 18:36:41 GMT
http://dbpedia.org/resource/Cancer
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FCancer%3E
http://sideeffects.embl.de/se/C0006826
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0006826%3E
CANCER
C0006826
cancers
malignancies
malignancy
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3350
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4160
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5493444
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5362420
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/315411
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/152945
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2803
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/25419
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4479097
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3387
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/598
RDF Description of CANCER
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/3084
_:header16873661861335206606842
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3084
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02859
FAS3
http://bio2rdf.org/pfam:PF00289
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00289%3E
biotin binding
EC 6.4.1.2
http://pfam.sanger.ac.uk/family?acc=PF08326
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF08326%3E
>6714 bp	ATGAGCGAAGAAAGCTTATTCGAGTCTTCTCCACAGAAGATGGAGTACGAAATTACAAAC	TACTCAGAAAGACATACAGAACTTCCAGGTCATTTCATTGGCCTCAATACAGTAGATAAA	CTAGAGGAGTCCCCGTTAAGGGACTTTGTTAAGAGTCACGGTGGTCACACGGTCATATCC	AAGATCCTGATAGCAAATAATGGTATTGCCGCCGTGAAAGAAATTAGATCCGTCAGAAAA	TGGGCATACGAGACGTTCGGCGATGACAGAACCGTCCAATTCGTCGCCATGGCCACCCCA	GAAGATCTGGAGGCCAACGCAGAATATATCCGTATGGCCGATCAATACATTGAAGTGCCA	GGTGGTACTAATAATAACAACTACGCTAACGTAGACTTGATCGTAGACATCGCCGAAAGA	GCAGACGTAGACGCCGTATGGGCTGGCTGGGGTCACGCCTCCGAGAATCCACTATTGCCT	GAAAAATTGTCCCAGTCTAAGAGGAAAGTCATCTTTATTGGGCCTCCAGGTAACGCCATG	AGGTCTTTAGGTGATAAAATCTCCTCTACCATTGTCGCTCAAAGTGCTAAAGTCCCATGT	ATTCCATGGTCTGGTACCGGTGTTGACACCGTTCACGTGGACGAGAAAACCGGTCTGGTC	TCTGTCGACGATGACATCTATCAAAAGGGTTGTTGTACCTCTCCTGAAGATGGTTTACAA	AAGGCCAAGCGTATTGGTTTTCCTGTCATGATTAAGGCATCCGAAGGTGGTGGTGGTAAA	GGTATCAGACAAGTTGAACGTGAAGAAGATTTCATCGCTTTATACCACCAGGCAGCCAAC	GAAATTCCAGGCTCCCCCATTTTCATCATGAAGTTGGCCGGTAGAGCGCGTCACTTGGAA	GTTCAACTGCTAGCAGATCAGTACGGTACAAATATTTCCTTGTTCGGTAGAGACTGTTCC	GTTCAGAGACGTCATCAAAAAATTATCGAAGAAGCACCAGTTACAATTGCCAAGGCTGAA	ACATTTCACGAGATGGAAAAGGCTGCCGTCAGACTGGGGAAACTAGTCGGTTATGTCTCT	GCCGGTACCGTGGAGTATCTATATTCTCATGATGATGGAAAATTCTACTTTTTAGAATTG	AACCCAAGATTACAAGTCGAGCATCCAACAACGGAAATGGTCTCCGGTGTTAACTTACCT	GCAGCTCAATTACAAATCGCTATGGGTATCCCTATGCATAGAATAAGTGACATTAGAACT	TTATATGGTATGAATCCTCATTCTGCCTCAGAAATCGATTTCGAATTCAAAACTCAAGAT	GCCACCAAGAAACAAAGAAGACCTATTCCAAAGGGTCATTGTACCGCTTGTCGTATCACA	TCAGAAGATCCAAACGATGGATTCAAGCCATCGGGTGGTACTTTGCATGAACTAAACTTC	CGTTCTTCCTCTAATGTTTGGGGTTACTTCTCCGTGGGTAACAATGGTAATATTCACTCC	TTTTCGGACTCTCAGTTCGGCCATATTTTTGCTTTTGGTGAAAATAGACAAGCTTCCAGG	AAACACATGGTTGTTGCCCTGAAGGAATTGTCCATTAGGGGTGATTTCAGAACTACTGTG	GAATACTTGATCAAACTTTTGGAAACTGAAGATTTCGAGGATAACACTATTACCACCGGT	TGGTTGGACGATTTGATTACTCATAAAATGACCGCTGAAAAGCCTGATCCAACTCTTGCC	GTCATTTGCGGTGCCGCTACAAAGGCTTTCTTAGCATCTGAAGAAGCCCGCCACAAGTAT	ATCGAATCCTTACAAAAGGGACAAGTTCTATCTAAAGACCTACTGCAAACTATGTTCCCT	GTAGATTTTATCCATGAGGGTAAAAGATACAAGTTCACCGTAGCTAAATCCGGTAATGAC	CGTTACACATTATTTATCAATGGTTCTAAATGTGATATCATACTGCGTCAACTATCTGAT	GGTGGTCTTTTGATTGCCATAGGCGGTAAATCGCATACCATCTATTGGAAAGAAGAAGTT	GCTGCTACAAGATTATCCGTTGACTCTATGACTACTTTGTTGGAAGTTGAAAACGATCCA	ACCCAGTTGCGTACTCCATCCCCTGGTAAATTGGTTAAATTCTTGGTGGAAAATGGTGAA	CACATTATCAAGGGCCAACCATATGCAGAAATTGAAGTTATGAAAATGCAAATGCCTTTG	GTTTCTCAAGAAAATGGTATCGTCCAGTTATTAAAGCAACCTGGTTCTACCATTGTTGCA	GGTGATATCATGGCTATTATGACTCTTGACGATCCATCCAAGGTCAAGCACGCTCTACCA	TTTGAAGGTATGCTGCCAGATTTTGGTTCTCCAGTTATCGAAGGAACCAAACCTGCCTAT	AAATTCAAGTCATTAGTGTCTACTTTGGAAAACATTTTGAAGGGTTATGACAACCAAGTT	ATTATGAACGCTTCCTTGCAACAATTGATAGAGGTTTTGAGAAATCCAAAACTGCCTTAC	TCAGAATGGAAACTACACATCTCTGCTTTACATTCAAGATTGCCTGCTAAGCTAGATGAA	CAAATGGAAGAGTTAGTTGCACGTTCTTTGAGACGTGGTGCTGTTTTCCCAGCTAGACAA	TTAAGTAAATTGATTGATATGGCCGTGAAGAATCCTGAATACAACCCCGACAAATTGCTG	GGCGCCGTCGTGGAACCATTGGCGGATATTGCTCATAAGTACTCTAACGGGTTAGAAGCC	CATGAACATTCTATATTTGTCCATTTCTTGGAAGAATATTACGAAGTTGAAAAGTTATTC	AATGGTCCAAATGTTCGTGAGGAAAATATCATTCTGAAATTGCGTGATGAAAACCCTAAA	GATCTAGATAAAGTTGCGCTAACTGTTTTGTCTCATTCGAAAGTTTCAGCGAAGAATAAC	CTGATCCTAGCTATCTTGAAACATTATCAACCATTGTGCAAGTTATCTTCTAAAGTTTCT	GCCATTTTCTCTACTCCTCTACAACATATTGTTGAACTAGAATCTAAGGCTACCGCTAAG	GTCGCTCTACAAGCAAGAGAAATTTTGATTCAAGGCGCTTTACCTTCGGTCAAGGAAAGA	ACTGAACAAATTGAACATATCTTAAAATCCTCTGTTGTGAAGGTTGCCTATGGCTCATCC	AATCCAAAGCGCTCTGAACCAGATTTGAATATCTTGAAGGACTTGATCGATTCTAATTAC	GTTGTGTTCGATGTTTTACTTCAATTCCTAACCCATCAAGACCCAGTTGTGACTGCTGCA	GCTGCTCAAGTCTATATTCGTCGTGCTTATCGTGCTTACACCATAGGAGATATTAGAGTT	CACGAAGGTGTCACAGTTCCAATTGTTGAATGGAAATTCCAACTACCTTCAGCTGCGTTC	TCCACCTTTCCAACTGTTAAATCTAAAATGGGTATGAACAGGGCTGTTTCTGTTTCAGAT	TTGTCATATGTTGCAAACAGTCAGTCATCTCCGTTAAGAGAAGGTATTTTGATGGCTGTG	GATCATTTAGATGATGTTGATGAAATTTTGTCACAAAGTTTGGAAGTTATTCCTCGTCAC	CAATCTTCTTCTAACGGACCTGCTCCTGATCGTTCTGGTAGCTCCGCATCGTTGAGTAAT	GTTGCTAATGTTTGTGTTGCTTCTACAGAAGGTTTCGAATCTGAAGAGGAAATTTTGGTA	AGGTTGAGAGAAATTTTGGATTTGAATAAGCAGGAATTAATCAATGCTTCTATCCGTCGT	ATCACATTTATGTTCGGTTTTAAAGATGGGTCTTATCCAAAGTATTATACTTTTAACGGT	CCAAATTATAACGAAAATGAAACAATTCGTCACATTGAGCCGGCTTTGGCCTTCCAACTG	GAATTAGGAAGATTGTCCAACTTCAACATTAAACCAATTTTCACTGATAATAGAAACATC	CATGTCTACGAAGCTGTTAGTAAGACTTCTCCATTGGATAAGAGATTCTTTACAAGAGGT	ATTATTAGAACGGGTCATATCCGTGATGACATTTCTATTCAAGAATATCTGACTTCTGAA	GCTAACAGATTGATGAGTGATATATTGGATAATTTAGAAGTCACCGACACTTCAAATTCT	GATTTGAATCATATCTTCATCAACTTCATTGCGGTGTTTGATATCTCTCCAGAAGATGTC	GAAGCCGCCTTCGGTGGTTTCTTAGAAAGATTTGGTAAGAGATTGTTGAGATTGCGTGTT	TCTTCTGCCGAAATTAGAATCATCATCAAAGATCCTCAAACAGGTGCCCCAGTACCATTG	CGTGCCTTGATCAATAACGTTTCTGGTTATGTTATCAAAACAGAAATGTACACCGAAGTC	AAGAACGCAAAAGGTGAATGGGTATTTAAGTCTTTGGGTAAACCTGGATCCATGCATTTA	AGACCTATTGCTACTCCTTACCCTGTTAAGGAATGGTTGCAACCAAAACGTTATAAGGCA	CACTTGATGGGTACCACATATGTCTATGACTTCCCAGAATTATTCCGCCAAGCATCGTCA	TCCCAAGGAAAAAATTTCTCTGCAGATGTTAAGTTAACAGATGATTTCTTTATTTCCAAC	GAGTTGATTGAAGATGAAAACGGCGAATTAACTGAGGTGGAAAGAGAACCTGGTGCCAAC	GCTATTGGTATGGTTGCCTTTAAGATTACTGTAAAGACTCCTGAATATCCAAGAGGCCGT	CAATTTGTTGTTGTTGCTAACGATATCACATTCAAGATCGGTTCCTTTGGTCCACAAGAA	GACGAATTCTTCAATAAGGTTACTGAATATGCTAGAAAGCGTGGTATCCCAAGAATTTAC	TTGGCTGCAAACTCAGGTGCCAGAATTGGTATGGCTGAAGAGATTGTTCCACTATTTCAA	GTTGCATGGAATGATGCTGCCAATCCGGACAAGGGCTTCCAATACTTATACTTAACAAGT	GAAGGTATGGAAACTTTAAAGAAATTTGACAAAGAAAATTCTGTTCTCACTGAACGTACT	GTTATAAACGGTGAAGAAAGATTTGTCATCAAGACAATTATTGGTTCTGAAGATGGGTTA	GGTGTCGAATGTCTACGTGGATCTGGTTTAATTGCTGGTGCAACGTCAAGGGCTTACCAC	GATATCTTCACTATCACCTTAGTCACTTGTAGATCCGTCGGTATCGGTGCTTATTTGGTT	CGTTTGGGTCAAAGAGCTATTCAGGTCGAAGGCCAGCCAATTATTTGGTATCGGTGCTTA	TTAACTGGTGCTCCTGAATCAACAAATGCTGGTAGAGAAGTTTATACTTCTAACTTACAA	TTGGGTGGTACTCAAATCATGTATAACAACGGTGTTTCACATTTGACTGCTGTTGACGAT	TTAGCTGGTGTAGAGAAGATTGTTGAATGGATGTCTTATGTTCCAGCCAAGCGTAATATG	CCAGTTCCTATCTTGGAAACTAAAGACACATGGGATAGACCAGTTGATTTCACTCCAACT	AATGATGAAACTTACGATGTAAGATGGATGATTGAAGGTCGTGAGACTGAAAGTGGATTT	GAATATGGTTTGTTTGATAAAGGGTCTTTCTTTGAAACTTTGTCAGGATGGGCCAAAGGT	GTTGTCGTTGGTAGAGCCCGTCTTGGTGGTATTCCACTGGGTGTTATTGGTGTTGAAACA	AGAACTGTCGAGAACTTGATTCCTGCTGATCCAGCTAATCCAAATAGTGCTGAAACATTA	ATTCAAGAACCTGGTCAAGTTTGGCATCCAAACTCCGCCTTCAAGACTGCTCAAGCTATC	AATGACTTTAACAACGGTGAACAATTGCCAATGATGATTTTGGCCAACTGGAGAGGTTTC	TCTGGTGGTCAACGTGATATGTTCAACGAAGTCTTGAAGTATGGTTCGTTTATTGTTGAC	GCATTGGTGGATTACAAACAACCAATTATTATCTATATCCCACCTACCGGTGAACTAAGA	GGTGGTTCATGGGTTGTTGTCGATCCAACTATCAACGCTGACCAAATGGAAATGTATGCC	GACGTCAACGCTAGAGCTGGTGTTTTGGAACCACAAGGTATGGTTGGTATCAAGTTCCGT	AGAGAAAAATTGCTGGACACCATGAACAGATTGGATGACAAGTACAGAGAATTGAGATCT	CAATTATCCAACAAGAGTTTGGCTCCAGAAGTACATCAGCAAATATCCAAGCAATTAGCT	GATCGTGAGAGAGAACTATTGCCAATTTACGGACAAATCAGTCTTCAATTTGCTGATTTG	CACGATAGGTCTTCACGTATGGTGGCCAAGGGTGTTATTTCTAAGGAACTGGAATGGACC	GAGGCACGTCGTTTCTTCTTCTGGAGATTGAGAAGAAGATTGAACGAAGAATATTTGATT	AAAAGGTTGAGCCATCAGGTAGGCGAAGCATCAAGATTAGAAAAGATCGCAAGAATTAGA	TCGTGGTACCCTGCTTCAGTGGACCATGAAGATGATAGGCAAGTCGCAACATGGATTGAA	GAAAACTACAAAACTTTGGACGATAAACTAAAGGGTTTGAAATTAGAGTCATTCGCTCAA	GACTTAGCTAAAAAGATCAGAAGCGACCATGACAATGCTATTGATGGATTATCTGAAGTT	ATCAAGATGTTATCTACCGATGATAAAGAAAAATTGTTGAAGACTTTGAAATAA
http://bio2rdf.org/pfam:PF08326
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF08326%3E
ATP + biotin-carboxyl-carrier protein + CO2 = ADP + phosphate + carboxybiotin-carboxyl-carrier protein
map00061	Fatty acid biosynthesis (path 1)
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9169873
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=1302498
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D1302498%3E
http://bio2rdf.org/pfam:PF00364
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00364%3E
http://pfam.sanger.ac.uk/family?acc=PF00364
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00364%3E
http://bio2rdf.org/uniprot:Q00955
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ00955%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=Z71631
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DZ71631%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11875433
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2880560
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12829626
ACC
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1350093
Acetyl-CoA carboxylase
Z71631
http://pfam.sanger.ac.uk/family?acc=PF02786
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF02786%3E
http://bio2rdf.org/pfam:PF02786
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF02786%3E
http://pfam.sanger.ac.uk/family?acc=PF00289
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00289%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/14562106
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8318018
http://bio2rdf.org/pfam:PF01039
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF01039%3E
Carries out three functions:biotin carboxyl carrier protein, biotin carboxylase and carboxyltransferase
COAC_YEAST
ligase activity
http://pfam.sanger.ac.uk/family?acc=PF01039
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF01039%3E
http://www.pdb.org/pdb/explore/explore.do?structureId=1OD4
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1OD4%3E
http://www.uniprot.org/uniprot/Q00955
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ00955%3E
>Acetyl-CoA carboxylase	MSEESLFESSPQKMEYEITNYSERHTELPGHFIGLNTVDKLEESPLRDFVKSHGGHTVIS	KILIANNGIAAVKEIRSVRKWAYETFGDDRTVQFVAMATPEDLEANAEYIRMADQYIEVP	GGTNNNNYANVDLIVDIAERADVDAVWAGWGHASENPLLPEKLSQSKRKVIFIGPPGNAM	RSLGDKISSTIVAQSAKVPCIPWSGTGVDTVHVDEKTGLVSVDDDIYQKGCCTSPEDGLQ	KAKRIGFPVMIKASEGGGGKGIRQVEREEDFIALYHQAANEIPGSPIFIMKLAGRARHLE	VQLLADQYGTNISLFGRDCSVQRRHQKIIEEAPVTIAKAETFHEMEKAAVRLGKLVGYVS	AGTVEYLYSHDDGKFYFLELNPRLQVEHPTTEMVSGVNLPAAQLQIAMGIPMHRISDIRT	LYGMNPHSASEIDFEFKTQDATKKQRRPIPKGHCTACRITSEDPNDGFKPSGGTLHELNF	RSSSNVWGYFSVGNNGNIHSFSDSQFGHIFAFGENRQASRKHMVVALKELSIRGDFRTTV	EYLIKLLETEDFEDNTITTGWLDDLITHKMTAEKPDPTLAVICGAATKAFLASEEARHKY	IESLQKGQVLSKDLLQTMFPVDFIHEGKRYKFTVAKSGNDRYTLFINGSKCDIILRQLSD	GGLLIAIGGKSHTIYWKEEVAATRLSVDSMTTLLEVENDPTQLRTPSPGKLVKFLVENGE	HIIKGQPYAEIEVMKMQMPLVSQENGIVQLLKQPGSTIVAGDIMAIMTLDDPSKVKHALP	FEGMLPDFGSPVIEGTKPAYKFKSLVSTLENILKGYDNQVIMNASLQQLIEVLRNPKLPY	SEWKLHISALHSRLPAKLDEQMEELVARSLRRGAVFPARQLSKLIDMAVKNPEYNPDKLL	GAVVEPLADIAHKYSNGLEAHEHSIFVHFLEEYYEVEKLFNGPNVREENIILKLRDENPK	DLDKVALTVLSHSKVSAKNNLILAILKHYQPLCKLSSKVSAIFSTPLQHIVELESKATAK	VALQAREILIQGALPSVKERTEQIEHILKSSVVKVAYGSSNPKRSEPDLNILKDLIDSNY	VVFDVLLQFLTHQDPVVTAAAAQVYIRRAYRAYTIGDIRVHEGVTVPIVEWKFQLPSAAF	STFPTVKSKMGMNRAVSVSDLSYVANSQSSPLREGILMAVDHLDDVDEILSQSLEVIPRH	QSSSNGPAPDRSGSSASLSNVANVCVASTEGFESEEEILVRLREILDLNKQELINASIRR	ITFMFGFKDGSYPKYYTFNGPNYNENETIRHIEPALAFQLELGRLSNFNIKPIFTDNRNI	HVYEAVSKTSPLDKRFFTRGIIRTGHIRDDISIQEYLTSEANRLMSDILDNLEVTDTSNS	DLNHIFINFIAVFDISPEDVEAAFGGFLERFGKRLLRLRVSSAEIRIIIKDPQTGAPVPL	RALINNVSGYVIKTEMYTEVKNAKGEWVFKSLGKPGSMHLRPIATPYPVKEWLQPKRYKA	HLMGTTYVYDFPELFRQASSSQWKNFSADVKLTDDFFISNELIEDENGELTEVEREPGAN	AIGMVAFKITVKTPEYPRGRQFVVVANDITFKIGSFGPQEDEFFNKVTEYARKRGIPRIY	LAANSGARIGMAEEIVPLFQVAWNDAANPDKGFQYLYLTSEGMETLKKFDKENSVLTERT	VINGEERFVIKTIIGSEDGLGVECLRGSGLIAGATSRAYHDIFTITLVTCRSVGIGAYLV	RLGQRAIQVEGQPIILTGAPAINKMLGREVYTSNLQLGGTQIMYNNGVSHLTAVDDLAGV	EKIVEWMSYVPAKRNMPVPILETKDTWDRPVDFTPTNDETYDVRWMIEGRETESGFEYGL	FDKGSFFETLSGWAKGVVVGRARLGGIPLGVIGVETRTVENLIPADPANPNSAETLIQEP	GQVWHPNSAFKTAQAINDFNNGEQLPMMILANWRGFSGGQRDMFNEVLKYGSFIVDALVD	YKQPIIIYIPPTGELRGGSWVVVDPTINADQMEMYADVNARAGVLEPQGMVGIKFRREKL	LDTMNRLDDKYRELRSQLSNKSLAPEVHQQISKQLADRERELLPIYGQISLQFADLHDRS	SRMVAKGVISKELEWTEARRFFFWRLRRRLNEEYLIKRLSHQVGEASRLEKIARIRSWYP	ASVDHEDDRQVATWIEENYKTLDDKLKGLKLESFAQDLAKKIRSDHDNAIDGLSEVIKML	STDDKEKLLKTLK
http://bio2rdf.org/pfam:PF02785
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF02785%3E
http://bio2rdf.org/pdb:1OD4
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1OD4%3E
http://pfam.sanger.ac.uk/family?acc=PF02785
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF02785%3E
RDF Description of Acetyl-CoA carboxylase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03781
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/57469
_:header17712997501335206607280
Mon, 23 Apr 2012 18:36:42 GMT
RDF Description of IMIQUIMOD
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00724
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00724%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0007117
http://www.fda.gov/cder/foi/label/2002/20723slr010_Aldara_lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2002%2F20723slr010_Aldara_lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0008767
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0009663
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0040147
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000057469
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000057469%3E
http://www.fda.gov/cder/foi/label/2002/20723s11s12lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2002%2F20723s11s12lbl.pdf%3E
http://sideeffects.embl.de/drugs/57469
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F57469%3E
http://www.fda.gov/cder/foi/label/2007/020723s020lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2007%2F020723s020lbl.pdf%3E
http://www.fda.gov/cder/foi/label/2001/20723s1lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2001%2F20723s1lbl.pdf%3E
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000057469&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000057469%26input_query_species%3D9606%3E
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=5LVzQpdJn4s=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3D5LVzQpdJn4s%3D%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0009952
CID0000057469
http://www.fda.gov/medwatch/SAFETY/2004/mar_PI/Aldara_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2004%2Fmar_PI%2FAldara_PI.pdf%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1976
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F1976%3E
http://www.fda.gov/cder/foi/label/2005/020723s018lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2005%2F020723s018lbl.pdf%3E
http://www.fda.gov/medwatch/SAFETY/2007/Mar_PI/Aldara_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2007%2FMar_PI%2FAldara_PI.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0022593
http://www.fda.gov/cder/foi/label/2004/20723s016lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2004%2F20723s016lbl.pdf%3E
http://dbpedia.org/resource/Imiquimod
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FImiquimod%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0026393
imiquimod
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0027962
http://www.fda.gov/cder/foi/label/2004/20723se1-015_aldara_lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2004%2F20723se1-015_aldara_lbl.pdf%3E
IMIQUIMOD
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0424109
Aldara
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00272
_:header20539393711335206607728
RDF Description of Betazole
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00272
http://dbpedia.org/page/Betazole
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FBetazole%3E
Betazolum [INN-Latin]
C5H9N3
Betazole is a histamine H2 agonist used in a test for measuring maximal production of gastric acidity or anacidity. This measurement can be used to diagnose diseases such as Zollinger-Ellison syndrome, whereby the volume of gastric and basal secretions is measured following betazole administration (greater than 60% of the maximal acid secretion following betazole stimulation). In another test, gastritis can be diagnosed given late absence of gastric acid which is unresponsive to betazole stimulation. Betazole can be used as a gastric secretory stimulant instead of histamine with the advantage of not provoking side effects and thus not requiring the use of antihistaminic compounds.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/124
DB00272
2-(2H-pyrazol-3-yl)ethanamine
http://www.drugbank.ca/drugs/DB00272
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00272%3E
http://dbpedia.org/resource/Betazole
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FBetazole%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/gastrointestinalAgents
Ametazole
Betazolo [DCIT]
For use clinically to test gastric secretory function.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/diagnosticAgents
http://bio2rdf.org/cas:105-20-4
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A105-20-4%3E
> 99%
Betazole is a histamine analogue. It produces the same effects as histamine, binding the H2 receptor which is a mediator of gastric acid secretion. This agonist action thereby results in an increase in the volume of gastric acid produced.
Histalog
InChI=1/C5H9N3/c6-3-1-5-2-4-7-8-5/h2,4H,1,3,6H2,(H,7,8)/f/h8H
Betazole
1.56e+02 mg/mL
Betazol [INN-Spanish]
Rapid and complete.
V04CG02
2008-08-26 15:46:07 UTC
JXDFEQONERDKSS-FZOZFQFYCD
A histamine H2 agonist used clinically to test gastric secretory function. [PubChem]
aprd00714
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/histamineAgonists
NCCC1=CC=NN1
http://en.wikipedia.org/wiki/Betazole
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FBetazole%3E
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Craighill_W_P_(William_Price)_1833-1909
_:header8924944061335206608213
Mon, 23 Apr 2012 18:36:43 GMT
RDF Description of Craighill, W. P. (William Price), 1833-1909 
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Craighill_W_P_(William_Price)_1833-1909
Craighill, W. P. (William Price), 1833-1909 
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13549
http://www4.wiwiss.fu-berlin.de/eurostat/data/regions/Gelderland
_:header15305011451335206608631
RDF Description of Gelderland
http://www4.wiwiss.fu-berlin.de/eurostat/resource/regions/Gelderland
http://ec.europa.eu/eurostat/ramon/rdfdata/nuts2008/NL22
http://www4.wiwiss.fu-berlin.de/eurostat/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fec.europa.eu%2Feurostat%2Framon%2Frdfdata%2Fnuts2008%2FNL22%3E
http://www4.wiwiss.fu-berlin.de/eurostat/resource/countries/Nederland
Gelderland
http://dbpedia.org/resource/Gelderland
http://www4.wiwiss.fu-berlin.de/eurostat/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FGelderland%3E
nl22
http://estatwrap.ontologycentral.com/dic/geo#NL22
http://www4.wiwiss.fu-berlin.de/eurostat/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Festatwrap.ontologycentral.com%2Fdic%2Fgeo%23NL22%3E
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01917
_:header18545760581335206609056
RDF Description of Putrescine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01917
Putrescine
1F3T
PUT
http://en.wikipedia.org/wiki/Putrescine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FPutrescine%3E
A toxic diamine formed by putrefaction from the decarboxylation of arginine and ornithine. [PubChem]
-0.70 [SANGSTER (1994)]
DB01917
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/113
http://bio2rdf.org/cpd:C00134
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC00134%3E
2008-08-26 16:29:57 UTC
http://dbpedia.org/page/Putrescine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FPutrescine%3E
NCCCCN
http://bio2rdf.org/chebi:17148
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fchebi%3A17148%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2429
http://bio2rdf.org/cas:110-60-1
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A110-60-1%3E
http://www.drugbank.ca/drugs/DB01917
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01917%3E
27.5 oC
KIDHWZJUCRJVML-UHFFFAOYAX
2.36e+02 mg/mL
http://dbpedia.org/resource/Putrescine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FPutrescine%3E
expt02702
InChI=1/C4H12N2/c5-3-1-2-4-6/h1-6H2
C4H12N2
butane-1,4-diamine
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0043246
_:header13522424401335206609518
Mon, 23 Apr 2012 18:36:44 GMT
RDF Description of lacerations
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0043246
http://dbpedia.org/resource/Wound
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FWound%3E
http://sideeffects.embl.de/se/C0043246
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0043246%3E
lacerations
C0043246
Laceration
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4192
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0235974
_:header17338257551335206609932
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/893
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F893%3E
http://dbpedia.org/resource/Pancreatic_cancer
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FPancreatic_cancer%3E
http://sideeffects.embl.de/se/C0235974
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0235974%3E
Pancreatic Cancer
C0235974
carcinoma of the pancreas
Pancreatic Carcinoma
RDF Description of Pancreatic Cancer
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0007286
_:header19799359961335206610394
Mon, 23 Apr 2012 18:36:45 GMT
http://dbpedia.org/resource/Carpal_tunnel_syndrome
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FCarpal_tunnel_syndrome%3E
http://sideeffects.embl.de/se/C0007286
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0007286%3E
carpal tunnel syndrome
C0007286
carpel tunnel syndrome
RDF Description of carpal tunnel syndrome
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/PTGDR
_:header17150615061335206610744
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PTGDR
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1500
http://symbol.bio2rdf.org/symbol:PTGDR
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3APTGDR%3E
PTGDR
http://bio2rdf.org/hgnc:9591
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A9591%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=9591
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D9591%3E
http://bio2rdf.org/geneid:5729
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fgeneid%3A5729%3E
http://www.dbpedia.org/resource/Prostaglandin_D2_receptor
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FProstaglandin_D2_receptor%3E
RDF Description of PTGDR
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Leeuwenhoek_Antoni_van_1632-1723
_:header13226786781335206611185
Mon, 23 Apr 2012 18:36:46 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Leeuwenhoek_Antoni_van_1632-1723
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext18929
Leeuwenhoek, Antoni van, 1632-1723
Leeuwenhoek, Antoni van, 1632-1723 
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19072
RDF Description of Leeuwenhoek, Antoni van, 1632-1723
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Joyce_James_1882-1941
_:header4480831521335206611586
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Joyce_James_1882-1941
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext20601
Joyce, James, 1882-1941
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7872
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext4217
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2817
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext2814
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext4300
RDF Description of Joyce, James, 1882-1941
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Seaman_Owen
_:header6201865681335206611983
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Seaman_Owen
Seaman, Owen 
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17654
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19127
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19151
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19105
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17634
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext18114
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext16107
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19350
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext20779
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17471
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext16113
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19334
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17629
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19382
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17397
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17596
RDF Description of Seaman, Owen 
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17653
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17994
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext20392
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19349
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext20334
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB04714
_:header16896143021335206612437
Mon, 23 Apr 2012 18:36:47 GMT
RDF Description of ISOPENTENYL PYROPHOSPHATE
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04714
DB04714
2007-09-11 17:49:28 UTC
NUHSROFQTUXZQQ-BZTMKREHCJ
InChI=1/C5H12O7P2/c1-5(2)3-4-11-14(9,10)12-13(6,7)8/h1,3-4H2,2H3,(H,9,10)(H2,6,7,8)/f/h6-7,9H
C5H12O7P2
2008-08-26 14:56:16 UTC
ISOPENTENYL PYROPHOSPHATE
3-methylbut-3-enyl phosphono hydrogen phosphate
CC(=C)CCO[P@](O)(=O)OP(O)(O)=O
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/5744
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/853
CC(=C)CCOP(O)(=O)OP(O)(O)=O
IPE
http://www.drugbank.ca/drugs/DB04714
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB04714%3E
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0042133
_:header17439614021335206612853
RDF Description of Uterine Fibroids
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0042133
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1165
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1165%3E
http://dbpedia.org/resource/Uterine_fibroids
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FUterine_fibroids%3E
http://sideeffects.embl.de/se/C0042133
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0042133%3E
Uterine Fibroids
C0042133
Fibroids
Uterine Leiomyomata
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Kotzebue_August_von_1761-1819
_:header17619980481335206613293
Mon, 23 Apr 2012 18:36:48 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Kotzebue_August_von_1761-1819
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext20217
Kotzebue, August von, 1761-1819
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext4554
RDF Description of Kotzebue, August von, 1761-1819
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/4121
_:header13324835171335206613764
RDF Description of Methyclothiazide
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0156221
Methyclothiazide
http://dbpedia.org/resource/Methyclothiazide
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FMethyclothiazide%3E
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000004121
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000004121%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0027726
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0032914
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1101
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F1101%3E
CID0000004121
http://sideeffects.embl.de/drugs/4121
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F4121%3E
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000004121&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000004121%26input_query_species%3D9606%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0037023
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00232%3E
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00620
_:header14968690521335206614163
Mon, 23 Apr 2012 18:36:49 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00620
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/azm1044.shtml
Sk-Triamcinolone
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/sprayNasal
Kenalog-10
Volon A
Aristocort
http://205.193.93.51/dpdonline/searchRequest.do?din=02229540
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02229540%3E
Tricortale
Viaderm Kc Crm (Gramicidin + Neomycin (Neomycin Sulfate) + Nystatin + Triamcinolone Acetonide)
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/ointmentTopical
Tri-Nasal
Triamcinolone
S01BA05
Trilone
http://bio2rdf.org/kegg:D00385
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD00385%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/suspensionIntra-articular
Triamcinolone diacetate
Cinolone
Triamcinolone hexacetonide
Delphicort
http://data.linkedct.org/resource/intervention/14605
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F14605%3E
Kenacomb Ont (Gramicidin + Neomycin (Neomycin Sulfate) + Nystatin + Triamcinolone Acetonide)
Tiamcinolonum [INN-Latin]
Omcilon
Triatex
Triamcinolon
A glucocorticoid given, as the free alcohol or in esterified form, orally, intramuscularly, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. (From Martindale, The Extra Pharmacopoeia, 30th ed, p739)
http://data.linkedct.org/resource/intervention/61993
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F61993%3E
2000-02-01	/drugs/620/fda_labels/349	2002-09-01	/drugs/620/fda_labels/222	2003-09-01	/drugs/620/fda_labels/1044	2003-12-01	/drugs/620/fda_labels/983	2006-02-01	/drugs/620/fda_labels/1051
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/glucocorticoids
Oribiotic Ointment (Bacitracin + Lidocaine + Neomycin (Neomycin Sulfate) + Nystatin + Triamcinolone Acetonide)
C21H27FO6
68:04.00
Kenacomb Mild Ointment (Gramicidin + Neomycin Sulfate + Nystatin + Triamcinolone Acetonide)
Panolog Ointment (Neomycin (Neomycin Sulfate) + Nystatin + Thiostrepton (Antibiotic of a Streptomyces Species) + Triamcinolone Acetonide)
http://dbpedia.org/page/Triamcinolone
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FTriamcinolone%3E
80 mg/L
Vetalog
Cinolone-T
Triderm
Panolog Cream (Neomycin (Neomycin Sulfate) + Nystatin + Thiostrepton (Antibiotic of a Streptomyces Species) + Triamcinolone Acetonide)
Rodinolone
Nasacort
http://www.drugbank.ca/drugs/DB00620
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00620%3E
Orion
Aristospan
Kenalog in Orabase
Aristocort A
Aristogel
Triamcet
http://data.linkedct.org/resource/intervention/20870
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F20870%3E
http://data.linkedct.org/resource/intervention/62743
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F62743%3E
Omicilon
Aristoform R Crm 0.1% (Clioquinol + Triamcinolone Acetonide)
A01AC01
Kenalog-H
D07XB02
Kenacomb Cream (Gramicidin + Neomycin Sulfate + Nystatin + Triamcinolone Acetonide)
Solvaderm Ointment (Neomycin (Neomycin Sulfate) + Nystatin + Thiostrepton (Antibiotic of a Streptomyces Species) + Triamcinolone Acetonide)
Azmacort
Trymex
http://en.wikipedia.org/wiki/Triamcinolone
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FTriamcinolone%3E
DB00620
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO
Nasacort Aq
8.47e-01 mg/mL
http://129.128.185.122/drugbank2/drugs/DB00620/inserts/947/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00620%2Finserts%2F947%2Ffull%3E
Fluoxyprednisolone
Oracort
Triacet
274 - 278 oC
Kenalog
http://data.linkedct.org/resource/intervention/60035
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F60035%3E
Derma-4 Ont (Neomycin Sulfate + Nystatin + Thiostrepton (Antibiotic of a Streptomyces Species) + Triamcinolone Acetonide)
Triamcinalone
Kenacort-Ag
http://www.rxlist.com/cgi/generic/triamaer.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric%2Ftriamaer.htm%3E
Tristoject
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/pasteDental
Triamcinolone acetonide
84:06.00
For the treatment of perennial and seasonal allergic rhinitis.
2008-08-26 15:16:55 UTC
Ledercort
R01AD11
H02AB08
Volon
http://data.linkedct.org/resource/intervention/14597
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F14597%3E
http://www.dbpedia.org/resource/Triamcinolone
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FTriamcinolone%3E
68%
Flutex
LD<sub>50</sub>=>500mg/kg (in rats)
-3.69 [ADME Research, USCD]
CC12CC(O)C3(F)C(CCC4=CC(=O)C=CC34C)C1CC(O)C2(O)C(=O)CO
InChI=1/C21H27FO6/c1-18-6-5-12(24)7-11(18)3-4-13-14-8-15(25)21(28,17(27)10-23)19(14,2)9-16(26)20(13,18)22/h5-7,13-16,23,25-26,28H,3-4,8-10H2,1-2H3/t13-,14-,15+,16-,18-,19-,20-,21-/m0/s1
aprd00422
http://data.linkedct.org/resource/intervention/55105
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F55105%3E
Kenacort
Celeste
Triamcinolonum [INN]
Fried et al., J. Am. Chem.. Soc. 80, 2338 (1958)
http://bio2rdf.org/cas:124-94-7
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A124-94-7%3E
Kenacomb Ointment (Gramicidin + Neomycin Sulfate + Nystatin + Triamcinolone Acetonide)
Kenacort-A
GFNANZIMVAIWHM-OBYCQNJPBA
Oralone
Nasacort Hfa
Kenacomb Mild Cream (Gramicidin + Neomycin Sulfate + Nystatin + Triamcinolone Acetonide)
Triam-Tablinen
88 minutes
1QMN_A
Ratio-Triacomb Regular Cream (Gramicidin + Neomycin (Neomycin Sulfate) + Nystatin + Triamcinolone Acetonide)
/drugs/620/safety_sheets/1048
Rapid absorption following oral administration
Theraderm Cream (Gramicidin + Neomycin (Neomycin Sulfate) + Nystatin + Triamcinolone Acetonide)
http://data.linkedct.org/resource/intervention/41593
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F41593%3E
Kenalog-40
Triamcinolona [INN-Spanish]
(8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
Fougera
Fluoxiprednisolone
Triamcinlon
The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition of arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.
http://129.128.185.122/drugbank2/drugs/DB00620/inserts/168/full
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/aerosolMeteredNasal
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/suspensionIntramuscular
Aristocort Tablets
Adcortyl
http://dbpedia.org/resource/Triamcinolone
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FTriamcinolone%3E
Polcortolon
Triamcinolone and its derivatives are synthetic glucocorticoids that are used for their antiinflammatory or immunosuppressive properties.
PA451748
Viaderm Kc Ont (Gramicidin + Neomycin (Neomycin Sulfate) + Nystatin + Triamcinolone Acetonide)
R03BA06
Mecomb Crm 0.1% (Gramicidin + Neomycin (Neomycin Sulfate) + Nystatin + Triamcinolone Acetonide)
Triacort
D07AB09
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/suspensionIntrasynovial
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB00312
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB01294
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB00237
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00945_DB00620
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB01351
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01045_DB00620
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01402_DB00620
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00545_DB00620
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB01010
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB00682
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB01400
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB00794
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00794_DB00620
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB00211
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB01398
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB01174
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB00545
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB01320
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB01397
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB01045
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB00754
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB00474
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01174_DB00620
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB01418
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB00266
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB00945
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB01346
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB01122
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB01125
RDF Description of Triamcinolone
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00211_DB00620
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB01355
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB00241
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB00418
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB01399
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB01354
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB00532
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01320_DB00620
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB01353
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB01352
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB00306
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB01341
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00620_DB01401
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0600086
_:header19077605391335206614637
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0600086
http://dbpedia.org/resource/Graves%27_disease
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FGraves%2527_disease%3E
http://sideeffects.embl.de/se/C0600086
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0600086%3E
toxic goiter
C0600086
RDF Description of toxic goiter
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01601
_:header8971164501335206615089
Mon, 23 Apr 2012 18:36:50 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01601
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01264_DB01601
2008-08-26 15:36:35 UTC
1MUI
KJHKTHWMRKYKJE-WDUOEAFFDT
expt00388
http://129.128.185.122/drugbank2/drugs/DB01601/inserts/4809/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB01601%2Finserts%2F4809%2Ffull%3E
Aluviran
http://dbpedia.org/resource/Lopinavir
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FLopinavir%3E
http://129.128.185.122/drugbank2/drugs/DB01601/inserts/4807/full
Lopinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4596
http://en.wikipedia.org/wiki/Lopinavir
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FLopinavir%3E
CC(C)C(N1CCCNC1=O)C(=O)NC(CC(O)C(CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3722
Lopinavir is an antiretroviral of the protease inhibitor class.
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/kal1581.shtml
http://205.193.93.51/dpdonline/searchRequest.do?din=02243643
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02243643%3E
DB01601
AB1
http://bio2rdf.org/cpd:C12871
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC12871%3E
http://129.128.185.122/drugbank2/drugs/DB01601/inserts/4808/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB01601%2Finserts%2F4808%2Ffull%3E
http://dbpedia.org/page/Lopinavir
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FLopinavir%3E
http://www.drugbank.ca/drugs/DB01601
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01601%3E
PA450264
http://data.linkedct.org/resource/intervention/27824
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F27824%3E
LPV
ABT-378
http://bio2rdf.org/cas:192725-17-0
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A192725-17-0%3E
1.92e-03 mg/mL
http://www.dbpedia.org/resource/Lopinavir
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FLopinavir%3E
Lopinavir
Lopinavir (ABT-378) is an antiretroviral of the protease inhibitor class. It is marketed by Abbott as Kaletra, a co-formulation with a sub-therapeutic dose of ritonavir, as a component of combination therapy to treat HIV/AIDS.
Administered alone, lopinavir has insufficient bioavailability; however, like several HIV protease inhibitors, its blood levels are greatly increased by low doses of ritonavir, a potent inhibitor of cytochrome P450 3A4.
CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1
InChI=1/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t30-,31-,32-,34-/m0/s1/f/h38-40H
Although human experience of acute overdosage with lopinavir is limited, accidental ingestion of the product by a young child could result in significant alcohol-related toxicity and could approach the potential lethal dose of alcohol.
http://bio2rdf.org/kegg:D01425
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD01425%3E
Lopinavir is highly bound to plasma proteins (98-99%).
http://www.rxlist.com/cgi/generic/kaletracaps.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric%2Fkaletracaps.htm%3E
http://data.linkedct.org/resource/intervention/40442
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F40442%3E
2007-08-29 18:45:55 UTC
C37H48N4O5
Hepatic. Lopinavir is extensively metabolized by the hepatic cytochrome P450 system, almost exclusively by the CYP3A isozyme.
(2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-di(phenyl)hexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide
Koletra
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01320_DB01601
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01048_DB01601
RDF Description of Lopinavir
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/ANKH
_:header179165731335206615417
RDF Description of ANKH
http://symbol.bio2rdf.org/symbol:ANKH
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AANKH%3E
ANKH
http://www.dbpedia.org/resource/ANKH
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FANKH%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/283
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2028
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/4029
_:header5496013241335206615979
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4029
Microsomal GST-III
microsome
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17632548
http://symbol.bio2rdf.org/symbol:MGST3
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AMGST3%3E
Also functions as a glutathione peroxidase
120-140
MGST3
9-29
http://pfam.sanger.ac.uk/family?acc=PF01124
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF01124%3E
http://bio2rdf.org/pfam:PF01124
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF01124%3E
>459 bp	ATGGCTGTCCTCTCTAAGGAATATGGTTTTGTGCTTCTAACTGGTGCTGCCAGCTTTATA	ATGGTGGCCCACCTAGCCATCAATGTTTCCAAGGCCCGCAAGAAGTACAAAGTGGAGTAT	CCTATCATGTACAGCACGGACCCTGAAAATGGGCACATCTTCAACTGCATTCAGCGAGCC	CACCAGAACACGTTGGAAGTGTATCCTCCCTTCTTATTTTTTCTAGCTGTTGGAGGTGTT	TACCACCCGCGTATAGCTTCTGGCCTGGGCTTGGCCTGGATTGTTGGACGAGTTCTTTAT	GCTTATGGCTATTACACGGGAGAACCCAGCAAGCGTAGTCGAGGAGCCCTGGGGTCCATC	GCCCTCCTGGGCTTGGTGGGCACAACTGTGTGCTCTGCTTTCCAGCATCTTGGTTGGGTT	AAAAGTGGCTTGGGCAGTGGACCCAAATGCTGCCATTAA
71-91
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=2583081
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D2583081%3E
AF026977
Microsomal glutathione S-transferase 3
1q23
MGST3_HUMAN
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AF026977
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAF026977%3E
>Microsomal glutathione S-transferase 3	MAVLSKEYGFVLLTGAASFIMVAHLAINVSKARKKYKVEYPIMYSTDPENGHIFNCIQRA	HQNTLEVYPPFLFFLAVGGVYHPRIASGLGLAWIVGRVLYAYGYYTGEPSKRSRGALGSI	ALLGLVGTTVCSAFQHLGWVKSGLGSGPKCCH
http://bio2rdf.org/uniprot:O14880
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AO14880%3E
http://bio2rdf.org/hgnc:7064
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A7064%3E
http://www.uniprot.org/uniprot/O14880
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FO14880%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9278457
http://www.genenames.org/data/hgnc_data.php?hgnc_id=7064
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D7064%3E
Microsomal GST- 3
map00480	Metabolism of xenobiotics by cytochrome P450
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/gene/MGST3
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fgene%2FMGST3%3E
RDF Description of Microsomal glutathione S-transferase 3
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Klopstock_Friedrich_Gottlieb_1724-1803
_:header12203516871335206616343
Mon, 23 Apr 2012 18:36:51 GMT
RDF Description of Klopstock, Friedrich Gottlieb, 1724-1803
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Klopstock_Friedrich_Gottlieb_1724-1803
Klopstock, Friedrich Gottlieb, 1724-1803
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext16238
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/EPB42
_:header13064704341335206616763
RDF Description of EPB42
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/EPB42
http://symbol.bio2rdf.org/symbol:EPB42
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AEPB42%3E
EPB42
http://www.dbpedia.org/resource/Protein_4.2
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FProtein_4.2%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3929
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1078
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/PICALM
_:header16153301611335206617158
Mon, 23 Apr 2012 18:36:52 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PICALM
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/gene/PICALM
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fgene%2FPICALM%3E
http://symbol.bio2rdf.org/symbol:PICALM
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3APICALM%3E
PICALM
http://www.dbpedia.org/resource/PICALM
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FPICALM%3E
RDF Description of PICALM
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/1373
_:header14620637291335206617559
RDF Description of Glucosylceramidase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/1373
Glucosylceramidase precursor
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12754519
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9516376
lumenalSide.Note=interactionWithSapon
GLCM_HUMAN
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3687939
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=M16328
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DM16328%3E
sphingolipid metabolism
http://www.genenames.org/data/hgnc_data.php?hgnc_id=4177
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D4177%3E
M16328
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9182788
Acid beta-glucosidase
http://pfam.sanger.ac.uk/family?acc=PF02055
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF02055%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8937765
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8294033
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10352942
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8829654
lytic vacuole
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9683600
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8118460
GBA
glucosylceramidase activity
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9061570
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8889591
vacuole
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8432537
http://www.uniprot.org/uniprot/P04062
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP04062%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3359914
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9040001
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3353383
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10649495
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10527671
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9637431
http://bio2rdf.org/hgnc:4177
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A4177%3E
Involved in glucosylceramidase activity
D-glucosyl-N-acylsphingosine + H(2)O = D- glucose + N-acylsphingosine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9650766
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1572652
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9331372
>1551 bp	ATGGCTGGCAGCCTCACAGGTTTGCTTCTACTTCAGGCAGTGTCGTGGGCATCAGGTGCC	CGCCCCTGCATCCCTAAAAGCTTCGGCTACAGCTCGGTGGTGTGTGTCTGCAATGCCACA	TACTGTGACTCCTTTGACCCCCCGACCTTTCCTGCCCTTGGTACCTTCAGCCGCTATGAG	AGTACACGCAGTGGGCGACGGATGGAGCTGAGTATGGGGCCCATCCAGGCTAATCACACG	GGCACAGGCCTGCTACTGACCCTGCAGCCAGAACAGAAGTTCCAGAAAGTGAAGGGATTT	GGAGGGGCCATGACAGATGCTGCTGCTCTCAACATCCTTGCCCTGTCACCCCCTGCCCAA	AATTTGCTACTTAAATCGTACTTCTCTGAAGAAGGAATCGGATATAACATCATCCGGGTA	CCCATGGCCAGCTGTGACTTCTCCATCCGCACCTACACCTATGCAGACACCCCTGATGAT	TTCCAGTTGCACAACTTCAGCCTCCCAGAGGAAGATACCAAGCTCAAGATACCCCTGATT	CACCGAGCCCTGCAGTTGGCCCAGCGTCCCGTTTCACTCCTTGCCAGCCCCTGGACATCA	CCCACTTGGCTCAAGACCAATGGAGCGGTGAATGGGAAGGGGTCACTCAAGGGACAGCCC	GGAGACATCTACCACCAGACCTGGGCCAGATACTTTGTGAAGTTCCTGGATGCCTATGCT	GAGCACAAGTTACAGTTCTGGGCAGTGACAGCTGAAAATGAGCCTTCTGCTGGGCTGTTG	AGTGGATACCCCTTCCAGTGCCTGGGCTTCACCCCTGAACATCAGCGAGACTTCATTGCC	CGTGACCTAGGTCCTACCCTCGCCAACAGTACTCACCACAATGTCCGCCTACTCATGCTG	GATGACCAACGCTTGCTGCTGCCCCACTGGGCAAAGGTGGTACTGACAGACCCAGAAGCA	GCTAAATATGTTCATGGCATTGCTGTACATTGGTACCTGGACTTTCTGGCTCCAGCCAAA	GCCACCCTAGGGGAGACACACCGCCTGTTCCCCAACACCATGCTCTTTGCCTCAGAGGCC	TGTGTGGGCTCCAAGTTCTGGGAGCAGAGTGTGCGGCTAGGCTCCTGGGATCGAGGGATG	CAGTACAGCCACAGCATCATCACGAACCTCCTGTACCATGTGGTCGGCTGGACCGACTGG	AACCTTGCCCTGAACCCCGAAGGAGGACCCAATTGGGTGCGTAACTTTGTCGACAGTCCC	ATCATTGTAGACATCACCAAGGACACGTTTTACAAACAGCCCATGTTCTACCACCTTGGC	CACTTCAGCAAGTTCATTCCTGAGGGCTCCCAGAGAGTGGGGCTGGTTGCCAGTCAGAAG	AACGACCTGGACGCAGTGGCACTGATGCATCCCGATGGCTCTGCTGTTGTGGTCGTGCTA	AACCGCTCCTCTAAGGATGTGCCTCTTACCATCAAGGATCCTGCTGTGGGCTTCCTGGAG	ACAATCTCACCTGGCTACTCCATTCACACCTACCTGTGGCATCGCCAGTGA
D-glucosyl-N-acylsphingosine + H2O = D-glucose + N-acylsphingosine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1974409
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9153297
EC 3.2.1.45
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9217217
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8790604
lysosome organization and biogenesis
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9279145
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9851895
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8889578
map00600	Glycosphingolipid metabolism
http://bio2rdf.org/pdb:1Y7V
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1Y7V%3E
21-39
Glucosylceramidase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10447266
D-glucosyl-N-acylsphingosine glucohydrolase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1972019
vacuole organization and biogenesis
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7627192
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=183008
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D183008%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8829663
http://symbol.bio2rdf.org/symbol:GBA
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AGBA%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10340647
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7916532
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8112750
>Glucosylceramidase precursor	MEFSSPSREECPKPLSRVSIMAGSLTGLLLLQAVSWASGARPCIPKSFGYSSVVCVCNAT	YCDSFDPPTFPALGTFSRYESTRSGRRMELSMGPIQANHTGTGLLLTLQPEQKFQKVKGF	GGAMTDAAALNILALSPPAQNLLLKSYFSEEGIGYNIIRVPMASCDFSIRTYTYADTPDD	FQLHNFSLPEEDTKLKIPLIHRALQLAQRPVSLLASPWTSPTWLKTNGAVNGKGSLKGQP	GDIYHQTWARYFVKFLDAYAEHKLQFWAVTAENEPSAGLLSGYPFQCLGFTPEHQRDFIA	RDLGPTLANSTHHNVRLLMLDDQRLLLPHWAKVVLTDPEAAKYVHGIAVHWYLDFLAPAK	ATLGETHRLFPNTMLFASEACVGSKFWEQSVRLGSWDRGMQYSHSIITNLLYHVVGWTDW	NLALNPEGGPNWVRNFVDSPIIVDITKDTFYKQPMFYHLGHFSKFIPEGSQRVGLVASQK	NDLDAVALMHPDGSAVVVVLNRSSKDVPLTIKDPAVGFLETISPGYSIHTYLWRRQ
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3864160
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10360404
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2914709
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9554746
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3001061
http://bio2rdf.org/pfam:PF02055
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF02055%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9554454
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/6091633
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10744424
http://bio2rdf.org/uniprot:P04062
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP04062%3E
Beta-glucocerebrosidase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3456607
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8076951
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7627184
Alglucerase
Imiglucerase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8780099
http://www.pdb.org/pdb/explore/explore.do?structureId=1Y7V
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1Y7V%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03106
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03740
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/2967
_:header79939451335206618127
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11677608
CDP-paratose 2-epimerase
http://www.pdb.org/pdb/explore/explore.do?structureId=1ORR
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1ORR%3E
CDP-3,6-dideoxy-D-glucose = CDP-3,6-dideoxy-D-mannose
>1017 bp	ATGAAGCTTTTAATTACCGGTGGATGTGGCTTCCTTGGGAGTAATCTTGCCTCCTTTGCT	TTAAGTCAAGGGATTGATTTAATTGTATTCGATAATCTATCACGTAAAGGTGCAACAGAT	AATTTACATTGGTTATCCTCCTTAGGAAACTTTGAGTTTGTACATGGTGATATTCGCAAC	AAAAATGATGTTACAAGATTAATAACTAAGTATATGCCTGATAGCTGTTTTCATCTTGCA	GGTCAAGTGGCAATGACTACATCTATTGACAATCCTTGTATGGATTTTGAAATTAATGTA	GGTGGAACTTTAAATTTACTTGAGGCAGTACGGCAGTATAATTCAAATTGTAATATAATT	TATTCATCAACAAATAAAGTATACGGCGATCTTGAGCAATATAAATACAATGAAACAGAA	ACTAGATACACTTGTGTAGATAAGCCTAATGGATATGATGAGAGCACACAATTAGATTTC	CACTCACCATATGGTTGTTCAAAAGGTGCTGCAGACCAATACATGCTTGATTATGCAAGG	ATTTTTGGTTTGAATACAGTGGTGTTCAGGCATTCATCAATGTATGGTGGGAGACAGTTT	GCTACTTATGATCAAGGCTGGGTAGGTTGGTTTTGTCAAAAAGCGGTTGAAATTAAAAAT	GGTATTAATAAACCCTTCACTATTTCTGGTAATGGTAAGCAAGTTAGGGATGTTTTGCAT	GCTGAAGATATGATTTCGTTATATTTCACTGCCTTGGCAAATGTATCAAAAATTAGGGGG	AACGCTTTTAATATTGGTGGTACCATTGTCAACAGCCTATCATTACTTGAATTATTCAAA	TTGCTTGAAGATTATTGCAACATAGATATGAGGTTCACTAATTTACCTGTAAGGGAAAGT	GATCAGCGTGTTTTTGTTGCAGATATTAAAAAAATCACTAATGCAATTGACTGGAGCCCG	AAAGTCTCGGCAAAAGATGGTGTCCAGAAAATGTATGATTGGACTAGTTCTATATGA
>CDP-paratose 2-epimerase	MKLLITGGCGFLGSNLASFALSQGIDLIVFDNLSRKGATDNLHWLSSLGNFEFVHGDIRN	KNDVTRLITKYMPDSCFHLAGQVAMTTSIDNPCMDFEINVGGTLNLLEAVRQYNSNCNII	YSSTNKVYGDLEQYKYNETETRYTCVDKPNGYDESTQLDFHSPYGCSKGAADQYMLDYAR	IFGLNTVVFRHSSMYGGRQFATYDQGWVGWFCQKAVEIKNGINKPFTISGNGKQVRDVLH	AEDMISLYFTALANVSKIRGNAFNIGGTIVNSLSLLELFKLLEDYCNIDMRFTNLPVRES	DQRVFVADIKKITNAIDWSPKVSAKDGVQKMYDWTSSI
http://www.uniprot.org/uniprot/P14169
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP14169%3E
rfbE
Catalyzes the isomeration of CDP-paratose to CDP- tyvelose
M29682
EC 5.1.3.10
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=154340
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D154340%3E
http://bio2rdf.org/uniprot:P14169
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP14169%3E
map00500	Starch and sucrose metabolism
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12644504
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12642575
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=M29682
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DM29682%3E
CDP-tyvelose 2-epimerase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2793833
RFBE_SALTI
http://bio2rdf.org/pdb:1ORR
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1ORR%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04555
RDF Description of CDP-paratose 2-epimerase
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/GAMT
_:header2570849021335206618434
Mon, 23 Apr 2012 18:36:53 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/GAMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2427
http://symbol.bio2rdf.org/symbol:GAMT
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AGAMT%3E
GAMT
http://bio2rdf.org/hgnc:4136
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A4136%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=4136
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D4136%3E
http://bio2rdf.org/geneid:2593
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fgeneid%3A2593%3E
http://www.dbpedia.org/resource/GAMT
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FGAMT%3E
RDF Description of GAMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/434
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0006105
_:header11928578851335206618921
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0006105
http://sideeffects.embl.de/se/C0006105
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0006105%3E
brain abscess
C0006105
RDF Description of brain abscess
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/912
_:header4969313501335206619327
Mon, 23 Apr 2012 18:36:54 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/912
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3561
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/CTSC
Periodontitis
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/disease/Periodontitis
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fdisease%2FPeriodontitis%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseaseClass/Ear%2CNose%2CThroat
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0031099
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fsider%2Fresource%2Fside_effects%2FC0031099%3E
http://www.dbpedia.org/resource/Periodontitis
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FPeriodontitis%3E
http://data.linkedct.org/resource/condition/9954
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fcondition%2F9954%3E
RDF Description of Periodontitis
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00972
_:header3823914521335206619745
RDF Description of Azelastine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00972
9.20e-03 mg/mL
PA448517
MBUVEWMHONZEQD-UHFFFAOYAN
http://129.128.185.122/drugbank2/drugs/DB00972/inserts/330/full
Azelastine is an antihistamine and mast cell stabilizer available as a nasal spray for hay fever and as eye drops for allergic conjunctivitis.
DB00972
Optivar
Astelin
http://www.dbpedia.org/resource/Azelastine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FAzelastine%3E
Antihistamines such as azelastine appear to compete with histamine for histamine H1- receptor sites on effector cells (mast cells). The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury response involving histamine release.
http://bio2rdf.org/cas:58581-89-8
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A58581-89-8%3E
CN1CCC[C@@H](CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=CC=CC=C2C1=O
Azelastinum [INN-Latin]
http://www.drugbank.ca/drugs/DB00972
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00972%3E
Azelastine
In-vitro studies in human plasma indicate that the plasma protein binding of azelastine and N-desmethylazelastine are approximately 88% and 97%, respectively.
Azelastina [INN-Spanish]
R01AC03
225 oC (hydrochloride salt)
S01GX07
http://dbpedia.org/page/Azelastine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FAzelastine%3E
aprd00813
CN1CCCC(CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=CC=CC=C2C1=O
/drugs/972/safety_sheets/999
Azelastine is a relatively selective histamine H1 antagonist and an inhibitor of the release of histamine and other mediators from cells (e.g. mast cells) involved in the allergic response. Based on in vitro studies using human cell lines, inhibition of other mediators involved in allergic reactions (e.g. leukotrienes and PAF) has been demonstrated with azelastine. Decreased chemotaxis and activation of eosinophils has also been demonstrated.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/histamineH1Antagonists
2008-08-26 16:56:26 UTC
Elimination half-life (based on intravenous and oral administration) is 22 hours. Elimination half-life of the active metabolite, desmethylazelastine, is 54 hours (after oral administration of azelastine).
http://129.128.185.122/drugbank2/drugs/DB00972/inserts/1188/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00972%2Finserts%2F1188%2Ffull%3E
Azelastine hydrochloride is oxidatively metabolized to the principal metabolite, N-desmethylazelastine, by the cytochrome P450 enzyme system, however the exact cytochrome P450 isoenzyme involved has not been determined. The major metabolite, desmethylazelastine, also has H1-receptor antagonist activity.
http://dbpedia.org/resource/Azelastine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FAzelastine%3E
C22H24ClN3O
http://bio2rdf.org/cpd:C07768
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC07768%3E
For the treatment of itching of the eye associated with allergic conjunctivitis.
4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1-one
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/opt1673.shtml
Sparingly soluble (hydrochloride salt)
http://en.wikipedia.org/wiki/Azelastine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FAzelastine%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/lipoxygenaseInhibitors
R06AX19
Absorption of azelastine following ocular administration was relatively low. Systemic bioavailability is approximately 40% after nasal administration.
2000-05-01	/drugs/972/fda_labels/602	2006-02-01	/drugs/972/fda_labels/606
http://www.rxlist.com/cgi/generic/optivar.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric%2Foptivar.htm%3E
InChI=1/C22H24ClN3O/c1-25-13-4-5-18(12-14-25)26-22(27)20-7-3-2-6-19(20)21(24-26)15-16-8-10-17(23)11-9-16/h2-3,6-11,18H,4-5,12-15H2,1H3
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00209_DB00972
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00382_DB00972
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00662_DB00972
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00427_DB00972
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/5726
_:header7563516551335206620255
Mon, 23 Apr 2012 18:36:55 GMT
RDF Description of ZIDOVUDINE
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0019693
http://www.fda.gov/cder/foi/label/2001/20518S4lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2001%2F20518S4lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/921
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F921%3E
http://www.fda.gov/cder/foi/label/2001/19655s36lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2001%2F19655s36lbl.pdf%3E
http://sideeffects.embl.de/drugs/5726
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F5726%3E
http://dbpedia.org/resource/Zidovudine
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FZidovudine%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2616
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2616%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0034902
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0281856
http://www.fda.gov/cder/foi/label/2006/019951s023lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2006%2F019951s023lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0000729
http://www.fda.gov/cder/foi/label/2003/19951slr019_retrovir_lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2003%2F19951slr019_retrovir_lbl.pdf%3E
zidovudine
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0085662
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=ylhZctFexv0=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DylhZctFexv0%3D%3E
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000005726
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000005726%3E
Retrovir
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3918
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3918%3E
http://www.fda.gov/cder/foi/label/2003/19951slr018_retrovir_lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2003%2F19951slr018_retrovir_lbl.pdf%3E
http://www.fda.gov/cder/foi/label/2001/20518s8lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2001%2F20518s8lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0027121
CID0000005726
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/4168
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F4168%3E
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=+17w9SzWwbE=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3D%2B17w9SzWwbE%3D%3E
http://www.fda.gov/cder/foi/label/2002/20518slr010,19910slr026,19655slr038_retrovir_lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2002%2F20518slr010%2C19910slr026%2C19655slr038_retrovir_lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1277
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F1277%3E
http://www.fda.gov/cder/foi/label/2001/19951s16lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2001%2F19951s16lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0032961
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=jnp+P01Zx1M=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3Djnp%2BP01Zx1M%3D%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0152032
http://www.fda.gov/cder/foi/label/2006/019910s032lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2006%2F019910s032lbl.pdf%3E
http://www.fda.gov/cder/foi/label/2006/020518s015lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2006%2F020518s015lbl.pdf%3E
http://www.fda.gov/medwatch/SAFETY/2003/03Jul_PI/RetrovirIV_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2003%2F03Jul_PI%2FRetrovirIV_PI.pdf%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3692
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3692%3E
http://www.fda.gov/cder/foi/label/2006/019655s043lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2006%2F019655s043lbl.pdf%3E
ZIDOVUDINE
http://www.fda.gov/cder/foi/label/2008/019910s033lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2008%2F019910s033lbl.pdf%3E
http://www.fda.gov/medwatch/SAFETY/2006/May_PIs/Retrovir_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2006%2FMay_PIs%2FRetrovir_PI.pdf%3E
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=osX0SEWeerY=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DosX0SEWeerY%3D%3E
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000005726&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000005726%26input_query_species%3D9606%3E
http://www.fda.gov/cder/foi/label/2001/19910s24lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2001%2F19910s24lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00495
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00495%3E
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=1FGbIFbI8cU=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3D1FGbIFbI8cU%3D%3E
http://www.fda.gov/medwatch/SAFETY/2003/03Oct_PI/Retrovir_PI.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2003%2F03Oct_PI%2FRetrovir_PI.pdf%3E
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Booth_Evangeline_1865-1950
_:header8247642311335206620581
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Booth_Evangeline_1865-1950
Booth, Evangeline, 1865-1950
RDF Description of Booth, Evangeline, 1865-1950
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7811
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/4942
_:header12325933641335206621113
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4942
http://www.pdb.org/pdb/explore/explore.do?structureId=1JNI
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1JNI%3E
>453 bp	GTGATTAATATGACTAAACAGGTATCTAAAATTTTAGCGGGATTATTTACCGCACTTTTT	GCTGGCTCACTGATGGCATCTGATGCACCAGCAGTGGGAAAAGATTTAACTCAAGCGGCA	GAAAATATTCCACCCGCATTTCATAATGCACCGCGTCAAGGCGAATTACCCGCATTGAAC	TATGTAAATCAGCCTCCAATGGTTCCACATAGTGTGGCAAACTATCAAGTGACAAAAAAT	GTAAATCAATGTTTAAATTGCCACAGCCCAGAAAATTCTCGTTTGAGCGGTGCAACTCGA	ATCAGCCCAACTCACTTTATGGATCGTGATGGAAAAGTAGGTTCAAGTTCATCGCCACGT	CGTTATTTCTGTTTACAATGTCACGTTTCTCAAGCAAACGTAGATCCGATTGTTCCAAAT	GATTTCAAACCGATGAAAGGTTACGGAAACTAA
>Diheme cytochrome c napB	MINMTKQVSKILAGLFTALFAGSLMASDAPAVGKDLTQAAENIPPAFHNAPRQGELPALN	YVNQPPMVPHSVANYQVTKNVNQCLNCHSPENSRLSGATRISPTHFMDRDGKVGSSSSPR	RYFCLQCHVSQANVDPIVPNDFKPMKGYGN
http://bio2rdf.org/pdb:1JNI
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1JNI%3E
napB
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11389694
http://www.uniprot.org/uniprot/P44654
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP44654%3E
NAPB_HAEIN
http://bio2rdf.org/uniprot:P44654
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP44654%3E
Diheme cytochrome c napB
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7542800
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11223519
periplasm(bySimilarity)
http://bio2rdf.org/pfam:PF03892
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF03892%3E
Small subunit of the periplasmic nitrate reductase (NAP). Only expressed at high levels during aerobic growth. NapAB complex receives electrons from the membrane-anchored tetraheme napC protein, thus allowing electron flow between membrane and periplasm. Essential function for nitrate assimilation and may have a role in anaerobic metabolism (By similarity)
L42023
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=L42023
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DL42023%3E
Diheme cytochrome c napB precursor
http://pfam.sanger.ac.uk/family?acc=PF03892
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF03892%3E
RDF Description of Diheme cytochrome c napB
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0007785
_:header2752808321335206621608
Mon, 23 Apr 2012 18:36:56 GMT
http://dbpedia.org/resource/Stroke
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FStroke%3E
http://sideeffects.embl.de/se/C0007785
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0007785%3E
cerebral infarction
C0007785
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/disease/Cerebral_Infarction
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fdisease%2FCerebral_Infarction%3E
Cerebral infarctions
RDF Description of cerebral infarction
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/274
_:header14004765401335206622066
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/274
15q26
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3272174
ACM5_HUMAN
http://www.uniprot.org/uniprot/P08912
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP08912%3E
CHRM5
>Muscarinic acetylcholine receptor M5	MEGDSYHNATTVNGTPVNHQPLERHRLWEVITIAAVTAVVSLITIVGNVLVMISFKVNSQ	LKTVNNYYLLSLACADLIIGIFSMNLYTTYILMGRWALGSLACDLWLALDYVASNASVMN	LLVISFDRYFSITRPLTYRAKRTPKRAGIMIGLAWLISFILWAPAILCWQYLVGKRTVPL	DECQIQFLSEPTITFGTAIAAFYIPVSVMTILYCRIYRETEKRTKDLADLQGSDSVTKAE	KRKPAHRALFRSCLRCPRPTLAQRERNQASWSSSRRSTSTTGKPSQATGPSANWAKAEQL	TTCSSYPSSEDEDKPATDPVLQVVYKSQGKESPGEEFSAEETEETFVKAETEKSDYDTPN	YLLSPAAAHRPKSQKCVAYKFRLVVKADGNQETNNGCHKVKIMPCPFPVAKEPSTKGLNP	NPSHQMTKRKRVVLVKERKAAQTLSAILLAFIITWTPYNIMVLVSTFCDKCVPVTLWHLG	YWLCYVNSTVNPICYALCNRTFRKTFKMLLLCRWKKKKVEEKLYWQGNSKLP
http://symbol.bio2rdf.org/symbol:CHRM5
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ACHRM5%3E
muscarinic acetylcholine receptor activity
479-498
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=177988
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D177988%3E
444-464
http://bio2rdf.org/uniprot:P08912
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP08912%3E
192-214
http://www.dbpedia.org/resource/Muscarinic_acetylcholine_receptor_M5
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FMuscarinic_acetylcholine_receptor_M5%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=1954
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D1954%3E
30-53
105-126
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=M80333
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DM80333%3E
Muscarinic acetylcholine receptor M5
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover
http://bio2rdf.org/hgnc:1954
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A1954%3E
M80333
>1599 bp	ATGGAAGGGGATTCTTACCACAATGCAACCACCGTCAATGGCACCCCAGTAAATCACCAG	CCTTTGGAACGCCACAGGTTGTGGGAAGTCATCACCATTGCAGCTGTGACTGCTGTGGTA	AGCCTGATCACCATTGTGGGCAATGTCTTGGTCATGATCTCCTTCAAAGTCAACAGCCAG	CTCAAGACAGTTAACAACTATTACCTGCTCAGCTTAGCCTGTGCAGATCTCATCATTGGA	ATCTTCTCCATGAACCTCTACACCACCTACATCCTCATGGGACGCTGGGCTCTCGGGAGT	CTGGCTTGTGACCTTTGGCTTGCACTGGACTACGTGGCCAGCAACGCTTCTGTCATGAAC	CTTCTGGTGATCAGTTTTGACCGTTACTTTTCCATCACAAGACCCTTGACATATCGGGCC	AAGCGTACTCCGAAAAGGGCTGGCATCATGATTGGCTTGGCCTGGCTGATCTCCTTCATC	CTCTGGGCCCCAGCAATCCTCTGCTGGCAGTACTTGGTTGGGAAGCGGACAGTTCCACTG	GATGAGTGCCAGATCCAGTTTCTCTCTGAGCCCACCATCACTTTTGGCACTGCCATTGCT	GCCTTCTACATCCCTGTTTCTGTCATGACCATCCTCTACTGTCGAATCTACCGGGAAACA	GAGAAGCGAACCAAGGACCTGGCTGACCTCCAGGGTTCTGACTCTGTGACCAAAGCTGAG	AAGAGAAAGCCAGCTCATAGGGCTCTGTTCAGATCCTGCTTGCGCTGTCCTCGACCCACC	CTGGCCCAGCGGGAAAGGAACCAGGCCTCCTGGTCATCCTCCCGCAGGAGCACCTCCACC	ACTGGGAAGCCATCCCAAGCCACTGGCCCAAGCGCCAATTGGGCCAAAGCTGAGCAGCTC	ACCACCTGTAGCAGCTACCCTTCCTCAGAGGATGAGGACAAGCCCGCCACTGACCCTGTC	CTCCAAGTGGTCTACAAGAGTCAGGGTAAGGAAAGCCCAGGGGAAGAATTCAGTGCTGAA	GAGACTGAGGAAACTTTTGTGAAAGCTGAAACTGAAAAAAGTGACTATGACACCCCAAAC	TACCTTCTGTCTCCAGCAGCTGCTCATAGACCCAAGAGTCAGAAATGTGTGGCCTATAAG	TTCCGATTGGTGGTAAAAGCTGACGGGAACCAGGAGACCAACAATGGCTGTCACAAGGTG	AAAATCATGCCCTGCCCCTTCCCAGTGGCCAAGGAACCTTCAACGAAAGGCCTCAATCCC	AACCCCAGCCATCAAATGACCAAACGAAAGAGAGTGGTCCTAGTCAAAGAGAGGAAAGCA	GCCCAGACACTGAGTGCCATTCTCCTGGCCTTCATCATCACATGGACCCCGTATAACATC	ATGGTCCTGGTTTCTACCTTCTGTGACAAGTGTGTCCCAGTCACCCTGTGGCACTTGGGC	TATTGGTTGTGCTATGTCAATAGCACTGTCAACCCCATCTGCTATGCCCTCTGCAACAGA	ACCTTCAGGAAGACCTTTAAGATGCTGCTTCTCTGCCGATGGAAAAAGAAAAAAGTGGAA	GAGAAGTTGTACTGGCAGGGGAACAGCAAGCTACCCTGA
67-87
147-169
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00785
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01069
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00767
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00725
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00340
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00572
RDF Description of Muscarinic acetylcholine receptor M5
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01403
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0018932
_:header1234684201335206622481
Mon, 23 Apr 2012 18:36:57 GMT
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0018932
http://dbpedia.org/resource/Hematochezia
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FHematochezia%3E
http://sideeffects.embl.de/se/C0018932
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0018932%3E
hematochezia
C0018932
RDF Description of hematochezia
http://www4.wiwiss.fu-berlin.de/factbook/data/Russia
_:header1989411281335206622997
http://www4.wiwiss.fu-berlin.de/factbook/resource/Russia
http://www4.wiwiss.fu-berlin.de/factbook/resource/Latvia
http://www4.wiwiss.fu-berlin.de/factbook/resource/Belarus
738000 km (includes 29000 km of expressways)
Russia
https://www.cia.gov/cia/publications/factbook/geos/rs.html
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Fcia%2Fpublications%2Ffactbook%2Fgeos%2Frs.html%3E
8% of GDP
UTC+3 (8 hours ahead of Washington, DC during Standard Time)
Rossiyskaya Federatsiya
administrative divisions have the same names as their administrative centers (exceptions have the administrative center name following in parentheses)
465 (Antigua and Barbuda 6, Bahamas 6, Belize 36, Bulgaria 1, Cambodia 105, Comoros 4, Cyprus 53, Dominica 2, Finland 1, Georgia 28, North Korea 1, Liberia 77, Malta 70, Marshall Islands 1, Mongolia 13, Panama 7, Saint Kitts and Nevis 5, Saint Vincent and the Grenadines 29, Sierra Leone 1, Tuvalu 2, Ukraine 1, Vanuatu 1, Venezuela 1, unknown 14)
http://www4.wiwiss.fu-berlin.de/factbook/resource/Kazakhstan
State Duma - percent of vote received by parties clearing the 5% threshold entitling them to a proportional share of the 225 party list seats - United Russia 37.1%, CPRF 12.7%, LDPR 11.6%, Motherland 9.1%, other 29.5%; total seats by party - United Russia 222, CPRF 53, LDPR 38, Motherland 37, Peoples Party 19, Yabloko 4, SPS 2, other 7, independents 65, repeat election required 3; note - seats by party as of 1 July 2006 - United Russia 309, CPRF 45, LDPR 35, Motherland 29, Peoples Party 12, independents 18, vacant 2
55 45 N, 37 35 E
48 oblasts (oblastey, singular - oblast), 21 republics (respublik, singular - respublika), 7 autonomous okrugs (avtonomnykh okrugov, singular - avtonomnyy okrug), 7 krays (krayev, singular - kray), 2 federal cities (goroda, singular - gorod), and 1 autonomous oblast (avtonomnaya oblast)
Russian(s)
the telephone system is experiencing significant changes; there are more than 1000 companies licensed to offer communication services; access to digital lines has improved, particularly in urban centers; Internet and e-mail services are improving; Russia has made progress toward building the telecommunications infrastructure necessary for a market economy; the estimated number of mobile subscribers jumped from fewer than 1000000 in 1998 to 1000000 in 2005; a large demand for main line service remains unsatisfied, but fixed-line operators continue to grow their services
bicameral Federal Assembly or Federalnoye Sobraniye consists of the Federation Council or Sovet Federatsii (178 seats; as of July 2000, members appointed by the top executive and legislative officials in each of the 88 federal administrative units - oblasts, krays, republics, autonomous okrugs and oblasts, and the federal cities of Moscow and Saint Petersburg; members serve four-year terms) and the State Duma or Gosudarstvennaya Duma (450 seats; as of 2007, all members elected by proportional representation from party lists winning at least 7% of the vote; members elected by popular vote to serve four-year terms)
State Duma - last held 7 December 2003 (next to be held in December 2007)
http://www4.wiwiss.fu-berlin.de/factbook/resource/Estonia
country code - 7; Russia is connected internationally by 3 undersea fiber-optic cables; digital switches in several cities provide more than 50000 lines for international calls; satellite earth stations provide access to Intelsat, Intersputnik, Eutelsat, Inmarsat, and Orbita systems
https://www.cia.gov/library/publications/the-world-factbook/maps/rs-map.gif
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Flibrary%2Fpublications%2Fthe-world-factbook%2Fmaps%2Frs-map.gif%3E
http://www4.wiwiss.fu-berlin.de/factbook/resource/Mongolia
federation
47570000000000 cu m (1 January 2005 est.)
https://www.cia.gov/library/publications/the-world-factbook/flags/rs-lgflag.gif
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Flibrary%2Fpublications%2Fthe-world-factbook%2Fflags%2Frs-lgflag.gif%3E
Constitutional Court; Supreme Court; Supreme Arbitration Court; judges for all courts are appointed for life by the Federation Council on the recommendation of the president
ranges from steppes in the south through humid continental in much of European Russia; subarctic in Siberia to tundra climate in the polar north; winters vary from cool along Black Sea coast to frigid in Siberia; summers vary from warm in the steppes to cool along Arctic coast
adopted 12 December 1993
http://www4.wiwiss.fu-berlin.de/factbook/resource/Georgia
Russia ended 2006 with its eighth straight year of growth, averaging 6.7% annually since the financial crisis of 1998. Although high oil prices and a relatively cheap ruble initially drove this growth, since 2003 consumer demand and, more recently, investment have played a significant role. Over the last five years, fixed capital investments have averaged real gains greater than 10% per year and personal incomes have achieved real gains more than 12% per year. During this time, poverty has declined steadily and the middle class has continued to expand. Russia has also improved its international financial position since the 1998 financial crisis. The federal budget has run surpluses since 2001 and ended 2006 with a surplus of 9% of GDP. Over the past several years, Russia has used its stabilization fund based on oil taxes to prepay all Soviet-era sovereign debt to Paris Club creditors and the IMF. Foreign debt has decreased to 39% of GDP, mainly due to decreasing state debt, although commercial debt to foreigners has risen strongly. Oil export earnings have allowed Russia to increase its foreign reserves from $12000000000 in 1999 to some $12000000000 at yearend 2006, the third largest reserves in the world. During PUTINs first administration, a number of important reforms were implemented in the areas of tax, banking, labor, and land codes. These achievements have raised business and investor confidence in Russias economic prospects, with foreign direct investment rising from $12000000000 in 2005 to an estimated $12000000000 in 2006. In 2006, Russias GDP grew 6.6%, while inflation was below 10% for the first time in the past 10 years. Growth was driven by non-tradable services and goods for the domestic market, as opposed to oil or mineral extraction and exports. Russia has signed a bilateral market access agreement with the US as a prelude to possible WTO entry, and its companies are involved in global merger and acquisition activity in the oil and gas, metals, and telecom sectors. Despite Russias recent success, serious problems persist. Oil, natural gas, metals, and timber account for more than 80% of exports and 32% of government revenues, leaving the country vulnerable to swings in world commodity prices. Russias manufacturing base is dilapidated and must be replaced or modernized if the country is to achieve broad-based economic growth. A 20% appreciation of the ruble over 2005-06 has made attracting additional investment more difficult. The banking system, while increasing consumer lending and growing at a high rate, is still small relative to the banking sectors of Russias emerging market peers. Political uncertainties ahead of the elections, corruption, and widespread lack of trust in institutions continue to dampen domestic and foreign investor sentiment. From 2002 to 2005, the government bureaucracy increased by 17% - 10.9% in 2005 alone. President PUTIN has granted more influence to forces within his government that desire to reassert state control over the economy. Russia has made little progress in building the rule of law, the bedrock of a modern market economy. The government has promised additional legislation to make its intellectual property protection WTO-consistent, but enforcement remains problematic.
Northern Asia (the area west of the Urals is considered part of Europe), bordering the Arctic Ocean, between Europe and the North Pacific Ocean
based on civil law system; judicial review of legislative acts
Moscow
.ru; note - Russia also has responsibility for a legacy domain ".su" that was allocated to the Soviet Union, and whose legal status and ownership are contested by the Russian Government, ICANN, and several Russian commercial entities
Ministries of the Government or "Government" composed of the premier and his deputies, ministers, and selected other individuals; all are appointed by the president
http://www4.wiwiss.fu-berlin.de/factbook/resource/Azerbaijan
http://www4.wiwiss.fu-berlin.de/factbook/resource/Norway
AM 323, FM 1500 est., shortwave 62
Gora Elbrus
cross-country digital trunk lines run from Saint Petersburg to Khabarovsk, and from Moscow to Novorossiysk; the telephone systems in 60 regional capitals have modern digital infrastructures; cellular services, both analog and digital, are available in many areas; in rural areas, the telephone services are still outdated, inadequate, and low density
three equal horizontal bands of white (top), blue, and red
president elected by popular vote for a four-year term (eligible for a second term); election last held 14 March 2004 (next to be held in March 2008); note - no vice president; if the president dies in office, cannot exercise his powers because of ill health, is impeached, or resigns, the premier serves as acting president until a new presidential election is held, which must be within three months; premier appointed by the president with the approval of the Duma
Vladimir Vladimirovich PUTIN reelected president; percent of vote - Vladimir Vladimirovich PUTIN 71.2%, Nikolay KHARITONOV 13.7%, other (no candidate above 5%) 15.1%
Russia Day, 12 June
Rossiya
RUR
$157300000000; including capital expenditures of $NA
broad plain with low hills west of Urals; vast coniferous forest and tundra in Siberia; uplands and mountains along southern border regions
Russia has adopted a mixed conscript-contract force; 18-27 years of age; males are registered for the draft at 17 years of age; length of compulsory military service is 2 years; plans call for reduction in mandatory service to 18 months in 2007 and to 1 year by 2008; 30% of Russian army personnel were contract servicemen at the end of 2005; planning calls for volunteer servicemen to compose 70% of armed forces by 2010, with the remaining servicemen consisting of conscripts; as of November 2006, the Armed Forces had more than 60 units manned with contract personnel totaling over 78000 contract privates and sergeants; 88 Ministry of Defense units have been designated as permanent readiness units and are expected to become all-volunteer by end 2007; these include most air force, naval, and nuclear arms units, as well as all airborne and naval infantry units, most motorized rifle brigades, and all special forces detachments
China and Russia have demarcated the once disputed islands at the Amur and Ussuri confluence and in the Argun River in accordance with the 2004 Agreement, ending their centuries-long border disputes; the sovereignty dispute over the islands of Etorofu, Kunashiri, Shikotan, and the Habomai group, known in Japan as the "Northern Territories" and in Russia as the "Southern Kurils," occupied by the Soviet Union in 1945, now administered by Russia, and claimed by Japan, remains the primary sticking point to signing a peace treaty formally ending World War II hostilities; Russia and Georgia agree on delimiting all but small, strategic segments of the land boundary and the maritime boundary; OSCE observers monitor volatile areas such as the Pankisi Gorge in the Akhmeti region and the Kodori Gorge in Abkhazia; Azerbaijan, Kazakhstan, and Russia signed equidistance boundaries in the Caspian seabed but the littoral states have no consensus on dividing the water column; Russia and Norway dispute their maritime limits in the Barents Sea and Russias fishing rights beyond Svalbards territorial limits within the Svalbard Treaty zone; various groups in Finland advocate restoration of Karelia (Kareliya) and other areas ceded to the Soviet Union following the Second World War but the Finnish Government asserts no territorial demands; in May 2005, Russia recalled its signatures to the 1996 border agreements with Estonia (1996) and Latvia (1997), when the two Baltic states announced issuance of unilateral declarations referencing Soviet occupation and ensuing territorial losses; Russia demands better treatment of ethnic Russians in Estonia and Latvia; Estonian citizen groups continue to press for realignment of the boundary based on the 1920 Tartu Peace Treaty that would bring the now divided ethnic Setu people and parts of the Narva region within Estonia; Lithuania and Russia committed to demarcating their boundary in 2006 in accordance with the land and maritime treaty ratified by Russia in May 2003 and by Lithuania in 1999; Lithuania operates a simplified transit regime for Russian nationals traveling from the Kaliningrad coastal exclave into Russia, while still conforming, as an EU member state with an EU external border, where strict Schengen border rules apply; preparations for the demarcation delimitation of land boundary with Ukraine have commenced; the dispute over the boundary between Russia and Ukraine through the Kerch Strait and Sea of Azov remains unresolved despite a December 2003 framework agreement and on-going expert-level discussions; Kazakhstan and Russia boundary delimitation was ratified on November 2005 and field demarcation should commence in 2007; Russian Duma has not yet ratified 1990 Bering Sea Maritime Boundary Agreement with the US
18.2% of GDP
$287400000000 (30 June 2006 est.)
http://www4.wiwiss.fu-berlin.de/factbook/resource/Finland
100 (Belgium 4, Canada 1, Cyprus 2, Estonia 1, Germany 2, Greece 1, Latvia 2, Malta 4, Norway 1, Switzerland 7, Turkey 63, Ukraine 11, US 1)
Russian ruble (RUR)
24 August 1991 (from Soviet Union)
President Vladimir Vladimirovich PUTIN (acting president 31 December 1999-6 May 2000, president since 7 May 2000)
Premier Mikhail Yefimovich FRADKOV (since 5 March 2004); First Deputy Premiers Dmitriy Anatolyevich MEDVEDEV (since 14 November 2005) and Sergey Borisovich IVANOV (since 15 February 2007), Deputy Premier Aleksandr Dmitriyevich ZHUKOV (since 9 March 2004)
Russian Federation
Caspian Sea
https://www.cia.gov/library/publications/the-world-factbook/flags/rs-flag.gif
http://www4.wiwiss.fu-berlin.de/factbook/sparql?query=DESCRIBE+%3Chttps%3A%2F%2Fwww.cia.gov%2Flibrary%2Fpublications%2Fthe-world-factbook%2Fflags%2Frs-flag.gif%3E
rs
air pollution from heavy industry, emissions of coal-fired electric plants, and transportation in major cities; industrial, municipal, and agricultural pollution of inland waterways and seacoasts; deforestation; soil erosion; soil contamination from improper application of agricultural chemicals; scattered areas of sometimes intense radioactive contamination; groundwater contamination from toxic waste; urban solid waste management; abandoned stocks of obsolete pesticides
Founded in the 12th century, the Principality of Muscovy, was able to emerge from over 200 years of Mongol domination (13th-15th centuries) and to gradually conquer and absorb surrounding principalities. In the early 17th century, a new Romanov Dynasty continued this policy of expansion across Siberia to the Pacific. Under PETER I (ruled 1682-1725), hegemony was extended to the Baltic Sea and the country was renamed the Russian Empire. During the 19th century, more territorial acquisitions were made in Europe and Asia. Defeat in the Russo-Japanese War of 1904-05 contributed to the Revolution of 1905, which resulted in the formation of a parliament and other reforms. Repeated devastating defeats of the Russian army in World War I led to widespread rioting in the major cities of the Russian Empire and to the overthrow in 1917 of the imperial household. The Communists under Vladimir LENIN seized power soon after and formed the USSR. The brutal rule of Iosif STALIN (1928-53) strengthened Communist rule and Russian dominance of the Soviet Union at a cost of tens of millions of lives. The Soviet economy and society stagnated in the following decades until General Secretary Mikhail GORBACHEV (1985-91) introduced glasnost (openness) and perestroika (restructuring) in an attempt to modernize Communism, but his initiatives inadvertently released forces that by December 1991 splintered the USSR into Russia and 14 other independent republics. Since then, Russia has struggled in its efforts to build a democratic political system and market economy to replace the social, political, and economic controls of the Communist period. While some progress has been made on the economic front, and Russias management of its windfall oil wealth has improved its financial standing, recent years have seen a recentralization of power under Vladimir PUTIN and democratic institutions remain weak. Russia has severely disabled the Chechen rebel movement, although sporadic violence still occurs throughout the North Caucasus.
1.39 children born/woman
http://www4.wiwiss.fu-berlin.de/factbook/resource/Poland
http://www4.wiwiss.fu-berlin.de/factbook/resource/Lithuania
approximately 1.8 times the size of the US
Russian
http://www4.wiwiss.fu-berlin.de/factbook/resource/Ukraine
Anapa, Kaliningrad, Murmansk, Nakhodka, Novorossiysk, Rostov-na-Donu, Saint Petersburg, Taganrog, Vanino, Vostochnyy
RDF Description of Russia
http://www4.wiwiss.fu-berlin.de/factbook/resource/Korea_North
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/1760
_:header49340311335206623404
Mon, 23 Apr 2012 18:36:58 GMT
RDF Description of Aminopeptidase N
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/1760
Aminopeptidase M
gp150
cytosol(potential).Note=aSoluble
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/15494415
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2901990
Release of an N-terminal amino acid, Xaa!Yaa- from a peptide, amide or arylamide. Xaa is preferably Ala, but may be most amino acids including Pro (slow action). When a terminal hydrophobic residue is followed by a prolyl residue, the two may be released as an intact Xaa-Pro dipeptide ALL_REAC (other) R00899 R04951 COFACTOR Manganese; Zinc
Broad specificity aminopeptidase. Plays a role in the final digestion of peptides generated from hydrolysis of proteins by gastric and pancreatic proteases. May play a critical role in the pathogenesis of cholesterol gallstone disease. May be involved in the metabolism of regulatory peptides of diverse cell types including small intestinal and tubular epithelial cells, macrophages, granulocytes and synaptic membranes from the CNS. Found to cleave antigen peptides bound to major histocompatibility complex class II molecules of presenting cells and to degrade neurotransmitters at synaptic junctions. Is also implicated as a regulator of IL-8 bioavailability in the endometrium, and therefore may contribute to the regulation of angiogenesis. Is used as a marker for acute myeloid leukemia and plays a role in tumor invasion. In case of human coronavirus 229E (HCoV-229E) infection, serves as receptor for HCoV-229E spike glycoprotein. Mediates as well human cytomegalovirus (HCMV) infection
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12551991
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1675638
9-32
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12473585
>Aminopeptidase N	MAKGFYISKSLGILGILLGVAAVCTIIALSVVYSQEKNKNANSSPVASTTPSASATTNPA	SATTLDQSKAWNRYRLPNTLKPDSYRVTLRPYLTPNDRGLYVFKGSSTVRFTCKEATDVI	IIHSKKLNYTLSQGHRVVLRGVGGSQPPDIDKTELVEPTEYLVVHLKGSLVKDSQYEMDS	EFEGELADDLAGFYRSEYMEGNVRKVVATTQMQAADARKSFPCFDEPAMKAEFNITLIHP	KDLTALSNMLPKGPSTPLPEDPNWNVTEFHTTPKMSTYLLAFIVSEFDYVEKQASNGVLI	RIWARPSAIAAGHGDYALNVTGPILNFFAGHYDTPYPLPKSDQIGLPDFNAGAMENWGLV	TYRENSLLFDPLSSSSSNKERVVTVIAHELAHQWFGNLVTIEWWNDLWLNEGFASYVEYL	GADYAEPTWNLKDLMVLNDVYRVMAVDALASSHPLSTPASEINTPAQISELFDAISYSKG	ASVLRMLSSFLSEDVFKQGLASYLHTFAYQNTIYLNLWDHLQEAVNNRSIQLPTTVRDIM	NRWTLQMGFPVITVDTSTGTLSQEHFLLDPDSNVTRPSEFNYVWIVPITSIRDGRQQQDY	WLIDVRAQNDLFSTSGNEWVLLNLNVTGYYRVNYDEENWRKIQTQLQRDHSAIPVINRAQ	IINDAFNLASAHKVPVTLALNNTLFLIEERQYMPWEAALSSLSYFKLMFDRSEVYGPMKN	YLKKQVTPLFIHFRNNTNNWREIPENLMDQYSEVNAISTACSNGVPECEEMVSGLFKQWM	ENPNNNPIHPNLRSTVYCNAIAQGGEEEWDFAWEQFRNATLVNEADKLRAALACSKELWI	LNRYLSYTLNPDLIRKQDATSTIISITNNVIGQGLVWDFVQSNWKKLFNDYGGGSFSFSN	LIQAVTRRFSTEYELQQLEQFKKDNEETGFGSGTRALEQALEKTKANIKWVKENKEVVLQ	WFTENSK
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9367365
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=28678
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D28678%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10676659
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8102610
ANPEP
hAPN
EC 3.4.11.2
X13276
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9452074
Aminopeptidase N
http://bio2rdf.org/uniprot:P15144
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP15144%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=X13276
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DX13276%3E
Alanyl aminopeptidase
single-passTypeIiMembraneProtein.Cytoplasm
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8105105
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17026984
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9634079
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8887485
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7576235
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10605003
http://www.genenames.org/data/hgnc_data.php?hgnc_id=500
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D500%3E
Myeloid plasma membrane glycoprotein CD13
>2904 bp	ATGGCCAAGGGCTTCTATATTTCCAAGTCCCTGGGCATCCTGGGGATCCTCCTGGGCGTG	GCAGCCGTGTGCACAATCATCGCACTGTCAGTGGTGTACTCCCAGGAGAAGAACAAGAAC	GCCAACAGCTCCCCCGTGGCCTCCACCACCCCGTCCGCCTCAGCCACCACCAACCCCGCC	TCGGCCACCACCTTGGACCAAAGTAAAGCGTGGAATCGTTACCGCCTCCCCAACACGCTG	AAACCCGATTCCTACCAGGTGACGCTGAGACCGTACCTCACCCCCAATGACAGGGGCCTG	TACGTTTTTAAGGGCTCCAGCACCGTCCGTTTCACCTGCAAGGAGGCCACTGACGTCATC	ATCATCCACAGCAAGAAGCTCAACTACACCCTCAGCCAGGGGCACAGGGTGGTCCTGCGT	GGTGTGGGAGGCTCCCAGCCCCCCGACATTGACAAGACTGAGCTGGTGGAGCCCACCGAG	TACCTGGTGGTGCACCTCAAGGGCTCCCTGGTGAAGGACAGCCAGTATGAGATGGACAGC	GAGTTCGAGGGGGAGTTGGCAGATGACCTGGCGGGCTTCTACCGCAGCGAGTACATGGAG	GGCAATGTCAGAAAGGTGGTGGCCACTACACAGATGCAGGCTGCAGATGCCCGGAAGTCC	TTCCCATGCTTCGATGAGCCGGCCATGAAGGCCGAGTTCAACATCACGCTTATCCACCCC	AAGGACCTGACAGCCCTGTCCAACATGCTTCCCAAAGGTCCCAGCACCCCACTTCCAGAA	GACCCCAACTGGAATGTCACTGAGTTCCACACCACGCCCAAGATGTCCACGTACTTGCTG	GCCTTCATTGTCAGTGAGTTCGACTACGTGGAGAAGCAGGCATCCAATGGTGTCTTGATC	CGGATCTGGGCCCGGCCCAGTGCCATTGCGGCGGGCCACGGCGATTATGCCCTGAACGTG	ACGGGCCCCATCCTTAACTTCTTTGCTGGTCATTATGACACACCCTACCCACTCCCAAAA	TCAGACCAGATTGGCCTGCCAGACTTCAACGCCGGCGCCATGGAGAACTGGGGACTGGTG	ACCTACCGGGAGAACTCCCTGCTGTTCGACCCCCTGTCCTCCTCCAGCAGCAACAAGGAG	CGGGTGGTCACTGTGATTGCTCATGAGCTGGCCCACCAGTGGTTCGGGAACCTGGTGACC	ATAGAGTGGTGGAATGACCTGTGGCTGAACGAGGGCTTCGCCTCCTACGTGGAGTACCTG	GGTGCTGACTATGCGGAGCCCACCTGGAACTTGAAAGACCTCATGGTGCTGAATGATGTG	TACCGCGTGATGGCAGTGGATGCACTGGCCTCCTCCCACCCGCTGTCCACACCCGCCTCG	GAGATCAACACGCCGGCCCAGATCAGTGAGCTGTTTGACGCCATCTCCTACAGCAAGGGC	GCCTCAGTCCTCAGGATGCTCTCCAGCTTCCTGTCCGAGGACGTATTCAAGCAGGGCCTG	GCGTCCTACCTCCACACCTTTGCCTACCAGAACACCATCTACCTGAACCTGTGGGACCAC	CTGCAGGAGGCTGTGAACAACCGGTCCATCCAACTCCCCACCACCGAGCGGGACATCATG	AACCGCTGGACCCTGCAGATGGGCTTCCCGGTCATCACGGTGGATACCAGCACGGGGACC	CTTTCCCAGGAGCACTTCCTCCTTGACCCCGATTCCAATGTTACCCGCCCCTCAGAATTC	AACTACGTGTGGATTGTGCCCATCACATCCATCAGAGATGGCAGACAGCAGCAGGACTAC	TGGCTGATGGATGTAAGAGCCCAGAACGATCTCTTCAGCACATCAGGCAATGAGTGGGTC	CTGCTGAACCTCAATGTGACGGGCTATTACCGGGTGAACTACGACGAAGAGAACTGGAGG	AAGATTCAGACTCAGCTGCAGAGAGACCACTCGGCCATCCCTGTCATCAATCGGGCACAG	ATCATTAATGACGCCTTCAACCTGGCCAGTGCCCATAAGGTCCCTGTCACTCTGGCGCTG	AACAACACCCTCTTCCTGATTGAAGAGAGACAGTACATGCCCTGGGAGGCCGCCCTGAGC	AGCCTGAGCTACTTCAAGCTCATGTTTGACCGCTCCGAGGTCTATGGCCCCATGAAGAAC	TACCTGAAGAAGCAGGTCACACCCCTCTTCATTCACTTCAGAAATAATACCAACAACTGG	AGGGAGATCCCAGAAAACCTGATGGACCAGTACAGCGAGGTTAATGCCATCAGCACCGCC	TGCTCCAACGGAGTTCCAGAGTGTGAGGAGATGGTCTCTGGCCTTTTCAAGCAGTGGATG	GAGAACCCCAATAATAACCCGATCCACCCCAACCTGCGGTCCACCGTCTACTGCAACGCT	ATCGCCCAGGGCGGGGAGGAGGAGTGGGACTTCGCCTGGGAGCAGTTCCGAAATGCCACA	CTGGTCAATGAGGCTGACAAGCTCCGGGCAGCCCTGGCCTGCAGCAAAGAGTTGTGGATC	CTGAACAGGTACCTGAGCTACACCCTGAACCCGGACTTAATCCGGAAGCAGGACGCCACC	TCTACCATCATCAGCATTACCAACAACGTCATTGGGCAAGGTCTGGTCTGGGACTTTGTC	CAGAGCAACTGGAAGAAGCCTTTTAACGATTATGGTGGTGGCTCGTTCTCCTTCTCCAAC	CTCATCCAGGCAGTGACACGACGATTCTCCACCGAGTATGAGCTGCAGCAGCTGGAGCAG	TTCAAGAAGGACAACGAGGAAACAGGCTTCGGCTCAGGCACCCGGGCCCTGGAGCAAGCC	CTGGAGAAGACGAAAGCCAACATCAAGTGGGTGAAGGAGAACAAGGAGGTGGTGCTCCAG	TGGTTCACAGAAAACAGCAAATAG
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11384645
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1705556
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1350662
AMPN_HUMAN
Microsomal aminopeptidase
CD13 antigen
15q25-q26
http://symbol.bio2rdf.org/symbol:ANPEP
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AANPEP%3E
http://www.uniprot.org/uniprot/P15144
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP15144%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2564851
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7902291
http://bio2rdf.org/hgnc:500
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A500%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9056417
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11559807
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/6149934
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB06196
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00973
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00912
_:header1962726101335206623929
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00912
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB00264
http://bio2rdf.org/kegg:D00594
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD00594%3E
http://129.128.185.122/drugbank2/drugs/DB00912/inserts/69/full
A10BX02
/drugs/912/safety_sheets/1221
2002-01-01	/drugs/912/fda_labels/514
http://bio2rdf.org/cas:135062-02-1
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A135062-02-1%3E
CCOC1=C(C=CC(CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N2CCCCC2)=C1)C(O)=O
Repaglinide closes ATP-dependent potassium channels in the b-cell membrane by binding at characterizable sites. This potassium channel blockade depolarizes the b-cell, which leads to an opening of calcium channels. The resulting increased calcium influx induces insulin secretion. The ion channel mechanism is highly tissue selective with low affinity for heart and skeletal muscle.
PA451234
http://www.rxlist.com/cgi/generic/prandin.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric%2Fprandin.htm%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1572
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1572%3E
LD<sub>50</sub> >1 g/kg (rat) (W. Grell)
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3566
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3566%3E
>98%
2008-08-26 15:21:46 UTC
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2173
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2173%3E
2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/meglitinides
aprd00439
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/709
Repaglinide
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/781
FAEKWTJYAYMJKF-DUDVQEBDDW
Repaglinidum [INN-Latin]
repaglinide
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2732%3E
http://dbpedia.org/page/Repaglinide
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FRepaglinide%3E
DB00912
http://data.linkedct.org/resource/intervention/51191
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F51191%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2169
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2169%3E
http://data.linkedct.org/resource/intervention/21875
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F21875%3E
Repaglinide is completely metabolized by oxidative biotransformation and direct conjugation with glucuronic acid after either an IV or oral dose.
http://129.128.185.122/drugbank2/drugs/DB00912/inserts/804/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00912%2Finserts%2F804%2Ffull%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/230
2.94e-03 mg/mL
68:20.16
1 hour
http://www.drugbank.ca/drugs/DB00912
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00912%3E
http://bio2rdf.org/cpd:C07670
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC07670%3E
http://dbpedia.org/resource/Repaglinide
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FRepaglinide%3E
http://data.linkedct.org/resource/intervention/20003
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F20003%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/578
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F578%3E
W. Grell et al., PCT Int. pat. Appl. WO 93 00,337
http://en.wikipedia.org/wiki/Repaglinide
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FRepaglinide%3E
http://205.193.93.51/dpdonline/searchRequest.do?din=02239925
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02239925%3E
CCOC1=C(C=CC(CC(=O)NC(CC(C)C)C2=CC=CC=C2N2CCCCC2)=C1)C(O)=O
AG-EE 623 ZW
Repaglinida [INN-Spanish]
130-131 oC
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2147%3E
Take upto 30 minutes before meals.
For the treatment of Type II diabetes mellitus.
AG-EE 388 ZW
Repaglinide is an oral blood glucose-lowering drug of the meglitinide class used in the management of type 2 diabetes mellitus (also known as non-insulin dependent diabetes mellitus or NIDDM). Repaglinide lowers blood glucose levels by stimulating the release of insulin from the pancreas. This action is dependent upon functioning beta cells in the pancreatic islets. Insulin release is glucose-dependent and diminishes at low glucose concentrations.
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1162
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F1162%3E
InChI=1/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1/f/h28,31H
Repaglinide is a blood-glucose lowering drug. It lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the beta cells. This depolarizes the beta cells, opening the cells' calcium channels, and the resulting calcium influx induces insulin secretion.
http://129.128.185.122/drugbank2/drugs/DB00912/inserts/1825/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00912%2Finserts%2F1825%2Ffull%3E
C27H36N2O4
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1246
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1246%3E
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/pra1343.shtml
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/139
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F139%3E
Rapid (bioavailability is 56%)
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2733%3E
Prandin
http://www.dbpedia.org/resource/Repaglinide
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FRepaglinide%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01016_DB00912
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01193_DB00912
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01120_DB00912
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01241_DB00912
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB01580
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB01359
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB01296
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00199_DB00912
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB00489
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB00571
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB00091
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB01382
RDF Description of Repaglinide
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01136_DB00912
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00414_DB00912
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01211_DB00912
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00335_DB00912
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00672_DB00912
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00960_DB00912
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB01120
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB00839
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB01321
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB01124
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB00612
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB00187
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00264_DB00912
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB00598
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00091_DB00912
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00571_DB00912
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB01297
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB00335
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB00672
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB01045
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB01193
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00222_DB00912
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB00373
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB00222
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00187_DB00912
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB01289
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB00521
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB01016
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01045_DB00912
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01580_DB00912
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB00199
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB01067
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB01241
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB01211
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB01136
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB00195
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB01295
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00373_DB00912
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB00912
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB01203
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01203_DB00912
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB00960
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00912_DB00414
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00598_DB00912
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/C1S
_:header15218025741335206624237
Mon, 23 Apr 2012 18:36:59 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/C1S
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1696
http://symbol.bio2rdf.org/symbol:C1S
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AC1S%3E
C1S
http://www.dbpedia.org/resource/C1S
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FC1S%3E
RDF Description of C1S
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00346
_:header9042875551335206624682
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00346_DB00862
http://129.128.185.122/drugbank2/drugs/DB00346/inserts/1827/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00346%2Finserts%2F1827%2Ffull%3E
82%-90%
2008-08-26 15:38:53 UTC
Alfuzosin is an alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Accordingly, alfuzosin is a selective inhibitor of the alpha1 subtype of alpha adrenergic receptors. In the human prostate, alfuzosin antagonizes phenylephrine (alpha1 agonist)-induced contractions, <i>in vitro</i>, and binds with high affinity to the alpha1c adrenoceptor, which is thought to be the predominant functional type in the prostate. Studies in normal human subjects have shown that alfuzosin competitively antagonized the pressor effects of phenylephrine (an alpha1 agonist) and the systolic pressor effect of norepinephrine. The antihypertensive effect of alfuzosin results from a decrease in systemic vascular resistance and the parent compound alfuzosin is primarily responsible for the antihypertensive activity.
DB00346
COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N(C)CCCNC(=O)[C@H]1CCCO1
Side effects are dizziness (due to postural hypotension), upper respiratory tract infection, headache, and fatigue.
http://data.linkedct.org/resource/intervention/44871
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F44871%3E
http://dbpedia.org/page/Alfuzosin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FAlfuzosin%3E
http://data.linkedct.org/resource/intervention/31403
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F31403%3E
aprd00490
Alfusosine
Absorption is 50% lower under fasting conditions
Xatral
Alfuzosin
http://data.linkedct.org/resource/intervention/1087
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F1087%3E
http://data.linkedct.org/resource/intervention/46964
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F46964%3E
C19H27N5O4
For the treatment of the signs and symptoms of benign prostatic hyperplasia.
http://data.linkedct.org/resource/intervention/23663
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F23663%3E
2.82e-01 mg/mL
http://129.128.185.122/drugbank2/drugs/DB00346/inserts/71/full
http://205.193.93.51/dpdonline/searchRequest.do?din=02245565
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02245565%3E
PA10357
http://en.wikipedia.org/wiki/Alfuzosin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FAlfuzosin%3E
http://www.drugbank.ca/drugs/DB00346
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00346%3E
G04CA01
Alfuzosin (INN, provided as the hydrochloride salt) is an alpha-adrenergic blocker used to treat benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate. [Wikipedia]
http://data.linkedct.org/resource/intervention/548
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F548%3E
Alfuzosin acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.
COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N(C)CCCNC(=O)C1CCCO1
Hepatic. Alfuzosin undergoes extensive metabolism by the liver, with only 11% of the administered dose excreted unchanged in the urine. Alfuzosin is metabolized by three metabolic pathways: oxidation, O-demethylations, and N-dealkylation. The metabolites are not pharmacologically active. CYP3A4 is the principal hepatic enzyme isoform involved in its metabolism.
N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide
10 hours
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FAlfuzosin%3E
Take after a meal (always the same meal), product bioavailability is reduced when taken on an empty stomach.
http://bio2rdf.org/kegg:D01692
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD01692%3E
http://bio2rdf.org/cas:81403-80-7
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A81403-80-7%3E
InChI=1/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23)/f/h21H,20H2
2003-06-12	/drugs/346/fda_labels/484
WNMJYKCGWZFFKR-YVLNATIJCY
http://www.dbpedia.org/resource/Alfuzosin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FAlfuzosin%3E
http://129.128.185.122/drugbank2/drugs/DB00346/inserts/806/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00346%2Finserts%2F806%2Ffull%3E
http://www.rxlist.com/cgi/generic/uroxatral.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric%2Furoxatral.htm%3E
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/uro1685.shtml
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00346_DB01167
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01167_DB00346
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00346_DB01026
RDF Description of Alfuzosin
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01026_DB00346
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0020438
_:header15319617781335206625221
Mon, 23 Apr 2012 18:37:00 GMT
RDF Description of hypercalcinuria
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0020438
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/537
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F537%3E
http://dbpedia.org/resource/Hypercalciuria
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FHypercalciuria%3E
http://sideeffects.embl.de/se/C0020438
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0020438%3E
hypercalcinuria
C0020438
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/3928
_:header11829891181335206625538
RDF Description of Spherocytosis, hereditary
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3928
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/SLC4A1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/EPB3
http://bio2rdf.org/omim:109270
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fomim%3A109270%3E
Spherocytosis, hereditary
http://www.dbpedia.org/resource/Hereditary_spherocytosis
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FHereditary_spherocytosis%3E
http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=109270
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fdispomim.cgi%3Fid%3D109270%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/chromosomalLocation/17q21-q22
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/AE1
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Roughead_William_1870-1952
_:header17429927771335206625964
RDF Description of Roughead, William, 1870-1952 
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Roughead_William_1870-1952
Roughead, William, 1870-1952 
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext12640
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/2614
_:header10952864081335206626503
Mon, 23 Apr 2012 18:37:01 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2614
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03137
http://www.pdb.org/pdb/explore/explore.do?structureId=1UYL
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1UYL%3E
U94395
HSP 86
Heat shock protein HSP 90-alpha
HS90A_PIG
http://bio2rdf.org/uniprot:O02705
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AO02705%3E
cytoplasm.Melanosome
HSP90AA1
>2202 bp	ATGCCCGAGGAAACCCAGACCCAAGACCAGCCGATGGAGGAGGAGGAGGTGGAGACGTTC	GCCTTCCAGGCGGAAATCGCCCAGTTGATGTCGTTGATCATCAACACTTTCTACTCGAAC	AAGGAGATCTTTCTGAGGGAGCTCATTTCCAACTCGTCCGATGCTTTGGACAAGATCAGA	TACGAAAGCCTGACGGATCCCAGTAAACTAGACTCCGGGAAAGAGCTGCACATTAATCTC	ATTCCGAACAAGCAAGACCGGACCCTCACGATAGTGGACACCGGCATCGGCATGACCAAG	GCCGACTTGATCAATAACCTTGGTACGATCGCCAAGTCTGGGACCAAGGCGTTCATGGAG	GCTTTGCAGGCCGGTGCCGATATCTCGATGATTGGCCAGTTCGGTGTCGGCTTCTACTCT	GCGTACCTGGTCGCTGAGAAAGTGACCGTTATCACCAAACACAACGATGACGAGCAGTAT	GCCTGGGAGTCTTCTGCAGGAGGATCTTTCACCGTTAGGACAGACACAGGAGAACCTATG	GGTCGTGGAACAAAGGTTATTCTACATCTGAAAGAAGACCAAACTGAGTACTTGGAAGAA	AGGAGAATAAAGGAGATTGTGAAGAAACACTCTCAGTTTATTGGCTACCCCATTACTCTC	TTCGTGGAGAAGGAACGTGATAAAGAAGTCAGTGACGACGAGGCGGAAGAAAAGGAAGAC	AAAGAGGAAGAAAAGGAGAAAGAAGAGAAGGAATCTGAGGATAAACCGGAGATAGAAGAT	GTTGGTTCTGATGAAGAGGAAGAAGAAAAGAAGGATGGTGACAAGAAGAAGAAGAAGAAG	ATCAAGGAGAAGTATATTGATCAAGAGGAACTCAACAAGACAAAGCCTATCTGGACCAGA	AACCCCGATGACATCACTAATGAAGAGTACGGGGAGTTCTATAAGAGCTTGACCAATGAC	TGGGAGGATCACTTGGCTGTGAAGCACTTTTCAGTCGAAGGGCAGTTGGAGTTCAGAGCC	CTTCTTTTCGTCCCAAGACGCGCTCCTTTCGACTTATTTGAAAACAGAAAGAAGAAGAAC	AACATCAAGCTGTATGTTCGCAGAGTGTTCATCATGGACAACTGCGAGGAGCTCATCCCT	GAGTATCTGAATTTCATTAGAGGCGTGGTGGACTCTGAGGATCTTCCTCTGAACATTTCT	CGTGAGATGTTGCAACAAAGCAAAATTTTGAAAGTCATCAGGAAGAATCTGGTCAAGAAA	TGCTTGGAGCTCTTTACTGAATTGGCCGAAGATAAAGAGAATTACAAGAAGTTCTATGAG	CAGTTCTCTAAAAATATTAAGCTTGGAATACATGAAGATTCTCAAAATCGGAAGAAGCTT	TCCGAGCTGTTGAGGTACTACACTTCTGCTTCTGGCGACGAGATGGTTTCCCTCAAGGAC	TATTGCACCAGAATGAAGGAGAACCAGAAACACATCTATTACATCACAGGTGAGACCAAG	GACCAGGTGGCCAACTCGGCCTTCGTGGAACGTCTGCGGAAGCACGGCCTGGAGGTGATC	TACATGATCGAGCCCATCGATGAGTACTGTGTGCAGCAGCTGAAGGAGTTTGAGGGGAAG	ACCTTAGTGTCAGTCACCAAAGAGGGCCTGGAGCTCCCGGAAGATGAAGAGGAGAAGAAG	AAACAGGAGGAGAAGAAGACAAAGTTTGAAAACCTCTGCAAGATCATGAAGGACATCTTG	GAGAAGAAAGTCGAAAAGGTGGTTGTGTCGAACCGGTTGGTGACCTCACCGTGCTGCATT	GTCACAAGCACATACGGCTGGACAGCAAACATGGAGAGAATCATGAAGGCTCAAGCCCTG	AGAGACAACTCGACAATGGGTTACATGGCAGCAAAGAAGCACCTGGAGATAAATCCAGAC	CATTCCATCATCGAGACCCTGAGGCAAAAGGCAGAGGCGGACAAGAACGACAAGTCCGTG	AAGGATCTGGTCATCCTGCTGTACGAAACCGCTCTGCTGTCTTCTGGCTTCAGCCTGGAA	GATCCCCAGACGCACGCCAACAGGATCTACAGGATGATCAAACTTGGTCTTGGTATTGAT	GAGGACGACCCCACCGCCGACGACAGCAGCGCTGCTGTGACGGAGGAGATGCCACCCCTG	GAAGGGGACGACGACACGTCCCGCATGGAGGAAGTCGATTAG
http://pfam.sanger.ac.uk/family?acc=PF00183
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00183%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9931505
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=1945447
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D1945447%3E
http://bio2rdf.org/pdb:1UYL
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1UYL%3E
http://bio2rdf.org/pfam:PF00183
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00183%3E
>Heat shock protein HSP 90-alpha	MPEETQTQDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIR	YESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFME	ALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPM	GRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAEEKED	KEEEKEKEEKESEDKPEIEDVGSDEEEEEKKDGDKKKKKKIKEKYIDQEELNKTKPIWTR	NPDDITNEEYGEFYKSLTNDWEDHLAVKHFSVEGQLEFRALLFVPRRAPFDLFENRKKKN	NIKLYVRRVFIMDNCEELIPEYLNFIRGVVDSEDLPLNISREMLQQSKILKVIRKNLVKK	CLELFTELAEDKENYKKFYEQFSKNIKLGIHEDSQNRKKLSELLRYYTSASGDEMVSLKD	YCTRMKENQKHIYYITGETKDQVANSAFVERLRKHGLEVIYMIEPIDEYCVQQLKEFEGK	TLVSVTKEGLELPEDEEEKKKQEEKKTKFENLCKIMKDILEKKVEKVVVSNRLVTSPCCI	VTSTYGWTANMERIMKAQALRDNSTMGYMAAKKHLEINPDHSIIETLRQKAEADKNDKSV	KDLVILLYETALLSSGFSLEDPQTHANRIYRMIKLGLGIDEDDPTADDSSAAVTEEMPPL	EGDDDTSRMEEVD
http://www.uniprot.org/uniprot/O02705
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FO02705%3E
Molecular chaperone. Has ATPase activity
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=U94395
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DU94395%3E
unfolded protein binding
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03504
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02550
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03093
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02359
RDF Description of Heat shock protein HSP 90-alpha
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03809
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02754
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03899
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03080
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04254
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04505
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04054
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/2673
_:header11680417771335206626942
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2673
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03719
http://www.uniprot.org/uniprot/P41148
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP41148%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=U01153
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DU01153%3E
endoplasmicReticulumLumen.SarcoplasmicReticulum.Melanosome
>Endoplasmin precursor	MRALWVLGLCCVLLTFGSVRADDEVDVDGTVEEDLGKSREGSRTDDEVVQREEEAIQLDG	LNASQIRELREKSEKFAFQAEVNRMMKLIINSLYKNKEIFLRELISNASDALDKIRLISL	TDENALAGNEELTVKIKCDKEKNLLHVTDTGVGMTREELVKNLGTIAKSGTSEFLNKMTE	AQEDGQSTSELIGQFGVGFYSAFLVADKVIVTSKHNNDTQHIWESDSNEFSVIADPRGNT	LGRGTTITLVLKEEASDYLELDTIKNLVKKYSQFINFPIYVWSSKTETVEEPMEEEEAAK	EEKEDSDDEAAVEEEEEEKKPKTKKVEKTVWDWELMNDIKPIWQRPSKEVEDDEYKAFYK	SFSKESDDPMAYIHFTAEGEVTFKSILFVPTSAPRGLFDEYGSKKSDYIKLYVRRVFITD	DFHDMMPKYLNFVKGVVDSDDLPLNVSRETLQQHKLLKVIRKKLVRKTLDMIKKIADEKY	NDTFWKEFGTNIKLGVIEDHSNRTRLAKLLRFQSSHHPSDITSLDQYVERMKEKQDKIYF	MAGSSRKEAESSPFVERLLKKGYEVIYLTEPVDEYCIQALPEFDGKRFQNVAKEGVKFDE	SEKTKESREAIEKEFEPLLNWMKDKALKDKIEKAVVSQRLTESPCALVASQYGWSGNMER	IMKAQAYQTGKDISTNYYASQKKTFEINPRHPLIKDMLRRVKEDEDDKTVSDLAVVLFET	ATLRSGYLLPDTKAYGDRIERMLRLSLNIDPDAKVEEEPEEEPEETTEDTTEDTEQDDEE	EMDAGTDDEEQETVKKSTAEKDEL
http://bio2rdf.org/uniprot:P41148
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP41148%3E
U01153
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=403497
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D403497%3E
Heat shock protein 90 kDa beta member 1
GRP94
94 kDa glucose-regulated protein
HSP90B1
Endoplasmin
>2415 bp	ATGAGGGCCCTGTGGGTGCTGGGCCTCTGCTGCGTCCTGCTGACCTTCGGGTCAGTCCGA	GCTGACGATGAAGTCGATGTGGATGGTACAGTGGAAGAGGATCTGGGTAAAAGTAGAGAA	GGCTCCAGGACAGATGATGAAGTAGTGCAGAGAGAGGAAGAAGCTATTCAGTTGGATGGA	TTAAATGCATCCCAAATAAGAGAACTTAGAGAAAAATCAGAAAAATTTGCCTTCCAAGCT	GAAGTGAATAGAATGATGAAACTTATCATCAATTCATTGTATAAAAATAAAGAGATTTTC	TTGAGAGAACTGATTTCAAATGCTTCTGATGCCTTAGATAAGATAAGGTTAATATCACTG	ACTGATGAAAATGCTCTTGCTGGAAATGAGGAACTAACTGTCAAAATTAAGTGTGACAAG	GAGAAGAATCTGCTACATGTCACAGACACTGGTGTGGGAATGACCCGGGAAGAGTTGGTT	AAAAACCTTGGTACCATAGCCAAATCTGGAACAAGCGAGTTTTTAAACAAAATGACTGAG	GCACAAGAGGATGGCCAGTCAACTTCTGAACTGATTGGGCAGTTTGGTGTCGGTTTCTAT	TCTGCCTTCCTTGTCGCAGATAAGGTTATTGTCACATCAAAACACAACAACGATACCCAG	CATATCTGGGAATCTGACTCCAATGAGTTCTCTGTAATTGCTGACCCACGAGGGAACACC	CTCGGACGGGGAACAACAATTACACTTGTTTTAAAAGAAGAAGCATCTGATTACCTTGAA	TTGGACACAATTAAAAATCTCGTCAAGAAATATTCACAGTTTATAAACTTCCCTATTTAT	GTGTGGAGCAGCAAGACTGAAACTGTTGAGGAGCCCATGGAAGAAGAAGAAGCAGCAAAA	GAAGAAAAAGAAGATTCTGATGATGAAGCTGCAGTGGAAGAAGAAGAGGAGGAAAAAAAA	CCAAAAACCAAAAAAGTTGAGAAAACTGTCTGGGATTGGGAGCTTATGAATGACATCAAA	CCAATATGGCAGAGACCATCAAAAGAAGTAGAAGATGACGAATACAAAGCTTTCTACAAA	TCATTTTCAAAGGAAAGTGATGACCCCATGGCTTATATCCACTTTACTGCTGAAGGGGAA	GTCACCTTCAAATCAATTTTATTTGTACCTACATCTGCTCCACGTGGTCTGTTTGATGAA	TATGGATCTAAGAAGAGTGATTACATTAAGCTTTACGTGCGCAGAGTATTCATCACAGAT	GACTTCCATGATATGATGCCCAAGTACCTTAACTTTGTCAAGGGTGTTGTGGACTCAGAT	GATCTCCCCTTGAATGTTTCCCGGGAAACTCTTCAGCAACATAAACTGCTTAAGGTGATT	AGAAAGAAGCTTGTCCGTAAAACTCTGGACATGATCAAGAAGATTGCTGATGAGAAGTAC	AATGATACTTTTTGGAAAGAATTTGGTACCAACATCAAGCTTGGTGTAATTGAAGACCAC	TCAAATCGAACACGTCTTGCTAAACTTCTTAGATTCCAGTCATCTCATCATCCAAGTGAC	ATAACCAGTCTAGACCAATACGTGGAAAGAATGAAGGAGAAGCAAGACAAAATCTACTTC	ATGGCTGGGTCTAGCAGAAAAGAGGCTGAATCTTCTCCATTTGTTGAGCGACTTCTGAAA	AAGGGCTATGAAGTGATTTATCTCACCGAACCTGTGGACGAATACTGCATTCAGGCTCTT	CCTGAGTTTGATGGGAAAAGGTTCCAGAATGTTGCCAAAGAAGGTGTGAAATTTGATGAA	AGTGAGAAAACAAAGGAGAGTCGTGAAGCGATTGAGAAAGAATTTGAGCCTCTGCTCAAC	TGGATGAAAGATAAAGCTCTCAAGGACAAGATTGAAAAGGCCGTGGTATCTCAGCGTCTG	ACAGAGTCTCCGTGTGCTCTGGTGGCCAGCCAGTATGGATGGTCTGGCAACATGGAGAGA	ATCATGAAAGCTCAAGCATACCAGACGGGCAAAGACATCTCTACAAATTACTATGCCAGC	CAAAAGAAAACATTTGAAATTAATCCCAGACATCCCCTGATCAAAGACATGCTGCGACGA	GTTAAGGAAGATGAAGATGACAAAACGGTATCGGATCTTGCTGTGGTTTTGTTTGAGACA	GCAACGCTGAGATCAGGCTATCTGCTACCAGACACTAAAGCATATGGAGATCGAATAGAA	AGAATGCTTCGCCTCAGTTTAAACATTGACCCTGATGCAAAGGTGGAAGAAGAACCAGAA	GAAGAACCCGAAGAGACAACCGAGGACACCACAGAAGACACAGAGCAGGACGATGAAGAA	GAAATGGATGCAGGAACAGACGACGAAGAACAAGAAACAGTAAAGAAATCTACAGCTGAA	AAAGATGAATTATAA
http://bio2rdf.org/pdb:1QYE
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1QYE%3E
Endoplasmin precursor
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8119936
ENPL_CANFA
Molecular chaperone that functions in the processing and transport of secreted proteins
http://www.pdb.org/pdb/explore/explore.do?structureId=1QYE
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1QYE%3E
RDF Description of Endoplasmin
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02935
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02575
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03758
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02103
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Hurston_Zora_Neale_1901?-1960
_:header1480113321335206627346
Mon, 23 Apr 2012 18:37:02 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Hurston_Zora_Neale_1901?-1960
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17187
Hurston, Zora Neale, 1901?-1960
RDF Description of Hurston, Zora Neale, 1901?-1960
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext15902
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB03515
_:header20560865301335206627799
RDF Description of Equilenin
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03515
Equilenin
EQU
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2920
DB03515
CC12CCC3=C(C=CC4=C3C=CC(O)=C4)C1CCC2=O
2008-08-26 16:03:57 UTC
5.20e-03 mg/mL
http://www.drugbank.ca/drugs/DB03515
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB03515%3E
(13S,14S)-3-hydroxy-13-methyl-12,14,15,16-tetrahydro-11H-cyclopenta[a]phenanthren-17-one
PDRGHUMCVRDZLQ-UHFFFAOYAO
InChI=1/C18H18O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h2-5,10,16,19H,6-9H2,1H3
C18H18O2
C[C@@]12CCC3=C(C=CC4=C3C=CC(O)=C4)[C@@H]1CCC2=O
1OGX
An estrogenic steroid produced by HORSES. It has a total of five double bonds in the A- and B-ring. High concentration of equilenin is found in the URINE of pregnant mares. [PubChem]
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2283
expt01356
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Tegner_Esaias_1782-1846
_:header18329842841335206628150
Mon, 23 Apr 2012 18:37:03 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Tegner_Esaias_1782-1846
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8518
Tegner, Esaias, 1782-1846
RDF Description of Tegner, Esaias, 1782-1846
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3759
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/520
_:header1579489251335206628549
RDF Description of Holt-Oram syndrome
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/520
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/TBX5
Holt-Oram syndrome
http://www.dbpedia.org/resource/Holt-Oram_syndrome
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FHolt-Oram_syndrome%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2629
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/CHK2
_:header7468261171335206629041
Mon, 23 Apr 2012 18:37:04 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/CHK2
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1682
http://symbol.bio2rdf.org/symbol:CHK2
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ACHK2%3E
CHK2
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1664
RDF Description of CHK2
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2963
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3482
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3659
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Jepson_Edgar_1863-1938
_:header4084029291335206629383
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Jepson_Edgar_1863-1938
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext4014
Jepson, Edgar, 1863-1938
Jepson, Edgar, 1863-1938 
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9808
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19043
RDF Description of Jepson, Edgar, 1863-1938
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19010
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19310
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/ALDH6A1
_:header11792720921335206629792
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/ALDH6A1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/756
http://symbol.bio2rdf.org/symbol:ALDH6A1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AALDH6A1%3E
ALDH6A1
http://www.dbpedia.org/resource/ALDH6A1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FALDH6A1%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3147
RDF Description of ALDH6A1
http://www4.wiwiss.fu-berlin.de/eurostat/data/regions/Limousin
_:header37571571335206630171
Mon, 23 Apr 2012 18:37:05 GMT
RDF Description of Limousin
http://www4.wiwiss.fu-berlin.de/eurostat/resource/regions/Limousin
fr63
http://ec.europa.eu/eurostat/ramon/rdfdata/nuts2008/FR63
http://www4.wiwiss.fu-berlin.de/eurostat/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fec.europa.eu%2Feurostat%2Framon%2Frdfdata%2Fnuts2008%2FFR63%3E
Limousin
http://www4.wiwiss.fu-berlin.de/eurostat/resource/countries/France
http://estatwrap.ontologycentral.com/dic/geo#FR63
http://www4.wiwiss.fu-berlin.de/eurostat/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Festatwrap.ontologycentral.com%2Fdic%2Fgeo%23FR63%3E
http://dbpedia.org/resource/Limousin_(province)
http://www4.wiwiss.fu-berlin.de/eurostat/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FLimousin_%28province%29%3E
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Leacock_Stephen_1869-1944
_:header14200049431335206630563
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Leacock_Stephen_1869-1944
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext4781
Leacock, Stephen, 1869-1944
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext4020
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3533
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext4077
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6340
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext4064
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext11504
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3532
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext20633
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext4682
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8457
RDF Description of Leacock, Stephen, 1869-1944
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext4069
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/3892
_:header19458569801335206631373
Mon, 23 Apr 2012 18:37:06 GMT
RDF Description of Sickle cell anemia
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3892
Sickle cell anemia
http://bio2rdf.org/omim:141900
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fomim%3A141900%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2869
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2869%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00893
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00893%3E
http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=141900
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fdispomim.cgi%3Fid%3D141900%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/chromosomalLocation/11p15.5
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1055
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0002895
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fsider%2Fresource%2Fside_effects%2FC0002895%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/HBB
http://data.linkedct.org/resource/condition/12092
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fcondition%2F12092%3E
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00383
_:header11564524061335206631811
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00383
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00502_DB00383
Oxyphencyclimine Hydrochloride
Syklifen
http://www.dbpedia.org/resource/Oxyphencyclimine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FOxyphencyclimine%3E
(1-methyl-5,6-dihydro-4H-pyrimidin-2-yl)methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate
Oxyphencyclimine is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. Oxyphencyclimine is an antimuscarinic, anticholinergic drug.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/anticholinergicAgents
Antulcus
http://bio2rdf.org/cpd:C07851
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC07851%3E
Setrol
Spazamin
Ulcociclinina
C20H28N2O3
Daricol
Daricon
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/617
Oximin
InChI=1/C20H28N2O3/c1-22-14-8-13-21-18(22)15-25-19(23)20(24,16-9-4-2-5-10-16)17-11-6-3-7-12-17/h2,4-5,9-10,17,24H,3,6-8,11-15H2,1H3
CN1CCCN=C1COC(=O)[C@@](O)(C1CCCCC1)C1=CC=CC=C1
Naridan
Zamanil
Cycmin
Caridan
DUDKAZCAISNGQN-UHFFFAOYAU
Gastrix
DB00383
http://www.drugbank.ca/drugs/DB00383
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00383%3E
Oxyphencyclimine is an anticholinergic drug (trade name Daricon) used in treating peptic ulcers.
Brit. pat. 795,758 (1958 to Pfizer)
Vio-Thene
W-T Anticholinergic
Enterex
2008-08-26 14:28:25 UTC
aprd00399
http://bio2rdf.org/cas:125-53-1
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A125-53-1%3E
CN1CCCN=C1COC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1
For the treatment of peptic ulcer disease and the relief of smooth muscle spasms in gastrointestinal disorders.
Manir
Oxifencicliminum [INN-Spanish]
5.67e-02 mg/mL
6.61 mg/L at 25oC
Oxyphencyclimine
Oxyphencyclimine binds the muscarinic acetylcholine receptor. It may block all three types of muscarinic receptors including M-1 receptors in the CNS and ganglia, M-2 receptors in the heart (vagus) and M-3 receptors at the parasympathetic NEJ system. The muscarinic acetylcholine receptors mediate various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Oxphencyclimine inhibits vagally mediated reflexes by antagonizing the action of acetylcholine. This in turn reduces the secretion of gastric acids in the stomach.
A03AA01
Oxyphencycliminum [INN-Latin]
Oxiphencycliminum
Dominil
RDF Description of Oxyphencyclimine
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/SURF1
_:header19877978321335206632127
Mon, 23 Apr 2012 18:37:07 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/SURF1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2894
http://symbol.bio2rdf.org/symbol:SURF1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ASURF1%3E
SURF1
http://www.dbpedia.org/resource/SURF1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FSURF1%3E
RDF Description of SURF1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/666
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/CRYGD
_:header19073936841335206632523
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/CRYGD
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1774
http://symbol.bio2rdf.org/symbol:CRYGD
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ACRYGD%3E
CRYGD
http://www.dbpedia.org/resource/Crystallin%2C_gamma_D
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FCrystallin%252C_gamma_D%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/202
RDF Description of CRYGD
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1781
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Illica_Luigi
_:header15268831401335206632986
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Illica_Luigi
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13843
Illica, Luigi
RDF Description of Illica, Luigi
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01288
_:header18560102791335206633472
Mon, 23 Apr 2012 18:37:08 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01288
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01151_DB01288
1.62e-01 mg/mL
C[C@H](CC1=CC=C(O)C=C1)NC[C@H](O)C1=CC(O)=CC(O)=C1
Symptoms of overdose include angina (chest pain), dizziness, dry mouth, fatigue, flu-like symptoms, headache, heart irregularities, high or low blood pressure, high blood sugar, insomnia, muscle cramps, nausea, nervousness, rapid heartbeat, seizures, and tremor.
Fenoterolum [inn-latin]
Fenoterol
Fenoterol is a beta agonist designed to open up the airways to the lungs.
http://205.193.93.51/dpdonline/searchRequest.do?din=00541389
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D00541389%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/149
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F149%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/sympathomimetics
http://en.wikipedia.org/wiki/Fenoterol
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FFenoterol%3E
Beta(2)-receptor stimulation in the lung causes relaxation of bronchial smooth muscle, bronchodilation, and increased bronchial airflow.
For the treatment of asthma.
5-[1-hydroxy-2-[1-(4-hydroxyphenyl)propan-2-ylamino]ethyl]benzene-1,3-diol
LSLYOANBFKQKPT-UHFFFAOYAY
Berotec
R03CC04
2008-08-26 14:57:05 UTC
2007-06-28 15:56:53 UTC
R03AC04
C17H21NO4
http://bio2rdf.org/cas:13392-18-2
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A13392-18-2%3E
G02CA03
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/aerosolMeteredRespiratory(inhalation)
PA10079
Duovent UDV (Fenoterol Hydrobromide + Ipratropium Bromide)
DB01288
An adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic. [PubChem]
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/solutionRespiratory(inhalation)
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/adrenergicBeta-agonists
Phenoterol
InChI=1/C17H21NO4/c1-11(6-12-2-4-14(19)5-3-12)18-10-17(22)13-7-15(20)9-16(21)8-13/h2-5,7-9,11,17-22H,6,10H2,1H3
http://dbpedia.org/page/Fenoterol
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FFenoterol%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3413
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3413%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/766
http://dbpedia.org/resource/Fenoterol
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FFenoterol%3E
12:12.08.12
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F116%3E
CC(CC1=CC=C(O)C=C1)NCC(O)C1=CC(O)=CC(O)=C1
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/tocolyticAgents
http://www.drugbank.ca/drugs/DB01288
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01288%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1598
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1598%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1499
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1499%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB01142
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00206_DB01288
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00373_DB01288
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB01580
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00335_DB01288
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB00571
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB01626
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB01297
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00780_DB01288
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00211_DB01288
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB01151
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB00540
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00968_DB01288
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB00264
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB00601
RDF Description of Fenoterol
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB01367
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB00968
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00321_DB01288
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00543_DB01288
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01171_DB01288
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01193_DB01288
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB00612
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB01089
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01136_DB01288
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB01242
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB00489
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01367_DB01288
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB01203
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01580_DB01288
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00540_DB01288
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB00211
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB01193
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00598_DB01288
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01142_DB01288
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB00373
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01247_DB01288
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB00321
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB01359
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00571_DB01288
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB01247
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00264_DB01288
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB01288
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB00187
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00458_DB01288
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01203_DB01288
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00187_DB01288
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB01171
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB00206
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB00726
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB01136
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01242_DB01288
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB00335
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB01295
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB00543
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB00598
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB00521
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB00386
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB00195
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB00752
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB00960
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB00780
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00601_DB01288
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01288_DB00458
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00960_DB01288
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/449
_:header17224290651335206633753
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2465
Glaucoma
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/CYP1B1
http://data.linkedct.org/resource/condition/5287
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fcondition%2F5287%3E
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/disease/Glaucoma
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fdisease%2FGlaucoma%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/MYOC
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fsider%2Fresource%2Fside_effects%2FC0017601%3E
http://www.dbpedia.org/resource/Glaucoma
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FGlaucoma%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00655
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00655%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/OPTN
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2460
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2467
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2462
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2461
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2466
RDF Description of Glaucoma
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/5695
_:header6064203661335206634308
Mon, 23 Apr 2012 18:37:09 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/5695
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04538
3-methylaspartate ammonia-lyase
>1242 bp	ATGAAAATTAAACAGGCGCTTTTCACCGCTGGCTACTCCTCATTCTATTTTGATGACCAG	CAGGCGATCAAAAATGGCGCAGGTCATGACGGGTTTATTTATACCGGCGATCCGGTCACC	CCGGGCTTTACTTCTGTGCGCCAGGCCGGCGAGTGCGTTTCCGTACAGCTGATTCTGGAA	AATGGTGCGGTGGCGGTGGGTGATTGCGCCGCGGTGCAGTACTCCGGTGCCGGTGGTCGC	GATCCGCTGTTCCTGGCTGAACATTTTATTCCGTTCCTCAACGACCACATTAAACCGCTG	CTCGAAGGTCGCGACGTGGATGCGTTCCTGCCGAACGCCCGTTTCTTCGACAAACTGCGT	ATCGACGGTAATTTGCTGCATACCGCCGTTCGCTACGGTCTGTCACAGGCACTGCTTGAT	GCCACCGCGCTGGCCTCGGGCCGCCTGAAAACGGAAGTGGTGTGTGATGAATGGCAACTG	CCCTGCGTACCGGAAGCCATTCCATTATTTGGTCAGAGCGGCGACGATCGCTACATCGCC	GTCGACAAGATGATCCTCAAAGGGGTTGACGTCCTGCCGCATGCGCTTATCAACAACGTG	GAAGAGAAGCTCGGTTTCAAAGGCGAAAAACTGCGTGAGTACGTGCGCTGGTTGTCCGAC	CGTATTCTCAGCCTGCGCAGCAGCCCACGCTACCATCCGACGCTGCATATCGATGTGTAT	GGCACCATCGGACTGATCTTCGATATGGACCCGGTACGCTGCGCCGAGTACATCGCCAGC	CTGGAAAAAGAGGCTCAGGGTCTGCCGCTGTACATTGAAGGCCCGGTTGATGCAGGCAAC	AAGCCGGATCAGATCCGCATGCTGACCGCCATCACCAAAGAGCTGACCCGCCTGGGTTCC	GGCGTGAAAATTGTCGCAGACGAATGGTGTAACACCTATCAGGACATTGTGGACTTCACC	GATGCCGGTAGCTGCCACATGGTGCAGATCAAAACCCCGGATCTCGGTGGCATTCACAAC	ATCGTTGACGCGGTGCTGTACTGCAACAAACACGGGATGGAAGCCTACCAGGGCGGTACC	TGTAACGAAACCGAAATCAGCGCCCGCACCTGCGTACATGTGGCTCTCGCCGCACGTCCG	ATGCGTATGCTGATCAAGCCTGGCATGGGCTTCGATGAAGGTCTCAATATCGTGTTTAAC	GAAATGAACCGCACCATCGCGCTGTTGCAGACTAAGGATTAA
http://bio2rdf.org/pdb:1KKR
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1KKR%3E
http://bio2rdf.org/pfam:PF05034
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF05034%3E
http://pfam.sanger.ac.uk/family?acc=PF07476
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF07476%3E
http://bio2rdf.org/uniprot:O66145
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AO66145%3E
http://pfam.sanger.ac.uk/family?acc=PF05034
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF05034%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AB005294
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAB005294%3E
http://www.pdb.org/pdb/explore/explore.do?structureId=1KKR
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1KKR%3E
O66145_CITAM
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11796115
http://www.uniprot.org/uniprot/O66145
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FO66145%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9830098
http://bio2rdf.org/pfam:PF07476
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF07476%3E
>3-methylaspartate ammonia-lyase	MKIKQALFTAGYSSFYFDDQQAIKNGAGHDGFIYTGDPVTPGFTSVRQAGECVSVQLILE	NGAVAVGDCAAVQYSGAGGRDPLFLAEHFIPFLNDHIKPLLEGRDVDAFLPNARFFDKLR	IDGNLLHTAVRYGLSQALLDATALASGRLKTEVVCDEWQLPCVPEAIPLFGQSGDDRYIA	VDKMILKGVDVLPHALINNVEEKLGFKGEKLREYVRWLSDRILSLRSSPRYHPTLHIDVY	GTIGLIFDMDPVRCAEYIASLEKEAQGLPLYIEGPVDAGNKPDQIRMLTAITKELTRLGS	GVKIVADEWCNTYQDIVDFTDAGSCHMVQIKTPDLGGIHNIVDAVLYCNKHGMEAYQGGT	CNETEISARTCVHVALAARPMRMLIKPGMGFDEGLNIVFNEMNRTIALLQTKD
AB005294
RDF Description of 3-methylaspartate ammonia-lyase
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Hale_Lucretia_P_(Lucretia_Peabody)_1820-1900
_:header9739352871335206634662
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Hale_Lucretia_P_(Lucretia_Peabody)_1820-1900
Hale, Lucretia P. (Lucretia Peabody), 1820-1900
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext15546
RDF Description of Hale, Lucretia P. (Lucretia Peabody), 1820-1900
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3028
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/1651
_:header12201900981335206635199
Mon, 23 Apr 2012 18:37:10 GMT
RDF Description of Cholecystokinins
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/1651
http://bio2rdf.org/pfam:PF00918
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00918%3E
3p22-p21.3
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=179996
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D179996%3E
L00354
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2168937
http://www.genenames.org/data/hgnc_data.php?hgnc_id=1569
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D1569%3E
>Cholecystokinins precursor	MNSGVCLCVLMAVLAAGALTQPVPPADPAGSGLQRAEEAPRRQLRVSQRTDGESRAHLGA	LLARYIQQARKAPSGRMSIVKNLQNLDPSHRISDRDYMGWMDFGRRSAEEYEYPS
http://www.dbpedia.org/resource/Cholecystokinin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FCholecystokinin%3E
http://bio2rdf.org/pdb:1D6G
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1D6G%3E
>348 bp	ATGAACAGCGGCGTGTGCCTGTGCGTGCTGATGGCGGTACTGGCGGCTGGCGCCCTGACG	CAGCCGGTGCCTCCCGCAGATCCCGCGGGCTCCGGGCTGCAGCGGGCAGAGGAGGCGCCC	CGTAGGCAGCTGAGGGTATCGCAGAGAACGGATGGCGAGTCCCGAGCGCACCTGGGCGCC	CTGCTGGCAAGATACATCCAGCAGGCCCGGAAAGCTCCTTCTGGACGAATGTCCATCGTT	AAGAACCTGCAGAACCTGGACCCCAGCCACAGGATAAGTGACCGGGACTACATGGGCTGG	ATGGATTTTGGCCGTCGCAGTGCCGAGGAGTATGAGTACCCCTCCTAG
http://bio2rdf.org/hgnc:1569
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A1569%3E
CCK
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8274713
Cholecystokinins precursor
http://pfam.sanger.ac.uk/family?acc=PF00918
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00918%3E
CCKN_HUMAN
http://www.pdb.org/pdb/explore/explore.do?structureId=1D6G
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1D6G%3E
Cholecystokinins
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=L00354
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DL00354%3E
http://www.uniprot.org/uniprot/P06307
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP06307%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2545992
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/11076522
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3856870
http://bio2rdf.org/uniprot:P06307
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP06307%3E
http://symbol.bio2rdf.org/symbol:CCK
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ACCK%3E
This peptide hormone induces gall bladder contraction and the release of pancreatic enzymes in the gut. Its function in the brain is not clear
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01497
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/947
_:header20949832441335206635465
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/947
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3634
Prader-Willi syndrome
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/NDN
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/SNRPN
http://www.dbpedia.org/resource/Prader-Willi_syndrome
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FPrader-Willi_syndrome%3E
RDF Description of Prader-Willi syndrome
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3635
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00612
_:header16063978551335206635955
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00612
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB00983
Concor
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/261
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F261%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/989
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F989%3E
7.07e-02 mg/mL
VHYCDWMUTMEGQY-UHFFFAOYAZ
CC(C)NC[C@@H](O)COC1=CC=C(COCCOC(C)C)C=C1
Binding to serum proteins is approximately 30%
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/zeb1667.shtml
Oral, mouse: LD<sub>50</sub> = 100 mg/kg; Skin, rabbit: LD<sub>50</sub> = 200 mg/kg;&nbsp;Skin, rat: LD<sub>50</sub> = 500 mg/kg. Symptoms of overdose include congestive heart failure (marked by sudden weight gain, swelling of the legs, feet, and ankles, fatigue, and shortness of breath), difficult or labored breathing, low blood pressure, low blood sugar, and slow heartbeat.
PA448641
2008-08-26 16:28:21 UTC
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/adrenergicBeta-antagonists
Isoten
For the management of hypertension and prophylaxis treatment of angina pectoris and heart failure.
Detensiel
http://bio2rdf.org/cas:66722-44-9
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A66722-44-9%3E
24:24.00
Soprol
Condylox
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/sympatholytics
http://en.wikipedia.org/wiki/Bisoprolol
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FBisoprolol%3E
http://dbpedia.org/resource/Bisoprolol
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FBisoprolol%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/193
100 oC
Zebeta
Bisoprolol
Bisoprolol Hemifumarate
http://data.linkedct.org/resource/intervention/54584
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F54584%3E
http://bio2rdf.org/kegg:D02342
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD02342%3E
A cardioselective beta-1-adrenergic blocker. It is effective in the management of hypertension and angina pectoris. [PubChem]
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fsider%2Fresource%2Fdrugs%2F2405%3E
2240 mg/L
C18H31NO4
9-12 hours
http://205.193.93.51/dpdonline/searchRequest.do?din=02247439
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02247439%3E
C07AB07
http://129.128.185.122/drugbank2/drugs/DB00612/inserts/458/full
Bisoprolol is a competitive, beta(1)-selective (cardioselective) adrenergic antagonist. Bisoprolol is used to treat hypertension, arrhythmias, coronary heart disease, glaucoma, and is also used to reduce non-fatal cardiac events in patients with heart failure. Activation of beta(1)-receptors (located mainly in the heart) by epinephrine increases the heart rate and the blood pressure, and the heart consumes more oxygen. Drugs such as Bisoprolol that block these receptors therefore have the reverse effect: they lower the heart rate and blood pressure and hence are used in conditions when the heart itself is deprived of oxygen. They are routinely prescribed in patients with ischemic heart disease. In addition, beta(1)-selective blockers prevent the release of renin, which is a hormone produced by the kidneys which leads to constriction of blood vessels. Bisoprolol is lipophilic and exhibits no intrinsic sympathomimetic activity (ISA) or membrane stabilizing activity.
Condyline
Bisoprolol Fumarate
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3734
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3734%3E
80%
Ziac (bisoprolol + hydrochlorothiazide)
Cardicor
InChI=1/C18H31NO4/c1-14(2)19-11-17(20)13-23-18-7-5-16(6-8-18)12-21-9-10-22-15(3)4/h5-8,14-15,17,19-20H,9-13H2,1-4H3
aprd00257
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1984
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1984%3E
Soloc
Bisoprolol fumerate
Euradal
CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1
http://129.128.185.122/drugbank2/drugs/DB00612/inserts/2372/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00612%2Finserts%2F2372%2Ffull%3E
Emconcor
Bisoprolol selectively blocks catecholamine stimulation of beta(1)-adrenergic receptors in the heart and vascular smooth muscle. This results in a reduction of heart rate, cardiac output, systolic and diastolic blood pressure, and possibly reflex orthostatic hypotension. Bisoprolol can also competitively block beta(2)-adrenergic responses in the bronchial and vascular smooth muscles, causing bronchospasm.
http://129.128.185.122/drugbank2/drugs/DB00612/inserts/1374/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00612%2Finserts%2F1374%2Ffull%3E
http://www.rxlist.com/cgi/generic3/bisoprolol.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric3%2Fbisoprolol.htm%3E
Emcor
http://bio2rdf.org/cpd:C06852
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC06852%3E
http://dbpedia.org/page/Bisoprolol
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FBisoprolol%3E
http://www.drugbank.ca/drugs/DB00612
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00612%3E
/drugs/612/safety_sheets/846
R. Jonas et al.;U.S. pat. 4,258,062 (1978,1981)
DB00612
Monocor
1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB00938
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB00575
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB01001
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB01310
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB01308
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB01306
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00414_DB00612
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB00696
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB00871
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00320_DB00612
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB01253
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB00247
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB01309
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB01289
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB00414
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB01067
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB00816
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00983_DB00612
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB00328
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB01050
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB00839
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00668_DB00612
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB01045
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB01064
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB00661
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01308_DB00612
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB00554
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00696_DB00612
RDF Description of Bisoprolol
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB01366
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00247_DB00612
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB00457
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00280_DB00612
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00816_DB00612
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01050_DB00612
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00554_DB00612
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00328_DB00612
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00672_DB00612
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB01016
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB01307
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB00280
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB01287
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB00281
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB00668
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00236_DB00612
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01045_DB00612
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB00672
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00871_DB00612
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01016_DB00612
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00457_DB00612
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB01291
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01120_DB00612
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB00320
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00575_DB00612
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB01382
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB01120
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00612_DB01124
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Layamon
_:header10726198541335206636423
Mon, 23 Apr 2012 18:37:11 GMT
RDF Description of Layamon
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Layamon
Layamon
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext14305
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/NEFL
_:header10268822621335206636801
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/NEFL
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1832
http://symbol.bio2rdf.org/symbol:NEFL
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ANEFL%3E
NEFL
http://www.dbpedia.org/resource/NEFL
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FNEFL%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1837
RDF Description of NEFL
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/4924
_:header13111023601335206637355
Mon, 23 Apr 2012 18:37:12 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4924
Cytochrome P450 2C8
EC 1.14.14.1
>Cytochrome P450 2C8	MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDICKSFTNFSKV	YGPVFTVYFGMNPIVVFHGYEAVKEALIDNGEEFSGRGNSPISQRITKGLGIISSNGKRW	KEIRRFSLTTLRNFGMGKRSIEDRVQEEAHCLVEELRKTKASPCDPTFILGCAPCNVICS	VVFQKRFDYKDQNFLTLMKRFNENFRILNSPWIQVCNNFPLLIDCFPGTHNKVLKNVALT	RSYIREKVKEHQASLDVNNPRDFIDCFLIKMEQEKDNQKSEFNIENLVGTVADLFVAGTE	TTSTTLRYGLLLLLKHPEVTAKVQEEIDHVIGRHRSPCMQDRSHMPYTDAVVHEIQRYSD	LVPTGVPHAVTTDTKFRNYLIPKGTTIMALLTSVLHDDKEFPNPNIFDPGHFLDKNGNFK	KSDYFMPFSAGKRICAGEGLARMELFLFLTTILQNFNLKSVDDLKNLNTTAVTKGIVSLP	PSYQICFIPV
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3500169
CP2C8_HUMAN
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2009263
http://bio2rdf.org/hgnc:2622
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A2622%3E
CYP2C8
http://www.pdb.org/pdb/explore/explore.do?structureId=1PQ2
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1PQ2%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=2622
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D2622%3E
P450 form 1
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3697070
>1473 bp	ATGGAACCTTTTGTGGTCCTGGTGCTGTGTCTCTCTTTTATGCTTCTCTTTTCACTCTGG	AGACAGAGCTGTAGGAGAAGGAAGCTCCCTCCTGGCCCCACTCCTCTTCCTATTATTGGA	AATATGCTACAGATAGATGTTAAGGACATCTGCAAATCTTTCACCAATTTCTCAAAAGTC	TATGGTCCTGTGTTCACCGTGTATTTTGGCATGAATCCCATAGTGGTGTTTCATGGATAT	GAGGCAGTGAAGGAAGCCCTGATTGATAATGGAGAGGAGTTTTCTGGAAGAGGCAATTCC	CCAATATCTCAAAGAATTACTAAAGGACTTGGAATCATTTCCAGCAATGGAAAGAGATGG	AAGGAGATCCGGCGTTTCTCCCTCACAAACTTGCGGAATTTTGGGATGGGGAAGAGGAGC	ATTGAGGACCGTGTTCAAGAGGAAGCTCACTGCCTTGTGGAGGAGTTGAGAAAAACCAAG	GCTTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCC	GTTGTTTTCCAGAAACGATTTGATTATAAAGATCAGAATTTTCTCACCCTGATGAAAAGA	TTCAATGAAAACTTCAGGATTCTGAACTCCCCATGGATCCAGGTCTGCAATAATTTCCCT	CTACTCATTGATTGTTTCCCAGGAACTCACAACAAAGTGCTTAAAAATGTTGCTCTTACA	CGAAGTTACATTAGGGAGAAAGTAAAAGAACACCAAGCATCACTGGATGTTAACAATCCT	CGGGACTTTATGGATTGCTTCCTGATCAAAATGGAGCAGGAAAAGGACAACCAAAAGTCA	GAATTCAATATTGAAAACTTGGTTGGCACTGTAGCTGATCTATTTGTTGCTGGAACAGAG	ACAACAAGCACCACTCTGAGATATGGACTCCTGCTCCTGCTGAAGCACCCAGAGGTCACA	GCTAAAGTCCAGGAAGAGATTGATCATGTAATTGGCAGACACAGGAGCCCCTGCATGCAG	GATAGGAGCCACATGCCTTACACTGATGCTGTAGTGCACGAGATCCAGAGATACAGTGAC	CTTGTCCCCACCGGTGTGCCCCATGCAGTGACCACTGATACTAAGTTCAGAAACTACCTC	ATCCCCAAGGGCACAACCATAATGGCATTACTGACTTCCGTGCTACATGATGACAAAGAA	TTTCCTAATCCAAATATCTTTGACCCTGGCCACTTTCTAGATAAGAATGGCAACTTTAAG	AAAAGTGACTACTTCATGCCTTTCTCAGCAGGAAAACGAATTTGTGCAGGAGAAGGACTT	GCCCGCATGGAGCTATTTTTATTTCTAACCACAATTTTACAGAACTTTAACCTGAAATCT	GTTGATGATTTAAAGAACCTCAATACTACTGCAGTTACCAAAGGGATTGTTTCTCTGCCA	CCCTCATACCAGATCTGCTTCATCCCTGTCTGA
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2729895
http://www.uniprot.org/uniprot/P10632
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP10632%3E
10q23.33
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=M17397
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DM17397%3E
CYPIIC8
P450 MP- 12/MP-20
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme responsible for the metabolism the anti- cancer drug paclitaxel (taxol)
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7574697
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3196692
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2216732
M17397
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/gene/CYP2C18
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fgene%2FCYP2C18%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1707679
http://bio2rdf.org/pdb:1PQ2
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1PQ2%3E
S-mephenytoin 4-hydroxylase
P450 IIC2
http://bio2rdf.org/uniprot:P10632
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP10632%3E
RDF Description of Cytochrome P450 2C8
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/1129
_:header11762223281335206637748
RDF Description of C-C chemokine receptor type 5
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/1129
CD195 antigen
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10089882
278-301
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9343222
CHEMR13
G-protein chemoattractant receptor activity
http://www.genenames.org/data/hgnc_data.php?hgnc_id=1606
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D1606%3E
3p21.31
C-C chemokine receptor activity
199-218
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8649511
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9388201
CCR5
C-C chemokine receptor type 5
peptide receptor activity, G-protein coupled
Involved in C-C chemokine receptor activity
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/gene/CCR5
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fgene%2FCCR5%3E
CC-CKR-5
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8699119
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9359654
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=1262811
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D1262811%3E
>1059 bp	ATGGATTATCAAGTGTCAAGTCCAATCTATGACATCAATTATTATACATCGGAGCCCTGC	CAAAAAATCAATGTGAAGCAAATCGCAGCCCGCCTCCTGCCTCCGCTCTACTCACTGGTG	TTCATCTTTGGTTTTGTGGGCAACATGCTGGTCATCCTCATCCTGATAAACTGCAAAAGG	CTGAAGAGCATGACTGACATCTACCTGCTCAACCTGGCCATCTCTGACCTGTTTTTCCTT	CTTACTGTCCCCTTCTGGGCTCACTATGCTGCCGCCCAGTGGGACTTTGGAAATACAATG	TGTCAACTCTTGACAGGGCTCTATTTTATAGGCTTCTTCTCTGGAATCTTCTTCATCATC	CTCCTGACAATCGATAGGTACCTGGCTGTCGTCCATGCTGTGTTTGCTTTAAAAGCCAGG	ACGGTCACCTTTGGGGTGGTGACAAGTGTGATCACTTGGGTGGTGGCTGTGTTTGCGTCT	CTCCCAGGAATCATCTTTACCAGATCTCAAAAAGAAGGTCTTCATTACACCTGCAGCTCT	CATTTTCCATACAGTCAGTATCAATTCTGGAAGAATTTCCAGACATTAAAGATAGTCATC	TTGGGGCTGGTCCTGCCGCTGCTTGTCATGGTCATCTGCTACTCGGGAATCCTAAAAACT	CTGCTTCGGTGTCGAAATGAGAAGAAGAGGCACAGGGCTGTGAGGCTTATCTTCACCATC	ATGATTGTTTATTTTCTCTTCTGGGCTCCCTACAACATTGTCCTTCTCCTGAACACCTTC	CAGGAATTCTTTGGCCTGAATAATTGCAGTAGCTCTAACAGGTTGGACCAAGCTATGCAG	GTGACAGAGACTCTTGGGATGACGCACTGCTGCATCAACCCCATCATCTATGCCTTTGTC	GGGGAGAAGTTCAGAAACTACCTCTTAGTCTTCTTCCAAAAGCACATTGCCAAACGCTTC	TGCAAATGCTGTTCTATTTTCCAGCAAGAGGCTCCCGAGCGAGCAAGCTCAGTTTACACC	CGATCCACTGGGGAGCAGGAAATATCTGTGGGCTTGTGA
CCR-5
>C-C chemokine receptor type 5	MDYQVSSPIYDINYYTSEPCQKINVKQIAARLLPPLYSLVFIFGFVGNMLVILILINCKR	LKSMTDIYLLNLAISDLFFLLTVPFWAHYAAAQWDFGNTMCQLLTGLYFIGFFSGIFFII	LLTIDRYLAVVHAVFALKARTVTFGVVTSVITWVVAVFASLPGIIFTRSQKEGLHYTCSS	HFPYSQYQFWKNFQTLKIVILGLVLPLLVMVICYSGILKTLLRCRNEKKRHRAVRLIFTI	MIVYFLFWAPYNIVLLLNTFQEFFGLNNCSSSNRLDQAMQVTETLGMTHCCINPIIYAFV	GEKFRNYLLVFFQKHIAKRFCKCCSIFQQEAPERASSVYTRSTGEQEISVGL
http://www.dbpedia.org/resource/C-C_chemokine_receptor_type_7
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FC-C_chemokine_receptor_type_7%3E
chemokine receptor activity
HIV-1 fusion coreceptor
142-166
X91492
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8663314
69-89
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8639485
CCR5_HUMAN
C-C CKR-5
http://bio2rdf.org/hgnc:1606
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A1606%3E
http://bio2rdf.org/uniprot:P51681
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP51681%3E
103-124
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8649512
31-58
http://www.uniprot.org/uniprot/P51681
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP51681%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=X91492
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DX91492%3E
http://symbol.bio2rdf.org/symbol:CCR5
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ACCR5%3E
Receptor for a C-C type chemokine. Binds to MIP-1-alpha, MIP-1-beta and RANTES and subsequently transduces a signal by increasing the intracellular calcium ions level. May play a role in the control of granulocytic lineage proliferation or differentiation. Acts as a coreceptor (CD4 being the primary receptor) for HIV-1 R5 isolates
236-260
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04835
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/771
_:header1568311991335206638171
Mon, 23 Apr 2012 18:37:13 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/771
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3193
Monilethrix
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/KRTHB6
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/KRTHB1
http://www.dbpedia.org/resource/Monilethrix
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FMonilethrix%3E
RDF Description of Monilethrix
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3192
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01111
_:header13791994321335206638639
RDF Description of Colistimethate
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01111
http://bio2rdf.org/cpd:C13553
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC13553%3E
Colistimethale Sodium
Colistimethate is a surface active agent which penetrates into and disrupts the bacterial cell membrane. Colistimethate is polycationic and has both hydrophobic and lipophilic moieties. It interacts with the bacterial cytoplasmic membrane, changing its permeability. This effect is bactericidal. There is also evidence that polymyxins enter the cell and precipitate cytoplasmic components, primarily ribosomes.
Colistimethate is a polymyxin antibiotic agent. Originally, colistimethate sodium was thought to be less toxic than polymyxin B; however, if the drugs are administered at comparable doses, their toxicities may be similar. Polymyxins are cationic polypeptides that disrupt the bacterial cell membrane through a detergentlike mechanism. With the development of less toxic agents, such as extended-spectrum penicillins and cephalosporins, parenteral polymyxin use was largely abandoned, except for the treatment of multidrug-resistant pulmonary infections in patients with cystic fibrosis. More recently, however, the emergence of multidrug-resistant gram-negative bacteria, such as <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i>, and the lack of new antimicrobial agents have led to the revived use of the polymyxins.
aprd00885
http://129.128.185.122/drugbank2/drugs/DB01111/inserts/1931/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB01111%2Finserts%2F1931%2Ffull%3E
http://205.193.93.51/dpdonline/searchRequest.do?din=02244849
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02244849%3E
http://www.drugbank.ca/drugs/DB01111
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01111%3E
Very poor absorption from gastrointestinal tract.
Colistimethate sodium
[Na+].[Na+].[Na+].[Na+].[Na+].CCC(C)CCCCC(=O)NC(CCNCS([O-])(=O)=O)C(=O)NC(C(C)O)C(=O)NC(CCNCS([O-])(=O)=O)C(=O)NC1CCNC(=O)C(NC(=O)C(CCNCS([O-])(=O)=O)NC(=O)C(CCNCS([O-])(=O)=O)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCNCS([O-])(=O)=O)NC1=O)C(C)O
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/70
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F70%3E
Colistin methanesulfonate sodium salt
Coly-Mycin M
4.11e+00 mg/mL
InChI=1/C58H110N16O28S5.5Na/c1-9-35(6)12-10-11-13-46(77)65-38(14-20-59-28-103(88,89)90)53(82)74-48(37(8)76)58(87)70-41(17-23-62-31-106(97,98)99)50(79)68-43-19-25-64-57(86)47(36(7)75)73-54(83)42(18-24-63-32-107(100,101)102)67-49(78)39(15-21-60-29-104(91,92)93)69-55(84)44(26-33(2)3)72-56(85)45(27-34(4)5)71-52(81)40(66-51(43)80)16-22-61-30-105(94,95)96;;;;;/h33-45,47-48,59-63,75-76H,9-32H2,1-8H3,(H,64,86)(H,65,77)(H,66,80)(H,67,78)(H,68,79)(H,69,84)(H,70,87)(H,71,81)(H,72,85)(H,73,83)(H,74,82)(H,88,89,90)(H,91,92,93)(H,94,95,96)(H,97,98,99)(H,100,101,102);;;;;/q;5*+1/p-5/fC58H105N16O28S5.5Na/h64-74H;;;;;/q-5;5m
Colistimethate
2006-01-01	/drugs/1111/fda_labels/103
2-3 hours following either intravenous or intramuscular administration in adults and in the pediatric population, including premature infants.
/drugs/1111/safety_sheets/1339
http://www.dbpedia.org/resource/Colistin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FColistin%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/powderForSolutionIntramuscular
http://129.128.185.122/drugbank2/drugs/DB01111/inserts/916/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB01111%2Finserts%2F916%2Ffull%3E
Colistin sodium methanesulfonate
http://bio2rdf.org/kegg:D02049
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD02049%3E
Coly-Mycin
pentasodium [[4-[[3-hydroxy-1-[[1-[[3-(1-hydroxyethyl)-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-6,9,18-tris[2-(sulfonatomethylamino)ethyl]-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]-1-oxo-4-(sulfonatomethylamino)butan-2-yl]amino]-1-oxobutan-2-yl]amino]-3-(6-methyloctanoylamino)-4-oxobutyl]amino]methanesulfonate
Colistin sodium methanesulfonate from bacillus colistinus
For the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly <i>Pseudomonas aeruginosa</i>.
http://bio2rdf.org/cas:8068-28-8
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A8068-28-8%3E
[Na+].[Na+].[Na+].[Na+].[Na+].CC[C@@H](C)CCCCC(=O)N[C@H](CCNCS([O-])(=O)=O)C(=O)N[C@H]([C@@H](C)O)C(=O)N[C@H](CCNCS([O-])(=O)=O)C(=O)N[C@@H]1CCNC(=O)[C@H](NC(=O)[C@@H](CCNCS([O-])(=O)=O)NC(=O)[C@@H](CCNCS([O-])(=O)=O)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CCNCS([O-])(=O)=O)NC1=O)[C@@H](C)O
DB01111
Gram-negative bacilli
C58H105N16Na5O28S5
Colistimethate is an antibiotic that has been shown to have bactericidal activity against aerobic gram-negative microorganisms. Colistimethate is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa.
Appreciable
2008-08-26 16:25:09 UTC
As 80% of the dose can be recovered unchanged in the urine, and there is no biliary excretion, it can be assumed that the remaining drug is inactivated in the tissues, however the mechanism is unknown.
IQWHCHZFYPIVRV-JGRPBGHACC
http://www.rxlist.com/cgi/generic2/colistimethate.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric2%2Fcolistimethate.htm%3E
Oral LD<sub>50</sub> in rats is 5450 mg/kg. Overdosage with colistimethate can cause neuromuscular blockade characterized by paresthesia, lethargy, confusion, dizziness, ataxia, nystagmus, disorders of speech and apnea. Respiratory muscle paralysis may lead to apnea, respiratory arrest and death.
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/2148
_:header2484327081335206639075
RDF Description of aminohippuric acid
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2148
CID0000002148
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000002148
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000002148%3E
aminohippuric acid
http://dbpedia.org/resource/Aminohippuric_acid
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FAminohippuric_acid%3E
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000002148&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000002148%26input_query_species%3D9606%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00345
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00345%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2493
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2493%3E
http://sideeffects.embl.de/drugs/2148
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F2148%3E
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Tyrrell_George_1861-1909
_:header13291840341335206639550
Mon, 23 Apr 2012 18:37:14 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Tyrrell_George_1861-1909
Tyrrell, George, 1861-1909
RDF Description of Tyrrell, George, 1861-1909
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext10139
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/2619
_:header14035687651335206640005
RDF Description of 6-phospho-beta-galactosidase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2619
A 6-phospho-beta-D-galactoside + H(2)O = 6- phospho-D-galactose + an alcohol
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=149400
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D149400%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=M28357
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DM28357%3E
6-phospho-beta-galactosidase
Beta-D-phosphogalactoside galactohydrolase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2125052
PBG
http://www.pdb.org/pdb/explore/explore.do?structureId=3PBG
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D3PBG%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2515252
disaccharide metabolism
http://www.uniprot.org/uniprot/P11546
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP11546%3E
LACG_LACLA
http://bio2rdf.org/pdb:3PBG
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A3PBG%3E
EC 3.2.1.85
M28357
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9223646
lactose catabolism via tagatose-6-phosphate
lactose metabolism
http://bio2rdf.org/pfam:PF00232
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00232%3E
cellular carbohydrate metabolism
PGALase
>6-phospho-beta-galactosidase	MTKTLPKDFIFGGATAAYQAEGATHTDGKGPVAWDKYLEDNYWYTAEPASDFYHKYPVDL	ELAEEYGVNGIRISIAWSRIFPTGYGEVNEKGVEFYHKLFAECHKRHVEPFVTLHHFDTP	EALHSNGDFLNRENIEHFIDYAAFCFEEFPEVNYWTTFNEIGPIGDGQYLVGKFPPGIKY	DLAKVFQSHHNMMVSHARAVKLYKDKGYKGEIGVVHALPTKYPYDPENPADVRAAELEDI	IHNKFILDATYLGHYSDKTMEGVNHILAENGGELDLRDEDFQALDAAKDLNDFLGINYYM	SDWMQAFDGETEIIHNGKGEKGSSKYQIKGVGRRVAPDYVPRTDWDWIIYPEGLYDQIMR	VKNDYPNYKKIYITENGLGYKDEFVDNTVYDDGRIDYVKQHLEVLSDAIADGANVKGYFI	WSLMDVFSWSNGYEKRYGLFYVDFDTQERYPKKSAHWYKKLAETQVIE
lacG
lactose catabolism
http://pfam.sanger.ac.uk/family?acc=PF00232
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00232%3E
a 6-phospho-beta-D-galactoside + H2O = 6-phospho-D-galactose + an alcohol
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3130294
http://bio2rdf.org/uniprot:P11546
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP11546%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1339371
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8535789
P-beta-Gal
>1407 bp	ATGACTAAAACACTTCCTAAAGATTTTATTTTTGGTGGTGCTACAGCTGCTTATCAAGCA	GAAGGTGCAACTCACACAGATGGTAAGGGCCCAGTAGCATGGGATAAGTATCTTGAAGAC	AATTATTGGTATACAGCAGAACCTGCAAGTGATTTTTACCATAAATACCCAGTTGATTTA	GAATTAGCTGAAGAATATGGTGTTAATGGTATTCGTATTTCTATTGCCTGGTCTCGTATT	TTCCCAACGGGTTACGGTGAAGTAAATGAAAAAGGTGTTGAATTCTACCATAAACTATTT	GCTGAATGCCACAAGCGTCATGTTGAACCATTTGTGACTTTGCATCATTTTGACACACCA	GAAGCTCTTCATTCAAATGGAGATTTCTTAAACCGCGAAAATATAGAACACTTTATAGAT	TATGCCGCTTTCTGTTTTGAAGAGTTTCCAGAAGTAAACTACTGGACAACTTTCAATGAA	ATTGGCCCAATTGGTGATGGTCAATACTTGGTTGGTAAATTCCCTCCAGGCATTAAATAT	GATCTTGCCAAAGTCTTCCAATCACACCACAACATGATGGTCTCTCATGCACGTGCTGTA	AAATTGTATAAGGATAAAGGTTATAAAGGTGAAATTGGTGTTGTTCATGCTTTACCAACT	AAATACCCTTATGATCCGGAAAATCCAGCAGATGTTCGTGCTGCTGAACTTGAAGACATC	ATCCATAACAAATTTATCTTGGATGCAACCTATCTTGGGCACTATTCAGATAAAACGATG	GAAGGTGTCAACCATATCCTAGCTGAGAATGGTGGAGAACTTGATCTTCGTGATGAAGAC	TTCCAAGCTCTTGACGCAGCTAAAGATTTGAATGATTTCCTTGGTATCAACTATTACATG	AGTGATTGGATGCAAGCTTTTGATGGTGAGACTGAAATCATTCACAATGGTAAGGGTGAA	AAAGGAAGCTCTAAGTACCAAATTAAGGGTGTTGGTCGTCGAGTAGCTCCTGACTATGTT	CCGCGCACAGACTGGGATTGGATTATTTATCCTGAAGGCTTGTATGACCAAATCATGCGA	GTGAAAAATGATTATCCGAATTACAAGAAGATTTACATCACTGAAAACGGTCTCGGATAC	AAAGATCAGTTTGTAGATAAAACTGTTTATGATGATGGTCGTATTGATTACGTGAAGCAA	CACTTGGAAGTTTTATCAGACGCGATTGCGGATGGTGCAAATGTTAAAGGTTACTTCATT	TGGTCACTTATGGACGTTTTCTCATGGTCAAATGGTTATGAAAAACGTTATGGATTGTTC	TATGTAGACTTTGATACGCAAGAACGCTATCCTAAGAAATCAGCACATTGGTATAAGAAA	TTAGCAGAAACTCAAGTGATAGAGTAA
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02312
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Conant_James_Bryant_1893-1978
_:header15657211321335206640503
Mon, 23 Apr 2012 18:37:15 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Conant_James_Bryant_1893-1978
Conant, James Bryant, 1893-1978 
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1234
RDF Description of Conant, James Bryant, 1893-1978 
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/3652
_:header1161729291335206640974
RDF Description of HYDROXYCHLOROQUINE SULFATE
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/4284
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F4284%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3136
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3136%3E
http://sideeffects.embl.de/drugs/3652
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F3652%3E
http://www.fda.gov/cder/foi/label/2007/009768s041lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2007%2F009768s041lbl.pdf%3E
HYDROXYCHLOROQUINE SULFATE
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=ntBnuq1iDFk=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DntBnuq1iDFk%3D%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2963
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2963%3E
http://www.fda.gov/cder/foi/anda/98/40-274_Hydroxychloroquine%20Sulfate_Prntlbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Fanda%2F98%2F40-274_Hydroxychloroquine%2520Sulfate_Prntlbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/532
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F532%3E
PLAQUENIL
CID0000003652
hydroxychloroquine
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C1260926
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000003652&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000003652%26input_query_species%3D9606%3E
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=gTMBVPH%2Fx48=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DgTMBVPH%252Fx48%3D%3E
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000003652
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000003652%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00608
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00608%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/384
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F384%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0027868
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01611
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01611%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/484
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F484%3E
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=Aeb5Dwb7SI0=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DAeb5Dwb7SI0%3D%3E
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Southworth_Emma_Dorothy_Eliza_Nevitte_1819-1899
_:header18731542791335206641308
Mon, 23 Apr 2012 18:37:16 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Southworth_Emma_Dorothy_Eliza_Nevitte_1819-1899
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext15774
Southworth, Emma Dorothy Eliza Nevitte, 1819-1899
RDF Description of Southworth, Emma Dorothy Eliza Nevitte, 1819-1899
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6376
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext16094
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3792
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext16039
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext14382
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Muller_Fritz_1821-1897
_:header17153429351335206641737
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Muller_Fritz_1821-1897
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6475
Muller, Fritz, 1821-1897
RDF Description of Muller, Fritz, 1821-1897
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/ADD1
_:header7300861671335206642133
Mon, 23 Apr 2012 18:37:17 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/ADD1
http://symbol.bio2rdf.org/symbol:ADD1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AADD1%3E
ADD1
http://bio2rdf.org/hgnc:243
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A243%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=243
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D243%3E
http://bio2rdf.org/geneid:118
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fgeneid%3A118%3E
http://www.dbpedia.org/resource/ADD1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FADD1%3E
RDF Description of ADD1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2700
http://www4.wiwiss.fu-berlin.de/dblp/data/person/205341
_:header9668140331335206642653
http://www4.wiwiss.fu-berlin.de/dblp/resource/person/205341
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/cacm/Ross64
Douglas T. Ross
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tse/RossS77
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/sigplan/Ross76
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/cacm/Ross61
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/icse/Ross89
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/cacm/Ross61b
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tse/Ross77a
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/cacm/Ross76
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/computer/Ross85a
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/ifip/Ross62
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/icse/RossS76
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/tse/Ross77
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/cacm/JohnsonPAR68
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/computer/Ross85
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/journals/cacm/Ross67a
RDF Description of Douglas T. Ross
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/MC3R
_:header8093397301335206642967
RDF Description of MC3R
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/MC3R
http://symbol.bio2rdf.org/symbol:MC3R
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AMC3R%3E
MC3R
http://www.dbpedia.org/resource/Melanocortin_3_receptor
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FMelanocortin_3_receptor%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3411
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/MC2R
_:header8403595371335206643226
Mon, 23 Apr 2012 18:37:18 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/MC2R
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2479
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/gene/MC2R
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fgene%2FMC2R%3E
http://symbol.bio2rdf.org/symbol:MC2R
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AMC2R%3E
MC2R
http://www.dbpedia.org/resource/ACTH_receptor
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FACTH_receptor%3E
RDF Description of MC2R
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/454
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Calder%C3%B3n_de_la_Barca_Pedro_1600-1681
_:header19170998671335206643595
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Calderón_de_la_Barca_Pedro_1600-1681
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6372
Calderón de la Barca, Pedro, 1600-1681
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6363
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6371
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext12173
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Calderón_de_la_Barca_Pedro_1600-1681
RDF Description of Calderón de la Barca, Pedro, 1600-1681
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/EDARADD
_:header10703025581335206643842
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/EDARADD
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2224
http://symbol.bio2rdf.org/symbol:EDARADD
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AEDARADD%3E
EDARADD
http://www.dbpedia.org/resource/EDARADD
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FEDARADD%3E
RDF Description of EDARADD
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/350
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0014544
_:header17624942451335206644139
Mon, 23 Apr 2012 18:37:19 GMT
http://dbpedia.org/resource/Seizure
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FSeizure%3E
EPILEPSY
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F372%3E
epileptic
C0014544
http://sideeffects.embl.de/se/C0014544
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0014544%3E
seizure disorders
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/disease/Epilepsy
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fdisease%2FEpilepsy%3E
seizure disorder
epileptic seizures
epilepsies
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3291
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2749
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3821
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/1986
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3405
RDF Description of EPILEPSY
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/TRIM24
_:header3137007331335206644399
RDF Description of TRIM24
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/TRIM24
http://symbol.bio2rdf.org/symbol:TRIM24
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ATRIM24%3E
TRIM24
http://bio2rdf.org/hgnc:11812
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A11812%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=11812
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D11812%3E
http://bio2rdf.org/geneid:8805
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fgeneid%3A8805%3E
http://www.dbpedia.org/resource/TRIM24
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FTRIM24%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4062
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Church_Richard_William_1815-1890
_:header1183597691335206644807
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Church_Richard_William_1815-1890
Church, Richard William, 1815-1890
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13888
RDF Description of Church, Richard William, 1815-1890
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/3829
_:header731548181335206645027
Mon, 23 Apr 2012 18:37:20 GMT
RDF Description of Sarcoma, synovial
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3829
http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=312820
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fdispomim.cgi%3Fid%3D312820%3E
Sarcoma, synovial
http://data.linkedct.org/resource/condition/11754
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fcondition%2F11754%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/SSRC
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/SSX1
http://bio2rdf.org/omim:312820
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fomim%3A312820%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1020
http://www4.wiwiss.fu-berlin.de/diseasome/resource/chromosomalLocation/Xp11.2
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/SERPINA3
_:header12968788801335206645311
RDF Description of SERPINA3
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/SERPINA3
http://symbol.bio2rdf.org/symbol:SERPINA3
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ASERPINA3%3E
SERPINA3
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1390
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/65
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/211
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1811
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00639
_:header128739561335206645633
RDF Description of Butoconazole
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00639
http://en.wikipedia.org/wiki/Butoconazole
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FButoconazole%3E
http://data.linkedct.org/resource/intervention/61611
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F61611%3E
http://www.drugbank.ca/drugs/DB00639
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00639%3E
Butoconazole is an imidazole derivative that has fungicidal activity <i>in vitro</i> against <i>Candida</i> spp. and has been demonstrated to be clinically effective against vaginal infections due to <i>Candida albicans</i>. <i>Candida albicans</i> has been identified as the predominant species responsible for vulvovaginal candidasis.
G01AF15
http://www.rxlist.com/cgi/generic2/butoconazole.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric2%2Fbutoconazole.htm%3E
DB00639
PA448701
http://dbpedia.org/page/Butoconazole
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FButoconazole%3E
http://129.128.185.122/drugbank2/drugs/DB00639/inserts/181/full
SWLMUYACZKCSHZ-UHFFFAOYAD
Butoconazolum [INN-Latin]
Femstat
Melts at about 159��C with decomposition (nitrate salt)
8.18e-04 mg/mL
http://bio2rdf.org/cas:64872-77-1
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A64872-77-1%3E
http://www.dbpedia.org/resource/Butoconazole
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FButoconazole%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/761
C19H17Cl3N2S
Butoconazole nitrate
aprd00834
Butoconazole is an imidazole antifungal used in gynecology.
/drugs/639/safety_sheets/769
http://129.128.185.122/drugbank2/drugs/DB00639/inserts/961/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00639%2Finserts%2F961%2Ffull%3E
Nitrate salt: 0.26 mg/ml (practically insoluble)
For the local treatment of vulvovaginal candidiasis (infections caused by Candida)
Oral, rat: LD<sub>50</sub> = >1720 mg/kg.
http://205.193.93.51/dpdonline/searchRequest.do?din=02248417
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02248417%3E
1-[4-(4-chlorophenyl)-2-(2,6-dichlorophenyl)sulfanylbutyl]imidazole
http://bio2rdf.org/cpd:C08066
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC08066%3E
http://bio2rdf.org/kegg:D00880
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD00880%3E
Butoconazole
2008-08-26 16:38:03 UTC
Butoconazol [INN-Spanish]
2003-05-01	/drugs/639/fda_labels/279
Femstat 3
ClC1=CC=C(CCC(CN2C=CN=C2)SC2=C(Cl)C=CC=C2Cl)C=C1
Following vaginal administration of butoconazole nitrate vaginal cream, 2% to 3 women, 1.7% (range 1.3-2.2%) of the dose was absorbed on average.
84:04.08.08
Fungi, yeast and protozoans
ClC1=CC=C(CC[C@H](CN2C=CN=C2)SC2=C(Cl)C=CC=C2Cl)C=C1
InChI=1/C19H17Cl3N2S/c20-15-7-4-14(5-8-15)6-9-16(12-24-11-10-23-13-24)25-19-17(21)2-1-3-18(19)22/h1-5,7-8,10-11,13,16H,6,9,12H2
Gynazole-1
http://dbpedia.org/resource/Butoconazole
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FButoconazole%3E
The exact mechanism of the antifungal action of butoconazole is unknown, however, it is presumed to function as other imidazole derivatives via inhibition of steroid synthesis. Imidazoles generally inhibit the conversion of lanosterol to ergosterol via the inhibition of the enzyme cytochrome P450 14&alpha;-demethylase, resulting in a change in fungal cell membrane lipid composition. This structural change alters cell permeability and, ultimately, results in the osmotic disruption or growth inhibition of the fungal cell.
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/myc1567.shtml
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Glyn_Elinor_1864-1943
_:header8541647291335206645952
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Glyn_Elinor_1864-1943
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext16692
Glyn, Elinor, 1864-1943
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext20718
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9470
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext13530
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext8899
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext11624
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17048
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext12450
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17821
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext11900
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext20512
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5310
RDF Description of Glyn, Elinor, 1864-1943
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext10959
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9809
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00438
_:header1668552651335206646227
Mon, 23 Apr 2012 18:37:21 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00438
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00438_DB00798
Semisynthetic, broad-spectrum antibacterial derived from cephaloridine and used especially for Pseudomonas and other gram-negative infections in debilitated patients. [PubChem]
Fortaz In Plastic Container
396 mg/L
http://dbpedia.org/resource/Ceftazidime
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FCeftazidime%3E
http://129.128.185.122/drugbank2/drugs/DB00438/inserts/2556/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00438%2Finserts%2F2556%2Ffull%3E
Ceftazidima [INN-Spanish]
aprd00857
The bactericidal activity of ceftazidime results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs).
ORFOPKXBNMVMKC-OFCFLKAKDM
For the treatment of patients with infections caused by susceptible strains of organisms in the following diseases: lower respiratory tract infections,skin and skin structure infections, urinary tract infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra abdominal infections (including peritonitis), and central nervous system infections (including meningitis).
Ceptaz
http://dbpedia.org/page/Ceftazidime
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FCeftazidime%3E
CAZ
PA448861
Ceftazidimum [INN-Latin]
5.73e-03 mg/mL
http://129.128.185.122/drugbank2/drugs/DB00438/inserts/1562/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00438%2Finserts%2F1562%2Ffull%3E
http://www.rxlist.com/cgi/generic2/ceftaz.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric2%2Fceftaz.htm%3E
http://data.linkedct.org/resource/intervention/16475
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F16475%3E
InChI=1/C22H22N6O7S2/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34)/b26-13-/t14-,18-/m1/s1/f/h25,33H,23H2
http://bio2rdf.org/cpd:C06889
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC06889%3E
Fortaz
http://bio2rdf.org/cas:78439-06-2
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A78439-06-2%3E
/drugs/438/safety_sheets/1352
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2369
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2369%3E
Ceftazidime
http://en.wikipedia.org/wiki/Ceftazidime
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FCeftazidime%3E
Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.
http://www.drugbank.ca/drugs/DB00438
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00438%3E
Tazicef
Ceftazidime overdosage has occurred in patients with renal failure. Reactions have included seizure activity, encephalopathy, asterixis, neuromuscular excitability, and coma.
The absorption of ceftazidime is directly proportional to the size of the dose.
Tazidime In Plastic Container
2002-03-01	/drugs/438/fda_labels/479
2008-08-26 16:47:47 UTC
DB00438
Pentacef
Ceftazidime pentahydrate
(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
CC(C)(ON=C(C(=O)NC1C2SCC(C[N+]3=CC=CC=C3)=C(N2C1=O)C([O-])=O)C1=CSC(N)=N1)C(O)=O
C22H22N6O7S2
08:12.06.12
http://205.193.93.51/dpdonline/searchRequest.do?din=00886963
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D00886963%3E
http://data.linkedct.org/resource/intervention/33936
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F33936%3E
Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic for parenteral administration. Ceftazidime is bactericidal in action exerting its effect by inhibition of enzymes responsible for cell-wall synthesis. A wide range of gram-negative organisms is susceptible to ceftazidime in vitro, including strains resistant to gentamicin and other aminoglycosides. In addition, ceftazidime has been shown to be active against gram-positive organisms. It is highly stable to most clinically important beta-lactamases, plasmid or chromosomal, which are produced by both gram-negative and gram-positive organisms and, consequently, is active against many strains resistant to ampicillin and other cephalosporins. Ceftazidime has activity against the gram-negative organisms <i>Pseudomonas</i> and <i>Enterobacteriaceae</i>. Its activity against <i>Pseudomonas</i> is a distinguishing feature of ceftazidime among the cephalosporins.
CC(C)(ON=C(C(=O)N[C@H]1[C@H]2SCC(C[N+]3=CC=CC=C3)=C(N2C1=O)C([O-])=O)C1=CSC(N)=N1)C(O)=O
J01DD02
Ceftazidime Sodium In Plastic Container
< 10%
Tazidime
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00798_DB00438
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00438_DB00955
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00955_DB00438
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00438_DB00994
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00438_DB01172
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00438_DB00684
RDF Description of Ceftazidime
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00479_DB00438
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00438_DB00479
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00438_DB01082
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00684_DB00438
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB06439
_:header8561939481335206646506
RDF Description of Tyloxapol
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB06439
http://dbpedia.org/page/Tyloxapol
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FTyloxapol%3E
http://www.drugbank.ca/drugs/DB06439
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB06439%3E
2008-08-27 22:04:43 UTC
2008-03-19 16:33:35 UTC
Alevaire
CN(C(=O)COC1=CC=CC=C1)C1=CC=CC=C1C(=O)NCC1=CC=CO1
N-(furan-2-ylmethyl)-2-[methyl-[2-(phenoxy)acetyl]amino]benzamide
DB06439
SGSZAVKEVSVBPS-QWOVJGMICH
C21H20N2O4
Tyloxapol is a non-ionic detergent often used as a surfactant.
Tyloxapol, when injected IP, blocks plasma lipolytic activity, and thus the breakdown of triglyceride-rich lipoproteins. It has also been shown to be inhibitor of lipoprotein lipase, thus preventing triglyceride uptake.
http://dbpedia.org/resource/Tyloxapol
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FTyloxapol%3E
3.01e-02 mg/mL
http://bio2rdf.org/kegg:D03261
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD03261%3E
Tyloxapol
Used as a surfactant to aid liquefaction and removal of mucopurulent (containing mucus and pus) bronchopulmonary secretions, administered by inhalation through a nebulizer or with a stream of oxygen. Also investigated for use/treatment in cystic fibrosis and pediatric indications.
/drugs/6440/safety_sheets/1474
InChI=1/C21H20N2O4/c1-23(20(24)15-27-16-8-3-2-4-9-16)19-12-6-5-11-18(19)21(25)22-14-17-10-7-13-26-17/h2-13H,14-15H2,1H3,(H,22,25)/f/h22H
Macrocyclon
http://www.dbpedia.org/resource/Tyloxapol
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FTyloxapol%3E
Acute oral LD50 in 1000 mg/kg in mouse and 5000 mg/kg in rat.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/surface-activeAgents
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/detergents
SuperVent
http://en.wikipedia.org/wiki/Tyloxapol
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FTyloxapol%3E
PA451816
http://bio2rdf.org/cas:25301-02-4
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A25301-02-4%3E
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/HER2
_:header11004072861335206646761
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/HER2
http://symbol.bio2rdf.org/symbol:HER2
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AHER2%3E
HER2
RDF Description of HER2
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Guyot_Yves_1843-1928
_:header7344453571335206647036
Mon, 23 Apr 2012 18:37:22 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Guyot_Yves_1843-1928
Guyot, Yves, 1843-1928
RDF Description of Guyot, Yves, 1843-1928
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17968
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Sophocles_495?_BC-406_BC
_:header19853637731335206647326
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Sophocles_495?_BC-406_BC
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext806
Sophocles, 495? BC-406 BC
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext14484
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext17839
RDF Description of Sophocles, 495? BC-406 BC
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext31
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/1158
_:header3165658491335206647549
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1158
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4104
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/HPD
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00135
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00135%3E
Tyrosinemia
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00142%3E
http://www.dbpedia.org/resource/Tyrosinemia
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FTyrosinemia%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/FAH
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00348
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00348%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02850
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB02850%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00120
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00120%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/TAT
RDF Description of Tyrosinemia
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4106
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4105
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/4203
_:header8899412661335206647968
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4203
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00613
>Histamine N-methyltransferase	MASSMRSLFSDHGKYVESFRRFLNHSTEHQCMQEFMDKKLPGIIGRIGDTKSEIKILSIG	GGAGEIDLQILSKVQAQYPGVCINNEVVEPSAEQIAKYKELVAKTSNLENVKFAWHKETS	SEYQSRMLEKKELQKWDFIHMIQMLYYVKDIPATLKFFHSLLGTNAKMLIIVVSGSSGWD	KLWKKYGSRFPQDDLCQYITSDDLTQMLDNLGLKYECYDLLSTMDISDCFIDGNENGDLL	WDFLTETCNFNATAPPDLRAELGKDLQEPEFSAKKEGKVLFNNTLSFIVIEA
HMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/6789797
HNMT
Histamine N-methyltransferase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1203620
http://bio2rdf.org/uniprot:P50135
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP50135%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7943261
HNMT_HUMAN
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=D16224
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DD16224%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9547362
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10803682
2q22.1
D16224
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/17222819
>879 bp	ATGGCATCTTCCATGAGGAGCTTGTTTTCTGACCACGGGAAATATGTTGAATCTTTCCGG	AGGTTTCTCAACCATTCCACGGAACACCAGTGCATGCAGGAATTCATGGACAAGAAGCTG	CCAGGCATAATAGGAAGGATTGGAGACACAAAATCAGAAATTAAGATTCTAAGCATAGGC	GGAGGTGCAGGTGAAATTGATCTTCAAATTCTCTCCAAAGTTCAGGCTCAATACCCAGGA	GTTTGTATCAACAATGAAGTTGTTGAGCCAAGTGCTGAACAAATTGCCAAATACAAAGAG	CTTGTAGCCAAGACATCGAACCTCGAGAACGTAAAGTTTGCTTGGCATAAGGAGACATCA	TCTGAATACCAAAGTAGAATGTTGGAGAAAAAGGAGCTTCAAAAGTGGGACTTTATTCAT	ATGATTCAAATGCTGTATTATGTAAAAGACATCCCAGCTACCCTGAAATTCTTCCATAGT	CTCTTAGGTACCAATGCTAAGATGCTCATTATTGTTGTGTCAGGAAGCAGTGGCTGGGAC	AAGCTGTGGAAAAAGTACGGATCACGCTTTCCCCAGGATGACCTCTGCCAGTATGTCACA	TCAGATGACCTCACTCAGATGCTGGACAACCTAGGGCTTAAGTATGAGTGCTATGACCTT	TTGTCCACCATGGATATATCTGACTGCTTTATTGATGGTAATGAAAATGGAGACCTGCTT	TGGGATTTTTTGACTGAAACCTGCAACTTTAATGCCACAGCACCACCTGATCTCAGAGCA	GAGCTTGGGAAAGATCTACAAGAGCCTGAATTTAGTGCTAAGAAAGAGGGGAAGGTTCTT	TTTAATAATACTCTGAGTTTCATAGTGATTGAGGCATAA
http://bio2rdf.org/hgnc:5028
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A5028%3E
http://www.uniprot.org/uniprot/P50135
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP50135%3E
EC 2.1.1.8
Inactivates histamine by N-methylation. Plays an important role in degrading histamine and in regulating the airway response to histamine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8605025
http://www.pdb.org/pdb/explore/explore.do?structureId=1JQD
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1JQD%3E
http://bio2rdf.org/pdb:1JQD
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1JQD%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=5028
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D5028%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8145732
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04655
RDF Description of Histamine N-methyltransferase
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/2443
_:header8482456781335206648328
Mon, 23 Apr 2012 18:37:23 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2443
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03570
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10984043
X07317
>447 bp	ATGCTACGTAAACTCGCTGCGGTATCCCTGCTGTCCCTGCTCAGTGCGCCGCTGCTGGCT	GCCGAGTGCTCGGTGGACATCCAGGGTAACGACCAGATGCAGTTCAACACCAATGCCATC	ACCGTCGACAAGAGCTGCAAGCAGTTCACCGTCAACCTGTCCCACCCCGGCAACCTGCCG	AAGAACGTCATGGGCCACAACTGGGTACTGAGCACCGCCGCCGACATGCAGGGCGTGGTC	ACCGACGGCATGGCTTCCGGCCTGGACAAGGATTACCTGAAGCCCGACGACAGCCGCGTC	ATCGCCCACACCAAGCTGATCGGCTCGGGCGAGAAGGACTCGGTGACCTTCGACGTCTCC	AAGCTGAAGGAAGGCGAGCAGTACATGTTCTTCTGCACCTTCCCGGGCCACTCCGCGCTG	ATGAAGGGCACCCTGACCCTGAAGTGA
http://pfam.sanger.ac.uk/family?acc=PF00127
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00127%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2537198
Transfers electrons from cytochrome c551 to cytochrome oxidase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2116366
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1633865
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=45292
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D45292%3E
http://www.pdb.org/pdb/explore/explore.do?structureId=1JZJ
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1JZJ%3E
http://bio2rdf.org/pdb:1JZJ
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1JZJ%3E
http://bio2rdf.org/uniprot:P00282
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP00282%3E
http://www.uniprot.org/uniprot/P00282
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP00282%3E
http://bio2rdf.org/pfam:PF00127
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00127%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/98639
Azurin
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9047369
azu
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8568881
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1420141
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=X07317
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DX07317%3E
AZUR_PSEAE
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3100334
>Azurin precursor	MLRKLAAVSLLSLLSAPLLAAECSVDIQGNDQMQFNTNAITVDKSCKQFTVNLSHPGNLP	KNVMGHNWVLSTAADMQGVVTDGMASGLDKDYLKPDDSRVIAHTKLIGSGEKDSVTFDVS	KLKEGEQYMFFCTFPGHSALMKGTLTLK
electron transporter activity
Azurin precursor
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9100002
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02586
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04085
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02003
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03871
RDF Description of Azurin
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03840
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04231
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04550
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04100
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03492
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/BSCL2
_:header1690450931335206648673
RDF Description of BSCL2
http://symbol.bio2rdf.org/symbol:BSCL2
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ABSCL2%3E
BSCL2
http://bio2rdf.org/hgnc:15832
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A15832%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=15832
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D15832%3E
http://bio2rdf.org/geneid:26580
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fgeneid%3A26580%3E
http://www.dbpedia.org/resource/BSCL2
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FBSCL2%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3894
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3940
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1057
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/2415
_:header4642855641335206648888
RDF Description of Fucosidosis
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2415
http://data.linkedct.org/resource/condition/5050
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fcondition%2F5050%3E
Fucosidosis
http://bio2rdf.org/omim:230000
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fomim%3A230000%3E
http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=230000
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fdispomim.cgi%3Fid%3D230000%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/chromosomalLocation/1p34
http://www.dbpedia.org/resource/Fucosidosis
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FFucosidosis%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/424
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/FUCA1
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/3998
_:header7482272581335206649219
Mon, 23 Apr 2012 18:37:24 GMT
RDF Description of SULFAMYLON
SULFAMYLON
http://sideeffects.embl.de/drugs/3998
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F3998%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0220981
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000003998&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000003998%26input_query_species%3D9606%3E
http://dbpedia.org/resource/Mafenide
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FMafenide%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1346
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F1346%3E
CID0000003998
mafenide
http://www.fda.gov/cder/foi/label/1998/19832lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F1998%2F19832lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2331
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2331%3E
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000003998
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000003998%3E
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Gladden_Washington_1836-1918
_:header21426831041335206649441
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Gladden_Washington_1836-1918
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6928
Gladden, Washington, 1836-1918
Gladden, Washington, 1836-1918 
RDF Description of Gladden, Washington, 1836-1918
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext12290
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext12759
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/4603
_:header4414300381335206649768
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4603
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02157
Coagulation factor X
Stuart factor
>1462 bp	ATGGCGGGCCTGCTGCATCTCGTTCTGCTCAGCACCGCCCTGGGCGGCCTCCTGCGGCCG	GCGGGGAGCGTGTTCCTGCCCCGGGACCAGGCCCACCGTGTCCTGCAGAGAGCCCGCAGG	GCCAACTCATTCTTGGAGGAGGTGAAGCAGGGAAACCTGGAGCGAGAGTGCCTGGAGGAG	GCCTGCTCACTAGAGGAGGCCCGCGAGGTCTTCGAGGACGCAGAGCAGACGGATGAATTC	TGGAGTAAATACAAAGATGGAGACCAGTGTGAAGGCCACCCGTGCCTGAATCAGGGCCAC	TGTAAAGACGGCATCGGAGACTACACCTGCACCTGTGCGGAAGGGTTTGAAGGCAAAAAC	TGCGAGTTCTCCACGCGTGAGATCTGCAGCCTGGACAATGGAGGCTGCGACCAGTTCTGC	AGGGAGGAGCGCAGCGAGGTGCGGTGCTCCTGCGCGCACGGCTACGTGCTGGGCGACGAC	AGCAAGTCCTGCGTGTCCACAGAGCGCTTCCCCTGTGGGAAGTTCACGCAGGGACGCAGC	CGGCGGTGGGCCATCCACACCAGCGAGGACGCGCTTGACGCCAGCGAGCTGGAGCACTAC	GACCCTGCAGACCTGAGCCCCACAGAGAGCTCCTTGGACCTGCTGGGCCTCAACAGGACC	GAGCCCAGCGCCGGGGAGGACGGCAGCCAGGTGGTCCGGATAGTGGGCGGCAGGGACTGC	GCGGAGGGCGAGTGCCCATGGCAGGCTCTGCTGGTCAACGAAGAGAACGAGGGATTCTGC	GGGGGCACCATCCTGAACGAGTTCTACGTCCTCACGGCTGCCCACTGCCTGCACCAGGCC	AAGAGGTTCACGGTGAGGGTCGGCGACCGGAACACAGAGCAGGAGGAGGGCAACGAGATG	GCACACGAGGTGGAGATGACTGTGAAGCACAGCCGCTTTGTCAAGGAGACCTACGACTTC	GACATCGCGGTGCTGAGGCTCAAGACGCCCATCCGGTTCCGCCGGAACGTGGCGCCCGCC	TGCCTGCCCGAGAAGGACTGGGCGGAGGCCACGCTGATGACCCAGAAGACGGGCATCGTC	AGCGGCTTCGGGCGCACGCACGAGAAGGGCCGCCTGTCGTCCACGCTCAAGATGCTGGAG	GTGCCCTACGTGGACCGCAGCACCTGTAAGCTGTCCAGCAGCTTCACCATTACGCCCAAC	ATGTTCTGCGCCGGCTACGACACCCAGCCCGAGGACGCCTGCCAGGGCGACAGTGGCGGC	CCCCACGTCACCCGCTTCAAGGACACCTACTTCGTCACAGGCATCGTCAGCTGGGGAGAA	GGGTGCGCGCGCAAGGGCAAGTTCGGCGTCTACACCAAGGTCTCCAACTTCCTCAAGTGG	ATCGACAAGATCATGAAGGCCAGGGCAGGGGCCGCGGGCAGCCGCGGCCACAGTGAAGCC	CCTGCCACCTGGACGGTCCCGC
http://www.uniprot.org/uniprot/P00743
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP00743%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=X00673
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DX00673%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/4264286
X00673
http://bio2rdf.org/pfam:PF00089
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00089%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1059122
http://bio2rdf.org/pdb:1KIG
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1KIG%3E
Coagulation factor X precursor
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/6766735
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1059093
F10
http://pfam.sanger.ac.uk/family?acc=PF00594
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00594%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/6546930
Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting
EC 3.4.21.6
hemostasis
http://bio2rdf.org/uniprot:P00743
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP00743%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/6330671
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3949800
blood coagulation
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/6688526
FA10_BOVIN
http://bio2rdf.org/pfam:PF00594
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00594%3E
>Coagulation factor X	MAGLLHLVLLSTALGGLLRPAGSVFLPRDQAHRVLQRARRANSFLEEVKQGNLERECLEE	ACSLEEAREVFEDAEQTDEFWSKYKDGDQCEGHPCLNQGHCKDGIGDYTCTCAEGFEGKN	CEFSTREICSLDNGGCDQFCREERSEVRCSCAHGYVLGDDSKSCVSTERFPCGKFTQGRS	RRWAIHTSEDALDASELEHYDPADLSPTESSLDLLGLNRTEPSAGEDGSQVVRIVGGRDC	AEGECPWQALLVNEENEGFCGGTILNEFYVLTAAHCLHQAKRFTVRVGDRNTEQEEGNEM	AHEVEMTVKHSRFVKETYDFDIAVLRLKTPIRFRRNVAPACLPEKDWAEATLMTQKTGIV	SGFGRTHEKGRLSSTLKMLEVPYVDRSTCKLSSSFTITPNMFCAGYDTQPEDACQGDSGG	PHVTRFKDTYFVTGIVSWGEGCARKGKFGVYTKVSNFLKWIDKIMKARAGAAGSRGHSEA	PATWTVPPPLPL
http://pfam.sanger.ac.uk/family?acc=PF00089
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00089%3E
organismal physiological process
http://www.pdb.org/pdb/explore/explore.do?structureId=1KIG
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1KIG%3E
1-23
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2261466
regulation of body fluids
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8243461
RDF Description of Coagulation factor X
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00511
_:header15729741151335206650070
Mon, 23 Apr 2012 18:37:25 GMT
RDF Description of Acetyldigitoxin
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00511
C43H66O14
http://dbpedia.org/page/Acetyldigitoxin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FAcetyldigitoxin%3E
Used for fast digitalization in congestive heart failure.
Cardioactive derivative of lanatoside A or of digitoxin used for fast digitalization in congestive heart failure.
http://en.wikipedia.org/wiki/Acetyldigitoxin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FAcetyldigitoxin%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/injectionIntravenous
2008-08-26 15:22:00 UTC
Acetyldigitoxin
The main pharmacological effects of acetyldigitoxin are on the heart. Extracardiac effects are responsible for many of the adverse effects. Its main cardiac effects are 1) a decrease of conduction of electrical impulses through the AV node, making it a commonly used drug in controlling the heart rate during atrial fibrillation or atrial flutter, and 2) an increase of force of contraction via inhibition of the Na<sup>+</sup>/K<sup>+</sup> ATPase pump.
http://bio2rdf.org/cas:25395-32-8
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A25395-32-8%3E
Acetyldigitoxin binds to a site on the extracellular aspect of the &alpha;-subunit of the Na<sup>+</sup>/K<sup>+</sup> ATPase pump in the membranes of heart cells (myocytes). This causes an increase in the level of sodium ions in the myocytes, which then leads to a rise in the level of calcium ions. The proposed mechanism is the following: inhibition of the Na<sup>+</sup>/K<sup>+</sup> pump leads to increased Na<sup>+</sup> levels, which in turn slows down the extrusion of Ca<sup>2+</sup> via the Na<sup>+</sup>/Ca<sup>2+</sup> exchange pump. Increased amounts of Ca<sup>2+</sup> are then stored in the sarcoplasmic reticulum and released by each action potential, which is unchanged by acetyldigitoxin. This is a different mechanism from that of catecholamines. Acetyldigitoxin also increases vagal activity via its central action on the central nervous system, thus decreasing the conduction of electrical impulses through the AV node. This is important for its clinical use in different arrhythmias.
0.0274 mg/L at 25 oC [MEYLAN,WM et al. (1996)]
http://dbpedia.org/resource/Acetyldigitoxin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FAcetyldigitoxin%3E
HPMZBILYSWLILX-NUZCUNEWBT
Bioavailability is 60 to 80% following oral administration.
DB00511
Toxicity includes ventricular tachycardia or ventricular fibrillation, or progressive bradyarrhythmias, or heart block. LD50 = 7.8 mg/kg (orally in mice).
Acigoxin
C[C@H]1O[C@H](C[C@H](OC(C)=O)[C@@H]1O)O[C@@H]1[C@@H](C)O[C@H](C[C@@H]1O)O[C@@H]1[C@@H](C)O[C@H](C[C@@H]1O)O[C@@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2CC[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1
1.23e-02 mg/mL
[(2R,3R,4S,6S)-3-hydroxy-6-[(2R,4S,6S)-4-hydroxy-6-[(2R,3S,4S,6R)-4-hydroxy-6-[[(5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-2-methyloxan-3-yl]oxy-2-methyloxan-3-yl]oxy-2-methyloxan-4-yl] acetate
http://www.drugbank.ca/drugs/DB00511
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00511%3E
InChI=1/C43H66O14/c1-21-38(48)33(54-24(4)44)19-37(51-21)57-40-23(3)53-36(18-32(40)46)56-39-22(2)52-35(17-31(39)45)55-27-9-12-41(5)26(16-27)7-8-30-29(41)10-13-42(6)28(11-14-43(30,42)49)25-15-34(47)50-20-25/h15,21-23,26-33,35-40,45-46,48-49H,7-14,16-20H2,1-6H3/t21-,22-,23-,26-,27?,28-,29+,30-,31+,32+,33+,35+,36+,37+,38-,39-,40?,41+,42-,43+/m1/s1
CC1OC(CC(OC(C)=O)C1O)OC1C(C)OC(CC1O)OC1C(C)OC(CC1O)OC1CCC2(C)C(CCC3C2CCC2(C)C(CCC32O)C2=CC(=O)OC2)C1
aprd01334
Acylanid
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/17
_:header16528172841335206650303
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/17
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1304
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/AAAS
Achalasia-addisonianism-alacrimia syndrome
RDF Description of Achalasia-addisonianism-alacrimia syndrome
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0016412
_:header577991071335206650604
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0016412
http://dbpedia.org/resource/Folate_deficiency
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FFolate_deficiency%3E
http://sideeffects.embl.de/se/C0016412
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0016412%3E
Folate deficiency
C0016412
deficiency of folic acid
folic acid deficiency
RDF Description of Folate deficiency
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/3519
_:header1872182031335206651086
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3519
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03342
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10547289
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=J02095
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DJ02095%3E
Hydrolysis of alpha-(2->3)-, alpha-(2->6)-, alpha-(2->8)- glycosidic linkages of terminal sialic acid residues in oligosaccharides, glycoproteins, glycolipids, colominic acid and synthetic substrates ALL_REAC (other) R03491 R04018 R04634 R04650 R05115 R05117 R05996(G) R05998(G) R05999(G) R06012(G) R06147(G) R06253(G) INHIBITOR 2-Deoxy-2,3-dehydro-N-acetylneuraminic acid
virion
>Neuraminidase	MLPSTVQTLTLLLTSGGVLLSLYVSASLSYLLYSDVLLKFSSTKTTAPTMSLECTNASNA	QTVNHSATKEMTFPPPEPEWTYPRLSCQGSTFQKALLISPHRFGEIKGNSAPLIIREPFV	ACGPKECRHFALTHYAAQPGGYYNGTRKDRNKLRHLVSVKLGKIPTVENSIFHMAAWSGS	ACHDGREWTYIGVDGPDNDALVKIKYGEAYTDTYHSYAHNILRTQESACNCIGGDCYLMI	TDGSASGISKCRFLKIREGRIIKEILPTGRVEHTEECTCGFASNKTIECACRDNSYTAKR	PFVKLNVETDTAEIRLMCTKTYLDTPRPDDGSIAGPCESNGDKWLGGIKGGFVHQRMASK	IGRWYSRTMSKTNRMGMELYVKYDGDPWTDSDALTLSGVMVSIEEPGWYSFGFEIKDKKC	DVPCIGIEMVHDGGKDTWHSAATAIYCLMGSGQLLWDTVTGVDMAL
http://pfam.sanger.ac.uk/family?acc=PF00064
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00064%3E
http://www.uniprot.org/uniprot/P03474
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP03474%3E
7-35
NA
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/6294654
http://bio2rdf.org/pdb:1INF
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1INF%3E
http://bio2rdf.org/uniprot:P03474
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP03474%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=325236
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D325236%3E
http://www.pdb.org/pdb/explore/explore.do?structureId=1INF
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1INF%3E
http://bio2rdf.org/pfam:PF00064
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00064%3E
single-passTypeIiMembraneProtein(
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7880809
>1401 bp	ATGCTACCTTCAACTGTACAAACATTAACCCTATTACTCACATCAGGGGGAGTATTATTA	TCACTATATGTGTCAGCCTCATTGTCATACTTATTGTATTCGGATGTATTGCTAAAATTT	TCATCAACAAAAACAACTGCACCAACAATGTCATTAGAGTGCACAAACGCATCAAATGCC	CAGACTGTGAACCATTCTGCAACAAAAGAGATGACATTTCCACCCCCAGAGCCGGAGTGG	ACATACCCTCGTTTATCTTGCCAGGGCTCAACCTTTCAGAAGGCACTCCTAATTAGCCCT	CATAGGTTCGGAGAGATCAAAGGAAACTCAGCTCCCTTGATAATAAGAGAACCTTTTGTT	GCTTGTGGACCAAAAGAATGCAGACACTTTGCTCTGACCCATTATGCAGCTCAGCCGGGG	GGATACTACAATGGAACAAGAAAGGACAGAAACAAGCTGAGGCATCTAGTATCAGTCAAA	TTGGGAAAAATCCCAACTGTGGAAAACTCCATTTTCCACATGGCAGCTTGGAGCGGATCC	GCATGCCATGATGGTAGAGAATGGACATATATCGGAGTTGATGGTCCTGACAATGATGCA	TTGGTCAAAATAAAATATGGAGAAGCATATACTGACACATATCATTCCTATGCACACAAC	ATCCTAAGAACACAAGAAAGTGCCTGCAATTGCATCGGGGGAGATTGTTATCTTATGATA	ACAGACGGCTCAGCTTCAGGAATTAGTAAATGCAGATTTCTTAAAATTAGAGAGGGTCGA	ATAATAAAAGAAATACTTCCAACAGGAAGAGTGGAGCACACTGAAGAGTGCACATGCGGG	TTCGCCAGCAATAAAACCATAGAATGTGCCTGTAGAGACAACAGTTACACAGCAAAAAGA	CCCTTTGTCAAATTAAATGTGGAAACTGATACAGCTGAAATAAGATTGATGTGCACAAAG	ACTTATCTAGACACTCCCAGACCGGATGATGGAAGCATAGCAGGGCCTTGCGAATCTAAT	GGAGACAAGTGGCTTGGAGGCATCAAAGGAGGATTCGTCCATCAAAGAATGGCATCTAAG	ATTGGAAGATGGTACTCCCGAACGATGTCTAAAACTAACAGAATGGGGATGGAACTGTAT	GTAAAGTATGATGGTGACCCATGGACTGACAGTGATGCTCTTACTCTTAGTGGAGTAATG	GTTTCCATAGAAGAACCTGGTTGGTATTCTTTTGGCTTCGAAATAAAGGACAAGAAATGT	GATGTCCCTTGTATTGGGATAGAGATGGTACACGATGGTGGAAAAGATACTTGGCATTCA	GCTGCAACAGCCATTTACTGTTTGATGGGCTCAGGACAATTGCTATGGGACACTGTCACA	GGCGTTGATATGGCTTTATAA
J02095
Neuraminidase
map00511	N-Glycan degradation
NRAM_INBLE
virionMembrane.CellMembrane
Catalyzes the removal of terminal sialic acid residues from viral and cellular glycoconjugates. Cleaves off the terminal sialic acids on the glycosylated HA during virus budding to facilitate virus release. Additionally helps virus spread through the circulation by further removing sialic acids from the cell surface. These cleavages prevent self-aggregation and ensure the efficient spread of the progeny virus from cell to cell. Otherwise, infection would be limited to one round of replication. Described as a receptor-destroying enzyme because it cleaves a terminal sialic acid from the cellular receptors. May facilitate viral invasion of the upper airways by cleaving the sialic acid moities on the mucin of the airway epithelial cells
EC 3.2.1.18
apicalCellMembrane
RDF Description of Neuraminidase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03475
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/COX15
_:header21209226211335206651320
Mon, 23 Apr 2012 18:37:26 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/COX15
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1753
http://symbol.bio2rdf.org/symbol:COX15
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ACOX15%3E
COX15
http://www.dbpedia.org/resource/COX15
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FCOX15%3E
RDF Description of COX15
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/196
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2895
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0149514
_:header18085939791335206651602
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0149514
http://sideeffects.embl.de/se/C0149514
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0149514%3E
Acute Bronchitis
C0149514
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4991
RDF Description of Acute Bronchitis
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01180
_:header9151485601335206651876
RDF Description of Rescinnamine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01180
http://www.drugbank.ca/drugs/DB01180
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01180%3E
Apolon
http://dbpedia.org/page/Rescinnamine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FRescinnamine%3E
238.5 oC
Anapral
Rescinnamine is an angiotensin-converting enzyme inhibitor used as an antihypertensive drug. It is an alkaloid obtained from <i>Rauwolfia serpentina</i> and other species of <i>Rauwolfia</i>. [Wikipedia]
Scinnamina
Used to treat hypertension. Rescinnamine inhibits angiotensin-converting enzyme. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex.
C35H42N2O9
Recitensina
Recinnamine
Cinatabs
Rescamin
Raurescine
Moderil
Resipal
Reserpinene
Reserpinine
Rescinpal
2008-08-26 14:16:45 UTC
Rescidan
3.49e-03 mg/mL
Anaprel
DB01180
Methyl Trimethoxycinnamoylreserpate
Resealoid
InChI=1/C35H42N2O9/c1-40-21-8-9-22-23-11-12-37-18-20-15-29(46-30(38)10-7-19-13-27(41-2)33(43-4)28(14-19)42-3)34(44-5)31(35(39)45-6)24(20)17-26(37)32(23)36-25(22)16-21/h7-10,13-14,16,20,24,26,29,31,34,36H,11-12,15,17-18H2,1-6H3/t20-,24+,26-,29-,31+,34+/m1/s1
Cinnaloid
Cinnasil
PA451235
Apoterin
Reserpinin
Rescinnamine
SZLZWPPUNLXJEA-LAFLMMDJBU
/drugs/1180/safety_sheets/1109
http://dbpedia.org/resource/Rescinnamine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FRescinnamine%3E
C02AA01
Raupyrol
Rescitens
Rozex
Rescin
Paresinan
aprd00112
http://en.wikipedia.org/wiki/Rescinnamine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FRescinnamine%3E
Binds to and inhibits the angiotensin converting enzyme. Rescinnamine competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion.
Normorescina
Rescisan
Rescaloid
Cartric
For the treatment of hypertension.
Cinamine
COC1C(CC2CN3CCC4=C(NC5=C4C=CC(OC)=C5)C3CC2C1C(=O)OC)OC(=O)C=CC1=CC(OC)=C(OC)C(OC)=C1
Trimethoxycinnamoyl Methyl Reserpate
Reskinnamin
http://bio2rdf.org/cas:24815-24-5
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A24815-24-5%3E
Raurescin
http://bio2rdf.org/cpd:C06540
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC06540%3E
http://bio2rdf.org/kegg:D00198
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD00198%3E
Rescinnamin
Tsuruselpi S
CO[C@H]1[C@@H](C[C@@H]2C[N@]3CCC4=C(NC5=C4C=CC(OC)=C5)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)C=CC1=CC(OC)=C(OC)C(OC)=C1
Apoterin S
Tuareg
Tenamine
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01062
_:header320435391335206652185
Mon, 23 Apr 2012 18:37:27 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01062
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00564_DB01062
http://129.128.185.122/drugbank2/drugs/DB01062/inserts/1358/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB01062%2Finserts%2F1358%2Ffull%3E
Oxybutinin
12.4-13.2 hours
http://data.linkedct.org/resource/intervention/45561
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F45561%3E
For the treatment of overactive bladder.
http://205.193.93.51/dpdonline/searchRequest.do?din=02260751
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02260751%3E
Oxibutinina [INN-Spanish]
http://dbpedia.org/page/Oxybutynin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FOxybutynin%3E
http://www.dbpedia.org/resource/Oxybutynin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FOxybutynin%3E
http://129.128.185.122/drugbank2/drugs/DB01062/inserts/445/full
Oxybutynin Base
XIQVNETUBQGFHX-UHFFFAOYAB
Oxybutynin is an antispasmodic, anticholinergic agent indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Oxybutynin relaxes bladder smooth muscle. Oxybutynin exhibits only one-fifth of the anticholinergic activity of atropine on the rabbit detrusor muscle, but four to ten times the antispasmodic activity. Antimuscarinic activity resides predominantly in the R-isomer.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/parasympatholytics
Oxybutynin Chloride
http://data.linkedct.org/resource/intervention/59351
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F59351%3E
C22H31NO3
Oxytrol
/drugs/1062/safety_sheets/882
Brit. pat. 940540 (1963 to Mead Johnson)
129-130 oC
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/dit1143.shtml
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/genitourinarySmoothMuscleRelaxants
http://www.rxlist.com/cgi/generic/ditropan.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric%2Fditropan.htm%3E
http://bio2rdf.org/cpd:C07360
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC07360%3E
DB01062
Ditropan
http://data.linkedct.org/resource/intervention/10486
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F10486%3E
Oxybutynin
http://data.linkedct.org/resource/intervention/59532
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F59532%3E
InChI=1/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3
http://bio2rdf.org/cas:5633-20-5
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A5633-20-5%3E
91%-93%
Oxibutyninum
PA450737
http://en.wikipedia.org/wiki/Oxybutynin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FOxybutynin%3E
http://dbpedia.org/resource/Oxybutynin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FOxybutynin%3E
CCN(CC)CC#CCOC(=O)[C@@](O)(C1CCCCC1)C1=CC=CC=C1
http://bio2rdf.org/kegg:D00465
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD00465%3E
oxybutynin
Oxybutynin is an anticholinergic medication used to relieve urinary and bladder difficulties, including frequent urination and inability to control urination, by decreasing muscle spasms of the bladder. It competitively antagonizes the M1, M2, and M3 subtypes of the muscarinic acetylcholine receptor.
Ditropan Xl
G04BD04
Oxybutyninum [INN-Latin]
http://data.linkedct.org/resource/intervention/45407
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F45407%3E
Oxybutynin Hydrochloride
LD<sub>50</sub>=1220 mg/kg (Orally in rats, Goldenthal)
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2487
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2487%3E
1998-12-01	/drugs/1062/fda_labels/1087	2003-02-01	/drugs/1062/fda_labels/826	2003-04-01	/drugs/1062/fda_labels/44
http://129.128.185.122/drugbank2/drugs/DB01062/inserts/2357/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB01062%2Finserts%2F2357%2Ffull%3E
Hepatic, primarily by CYP3A4
Oxybutynine [INN-French]
4-diethylaminobut-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylacetate
aprd00427
http://www.drugbank.ca/drugs/DB01062
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01062%3E
Oxybutynin exerts a direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle. No blocking effects occur at skeletal neuromuscular junctions or autonomic ganglia (antinicotinic effects).
oxybutynin topical gel
Rapidly absorbed from gastrointestinal tract.
2008-08-26 16:55:11 UTC
1.00e-02 mg/mL
CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/patchTransdermal
http://data.linkedct.org/resource/intervention/19295
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F19295%3E
transdermal patch
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01062_DB00843
RDF Description of Oxybutynin
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00662_DB01062
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01062_DB00564
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00843_DB01062
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00382_DB01062
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01062_DB00989
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00209_DB01062
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01062_DB00674
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00427_DB01062
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00674_DB01062
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/4434
_:header8290193781335206652565
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3566737
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/3680258
>726 bp	ATGGCGGCTTCGGGCGAGGCGCGCCGAGTGCTGGTGTACGGCGGCAGGGGTGCTCTGGGC	TCGCGCTGCGTACAGGCCTTCCGGGCCCGCAACTGGTGGGTTGCCAGCATTGATGTGGTG	GAGAATGAAGAGGCCAGTGCCAGCGTGATTGTTAAGATGACAGATTCATTCACGGAGCAG	GCTGACCAGGTCACTGCTGAGGTCGGGAAGCTCCTAGGTGACCAGAAGGTGGATGCCATT	CTCTGTGTGGCTGGAGGATGGGCCGGGGGCAATGCCAAATCCAAGTCACTCTTTAAAAAC	TGTGACCTGATGTGGAAGCAGAGTATTTGGACATCCACCATCTCTAGCCACTTGGCCACA	AAGCACCTGAAGGAAGGAGGCCTCTTGACCCTGGCCGGGGCCAAAGCTGCGTTGGATGGG	ACTCCTGGGATGATTGGCTACGGCATGGCCAAGGGAGCCGTCCATCAGCTCTGCCAGAGC	CTTGCAGGGAAGAACAGTGGCATGCCGTCTGGGGCTGCCGCCATTGCTGTGCTTCCCGTC	ACCCTGGATACTCCGATGAACAGGAAATCAATGCCCGAGGCAGACTTCAGCTCCTGGACA	CCCTTAGAGTTCCTGGTGGAGACCTTCCATGACTGGATCACTGGGAACAAACGGCCAAAC	TCAGGAAGCCTAATCCAGGTGGTAACCACAGACGGGAAGACAGAGCTTACTCCAGCCTAT	TTCTAA
http://bio2rdf.org/pdb:1DIR
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1DIR%3E
HDHPR
Qdpr
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1898002
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1631094
>Dihydropteridine reductase	MAASGEARRVLVYGGRGALGSRCVQAFRARNWWVASIDVVENEEASASVIVKMTDSFTEQ	ADQVTAEVGKLLGDQKVDAILCVAGGWAGGNAKSKSLFKNCDLMWKQSIWTSTISSHLAT	KHLKEGGLLTLAGAKAALDGTPGMIGYGMAKGAVHQLCQSLAGKNSGMPSGAAAIAVLPV	TLDTPMNRKSMPEADFSSWTPLEFLVETFHDWITGNKRPNSGSLIQVVTTDGKTELTPAY	F
http://bio2rdf.org/uniprot:P11348
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP11348%3E
http://www.pdb.org/pdb/explore/explore.do?structureId=1DIR
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1DIR%3E
Quinoid dihydropteridine reductase
The product of this enzyme, tetrahydrobiopterin (BH-4), is an essential cofactor for phenylalanine, tyrosine, and tryptophan hydroxylases
http://www.uniprot.org/uniprot/P11348
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP11348%3E
Dihydropteridine reductase
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=J03481
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DJ03481%3E
J03481
EC 1.5.1.34
DHPR_RAT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8304094
RDF Description of Dihydropteridine reductase
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/4702
_:header8147138981335206652912
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4702
>Alpha-glucuronidase	MSTFARLFLCLVFFASLQPAMAQTEDGYDMWLRYQPIADQTLLKTYQKQIRHLHVAGDSP	TINAAAAELQRGLSGLLNKPIVARDEKLKDYSLVIGTPDNSPLIASLNLGERLQALGAEG	YLLEQTRINKRHVVIVAANSDVGVLYGSFHLLRLIQTQHALEKLSLSSAPRLQHRVVNHW	DNLNRVVERGYAGLSLWDWGSLPNYLAPRYTDYARINASLGINGTVINNVNADPRVLSDQ	FLQKIAALADAFRPYGIKMYLSINFNSPRAFGDVDTADPLDPRVQQWWKTRAQKIYSYIP	DFGGFLVKADSEGQPGPQGYGRDHAEGANMLAAALKPFGGVVFWRAFVYHPDIEDRFRGA	YDEFMPLDGKFADNVILQIKNGPIDFQPREPFSALFAGMSRTNMMMEFQITQEYFGFATH	LAYQGPLFEESLKTETHARGEGSTIGNILEGKVFKTRHTGMAGVINPGTDRNWTGHPFVQ	SSWYAFGRMAWDHQISAATAADEWLRMTFSNQPAFIEPVKQMMLVSREAGVNYRSPLGLT	HLYSQGDHYGPAPWTDDLPRADWTAVYYHRASKTGIGFNRTKTGSNALAQYPEPIAKAWG	DLNSVPEDLILWFHHLSWDHRMQSGRNLWQELVHKYYQGVEQVRAMQRTWDQQEAYVDAA	RFAQVKALLQVQEREAVRWRNSCVLYFQSVAGRPIPANYEQPEHDLEYYKMLARTTYVPE	PWHPASSSRVLK
AY065638
Q8VP74_9GAMM
alpha-glucuronidase activity
http://bio2rdf.org/uniprot:Q8VP74
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ8VP74%3E
http://pfam.sanger.ac.uk/family?acc=PF07488
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF07488%3E
http://bio2rdf.org/pdb:1GQL
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1GQL%3E
>2199 bp	ATGTCCACGTTTGCCCGGTTATTCCTTTGCCTTGTGTTTTTTGCCAGCCTGCAGCCAGCC	ATGGCCCAGACTGAAGATGGTTATGATATGTGGTTGCGTTACCAACCCATTGCAGACCAG	ACGTTGCTGAAAACCTACCAAAAACAGATTCGTCATCTGCATGTGGCGGGCGATAGTCCA	ACCATAAACGCGGCTGCTGCTGAATTACAGCGAGGATTATCGGGCTTGCTGAACAAACCG	ATTGTTGCGCGCGATGAAAAACTCAAGGACTACAGTCTGGTCATTGGCACCCCCGACAAT	TCTCCCCTGATTGCCTCACTGAATCTCGGTGAGCGTTTGCAAGCCCTGGGCGCTGAAGGC	TATTTGCTGGAGCAGACCCGCATTAACAAGCGCCATGTAGTGATTGTTGCGGCGAATTCC	GACGTGGGTGTGCTCTATGGCAGTTTTCACCTGCTGCGCCTGATCCAGACGCAGCACGCG	TTGGAAAAACTATCACTGTCCAGCGCCCCGCGCTTGCAGCATCGTGTTGTTAACCATTGG	GATAACCTTAACCGTGTGGTGGAGCGCGGTTATGCCGGTTTGTCTCTGTGGGATTGGGGC	TCCTTGCCGAATTATTTAGCGCCGCGCTATACCGACTATGCGCGTATCAATGCGTCCCTG	GGTATTAACGGTACGGTGATCAATAATGTTAACGCCGACCCGCGTGTATTGAGTGATCAA	TTTTTGCAGAAAATCGCAGCACTCGCCGATGCGTTCCGCCCATACGGCATCAAGATGTAT	TTATCCATTAATTTCAATTCACCGCGCGCGTTTGGCGACGTGGATACGGCGGATCCATTA	GACCCGCGTGTACAGCAGTGGTGGAAAACCCGCGCCCAAAAAATTTATTCCTATATCCCC	GATTTTGGCGGTTTCCTGGTGAAGGCTGATTCTGAAGGGCAACCCGGCCCACAGGGATAT	GGCCGCGACCATGCCGAGGGTGCCAACATGCTCGCTGCCGCACTGAAGCCGTTCGGCGGT	GTGGTTTTCTGGCGCGCCTTTGTGTATCACCCGGATATTGAAGATCGTTTCCGCGGTGCC	TATGACGAATTTATGCCGTTGGATGGCAAGTTTGCCGATAACGTTATCCTGCAAATTAAA	AATGGCCCGATTGATTTCCAGCCGCGTGAACCCTTCTCGGCATTGTTTGCCGGTATGTCG	CGCACCAATATGATGATGGAGTTCCAAATTACCCAGGAATATTTCGGGTTTGCGACACAC	CTGGCCTATCAAGGGCCCTTGTTTGAAGAATCCCTGAAAACAGAAACCCATGCCCGGGGT	GAGGGTTCTACCATTGGCAATATCCTCGAAGGCAAGGTGTTTAAAACCCGCCATACCGGT	ATGGCCGGTGTGATTAATCCGGGCACAGACCGCAACTGGACCGGGCATCCCTTTGTGCAA	TCCAGCTGGTATGCGTTCGGGCGCATGGCCTGGGATCACCAGATCAGTGCTGCCACCGCT	GCCGATGAATGGTTGCGTATGACCTTCAGCAACCAGCCGGCATTTATTGAACCGGTAAAA	CAAATGATGCTGGTGTCGCGCGAGGCCGGGGTTAACTATCGTTCACCACTTGGGTTGACG	CATTTGTACTCACAGGGCGATCACTATGGCCCGGCGCCCTGGACGGATGACTTACCGCGC	GCAGACTGGACGGCGGTTTATTACCATCGCGCCAGTAAAACCGGCATAGGATTCAATCGC	ACCAAAACCGGCTCCAATGCCCTGGCACAATATCCCGAGCCTATCGCCAAGGCCTGGGGC	GATCTTAATAGCGTACCTGAGGATTTAATCCTGTGGTTCCATCACCTGAGTTGGGATCAC	CGCATGCAATCCGGTCGCAACCTGTGGCAAGAATTGGTGCATAAATATTATCAAGGTGTT	GAACAGGTTCGCGCCATGCAGCGCACCTGGGACCAGCAAGAGGCTTATGTGGATGCAGCG	CGTTTTGCCCAGGTCAAAGCCTTATTACAGGTGCAGGAGCGCGAGGCTGTTCGCTGGCGG	AACTCCTGTGTGCTCTATTTCCAATCGGTAGCCGGTAGACCCATTCCTGCCAACTATGAG	CAACCGGAACACGACCTGGAATATTACAAAATGCTGGCGCGTACTACGTACGTGCCCGAA	CCCTGGCATCCGGCAAGCTCCAGTCGCGTGTTGAAATAA
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AY065638
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAY065638%3E
Involved in alpha-glucuronidase activity
http://bio2rdf.org/pfam:PF03648
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF03648%3E
Alpha-glucuronidase
http://bio2rdf.org/pfam:PF07488
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF07488%3E
polysaccharide metabolism
http://pfam.sanger.ac.uk/family?acc=PF07477
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF07477%3E
http://bio2rdf.org/pfam:PF07477
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF07477%3E
polysaccharide catabolism
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12169619
http://pfam.sanger.ac.uk/family?acc=PF03648
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF03648%3E
xylan catabolism
glcA67A
cellular polysaccharide catabolism
http://www.uniprot.org/uniprot/Q8VP74
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ8VP74%3E
http://www.pdb.org/pdb/explore/explore.do?structureId=1GQL
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1GQL%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04303
RDF Description of Alpha-glucuronidase
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/1128
_:header2235064281335206653171
Mon, 23 Apr 2012 18:37:28 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1128
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4034
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fsider%2Fresource%2Fside_effects%2FC0836924%3E
http://data.linkedct.org/resource/condition/12977
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fcondition%2F12977%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/THPO
Thrombocythemia
RDF Description of Thrombocythemia
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4035
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/520
_:header10481692561335206653514
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/520
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00828
>1260 bp	ATGGATAAATTTCGTGTTCAGGGGCCAACGAAGCTCCAGGGCGAAGTCACAATTTCCGGC	GCTAAAAATGCTGCTCTGCCTATCCTTTTTGCCGCACTACTGGCGGAAGAACCGGTAGAG	ATCCAGAACGTCCCGAAACTGAAAGACGTCGATACATCAATGAAGCTGCTAAGCCAGCTG	GGTGCGAAAGTAGAACGTAATGGTTCTGTGCATATTGATGCCCGCGACGTTAATGTATTC	TGCGCACCTTACGATCTGGTTAAAACCATGCGTGCTTCTATCTGGGCGCTGGGGCCGCTG	GTAGCGCGCTTTGGTCAGGGGCAAGTTTCACTACCTGGCGGTTGTACGATCGGTGCGCGT	CCGGTTGATCTACACATTTCTGGCCTCGAACAATTAGGCGCGACCATCAAACTGGAAGAA	GGTTACGTTAAAGCTTCCGTCGATGGTCGTTTGAAAGGTGCACATATCGTGATGGATAAA	GTCAGCGTTGGCGCAACGGTGACCATCATGTGTGCTGCAACCCTGGCGGAAGGCACCACG	ATTATTGAAAACGCAGCGCGTGAACCGGAAATCGTCGATACCGCGAACTTCCTGATTACG	CTGGGTGCGAAAATTAGCGGTCAGGGCACCGATCGTATCGTCATCGAAGGTGTGGAACGT	TTAGGCGGCGGTGTCTATCGCGTTCTGCCGGATCGTATCGAAACCGGTACTTTCCTGGTG	GCGGCGGCGATTTCTCGCGGCAAAATTATCTGCCGTAACGCGCAGCCAGATACTCTCGAC	GCCGTGCTGGCGAAACTGCGTGACGCTGGAGCGGACATCGAAGTCGGCGAAGACTGGATT	AGCCTGGATATGCATGGCAAACGTCCGAAGGCTGTTAACGTACGTACCGCGCCGCATCCG	GCATTCCCGACCGATATGCAGGCCCAGTTCACGCTGTTGAACCTGGTGGCAGAAGGGACC	GGGTTTATCACCGAAACGGTCTTTGAAAACCGCTTTATGCATGTGCCAGAGCTGAGCCGT	ATGGGCGCGCACGCCGAAATCGAAAGCAATACCGTTATTTGTCACGGTGTTGAAAAACTT	TCTGGCGCACAGGTTATGGCAACCGATCTGCGTGCATCAGCAAGCCTGGTGCTGGCTGGC	TGTATTGCGGAAGGGACGACGGTGGTTGATCGTATTTATCACATCGATCGTGGCTACGAA	CGCATTGAAGACAAACTGCGCGCTTTAGGTGCAAATATTGAGCGTGTGAAAGGCGAATAA
http://www.pdb.org/pdb/explore/explore.do?structureId=1UAE
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1UAE%3E
MURA_ECOLI
http://www.uniprot.org/uniprot/P0A749
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP0A749%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8664284
UDP-N-acetylglucosamine 1-carboxyvinyltransferase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9485407
http://bio2rdf.org/pdb:1UAE
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1UAE%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=M92358
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DM92358%3E
http://pfam.sanger.ac.uk/family?acc=PF00275
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00275%3E
phosphoenolpyruvate + UDP-N-acetyl-D-glucosamine = phosphate + UDP-N-acetyl-3-O-(1-carboxyvinyl)-D-glucosamine
map00530	Aminosugars metabolism
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12562791
UDP-N-acetylglucosamine enolpyruvyl transferase
amine metabolism
murA
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8994972
>UDP-N-acetylglucosamine 1-carboxyvinyltransferase	MDKFRVQGPTKLQGEVTISGAKNAALPILFAALLAEEPVEIQNVPKLKDVDTSMKLLSQL	GAKVERNGSVHIDARDVNVFCAPYDLVKTMRASIWALGPLVARFGQGQVSLPGGCTIGAR	PVDLHISGLEQLGATIKLEEGYVKASVDGRLKGAHIVMDKVSVGATVTIMCAATLAEGTT	IIENAAREPEIVDTANFLITLGAKISGQGTDRIVIEGVERLGGGVYRVLPDRIETGTFLV	AAAISRGKIICRNAQPDTLDAVLAKLRDAGADIEVGEDWISLDMHGKRPKAVNVRTAPHP	AFPTDMQAQFTLLNLVAEGTGFITETVFENRFMHVPELSRMGAHAEIESNTVICHGVEKL	SGAQVMATDLRASASLVLAGCIAEGTTVVDRIYHIDRGYERIEDKLRALGANIERVKGE
EPT
EC 2.5.1.7
UDP-N-acetylgalactosamine biosynthesis
UDP-N-acetylgalactosamine metabolism
Cell wall formation. Adds enolpyruvyl to UDP-N- acetylglucosamine. Target for the antibiotic phosphomycin
http://bio2rdf.org/pfam:PF00275
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00275%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10103182
M92358
http://bio2rdf.org/uniprot:P0A749
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP0A749%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=146902
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D146902%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/15531591
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1512209
amino sugar metabolism
nitrogen compound metabolism
Enoylpyruvate transferase
RDF Description of UDP-N-acetylglucosamine 1-carboxyvinyltransferase
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/5320
_:header7832170531335206653874
RDF Description of KLARON
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5320
http://www.fda.gov/cder/foi/label/2003/19931slr008_Aventis_lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2003%2F19931slr008_Aventis_lbl.pdf%3E
KLARON
http://dbpedia.org/resource/Sulfacetamide
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FSulfacetamide%3E
sulfacetamide
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3987
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3987%3E
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000005320
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000005320%3E
CID0000005320
http://sideeffects.embl.de/drugs/5320
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F5320%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0151798
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000005320&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000005320%26input_query_species%3D9606%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00634
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00634%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0001144
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/764
_:header21245117391335206654158
Mon, 23 Apr 2012 18:37:29 GMT
RDF Description of Migraine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01427
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01427%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00957
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00957%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00005
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00005%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/237
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F237%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00269
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00269%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3888
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3888%3E
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fsider%2Fresource%2Fside_effects%2FC0149931%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02715
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB02715%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01185
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01185%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00304
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00304%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1832
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F1832%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04573
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB04573%3E
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00608%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1804
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F1804%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1469
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F1469%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/363
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F363%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00640
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00640%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3928
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3928%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00351
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00351%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2038
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2038%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03802
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB03802%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01296
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01296%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3768
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3768%3E
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00286%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00858
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00858%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00947
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00947%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/EDNRA
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/ESR1
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/4073
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F4073%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00704
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00704%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00539
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00539%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2452
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2452%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2017
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2017%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2068
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2068%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00481
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00481%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3846
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3846%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01366
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01366%3E
http://data.linkedct.org/resource/condition/8122
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fcondition%2F8122%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/292
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F292%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00396
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00396%3E
Migraine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01196
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01196%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00977
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00977%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/4109
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F4109%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04471
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB04471%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/39
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F39%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2282
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2282%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3371
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3371%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3810
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3810%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3914
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3914%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1516
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F1516%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/165
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F165%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1357
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F1357%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00675
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00675%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00603
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00603%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01943
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01943%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2675
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2675%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/774
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F774%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/468
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F468%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01006
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01006%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01183
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01183%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00506
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00506%3E
http://www.dbpedia.org/resource/Migraine
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FMigraine%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00890
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00890%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01411
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01411%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2153
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2153%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00559
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00559%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04575
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB04575%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2846
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2846%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00367
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00367%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02634
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB02634%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2453
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2453%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00823
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00823%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/TNF
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1244
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F1244%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/ATP1A2
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01065
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01065%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00882
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00882%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01232
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01232%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01407
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01407%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00065
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00065%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/694
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F694%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2082
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2082%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01357
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01357%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00783
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00783%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2040
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2040%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00255
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00255%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/4008
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F4008%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2819
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2819%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00294
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00294%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03742
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB03742%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1274
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F1274%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2025
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2025%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2221
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2221%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/574
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F574%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1369
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F1369%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/648
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F648%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02615
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB02615%3E
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01395%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2036
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2036%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01041
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01041%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01406
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB01406%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00051
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00051%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3164
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3163
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0025362
_:header1991223671335206654480
RDF Description of mental retardation
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0025362
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F746%3E
http://sideeffects.embl.de/se/C0025362
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0025362%3E
mental retardation
C0025362
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Haldeman-Julius_E_(Emanuel)_1889-1951
_:header13238308691335206654708
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Haldeman-Julius_E_(Emanuel)_1889-1951
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext945
Haldeman-Julius, E. (Emanuel), 1889-1951
Haldeman-Julius, E. (Emanuel), 1889-1951 
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext19404
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext16340
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext18062
RDF Description of Haldeman-Julius, E. (Emanuel), 1889-1951
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext20336
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/3344
_:header1531617131335206655072
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3344
CTP + 2-C-methyl-D-erythritol 4-phosphate = diphosphate + 4-(cytidine 5'-diphospho)-2-C-methyl-D-erythritol
ispD
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10360571
2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase activity
>2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase	MNVAILLAAGKGERMSENVPKQFLEIEGRMLFEYPLSTFLKSEAIDGVVIVTRREWFEVV	EKRVFHEKVLGIVEGGDTRSQSVRSALEFLEKFSPSYVLVHDSARPFLRKKHVSEVLRRA	RETGAATLALKNSDALVRVENDRIEYIPRKGVYRILTPQAFSYEILKKAHENGGEWADDT	EPVQKLGVKIALVEGDPLCFKVTFKEDLELARIIAREWERIP
http://bio2rdf.org/pdb:1VPA
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1VPA%3E
2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase
ISPD_THEMA
4-diphosphocytidyl-2C-methyl-D-erythritol synthase activity
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AE000512
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DAE000512%3E
http://bio2rdf.org/uniprot:Q9X1B3
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AQ9X1B3%3E
isoprenoid metabolism
AE000512
isoprenoid biosynthesis
http://www.uniprot.org/uniprot/Q9X1B3
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FQ9X1B3%3E
EC 2.7.7.60
MCT
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=4981955
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D4981955%3E
>669 bp	ATGAACGTAGCGATTCTCCTTGCAGCGGGAAAAGGTGAAAGAATGTCTGAAAACGTTCCA	AAACAGTTCCTCGAGATAGAGGGAAGGATGCTTTTCGAGTATCCGCTTTCCACGTTTTTG	AAAAGTGAAGCGATAGATGGTGTTGTGATAGTGACACGAAGAGAGTGGTTCGAAGTTGTA	GAGAAAAGAGTGTTCCACGAAAAAGTACTCGGAATTGTCGAGGGTGGAGATACACGAAGC	CAGAGTGTGAGAAGCGCCCTCGAATTTCTTGAAAAGTTCTCTCCCTCTTACGTTCTCGTA	CACGACTCAGCACGGCCGTTTCTGAGGAAGAAACACGTGTCGGAGGTTCTCAGAAGAGCC	CGCGAAACGGGAGCGGCAACCCTCGCGTTGAAGAATTCCGACGCGCTCGTAAGAGTTGAG	AACGACAGAATAGAATACATCCCAAGAAAAGGAGTGTACAGAATTCTTACACCGCAGGCT	TTTTCTTACGAGATTTTGAAAAAGGCCCATGAAAATGGTGGCGAATGGGCAGACGACACG	GAACCTGTTCAAAAGCTCGGAGTGAAAATAGCCTTGGTCGAGGGAGATCCTTTGTGTTTC	AAAGTGACGTTTAAAGAAGACCTGGAACTGGCGAGAATCATCGCCAGAGAATGGGAGAGG	ATACCATGA
http://pfam.sanger.ac.uk/family?acc=PF01128
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF01128%3E
MEP cytidylyltransferase
http://www.pdb.org/pdb/explore/explore.do?structureId=1VPA
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1VPA%3E
4-diphosphocytidyl-2C-methyl-D-erythritol synthase
http://bio2rdf.org/pfam:PF01128
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF01128%3E
Catalyzes the formation of 4-diphosphocytidyl-2-C- methyl-D-erythritol from CTP and 2-C-methyl-D-erythritol 4- phosphate (MEP)
RDF Description of 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02431
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB03696
_:header13714438961335206655385
Mon, 23 Apr 2012 18:37:30 GMT
RDF Description of Lanosterol
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03696
http://bio2rdf.org/cas:79-63-0
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A79-63-0%3E
C30H50O
InChI=1/C30H50O/c1-20(2)10-9-11-21(3)22-14-18-30(8)24-12-13-25-27(4,5)26(31)16-17-28(25,6)23(24)15-19-29(22,30)7/h10,21-22,25-26,31H,9,11-19H2,1-8H3
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2672
1W6K
DB03696
CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C1(C)CCC(O)C(C)(C)C1CC3
http://bio2rdf.org/chebi:16521
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fchebi%3A16521%3E
3.76e-04 mg/mL
CAHGCLMLTWQZNJ-UHFFFAOYAM
C[C@@H](CCC=C(/C)C)[C@@H]1CC[C@]2(C)C3=C(CC[C@]12C)[C@]1(C)CC[C@@H](O)C(C)(C)[C@H]1CC3
(3S,5R,10S,13R,14R,17R)-4,4,10,13,14-pentamethyl-17-[(2R)-6-methylhept-5-en-2-yl]-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol
expt02002
2008-08-26 14:13:43 UTC
LAN
Lanosterol
http://bio2rdf.org/cpd:C01724
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC01724%3E
http://www.drugbank.ca/drugs/DB03696
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB03696%3E
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0006267
_:header954235841335206655668
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0006267
http://sideeffects.embl.de/se/C0006267
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0006267%3E
bronchiectasis
C0006267
RDF Description of bronchiectasis
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/581
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/NDUFS6
_:header9016850211335206655866
RDF Description of NDUFS6
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/NDUFS6
http://symbol.bio2rdf.org/symbol:NDUFS6
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ANDUFS6%3E
NDUFS6
http://www.dbpedia.org/resource/NDUFS6
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FNDUFS6%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1958
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/258
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Eeden_Frederik_van_1860-1932
_:header4621136711335206656079
Mon, 23 Apr 2012 18:37:31 GMT
RDF Description of Eeden, Frederik van, 1860-1932
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Eeden_Frederik_van_1860-1932
Eeden, Frederik van, 1860-1932
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9111
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext10819
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/BCAM
_:header718156101335206656370
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/BCAM
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1633
http://symbol.bio2rdf.org/symbol:BCAM
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ABCAM%3E
BCAM
http://www.dbpedia.org/resource/BCAM
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FBCAM%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1619
RDF Description of BCAM
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00854
_:header5007135691335206656631
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00854
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00704_DB00854
Levorphanol is well absorbed after PO administration with peak plasma concentrations occurring approximately 1 hour after dosing.
http://www.drugbank.ca/drugs/DB00854
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00854%3E
CN1CC[C@]23CCCC[C@H]2[C@H]1CC1=C3C=C(O)C=C1
1.73e-01 mg/mL
2008-08-26 16:47:14 UTC
Antalgin
11-16 hours
Lemoran
Levorphanol
PA450219
http://www.rxlist.com/cgi/generic2/levorphanol.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric2%2Flevorphanol.htm%3E
Levorphanol Tartrate
Cetarin
198-199 oC
Dea No. 9220
Dromoran
http://en.wikipedia.org/wiki/Levorphanol
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FLevorphanol%3E
Levorphanol is extensively metabolized in the liver and is eliminated as the glucuronide metabolite.
Racemic Dromoran
Dea No. 9733
A narcotic analgesic that may be habit-forming. It is nearly as effective orally as by injection. [PubChem]
Levorfanolo [Dcit]
Methorphinan
Racemethorphanum
http://129.128.185.122/drugbank2/drugs/DB00854/inserts/1088/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00854%2Finserts%2F1088%2Ffull%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/injectionSolutionSubcutaneous
Woods LA, et al. J Pharmacol Exp Ther. 1958 Sep;124(1):1-8.
Like other mu-agonist opioids it is believed to act at receptors in the periventricular and periaqueductal gray matter in both the brain and spinal cord to alter the transmission and perception of pain.
C17H23NO
LD<sub>50</sub>=150 mg/kg (orally in rats). Signs of overdose include nausea, emesis, dizziness, respiratory depression, hypotension, urinary retention, cardiac arrhythmias, allergic reactions, skin rash, and uticaria.
Levo-Dromoran
Levorphanol is a potent synthetic opioid analgesic indicated for the management of moderate to severe pain or as a preoperative medication where an opioid analgesic is appropriate. Levorphanol is similar to morphine in its actions, however it is up to 8 times more potent than morphine. Levorphanol produces a degree of respiratory depression similar to that produced by morphine at equianalgesic doses, and like many mu-opioid drugs, levorphanol produces euphoria or has a positive effect on mood in many individuals.
http://dbpedia.org/page/Levorphanol
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FLevorphanol%3E
DB00854
http://129.128.185.122/drugbank2/drugs/DB00854/inserts/2099/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00854%2Finserts%2F2099%2Ffull%3E
Levorphanol Dl-Form
Methorfinan [Czech]
Levorphanal
CN1CCC23CCCCC2C1CC1=C3C=C(O)C=C1
http://dbpedia.org/resource/Levorphanol
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FLevorphanol%3E
Take without regard to meals. Avoid alcohol.
Racemorfano [INN-Spanish]
Levorphan
http://bio2rdf.org/cpd:C08014
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC08014%3E
Aromarone
1840 mg/L
/drugs/854/safety_sheets/803
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/injectionSolutionIntravenous
For the management of moderate to severe pain or as a preoperative medication where an opioid analgesic is appropriate
aprd00764
Levorfanol [INN-Spanish]
http://www.dbpedia.org/resource/Levorphanol
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FLevorphanol%3E
http://bio2rdf.org/cas:77-07-6
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A77-07-6%3E
InChI=1/C17H23NO/c1-18-9-8-17-7-3-2-4-14(17)16(18)10-12-5-6-13(19)11-15(12)17/h5-6,11,14,16,19H,2-4,7-10H2,1H3/t14-,16-,17-/m0/s1
Levorphanolum [INN-Latin]
JAQUASYNZVUNQP-XIRDDKMYBC
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00501_DB00854
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00854_DB00501
RDF Description of Levorphanol
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00854_DB00704
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00242
_:header21469987921335206657045
RDF Description of Cladribine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00242
http://bio2rdf.org/kegg:D01370
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD01370%3E
http://129.128.185.122/drugbank2/drugs/DB00242/inserts/1337/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00242%2Finserts%2F1337%2Ffull%3E
http://en.wikipedia.org/wiki/Cladribine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FCladribine%3E
http://data.linkedct.org/resource/intervention/34202
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F34202%3E
2-CdA
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fsider%2Fresource%2Fdrugs%2F1546%3E
http://dbpedia.org/resource/Cladribine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FCladribine%3E
Symptoms of overdose include irreversible neurologic toxicity (paraparesis/quadriparesis), acute nephrotoxicity, and severe bone marrow suppression resulting in neutropenia, anemia and thrombocytopenia.
PTOAARAWEBMLNO-WQWZRESVDN
/drugs/242/safety_sheets/1212
Leustatin
cladribine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/277
L01BB04
http://www.drugbank.ca/drugs/DB00242
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00242%3E
Cladribine is structurally related to fludarabine and pentostatin but has a different mechanism of action. It is phosphorylated to its corresponding nucleotide CdATP, which accumulates and is incorporated into the DNA of cells such as lymphocytes. High levels of CdATP lead to DNA strand breaks, inhibition of DNA synthesis, and cell death. Unlike other antimetabolite drugs, cladribine has cytotoxic effects on resting as well as proliferating lymphocytes. However, it does cause cells to accumulate at the G1/S phase junction, suggesting that cytotoxicity is associated with events critical to cell entry into S phase. It also binds purine nucleoside phosphorylase (PNP), however no relationship between this binding and a mechanism of action has been established.
DB00242
6.35e+00 mg/mL
(2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
2008-08-26 16:10:55 UTC
2-Chloro-2'-deoxyadenosine
InChI=1/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1/f/h12H2
http://data.linkedct.org/resource/intervention/192
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F192%3E
http://129.128.185.122/drugbank2/drugs/DB00242/inserts/433/full
5.4 hours
2-Chlorodeoxyadenosine
215 oC
http://bio2rdf.org/cas:4291-63-8
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A4291-63-8%3E
Mylinax
http://data.linkedct.org/resource/intervention/3125
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F3125%3E
Chlorodeoxyadenosine
http://205.193.93.51/dpdonline/searchRequest.do?din=02022117
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02022117%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2749
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F2749%3E
Cladribine
NC1=C2N=CN(C3CC(O)C(CO)O3)C2=NC(Cl)=N1
aprd00260
Cladribine is a synthetic antineoplastic agent with immunosuppressive effects. Cladribine is one of a group of chemotherapy drugs known as the anti-metabolites.&nbsp;Anti-metabolites stop cells making and repairing DNA. Cancer cells need to make and repair DNA in order to grow and multiply.
1RT9
For the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms.
NC1=C2N=CN([C@H]3C[C@H](O)[C@@H](CO)O3)C2=NC(Cl)=N1
2-Chloro-2'-deoxy-beta-adenosine
Oral bioavailability is 34 to 48%.
An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. [PubChem]
PA449027
http://dbpedia.org/page/Cladribine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FCladribine%3E
http://www.dbpedia.org/resource/Cladribine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FCladribine%3E
C10H12ClN5O3
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3870
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F3870%3E
http://129.128.185.122/drugbank2/drugs/DB00242/inserts/2337/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00242%2Finserts%2F2337%2Ffull%3E
Metabolized in all cells with deoxycytidine kinase activity to 2-chloro-2'-deoxyadenosine-5'-triphosphate
http://www.rxlist.com/cgi/generic3/cladribine.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric3%2Fcladribine.htm%3E
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/1093
_:header12751431831335206657290
Mon, 23 Apr 2012 18:37:32 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1093
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3978
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/KRT17
Steatocystoma multiplex
http://www.dbpedia.org/resource/Steatocystoma_multiplex
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FSteatocystoma_multiplex%3E
RDF Description of Steatocystoma multiplex
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/462
_:header8549351041335206657520
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/462
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2492
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB04789
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB04789%3E
Glycine encephalopathy
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/GNMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00118
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00118%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/GLDC
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB04272%3E
http://www.dbpedia.org/resource/D-Glyceric_acidemia
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FD-Glyceric_acidemia%3E
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00116%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/GCSH
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/AMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03131
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB03131%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2491
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2493
RDF Description of Glycine encephalopathy
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2490
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/TNNC1
_:header5245398551335206657809
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/TNNC1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1746
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/gene/TNNC1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fgene%2FTNNC1%3E
http://symbol.bio2rdf.org/symbol:TNNC1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ATNNC1%3E
TNNC1
http://www.dbpedia.org/resource/Troponin_C_type_1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FTroponin_C_type_1%3E
RDF Description of TNNC1
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/BRCA2
_:header825637611335206658040
Mon, 23 Apr 2012 18:37:33 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/BRCA2
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4177
http://symbol.bio2rdf.org/symbol:BRCA2
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ABRCA2%3E
BRCA2
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1675
RDF Description of BRCA2
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1197
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3656
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2374
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1670
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3513
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/394
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01177
_:header7714347601335206658369
RDF Description of Idarubicin
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01177
CC1OC(CC(N)C1O)OC1CC(O)(CC2=C1C(O)=C1C(=O)C3=CC=CC=C3C(=O)C1=C2O)C(C)=O
C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(CC2=C1C(O)=C1C(=O)C3=CC=CC=C3C(=O)C1=C2O)C(C)=O
Idarubicine [INN-French]
Idarubicin Hcl
http://dbpedia.org/page/Idarubicin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FIdarubicin%3E
http://data.linkedct.org/resource/intervention/39657
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F39657%3E
http://129.128.185.122/drugbank2/drugs/DB01177/inserts/2324/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB01177%2Finserts%2F2324%2Ffull%3E
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. [PubChem]
http://www.drugbank.ca/drugs/DB01177
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01177%3E
(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
http://www.rxlist.com/cgi/generic2/idarubicin.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric2%2Fidarubicin.htm%3E
InChI=1/C26H27NO9/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3/t10-,15-,16-,17-,21+,26-/m0/s1
XDXDZDZNSLXDNA-TZNDIEGXBV
Idarubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Idarubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.
DB01177
Idarubicinum [INN-Latin]
http://205.193.93.51/dpdonline/searchRequest.do?din=02065630
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02065630%3E
For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
http://data.linkedct.org/resource/intervention/24011
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F24011%3E
http://129.128.185.122/drugbank2/drugs/DB01177/inserts/1325/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB01177%2Finserts%2F1325%2Ffull%3E
Idarubicin Aglycone
Idarubicin
Idarubicin HCl PFS
Idarubicin Hydrochloride
aprd00126
Bacteria
C26H27NO9
L01DB06
Idarubicina [INN-Spanish]
Idarubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Idarubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Idarubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. The anthracyclines are cell cycle-nonspecific.
http://data.linkedct.org/resource/intervention/7072
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F7072%3E
http://dbpedia.org/resource/Idarubicin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FIdarubicin%3E
http://en.wikipedia.org/wiki/Idarubicin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FIdarubicin%3E
2008-08-26 14:12:07 UTC
http://data.linkedct.org/resource/intervention/18002
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F18002%3E
Idamycin PFS
Idamycin
7.72e-01 mg/mL
http://data.linkedct.org/resource/intervention/58451
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F58451%3E
http://www.dbpedia.org/resource/Idarubicin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FIdarubicin%3E
http://data.linkedct.org/resource/intervention/40107
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F40107%3E
http://bio2rdf.org/cas:58957-92-9
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A58957-92-9%3E
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Prest_Thomas_Preskett
_:header19594125891335206658625
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Prest_Thomas_Preskett
Prest, Thomas Preskett
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext14833
RDF Description of Prest, Thomas Preskett
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/CSRP3
_:header4483250421335206658868
RDF Description of CSRP3
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/CSRP3
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/gene/CSRP3
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fgene%2FCSRP3%3E
http://symbol.bio2rdf.org/symbol:CSRP3
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ACSRP3%3E
CSRP3
http://bio2rdf.org/hgnc:2472
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A2472%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=2472
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D2472%3E
http://bio2rdf.org/geneid:8048
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fgeneid%3A8048%3E
http://www.dbpedia.org/resource/CSRP3
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FCSRP3%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1737
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/FKHR
_:header7282095761335206659135
Mon, 23 Apr 2012 18:37:34 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/FKHR
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3786
http://symbol.bio2rdf.org/symbol:FKHR
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AFKHR%3E
FKHR
RDF Description of FKHR
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01059
_:header16545397811335206659555
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01059
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01059_DB00651
Via liver and kidney
2003-06-01	/drugs/1059/fda_labels/135	2004-07-01	/drugs/1059/fda_labels/206
A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. [PubChem]
OGJPXUAPXNRGGI-QWOVJGMICW
Norfloxacin
http://en.wikipedia.org/wiki/Norfloxacin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FNorfloxacin%3E
http://www.rxlist.com/cgi/generic3/norfloxacin.htm
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rxlist.com%2Fcgi%2Fgeneric3%2Fnorfloxacin.htm%3E
227-228 oC
http://205.193.93.51/dpdonline/searchRequest.do?din=02246596
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FsearchRequest.do%3Fdin%3D02246596%3E
S01AX12
DB01059
Avoid high doses of caffeine.
C16H18FN3O3
1-ethyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
http://129.128.185.122/drugbank2/drugs/DB01059/inserts/1330/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB01059%2Finserts%2F1330%2Ffull%3E
CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1
J01MA06
1.01e+00 mg/mL
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/nor1302.shtml
Take on an empty stomach. Drink liberally.
http://data.linkedct.org/resource/intervention/9995
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F9995%3E
InChI=1/C16H18FN3O3/c1-2-19-9-11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5-3-18-4-6-20/h7-9,18H,2-6H2,1H3,(H,22,23)/f/h22H
http://bio2rdf.org/cpd:C06687
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC06687%3E
Noroxin
1.78E+005 mg/L
2008-08-26 15:36:47 UTC
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/477
aprd00469
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/815
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F815%3E
http://www.drugbank.ca/drugs/DB01059
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01059%3E
PA450654
08:12.18
/drugs/1059/safety_sheets/1112
http://129.128.185.122/drugbank2/drugs/DB01059/inserts/2329/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB01059%2Finserts%2F2329%2Ffull%3E
Rapid
10 and 15% (Serum protein binding)
Norfloxacin is a quinolone/fluoroquinolone antibiotic. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/404
http://bio2rdf.org/cas:70458-96-7
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A70458-96-7%3E
http://data.linkedct.org/resource/intervention/27716
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdata.linkedct.org%2Fresource%2Fintervention%2F27716%3E
http://dbpedia.org/page/Norfloxacin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FNorfloxacin%3E
The bactericidal action of Norfloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination. Norfloxacin is a broad-spectrum antibiotic that is active against both gram-positive and gram-negative bacterias. The fluorine atom at the 6 position increases potency against gram-negative organisms, and the piperazine moiety at the 7 position is responsible for anti-pseudomonal activity
Chibroxin
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/quinolones
http://dbpedia.org/resource/Norfloxacin
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FNorfloxacin%3E
http://bio2rdf.org/kegg:D00210
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD00210%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01059_DB01223
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01378_DB01059
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01059_DB00091
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00363_DB01059
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01059_DB00277
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01059_DB00363
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00382_DB01059
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01059_DB01402
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01059_DB00529
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01059_DB00364
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01059_DB01303
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01059_DB01378
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00091_DB01059
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01303_DB01059
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00893_DB01059
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01059_DB01593
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01059_DB01377
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01373_DB01059
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01059_DB00201
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01223_DB01059
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01059_DB01125
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01059_DB00682
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB00277_DB01059
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01059_DB01418
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01059_DB01373
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01059_DB01592
RDF Description of Norfloxacin
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01059_DB01370
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drug_interactions/DB01059_DB00266
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Skeat_Walter_William_1835-1912
_:header10765477631335206659827
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Skeat_Walter_William_1835-1912
Skeat, Walter William, 1835-1912
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext15755
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext10625
RDF Description of Skeat, Walter William, 1835-1912
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/2439
_:header4576196551335206660160
Mon, 23 Apr 2012 18:37:35 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/2439
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03488
alpha,alpha-trehalose-phosphate synthase (UDP-forming) activity
UDP-glucose-glucosephosphate glucosyltransferase
>Alpha,alpha-trehalose-phosphate synthase [UDP-forming]	MSRLVVVSNRIAPPDEHAASAGGLAVGILGALKAAGGLWFGWSGETGNEDQPLKKVKKGN	ITWASFNLSEQDLDEYYNQFSNAVLWPAFHYRLDLVQFQRPAWDGYLRVNALLADKLLPL	LQDDDIIWIHDYHLLPFAHELRKRGVNNRIGFFLHIPFPTPEIFNALPTYDTLLEQLCDY	DLLGFQTENDRLAFLDCLSNLTRVTTRSAKSHTAWGKAFRTEVYPIGIEPKEIAKQAAGP	LPPKLAQLKAELKNVQNIFSVERLDYSKGLPERFLAYEALLEKYPQHHGKIRYTQIAPTS	RGDVQAYQDIRHQLENEAGRINGKYGQLGWTPLYYLNQHFDRKLLMKIFRYSDVGLVTPL	RDGMNLVAKEYVAAQDPANPGVLVLSQFAGAANELTSALIVNPYDRDEVAAALDRALTMS	LAERISRHAEMLDVIVKNDINHWQECFISDLKQIVPRSAESQQRDKVATFPKLA
>1425 bp	ATGAGTCGTTTAGTCGTAGTATCTAACCGGATTGCACCACCAGACGAGCACGCCGCCAGT	GCCGGTGGCCTTGCCGTTGGCATACTGGGGGCACTGAAAGCCGCAGGCGGACTGTGGTTT	GGCTGGAGTGGTGAAACAGGGAATGAGGATCAGCCGCTAAAAAAGGTGAAAAAAGGTAAC	ATTACGTGGGCCTCTTTTAACCTCAGCGAACAGGACCTTGACGAATACTACAACCAATTC	TCCAATGCCGTTCTCTGGCCCGCTTTTCATTATCGGCTCGATCTGGTGCAATTTCAGCGT	CCTGCCTGGGACGGCTATCTACGCGTAAATGCGTTGCTGGCAGATAAATTACTGCCGCTG	TTGCAAGACGATGACATTATCTGGATCCACGATTATCACCTGTTGCCATTTGCGCATGAA	TTACGCAAACGGGGAGTGAATAATCGCATTGGTTTCTTTCTGCATATTCCTTTCCCGACA	CCGGAAATCTTCAACGCGCTGCCGACATATGACACCTTGCTTGAACAGCTTTGTGATTAT	GATTTGCTGGGTTTCCAGACAGAAAACGATCGTCTGGCGTTCCTGGATTGTCTTTCTAAC	CTGACCCGCGTCACGACACGTAGCGCAAAAAGCCATACAGCCTGGGGCAAAGCATTTCGA	ACAGAAGTCTACCCGATCGGCATTGAACCGAAAGAAATAGCCAAACAGGCTGCCGGGCCA	CTGCCGCCAAAACTGGCGCAACTTAAAGCGGAACTGAAAAACGTACAAAATATCTTTTCT	GTCGAACGGCTGGATTATTCCAAAGGTTTGCCAGAGCGTTTTCTCGCCTATGAAGCGTTG	CTGGAAAAATATCCGCAGCATCATGGTAAAATTCGTTATACCCAGATTGCACCAACGTCG	CGTGGTGATGTGCAAGCCTATCAGGATATTCGTCATCAGCTCGAAAATGAAGCTGGACGA	ATTAATGGTAAATACGGGCAATTAGGCTGGACGCCGCTTTATTATTTGAATCAGCATTTT	GACCGTAAATTACTGATGAAAATATTCCGCTACTCTGACGTGGGCTTAGTGACGCCACTG	CGTGACGGGATGAACCTGGTAGCAAAAGAGTATGTTGCTGCTCAGGACCCAGCCAATCCG	GGCGTTCTTGTTCTTTCGCAATTTGCGGGAGCGGCAAACGAGTTAACGTCGGCGTTAATT	GTTAACCCCTACGATCGTGACGAAGTTGCAGCTGCGCTGGATCGTGCATTGACTATGTCG	CTGGCGGAACGTATTTCCCGTCATGCAGAAATGCTGGACGTTATCGTGAAAAACGATATT	AACCACTGGCAGGAGTGCTTCATTAGCGACCTAAAGCAGATAGTTCCGCGAAGCGCGGAA	AGCCAGCAGCGCGATAAAGTTGCTACCTTTCCAAAGCTTGCGTAG
UDP-glucose + D-glucose 6-phosphate = UDP + alpha,alpha-trehalose 6-phosphate
http://www.uniprot.org/uniprot/P31677
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP31677%3E
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=577561
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D577561%3E
http://www.pdb.org/pdb/explore/explore.do?structureId=1UQU
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1UQU%3E
trehalose biosynthesis
EC 2.4.1.15
UDP-glycosyltransferase activity
http://bio2rdf.org/pdb:1UQU
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1UQU%3E
http://bio2rdf.org/uniprot:P31677
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP31677%3E
http://pfam.sanger.ac.uk/family?acc=PF00982
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF00982%3E
otsA
trehalose metabolism
http://bio2rdf.org/pfam:PF00982
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF00982%3E
UDP-glucosyltransferase activity
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9097040
X69160
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8045430
OTSA_ECOLI
Trehalose-6-phosphate synthase
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=X69160
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DX69160%3E
Alpha,alpha-trehalose-phosphate synthase [UDP-forming]
RDF Description of Alpha,alpha-trehalose-phosphate synthase [UDP-forming]
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03366
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02007
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01426
_:header2594496971335206660464
RDF Description of Ajmaline
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01426
InChI=1/C20H26N2O2/c1-3-10-11-8-14-17-20(12-6-4-5-7-13(12)21(17)2)9-15(16(11)18(20)23)22(14)19(10)24/h4-7,10-11,14-19,23-24H,3,8-9H2,1-2H3/t10-,11-,14-,15-,16?,17-,18-,19+,20+/m0/s1
Ajmalin
http://www.drugbank.ca/drugs/DB01426
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01426%3E
http://bio2rdf.org/chebi:28462
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fchebi%3A28462%3E
http://en.wikipedia.org/wiki/Ajmaline
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FAjmaline%3E
1.81 [HANSCH,C ET AL. (1995)]
http://dbpedia.org/page/Ajmaline
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FAjmaline%3E
C20H26N2O2
CCC1C2CC3C4N(C)C5=CC=CC=C5C44CC(C2C4O)N3C1O
http://dbpedia.org/resource/Ajmaline
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FAjmaline%3E
http://bio2rdf.org/cpd:C06542
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC06542%3E
An alkaloid found in the root of Rauwolfia serpentina, among other plant sources. It is a class Ia antiarrhythmic agent that apparently acts by changing the shape and threshold of cardiac action potentials. [PubChem]
C01BA05
2007-07-24 12:27:26 UTC
Ajmaline
http://bio2rdf.org/cas:4360-12-7
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A4360-12-7%3E
CJDRUOGAGYHKKD-NNAJWNLHBZ
2008-08-26 14:30:17 UTC
DB01426
http://bio2rdf.org/kegg:D00199
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD00199%3E
C01BA08
4.09e+00 mg/mL
http://www.dbpedia.org/resource/Ajmaline
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FAjmaline%3E
CC[C@H]1[C@@H]2C[C@H]3[C@@H]4N(C)C5=CC=CC=C5[C@]44C[C@@H]([C@H]2[C@@H]4O)[N@]3[C@@H]1O
-2.82 [ADME Research, USCD]
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Dent_John_Charles_1841-1888
_:header9241440681335206660698
RDF Description of Dent, John Charles, 1841-1888
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Dent_John_Charles_1841-1888
Dent, John Charles, 1841-1888
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext6917
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9910
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB01527
_:header13750450231335206660984
RDF Description of Clortermine
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01527
HXCXASJHZQXCKK-UHFFFAOYAM
Clortermine
CC(C)(N)CC1=CC=CC=C1Cl
http://dbpedia.org/resource/Clortermine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FClortermine%3E
DB01527
C10H14ClN
http://dbpedia.org/page/Clortermine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FClortermine%3E
http://en.wikipedia.org/wiki/Clortermine
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FClortermine%3E
1-(2-chlorophenyl)-2-methylpropan-2-amine
2007-07-31 13:10:15 UTC
http://bio2rdf.org/kegg:D03566
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fkegg%3AD03566%3E
2008-08-26 14:25:57 UTC
InChI=1/C10H14ClN/c1-10(2,12)7-8-5-3-4-6-9(8)11/h3-6H,7,12H2,1-2H3
http://www.drugbank.ca/drugs/DB01527
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01527%3E
http://bio2rdf.org/cas:10389-73-8
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A10389-73-8%3E
1.05e-01 mg/mL
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/PSTPIP1
_:header18848670001335206661260
Mon, 23 Apr 2012 18:37:36 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PSTPIP1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/976
http://symbol.bio2rdf.org/symbol:PSTPIP1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3APSTPIP1%3E
PSTPIP1
http://www.dbpedia.org/resource/PSTPIP1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FPSTPIP1%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3698
RDF Description of PSTPIP1
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Stratton-Porter_Gene_1863-1924
_:header5793355851335206661519
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Stratton-Porter_Gene_1863-1924
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext349
Stratton-Porter, Gene, 1863-1924
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext111
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext533
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext286
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext9489
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext532
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext904
RDF Description of Stratton-Porter, Gene, 1863-1924
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext125
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3722
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext4907
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/148
_:header21209145381335206661912
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/148
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00097
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8929952
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=903746
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D903746%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7714085
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2293030
Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9514160
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9626144
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9661624
Luteinizing hormone receptor
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=M73746
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DM73746%3E
2p21
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10580072
http://bio2rdf.org/uniprot:P22888
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP22888%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9858858
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9215288
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9467560
lutropin-choriogonadotropic hormone receptor activity
>2058 bp	ATGAAGCAGCGGTTCTCGCCGCTGCAGCTGCTGAAGCTGCTGCTGCTGCTGCAGGCGCCG	CTGCCACGAGCGCTGCGCAGGCTCTGCCCTGAGCCCTGCAACTGCGTGCCCGACGGCGCC	CTGCGTGCCCCGGCCCCACGGCCGTCCACTCGACTATCACTTGCCTACCTCCCTGTCAAA	GTGATCCCATCTCAAAGTTTCAGAGGACTTAATGAGGTCATAAAAATTGAAATCTCTCAG	ATTGATTCCCTGGAAAGGATAGAAGCTAATGCCTTTGACAACCTCCTCAATTTGTCTGAA	ATACTGATCCAGAACACCAAAAATCTGAGATACATTGAGCCCGGAGCATTTATAAATCTT	CCCCGATTAAAATACTTGAGCATCTGTAACACAGGCATCAGAAAGTTTCCAGATGTTACG	AAGGTCTTCTCCTCTGAATCAAATTTCATTCTGGAAATTTGTGATAACTTACACATAACC	ACCATACCAGGAAATGCTTTTCAAGGGATGAATAATGAATCTGTAACACTCAAACTATAT	GGAAATGGATTTGAAGAAGTACAAAGTCATGCATTCAATGGGACGACACTGACTTCACTG	GAGCTAAAGGAAAACGTACATCTGGAGAAGATGCACAATGGAGCCTTCCGTGGGGCCACA	GGGCCGAAAACCTTGGATATTTCTTCCACCAAATTGCAGGCCCTGCCGAGCTATGGCCTA	GAGTCCATTCAGAGGCTAATTGCCACGTCATCCTATTCTCTAAAAAAATTGCCATCAAAA	CAAACATTTGTCAATCTCCTGAGGGCCACGCTTCATTACCCCAGCCACTGCTGTGCATTT	AGAAACTTGCCAACGAAAGAGCTAAACTTCTCACATTCCATTTCTGAAAACTTTTCCAAA	CAATGTGAAAGCACAGTAAGGAAAAGTGAACTGAGTGGCTGGGACTATGAATATGGTTTC	TGCTTACCCAAGACACCCCGATGTGCTCCTGAACCAGATGCTTTTAATCCCTGTGAAGAC	ATTATGGGCTATGACTTCCTTAGGGTCCTGATTTGGCTGATTAATATTCTAGCCATCATG	GGAAACATGACTGTTCTTTTTGTTCTCCTGACAAGTCGTTACAAACTTACAGTGCCTCGT	TTTCTCATGTGCAATCTCTCCTTTGCAGACTTTTGCATGGGGCTCTATCTGCTGCTCATA	GCCTCAGTTGATTCCCAAACCAAGGGCCAGTACTATAACCATGCCATAGACTGGCAGACA	GGGAGTGGGTGCAGCACTGCTGGCTTTTTCACTGTATTAGCAAGTGAACTTTCTGTCTAC	ACCCTCACCGTCATCACTCTAGAAAGATGGCACACCATCACCTATGCTATTCACCTGGAC	CAAAAGCTGCGATTAAGACATGCCATTCTGATTATGCTTGGAGGCTGGCTCTTTTCTTCT	CTAATTGCTATGTTGCCCCTTGTCGGGGTCAGCAATTACATGAAGGTCAGTATTTGCTTC	CCCATGGATGTGGAAACCACTCTCTCACAAGTCTATATATTAACCATCCTGATTCTCAAT	GTGGTGGCCTTCTTAATAATTTGTGCTTGCTACATTAAAATTTATTTTGCAGTTCGAAAC	CCAGAATTAATGGCTACCAATAAAGATACAAAGATTGCTAAGAAAATGGCAATCCTCATC	TTCACCGATTTTACCTGCATGGCACCTATCTCTTTTTTTGCCATCTCAGCTGCCTTCAAA	GTACCTCTTATCACAGTAACCAACTCTAAAGTTTTACTGGTTCTTTTTTATCCCATCAAT	TCTTGTGCCAATCCATTTCTGTATGCAATATTCACTAAGACATTCCAAAGAGATTTCTTT	CTTTTGCTGAGCAAATTTGGCTGCTGTAAACGTCGGGCTGATCCTCTTTATAGAAGGAAA	GATTTTTCAGCTTACACCTCCAACTGCAAAAATGGCTTCACTGGATCAAATAAGCCTTCT	CAATCCACCTTGAAGTTGTCCACATTGCACTGTCAAGGTACAGCTCTCCTAGACAAGACT	CGCTACACAGAGTGTTAA
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8747461
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7692306
606-627
>Lutropin-choriogonadotropic hormone receptor precursor	MKQRFSALQLLKLLLLLQPPLPRALREALCPEPCNCVPDGALRCPGPTAGLTRLSLAYLP	VKVIPSQAFRGLNEVIKIEISQIDSLERIEANAFDNLLNLSEILIQNTKNLRYIEPGAFI	NLPRLKYLSICNTGIRKFPDVTKVFSSESNFILEICDNLHITTIPGNAFQGMNNESVTLK	LYGNGFEEVQSHAFNGTTLTSLELKENVHLEKMHNGAFRGATGPKTLDISSTKLQALPSY	GLESIQRLIATSSYSLKKLPSRETFVNLLEATLTYPSHCCAFRNLPTKEQNFSHSISENF	SKQCESTVRKVSNKTLYSSMLAESELSGWDYEYGFCLPKTPRCAPEPDAFNPCEDIMGYD	FLRVLIWLINILAIMGNMTVLFVLLTSRYKLTVPRFLMCNLSFADFCMGLYLLLIASVDS	QTKGQYYNHAIDWQTGSGCSTAGFFTVFASELSVYTLTVITLERWHTITYAIHLDQKLRL	RHAILIMLGGWLFSSLIAMLPLVGVSNYMKVSICFPMDVETTLSQVYILTILILNVVAFF	IICACYIKIYFAVRNPELMATNKDTKIAKKMAILIFTDFTCMAPISFFAISAAFKVPLIT	VTNSKVLLVLFYPINSCANPFLYAIFTKTFQRDFFLLLSKFGCCKRRAELYRRKDFSAYT	SNCKNGFTGSNKPSQSTLKLSTLHCQGTALLDKTRYTEC
LHR
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8559204
364-385
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7719343
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2244890
LSH- R
protein-hormone receptor activity
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9626653
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7629248
http://bio2rdf.org/hgnc:6585
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A6585%3E
LSHR_HUMAN
526-549
Lutropin-choriogonadotropic hormone receptor
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7757065
M73746
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8281137
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12606382
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7556872
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9851790
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8829636
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ALHCGR%3E
http://www.uniprot.org/uniprot/P22888
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP22888%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1922095
440-462
571-594
http://www.genenames.org/data/hgnc_data.php?hgnc_id=6585
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D6585%3E
Lutropin-choriogonadotropic hormone receptor precursor
LH/CG-R
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/15967102
483-505
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00032
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00050
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00044
RDF Description of Lutropin-choriogonadotropic hormone receptor
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00014
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Droz_Gustave_1832-1895
_:header9259681511335206662154
Mon, 23 Apr 2012 18:37:37 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Droz_Gustave_1832-1895
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3924
Droz, Gustave, 1832-1895
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3926
RDF Description of Droz, Gustave, 1832-1895
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3925
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext3923
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext7575
http://www4.wiwiss.fu-berlin.de/sider/data/side_effects/C0162835
_:header20645297441335206662453
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3375
http://dbpedia.org/resource/Hypopigmentation
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FHypopigmentation%3E
http://sideeffects.embl.de/se/C0162835
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fse%2FC0162835%3E
hypopigmentation
C0162835
depigmentation
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3553
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/4630253
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2133
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/12536
RDF Description of hypopigmentation
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3000
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/2266
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/3392
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/5381
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/52421
http://www4.wiwiss.fu-berlin.de/sider/resource/drugs/7638
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/HOXA11
_:header18236958491335206662696
RDF Description of HOXA11
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/HOXA11
http://symbol.bio2rdf.org/symbol:HOXA11
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AHOXA11%3E
HOXA11
http://www.dbpedia.org/resource/HOXA11
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FHOXA11%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/980
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3704
http://www4.wiwiss.fu-berlin.de/diseasome/data/diseases/831
_:header6807035901335206662968
RDF Description of Neurofibrosarcoma
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/831
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/MXI1
Neurofibrosarcoma
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3356
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Kandinsky_Wassily_1866-1944
_:header10631270551335206663223
Mon, 23 Apr 2012 18:37:38 GMT
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Kandinsky_Wassily_1866-1944
Kandinsky, Wassily, 1866-1944
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext5321
RDF Description of Kandinsky, Wassily, 1866-1944
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/3533
_:header1723880131335206663602
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3533
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03980
http://www.pdb.org/pdb/explore/explore.do?structureId=1LEZ
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1LEZ%3E
CRK1
U10871
receptor signaling protein serine/threonine kinase activity
MAP kinase p38 alpha
>Mitogen-activated protein kinase 14	MSQERPTFYRQELNKTIWEVPERYQNLSPVGSGAYGSVCAAFDTKTGHRVAVKKLSRPFQ	SIIHAKRTYRELRLLKHMKHENVIGLLDVFTPARSLEEFNDVYLVTHLMGADLNNIVKCQ	KLTDDHVQFLIYQILRGLKYIHSADIIHRDLKPSNLAVNEDCELKILDFGLARHTDDEMT	GYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELLTGRTLFPGTDHIDQLKLILRLVG	TPGAELLKKISSESARNYIQSLAQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAA	QALAHAYFAQYHDPDDEPVADPYDQSFESRDLLIDEWKSLTYDEVISFVPPPLDQEEMES
Mitogen-activated protein kinase 14
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7914033
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/7839144
MAP kinase activity
cytoplasm.Nucleus
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10943842
Mitogen-activated protein kinase p38 alpha
http://www.uniprot.org/uniprot/P47811
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP47811%3E
MK14_MOUSE
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/12391307
Involved in MAP kinase activity
>1083 bp	ATGTCGCAGGAGAGGCCCACGTTCTACCGGCAGGAGCTGAACAAGACCATCTGGGAGGTG	CCCGAACGATACCAGAACCTGTCCCCGGTGGGCTCGGGCGCCTATGGCTCGGTGTGTGCT	GCTTTTGATACAAAGACGGGGCATCGTGTGGCAGTTAAGAAGCTGTCGAGACCGTTTCAG	TCCATCATTCACGCCAAAAGGACCTACCGAGAGTTGCGTCTGCTGAAGCACATGAAACAC	GAAAATGTGATTGGTCTGTTGGATGTGTTCACACCCGCAAGGTCACTGGAGGAATTCAAT	GACGTGTACCTGGTGACCCATCTCATGGGGGCGGACCTGAACAACATCGTGAAGTGCCAG	AAGCTGACCGACGACCACGTTCAGTTTCTCATCTACCAGATCCTCCGAGGGCTGAAGTAT	ATACATTCGGCTGACATAATTCACAGGGACCTAAAGCCCAGCAACCTAGCTGTGAACGAA	GACTGTGAGCTCAAGATTCTGGATTTTGGGCTGGCTCGGCACACTGATGATGAGATGACA	GGCTACGTGGCTACCAGGTGGTACCGAGCCCCAGAGATCATGCTGAATTGGATGCACTAT	AACCAGACAGTGGATATTTGGTCCGTGGGCTGCATCATGGCTGAGCTGTTGACCGGAAGA	ACGTTGTTTCCTGGTACAGACCATATTGATCAGTTGAAGCTCATTTTAAGACTCGTTGGA	ACCCCAGGGGCTGAGCTTCTGAAGAAAATCTCCTCAGAGTCTGCAAGAAACTACATTCAG	TCTCTGGCCCAGATGCCGAAGATGAACTTCGCAAATGTATTTATTGGTGCCAATCCCCTG	GCTGTCGACCTACTGGAGAAGATGCTCGTTTTGGACTCAGATAAGAGGATCACAGCAGCC	CAAGCTCTTGCGCATGCCTACTTTGCTCAGTACCACGACCCTGATGATGAGCCTGTTGCT	GACCCTTATGACCAGTCCTTTGAAAGCAGGGACCTTCTCATAGATGAGTGGAAGAGCCTG	ACCTATGATGAAGTCATCAGCTTTGTGCCACCACCCCTTGACCAAGAAGAAATGGAGTCC	TGA
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/9122194
EC 2.7.11.24
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=U10871
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DU10871%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10601328
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=531125
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3D531125%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10704466
http://bio2rdf.org/pdb:1LEZ
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1LEZ%3E
Responds to activation by environmental stress, pro- inflammatory cytokines and lipopolysaccharide (LPS) by phosphorylating a number of transcription factors, such as ELK1 and ATF2 and several downstream kinases, such as MAPKAPK2 and MAPKAPK5. Plays a critical role in the production of some cytokines, for example IL-6. Required in mid-fetal development for the growth of embryo-derived blood vessels in the labyrinth layer of the placenta. Also plays an essential role in developmental and stress-induced erythropoiesis, through regulation of EPO gene expression
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/8444355
http://bio2rdf.org/uniprot:P47811
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP47811%3E
Mapk14
RDF Description of Mitogen-activated protein kinase 14
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Mansfield_Katherine_1888-1923
_:header5657664621335206663873
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Mansfield_Katherine_1888-1923
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1429
Mansfield, Katherine, 1888-1923
RDF Description of Mansfield, Katherine, 1888-1923
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext20267
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext1472
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/6918453
_:header13335541311335206664477
Mon, 23 Apr 2012 18:37:39 GMT
RDF Description of AURANOFIN
CID0006918453
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0003872
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00995
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00995%3E
http://sideeffects.embl.de/drugs/6918453
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F6918453%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0039103
http://dbpedia.org/resource/Auranofin
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FAuranofin%3E
http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/95
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdailymed%2Fresource%2Fdrugs%2F95%3E
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0006918453&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0006918453%26input_query_species%3D9606%3E
AURANOFIN
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0006918453
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0006918453%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0017658
auranofin
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=r1Xq7lQzfz8=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3Dr1Xq7lQzfz8%3D%3E
http://www4.wiwiss.fu-berlin.de/dblp/data/person/353853
_:header5908124211335206664772
http://www4.wiwiss.fu-berlin.de/dblp/resource/person/353853
Robert Hyatt
http://www4.wiwiss.fu-berlin.de/dblp/resource/record/conf/acm/WhitlockDH88
RDF Description of Robert Hyatt
http://www4.wiwiss.fu-berlin.de/sider/data/drugs/861
_:header19901635281335206665081
RDF Description of LIOTHYRONINE
http://dbpedia.org/resource/Liothyronine_sodium
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FLiothyronine_sodium%3E
LIOTHYRONINE
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=SGoDW9vL70Q=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DSGoDW9vL70Q%3D%3E
http://sideeffects.embl.de/drugs/861
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsideeffects.embl.de%2Fdrugs%2F861%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0027145
Triostat
http://stitch.embl.de/cgi/show_network_section.pl?identifier=-CID0000000861&input_query_species=9606
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fstitch.embl.de%2Fcgi%2Fshow_network_section.pl%3Fidentifier%3D-CID0000000861%26input_query_species%3D9606%3E
liothyronine
http://205.193.93.51/dpdonline/displayInfo.do?drugCode=PM4Bco3+9iA=
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F205.193.93.51%2Fdpdonline%2FdisplayInfo.do%3FdrugCode%3DPM4Bco3%2B9iA%3D%3E
http://www4.wiwiss.fu-berlin.de/stitch/resource/chemicals/CID0000000861
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fstitch%2Fresource%2Fchemicals%2FCID0000000861%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0342208
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0040137
http://www.fda.gov/cder/foi/label/2002/20105s2lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2002%2F20105s2lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00279
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdrugbank%2Fresource%2Fdrugs%2FDB00279%3E
CID0000000861
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0677607
Cytomel
http://www.fda.gov/cder/foi/label/2002/10379s47lbl.pdf
http://www4.wiwiss.fu-berlin.de/sider/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.fda.gov%2Fcder%2Ffoi%2Flabel%2F2002%2F10379s47lbl.pdf%3E
http://www4.wiwiss.fu-berlin.de/sider/resource/side_effects/C0010308
http://www4.wiwiss.fu-berlin.de/drugbank/data/targets/5358
_:header441943501335206665431
Mon, 23 Apr 2012 18:37:40 GMT
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/5358
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03579
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/10876155
4-amino-4-deoxychorismate lyase
http://bio2rdf.org/pfam:PF01063
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpfam%3APF01063%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2251281
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=M93135
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fviewer.fcgi%3Fval%3DM93135%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/1644759
http://www4.wiwiss.fu-berlin.de/drugbank/resource/references/2071583
PABC_ECOLI
Aminodeoxychorismate lyase
http://bio2rdf.org/pdb:1I2L
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fpdb%3A1I2L%3E
pabC
http://www.pdb.org/pdb/explore/explore.do?structureId=1I2L
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.pdb.org%2Fpdb%2Fexplore%2Fexplore.do%3FstructureId%3D1I2L%3E
EC 4.1.3.38
http://bio2rdf.org/uniprot:P28305
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Funiprot%3AP28305%3E
>810 bp	ATGTTCTTAATTAACGGTCATAAGCAGGAATCGCTGGCAGTAAGCGATCGGGCAACGCAG	TTTGGTGATGGTTGTTTTACCACCGCCAGAGTTATCGACGGTAAAGTCAGTTTGTTATCG	GCGCATATCCAGCGACTACAGGATGCTTGTCAGCGGTTGATGATTTCCTGTGACTTCTGG	CCTCAGCTTGAACAAGAGATGAAAACGCTGGCAGCAGAACAGCAAAATGGTGTGCTGAAA	GTCGTGATCAGTCGCGGTAGTGGCGGGCGAGGGTACAGCACATTGAACAGCGGACCGGCA	ACGCGGATTCTCTCCGTTACGGCTTATCCTGCACATTACGACCGTTTGCGTAACGAGGGG	ATTACGTTGGCGCTAAGCCCGGTGCGGCTGGGGCGCAATCCTCATCTTGCAGGTATTAAA	CATCTCAATCGTCTTGAGCAAGTATTGATTCGCTCTCATCTTGAGCAGACAAACGCTGAT	GAGGCGCTGGTCCTTGACAGCGAAGGGTGGGTTACGGAATGCTGTGCGGCTAATTTGTTC	TGGCGGAAGGGCAACGTAGTTTATACGCCGCGACTGGATCAGGCAGGTGTTAACGGCATT	ATGCGACAATTCTGTATCCGTTTGCTGGCACAATCCTCTTATCAGCTTGTCGAAGTGCAA	GCCTCTCTGGAAGAGTCGTTGCAGGCAGATGAGATGGTTATTTGTAATGCGTTAATGCCA	GTGATGCCCGTATGTGCCTGTGGCGATGTCTCCTTTTCGTCAGCAACGTTATATGAATAT	TTAGCCCCACTTTGTGAGCGCCCGAATTAG
Converts 4-amino-4-deoxychorismate into 4-aminobenzoate (PABA) and pyruvate
>Aminodeoxychorismate lyase	MFLINGHKQESLAVSDRATQFGDGCFTTARVIDGKVSLLSAHIQRLQDACQRLMISCDFW	PQLEQEMKTLAAEQQNGVLKVVISRGSGGRGYSTLNSGPATRILSVTAYPAHYDRLRNEG	ITLALSPVRLGRNPHLAGIKHLNRLEQVLIRSHLEQTNADEALVLDSEGWVTECCAANLF	WRKGNVVYTPRLDQAGVNGIMRQFCIRLLAQSSYQLVEVQASLEESLQADEMVICNALMP	VMPVCACGDVSFSSATLYEYLAPLCERPN
http://pfam.sanger.ac.uk/family?acc=PF01063
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpfam.sanger.ac.uk%2Ffamily%3Facc%3DPF01063%3E
http://www.uniprot.org/uniprot/P28305
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.uniprot.org%2Funiprot%2FP28305%3E
M93135
ADCL
ADC lyase
RDF Description of Aminodeoxychorismate lyase
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/COL5A1
_:header19241302421335206665656
RDF Description of COL5A1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/COL5A1
http://symbol.bio2rdf.org/symbol:COL5A1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ACOL5A1%3E
COL5A1
http://www.dbpedia.org/resource/COL5A1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FCOL5A1%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2241
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2239
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/353
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00256
_:header18348817651335206665962
RDF Description of Lymecycline
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00256
CTC
Do not to take any indigestion remedies, iron or zinc supplements at the same time as this medicine.
WKZUQOQLOHMCQC-XHJBQRPKBZ
Aureomykoin
Chrysomykine
Acronize
Tetra 5
Aurofac
Tocopherex
Aureomycin monohydrochloride
Chlortetracycline
Biovetin
Duomycin
http://en.wikipedia.org/wiki/Lymecycline
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FLymecycline%3E
Chlortetracycline hydrochloride
Biomycin hydrochloride
Aureocina
http://129.128.185.122/drugbank2/drugs/DB00256/inserts/2679/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00256%2Finserts%2F2679%2Ffull%3E
Lymecycline is a tetracycline broad-spectrum antibiotic. It is approximately 5000 times more soluble than tetracycline base and is unique amongst tetracyclines in that it is absorbed by the "active transport" process across the intestinal wall, making use of the same fast and efficient mechanism by which carbohydrates are absorbed. It inhibits cell growth by inhibiting translation.
Biomycin
J01AA04
Aureomycin hydrochloride
Orospray
CN(C)C1C2CC3C(C(=O)C2(O)C(=O)C(C1=O)=C(N)O)=C(O)C1=C(O)C=CC(Cl)=C1C3(C)O
A tetracycline with a 7-chloro substitution. [PubChem]
DB00256
Aureocarmyl
http://www.dbpedia.org/resource/Lymecycline
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FLymecycline%3E
For the treatment of infections and to treat acne. It may also be used to treat urinary tract infections, gum disease, and other bacterial infections such as gonorrhea and chlamydia. Lymecycline is also used commonly as a prophylactic treatment for infection by <i>Bacillus anthracis</i> (anthrax). It is also effective against <i>Yersinia pestis</i> and malaria and is also prescribed for the treatment of Lyme disease.
2008-08-26 15:46:17 UTC
http://www.dbpedia.org/resource/Chlortetracycline
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FChlortetracycline%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/antiprotozoals
Soluble (at all physiological pH values)
Biomitsin hydrochloride
Adverse effects include nausea, vomiting, diarrhoea, glossitis, enterocolitis, dysphagia, dermatitis, hypersensitivity reactions, proctitis, and vaginitis.
Isphamycin
Aureocycline
http://dbpedia.org/resource/Lymecycline
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FLymecycline%3E
Aureociclin
Tetralysal
Tetrlysal 300
InChI=1/C22H23ClN2O8/c1-21(32)7-6-8-15(25(2)3)17(28)13(20(24)31)19(30)22(8,33)18(29)11(7)16(27)12-10(26)5-4-9(23)14(12)21/h4-5,7-8,15,26-27,31-33H,6,24H2,1-3H3/b20-13-/t7-,8-,15-,21-,22-/m0/s1
http://129.128.185.122/drugbank2/drugs/DB00256/inserts/1700/full
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2F129.128.185.122%2Fdrugbank2%2Fdrugs%2FDB00256%2Finserts%2F1700%2Ffull%3E
http://129.128.185.122/drugbank2/drugs/DB00256/inserts/685/full
Absorption is fast and efficient. Bioavailability is 100% following oral administration.
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3368
Aureomicina
Lymecycline
Clorocipan
Aureomycin
Chlortetracyclinium chloride
Auxeomycin
http://dbpedia.org/page/Lymecycline
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FLymecycline%3E
Biomycin A
Aureomycin A-377
Flamycin
Aureociclina
CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)[C@]2(O)C(=O)C(C1=O)=C(N)O)=C(O)C1=C(O)C=CC(Cl)=C1[C@@]3(C)O
Centraureo
Chlortetracyclin
http://www.drugbank.ca/drugs/DB00256
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00256%3E
Acronize PD
Psittacin hydrochloride
(2Z,4S,4aS,5aS,6S,12aS)-2-(amino-hydroxymethylidene)-7-chloro-4-dimethylamino-6,10,11,12a-tetrahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione
Chlorotetracycline hydrochloride
Chlorotetracycline
Aurofac 10
B-Aureo
aprd00565
C22H23ClN2O8
CLTC
Chrusomykine
Biomitsin
7-Chlorotetracycline
expt01049
Lymecycline inhibits cell growth by inhibiting translation. It binds to the 30S ribosomal subunit and prevents the amino-acyl tRNA from binding to the A site of the ribosome. The binding is reversible in nature. Lymecycline is lipophilic and can easily pass through the cell membrane or passively diffuses through porin channels in the bacterial membrane. Cells become resistant to lymecycline by at least two mechanisms: efflux and ribosomal protection. In efflux, a resistance gene encodes a membrane protein that actively pumps lymecycline out of the cell. This is the mechanism of action of the tetracycline resistance gene on the artificial plasmid pBR322. In ribosomal protection, a resistance gene encodes a protein which binds to the ribosome and prevents lymecycline from acting on the ribosome.
2.34e-01 mg/mL
http://bio2rdf.org/cas:992-21-2
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A992-21-2%3E
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/DSPP
_:header4482700561335206666222
Mon, 23 Apr 2012 18:37:41 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/DSPP
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2135
http://symbol.bio2rdf.org/symbol:DSPP
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ADSPP%3E
DSPP
http://bio2rdf.org/hgnc:3054
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A3054%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=3054
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D3054%3E
http://bio2rdf.org/geneid:1834
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fgeneid%3A1834%3E
http://www.dbpedia.org/resource/DSPP
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FDSPP%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2134
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2079
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/303
RDF Description of DSPP
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/312
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2136
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/313
http://www4.wiwiss.fu-berlin.de/gutendata/data/people/Turner_Nat
_:header8608583851335206666495
http://www4.wiwiss.fu-berlin.de/gutendata/resource/people/Turner_Nat
Turner, Nat
RDF Description of Turner, Nat
http://www4.wiwiss.fu-berlin.de/gutendata/resource/etext15333
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/NR4A3
_:header4882991191335206666740
RDF Description of NR4A3
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/NR4A3
http://symbol.bio2rdf.org/symbol:NR4A3
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ANR4A3%3E
NR4A3
http://www.dbpedia.org/resource/Neuron-derived_orphan_receptor_1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FNeuron-derived_orphan_receptor_1%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/230
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/NEUROD1
_:header19840182191335206667005
RDF Description of NEUROD1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/NEUROD1
http://symbol.bio2rdf.org/symbol:NEUROD1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3ANEUROD1%3E
NEUROD1
http://www.dbpedia.org/resource/NEUROD1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FNEUROD1%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2159
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/ELA2
_:header5213562711335206667254
Mon, 23 Apr 2012 18:37:42 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/ELA2
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2550
http://symbol.bio2rdf.org/symbol:ELA2
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AELA2%3E
ELA2
http://www.dbpedia.org/resource/Neutrophil_elastase
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FNeutrophil_elastase%3E
RDF Description of ELA2
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/493
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3366
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/KCNQ1
_:header18179711711335206667499
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/KCNQ1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1527
http://symbol.bio2rdf.org/symbol:KCNQ1
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3AKCNQ1%3E
KCNQ1
http://bio2rdf.org/hgnc:6294
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fhgnc%3A6294%3E
http://www.genenames.org/data/hgnc_data.php?hgnc_id=6294
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.genenames.org%2Fdata%2Fhgnc_data.php%3Fhgnc_id%3D6294%3E
http://bio2rdf.org/geneid:3784
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fgeneid%3A3784%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/627
RDF Description of KCNQ1
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2988
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/124
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2830
http://www4.wiwiss.fu-berlin.de/drugbank/data/drugs/DB00139
_:header5002288331335206667825
RDF Description of Succinic acid
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3530
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3530%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3940
-0.2 [ADME Research, USCD]
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/97
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/835
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F835%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/dosageforms/solution/DropsOral
Dihydrofumaric acid
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4001
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/766
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F766%3E
Katasuccin
1,2-Ethanedicarboxylic acid
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3132
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3132%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4000
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3964
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/673
http://bio2rdf.org/cpd:C00042
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcpd%3AC00042%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3527
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3527%3E
Succinicun acidum
OC(=O)CCC(O)=O
Ubicoenzyme (Beet + Cerium-Oxalate + Citric Acid + Hydrastis Canadensis + Lipoic Acid + Alpha + Nadidum + Oyster Shells + Selenium + Silicon Dioxide + Succinic Acid + Sulfur + Thuja Occidentalis)
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3951
http://www.drugbank.ca/drugs/DB00139
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00139%3E
Sal succini
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/197
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3529
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3529%3E
Succinate is an essential component of the Krebs or citric acid cycle and serves an electron donor in the production of fumaric acid and FADH2. It also has been shown to be a good "natural" antibiotic because of its relative acidic or caustic nature (high concentrations can even cause burns). Succinate supplements have been shown to help reduce the effects of hangovers by activating the degradation of acetaldehyde - a toxic byproduct of alcohol metabolism - into CO2 and H2O through aerobic metabolism. Succinic acid has been shown to stimulate neural system recovery and bolster the immune system. Claims have also been made that it boosts awareness, concentration and reflexes.
Asuccin
Succinic acid
Kyselina jantarova
185-188 oC
SIN
Succinellite
http://dbpedia.org/page/Succinate
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fpage%2FSuccinate%3E
Amber acid
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F353%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/170
Spirit of amber
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/585
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F666%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3999
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4009
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/897
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F897%3E
Succinate
http://en.wikipedia.org/wiki/Succinate
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fen.wikipedia.org%2Fwiki%2FSuccinate%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4008
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/748
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F748%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3175
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3175%3E
butanedioic acid
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/1410
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3945
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2244
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2244%3E
1CZE
Acid of amber
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4010
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/25
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3178
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3178%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3578
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3578%3E
Ethylene succinic acid
Butanedionic acid
2.11e+02 mg/mL
http://bio2rdf.org/cas:110-15-6
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fcas%3A110-15-6%3E
Succinicum acidum
http://bio2rdf.org/chebi:15741
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fbio2rdf.org%2Fchebi%3A15741%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1265
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1265%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/67
2008-08-26 15:22:40 UTC
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/391
KDYFGRWQOYBRFD-AOTPWWKUCA
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3580
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3580%3E
Ethylenesuccinic acid
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/921
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F921%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4007
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/anti-ulcerAgents
Ethanedicarboxylic acid
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/498
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4006
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3526
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3526%3E
Dicarboxylic acid
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4003
nutr00054
A water-soluble, colorless crystal with an acid taste that is used as a chemical intermediate, in medicine, the manufacture of lacquers, and to make perfume esters. It is also used in foods as a sequestrant, buffer, and a neutralizing agent. (Hawley&#39;s Condensed Chemical Dictionary, 12th ed, p1099; McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed, p1851)
Butanedioic acid
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4002
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1101
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1101%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3528
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3528%3E
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3370
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F3370%3E
/drugs/139/safety_sheets/856
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1726
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F1726%3E
Bernsteinsaure
C4H6O4
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/3949
InChI=1/C4H6O4/c5-3(6)1-2-4(7)8/h1-2H2,(H,5,6)(H,7,8)/f/h5,7H
DB00139
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/194
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F194%3E
http://dbpedia.org/resource/Succinate
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FSuccinate%3E
83.2 mg/mL at 25 oC [YALKOWSKY,SH & HE,Y (2003)]
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/643
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F643%3E
Oral rat LD<sub>50</sub>: 2260 mg/kg
For nutritional supplementation, also for treating dietary shortage or imbalance
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/2893
http://www4.wiwiss.fu-berlin.de/drugbank/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fdiseasome%2Fresource%2Fdiseases%2F2893%3E
http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugcategory/radiation-protectiveAgents
http://www4.wiwiss.fu-berlin.de/drugbank/resource/targets/4005
http://www4.wiwiss.fu-berlin.de/diseasome/data/genes/PAPSS2
_:header19452752761335206668072
Mon, 23 Apr 2012 18:37:43 GMT
http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PAPSS2
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3860
http://purl.org/net/tcm/tcm.lifescience.ntu.edu.tw/id/gene/PAPSS2
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fpurl.org%2Fnet%2Ftcm%2Ftcm.lifescience.ntu.edu.tw%2Fid%2Fgene%2FPAPSS2%3E
http://symbol.bio2rdf.org/symbol:PAPSS2
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsymbol.bio2rdf.org%2Fsymbol%3APAPSS2%3E
PAPSS2
http://www.dbpedia.org/resource/PAPSS2
http://www4.wiwiss.fu-berlin.de/diseasome/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.dbpedia.org%2Fresource%2FPAPSS2%3E
RDF Description of PAPSS2
http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1039
http://data.linkedmdb.org/data/film/41187
_:header1240490271335206701738
Mon, 23 Apr 2012 18:45:02 GMT
http://data.linkedmdb.org/resource/film/41187
http://data.linkedmdb.org/resource/film_film_distributor_relationship/7456
http://data.linkedmdb.org/resource/producer/12016
http://data.linkedmdb.org/resource/performance/110078
http://data.linkedmdb.org/resource/music_contributor/1874
1995-08-25
http://data.linkedmdb.org/resource/actor/29877
http://data.linkedmdb.org/resource/director/8391
http://data.linkedmdb.org/resource/actor/40786
http://data.linkedmdb.org/resource/writer/13046
http://data.linkedmdb.org/resource/producer/12107
http://data.linkedmdb.org/resource/actor/973
http://data.linkedmdb.org/resource/actor/32849
http://data.linkedmdb.org/resource/performance/108675
http://data.linkedmdb.org/resource/performance/86464
http://data.linkedmdb.org/resource/actor/54073
http://data.linkedmdb.org/resource/performance/76064
http://data.linkedmdb.org/resource/performance/80451
http://data.linkedmdb.org/resource/producer/9660
http://www.freebase.com/view/guid/9202a8c04000641f80000000004e314c
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000004e314c%3E
Lord of Illusions
RDF Description of Lord of Illusions
http://data.linkedmdb.org/resource/film_film_distributor_relationship/12903
http://data.linkedmdb.org/data/film/69933
_:header17637801281335206702364
Mon, 23 Apr 2012 18:45:03 GMT
http://www.freebase.com/view/guid/9202a8c04000641f8000000009d67fb3
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f8000000009d67fb3%3E
RDF Description of The Return of Clint the Stranger
http://data.linkedmdb.org/resource/film/69933
http://data.linkedmdb.org/resource/performance/146654
1972-12-14
The Return of Clint the Stranger
http://data.linkedmdb.org/resource/actor/31032
http://data.linkedmdb.org/resource/director/16220
http://data.linkedmdb.org/data/producer/9853
_:header6025084511335206702516
http://data.linkedmdb.org/resource/producer/9853
Jeff Bridges (Producer)
Jeff Bridges
http://www.freebase.com/view/guid/9202a8c04000641f800000000006cb66
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f800000000006cb66%3E
http://data.linkedmdb.org/resource/film/7793
RDF Description of Jeff Bridges (Producer)
http://data.linkedmdb.org/resource/film/97216
http://data.linkedmdb.org/resource/film/25173
http://data.linkedmdb.org/data/producer/10708
_:header9474027441335206702771
Mon, 23 Apr 2012 18:45:04 GMT
http://www.freebase.com/view/guid/9202a8c04000641f80000000003610d9
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000003610d9%3E
http://data.linkedmdb.org/resource/producer/10708
http://data.linkedmdb.org/resource/film/40378
Nigel Sinclair (Producer)
Nigel Sinclair
RDF Description of Nigel Sinclair (Producer)
http://data.linkedmdb.org/resource/film/3452
http://data.linkedmdb.org/resource/film/56363
http://data.linkedmdb.org/resource/film/51
http://data.linkedmdb.org/resource/film/578
http://data.linkedmdb.org/resource/film/41735
http://data.linkedmdb.org/resource/film/77169
http://data.linkedmdb.org/resource/film/98525
http://data.linkedmdb.org/resource/film/43871
http://data.linkedmdb.org/resource/film/39261
http://data.linkedmdb.org/data/producer/10743
_:header7605020971335206703134
RDF Description of Sherwood Schwartz (Producer)
http://data.linkedmdb.org/resource/producer/10743
Sherwood Schwartz (Producer)
Sherwood Schwartz
http://www.freebase.com/view/guid/9202a8c04000641f80000000003818e5
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000003818e5%3E
http://data.linkedmdb.org/resource/film/42653
http://data.linkedmdb.org/data/film/64002
_:header7620539861335206704123
http://data.linkedmdb.org/resource/film/64002
Mr. Sardonicus
http://data.linkedmdb.org/resource/actor/45462
http://data.linkedmdb.org/resource/actor/38298
http://data.linkedmdb.org/resource/director/9859
http://data.linkedmdb.org/resource/performance/128933
http://www.freebase.com/view/guid/9202a8c04000641f8000000009016d70
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f8000000009016d70%3E
http://data.linkedmdb.org/resource/performance/128932
RDF Description of Mr. Sardonicus
http://data.linkedmdb.org/data/film/405
_:header6787991971335206705114
Mon, 23 Apr 2012 18:45:05 GMT
http://data.linkedmdb.org/resource/film/405
http://data.linkedmdb.org/resource/interlink/226
Ronin
http://data.linkedmdb.org/resource/performance/24834
http://data.linkedmdb.org/resource/actor/29625
http://data.linkedmdb.org/resource/performance/24837
http://data.linkedmdb.org/resource/writer/4346
http://data.linkedmdb.org/resource/performance/41888
http://mpii.de/yago/resource/Ronin_%28film%29
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fmpii.de%2Fyago%2Fresource%2FRonin_%2528film%2529%3E
http://data.linkedmdb.org/resource/editor/588
http://data.linkedmdb.org/resource/editor/3070
http://data.linkedmdb.org/resource/music_contributor/5716
http://data.linkedmdb.org/resource/director/8439
http://data.linkedmdb.org/resource/actor/32553
http://data.linkedmdb.org/resource/actor/32467
http://www.freebase.com/view/guid/9202a8c04000641f800000000012da8f
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f800000000012da8f%3E
http://data.linkedmdb.org/resource/performance/24835
http://data.linkedmdb.org/resource/actor/29707
http://data.linkedmdb.org/resource/film_genre/13
http://data.linkedmdb.org/resource/film_format/66
http://dbpedia.org/resource/Ronin_%28film%29
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FRonin_%2528film%2529%3E
http://data.linkedmdb.org/resource/film_cut/5318
http://data.linkedmdb.org/resource/cinematographer/201
http://data.linkedmdb.org/resource/film_genre/47
http://data.linkedmdb.org/resource/writer/13057
http://data.linkedmdb.org/resource/actor/32758
http://data.linkedmdb.org/resource/performance/24832
http://data.linkedmdb.org/resource/cinematographer/1585
http://data.linkedmdb.org/resource/film_location/8
http://www.rottentomatoes.com/alias?type=imdbid&s=0122690
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rottentomatoes.com%2Falias%3Ftype%3Dimdbid%26s%3D0122690%3E
http://data.linkedmdb.org/resource/actor/45842
http://data.linkedmdb.org/resource/performance/89506
http://www.imdb.com/title/tt0122690
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.imdb.com%2Ftitle%2Ftt0122690%3E
http://data.linkedmdb.org/resource/producer/167
1998-09-12
http://data.linkedmdb.org/resource/performance/24833
http://data.linkedmdb.org/resource/performance/24836
http://www4.wiwiss.fu-berlin.de/flickrwrappr/photos/Ronin_(film)
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fflickrwrappr%2Fphotos%2FRonin_%28film%29%3E
http://data.linkedmdb.org/resource/actor/42049
http://data.linkedmdb.org/resource/actor/30323
http://data.linkedmdb.org/resource/interlink/134336
http://data.linkedmdb.org/resource/interlink/37292
http://data.linkedmdb.org/resource/film_film_distributor_relationship/13798
http://data.linkedmdb.org/resource/interlink/18759
RDF Description of Ronin
http://data.linkedmdb.org/resource/interlink/70422
http://data.linkedmdb.org/resource/film_film_distributor_relationship/12740
http://data.linkedmdb.org/data/film/301
_:header18072299221335206706102
Mon, 23 Apr 2012 18:45:06 GMT
http://dbpedia.org/resource/Michael_Collins_%28film%29
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FMichael_Collins_%2528film%2529%3E
http://data.linkedmdb.org/resource/film/301
http://data.linkedmdb.org/resource/interlink/66333
http://data.linkedmdb.org/resource/film_cut/4169
http://data.linkedmdb.org/resource/performance/55360
http://www.imdb.com/title/tt0117039
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.imdb.com%2Ftitle%2Ftt0117039%3E
http://data.linkedmdb.org/resource/film_subject/736
http://www.rottentomatoes.com/alias?type=imdbid&s=0117039
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rottentomatoes.com%2Falias%3Ftype%3Dimdbid%26s%3D0117039%3E
Michael Collins
http://data.linkedmdb.org/resource/performance/19551
http://data.linkedmdb.org/resource/performance/58435
http://data.linkedmdb.org/resource/performance/61178
http://data.linkedmdb.org/resource/actor/29959
http://data.linkedmdb.org/resource/director/8996
http://data.linkedmdb.org/resource/actor/36663
http://data.linkedmdb.org/resource/country/IE
http://www.freebase.com/view/guid/9202a8c04000641f80000000000ae8a4
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000000ae8a4%3E
http://data.linkedmdb.org/resource/actor/36564
http://data.linkedmdb.org/resource/performance/84059
http://data.linkedmdb.org/resource/actor/35239
http://data.linkedmdb.org/resource/production_company/127
http://data.linkedmdb.org/resource/actor/30721
http://sws.geonames.org/2963597/
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsws.geonames.org%2F2963597%2F%3E
http://data.linkedmdb.org/resource/actor/29532
http://data.linkedmdb.org/resource/music_contributor/5222
http://data.linkedmdb.org/resource/performance/19552
http://data.linkedmdb.org/resource/actor/29720
http://mpii.de/yago/resource/Michael_Collins_%28film%29
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fmpii.de%2Fyago%2Fresource%2FMichael_Collins_%2528film%2529%3E
http://data.linkedmdb.org/resource/actor/32300
http://data.linkedmdb.org/resource/actor/34177
http://www4.wiwiss.fu-berlin.de/flickrwrappr/photos/Michael_Collins_(film)
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fflickrwrappr%2Fphotos%2FMichael_Collins_%28film%29%3E
http://data.linkedmdb.org/resource/writer/14176
http://data.linkedmdb.org/resource/producer/12553
http://data.linkedmdb.org/resource/performance/84295
http://data.linkedmdb.org/resource/performance/49467
http://data.linkedmdb.org/resource/actor/38566
http://data.linkedmdb.org/resource/performance/19550
http://data.linkedmdb.org/resource/performance/69597
http://data.linkedmdb.org/resource/interlink/37237
http://data.linkedmdb.org/resource/interlink/171
http://data.linkedmdb.org/resource/interlink/18704
http://data.linkedmdb.org/resource/film_film_distributor_relationship/6551
http://data.linkedmdb.org/resource/interlink/134218
RDF Description of Michael Collins
http://data.linkedmdb.org/data/film/40686
_:header4797335981335206707101
Mon, 23 Apr 2012 18:45:07 GMT
http://www.freebase.com/view/guid/9202a8c04000641f800000000043548f
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f800000000043548f%3E
http://data.linkedmdb.org/resource/film/40686
http://data.linkedmdb.org/resource/film/2914
http://data.linkedmdb.org/resource/producer/3476
http://data.linkedmdb.org/resource/director/9875
Luxo Jr.
http://data.linkedmdb.org/resource/writer/15590
http://data.linkedmdb.org/resource/producer/11012
http://data.linkedmdb.org/resource/film/2840
http://data.linkedmdb.org/resource/production_company/22
RDF Description of Luxo Jr.
http://data.linkedmdb.org/data/film/49680
_:header8705070851335206708095
Mon, 23 Apr 2012 18:45:08 GMT
RDF Description of The End of Violence
http://data.linkedmdb.org/resource/film/49680
The End of Violence
http://data.linkedmdb.org/resource/performance/40285
http://www.freebase.com/view/guid/9202a8c04000641f8000000000edc952
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f8000000000edc952%3E
http://data.linkedmdb.org/resource/actor/31184
http://data.linkedmdb.org/resource/writer/13289
http://data.linkedmdb.org/resource/actor/52659
http://data.linkedmdb.org/resource/performance/40286
http://data.linkedmdb.org/resource/producer/9777
http://data.linkedmdb.org/resource/producer/13062
http://data.linkedmdb.org/resource/actor/31141
http://data.linkedmdb.org/resource/music_contributor/6118
http://data.linkedmdb.org/resource/performance/53181
http://data.linkedmdb.org/resource/music_contributor/4389
http://data.linkedmdb.org/resource/actor/29760
http://data.linkedmdb.org/resource/performance/40283
http://data.linkedmdb.org/resource/music_contributor/1759
http://data.linkedmdb.org/resource/actor/33580
http://data.linkedmdb.org/resource/performance/77155
http://data.linkedmdb.org/resource/actor/31306
http://data.linkedmdb.org/resource/performance/40284
http://data.linkedmdb.org/resource/writer/19121
http://data.linkedmdb.org/resource/director/8502
http://data.linkedmdb.org/resource/film_film_distributor_relationship/9140
http://data.linkedmdb.org/data/film/1667
_:header2960156541335206709102
Mon, 23 Apr 2012 18:45:09 GMT
http://www.rottentomatoes.com/alias?type=imdbid&s=0058947
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rottentomatoes.com%2Falias%3Ftype%3Dimdbid%26s%3D0058947%3E
http://www4.wiwiss.fu-berlin.de/flickrwrappr/photos/Battle_of_the_Bulge_(film)
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fflickrwrappr%2Fphotos%2FBattle_of_the_Bulge_%28film%29%3E
http://dbpedia.org/resource/Battle_of_the_Bulge_%28film%29
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FBattle_of_the_Bulge_%2528film%2529%3E
http://data.linkedmdb.org/resource/film/1667
1965-12-16
http://data.linkedmdb.org/resource/actor/29804
Battle of the Bulge
http://data.linkedmdb.org/resource/writer/6294
http://data.linkedmdb.org/resource/performance/3753
http://data.linkedmdb.org/resource/actor/34817
http://data.linkedmdb.org/resource/producer/11833
http://www.freebase.com/view/guid/9202a8c04000641f80000000003cd3d7
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000003cd3d7%3E
http://data.linkedmdb.org/resource/actor/43
http://data.linkedmdb.org/resource/producer/13669
http://data.linkedmdb.org/resource/writer/1275
http://data.linkedmdb.org/resource/performance/3755
http://data.linkedmdb.org/resource/music_contributor/4856
http://data.linkedmdb.org/resource/writer/1098
http://www.imdb.com/title/tt0058947
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.imdb.com%2Ftitle%2Ftt0058947%3E
http://data.linkedmdb.org/resource/producer/1068
http://data.linkedmdb.org/resource/film_cut/751
http://data.linkedmdb.org/resource/producer/11579
http://data.linkedmdb.org/resource/writer/1276
http://mpii.de/yago/resource/Battle_of_the_Bulge_%28film%29
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fmpii.de%2Fyago%2Fresource%2FBattle_of_the_Bulge_%2528film%2529%3E
http://data.linkedmdb.org/resource/director/9962
http://data.linkedmdb.org/resource/writer/16556
http://data.linkedmdb.org/resource/performance/3754
http://data.linkedmdb.org/resource/interlink/37943
http://data.linkedmdb.org/resource/interlink/19410
http://data.linkedmdb.org/resource/film_film_distributor_relationship/7207
RDF Description of Battle of the Bulge
http://data.linkedmdb.org/resource/interlink/877
http://data.linkedmdb.org/resource/interlink/135472
http://data.linkedmdb.org/data/film/9612
_:header17440508941335206709881
Mon, 23 Apr 2012 18:45:10 GMT
http://data.linkedmdb.org/resource/film/9612
http://data.linkedmdb.org/resource/interlink/141835
http://data.linkedmdb.org/resource/performance/193376
http://data.linkedmdb.org/resource/actor/42967
1984-07-27
http://data.linkedmdb.org/resource/actor/38081
http://data.linkedmdb.org/resource/performance/118254
http://data.linkedmdb.org/resource/director/8999
http://data.linkedmdb.org/resource/writer/14457
http://data.linkedmdb.org/resource/actor/60851
http://data.linkedmdb.org/resource/film/3286
Cheech & Chong's The Corsican Brothers
http://data.linkedmdb.org/resource/performance/145615
http://data.linkedmdb.org/resource/actor/32334
http://data.linkedmdb.org/resource/actor/36594
http://data.linkedmdb.org/resource/performance/145617
http://data.linkedmdb.org/resource/performance/145616
http://data.linkedmdb.org/resource/actor/31654
http://data.linkedmdb.org/resource/actor/35519
http://data.linkedmdb.org/resource/performance/60725
http://data.linkedmdb.org/resource/music_contributor/1723
http://www.freebase.com/view/guid/9202a8c04000641f80000000011d143e
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000011d143e%3E
http://data.linkedmdb.org/resource/performance/118253
http://data.linkedmdb.org/resource/film_cut/17140
RDF Description of Cheech & Chong's The Corsican Brothers
http://data.linkedmdb.org/resource/film_film_distributor_relationship/14900
http://data.linkedmdb.org/resource/interlink/73485
http://data.linkedmdb.org/data/film/73852
_:header21275143331335206710448
Mon, 23 Apr 2012 18:45:11 GMT
http://www.freebase.com/view/guid/9202a8c04000641f800000000ad2ba72
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f800000000ad2ba72%3E
RDF Description of Cheerleader Queens
http://data.linkedmdb.org/resource/film/73852
http://data.linkedmdb.org/resource/director/3443
2003-02-21
Cheerleader Queens
http://data.linkedmdb.org/data/film/40652
_:header1703407351335206711192
Mon, 23 Apr 2012 18:45:12 GMT
http://data.linkedmdb.org/resource/film/40652
http://data.linkedmdb.org/resource/director/8650
The Kennel Murder Case
http://data.linkedmdb.org/resource/actor/32891
http://data.linkedmdb.org/resource/performance/117142
http://data.linkedmdb.org/resource/performance/117141
http://www.freebase.com/view/guid/9202a8c04000641f80000000004209c7
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000004209c7%3E
http://data.linkedmdb.org/resource/actor/30336
RDF Description of The Kennel Murder Case
http://data.linkedmdb.org/data/actor/780
_:header20189687981335206711447
http://data.linkedmdb.org/resource/actor/780
http://data.linkedmdb.org/resource/film/1670
http://www4.wiwiss.fu-berlin.de/flickrwrappr/photos/Patti_D'Arbanville
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fflickrwrappr%2Fphotos%2FPatti_D%27Arbanville%3E
http://mpii.de/yago/resource/Patti_D%27Arbanville
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fmpii.de%2Fyago%2Fresource%2FPatti_D%2527Arbanville%3E
http://dbpedia.org/resource/Patti_D%27Arbanville
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FPatti_D%2527Arbanville%3E
Patti D'Arbanville
http://data.linkedmdb.org/resource/performance/114185
http://data.linkedmdb.org/resource/performance/19852
http://data.linkedmdb.org/resource/performance/83329
http://data.linkedmdb.org/resource/performance/11674
http://www.freebase.com/view/guid/9202a8c04000641f80000000007ead08
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000007ead08%3E
Patti D'Arbanville (Actor)
http://data.linkedmdb.org/resource/performance/68149
http://data.linkedmdb.org/resource/performance/99330
http://data.linkedmdb.org/resource/interlink/93974
http://data.linkedmdb.org/resource/film/3832
http://data.linkedmdb.org/resource/film/43681
RDF Description of Patti D'Arbanville (Actor)
http://data.linkedmdb.org/resource/film/6051
http://data.linkedmdb.org/resource/interlink/105795
http://data.linkedmdb.org/resource/film/54572
http://data.linkedmdb.org/resource/interlink/117616
http://data.linkedmdb.org/resource/film/41299
http://data.linkedmdb.org/data/film/54526
_:header8506325401335206712783
Mon, 23 Apr 2012 18:45:13 GMT
http://www.freebase.com/view/guid/9202a8c04000641f800000000839f4ad
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f800000000839f4ad%3E
http://data.linkedmdb.org/resource/film/54526
Spy Chasers
http://data.linkedmdb.org/resource/actor/32268
http://data.linkedmdb.org/resource/actor/38149
http://data.linkedmdb.org/resource/performance/114136
http://data.linkedmdb.org/resource/actor/32052
http://data.linkedmdb.org/resource/performance/114135
http://data.linkedmdb.org/resource/performance/114137
1955-07-31
http://data.linkedmdb.org/resource/director/10426
RDF Description of Spy Chasers
http://data.linkedmdb.org/data/film/47126
_:header4650349481335206714728
http://data.linkedmdb.org/resource/film/47126
http://data.linkedmdb.org/resource/director/799
2006-08-29
http://data.linkedmdb.org/resource/director/800
http://data.linkedmdb.org/resource/production_company/738
Baghdad ER
http://data.linkedmdb.org/resource/director/3116
http://www.freebase.com/view/guid/9202a8c04000641f8000000000bf33bd
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f8000000000bf33bd%3E
http://data.linkedmdb.org/resource/producer/6053
RDF Description of Baghdad ER
http://data.linkedmdb.org/resource/film_film_distributor_relationship/11631
http://data.linkedmdb.org/data/film/2572
_:header12681122741335206718788
Mon, 23 Apr 2012 18:45:16 GMT
http://www.freebase.com/view/guid/9202a8c04000641f80000000005646e7
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000005646e7%3E
http://data.linkedmdb.org/resource/film/2572
http://data.linkedmdb.org/resource/film_cut/867
http://data.linkedmdb.org/resource/director/9690
http://data.linkedmdb.org/resource/performance/4343
http://data.linkedmdb.org/resource/cinematographer/183
http://data.linkedmdb.org/resource/actor/44171
http://data.linkedmdb.org/resource/editor/2398
http://data.linkedmdb.org/resource/actor/29669
http://data.linkedmdb.org/resource/performance/4346
http://www.rottentomatoes.com/alias?type=imdbid&s=0303356
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rottentomatoes.com%2Falias%3Ftype%3Dimdbid%26s%3D0303356%3E
http://data.linkedmdb.org/resource/music_contributor/371
http://data.linkedmdb.org/resource/producer/10869
http://data.linkedmdb.org/resource/performance/4347
http://data.linkedmdb.org/resource/performance/4345
http://data.linkedmdb.org/resource/editor/318
Biggie & Tupac
http://data.linkedmdb.org/resource/production_company/86
http://data.linkedmdb.org/resource/producer/1181
http://data.linkedmdb.org/resource/actor/34874
http://data.linkedmdb.org/resource/actor/39434
2002-01-11
http://data.linkedmdb.org/resource/actor/44189
http://data.linkedmdb.org/resource/actor/47098
http://data.linkedmdb.org/resource/performance/118676
http://data.linkedmdb.org/resource/performance/4344
http://www.imdb.com/title/tt0303356
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.imdb.com%2Ftitle%2Ftt0303356%3E
http://data.linkedmdb.org/resource/film_film_distributor_relationship/10936
http://data.linkedmdb.org/resource/interlink/136276
RDF Description of Biggie & Tupac
http://data.linkedmdb.org/data/film/39529
_:header11160106241335206720074
Mon, 23 Apr 2012 18:45:19 GMT
http://www.freebase.com/view/guid/9202a8c04000641f8000000000273f41
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f8000000000273f41%3E
http://data.linkedmdb.org/resource/film/39529
http://data.linkedmdb.org/resource/director/1923
http://data.linkedmdb.org/resource/performance/21958
http://data.linkedmdb.org/resource/music_contributor/171
http://data.linkedmdb.org/resource/actor/808
http://data.linkedmdb.org/resource/actor/5733
One Perfect Day
http://data.linkedmdb.org/resource/music_contributor/5841
http://sws.geonames.org/2077456/
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsws.geonames.org%2F2077456%2F%3E
http://data.linkedmdb.org/resource/actor/37352
http://data.linkedmdb.org/resource/performance/82411
http://data.linkedmdb.org/resource/music_contributor/4659
http://data.linkedmdb.org/resource/actor/40365
http://data.linkedmdb.org/resource/performance/21959
http://data.linkedmdb.org/resource/performance/21960
http://data.linkedmdb.org/resource/performance/21961
http://data.linkedmdb.org/resource/actor/5732
http://data.linkedmdb.org/resource/writer/3985
http://data.linkedmdb.org/resource/writer/3986
http://data.linkedmdb.org/resource/country/AU
RDF Description of One Perfect Day
http://data.linkedmdb.org/data/film/80316
_:header18628934301335206721956
Mon, 23 Apr 2012 18:45:20 GMT
RDF Description of Eline Vere
http://data.linkedmdb.org/resource/film/80316
http://data.linkedmdb.org/resource/director/284
1991-03-01
Eline Vere
http://www.freebase.com/view/guid/9202a8c04000641f800000000be8b339
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f800000000be8b339%3E
http://data.linkedmdb.org/data/film/54379
_:header15559038081335206723342
Mon, 23 Apr 2012 18:45:22 GMT
RDF Description of The Eyes of Mystery
http://data.linkedmdb.org/resource/film/54379
http://data.linkedmdb.org/resource/performance/134337
http://www.freebase.com/view/guid/9202a8c04000641f80000000083859bf
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000083859bf%3E
1918-01-21
The Eyes of Mystery
http://data.linkedmdb.org/resource/performance/155109
http://data.linkedmdb.org/resource/actor/54985
http://data.linkedmdb.org/resource/producer/222
http://data.linkedmdb.org/resource/director/8498
http://data.linkedmdb.org/resource/actor/10839
http://data.linkedmdb.org/data/film/38514
_:header8046840991335206724004
Mon, 23 Apr 2012 18:45:23 GMT
http://data.linkedmdb.org/resource/film/38514
http://data.linkedmdb.org/resource/film_film_distributor_relationship/261
http://data.linkedmdb.org/resource/performance/2391
http://data.linkedmdb.org/resource/performance/99062
http://data.linkedmdb.org/resource/actor/30085
Anatomy of a Murder
http://data.linkedmdb.org/resource/performance/2390
http://www.freebase.com/view/guid/9202a8c04000641f80000000000a0097
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000000a0097%3E
http://data.linkedmdb.org/resource/actor/426
http://data.linkedmdb.org/resource/film_subject/329
http://data.linkedmdb.org/resource/director/8517
http://data.linkedmdb.org/resource/performance/89210
http://data.linkedmdb.org/resource/writer/19967
http://data.linkedmdb.org/resource/performance/2389
http://data.linkedmdb.org/resource/actor/30845
http://data.linkedmdb.org/resource/music_contributor/4121
http://data.linkedmdb.org/resource/performance/2392
http://data.linkedmdb.org/resource/production_company/33
http://data.linkedmdb.org/resource/actor/35085
http://data.linkedmdb.org/resource/writer/274
http://data.linkedmdb.org/resource/actor/29520
http://data.linkedmdb.org/resource/actor/29449
http://data.linkedmdb.org/resource/producer/9796
http://data.linkedmdb.org/resource/film_production_designer/37
RDF Description of Anatomy of a Murder
http://data.linkedmdb.org/data/film/83111
_:header1175625281335206724767
Mon, 23 Apr 2012 18:45:25 GMT
http://data.linkedmdb.org/resource/film/83111
Crack in the Mirror
1960-05-19
http://data.linkedmdb.org/resource/performance/169015
http://data.linkedmdb.org/resource/producer/10094
http://data.linkedmdb.org/resource/actor/38654
http://www.freebase.com/view/guid/9202a8c04000641f800000000c402778
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f800000000c402778%3E
http://data.linkedmdb.org/resource/director/9958
http://data.linkedmdb.org/resource/performance/169013
http://data.linkedmdb.org/resource/performance/169014
http://data.linkedmdb.org/resource/actor/34903
http://data.linkedmdb.org/resource/actor/29602
http://data.linkedmdb.org/resource/film_film_distributor_relationship/11267
RDF Description of Crack in the Mirror
http://data.linkedmdb.org/data/film/46667
_:header1500071351335206726143
Mon, 23 Apr 2012 18:45:26 GMT
http://data.linkedmdb.org/resource/film/46667
http://data.linkedmdb.org/resource/film_film_distributor_relationship/8675
http://data.linkedmdb.org/resource/actor/33055
http://data.linkedmdb.org/resource/performance/96198
http://www.freebase.com/view/guid/9202a8c04000641f8000000000b58aff
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f8000000000b58aff%3E
http://data.linkedmdb.org/resource/performance/96200
Gang Related
http://data.linkedmdb.org/resource/performance/96199
http://data.linkedmdb.org/resource/actor/29874
http://data.linkedmdb.org/resource/actor/32252
http://data.linkedmdb.org/resource/performance/12075
http://data.linkedmdb.org/resource/actor/40358
http://data.linkedmdb.org/resource/actor/31644
http://data.linkedmdb.org/resource/performance/12078
1997-10-10
http://data.linkedmdb.org/resource/performance/12076
http://data.linkedmdb.org/resource/writer/18206
http://data.linkedmdb.org/resource/actor/33765
http://data.linkedmdb.org/resource/actor/32483
http://data.linkedmdb.org/resource/director/12243
http://data.linkedmdb.org/resource/performance/12079
http://data.linkedmdb.org/resource/performance/12077
http://data.linkedmdb.org/resource/film_film_distributor_relationship/14778
RDF Description of Gang Related
http://data.linkedmdb.org/data/film/14365
_:header15467172731335206726945
Mon, 23 Apr 2012 18:45:27 GMT
http://data.linkedmdb.org/resource/film/14365
http://data.linkedmdb.org/resource/interlink/145246
http://www.freebase.com/view/guid/9202a8c04000641f800000000558bf72
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f800000000558bf72%3E
http://data.linkedmdb.org/resource/music_contributor/4725
http://www.lingvoj.org/lingvo/ta
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.lingvoj.org%2Flingvo%2Fta%3E
http://data.linkedmdb.org/resource/director/10271
Chennai 600028
RDF Description of Chennai 600028
http://data.linkedmdb.org/data/film/40977
_:header2813285051335207001498
Mon, 23 Apr 2012 18:50:02 GMT
http://www.freebase.com/view/guid/9202a8c04000641f80000000004a4d94
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000004a4d94%3E
http://data.linkedmdb.org/resource/film/40977
http://data.linkedmdb.org/resource/film_film_distributor_relationship/1029
http://data.linkedmdb.org/resource/performance/1070
1978-08-29
http://data.linkedmdb.org/resource/performance/1075
http://data.linkedmdb.org/resource/writer/804
http://data.linkedmdb.org/resource/writer/834
http://data.linkedmdb.org/resource/director/8537
http://data.linkedmdb.org/resource/actor/30968
A Wedding
http://data.linkedmdb.org/resource/performance/1074
http://data.linkedmdb.org/resource/performance/1073
http://data.linkedmdb.org/resource/writer/19186
http://data.linkedmdb.org/resource/actor/31281
http://data.linkedmdb.org/resource/actor/38589
http://data.linkedmdb.org/resource/producer/9812
http://data.linkedmdb.org/resource/performance/1072
http://data.linkedmdb.org/resource/actor/30941
http://data.linkedmdb.org/resource/actor/33797
http://data.linkedmdb.org/resource/performance/1071
http://data.linkedmdb.org/resource/actor/33017
http://data.linkedmdb.org/resource/writer/13352
RDF Description of A Wedding
http://data.linkedmdb.org/data/film/89161
_:header12699944431335207002122
http://www.freebase.com/view/guid/9202a8c04000641f800000000e01544a
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f800000000e01544a%3E
http://data.linkedmdb.org/resource/film/89161
http://data.linkedmdb.org/resource/director/20486
Kiss Of Life
RDF Description of Kiss Of Life
http://data.linkedmdb.org/data/film/4003
_:header18474571651335207002945
Mon, 23 Apr 2012 18:50:03 GMT
RDF Description of Fire and Ice
http://data.linkedmdb.org/resource/film/4003
http://data.linkedmdb.org/resource/production_company/29
http://data.linkedmdb.org/resource/director/8662
http://data.linkedmdb.org/resource/producer/10346
http://data.linkedmdb.org/resource/music_contributor/4439
http://data.linkedmdb.org/resource/actor/32595
http://www.freebase.com/view/guid/9202a8c04000641f800000000079f794
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f800000000079f794%3E
http://data.linkedmdb.org/resource/performance/94767
http://data.linkedmdb.org/resource/performance/55150
http://data.linkedmdb.org/resource/film_cut/2326
1983-08-27
Fire and Ice
http://data.linkedmdb.org/resource/producer/9933
http://data.linkedmdb.org/resource/writer/14528
http://data.linkedmdb.org/resource/writer/14658
http://www.imdb.com/title/tt0085542
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.imdb.com%2Ftitle%2Ftt0085542%3E
http://data.linkedmdb.org/resource/performance/51289
http://www.rottentomatoes.com/alias?type=imdbid&s=0085542
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rottentomatoes.com%2Falias%3Ftype%3Dimdbid%26s%3D0085542%3E
http://data.linkedmdb.org/resource/actor/10049
http://data.linkedmdb.org/resource/actor/34216
http://data.linkedmdb.org/resource/performance/107205
http://data.linkedmdb.org/resource/actor/42561
http://data.linkedmdb.org/resource/interlink/71790
http://data.linkedmdb.org/resource/interlink/137498
http://data.linkedmdb.org/resource/film_film_distributor_relationship/1644
http://data.linkedmdb.org/data/film/39240
_:header13253783181335207003567
Mon, 23 Apr 2012 18:50:04 GMT
http://data.linkedmdb.org/resource/film/39240
http://data.linkedmdb.org/resource/performance/6572
1987-02-05
http://data.linkedmdb.org/resource/performance/6575
http://data.linkedmdb.org/resource/producer/942
http://data.linkedmdb.org/resource/producer/1595
http://data.linkedmdb.org/resource/performance/141940
http://data.linkedmdb.org/resource/actor/42419
http://data.linkedmdb.org/resource/actor/37346
http://data.linkedmdb.org/resource/director/15109
Cherry 2000
http://data.linkedmdb.org/resource/producer/94
http://data.linkedmdb.org/resource/producer/1594
http://data.linkedmdb.org/resource/performance/6573
http://data.linkedmdb.org/resource/performance/6574
http://data.linkedmdb.org/resource/performance/80868
http://data.linkedmdb.org/resource/writer/1765
http://data.linkedmdb.org/resource/producer/908
http://data.linkedmdb.org/resource/actor/32521
http://data.linkedmdb.org/resource/writer/18201
http://www.freebase.com/view/guid/9202a8c04000641f80000000001f15fd
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000001f15fd%3E
http://data.linkedmdb.org/resource/actor/705
http://data.linkedmdb.org/resource/music_contributor/4701
http://data.linkedmdb.org/resource/actor/41667
http://data.linkedmdb.org/resource/film_film_distributor_relationship/14370
RDF Description of Cherry 2000
http://data.linkedmdb.org/data/film/66799
_:header645294071335207004342
Mon, 23 Apr 2012 18:50:05 GMT
http://data.linkedmdb.org/resource/film/66799
http://data.linkedmdb.org/resource/director/16535
http://data.linkedmdb.org/resource/performance/139790
Pigen og greven
1966-11-25
http://data.linkedmdb.org/resource/actor/34477
http://data.linkedmdb.org/resource/producer/14766
http://www.freebase.com/view/guid/9202a8c04000641f800000000940cbb7
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f800000000940cbb7%3E
RDF Description of Pigen og greven
http://data.linkedmdb.org/data/film/634
_:header6380981751335207004994
http://data.linkedmdb.org/resource/film/634
http://data.linkedmdb.org/resource/director/10258
http://data.linkedmdb.org/resource/actor/34756
http://data.linkedmdb.org/resource/performance/31107
http://data.linkedmdb.org/resource/writer/5100
http://data.linkedmdb.org/resource/performance/88166
The Fast and the Furious
http://data.linkedmdb.org/resource/actor/49209
http://data.linkedmdb.org/resource/performance/31108
http://www.rottentomatoes.com/alias?type=imdbid&s=0232500
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rottentomatoes.com%2Falias%3Ftype%3Dimdbid%26s%3D0232500%3E
http://data.linkedmdb.org/resource/writer/17870
http://data.linkedmdb.org/resource/actor/33977
http://data.linkedmdb.org/resource/actor/31595
http://data.linkedmdb.org/resource/editor/2699
http://data.linkedmdb.org/resource/film_cut/6703
http://data.linkedmdb.org/resource/film_cut/12924
http://data.linkedmdb.org/resource/producer/14112
2001-06-22
http://www.imdb.com/title/tt0232500
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.imdb.com%2Ftitle%2Ftt0232500%3E
http://data.linkedmdb.org/resource/film/39336
http://data.linkedmdb.org/resource/performance/31109
http://data.linkedmdb.org/resource/performance/83848
http://data.linkedmdb.org/resource/writer/5099
http://www.freebase.com/view/guid/9202a8c04000641f800000000018f06a
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f800000000018f06a%3E
http://data.linkedmdb.org/resource/actor/31256
http://data.linkedmdb.org/resource/actor/35400
http://data.linkedmdb.org/resource/performance/31106
http://data.linkedmdb.org/resource/actor/32167
http://data.linkedmdb.org/resource/performance/87542
http://data.linkedmdb.org/resource/writer/734
http://data.linkedmdb.org/resource/music_contributor/4006
http://data.linkedmdb.org/resource/interlink/134553
RDF Description of The Fast and the Furious
http://data.linkedmdb.org/resource/film_film_distributor_relationship/338
http://data.linkedmdb.org/resource/interlink/70521
http://data.linkedmdb.org/data/producer/13980
_:header12588831291335207005121
Mon, 23 Apr 2012 18:50:06 GMT
http://data.linkedmdb.org/resource/producer/13980
http://data.linkedmdb.org/resource/film/93361
Harry S. Webb (Producer)
Harry S. Webb
http://www.freebase.com/view/guid/9202a8c04000641f80000000074d84a4
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000074d84a4%3E
http://data.linkedmdb.org/resource/film/21357
http://data.linkedmdb.org/resource/film/96787
http://data.linkedmdb.org/resource/film/96611
http://data.linkedmdb.org/resource/film/93231
http://data.linkedmdb.org/resource/film/91347
http://data.linkedmdb.org/resource/film/96629
http://data.linkedmdb.org/resource/film/96511
http://data.linkedmdb.org/resource/film/93424
http://data.linkedmdb.org/resource/film/93274
RDF Description of Harry S. Webb (Producer)
http://data.linkedmdb.org/data/film/78545
_:header21034292791335207006111
http://data.linkedmdb.org/resource/film/78545
http://data.linkedmdb.org/resource/director/9345
1974-10-25
http://data.linkedmdb.org/resource/performance/161322
Petersen
http://data.linkedmdb.org/resource/actor/44583
http://www.freebase.com/view/guid/9202a8c04000641f800000000b90085b
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f800000000b90085b%3E
http://data.linkedmdb.org/resource/performance/161321
http://data.linkedmdb.org/resource/actor/39421
RDF Description of Petersen
http://data.linkedmdb.org/data/film/3723
_:header8524070651335207006854
Mon, 23 Apr 2012 18:50:07 GMT
http://www.imdb.com/title/tt0299404/
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.imdb.com%2Ftitle%2Ftt0299404%2F%3E
http://www.rottentomatoes.com/alias?type=imdbid&s=0299404/
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rottentomatoes.com%2Falias%3Ftype%3Dimdbid%26s%3D0299404%2F%3E
RDF Description of Trudeau
http://data.linkedmdb.org/resource/film/3723
http://data.linkedmdb.org/resource/performance/81464
Trudeau
http://data.linkedmdb.org/resource/performance/77759
http://data.linkedmdb.org/resource/performance/79419
http://data.linkedmdb.org/resource/director/12522
http://data.linkedmdb.org/resource/actor/33420
http://data.linkedmdb.org/resource/performance/84540
http://www.freebase.com/view/guid/9202a8c04000641f800000000073b278
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f800000000073b278%3E
http://data.linkedmdb.org/resource/performance/159258
http://data.linkedmdb.org/resource/actor/34133
http://data.linkedmdb.org/resource/actor/10864
http://data.linkedmdb.org/resource/actor/39835
http://data.linkedmdb.org/resource/actor/38672
http://data.linkedmdb.org/data/film/60319
_:header17040965871335207007860
Mon, 23 Apr 2012 18:50:08 GMT
http://data.linkedmdb.org/resource/film/60319
http://data.linkedmdb.org/resource/director/8608
http://www.freebase.com/view/guid/9202a8c04000641f800000000900a4e9
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f800000000900a4e9%3E
http://data.linkedmdb.org/resource/actor/1546
A Hole in My Heart
http://data.linkedmdb.org/resource/performance/123664
RDF Description of A Hole in My Heart
http://data.linkedmdb.org/data/film/39955
_:header1821382111335207009239
Mon, 23 Apr 2012 18:50:09 GMT
http://data.linkedmdb.org/resource/film/39955
http://data.linkedmdb.org/resource/film_film_distributor_relationship/4911
http://data.linkedmdb.org/resource/producer/4730
http://data.linkedmdb.org/resource/performance/28989
http://data.linkedmdb.org/resource/actor/34362
http://data.linkedmdb.org/resource/performance/145205
http://data.linkedmdb.org/resource/actor/49583
http://data.linkedmdb.org/resource/performance/80178
http://data.linkedmdb.org/resource/performance/79173
http://www.freebase.com/view/guid/9202a8c04000641f8000000000320303
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f8000000000320303%3E
http://data.linkedmdb.org/resource/performance/28990
http://data.linkedmdb.org/resource/performance/28988
http://sws.geonames.org/2635167/
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsws.geonames.org%2F2635167%2F%3E
http://data.linkedmdb.org/resource/actor/29873
The 51st State
http://data.linkedmdb.org/resource/producer/16486
http://data.linkedmdb.org/resource/actor/34262
http://data.linkedmdb.org/resource/actor/31722
http://data.linkedmdb.org/resource/producer/2287
http://data.linkedmdb.org/resource/performance/82874
http://data.linkedmdb.org/resource/actor/31772
http://data.linkedmdb.org/resource/director/10049
http://data.linkedmdb.org/resource/country/GB
http://data.linkedmdb.org/resource/producer/11576
http://data.linkedmdb.org/resource/actor/35061
http://data.linkedmdb.org/resource/writer/16124
RDF Description of The 51st State
http://data.linkedmdb.org/resource/film_film_distributor_relationship/13819
http://data.linkedmdb.org/data/producer/16637
_:header10106151811335207010620
Mon, 23 Apr 2012 18:50:11 GMT
http://data.linkedmdb.org/resource/producer/16637
http://data.linkedmdb.org/resource/film/83177
Susan Downey (Producer)
Susan Downey
http://www.freebase.com/view/guid/9202a8c04000641f800000000b515b0b
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f800000000b515b0b%3E
http://data.linkedmdb.org/resource/film/19426
http://data.linkedmdb.org/resource/film/55820
http://data.linkedmdb.org/resource/film/17222
http://data.linkedmdb.org/resource/film/19022
http://data.linkedmdb.org/resource/film/42362
http://data.linkedmdb.org/resource/film/88280
http://data.linkedmdb.org/resource/film/2967
http://data.linkedmdb.org/resource/film/40109
http://data.linkedmdb.org/resource/film/69914
http://data.linkedmdb.org/resource/film/67033
RDF Description of Susan Downey (Producer)
http://data.linkedmdb.org/data/film/42786
_:header495279671335207011091
http://data.linkedmdb.org/resource/film/42786
http://data.linkedmdb.org/resource/film_film_distributor_relationship/7859
http://data.linkedmdb.org/resource/performance/15846
Jefferson in Paris
http://data.linkedmdb.org/resource/performance/15849
http://data.linkedmdb.org/resource/producer/11187
http://data.linkedmdb.org/resource/writer/14536
http://data.linkedmdb.org/resource/actor/47198
http://data.linkedmdb.org/resource/producer/10878
http://data.linkedmdb.org/resource/director/97
http://data.linkedmdb.org/resource/production_company/41
http://data.linkedmdb.org/resource/film_subject/664
http://data.linkedmdb.org/resource/actor/47313
http://data.linkedmdb.org/resource/producer/12865
http://data.linkedmdb.org/resource/performance/15847
http://data.linkedmdb.org/resource/performance/15851
http://data.linkedmdb.org/resource/performance/15853
http://data.linkedmdb.org/resource/music_contributor/5673
http://www.freebase.com/view/guid/9202a8c04000641f80000000006dcfab
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000006dcfab%3E
http://data.linkedmdb.org/resource/actor/29741
http://data.linkedmdb.org/resource/film_subject/431
http://data.linkedmdb.org/resource/film_subject/838
http://data.linkedmdb.org/resource/performance/78515
http://data.linkedmdb.org/resource/performance/15852
http://data.linkedmdb.org/resource/performance/15857
http://data.linkedmdb.org/resource/actor/32416
http://data.linkedmdb.org/resource/film_subject/984
http://data.linkedmdb.org/resource/performance/15848
http://data.linkedmdb.org/resource/performance/15854
http://data.linkedmdb.org/resource/producer/12370
http://data.linkedmdb.org/resource/actor/30708
http://data.linkedmdb.org/resource/music_contributor/5426
http://data.linkedmdb.org/resource/actor/47560
http://data.linkedmdb.org/resource/performance/185043
http://data.linkedmdb.org/resource/music_contributor/27
http://data.linkedmdb.org/resource/film_subject/746
http://data.linkedmdb.org/resource/performance/15858
http://data.linkedmdb.org/resource/actor/34911
http://data.linkedmdb.org/resource/actor/36553
http://data.linkedmdb.org/resource/performance/15855
http://data.linkedmdb.org/resource/actor/33987
http://data.linkedmdb.org/resource/actor/67144
http://data.linkedmdb.org/resource/actor/30096
http://data.linkedmdb.org/resource/editor/857
http://data.linkedmdb.org/resource/actor/42836
http://data.linkedmdb.org/resource/editor/629
http://data.linkedmdb.org/resource/performance/15856
http://data.linkedmdb.org/resource/performance/15850
RDF Description of Jefferson in Paris
http://data.linkedmdb.org/data/actor/909
_:header18879824151335207011963
Mon, 23 Apr 2012 18:50:12 GMT
http://data.linkedmdb.org/resource/actor/909
http://data.linkedmdb.org/resource/film/46360
Charles Kalani, Jr. (Actor)
Charles Kalani, Jr.
http://data.linkedmdb.org/resource/performance/82268
http://data.linkedmdb.org/resource/performance/77100
http://data.linkedmdb.org/resource/performance/88054
http://dbpedia.org/resource/Charles_Kalani%2C_Jr.
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FCharles_Kalani%252C_Jr.%3E
http://data.linkedmdb.org/resource/performance/86326
http://data.linkedmdb.org/resource/performance/45528
http://www4.wiwiss.fu-berlin.de/flickrwrappr/photos/Charles_Kalani,_Jr.
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fflickrwrappr%2Fphotos%2FCharles_Kalani%2C_Jr.%3E
http://data.linkedmdb.org/resource/performance/96832
http://data.linkedmdb.org/resource/performance/82708
http://mpii.de/yago/resource/Charles_Kalani%2C_Jr.
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fmpii.de%2Fyago%2Fresource%2FCharles_Kalani%252C_Jr.%3E
http://www.freebase.com/view/guid/9202a8c04000641f80000000008f825e
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000008f825e%3E
http://data.linkedmdb.org/resource/film/9876
http://data.linkedmdb.org/resource/film/7802
http://data.linkedmdb.org/resource/film/40893
RDF Description of Charles Kalani, Jr. (Actor)
http://data.linkedmdb.org/resource/film/887
http://data.linkedmdb.org/resource/film/42802
http://data.linkedmdb.org/resource/film/39882
http://data.linkedmdb.org/resource/interlink/98787
http://data.linkedmdb.org/resource/interlink/110608
http://data.linkedmdb.org/resource/interlink/86966
http://data.linkedmdb.org/data/film/42440
_:header17235801241335207013437
Mon, 23 Apr 2012 18:50:13 GMT
http://www.freebase.com/view/guid/9202a8c04000641f800000000067d76c
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f800000000067d76c%3E
RDF Description of The Hour-Glass Sanatorium
http://data.linkedmdb.org/resource/film/42440
http://data.linkedmdb.org/resource/music_contributor/1810
http://sws.geonames.org/798544/
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsws.geonames.org%2F798544%2F%3E
http://data.linkedmdb.org/resource/country/PL
http://data.linkedmdb.org/resource/actor/64212
http://data.linkedmdb.org/resource/director/10396
The Hour-Glass Sanatorium
http://data.linkedmdb.org/resource/performance/191982
http://data.linkedmdb.org/resource/writer/16215
http://data.linkedmdb.org/resource/film_location/1269
http://data.linkedmdb.org/data/film/47371
_:header21359051081335207014060
Mon, 23 Apr 2012 18:50:14 GMT
http://www.freebase.com/view/guid/9202a8c04000641f8000000000c2d51c
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f8000000000c2d51c%3E
http://data.linkedmdb.org/resource/film/47371
http://data.linkedmdb.org/resource/director/13090
http://data.linkedmdb.org/resource/music_contributor/712
http://data.linkedmdb.org/resource/performance/21197
Night of the Seagulls
http://data.linkedmdb.org/resource/performance/21196
http://data.linkedmdb.org/resource/actor/5599
1976-07-26
http://data.linkedmdb.org/resource/film/47360
http://data.linkedmdb.org/resource/country/ES
http://sws.geonames.org/2510769/
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fsws.geonames.org%2F2510769%2F%3E
http://data.linkedmdb.org/resource/writer/19034
http://data.linkedmdb.org/resource/actor/5600
http://data.linkedmdb.org/resource/editor/1048
http://data.linkedmdb.org/resource/producer/3802
RDF Description of Night of the Seagulls
http://data.linkedmdb.org/data/producer/1465
_:header10788852561335207014181
Mon, 23 Apr 2012 18:50:15 GMT
http://data.linkedmdb.org/resource/producer/1465
http://data.linkedmdb.org/resource/film/47768
Luiz Carlos Barreto (Producer)
Luiz Carlos Barreto
http://www.freebase.com/view/guid/9202a8c04000641f80000000010d7d48
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000010d7d48%3E
RDF Description of Luiz Carlos Barreto (Producer)
http://data.linkedmdb.org/data/film/17931
_:header13050140431335207015057
RDF Description of Brother Orchid
http://data.linkedmdb.org/resource/film/17931
http://mpii.de/yago/resource/Brother_Orchid
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fmpii.de%2Fyago%2Fresource%2FBrother_Orchid%3E
http://data.linkedmdb.org/resource/film_cut/10135
http://data.linkedmdb.org/resource/producer/11732
Brother Orchid
http://data.linkedmdb.org/resource/writer/15432
http://data.linkedmdb.org/resource/editor/2488
1940-06-08
http://data.linkedmdb.org/resource/performance/64492
http://data.linkedmdb.org/resource/actor/29486
http://data.linkedmdb.org/resource/actor/30752
http://data.linkedmdb.org/resource/music_contributor/5160
http://data.linkedmdb.org/resource/performance/67986
http://data.linkedmdb.org/resource/producer/10879
http://data.linkedmdb.org/resource/actor/32670
http://www4.wiwiss.fu-berlin.de/flickrwrappr/photos/Brother_Orchid
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fflickrwrappr%2Fphotos%2FBrother_Orchid%3E
http://data.linkedmdb.org/resource/performance/88718
http://www.freebase.com/view/guid/9202a8c04000641f8000000005747c9d
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f8000000005747c9d%3E
http://dbpedia.org/resource/Brother_Orchid
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FBrother_Orchid%3E
http://data.linkedmdb.org/resource/interlink/26497
http://data.linkedmdb.org/resource/interlink/148085
http://data.linkedmdb.org/resource/interlink/7964
http://data.linkedmdb.org/resource/interlink/75858
http://data.linkedmdb.org/resource/interlink/45030
http://data.linkedmdb.org/data/film/2617
_:header2899508181335207015927
Mon, 23 Apr 2012 18:50:16 GMT
http://www4.wiwiss.fu-berlin.de/flickrwrappr/photos/A_Scanner_Darkly_(film)
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fflickrwrappr%2Fphotos%2FA_Scanner_Darkly_%28film%29%3E
http://data.linkedmdb.org/resource/film/2617
http://data.linkedmdb.org/resource/interlink/136317
http://data.linkedmdb.org/resource/performance/934
http://data.linkedmdb.org/resource/producer/12681
2006-07-07
http://data.linkedmdb.org/resource/film_regional_release_date/59
http://data.linkedmdb.org/resource/film_cut/11870
http://www4.wiwiss.fu-berlin.de/bookmashup/books/0385016131
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww4.wiwiss.fu-berlin.de%2Fbookmashup%2Fbooks%2F0385016131%3E
http://data.linkedmdb.org/resource/director/9502
http://data.linkedmdb.org/resource/producer/5968
http://data.linkedmdb.org/resource/production_company/126
http://data.linkedmdb.org/resource/film_location/1287
http://data.linkedmdb.org/resource/performance/938
http://data.linkedmdb.org/resource/production_company/277
A Scanner Darkly
http://mpii.de/yago/resource/A_Scanner_Darkly_%28film%29
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fmpii.de%2Fyago%2Fresource%2FA_Scanner_Darkly_%2528film%2529%3E
http://data.linkedmdb.org/resource/actor/30719
http://data.linkedmdb.org/resource/producer/550
http://data.linkedmdb.org/resource/performance/937
http://www.imdb.com/title/tt0405296
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.imdb.com%2Ftitle%2Ftt0405296%3E
http://www.freebase.com/view/guid/9202a8c04000641f8000000000574201
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f8000000000574201%3E
http://data.linkedmdb.org/resource/film_story_contributor/255
http://data.linkedmdb.org/resource/writer/15004
http://data.linkedmdb.org/resource/film_location/237
http://www.rottentomatoes.com/alias?type=imdbid&s=0405296
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.rottentomatoes.com%2Falias%3Ftype%3Dimdbid%26s%3D0405296%3E
http://data.linkedmdb.org/resource/performance/936
http://dbpedia.org/resource/A_Scanner_Darkly_%28film%29
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fdbpedia.org%2Fresource%2FA_Scanner_Darkly_%2528film%2529%3E
http://data.linkedmdb.org/resource/actor/30728
http://data.linkedmdb.org/resource/music_contributor/5668
http://data.linkedmdb.org/resource/producer/548
http://data.linkedmdb.org/resource/cinematographer/141
http://data.linkedmdb.org/resource/actor/29689
http://data.linkedmdb.org/resource/performance/935
http://data.linkedmdb.org/resource/producer/10012
http://data.linkedmdb.org/resource/production_company/160
http://data.linkedmdb.org/resource/editor/118
http://data.linkedmdb.org/resource/film_location/734
http://data.linkedmdb.org/resource/producer/549
http://data.linkedmdb.org/resource/actor/33631
http://data.linkedmdb.org/resource/producer/9757
http://data.linkedmdb.org/resource/interlink/38403
RDF Description of A Scanner Darkly
http://data.linkedmdb.org/resource/interlink/71298
http://data.linkedmdb.org/resource/interlink/19870
http://data.linkedmdb.org/resource/film_film_distributor_relationship/16
http://data.linkedmdb.org/resource/film_film_distributor_relationship/15
http://data.linkedmdb.org/resource/interlink/1337
http://data.linkedmdb.org/resource/interlink/55612
http://data.linkedmdb.org/data/film/66610
_:header20050257271335207016543
Mon, 23 Apr 2012 18:50:17 GMT
http://data.linkedmdb.org/resource/film/66610
FrÃ¸ken Kirkemus
http://data.linkedmdb.org/resource/performance/139910
http://data.linkedmdb.org/resource/director/15740
http://www.freebase.com/view/guid/9202a8c04000641f80000000093f77f4
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000093f77f4%3E
1941-12-26
http://data.linkedmdb.org/resource/producer/14763
http://data.linkedmdb.org/resource/director/15802
http://data.linkedmdb.org/resource/actor/11096
RDF Description of FrÃ¸ken Kirkemus
http://data.linkedmdb.org/data/producer/9964
_:header4394367321335207016678
Mon, 23 Apr 2012 18:50:18 GMT
http://data.linkedmdb.org/resource/producer/9964
http://data.linkedmdb.org/resource/film/18544
Neil Aspinall (Producer)
Neil Aspinall
http://www.freebase.com/view/guid/9202a8c04000641f80000000000eee60
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000000eee60%3E
RDF Description of Neil Aspinall (Producer)
http://data.linkedmdb.org/resource/film/5762
http://data.linkedmdb.org/data/producer/382
_:header3768971791335207016912
http://www.freebase.com/view/guid/9202a8c04000641f80000000010c3ca6
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000010c3ca6%3E
RDF Description of Daniel Grodnik (Producer)
http://data.linkedmdb.org/resource/producer/382
Daniel Grodnik (Producer)
Daniel Grodnik
http://data.linkedmdb.org/resource/film/67747
http://data.linkedmdb.org/resource/film/1349
http://data.linkedmdb.org/resource/film/4249
http://data.linkedmdb.org/data/film/40429
_:header9829056871335207017900
http://data.linkedmdb.org/resource/film/40429
http://data.linkedmdb.org/resource/film_film_distributor_relationship/7211
http://data.linkedmdb.org/resource/film_location/1372
http://www.freebase.com/view/guid/9202a8c04000641f80000000003ce42b
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000003ce42b%3E
1985-11-01
http://data.linkedmdb.org/resource/music_contributor/64
http://data.linkedmdb.org/resource/writer/14346
http://data.linkedmdb.org/resource/actor/37138
http://data.linkedmdb.org/resource/performance/36919
http://data.linkedmdb.org/resource/actor/48404
http://data.linkedmdb.org/resource/actor/31605
http://data.linkedmdb.org/resource/performance/36918
http://data.linkedmdb.org/resource/performance/191657
http://data.linkedmdb.org/resource/writer/5686
http://data.linkedmdb.org/resource/director/9089
To Live and Die in L.A.
http://data.linkedmdb.org/resource/actor/54125
http://data.linkedmdb.org/resource/performance/36917
http://data.linkedmdb.org/resource/actor/33048
http://data.linkedmdb.org/resource/performance/80852
http://data.linkedmdb.org/resource/actor/33822
http://data.linkedmdb.org/resource/performance/36920
http://data.linkedmdb.org/resource/actor/31048
http://data.linkedmdb.org/resource/producer/1783
http://data.linkedmdb.org/resource/performance/36916
http://data.linkedmdb.org/resource/film_film_distributor_relationship/12842
RDF Description of To Live and Die in L.A.
http://data.linkedmdb.org/data/film/46611
_:header13289751061335207018554
Mon, 23 Apr 2012 18:50:19 GMT
http://data.linkedmdb.org/resource/film/46611
http://data.linkedmdb.org/resource/performance/116934
http://data.linkedmdb.org/resource/actor/43040
The Hireling
http://data.linkedmdb.org/resource/actor/9988
http://data.linkedmdb.org/resource/performance/53098
http://data.linkedmdb.org/resource/writer/19130
http://data.linkedmdb.org/resource/performance/116933
http://data.linkedmdb.org/resource/actor/30706
http://data.linkedmdb.org/resource/performance/96170
http://data.linkedmdb.org/resource/director/19697
http://www.freebase.com/view/guid/9202a8c04000641f8000000000b49688
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f8000000000b49688%3E
http://data.linkedmdb.org/resource/film_film_distributor_relationship/2351
RDF Description of The Hireling
http://data.linkedmdb.org/data/film/44235
_:header20011651821335207019321
Mon, 23 Apr 2012 18:50:20 GMT
RDF Description of Ponette
http://data.linkedmdb.org/resource/film/44235
http://www.freebase.com/view/guid/9202a8c04000641f80000000008748aa
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000008748aa%3E
1996-09-25
http://data.linkedmdb.org/resource/producer/6137
Ponette
http://data.linkedmdb.org/resource/director/12864
http://data.linkedmdb.org/resource/performance/23174
http://data.linkedmdb.org/resource/actor/39262
http://data.linkedmdb.org/resource/writer/18821
http://data.linkedmdb.org/resource/music_contributor/6207
http://data.linkedmdb.org/data/film/66606
_:header16419860221335207019933
http://www.freebase.com/view/guid/9202a8c04000641f80000000093f6ff4
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000093f6ff4%3E
http://data.linkedmdb.org/resource/film/66606
1935-11-16
http://data.linkedmdb.org/resource/actor/30348
I Found Stella Parish
http://data.linkedmdb.org/resource/actor/33328
http://data.linkedmdb.org/resource/performance/139913
http://data.linkedmdb.org/resource/performance/139912
http://data.linkedmdb.org/resource/actor/48743
http://data.linkedmdb.org/resource/performance/196470
http://data.linkedmdb.org/resource/film_film_distributor_relationship/10353
RDF Description of I Found Stella Parish
http://data.linkedmdb.org/data/producer/10081
_:header21086556501335207020006
Mon, 23 Apr 2012 18:50:21 GMT
http://data.linkedmdb.org/resource/producer/10081
http://data.linkedmdb.org/resource/film/22661
Al Christie (Producer)
Al Christie
http://www.freebase.com/view/guid/9202a8c04000641f8000000000147ac4
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f8000000000147ac4%3E
http://data.linkedmdb.org/resource/film/22810
RDF Description of Al Christie (Producer)
http://data.linkedmdb.org/resource/film/20026
http://data.linkedmdb.org/resource/film/22808
http://data.linkedmdb.org/data/film/55634
_:header13972183991335207020905
RDF Description of The Courtneys of Curzon Street
http://data.linkedmdb.org/resource/film/55634
The Courtneys of Curzon Street
http://data.linkedmdb.org/resource/actor/31471
http://www.freebase.com/view/guid/9202a8c04000641f80000000087b4b1b
http://data.linkedmdb.org/sparql?query=DESCRIBE+%3Chttp%3A%2F%2Fwww.freebase.com%2Fview%2Fguid%2F9202a8c04000641f80000000087b4b1b%3E
http://data.linkedmdb.org/resource/director/14170
1947-04-11
http://data.linkedmdb.org/resource/actor/154
http://data.linkedmdb.org/resource/performance/114985
http://data.linkedmdb.org/resource/performance/195981
